Abacavir  
 TRIANGLE Analgesics:   abacavirpossiblyreducesplasmaconcentrationof METHADONE  
 TRIANGLE Antibacterials:  plasmaconcentrationofabacavirpossiblyreducedby RIFAMPICIN  
 TRIANGLE Antiepileptics: plasmaconcentrationofabacavirpossiblyreducedby FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE 
Antivirals: abacavirpossiblyreduceseffectsofl RIBAVIRIN ;plasmaconcentrationofabacavirreducedbyl TIPRANAVIR 
Orlistat: absorptionofabacavirpossiblyreducedbyl ORLISTATA bataceptlCytotoxics:  increasedriskofside-effectswhenabataceptgivenwith ADALIMUMAB ;avoidconcomitantuseofabataceptwithl CERTOLIZUMABPEGOL ,l GOLIMUMAB orl INFLIXIMAB 
Etanercept: avoidconcomitantuseofabataceptwithl ETANERCEPT 
Vaccines: riskofgeneralisedinfectionswhenabataceptgivenwithlivel VACCINES â€”avoidconcomitantuse
Abiraterone 
 TRIANGLE Analgesics:abirateroneincreasesplasmaconcentrationof DEXTROMETHORPHAN 
Antibacterials: plasmaconcentrationofabirateronepossiblyreducedbyl RIFABUTIN â€”manufacturerofabirateroneadvisesavoidconcomitantuse;plasmaconcentrationofabirateronereducedbylRIFAMPICINâ€”manufacturerofabirateroneadvisesavoidconcomitantuse
 Antidepressants:  plasmaconcentrationofabirateronepossiblyreducedbyl STJOHN â€™ SWORT â€”manufacturerofabirateroneadvisesavoidconcomitantuse
Antiepileptics: plasmaconcentrationofabirateronepossiblyreducedbyl CARBAMAZEPINE ,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONEâ€”manufacturerofabirateroneadvisesavoidconcomitantuse
 Acarbose see Antidiabetics
 ACE Inhibitors 
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith AL CO HOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith ALDESLEUKIN 
Aliskiren: increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenACEinhibitorsgivenwithl ALISKIREN â€”avoidconcomitantuse 
 TRIANGLE Allopurinol: manufacturersstatepossibleincreasedriskofleucopeniaandhypersensitivityreactionswhenACEinhibitorsgivenwith ALLOPURINOL especiallyinrenalimpairment 
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenACEinhibitorsgivenwith ALPHA - BLOCKERS  
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics:increasedriskofrenalimpairmentwhenACEinhibitorsgivenwith  NSAID S ,alsohypotensiveeffectantagonisedlAngiotensin- IIR eceptor
 Antagonists: increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenACEinhibitorsgivenwithl ANGIOTENSIN - IIRECEPTORANTAGONISTS â€”avoidconcomitantuse 
 TRIANGLE Antacids: absorptionofACEinhibitorspossiblyreducedby ANTACIDS ;absorptionofcaptopril,enalaprilandfosinoprilreducedbyANTACIDS 
 TRIANGLE Antibacterials:plasmaconcentrationofactivemetaboliteofimidaprilreducedbyRIFAMPICIN(reducedantihypertensiveeffect);quinapriltabletsreduceabsorptionof TETRACYCLINES (quinapriltabletscontainmagnesiumcarbonate);possibleincreasedriskofhyperkalaemiawhenACEinhibitorsgivenwith TRIMETHOPRIM  
 TRIANGLE Antidepressants:hypotensiveeffectofACEinhibitorspossiblyenhancedby MAOIS  
 TRIANGLE Antidiabetics: ACEinhibitorspossiblyenhancehypoglycaemiceffectof INSULIN , METFORMIN and SULFONYLUREAS  
 TRIANGLE Antipsychotics: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith ANTIPSYCHOTICS  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Avanafil: hypotensiveeffectofenalaprilpossiblyenhancedby AVANAFIL  
 TRIANGLE Azathioprine: increasedriskofanaemiaorleucopeniawhencaptoprilgivenwith AZATHIOPRINE especiallyinrenalimpairment;increasedriskofanaemiawhenenalaprilgivenwithAZATHIOPRINEespeciallyinrenalimpairment
BeeVenomExtracts: possiblesevereanaphylactoidreactionwhenACEinhibitorsgivenwithl BEEVENOMEXTRACTS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenACEinhibitorsgivenwith BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE CardiacGlycosides: captoprilpossiblyincreasesplasmaconcentrationof DIGOXIN 
Ciclosporin: increasedriskofhyperkalaemiawhenACEinhibitorsgivenwithl CICLOSPORIN  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith CLONIDINE ;antihypertensiveeffectofcaptoprilpossiblydelayedbyprevioustreatmentwithCLONIDINE 
 TRIANGLE Corticosteroids: hypotensiveeffectofACEinhibitorsantagonisedby CORTICOSTEROIDS  
Cytotoxics:increasedriskofangioedemawhenACEinhibitorsgivenwithl EVEROLIMUS  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith DIAZOXIDE 
Diuretics: enhancedhypotensiveeffectwhenACEinhibitorsgivenwithl DIURETICS ;increasedriskofseverehyperkalaemiawhenACEinhibitorsgivenwithl POTASSIUM - SPARINGDIURETICSANDALDOSTERONEANTAGONISTS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhenACEinhibitorsgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA 
Lithium: ACEinhibitorsreduceexcretionofl LITHIUM (increasedplasmaconcentration) 
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofACEinhibitorsantagonisedby OESTROGENS 
PotassiumSalts: increasedriskofseverehyperkalaemiawhenACEinhibitorsgivenwithl POTASSIUMSALTS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith ALPROSTADIL 
SodiumAurothiomalate: flushingandhypotensionreportedwhenACEinhibitorsgivenwithl SODIUMAUROTHIOMALATE  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenACEinhibitorsgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE 
WaspVenomExtracts: possiblesevereanaphylactoidreactionwhenACEinhibitorsgivenwithl WASPVENOMEXTRACTS
 Acebutolol see Beta-blockers 
 Aceclofenac see  NSAIDs 
 Acemetacin see  NSAIDs 
 Acenocoumarol see Coumarins 
 Acetazolamide see Diuretics 
 Aciclovir
 NOTEI nteractionsdonotapplytotopicalaciclovirpreparations 
 TRIANGLE Aminophylline: aciclovirpossiblyincreasesplasmaconcentrationof AMINOPHYLLINE 
 TRIANGLE Ciclosporin: increasedriskofnephrotoxicitywhenaciclovirgivenwith CICLOSPORIN  
 TRIANGLE Mycophenolate: plasmaconcentrationofaciclovirincreasedby MY CO PHENOLATE ,alsoplasmaconcentrationofinactivemetaboliteofmycophenolateincreased 
 TRIANGLE Tacrolimus: possibleincreasedriskofnephrotoxicitywhenaciclovirgivenwith TACROLIMUS  
 TRIANGLE Theophylline:  aciclovirpossiblyincreasesplasmaconcentrationof  THEOPHYLLINE 
 Acitretin see Retinoids 
 Aclidinium see Antimuscarinics 
 Acrivastine see Antihistamines 
Adalimumab
Anakinra: avoidconcomitantuseofadalimumabwithl ANAKINRA  
 Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
Adefovir 
 TRIANGLE Antivirals:  avoidanceofadefoviradvisedbymanufacturerof TENOFOVIR  
 TRIANGLE Interferons: manufacturerofadefoviradvisescautionwith PEGINTERFERONALFAA denosine NOTEP ossibilityofinteractionwithdrugstendingtoimpairmyocardialconduction 
 TRIANGLE Aminophylline: anti-arrhythmiceffectofadenosineantagonisedby AMINOPHYLLINE â€”manufacturerofadenosineadvisesavoidaminophyllinefor24hoursbeforeadenosine 
 TRIANGLE Anaesthetics,Local: increasedmyocardialdepressionwhenanti-arrhythmicsgivenwith BUPIVACAINE , LEVOBUPIVACAINE , PRILOCAINE or ROPIVACAINE  
 lAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherl ANTI - ARRHYTHMICS 
Antipsychotics: increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongthe QT intervalgivenwithl ANTIPSYCHOTICS thatprolongtheQTintervallBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithl BETA - BLOCKERS  
 TRIANGLE Caffeinecitrate: anti-arrhythmiceffectofadenosineantagonisedby CAFFEINECITRATE â€”manufacturerofadenosineadvisesavoidcaffeinecitrateforatleast12hoursbeforeadenosine
Dipyridamole: effectofadenosineenhancedandextendedbyl DIPYRIDAMOLE (importantriskoftoxicity)â€”reducedoseofadenosine,seep87 
 TRIANGLE Nicotine: effectsofadenosinepossiblyenhancedby NICOTINE  
 TRIANGLE Theophylline:anti-arrhythmiceffectofadenosineantagonisedbyTHEOPHYLLINEâ€”manufacturerofadenosineadvisesavoidtheophyllinefor24hoursbeforeadenosineAdrenaline(epinephrine)seeSympathomimeticsAdrenergicNeurone
Blockers 
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith ALCOHOL  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith ALPHA -BLOCKERS lAnaesthetics,General: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithl GENERALANAESTHETICS  
 TRIANGLE Analgesics: hypotensiveeffectofadrenergicneuroneblockersantagonisedby NSAIDS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antidepressants: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith MAOIS ;hypotensiveeffectofadrenergicneuroneblockersantagonisedby TRICYCLICS  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithBETA-BLOCKERS 
 TRIANGLE Calcium-channelBlockers:  enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith CLONIDINE  
 TRIANGLE Corticosteroids: hypotensiveeffectofadrenergicneuroneblockersantagonisedby CORTICOSTEROIDS  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofadrenergicneuroneblockersantagonisedby OESTROGENS  
 TRIANGLE Pizotifen: hypotensiveeffectofadrenergicneuroneblockersantagonisedby PIZOTIFEN  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith ALPROSTADIL 
Sympathomimetics: increasedriskofhypertensionwhenguanethidinegivenwithl ADRENALINE ( EPINEPHRINE );hypotensiveeffectofguanethidineantagonisedbyl DEXAMFETAMINE andl LISDEXAMFETAMINE ;hypotensiveeffectofadrenergicneuroneblockersantagonisedbyl EPHEDRINE ,l ISOMETHEPTENE ,l METARAMINOL ,l METHYLPHENIDATE ,l NORADRENALINE ( NOREPINEPHRINE ),l OXYMETAZOLINE ,l PHENYLEPHRINE ,l PSEUDOEPHEDRINE andl XYLOMETAZOLINE  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenadrenergicneuroneblockersgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE
 Adsorbents see Kaolin 
Afatinib
 TRIANGLE Antibacterials: plasmaconcentrationofafatinibpossiblyincreasedby ERYTHROMYCIN â€”manufacturerofafatinibadvisesseparatingadministrationoferythromycinby6to12hours;plasmaconcentrationofafatinibreducedby RIFAMPICIN  
 TRIANGLE Antifungals: plasmaconcentrationofafatinibpossiblyincreasedby ITRACONAZOLE and KETOCONAZOLE â€”manufacturerofafatinibadvisesseparatingadministrationofitraconazoleandketoconazoleby6to12hourslAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Antivirals:plasmaconcentrationofafatinibincreasedby RITONAVIR â€”manufacturerofafatinibadvisesseparatingadministrationofritonavirby6to12hours;plasmaconcentrationofafatinibpossiblyincreasedby SAQUINAVIR â€”manufacturerofafatinibadvisesseparatingadministrationofsaquinavirby6to12hours 
 TRIANGLE Calcium-channelBlockers:plasmaconcentrationofafatinibpossiblyincreasedby VERAPAMIL â€”manufacturerofafatinibadvisesseparatingadministrationofverapamilby6to12hours BNF 
 TRIANGLE Ciclosporin: plasmaconcentrationofafatinibpossiblyincreasedby CICLOSPORIN â€”manufacturerofafatinibadvisesseparatingadministrationofciclosporinby6to12hours 
 TRIANGLE Tacrolimus: plasmaconcentrationofafatinibpossiblyincreasedby TACROLIMUS â€”manufacturerofafatinibadvisesseparatingadministrationoftacrolimusby6to12hoursAgalsidaseAlfaand
 dBeta 
 TRIANGLE Anti-arrhythmics:effectsofagalsidasealfaandbetapossiblyinhibitedby AMIODARONE (manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) 
 TRIANGLE Antibacterials: effectsofagalsidasealfaandbetapossiblyinhibitedby GENTAMICIN (manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) 
 TRIANGLE Antimalarials: effectsofagalsidasealfaandbetapossiblyinhibitedby CHLOROQUINE and HYDROXYCHLOROQUINE (manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse)AgomelatinelAntibacterials:  manufacturerofagomelatineadvisesavoidconcomitantusewithl CIPROFLOXACIN  
 
Antidepressants:  metabolismofagomelatineinhibitedbyl FLUVOXAMINE (increasedplasmaconcentration)
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINEA lbendazole 
 TRIANGLE Anthelmintics:  plasmaconcentrationofbothdrugspossiblyreducedwhenalbendazolegivenwith LEVAMISOLE  l
 Antiepileptics:  plasmaconcentrationofalbendazolereducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”considerincreasingalbendazoledosewhengivenforsystemicinfections
 Antivirals:  plasmaconcentrationofactivemetaboliteofalbendazolereducedbyl RITONAVIR â€”considerincreasingalbendazoledosewhengivenforsystemicinfections 
 TRIANGLE Corticosteroids: plasmaconcentrationofactivemetaboliteofalbendazoleincreasedby DEXAMETHASONE  
 TRIANGLE GrapefruitJuice: plasmaconcentrationofactivemetaboliteofalbendazoleincreasedby GRAPEFRUITJUICE  
 TRIANGLE Ulcer-healingDrugs:  effectsofalbendazolepossiblyenhancedby CIMETIDINEA lcohol 
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhenalcoholgivenwith ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenalcoholgivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alpha-blockers:increasedsedativeeffectwhenalcoholgivenwith INDORAMIN ;enhancedhypotensiveeffectwhenalcoholgivenwith ALPHA -BLOCKERS 
 TRIANGLE Analgesics: enhancedhypotensiveandsedativeeffectswhenalcoholgivenwith OPIOIDANALGESICS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenalcoholgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Anthelmintics:possibilityofdisulfiram-likereactionwhenalcoholgivenwithLEVAMISOLE 
Antibacterials:disulfiram-likereactionwhenalcoholgivenwith METRONIDAZOLE ;possibilityofdisulfiram-likereactionwhenalcoholgivenwith TINIDAZOLE ;increasedriskofconvulsionswhenalcoholgivenwithl CYCLOSERINE 
Anticoagulants: majorchangesinconsumptionofalcoholmayaffectanticoagulantcontrolwithl COUMARINS orl PHENINDIONE  
 lAntidepressants:somebeveragescontainingalcoholandsomedealcoholisedbeveragescontaintyraminewhichinteractswithl MAOIS (hypertensivecrisis)â€”ifnotyramine,enhancedhypotensiveeffect;sedativeeffectspossiblyincreasedwhenalcoholgivenwith SSRIS ;increasedsedativeeffectwhenalcoholgivenwithl MIRTAZAPINE ,l TRICYCLIC - RELATEDANTIDEPRESSANTS orl TRICYCLICS  
 TRIANGLE Antiepileptics:alcoholpossiblyincreases CNS side-effectsofCARBAMAZEPINE;chronicheavyconsumptionofalcoholpossiblyreducesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;increasedsedativeeffectwhenalcoholgivenwithPHENOBARBITALorPRIMIDONE;increasedriskofblurredvisionwhenalcoholgivenwith RETIGABINE  
 TRIANGLE Antifungals: possibilityofdisulfiram-likereactionwhenalcoholgivenwith KETOCONAZOLE ;effectsofalcoholpossiblyenhancedby GRISEOFULVIN  
 TRIANGLE Antihistamines: increasedsedativeeffectwhenalcoholgivenwith ANTIHISTAMINES (possiblylesseffectwithnon-sedatingantihistamines) 
 TRIANGLE Antimuscarinics: increasedsedativeeffectwhenalcoholgivenwith HYOSCINE  
 TRIANGLE Antipsychotics: increasedsedativeeffectwhenalcoholgivenwith ANTIPSYCHOTICS  
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhenalcoholgivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Avanafil: possibleenhancedhypotensiveeffectwhenalcoholgivenwith AVANAFIL  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenalcoholgivenwith BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenalcoholgivenwith CALCIUM - CHANNELBLOCKERS ;plasmaconcentrationofalcoholpossiblyincreasedby VERAPAMIL  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenalcoholgivenwith CLONIDINE 
Cytotoxics: disulfiram-likereactionwhenalcoholgivenwith PROCARBAZINE ;avoidanceofalcoholadvisedbymanufacturerofl TRABECTEDIN 
Dapoxetine: increasedsedativeeffectwhenalcoholgivenwithl DAPOXETINE  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenalcoholgivenwith DIAZOXIDE  
 TRIANGLE Disulfiram: disulfiramreactionwhenalcoholgivenwith DISULFIRAM  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenalcoholgivenwith DIURETICS  
 TRIANGLE Dopaminergics: alcoholreducestoleranceto BROMOCRIPTINE  
 TRIANGLE Lipid-regulatingDrugs:avoidanceofalcoholadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Lofexidine: increasedsedativeeffectwhenalcoholgivenwith LOFEXIDINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenalcoholgivenwith METHYLDOPA  
 TRIANGLE Metoclopramide: absorptionofalcoholpossiblyincreasedby METOCLOPRAMIDE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenalcoholgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: increasedsedativeeffectwhenalcoholgivenwith BACLOFEN , METHOCARBAMOL or TIZANIDINE  
 TRIANGLE Nicorandil: alcoholpossiblyenhanceshypotensiveeffectof NICORANDIL  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenalcoholgivenwith NITRATES 
Paraldehyde: increasedsedativeeffectwhenalcoholgivenwithl PARALDEHYDE 
Retinoids: presenceofalcoholcausesetretinatetobeformedfroml ACITRETIN (increasedriskofteratogenicityinwomenofchild-bearingpotential) 
 TRIANGLE Sympathomimetics: alcoholpossiblyenhanceseffectsof METHYLPHENIDATE  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenalcoholgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEA ldesleukin 
 TRIANGLE ACE
 Inhibitors: enhancedhypotensiveeffectwhenaldesleukingivenwithACEINHIBITORS 
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenaldesleukingivenwithALPHA-BLOCKERS 
 TRIANGLE Angiotensin-II
 ReceptorAntagonists: enhancedhypotensiveeffectwhenaldesleukingivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS 
 TRIANGLE Antivirals:aldesleukinpossiblyincreasesplasmaconcentrationof INDINAVIR 
 TRIANGLE  Beta-blockers:enhancedhypotensiveeffectwhenaldesleukingivenwith BETA - BLOCKERS  
 TRIANGLE Calcium-channelBlockers:   enhancedhypotensiveeffectwhenaldesleukingivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine:  enhancedhypotensiveeffectwhenaldesleukingivenwith CLONIDINE 
Corticosteroids: manufacturerofaldesleukinadvisesavoidconcomitantusewithl  CO RTICOSTEROIDS  
Cytotoxics:  manufacturerofaldesleukinadvisesavoidconcomitantusewithl CISPLATIN ,l DACARBAZINE andl VINBLASTINE  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenaldesleukingivenwith DIAZOXIDE  
 TRIANGLE Diuretics:   enhancedhypotensiveeffectwhenaldesleukingivenwith DIURETICS  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenaldesleukingivenwith METHYLDOPA  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenaldesleukingivenwith MOXONIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenaldesleukingivenwith NITRATES  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenaldesleukingivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEA lemtuzumab
 Antipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuseAlendronic
 Acid see Bisphosphonates 
 Alfacalcidol see Vitamins 
 Alfentanil see Opioid 
 Analgesics 
 Alfuzosin see Alpha-blockers 
 Alimemazine see Antihistamines 
 Aliskirenl
 ACE Inhibitors:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenaliskirengivenwithl ACEINHIBITORS â€”avoidconcomitantuse 
 TRIANGLE Analgesics:  hypotensiveeffectofaliskirenpossiblyantagonisedby NSAIDS  
 lAngiotensin- IIR eceptor
 Antagonists: increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenaliskirengivenwithl ANGIOTENSIN - IIRECEPTORANTAGONISTS â€”avoidconcomitantuse;plasmaconcentrationofaliskirenpossiblyreducedby IRBESARTAN  
 TRIANGLE Antibacterials:  plasmaconcentrationofaliskirenreducedby RIFAMPICIN  
 TRIANGLE Anticoagulants:  increasedriskofhyperkalaemiawhenaliskirengivenwith HEPARINS  
 
Antifungals:  plasmaconcentrationofaliskirenincreasedby KETOCONAZOLE ;plasmaconcentrationofaliskirenincreasedbyl ITRACONAZOLE â€”avoidconcomitantuse 
 TRIANGLE Calcium-channelBlockers:plasmaconcentrationofaliskirenincreasedby VERAPAMIL  l
 Ciclosporin:  plasmaconcentrationofaliskirenincreasedbyl CICLOSPORIN â€”avoidconcomitantuse 
 TRIANGLE Diuretics:aliskirenreducesplasmaconcentrationof FUROSEMIDE ;increasedriskofhyperkalaemiawhenaliskirengivenwith POTASSIUM - SPARINGDIURETICSANDALDOSTERONEANTAGONISTS 
GrapefruitJuice: plasmaconcentrationofaliskirenreducedbyl GRAPEFRUITJUICE â€”avoidconcomitantuse 
 TRIANGLE PotassiumSalts: increasedriskofhyperkalaemiawhenaliskirengivenwith POTASSIUMSALTS
 Alitretinoin see Retinoids 
 Alkylating 
 Drugs see Bendamustine
,Busulfan,Carmustine,Cyclophosphamide,Estramustine,Ifosfamide,Lomustine,Melphalan,andThiotepa
 aAllopurinol 
 TRIANGLE ACEInhibitors:  manufacturersstatepossibleincreasedriskofleucopeniaandhypersensitivityreactionswhenallopurinolgivenwithACEINHIBITORSespeciallyinrenalimpairment 
 TRIANGLE Antibacterials:increasedriskofrashwhenallopurinolgivenwith AMOXICILLIN , AMPICILLIN orCO- AMOXICLAV  
 TRIANGLE Anticoagulants:allopurinolpossiblyenhancesanticoagulanteffectof COUMARINS  
 
Antivirals:  allopurinolincreasesplasmaconcentrationofl DIDANOSINE (riskoftoxicity)â€”avoidconcomitantuse
Azathioprine: allopurinolenhanceseffectsandincreasestoxicityofl AZATHIOPRINE (reducedoseofazathioprinetoonequarterofusualdose) 
 TRIANGLE Ciclosporin:allopurinolpossiblyincreasesplasmaconcentrationofCICLOSPORIN(riskofnephrotoxicity)lCytotoxics:avoidanceofallopurinoladvisedbymanufacturerofl CAPECITABINE ;allopurinolenhanceseffectsandincreasestoxicityofl MERCAPTOPURINE (reducedoseofmercaptopurinetoonequarterofusualdose) 
 TRIANGLE Diuretics:increasedriskofhypersensitivitywhenallopurinolgivenwith THIAZIDESANDRELATEDDIURETICS especiallyinrenalimpairment 
 TRIANGLE Theophylline: allopurinolpossiblyincreasesplasmaconcentrationof THEOPHYLLINE
 Almotriptan see 
5 HT 1-receptorAgonists(underHT)
 Alogliptin see Antidiabetics 
 Alpha
2-adrenoceptor
 Stimulants see Apraclonidine
,Brimonidine,Clonidine,andMethyldopaAlpha-blockers 
 TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenalpha-blockersgivenwithACEINHIBITORS 
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenalpha-blockersgivenwith ADRENERGICNEURONEBLOCKERS  
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenalpha-blockersgivenwith ALCOHOL ;increasedsedativeeffectwhenindoramingivenwithALCOHOL 
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenalpha-blockersgivenwith ALDESLEUKIN  lAnaesthetics,General: enhancedhypotensiveeffectwhenalpha-blockersgivenwithl GENERALANAESTHETICS  
 TRIANGLE Analgesics:hypotensiveeffectofalpha-blockersantagonisedbyNSAIDS 
 TRIANGLE Angiotensin-II
 ReceptorAntagonists: enhancedhypotensiveeffectwhenalpha-blockersgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS
Antidepressants: manufacturerofindoraminadvisesavoidconcomitantusewithl MAOIS ;enhancedhypotensiveeffectwhenalpha-blockersgivenwithMAOIS 
 lAntifungals:plasmaconcentrationofalfuzosinpossiblyincreasedbyKETOCONAZOLE;plasmaconcentrationoftamsulosinincreasedbylKETOCONAZOLE 
 TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenalpha-blockersgivenwith ANTIPSYCHOTICS  
 lAntivirals:plasmaconcentrationofdoxazosinandtamsulosinpossiblyincreasedby BOCEPREVIR â€”manufacturerofbocepreviradvisesavoidconcomitantuse;plasmaconcentrationofalfuzosinpossiblyincreasedbyl RITONAVIR â€”avoidconcomitantuse;avoidanceofalfuzosinadvisedbymanufacturerofl TELAPREVIR  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveandsedativeeffectswhenalpha-blockersgivenwith ANXIOLYTICSANDHYPNOTICS 
Avanafil: enhancedhypotensiveeffectwhenalpha-blockersgivenwithl AVANAFIL â€”whenpatientisstableonthealphablockerinitiateavanafilatthelowestpossibledoselBeta-blockers:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlBETA-BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosinlCalcium-channelBlockers:enhancedhypotensiveeffectwhenalpha-blockersgivenwithlCALCIUM-CHANNELBLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin;plasmaconcentrationoftamsulosinincreasedbyVERAPAMIL 
 TRIANGLE CardiacGlycosides: prazosinincreasesplasmaconcentrationof DIGOXIN  
 TRIANGLE Clonidine:enhancedhypotensiveeffectwhenalpha-blockersgivenwith CLONIDINEBNF 
Cobicistat: plasmaconcentrationofalfuzosinpossiblyincreasedbyl  CO BICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse  
 TRIANGLE Corticosteroids: hypotensiveeffectofalpha-blockersantagonisedby CORTICOSTEROIDS  
 TRIANGLE Cytotoxics: avoidanceofalfuzosinadvisedbymanufacturerof IDELALISIB  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenalpha-blockersgivenwith DIAZOXIDE  
 
Diuretics:  enhancedhypotensiveeffectwhenalpha-blockersgivenwithl DIURETICS ,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin 
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhenalpha-blockersgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE Methyldopa:  enhancedhypotensiveeffectwhenalpha-blockersgivenwith METHYLDOPA 
Moxisylyte: possiblesevereposturalhypotensionwhenalpha-blockersgivenwithl MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenalpha-blockersgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhenalpha-blockersgivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenalpha-blockersgivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofalpha-blockersantagonisedby OESTROGENS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenalpha-blockersgivenwith ALPROSTADIL 
Sildenafil: enhancedhypotensiveeffectwhenalpha-blockersgivenwithl SILDENAFIL (avoidalpha-blockersfor4hoursaftersildenafil)â€”whenpatientisstableonthealphablockerinitiatesildenafilatthelowestpossibledose
Sympathomimetics: avoidconcomitantuseoftolazolinewithl ADRENALINE ( EPINEPHRINE )orl DOPAMINE 
Tadalafil: enhancedhypotensiveeffectwhenalpha-blockersgivenwithl TADALAFIL â€”whenpatientisstableonthealphablockerinitiatetadalafilatthelowestpossibledose;enhancedhypotensiveeffectwhendoxazosingivenwithlTADALAFILâ€”manufactureroftadalafiladvisesavoidconcomitantuselUlcer-healing
 Drugs: effectsoftolazolineantagonisedbyl CIMETIDINE andl RANITIDINE 
Vardenafil: enhancedhypotensiveeffectwhenalpha-blockersgivenwithl VARDENAFIL â€”whenpatientisstableonthealphablockerinitiatevardenafilatthelowestpossibledoseâ€”separatedosesby6hours(exceptwithtamsulosin) 
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenalpha-blockersgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEA lpha-blockers(post-synaptic)seeAlpha-blockers
 Alprazolam see Anxiolyticsand 
 Hypnotics 
 Alprostadil see Prostaglandins 
 Aluminium 
 Hydroxide see Antacids 
Amantadine
 TRIANGLE Antipsychotics: increasedriskofextrapyramidalside-effectswhenamantadinegivenwith ANTIPSYCHOTICS  
 TRIANGLE Bupropion: increasedriskofside-effectswhenamantadinegivenwith BUPROPION 
Memantine: increasedriskof CNS toxicitywhenamantadinegivenwithl MEMANTINE (manufacturerofmemantineadvisesavoidconcomitantuse);effectsofdopaminergicspossiblyenhancedbyMEMANTINE 
 TRIANGLE Methyldopa:increasedriskofextrapyramidalside-effectswhenamantadinegivenwithMETHYLDOPA;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA 
 TRIANGLE Tetrabenazine: increasedriskofextrapyramidalside-effectswhenamantadinegivenwith TETRABENAZINEA mbrisentan 
 Amikacin see Aminoglycosides 
 Amiloride see Diuretics 
Aminoglycosides
 TRIANGLE Analgesics: plasmaconcentrationofamikacinandgentamicininneonatespossiblyincreasedby INDOMETACIN  
 
Antibacterials:  neomycinreducesabsorptionof PHENOXYMETHYLPENICILLIN ;increasedriskofnephrotoxicitywhenaminoglycosidesgivenwith COLISTIMETHATESODIUM or POLYMYXINS ;increasedriskofnephrotoxicityandototoxicitywhenaminoglycosidesgivenwith CAPREOMYCIN orl VANCOMYCIN ;possibleincreasedriskofnephrotoxicitywhenaminoglycosidesgivenwith CEPHALOSPORINS 
Anticoagulants: experienceinanticoagulantclinicssuggeststhat INR possiblyalteredwhenneomycin(givenforlocalactionongut)isgivenwithl COUMARINS orl PHENINDIONE  
 TRIANGLE Antidiabetics: neomycinpossiblyenhanceshypoglycaemiceffectof ACARBOSE ,alsoseverityofgastro-intestinaleffectsincreased 
 TRIANGLE Antifungals: increasedriskofnephrotoxicitywhenaminoglycosidesgivenwith AMPHOTERICIN  
 TRIANGLE Bisphosphonates: increasedriskofhypocalcaemiawhenaminoglycosidesgivenwith BISPHOSPHONATES  
 TRIANGLE CardiacGlycosides: gentamicinpossiblyincreasesplasmaconcentrationof DIGOXIN ;neomycinreducesabsorptionofDIGOXIN 
Ciclosporin:increasedriskofnephrotoxicitywhenaminoglycosidesgivenwithlCICLOSPORIN
Cytotoxics: neomycinpossiblyreducesabsorptionof METHOTREXATE ;neomycinreducesbioavailabilityof SORAFENIB ;increasedriskofnephrotoxicityandpossiblyofototoxicitywhenaminoglycosidesgivenwithl PLATINUMCOMPOUNDS  
 lDiuretics:increasedriskofotoxicitywhenaminoglycosidesgivenwithl LOOPDIURETICS  
 TRIANGLE Mannitol: manufactureroftobramycinadvisesavoidconcomitantusewith MANNITOL 
MuscleRelaxants: aminoglycosidesenhanceeffectsofl NON - DEPOLARISINGMUSCLERELAXANTS andl SUXAMETHONIUM 
Parasympathomimetics: aminoglycosidesantagoniseeffectsofl NEOSTIGMINE andl PYRIDOSTIGMINE 
Tacrolimus: increasedriskofnephrotoxicitywhenaminoglycosidesgivenwithl TACROLIMUS  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein BNF  
 TRIANGLE Vitamins: neomycinpossiblyreducesabsorptionof VITAMINAA minophylline 
 TRIANGLE Allopurinol: plasmaconcentrationofaminophyllinepossiblyincreasedby ALLOPURINOL  
 TRIANGLE Anaesthetics,General: increasedriskofconvulsionswhenaminophyllinegivenwith KETAMINE  
 TRIANGLE Anti-arrhythmics:aminophyllineantagonisesanti-arrhythmiceffectof ADENOSINE â€”manufacturerofadenosineadvisesavoidaminophyllinefor24hoursbeforeadenosine;plasmaconcentrationofaminophyllineincreasedby PROPAFENONE  
 lAntibacterials:plasmaconcentrationofaminophyllinepossiblyincreasedby CLARITHROMYCIN and ISONIAZID ;plasmaconcentrationofaminophyllineincreasedbyl ERYTHROMYCIN (alsoaminophyllinemayreduceabsorptionoforalerythromycin);plasmaconcentrationofaminophyllineincreasedbyl CIPROFLOXACIN andl NORFLOXACIN ;metabolismofaminophyllineacceleratedbyRIFAMPICIN(reducedplasmaconcentration);possibleincreasedriskofconvulsionswhenaminophyllinegivenwithl QUINOLONES 
Antidepressants: plasmaconcentrationofaminophyllineincreasedbyl FLUVOXAMINE (concomitantuseshouldusuallybeavoided,butwherenotpossiblehalveaminophyllinedoseandmonitorplasma-aminophyllineconcentration);plasmaconcentrationofaminophyllinepossiblyreducedby STJOHN â€™ SWORT 
Antifungals: plasmaconcentrationofaminophyllinepossiblyincreasedbyl FLUCONAZOLE andl KETOCONAZOLE  
 
Antivirals:  plasmaconcentrationofaminophyllinepossiblyincreasedby ACICLOVIR and VALACICLOVIR ;metabolismofaminophyllineacceleratedbyl RITON AV IR (reducedplasmaconcentration)  
 TRIANGLE AnxiolyticsandHypnotics: aminophyllinepossiblyreduceseffectsof BENZODIAZEPINES  
 TRIANGLE Caffeinecitrate: avoidanceofaminophyllineadvisedbymanufacturerof CAFFEINECITRATE  
 lCalcium-channelBlockers: plasmaconcentrationofaminophyllinepossiblyincreasedbyl CALCIUM - CHANNEL BLOCKERS  (enhancedeffect);plasmaconcentrationofaminophyllineincreasedby DILTIAZEM ;plasmaconcentrationofaminophyllineincreasedbyl VERAPAMIL (enhancedeffect) 
 TRIANGLE Corticosteroids: increasedriskofhypokalaemiawhenaminophyllinegivenwith CORTICOSTEROIDS  
 TRIANGLE Cytotoxics: plasmaconcentrationofaminophyllinepossiblyincreasedby METHOTREXATE 
Deferasirox: plasmaconcentrationofaminophyllineincreasedbyl DEFERASIROX (considerreducingdoseofaminophylline) 
 TRIANGLE Disulfiram: metabolismofaminophyllineinhibitedby DISULFIRAM (increasedriskoftoxicity) 
 TRIANGLE Diuretics: increasedriskofhypokalaemiawhenaminophyllinegivenwith ACETAZOLAMIDE , LOOPDIURETICS or THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE Doxapram: increased CNS stimulationwhenaminophyllinegivenwith DOXAPRAM 
Interferons: metabolismofaminophyllineinhibitedbyl INTERFERONALFA andl PEGINTERFERONALFA (considerreducingdoseofaminophylline) 
 TRIANGLE LeukotrieneReceptorAntagonists: plasmaconcentrationofaminophyllinepossiblyincreasedby ZAFIRLUKAST ,alsoplasmaconcentrationofzafirlukastreduced 
 TRIANGLE Lithium: aminophyllineincreasesexcretionof LITHIUM (reducedplasmaconcentration) 
 TRIANGLE Oestrogens: plasmaconcentrationofaminophyllineincreasedby OESTROGENS (considerreducingdoseofaminophylline) 
 TRIANGLE Pentoxifylline: plasmaconcentrationofaminophyllineincreasedby PENTOXIFYLLINE  
 TRIANGLE Roflumilast: avoidanceofaminophyllineadvisedbymanufacturerof ROFLUMILAST  
 TRIANGLE Sulfinpyrazone: plasmaconcentrationofaminophyllinereducedby SULFINPYRAZONE  
 TRIANGLE Sympathomimetics: manufacturerofaminophyllineadvisesavoidconcomitantusewith EPHEDRINE inchildren 
 TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhenaminophyllinegivenwithhighdosesof BETA 2 SYMPATHOMIMETICS  
 lUlcer-healing
 Drugs: metabolismofaminophyllineinhibitedbyl CIMETIDINE (increasedplasmaconcentration);absorptionofaminophyllinepossiblyreducedby SUCRALFATE (giveatleast2hoursapart) 
 TRIANGLE Vaccines: plasmaconcentrationofaminophyllinepossiblyincreasedby INFLUENZAVACCINE
 Aminosalicylates see individualdrugs 
 Amiodarone
 NOTEA miodaronehasalonghalf-life;thereisapotentialfordruginteractionstooccurforseveralweeks(orevenmonths)aftertreatmentwithithasbeenstopped 
 TRIANGLE AgalsidaseAlfaandBeta: amiodaronepossiblyinhibitseffectsof AGALSIDASEALFAANDBETA (manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) 
 TRIANGLE Anaesthetics,Local: increasedmyocardialdepressionwhenanti-arrhythmicsgivenwith BUPIVACAINE , LEVOBUPIVACAINE , PRILOCAINE or ROPIVACAINE  
Antibacterials: increasedriskofventriculararrhythmiaswhenamiodaronegivenwithparenterall ERYTHROMYCIN â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl LEVOFLOXACIN orl MOXIFLOXACIN â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwith SULFAMETHOXAZOLE and TRIMETHOPRIM (asco-trimoxazole)â€”manufacturerofamiodaroneadvisesavoidconcomitantuseofco-trimoxazole;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl DELAMANID ;avoidanceofamiodaroneadvisedbymanufacturerof FIDAXOMICIN ;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwithl TELITHROMYCIN 
Anticoagulants: amiodaroneinhibitsmetabolismofl COUMARINS andl PHENINDIONE (enhancedanticoagulanteffect);amiodaroneincreasesplasmaconcentrationofl DABIGATRAN (seeunderDabigatranEtexilate,p117)
Antidepressants: avoidanceofamiodaroneadvisedbymanufacturerofl CITALOPRAM andl ESCITALOPRAM (riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl TRICYCLICS â€”avoidconcomitantuselAntiepileptics:amiodaroneinhibitsmetabolismoflFOSPHENYTOINandlPHENYTOIN(increasedplasmaconcentration)
Antihistamines: increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: avoidanceofamiodaroneadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE (riskofventriculararrhythmias);avoidanceofamiodaroneadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl CHLOROQUINE ,l HYDROXYCHLOROQUINE ,l MEFLOQUINE orl QUININE â€”avoidconcomitantuse
Antimuscarinics: increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl TOLTERODINE 
Antipsychotics: increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongthe QT intervalgivenwithl ANTIPSYCHOTICS thatprolongtheQTinterval;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl BENPERIDOL â€”manufacturerofbenperidoladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl AMISULPRIDE ,l DROPERIDOL ,l HALOPERIDOL ,l PHENOTHIAZINES ,l PIMOZIDE orl ZUCLOPENTHIXOL â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl SULPIRIDE  
 lAntivirals:plasmaconcentrationofamiodaronepossiblyincreasedbyl ATAZANAVIR ;possibleincreasedriskofbradycardiawhenamiodaronegivenwithl DACLATASVIR andl SIMEPREVIR (withsofosbuvir)â€”seeunderAmiodarone,p88;plasmaconcentrationofamiodaronepossiblyincreasedbyl FOSAMPRENAVIR (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);plasmaconcentrationofamiodaronepossiblyincreasedbyl INDINAVIR â€”avoidconcomitantuse;plasmaconcentrationofamiodaroneincreasedbylRITONAVIR(increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl SAQUINAVIR â€”avoidconcomitantuse;possibleincreasedriskofbradycardiawhenamiodaronegivenwithl SOFOSBUVIR â€”seeunderAmiodarone,p88;avoidanceofamiodaroneadvisedbymanufacturerofl TELAPREVIR (riskofventriculararrhythmias)
Atomoxetine: increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl ATOMOXETINE  
 lBeta-blockers:increasedriskofbradycardia,AVblockandmyocardialdepressionwhenamiodaronegivenwithlBETA-BLOCKERS;increasedmyocardialdepressionwhenanti- BNF 
 
CardiacGlycosides:  amiodaroneincreasesplasmaconcentrationofl DIGOXIN (halvedoseofdigoxin)  
 TRIANGLE Ciclosporin: amiodaronepossiblyincreasesplasmaconcentrationof CICLOSPORIN 
Cobicistat: plasmaconcentrationofamiodaronepossiblyincreasedbyl  CO BICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Colchicine: amiodaronepossiblyincreasesriskofl COLCHICINE toxicity
 
Cytotoxics:   amiodaronepossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationofamiodaroneby6to12hours;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwithl BOSUTINIB ;amiodaronepossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofamiodaroneadvisedbymanufacturerof IDELALISIB ;possibleincreasedriskofventriculararrhythmiaswhenamiodaronegivenwithl VANDETANIB â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl ARSENICTRIOXIDE  
 TRIANGLE Diuretics:   increasedcardiactoxicitywithamiodaroneifhypokalaemiaoccurswith ACETAZOLAMIDE , LOOP DIURETICS  or THIAZIDESANDRELATEDDIURETICS ;amiodaroneincreasesplasmaconcentrationof EPLERENONE (reducedoseofeplerenone)
Fingolimod: possibleincreasedriskofbradycardiawhenamiodaronegivenwithl FINGOLIMOD  
 TRIANGLE GrapefruitJuice: plasmaconcentrationofamiodaroneincreasedby GRAPEFRUITJUICE 
Ivabradine: increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl IVABRADINE  
 lLipid-regulatingDrugs:  increasedriskofmyopathywhenamiodaronegivenwithl SIMVASTATIN (seeunderSimvastatin,p181);separatingadministrationfromamiodaroneby12hoursadvisedbymanufacturerof LOMITAPIDE 
Lithium: manufacturerofamiodaroneadvisesavoidconcomitantusewithl LITHIUM (riskofventriculararrhythmias) 
 TRIANGLE Orlistat: plasmaconcentrationofamiodaronepossiblyreducedby ORLISTAT  l
 PentamidineIsetionate:  increasedriskofventriculararrhythmiaswhenamiodaronegivenwithl PENTAMIDINEISETIONATE â€”avoidconcomitantuse 
 TRIANGLE ThyroidHormones: amiodaronecanaffectserumconcentrationsof THYROIDHORMONES â€”monitorthyroidfunctionclosely 
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofamiodaroneincreasedby CIMETIDINE
 Amisulpride see Antipsychotics 
 Amitriptyline see Antidepressants
,Tricyclic
 Amlodipine see Calcium-channel 
 Blockers 
 Amoxicillin see Penicillins 
 Amphotericin
 NOTEC losemonitoringrequiredwithconcomitantadministrationofnephrotoxicdrugsorcytotoxics 
 TRIANGLE Antibacterials:  increasedriskofnephrotoxicitywhenamphotericingivenwith AMINOGLYCOSIDES or POLYMYXINS ;possibleincreasedriskofnephrotoxicitywhenamphotericingivenwith VANCOMYCIN  
 TRIANGLE Antifungals: amphotericinreducesrenalexcretionandincreasescellularuptakeof FLUCYTOSINE (toxicitypossiblyincreased);effectsofamphotericinpossiblyantagonisedby IMIDAZOLES and TRIAZOLES ;plasmaconcentrationofamphotericinpossiblyincreasedby MICAFUNGIN  
Ciclosporin: increasedriskofnephrotoxicitywhenamphotericingivenwithlCICLOSPORIN
Corticosteroids: increasedriskofhypokalaemiawhenamphotericingivenwithl CORTICOSTEROIDS â€”avoidconcomitantuseunlesscorticosteroidsneededtocontrolreactionslCytotoxics:increasedriskofventriculararrhythmiaswhenamphotericingivenwithlARSENICTRIOXIDE 
 TRIANGLE Diuretics:increasedriskofhypokalaemiawhenamphotericingivenwithLOOPDIURETICSorTHIAZIDESANDRELATEDDIURETICS 
 TRIANGLE PentamidineIsetionate:possibleincreasedriskofnephrotoxicitywhenamphotericingivenwithPENTAMIDINEISETIONATE
SodiumStibogluconate: possibleincreasedriskofarrhythmiaswhenamphotericingivenafterl SODIUMSTIBOGLUCONATE â€”manufacturerofsodiumstibogluconateadvisesgiving14daysapart
Tacrolimus: increasedriskofnephrotoxicitywhenamphotericingivenwithl TACROLIMUS
 Ampicillin see Penicillins 
 Anabolic 
 Steroids 
 
Anticoagulants: anabolicsteroidsenhanceanticoagulanteffectofl COUMARINS andl PHENINDIONE  
 TRIANGLE Antidiabetics: anabolicsteroidspossiblyenhancehypoglycaemiceffectof ANTIDIABETICSA naesthetics,General NOTES eealsoSurgeryandLong-termMedication,underGeneralAnaesthesiain BNF  
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith ACEINHIBITORS 
AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithl ADRENERGICNEURONEBLOCKERS  
 lAlpha-blockers:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithl ALPHA -BLOCKERS 
 TRIANGLE Aminophylline: increasedriskofconvulsionswhenketaminegivenwith AMINOPHYLLINE  
 TRIANGLE Analgesics: metabolismofetomidateinhibitedby FENTANYL (considerreducingdoseofetomidate);effectsofthiopentalpossiblyenhancedby ASPIRIN ;effectsofintravenousgeneralanaestheticsandvolatileliquidgeneralanaestheticspossiblyenhancedby OPIOIDANALGESICS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antibacterials:increasedriskofhepatotoxicitywhenisofluranegivenwith ISONIAZID ;effectsofthiopentalenhancedby SULFONAMIDES ;hypersensitivity-likereactionscanoccurwhengeneralanaestheticsgivenwithintravenousVANCOMYCIN 
 TRIANGLE Antidepressants: increasedriskofarrhythmiasandhypotensionwhengeneralanaestheticsgivenwith TRICYCLICS 
Antipsychotics: enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithl ANTIPSYCHOTICS ;effectsofthiopentalenhancedby DROPERIDOL  
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhengeneralanaestheticsgivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithBETA-BLOCKERS 
 lCalcium-channelBlockers:enhancedhypotensiveeffectwhengeneralanaestheticsorisofluranegivenwith CALCIUM - CHANNELBLOCKERS ;generalanaestheticsenhancehypotensiveeffectoflVERAPAMIL(alsoAVdelay) 
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith CLONIDINE  
 lCytotoxics:nitrousoxideincreasesantifolateeffectofl METHOTREXATE â€”avoidconcomitantuse 
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith DIAZOXIDE  
 TRIANGLE Diuretics:enhancedhypotensiveeffectwhengeneralanaestheticsgivenwithDIURETICS
Dopaminergics: increasedriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwithlCO- BENELDOPA ,lCO- CARELDOPA orl LEVODOPA 
Doxapram: increasedriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwithl DOXAPRAM (avoiddoxapramforatleast10minutesaftervolatileliquidgeneralanaesthetics)
Memantine: increasedriskof CNS toxicitywhenketaminegivenwithl MEMANTINE (manufacturerofmemantineadvisesavoidconcomitantuse)  
 TRIANGLE  Methyldopa:  enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith METHYLDOPA  
 TRIANGLE Metoclopramide: effectsofthiopentalenhancedby METOCLOPRAMIDE  
 TRIANGLE Moxonidine:  enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith MOXONIDINE  l
 MuscleRelaxants:  increasedriskofmyocardialdepressionandbradycardiawhenpropofolgivenwithl SUXAMETHONIUM ;volatileliquidgeneralanaestheticsenhanceeffectsof NON - DEPOLARISINGMUSCLERELAXANTS andSUXAMETHONIUM;ketamineenhanceseffectsof ATRACURIUM  
 TRIANGLE Nitrates:  enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith NITRATES  
 TRIANGLE Oxytocin: oxytociceffectpossiblyreduced,alsoenhancedhypotensiveeffectandriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwith OXYTOCIN 
Sympathomimetics: manufacturerofisofluraneadvisesavoidconcomitantusewithl SYMPATHOMIMETICS (riskofventriculararrhythmias);increasedriskofarrhythmiaswhenvolatileliquidgeneralanaestheticsgivenwithl ADRENALINE ( EPINEPHRINE )orl NORADRENALINE ( NOREPINEPHRINE );increasedriskofhypertensionwhenvolatileliquidgeneralanaestheticsgivenwithl METHYLPHENIDATE  
 TRIANGLE Theophylline: increasedriskofconvulsionswhenketaminegivenwith THEOPHYLLINE  
 TRIANGLE VasodilatorAntihypertensives:  enhancedhypotensiveeffectwhengeneralanaestheticsgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEA naesthetics,General(intravenous)seeAnaesthetics,GeneralAnaesthetics,General(volatileliquids)seeAnaesthetics,Genera
 lAnaesthetics,
 Local see Bupivacaine
,Chloroprocaine,Levobupivacaine,Lidocaine,Prilocaine,andRopivacaineAnagrelidelCilostazol: manufacturerofanagrelideadvisesavoidconcomitantusewithl CILOSTAZOL  
 lPhosphodiesteraseType-3Inhibitors:  manufacturerofanagrelideadvisesavoidconcomitantusewithl ENOXIMONE andl MILRINONEA nakinra
Cytotoxics: avoidconcomitantuseofanakinrawithl ADALIMUMAB ,l CERTOLIZUMABPEGOL ,l GOLIMUMAB orl INFLIXIMAB 
Etanercept: avoidconcomitantuseofanakinrawithl ETANERCEPT 
Vaccines: riskofgeneralisedinfectionswhenanakinragivenwithlivel VACCINES â€”avoidconcomitantuse
 Analgesics see Aspirin
,Nefopam, NSAID s,OpioidAnalgesics,andParacetamolAngiotensin-  II R eceptorAntagonistsl ACE Inhibitors:increasedriskofhyperkalaemia,hypotension,andimpairedrenalfunctionwhenangiotensin-IIreceptorantagonistsgivenwithl ACEINHIBITORS â€”avoidconcomitantuse 
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith AL CO HOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith ALDESLEUKIN 
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith ALPHA -BLOCKERS 
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics: increasedriskofrenalimpairmentwhenangiotensin-IIreceptorantagonistsgivenwith NSAIDS ,alsohypotensiveeffectantagonised 
 TRIANGLE Antibacterials: plasmaconcentrationoflosartananditsactivemetabolitereducedby RIFAMPICIN ;possibleincreasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwith TRIMETHOPRIM  
 TRIANGLE Anticoagulants: increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwith HEPARINS  
 TRIANGLE Antidepressants: hypotensiveeffectofangiotensin-IIreceptorantagonistspossiblyenhancedby MAOIS  
 TRIANGLE Antipsychotics: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith ANTIPSYCHOTICS  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith CALCIUM - CHANNELBLOCKERS 
Ciclosporin: increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithl CICLOSPORIN  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith CLONIDINE  
 TRIANGLE Corticosteroids: hypotensiveeffectofangiotensin-IIreceptorantagonistsantagonisedby CORTICOSTEROIDS  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith DIAZOXIDE 
Diuretics: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithl DIURETICS ;increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithl POTASSIUM - SPARINGDIURETICSANDALDOSTERONEANTAGONISTS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA 
Lithium: angiotensin-IIreceptorantagonistsreduceexcretionofl LITHIUM (increasedplasmaconcentration) 
 TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithMETHYLDOPA 
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith MOXISYLYTE  
 TRIANGLE Moxonidine:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithMOXONIDINE 
 TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithNITRATES 
 TRIANGLE Oestrogens: hypotensiveeffectofangiotensin-IIreceptorantagonistsantagonisedby OESTROGENS 
PotassiumSalts: increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwithl POTASSIUMSALTS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwith ALPROSTADIL  
 TRIANGLE Tacrolimus: increasedriskofhyperkalaemiawhenangiotensin-IIreceptorantagonistsgivenwith TACROLIMUS  
 TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenangiotensin-IIreceptorantagonistsgivenwithHYDRALAZINE,MINOXIDILorSODIUMNITROPRUSSIDEAntacids NOTEA ntacidsshouldpreferablynotbetakenatthesametimeasotherdrugssincetheymayimpairabsorption 
 TRIANGLE ACEInhibitors:antacidspossiblyreduceabsorptionofACEINHIBITORS;antacidsreduceabsorptionof CAPTOPRIL , ENALAPRIL and FOSINOPRILBNF 
 TRIANGLE Analgesics: antacidspossiblyreduceabsorptionof ACEMETACIN ;alkalineurineduetosomeantacidsincreasesexcretionof ASPIRIN  
 TRIANGLE Anthelmintics: sodiumbicarbonateincreasestheexcretionof  DI ETHYLCARBAMAZINE  
 TRIANGLE Antibacterials: antacidsreduceabsorptionof AZITHROMYCIN , CEFACLOR , CIPR OFLOXACIN  , ISONIAZID , LEVOFLOXACIN , MOXIFLOXACIN , NORFLOXACIN ,OFLOXACIN, RIFAMPICIN and TETRACYCLINES ;avoidconcomitantuseofantacidswith METHENAMINE ;oralmagnesiumsalts(asmagnesiumtrisilicate)reduceabsorptionof NITROFURANTOIN  
 TRIANGLE Antiepileptics: antacidsreduceabsorptionof FOS PHENYTOIN  , GABAPENTIN andPHENYTOIN 
 TRIANGLE Antifungals: antacidsreduceabsorptionof ITRACONAZOLE and KETOCONAZOLE  
 TRIANGLE Antihistamines: antacidsreduceabsorptionof FEXOFENADINE  
 TRIANGLE Antimalarials: antacidsreduceabsorptionof CHLOROQUINE and HYDROXYCHLOROQUINE ;oralmagnesiumsalts(asmagnesiumtrisilicate)reduceabsorptionof PROGUANIL  
 TRIANGLE Antipsychotics: antacidsreduceabsorptionof PHENOTHIAZINES and SULPIRIDE  
 TRIANGLE Antivirals: antacidsreduceabsorptionof ATAZANAVIR (giveatleast2hoursbeforeor1hourafterantacids);aluminiumhydroxidereducesabsorptionof DOLUTEGRAVIR â€”manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteraluminiumhydroxide;oralmagnesiumsaltsreduceabsorptionofDOLUTEGRAVIRâ€”manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteroralmagnesiumsalts;aluminiumhydroxidereducesabsorptionof ELVITEGRAVIR (giveatleast4hoursapart);oralmagnesiumsaltsreduceabsorptionofELVITEGRAVIR(giveatleast4hoursapart);aluminiumhydroxidereducesplasmaconcentrationof RALTEGRAVIR â€”manufacturerofraltegraviradvisesavoidconcomitantuse;oralmagnesiumsaltsreduceplasmaconcentrationofRALTEGRAVIRâ€”manufacturerofraltegraviradvisesavoidconcomitantuse;manufacturerofrilpivirineadvisesgiveantacids2hoursbeforeor4hoursafter RILPIVIRINE ;antacidsreduceabsorptionof TIPRANAVIR (giveatleast2hoursapart) 
 TRIANGLE BileAcids: antacidspossiblyreduceabsorptionof BILEACIDS  
 TRIANGLE Bisphosphonates: antacidsreduceabsorptionof BISPHOSPHONATES  
 TRIANGLE CardiacGlycosides: antacidspossiblyreduceabsorptionof DIGOXIN  
 TRIANGLE Corticosteroids: antacidsreduceabsorptionof DEFLAZACORT 
Cytotoxics: aluminiumhydroxideandoralmagnesiumsaltspossiblyreduceabsorptionof ESTRAMUSTINE â€”manufacturerofestramustineadvisesavoidconcomitantadministration;separatingadministrationwithantacidsbyabout12hoursadvisedbymanufacturerof BOSUTINIB ;antacidspossiblyreduceplasmaconcentrationofl ERLOTINIB â€”giveantacidsatleast4hoursbeforeor2hoursaftererlotinib 
 TRIANGLE Deferasirox: antacidscontainingaluminiumpossiblyreduceabsorptionof DEFERASIROX (manufacturerofdeferasiroxadvisesavoidconcomitantuse) 
 TRIANGLE Deferiprone: antacidscontainingaluminiumpossiblyreduceabsorptionof DEFERIPRONE (manufacturerofdeferiproneadvisesavoidconcomitantuse) 
 TRIANGLE Dipyridamole: antacidspossiblyreduceabsorptionof DIPYRIDAMOLE  
 TRIANGLE Eltrombopag: antacidsreduceabsorptionof ELTROMBOPAG (giveatleast4hoursapart) 
 TRIANGLE Folates: antacidspossiblyreduceabsorptionof FOLICACID (manufactureroffolicacidadvisesgiveatleast2hoursapart) 
 TRIANGLE IronSalts: oralmagnesiumsalts(asmagnesiumtrisilicate)reduceabsorptionoforal IRONSALTS  
 TRIANGLE Lipid-regulatingDrugs:  antacidsreduceabsorptionof ROSUVASTATIN  
 TRIANGLE Lithium: sodiumbicarbonateincreasesexcretionof LITHIUM (reducedplasmaconcentration) 
 TRIANGLE Mycophenolate: antacidsreduceabsorptionof MYCOPHENOLATE  
 TRIANGLE Penicillamine: antacidsreduceabsorptionof PENICILLAMINE  
 TRIANGLE Riociguat: antacidsreduceabsorptionof RIOCIGUAT (giveatleast2hoursbeforeor1hourafterriociguat) 
 TRIANGLE Sympathomimetics: aluminiumhydroxidepossiblyincreasesabsorptionof PSEUDOEPHEDRINE  
 TRIANGLE ThyroidHormones: antacidspossiblyreduceabsorptionof LEVOTHYROXINE  
 TRIANGLE Ulcer-healingDrugs:antacidspossiblyreduceabsorptionof LANSOPRAZOLE
 Antazoline see Antihistamines 
 Anthelmintics see individualdrugs 
 Anthrax 
 Vaccine see Vaccines 
 Anti-DImmunoglobulins see Immunoglobulins 
 Anti
-arrhythmicsseeAdenosine,Amiodarone,Disopyramide,Dronedarone,Flecainide,Lidocaine,andPropafenone
 Antibacterials see individualdrugs 
 Antibiotics
(cytotoxic)seeBleomycin,Doxorubicin,Epirubicin,Idarubicin,Mitomycin,Mitoxantrone,andPixantrone
 Anticoagulants see Apixaban
,Argatroban,Bivalirudin,Coumarins,Dabigatran,Danaparoid,Fondaparinux,Heparins,Phenindione,andRivaroxaban
 Antidepressants see Agomelatine
;Antidepressants, SSRI ;Antidepressants,Tricyclic;Antidepressants,Tricyclic(related); MAOI s;Mirtazapine;Moclobemide;Reboxetine;StJohnâ€™sWort;VenlafaxineAntidepressants,NoradrenalineRe-uptake
 Inhibitors see Reboxetine 
 Antidepressants
, SSRINOT
 E see also 
Dapoxetine
Aminophylline: fluvoxamineincreasesplasmaconcentrationofl AMINOPHYLLINE (concomitantuseshouldusuallybeavoided,butwherenotpossiblehalveaminophyllinedoseandmonitorplasma-aminophyllineconcentration) 
 TRIANGLE Anaesthetics,Local: fluvoxamineinhibitsmetabolismof ROPIVACAINE â€”avoidprolongedadministrationofropivacaine
Analgesics: increasedriskofbleedingwhenSSRIsgivenwithl NSAIDS orlASPIRIN;possibleincreasedserotonergiceffectswhenSSRIsgivenwith FENTANYL ;fluoxetine,fluvoxamine,paroxetineandsertralinepossiblyincreaseplasmaconcentrationof METHADONE ;increasedriskof CNS toxicitywhenSSRIsgivenwithl TRAMADOL  
 lAnti-arrhythmics:manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl AMIODARONE (riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl DISOPYRAMIDE (riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl DRONEDARONE (riskofventriculararrhythmias);fluoxetineincreasesplasmaconcentrationof FLECAINIDE ;fluoxetineandparoxetinepossiblyinhibitmetabolismof PROPAFENONE 
Antibacterials: manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithintravenousl ERYTHROMYCIN (riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithlMOXIFLOXACIN(riskofventriculararrhythmias);possibleincreasedriskofventriculararrhythmiaswhencitalopramgivenwithl TELITHROMYCIN 
Anticoagulants: SSRIspossiblyenhanceanticoagulanteffectofl COUMARINS ;possibleincreasedriskofbleedingwhenSSRIsgivenwithl DABIGATRAN 
Antidepressants: avoidanceoffluvoxamineadvisedbymanufacturerofl REBOXETINE ;possibleincreasedserotonergiceffectswhenSSRIsgivenwith DULOXETINE ;fluvoxamineinhibitsmetabolismoflDULOXETINEâ€”avoidconcomitantuse;citalopram,escitalopram,fluvoxamine,paroxetineorsertralineshouldnotbestarteduntil2weeksafterstoppingl MAOIS ,alsoMAOIsshouldnotbestarteduntilatleast1weekafterstoppingcitalopram,escitalopram,fluvoxamine,paroxetineorsertraline;fluoxetineshouldnot
Antidepressants, SSRI  
Antiepileptics: SSRIsantagoniseanticonvulsanteffectofl ANTIEPILEPTICS (convulsivethresholdlowered);fluoxetineandfluvoxamineincreaseplasmaconcentrationofl CARBAMAZEPINE ;fluoxetineandfluvoxamineincreaseplasmaconcentrationofl FOS PHENYTOIN  ;plasmaconcentrationofsertralinepossiblyreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofparoxetinereducedbyFOSPHENYTOIN, PHENOBARBITAL ,PHENYTOINand PRIMIDONE ;fluoxetineandfluvoxamineincreaseplasmaconcentrationoflPHENYTOIN  
 TRIANGLE Antifungals: plasmaconcentrationofparoxetinepossiblyincreasedby TERBINAFINE 
Antihistamines: manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl MIZOLASTINE (riskofventriculararrhythmias);antidepressanteffectofSSRIspossiblyantagonisedby CYPROHEPTADINE 
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE ;possibleincreasedriskofventriculararrhythmiaswhencitalopramorescitalopramgivenwithlARTEMETHERWITHLUMEFANTRINEâ€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhencitalopramorescitalopramgivenwithlARTENIMOLWITHPIPERAQUINEâ€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhencitalopramandescitalopramgivenwithl CHLOROQUINE ;possibleincreasedriskofventriculararrhythmiaswhencitalopramorescitalopramgivenwithl QUININE â€”avoidconcomitantuse 
 TRIANGLE Antimuscarinics: paroxetineincreasesplasmaconcentrationof DARIFENACIN and PROCYCLIDINE 
Antipsychotics: avoidanceoffluoxetine,fluvoxamineandsertralineadvisedbymanufacturerofl DROPERIDOL (riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl HALOPERIDOL (riskofventriculararrhythmias);fluoxetineincreasesplasmaconcentrationofl CLOZAPINE ,lHALOPERIDOLand RISPERIDONE ;fluvoxaminepossiblyincreasesplasmaconcentrationof ASENAPINE andHALOPERIDOL;paroxetineinhibitsmetabolismof PERPHENAZINE (reducedoseofperphenazine);fluoxetineandparoxetinepossiblyincreaseplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);plasmaconcentrationofparoxetinepossiblyincreasedbyASENAPINE;fluvoxamine,paroxetineandsertralineincreaseplasmaconcentrationoflCLOZAPINE;citaloprampossiblyincreasesplasmaconcentrationofCLOZAPINE(increasedriskoftoxicity);fluvoxamineincreasesplasmaconcentrationof OLANZAPINE ;manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl PHENOTHIAZINES (riskofventriculararrhythmias);manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl PIMOZIDE (riskofventriculararrhythmias);SSRIspossiblyincreaseplasmaconcentrationoflPIMOZIDE(increasedriskofventricularAntidepressants,SSRI 
Antivirals: plasmaconcentrationofparoxetineandsertralinepossiblyreducedby DARUN AV IR ;plasmaconcentrationofSSRIspossiblyincreasedbyl RITONAVIR ;plasmaconcentrationofparoxetinepossiblyreducedbyRITONAVIR
AnxiolyticsandHypnotics: fluoxetineincreasesplasmaconcentrationof ALPRAZOLAM ;fluvoxamineincreasesplasmaconcentrationofsome BENZODIAZEPINES ;fluvoxamineincreasesplasmaconcentrationofl MELATONIN â€”avoidconcomitantuse;sedativeeffectspossiblyincreasedwhensertralinegivenwith ZOLPIDEM  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE ;fluoxetineandparoxetinepossiblyinhibitmetabolismofATOMOXETINE 
 lBeta-blockers:citalopramandescitalopramincreaseplasmaconcentrationof METOPROLOL ;paroxetinepossiblyincreasestheplasmaconcentrationoflMETOPROLOLâ€”increasedriskofAVblock(manufacturerofparoxetineadvisesavoidconcomitantuseincardiacinsufficiency);fluvoxamineincreasesplasmaconcentrationof PROPRANOLOL ;increasedriskofventriculararrhythmiaswhencitalopramgivenwithl SOTALOL â€”avoidconcomitantuse;manufacturerofescitalopramadvisesavoidconcomitantusewithlSOTALOL(riskofventriculararrhythmias) 
 TRIANGLE Bupropion: plasmaconcentrationofcitaloprampossiblyincreasedby BUPROPION  
 TRIANGLE Calcium-channelBlockers: fluoxetinepossiblyinhibitsmetabolismof NIFEDIPINE (increasedplasmaconcentration)
Clopidogrel: fluoxetineandfluvoxaminepossiblyreduceantiplateleteffectofl CLOPIDOGREL 
Dapoxetine: possibleincreasedriskofserotonergiceffectswhenSSRIsgivenwithl DAPOXETINE (manufacturerofdapoxetineadvisesSSRIsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingSSRIs)
Dopaminergics: increasedriskofCNStoxicitywhenSSRIsgivenwithl RASAGILINE ;fluvoxamineshouldnotbestarteduntil2weeksafterstoppinglRASAGILINE;fluoxetineshouldnotbestarteduntil2weeksafterstoppinglRASAGILINE,alsorasagilineshouldnotbestarteduntilatleast5weeksafterstoppingfluoxetine;avoidanceofcitalopramandescitalopramadvisedbymanufacturerof SELEGILINE ;increasedriskofhypertensionandCNSexcitationwhenfluvoxamineorsertralinegivenwithlSELEGILINE(selegilineshouldnotbestarteduntil1weekafterstoppingfluvoxamineorsertraline,avoidfluvoxamineorsertralinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenparoxetinegivenwithlSELEGILINE(selegilineshouldnotbestarteduntil2weeksafterstoppingparoxetine,avoidparoxetinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenfluoxetinegivenwithlSELEGILINE(selegilineshouldnotbestarteduntil5weeksafterstoppingfluoxetine,avoidfluoxetinefor2weeksafterstoppingselegiline) 
 TRIANGLE GrapefruitJuice: plasmaconcentrationofsertralinepossiblyincreasedby GRAPEFRUITJUICE  lHormone
 Antagonists:  fluoxetineandparoxetinepossiblyinhibitmetabolismofl TAMOXIFEN toactivemetabolite(avoidconcomitantuse)l5 HT 1-receptor
 Agonists: increasedriskofCNStoxicitywhencitalopramgivenwithl5HT1 AGONISTS (manufacturerofcitalopramadvisesavoidconcomitantuse);fluvoxamineinhibitsthemetabolismof FROVATRIPTAN ;possibleincreasedserotonergiceffectswhenSSRIsgivenwith NARATRIPTAN ;CNStoxicityreportedwhensertralinegivenwith SUMATRIPTAN ;increasedriskofCNStoxicitywhencitalopram,escitalopram,fluoxetine,fluvoxamineorparoxetinegivenwithlSUMATRIPTAN;fluvoxaminepossiblyinhibitsmetabolismof ZOLMITRIPTAN (reducedoseofzolmitriptan) 
 TRIANGLE 5HT3-receptorAntagonists:possibleincreasedserotonergiceffectswhenSSRIsgivenwith5HT3 ANTAGONISTSBNF 
 TRIANGLE  Lipid-regulatingDrugs:  separatingadministrationfromfluoxetineandfluvoxamineby12hoursadvisedbymanufacturerof LOMITAPIDE 
Lithium: Increasedriskof CNS effectswhenSSRIsgivenwithl LITHIUM (lithiumtoxicityreported)
Methylthioninium: riskofCNStoxicitywhenSSRIsgivenwithl METHYLTHIONINIUM â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) 
 TRIANGLE Metoclopramide: CNStoxicityreportedwhenSSRIsgivenwith METOCLOPRAMIDE 
MuscleRelaxants: fluvoxamineincreasesplasmaconcentrationofl TIZANIDINE (increasedriskoftoxicity)â€”avoidconcomitantuse 
 TRIANGLE Parasympathomimetics: paroxetineincreasesplasmaconcentrationof GALANTAMINE 
PentamidineIsetionate: manufacturerofcitalopramandescitalopramadvisesavoidconcomitantusewithl PENTAMIDINEISETIONATE (riskofventriculararrhythmias)
Pirfenidone: fluvoxamineincreasesplasmaconcentrationofl PIRFENIDONE â€”manufacturerofpirfenidoneadvisesavoidconcomitantuse
Pomalidomide: fluvoxamineincreasesplasmaconcentrationofl POMALIDOMIDE  
 TRIANGLE Ranolazine: paroxetineincreasesplasmaconcentrationof RANOLAZINE  
 TRIANGLE Roflumilast: fluvoxamineinhibitsthemetabolismof ROFLUMILAST  
 TRIANGLE Sympathomimetics: metabolismofSSRIspossiblyinhibitedby METHYLPHENIDATE 
Theophylline: fluvoxamineincreasesplasmaconcentrationofl THEOPHYLLINE (concomitantuseshouldusuallybeavoided,butwherenotpossiblehalvetheophyllinedoseandmonitorplasma-theophyllineconcentration) 
 TRIANGLE Ticagrelor: possibleincreasedriskofbleedingwhencitalopram,paroxetineorsertralinegivenwith TICAGRELOR  
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofcitalopram,escitalopramandsertralineincreasedby CIMETIDINE ;fluvoxaminepossiblyincreasesplasmaconcentrationof LANSOPRAZOLE ;plasmaconcentrationofescitalopramincreasedby OMEPRAZOLEA ntidepressants,SSRI(related)seeDuloxetineandVenlafaxineAntidepressants,Tricyclic 
 TRIANGLE AdrenergicNeuroneBlockers: tricyclicsantagonisehypotensiveeffectof ADRENERGICNEURONEBLOCKERS 
Alcohol: increasedsedativeeffectwhentricyclicsgivenwithl ALCOHOL  
 TRIANGLE Alpha2-adrenoceptor
 Stimulants: avoidanceoftricyclicsadvisedbymanufacturerof APRA CLONIDINE  and BRIMONIDINE  
 TRIANGLE Anaesthetics,General: increasedriskofarrhythmiasandhypotensionwhentricyclicsgivenwith GENERALANAESTHETICS 
Analgesics: increasedriskofCNStoxicitywhentricyclicsgivenwithl TRAMADOL ;side-effectspossiblyincreasedwhentricyclicsgivenwith NEFOPAM ;sedativeeffectspossiblyincreasedwhentricyclicsgivenwith OPIOIDANALGESICS  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhentricyclicsgivenwithl AMIODARONE â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhentricyclicsgivenwithl DISOPYRAMIDE orl FLECAINIDE ;avoidanceoftricyclicsadvisedbymanufacturerofl DRONEDARONE (riskofventriculararrhythmias);increasedriskofarrhythmiaswhentricyclicsgivenwithl PROPAFENONE 
Antibacterials: increasedriskofventriculararrhythmiaswhentricyclicsgivenwithl MOXIFLOXACIN â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhentricyclicsthatprolongthe QT intervalgivenwithl DELAMANID ;possibleincreasedriskofventriculararrhythmiaswhentricyclicsgivenwithl TELITHROMYCIN 
Anticoagulants: tricyclicsmayenhanceorreduceanticoagulanteffectofl COUMARINS 
Antiepileptics: tricyclicsantagoniseanticonvulsanteffectofl ANTIEPILEPTICS (convulsivethresholdlowered);metabolismoftricyclicsacceleratedbyl CARBAMAZEPINE (reducedplasmaconcentrationandreducedeffect);plasmaconcentrationoftricyclicspossiblyreducedbyl FOS PHENYTOIN  andlPHENYTOIN;metabolismoftricyclicspossiblyacceleratedbyl PHENOBARBITAL andl PRIMIDONE (reducedplasmaconcentration) 
 TRIANGLE Antifungals: plasmaconcentrationofamitriptylineandnortriptylinepossiblyincreasedby FLUCONAZOLE ;plasmaconcentrationoftricyclicspossiblyincreasedby TERBINAFINE  
 TRIANGLE Antihistamines: increasedantimuscarinicandsedativeeffectswhentricyclicsgivenwith ANTIHISTAMINES 
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE  
 TRIANGLE Antimuscarinics: increasedriskofantimuscarinicside-effectswhentricyclicsgivenwith ANTIMUSCARINICS 
Antipsychotics: avoidanceoftricyclicsadvisedbymanufacturerofl DROPERIDOL ,l FLUPHENAZINE ,l HALOPERIDOL ,l SULPIRIDE andl ZUCLOPENTHIXOL (riskofventriculararrhythmias);possibleincreasedantimuscarinicside-effectswhentricyclicsgivenwith CLOZAPINE ;increasedriskofantimuscarinicside-effectswhentricyclicsgivenwith PHENOTHIAZINES ;possibleincreasedriskofventriculararrhythmiaswhentricyclicsgivenwithl RISPERIDONE 
Antivirals: plasmaconcentrationoftricyclicspossiblyincreasedbyl RITONAVIR ;increasedriskofventriculararrhythmiaswhentricyclicsgivenwithl SAQUINAVIR â€”avoidconcomitantuse 
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhentricyclicsgivenwith ANXIOLYTICSANDHYPNOTICS 
Atomoxetine: increasedriskofventriculararrhythmiaswhentricyclicsgivenwithl ATOMOXETINE ;possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINE 
 lBeta-blockers:plasmaconcentrationofimipramineincreasedby LABETALOL and PROPRANOLOL ;increasedriskofventriculararrhythmiaswhentricyclicsgivenwithl SOTALOL  
 TRIANGLE Bupropion: plasmaconcentrationoftricyclicspossiblyincreasedby BUPROPION (possibleincreasedriskofconvulsions) 
 TRIANGLE Calcium-channelBlockers: plasmaconcentrationofimipramineincreasedby DILTIAZEM and VERAPAMIL ;plasmaconcentrationoftricyclicspossiblyincreasedbyDILTIAZEMandVERAPAMIL 
 TRIANGLE CannabisExtract: possibleincreasedriskofhypertensionandtachycardiawhentricyclicsgivenwith CANNABISEXTRACT 
Clonidine: tricyclicsantagonisehypotensiveeffectoflCLONIDINE,alsoincreasedriskofhypertensiononclonidinewithdrawal
Cytotoxics: increasedriskofventriculararrhythmiaswhenamitriptylineorclomipraminegivenwithl ARSENICTRIOXIDE 
Dapoxetine: possibleincreasedriskofserotonergiceffectswhentricyclicsgivenwithl DAPOXETINE (manufacturerofdapoxetineadvisestricyclicsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingtricyclics) 
 TRIANGLE Disulfiram: metabolismoftricyclicsinhibitedby DISULFIRAM (increasedplasmaconcentration);concomitantamitriptylinereportedtoincreaseDISULFIRAMreactionwithalcohol 
 TRIANGLE Diuretics: increasedriskofposturalhypotensionwhentricyclicsgivenwith DIURETICS 
Dopaminergics: cautionwithtricyclicsadvisedbymanufacturerof ENTACAPONE ;increasedriskofCNStoxicity
 TRIANGLE Histamine: tricyclicstheoreticallyantagoniseeffectsof HISTAMINE â€”manufacturerofhistamineadvisesavoidconcomitantuse 
 TRIANGLE Lithium: riskoftoxicitywhentricyclicsgivenwith LITHIUM 
Methylthioninium: riskofCNStoxicitywhenclomipraminegivenwithl METHYLTHIONINIUM â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) 
 TRIANGLE Moxonidine: tricyclicspossiblyantagonisehypotensiveeffectof MOXONIDINE (manufacturerofmoxonidineadvisesavoidconcomitantuse) 
 TRIANGLE MuscleRelaxants: tricyclicsenhancemusclerelaxanteffectof BACLOFEN  
 TRIANGLE Nicorandil: tricyclicspossiblyenhancehypotensiveeffectof NICORANDIL  
 TRIANGLE Nitrates:  tricyclicsreduceeffectsofsublingualtabletsof NITRATES (failuretodissolveundertongueowingtodrymouth) 
 TRIANGLE Oestrogens: antidepressanteffectoftricyclicsantagonisedby OESTROGENS (butside-effectsoftricyclicspossiblyincreasedduetoincreasedplasmaconcentration)
PentamidineIsetionate: increasedriskofventriculararrhythmiaswhentricyclicsgivenwithl PENTAMIDINEISETIONATE  
 TRIANGLE SodiumOxybate: increasedriskofside-effectswhentricyclicsgivenwith SODIUMOXYBATE 
Sympathomimetics: increasedriskofhypertensionandarrhythmiaswhentricyclicsgivenwithl ADRENALINE ( EPINEPHRINE )(butlocalanaestheticswithadrenalineappeartobesafe);metabolismoftricyclicspossiblyinhibitedby METHYLPHENIDATE ;increasedriskofhypertensionandarrhythmiaswhentricyclicsgivenwithl NORADRENALINE ( NOREPINEPHRINE )or PHENYLEPHRINE  
 TRIANGLE ThyroidHormones: effectsoftricyclicspossiblyenhancedby THYROIDHORMONES ;effectsofamitriptylineandimipramineenhancedbyTHYROIDHORMONES 
 TRIANGLE Ulcer-healing
 Drugs: plasmaconcentrationoftricyclicspossiblyincreasedby CIMETIDINE ;metabolismofamitriptyline,doxepin,imipramineandnortriptylineinhibitedbyCIMETIDINE(increasedplasmaconcentration)Antidepressants,Tricyclic(related)
 Alcohol:  increasedsedativeeffectwhentricyclic-relatedantidepressantsgivenwithl ALCOHOL  
 TRIANGLE Alpha2-adrenoceptor
 Stimulants: avoidanceoftricyclic-relatedantidepressantsadvisedbymanufacturerof APRACLONIDINE and BRIMONIDINE  
 TRIANGLE Antibacterials: plasmaconcentrationoftrazodonepossiblyincreasedby CLARITHROMYCIN  
 TRIANGLE Anticoagulants: trazodonemayenhanceorreduceanticoagulanteffectof WARFARIN  l
 Antidepressants:  tricyclic-relatedantidepressantsshouldnotbestarteduntil2weeksafterstoppingl  MAOI S ,alsoMAOIsshouldnotbestarteduntilatleast1â€“2weeksafterstoppingtricyclic-relatedantidepressants;afterstoppingtricyclic-relatedantidepressantsdonotstartl MOCLOBEMIDE foratleast1week
 Antiepileptics:  tricyclic-relatedantidepressantspossiblyantagoniseanticonvulsanteffectofl ANTIEPILEPTICS (convulsivethresholdlowered);plasmaconcentrationofmianserinandtrazodonereducedbyl CARBAMAZEPINE ;plasmaconcentrationofmianserinreducedbyl FOS PHENYTOIN  andlPHENYTOIN;metabolismofmianserinacceleratedbyl PHENOBARBITAL andl PRIMIDONE (reducedplasmaconcentration) 
 TRIANGLE Antihistamines: possibleincreasedantimuscarinicandsedativeeffectswhentricyclic-relatedantidepressantsgivenwith ANTIHISTAMINES 
 TRIANGLE Antimuscarinics: possibleincreasedantimuscarinicside-effectswhentricyclic-relatedantidepressantsgivenwith ANTIMUSCARINICS 
Antivirals: plasmaconcentrationoftrazodoneincreasedbyl RITONAVIR (increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhentrazodonegivenwithl SAQUINAVIR â€”avoidconcomitantuse;plasmaconcentrationoftrazodonepossiblyincreasedby TELAPREVIR  
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhentricyclic-relatedantidepressantsgivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhentricyclic-relatedantidepressantsgivenwith DIAZOXIDE  
 TRIANGLE Nitrates:tricyclic-relatedantidepressantspossiblyreduceeffectsofsublingualtabletsofNITRATES(failuretodissolveundertongueowingtodrymouth) 
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhentricyclic-relatedantidepressantsgivenwith HYDRALAZINE or SODIUMNITROPRUSSIDEA ntidiabetics NOTEO therdrugsadministeredorallymayneedtobetakenatleast1hourbeforeor4hoursafterlixisenatideinjection,ortakenwithamealwhenlixisenatideisnotadministered,tominimisepossibleinterferencewithabsorptionNOTEOtherdrugsadministeredorallymayneedtobetakenatleast1hourbeforeor4hoursafterexenatideinjection,ortakenwithamealwhenexenatideisnotadministered,tominimisepossibleinterferencewithabsorption 
 TRIANGLE  ACE Inhibitors:hypoglycaemiceffectofinsulin,metforminandsulfonylureaspossiblyenhancedby ACEINHIBITORS  
 TRIANGLE Alcohol:hypoglycaemiceffectofantidiabeticsenhancedbyALCOHOL;increasedriskoflacticacidosiswhenmetformingivenwithALCOHOL 
 TRIANGLE AnabolicSteroids: hypoglycaemiceffectofantidiabeticspossiblyenhancedby ANABOLICSTEROIDS 
Analgesics: effectsofsulfonylureaspossiblyenhancedbyl NSAIDS ;lixisenatidepossiblyreducestheabsorptionof PARACETAMOL whengiven1to4hoursbeforeparacetamol 
 TRIANGLE Anti-arrhythmics:hypoglycaemiceffectofgliclazide,insulinandmetforminpossiblyenhancedby DISOPYRAMIDE 
Antibacterials: hypoglycaemiceffectofacarbosepossiblyenhancedby NEOMYCIN ,alsoseverityofgastro-intestinaleffectsincreased;effectsofrepaglinideenhancedbyCLARITHROMYCIN;effectsofglibenclamidepossiblyenhancedby NORFLOXACIN ;plasmaconcentrationofcanagliflozinandnateglinidereducedbyl RIFAMPICIN ;effectsoflinagliptinpossiblyreducedbyRIFAMPICIN;hypoglycaemiceffectofrepaglinidepossiblyantagonisedbyRIFAMPICIN;effectsofsulfonylureasenhancedbyl CHLORAMPHENICOL ;metabolismoftolbutamideacceleratedbyl RIFAMYCINS (reducedeffect);metabolismofsulfonylureaspossiblyacceleratedbylRIFAMYCINS(reducedeffect);effectsofsulfonylureasrarelyenhancedby SULFONAMIDES and TRIMETHOPRIM ;hypoglycaemiceffectofsulfonylureaspossiblyenhancedby TETRACYCLINES ;hypoglycaemiceffectofrepaglinidepossiblyenhancedbyTRIMETHOPRIMâ€”manufactureradvisesavoidconcomitantuse
Anticoagulants: exenatidepossiblyenhancesanticoagulanteffectofWARFARIN;hypoglycaemiceffectofsulfonylureaspossiblyenhancedbyl COUMARINS ,alsopossiblechangestoanticoagulanteffect 
 TRIANGLE Antidepressants:hypoglycaemiceffectofantidiabeticspossiblyenhancedbyMAOIS;hypoglycaemiceffectofinsulin,metforminandsulfonylureasenhancedbyMAOIS 
 TRIANGLE Antidiabetics: manufacturerofdapagliflozinadvisesavoidconcomitantusewith PIOGLITAZONE  
 TRIANGLE Antiepileptics:tolbutamidetransientlyincreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN(possibilityoftoxicity);plasmaconcentrationofglibenclamidepossiblyreducedby TOPIRAMATE ;plasmaconcentrationofmetforminpossiblyincreasedbyTOPIRAMATE
Antifungals: plasmaconcentrationofpioglitazone,saxagliptinandtolbutamideincreasedby KETOCONAZOLE ;plasma BNF 
 TRIANGLE Antihistamines: thrombocytecountdepressedwhenmetformingivenwith KETOTIFEN (manufacturerofketotifenadvisesavoidconcomitantuse) 
 TRIANGLE Antipsychotics: hypoglycaemiceffectofsulfonylureaspossiblyantagonisedby PHENOTHIAZINES  
 TRIANGLE Antivirals: plasmaconcentrationoftolbutamidepossiblyincreasedby RITONAVIR ;plasmaconcentrationofmetforminincreasedby TELAPREVIR (considerreducingdoseofmetformin) 
 TRIANGLE Aprepitant: plasmaconcentrationoftolbutamidereducedby APREPITANT  
 TRIANGLE Beta-blockers:warningsignsofhypoglycaemia(suchastremor)withantidiabeticsmaybemaskedwhengivenwith BETA - BLOCKERS ;hypoglycaemiceffectofinsulinenhancedbyBETA-BLOCKERS
Bosentan: increasedriskofhepatotoxicitywhenglibenclamidegivenwithl BOSENTAN â€”avoidconcomitantuse 
 TRIANGLE Calcium-channelBlockers: glucosetoleranceoccasionallyimpairedwheninsulingivenwith NIFEDIPINE  
 TRIANGLE CardiacGlycosides: canagliflozinandsitagliptinincreaseplasmaconcentrationof DIGOXIN ;acarbosepossiblyreducesplasmaconcentrationofDIGOXIN 
 TRIANGLE Ciclosporin: hypoglycaemiceffectofrepaglinidepossiblyenhancedby CICLOSPORIN  
 TRIANGLE Corticosteroids: hypoglycaemiceffectofantidiabeticsantagonisedby CORTICOSTEROIDS 
Cytotoxics: avoidanceofrepaglinideadvisedbymanufacturerofl LAPATINIB ;plasmaconcentrationofmetforminpossiblyincreasedby VANDETANIB (considerreducingdoseofmetformin) 
 TRIANGLE Deferasirox: plasmaconcentrationofrepaglinideincreasedby DEFERASIROX  
 TRIANGLE Diazoxide: hypoglycaemiceffectofantidiabeticsantagonisedby DIAZOXIDE  
 TRIANGLE Diuretics: canagliflozinpossiblyenhancesdiureticeffectof DIURETICS ;manufacturerofcanagliflozinadvisesavoidconcomitantusewith LOOPDIURETICS ;hypoglycaemiceffectofantidiabeticsantagonisedbyLOOPDIURETICSand THIAZIDESANDRELATEDDIURETICS ;dapagliflozinpossiblyenhancesdiureticeffectofLOOPDIURETICSandTHIAZIDESANDRELATEDDIURETICS 
 TRIANGLE Fosaprepitant: plasmaconcentrationoftolbutamidereducedby FOSAPREPITANT  
 TRIANGLE HormoneAntagonists: requirementsforantidiabeticspossiblyreducedby LANREOTIDE , OCTREOTIDE and PASIREOTIDE  
 TRIANGLE Leflunomide: hypoglycaemiceffectoftolbutamidepossiblyenhancedby LEFLUNOMIDE  
 lLipid-regulatingDrugs:  absorptionofglibenclamideandglipizidereducedby COLESEVELAM ;absorptionofglimepiridereducedbyCOLESEVELAMâ€”manufacturerofglimepirideadvisesgiveatleast4hoursbeforecolesevelam;hypoglycaemiceffectofacarbosepossiblyenhancedby COLESTYRAMINE ;hypoglycaemiceffectofnateglinidepossiblyenhancedby GEMFIBROZIL ;increasedriskofseverehypoglycaemiawhenrepaglinidegivenwithlGEMFIBROZILâ€”avoidconcomitantuse;plasmaconcentrationofglibenclamidepossiblyincreasedby FLUVASTATIN ;manufacturerofcanagliflozinadvisesgiveatleast1hourbeforeor4â€“6hoursafter BILEACIDSEQUESTRANTS ;maybeimprovedglucosetoleranceandanadditiveeffectwheninsulinorsulfonylureasgivenwith FIBRATES ;separatingadministrationfromlinagliptinby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Orlistat: avoidanceofacarboseadvisedbymanufacturerof ORLISTAT  
 TRIANGLE Pancreatin: hypoglycaemiceffectofacarboseantagonisedby PANCREATIN  
 TRIANGLE Progestogens: hypoglycaemiceffectofantidiabeticsantagonisedby PROGESTOGENS 
Sulfinpyrazone: effectsofsulfonylureasenhancedbyl SULFINPYRAZONE  
 TRIANGLE Teriflunomide: plasmaconcentrationofrepaglinideincreasedby TERIFLUNOMIDE  
 TRIANGLE Testosterone: hypoglycaemiceffectofantidiabeticspossiblyenhancedby TESTOSTERONE  
 TRIANGLE Ulcer-healingDrugs:excretionofmetforminreducedby CIMETIDINE (increasedplasmaconcentration);hypoglycaemiceffectofsulfonylureasenhancedby CIMETIDINE
 Antiepileptics see Carbamazepine
,Eslicarbazepine,Ethosuximide,Fosphenytoin,Gabapentin,Lacosamide,Lamotrigine,Levetiracetam,Oxcarbazepine,Perampanel,Phenobarbital,Phenytoin,Pregabalin,Primidone,Retigabine,Rufinamide,Sodiumvalproate,Stiripentol,Tiagabine,Topiramate,Valproicacid,Vigabatrin,andZonisamide
 Antifungals see Amphotericin
;Antifungals,Imidazole;Antifungals,Triazole;Caspofungin;Flucytosine;Griseofulvin;Micafungin;TerbinafineAntifungals,Imidazole 
 TRIANGLE Alcohol: possibilityofdisulfiram-likereactionwhenketoconazolegivenwith ALCOHOL  
 TRIANGLE Aliskiren: ketoconazoleincreasesplasmaconcentrationof ALISKIREN  
 lAlpha-blockers:ketoconazolepossiblyincreasesplasmaconcentrationof ALFUZOSIN ;ketoconazoleincreasesplasmaconcentrationofl TAMSULOSIN 
Aminophylline: ketoconazolepossiblyincreasesplasmaconcentrationofl AMINOPHYLLINE 
Analgesics: ketoconazoleinhibitsmetabolismofl BUPRENORPHINE (reducedoseofbuprenorphine);possibleincreasedriskofventriculararrhythmiaswhenketoconazolegivenwithl METHADONE â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationof OXYCODONE ;manufacturerofketoconazoleadvisesavoidconcomitantusewith PARACETAMOL  
 TRIANGLE Antacids: absorptionofketoconazolereducedby ANTACIDS  
 TRIANGLE Anthelmintics: ketoconazoleincreasesplasmaconcentrationof PRAZIQUANTEL  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenketoconazolegivenwithl DISOPYRAMIDE â€”avoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationofl DRONEDARONE â€”avoidconcomitantuse
Antibacterials: manufacturerofketoconazoleadvisesavoidconcomitantl CLARITHROMYCIN insevererenalimpairment;metabolismofketoconazoleacceleratedbyl RIFAMPICIN (reducedplasmaconcentration),alsoplasmaconcentrationofrifampicinmaybereducedbyketoconazole;ketoconazoleincreasesplasmaconcentrationof BEDAQUILINE â€”avoidconcomitantuseifketoconazolegivenformorethan14days;avoidanceofketoconazoleadvisedbymanufacturerof FIDAXOMICIN ;plasmaconcentrationofketoconazolepossiblyreducedby ISONIAZID ;ketoconazoleincreasestheplasmaconcentrationofl TELITHROMYCIN â€”avoidinsevererenalandhepaticimpairment
Anticoagulants: ketoconazoleincreasesplasmaconcentrationofl APIXABAN â€”manufacturerofapixabanadvisesavoidconcomitantuse;miconazoleenhancesanticoagulanteffectofl COUMARINS (miconazoleoralgelandpossiblyvaginalandtopicalformulationsabsorbed);ketoconazoleenhancesanticoagulanteffectoflCOUMARINS;ketoconazoleincreasesplasmaconcentrationofl DABIGATRAN andl RIVAROXABAN â€”avoidconcomitantuse
Antidepressants: avoidanceofimidazolesadvisedbymanufacturerofl REBOXETINE ;ketoconazoleincreasesplasmaconcentrationof MIRTAZAPINE 
Antidiabetics: miconazoleenhanceshypoglycaemiceffectofl GLICLAZIDE andl GLIPIZIDE â€”avoidconcomitantuse;
Antiepileptics: miconazolepossiblyincreasesplasmaconcentrationof CARBAMAZEPINE ;plasmaconcentrationofketoconazolepossiblyreducedbyCARBAMAZEPINE,alsoplasmaconcentrationofcarbamazepinepossiblyincreased;plasmaconcentrationofketoconazolereducedbyl FOS PHENYTOIN  andlPHENYTOIN;miconazoleenhancesanticonvulsanteffectoflFOSPHENYTOINandlPHENYTOIN(plasmaconcentrationoffosphenytoinandphenytoinincreased);ketoconazoleincreasesplasmaconcentrationof PERAMPANEL   
 TRIANGLE Antifungals: imidazolespossiblyantagoniseeffectsof AMPHOTERICIN 
Antihistamines: imidazolespossiblyinhibitmetabolismofl MIZOLASTINE (avoidconcomitantuse)
Antimalarials: avoidanceofimidazolesadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;avoidanceofimidazolesadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias);ketoconazoleincreasesplasmaconcentrationof MEFLOQUINE 
Antimuscarinics: absorptionofketoconazolereducedby ANTIMUSCARINICS ;ketoconazoleincreasesplasmaconcentrationof DARIFENACIN â€”avoidconcomitantuse;manufactureroffesoterodineadvisesdosereductionwhenketoconazolegivenwith FESOTERODINE â€”consultfesoterodineproductliterature;ketoconazoleincreasesplasmaconcentrationof OXYBUTYNIN ;ketoconazoleincreasesplasmaconcentrationofl SOLIFENACIN â€”seeunderSolifenacin,p670;avoidanceofketoconazoleadvisedbymanufacturerofl TOLTERODINE 
Antipsychotics: ketoconazoleinhibitsmetabolismofl ARIPIPRAZOLE (reducedoseofaripiprazole);ketoconazoleincreasesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenimidazolesgivenwithl PIMOZIDE â€”avoidconcomitantuse;imidazolespossiblyincreaseplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse
Antivirals: ketoconazoleincreasesplasmaconcentrationofl BOCEPREVIR ;ketoconazoleincreasestheplasmaconcentrationofl DACLATASVIR â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofbothdrugsincreasedwhenketoconazolegivenwith DARUNAVIR ;plasmaconcentrationofketoconazolereducedbyl EFAVIRENZ ;plasmaconcentrationofketoconazoleincreasedby FOSAMPRENAVIR (alsoplasmaconcentrationoffosamprenavirpossiblyincreased);ketoconazoleincreasesplasmaconcentrationofl INDINAVIR andl MARAVIROC (considerreducingdoseofindinavirandmaraviroc);plasmaconcentrationofketoconazolereducedbyl NEVIRAPINE â€”avoidconcomitantuse;plasmaconcentrationofketoconazoleincreasedbyl RITONAVIR (reducedoseofketoconazole);imidazolespossiblyincreaseplasmaconcentrationof SAQUINAVIR ;ketoconazoleincreasesplasmaconcentrationoflSAQUINAVIRâ€”manufacturerofketoconazoleadvisesavoidconcomitantuse;avoidanceofketoconazoleadvisedbymanufacturerofl SIMEPREVIR ;plasmaconcentrationofbothdrugspossiblyincreasedwhenketoconazolegivenwith TELAPREVIR (increasedriskofventriculararrhythmias)â€”reducedoseofketoconazole
AnxiolyticsandHypnotics: ketoconazoleincreasesplasmaconcentrationofl ALPRAZOLAM â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationofl MIDAZOLAM (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam);ketoconazoleincreasesplasmaconcentrationof ZOLPIDEM  
 TRIANGLE Aprepitant: ketoconazoleincreasesplasmaconcentrationof APREPITANT 
 TRIANGLE Beta-blockers:ketoconazolepossiblyincreasesplasmaconcentrationof NADOLOL  
 TRIANGLE Bosentan: ketoconazoleincreasesplasmaconcentrationof BOSENTAN  
 lCalcium-channelBlockers: ketoconazoleinhibitsmetabolismofl FELODIPINE (increasedplasmaconcentration)â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;avoidanceofketoconazoleadvisedbymanufacturerof LERCANIDIPINE ;ketoconazolepossiblyinhibitsmetabolismof DIHYDROPYRIDINES (increasedplasmaconcentration) 
 TRIANGLE CannabisExtract: ketoconazoleincreasesplasmaconcentrationof CANNABISEXTRACT 
Ciclosporin: ketoconazoleinhibitsmetabolismofl CICLOSPORIN (increasedplasmaconcentration);miconazolepossiblyinhibitsmetabolismoflCICLOSPORIN(increasedplasmaconcentration)
Cilostazol: ketoconazoleincreasesplasmaconcentrationofl CILOSTAZOL (seeunderCilostazol,p206) 
 TRIANGLE Cinacalcet: ketoconazoleinhibitsmetabolismof CINACALCET (increasedplasmaconcentration)
Clopidogrel: ketoconazolepossiblyreducesantiplateleteffectofl CLOPIDOGREL  
 TRIANGLE Cobicistat: plasmaconcentrationofketoconazolepossiblyincreasedby COBICISTAT â€”manufacturerofcobicistatadvisesreducedoseofketoconazole
Colchicine: ketoconazolepossiblyincreasesriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)
Corticosteroids: ketoconazolepossiblyinhibitsmetabolismof CORTICOSTEROIDS ;ketoconazoleincreasestheplasmaconcentrationofinhaledandoral(andpossiblyalsointranasalandrectal)l BUDESONIDE ;ketoconazoleincreasesplasmaconcentrationofactivemetaboliteofl CICLESONIDE ;ketoconazolepossiblyincreasesplasmaconcentrationofinhaled FLUTICASONE ;ketoconazoleinhibitsthemetabolismof METHYLPREDNISOLONE ;ketoconazoleincreasesplasmaconcentrationofinhaled MOMETASONE 
Cytotoxics: ketoconazoleinhibitsthemetabolismof IFOSFAMIDE ;possibleincreasedriskofneutropeniawhenketoconazolegivenwithl BRENTUXIMABVEDOTIN ;ketoconazolepossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationofketoconazoleby6to12hours;ketoconazoleincreasesplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consultaxitinibproductliterature);ketoconazoleincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;ketoconazoleincreasesplasmaconcentrationof BORTEZOMIB , CABOZANTINIB , DABRAFENIB , ETOPOSIDE , IDELALISIB , IMATINIB and PONATINIB ;ketoconazoleincreasesplasmaconcentrationofl CRIZOTINIB ,l LAPATINIB ,l NILOTINIB andl REGORAFENIB â€”avoidconcomitantuse;ketoconazolepossiblyincreasesplasmaconcentrationof DASATINIB ;ketoconazoleinhibitsmetabolismof ERLOTINIB and SUNITINIB (increasedplasmaconcentration);ketoconazoleincreasesplasmaconcentrationofl EVEROLIMUS â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);ketoconazoleincreasesplasmaconcentrationofl PAZOPANIB (reducedoseofpazopanib);manufacturerofruxolitinibadvisesdosereductionwhenketoconazolegivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature;ketoconazoleincreasesplasmaconcentrationofactivemetaboliteofl TEMSIROLIMUS â€”avoidconcomitantuse;avoidanceofketoconazoleadvisedbymanufacturerofl CABAZITAXEL ;invitrostudiessuggestapossibleinteractionbetweenketoconazoleand DOCETAXEL (consultdocetaxelproductliterature);ketoconazolereducesplasmaconcentrationofl IRINOTECAN (butconcentrationofactivemetaboliteofirinotecanincreased)â€”avoidconcomitantuse;ketoconazoleincreasesplasmaconcentrationofl VINFLUNINE â€”manufacturerofvinflunineadvisesavoidconcomitantuse BNF 
Dapoxetine: ketoconazoleincreasesplasmaconcentrationofl DAPOXETINE â€”manufacturerofdapoxetineadvisesavoidconcomitantuse
Diuretics: ketoconazoleincreasesplasmaconcentrationofl EPLERENONE â€”avoidconcomitantuse
Domperidone: manufacturerofketoconazoleadvisesavoidconcomitantusewithl DOMPERIDONE (riskofventriculararrhythmias)
ErgotAlkaloids: manufacturerofketoconazoleadvisesavoidconcomitantusewithl ERGOTALKALOIDS ;increasedriskofergotismwhenimidazolesgivenwithl ERGOTAMINE â€”avoidconcomitantuse
Fingolimod: ketoconazoleincreasesplasmaconcentrationofl FINGOLIMOD   
 TRIANGLE Fosaprepitant: ketoconazoleincreasesplasmaconcentrationof FOSAPREPITANT  
 TRIANGLE HormoneAntagonists: manufacturerofketoconazoleadvisesavoidconcomitantusewith PASIREOTIDE l5 HT 1-receptor
 Agonists: ketoconazoleincreasesplasmaconcentrationof ALMOTRIPTAN (increasedriskoftoxicity);ketoconazoleincreasesplasmaconcentrationofl ELETRIPTAN (riskoftoxicity)â€”avoidconcomitantuse
Ivabradine: ketoconazoleincreasesplasmaconcentrationofl IVABRADINE â€”avoidconcomitantuse
Ivacaftor: ketoconazoleincreasesplasmaconcentrationofl IVACAFTOR (seeunderIvacaftor,p257) 
 TRIANGLE Lanthanum: absorptionofketoconazolepossiblyreducedby LANTHANUM (giveatleast2hoursapart)
Lenalidomide: ketoconazolepossiblyincreasesplasmaconcentrationofl LENALIDOMIDE (increasedriskoftoxicity)lLipid-regulatingDrugs:  possibleincreasedriskofmyopathywhenimidazolesgivenwith ATORVASTATIN ;possibleincreasedriskofmyopathywhenketoconazolegivenwithlATORVASTATINâ€”manufacturerofketoconazoleadvisesavoidconcomitantuse;increasedriskofmyopathywhenketoconazolegivenwithl SIMVASTATIN (avoidconcomitantuse);possibleincreasedriskofmyopathywhenmiconazolegivenwithlSIMVASTATIN;ketoconazoleincreasesplasmaconcentrationofl LOMITAPIDE â€”avoidconcomitantuse 
 TRIANGLE Macitentan: ketoconazoleincreasesplasmaconcentrationof MACITENTAN  
 TRIANGLE Mirabegron: whengivenwithketoconazoleavoidorreducedoseof MIRABEGRON inhepaticorrenalimpairmentâ€”seeMirabegron,p671
Nintedanib: ketoconazoleincreasesplasmaconcentrationofl NINTEDANIB  
 TRIANGLE Oestrogens: anecdotalreportsofcontraceptivefailurewhenimidazolesgivenwith OESTROGENS  
 TRIANGLE Parasympathomimetics: ketoconazoleincreasesplasmaconcentrationof GALANTAMINE 
Ranolazine: ketoconazoleincreasesplasmaconcentrationofl RANOLAZINE â€”avoidconcomitantuse
Retinoids: ketoconazoleincreasesplasmaconcentrationof ALI TRETINOIN  ;ketoconazolepossiblyincreasesriskoflTRETINOINtoxicity 
 TRIANGLE Riociguat: avoidanceofketoconazoleadvisedbymanufacturerof RIOCIGUAT 
Sildenafil: ketoconazoleincreasesplasmaconcentrationofl SILDENAFIL â€”reduceinitialdoseofsildenafilforerectiledysfunctionandavoidconcomitantuseofsildenafilforpulmonaryhypertension
Sirolimus: ketoconazoleincreasesplasmaconcentrationofl SIROLIMUS â€”avoidconcomitantuse;miconazoleincreasesplasmaconcentrationoflSIROLIMUS 
 lSympathomimetics,Beta2:ketoconazoleincreasesplasmaconcentrationof OLODATEROL ;ketoconazoleinhibitsmetabolismofl SALMETEROL (increasedplasmaconcentration)
Tacrolimus: ketoconazoleincreasesplasmaconcentrationofl TACROLIMUS (considerreducingdoseoftacrolimus);miconazoleoralgelpossiblyincreasesplasmaconcentrationoflTACROLIMUS
Theophylline: ketoconazolepossiblyincreasesplasmaconcentrationofl THEOPHYLLINE 
Ticagrelor: ketoconazoleincreasesplasmaconcentrationofl TICAGRELOR â€”manufacturerofticagreloradvisesavoidconcomitantuse 
 TRIANGLE Tolvaptan: ketoconazoleincreasesplasmaconcentrationof TOLVAPTAN â€”manufacturerofketoconazoleadvisesavoidconcomitantuse 
 TRIANGLE Ulcer-healingDrugs:absorptionofketoconazolereducedby HISTAMINEH 2- ANTAGONISTS , PROTONPUMPINHIBITORS and SUCRALFATE  
 TRIANGLE Ulipristal: ketoconazoleincreasesplasmaconcentrationoflow-dose ULIPRISTAL â€”manufactureroflow-doseulipristaladvisesavoidconcomitantuse
Vardenafil: ketoconazoleincreasesplasmaconcentrationofl VARDENAFIL â€”avoidconcomitantuse 
 TRIANGLE Vitamins: miconazolepossiblyreduceseffectsof ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL and VITAMIND ;ketoconazolepossiblyincreasesplasmaconcentrationof PARICALCITOLA ntifungals,
 Polyene see Amphotericin 
 Antifungals
,Triazole NOTEI ngeneral,fluconazoleinteractionsrelatetomultiple-dosetreatment
Aliskiren: itraconazoleincreasesplasmaconcentrationofl ALISKIREN â€”avoidconcomitantuse
Aminophylline: fluconazolepossiblyincreasesplasmaconcentrationofl AMINOPHYLLINE 
Analgesics: fluconazoleincreasesplasmaconcentrationof CELECOXIB (halvedoseofcelecoxib);voriconazoleincreasesplasmaconcentrationof DICLOFENAC , IBUPROFEN andl OXYCODONE ;fluconazoleincreasesplasmaconcentrationof FLURBIPROFEN ,IBUPROFENand METHADONE ;fluconazoleincreasesplasmaconcentrationof PARECOXIB (reducedoseofparecoxib);voriconazoleincreasesplasmaconcentrationofl ALFENTANIL andlMETHADONE(considerreducingdoseofalfentanilandmethadone);fluconazoleinhibitsmetabolismofALFENTANIL(riskofprolongedordelayedrespiratorydepression);itraconazolepossiblyinhibitsmetabolismofALFENTANIL;triazolespossiblyincreaseplasmaconcentrationofl FENTANYL ;itraconazolepossiblyincreasesplasmaconcentrationoflMETHADONE(increasedriskofventriculararrhythmias);itraconazoleincreasesplasmaconcentrationofOXYCODONE 
 TRIANGLE Antacids: absorptionofitraconazolereducedby ANTACIDS  
 lAnti-arrhythmics:manufacturerofitraconazoleadvisesavoidconcomitantusewithl DISOPYRAMIDE ;avoidanceofitraconazole,posaconazoleandvoriconazoleadvisedbymanufacturerofl DRONEDARONE 
Antibacterials: plasmaconcentrationofitraconazoleincreasedby CLARITHROMYCIN ;manufactureroffluconazoleadvisesavoidconcomitantusewith ERYTHROMYCIN ;triazolespossiblyincreaseplasmaconcentrationofl RIFABUTIN (increasedriskofuveitisâ€”reducerifabutindose);posaconazoleincreasesplasmaconcentrationoflRIFABUTIN(alsoplasmaconcentrationofposaconazolereduced);voriconazoleincreasesplasmaconcentrationoflRIFABUTIN,alsorifabutinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforrifabutintoxicity);fluconazoleincreasesplasmaconcentrationoflRIFABUTIN(increasedriskofuveitisâ€”reducerifabutindose);plasmaconcentrationofitraconazolereducedbylRIFABUTINandl RIFAMPICIN â€”manufacturerofitraconazoleadvisesavoidconcomitantuse;plasmaconcentrationofposaconazolereducedbylRIFAMPICIN;plasmaconcentrationofvoriconazolereducedbylRIFAMPICINâ€”avoidconcomitantuse;metabolismoffluconazoleacceleratedbylRIFAMPICIN(reducedplasmaconcentration);fluconazolepossiblyincreasesplasmaconcentrationof BEDAQUILINE â€”avoidconcomitantuseiffluconazolegivenformorethan14days
Anticoagulants: avoidanceofitraconazole,posaconazoleandvoriconazoleadvisedbymanufacturerof APIXABAN ;fluconazole,itraconazoleandvoriconazoleenhance
Antidepressants: avoidanceoftriazolesadvisedbymanufacturerofl REBOXETINE ;fluconazolepossiblyincreasesplasmaconcentrationof AMITRIPTYLINE and NORTRIPTYLINE ;plasmaconcentrationofvoriconazolereducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse
Antidiabetics: posaconazolepossiblyenhanceshypoglycaemiceffectof GLIPIZIDE ;fluconazolepossiblyenhanceshypoglycaemiceffectof NATEGLINIDE ;itraconazolepossiblyenhanceshypoglycaemiceffectof REPAGLINIDE ;fluconazoleincreasesplasmaconcentrationofl SULFONYLUREAS ;voriconazolepossiblyincreasesplasmaconcentrationofSULFONYLUREAS
Antiepileptics: fluconazolepossiblyincreasesplasmaconcentrationof CARBAMAZEPINE ;plasmaconcentrationofvoriconazolepossiblyreducedbylCARBAMAZEPINE,l PHENOBARBITAL andl PRIMIDONE â€”avoidconcomitantuse;plasmaconcentrationofitraconazoleandposaconazolepossiblyreducedbylCARBAMAZEPINE;voriconazoleincreasesplasmaconcentrationofl FOS PHENYTOIN  andlPHENYTOIN,alsofosphenytoinandphenytoinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforfosphenytoinandphenytointoxicity);plasmaconcentrationofposaconazolereducedbylFOSPHENYTOINandlPHENYTOIN;plasmaconcentrationofitraconazolereducedbylFOSPHENYTOINandlPHENYTOINâ€”avoidconcomitantuse;fluconazoleincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN(considerreducingdoseoffosphenytoinandphenytoin);plasmaconcentrationofitraconazoleandposaconazolepossiblyreducedbylPHENOBARBITAL;plasmaconcentrationofitraconazoleandposaconazolepossiblyreducedbylPRIMIDONE  
 TRIANGLE Antifungals: triazolespossiblyantagoniseeffectsof AMPHOTERICIN ;monitoringforincreasedvoriconazolesideeffectsadvisedbymanufacturerof FLUCONAZOLE ifvoriconazolegivenafterfluconazole;plasmaconcentrationofitraconazoleincreasedby MICAFUNGIN (considerreducingdoseofitraconazole);plasmaconcentrationoffluconazoleincreasedby TERBINAFINE 
Antihistamines: itraconazoleinhibitsmetabolismofl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: avoidanceoftriazolesadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;avoidanceoftriazolesadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias)
Antimuscarinics: avoidanceofitraconazoleadvisedbymanufacturerof DARIFENACIN and TOLTERODINE ;manufactureroffesoterodineadvisesdosereductionwhenitraconazolegivenwith FESOTERODINE â€”consultfesoterodineproductliterature;itraconazolepossiblyincreasesplasmaconcentrationofl SOLIFENACIN â€”seeunderSolifenacin,p670
Antipsychotics: itraconazolepossiblyincreasesplasmaconcentrationof HALOPERIDOL ;itraconazolepossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;fluconazolepossiblyincreasestheplasmaconcentrationoflLURASIDONE(seeunderLurasidone,p315);increasedriskofventriculararrhythmiaswhentriazolesgivenwithl PIMOZIDE â€”avoidconcomitantuse;triazolespossiblyincreaseplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse;itraconazolepossiblyincreasesside-effectsof RISPERIDONE 
AnxiolyticsandHypnotics: itraconazoleincreasesplasmaconcentrationof ALPRAZOLAM ;fluconazoleandvoriconazoleincreaseplasmaconcentrationofl DIAZEPAM (riskofprolongedsedation);fluconazole,itraconazole,posaconazoleandvoriconazoleincreaseplasmaconcentrationofl MIDAZOLAM (riskofprolongedsedation);itraconazoleincreasesplasmaconcentrationof BUSPIRONE (reducedoseofbuspirone)
Avanafil: itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse;fluconazolepossiblyincreasesplasmaconcentrationoflAVANAFILâ€”seeunderAvanafil,p698
Bosentan: fluconazolepossiblyincreasesplasmaconcentrationofl BOSENTAN â€”avoidconcomitantuse;itraconazolepossiblyincreasesplasmaconcentrationofBOSENTAN 
 lCalcium-channelBlockers: negativeinotropiceffectpossiblyincreasedwhenitraconazolegivenwith CALCIUM - CHANNELBLOCKERS ;itraconazoleinhibitsmetabolismofl FELODIPINE (increasedplasmaconcentration);avoidanceofitraconazoleadvisedbymanufacturerof LERCANIDIPINE ;itraconazolepossiblyinhibitsmetabolismof DIHYDROPYRIDINES (increasedplasmaconcentration)
CardiacGlycosides: itraconazoleincreasesplasmaconcentrationofl DIGOXIN 
Ciclosporin: fluconazole,itraconazole,posaconazoleandvoriconazoleinhibitmetabolismofl CICLOSPORIN (increasedplasmaconcentration)
Cilostazol: itraconazolepossiblyincreasesplasmaconcentrationofl CILOSTAZOL (seeunderCilostazol,p206)
Clopidogrel: fluconazole,itraconazoleandvoriconazolepossiblyreduceantiplateleteffectofl CLOPIDOGREL  
 TRIANGLE Cobicistat: plasmaconcentrationofitraconazolepossiblyincreasedby COBICISTAT â€”manufacturerofcobicistatadvisesreducedoseofitraconazole
Colchicine: itraconazolepossiblyincreasesriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)
Corticosteroids: itraconazolepossiblyinhibitsmetabolismof CORTICOSTEROIDS and METHYLPREDNISOLONE ;itraconazoleincreasestheplasmaconcentrationofinhaledandoral(and BNF 
Cytotoxics: itraconazoleinhibitsmetabolismof BUSULFAN (increasedriskoftoxicity);fluconazoleanditraconazolepossiblyincreaseside-effectsof CYCLOPHOSPHAMIDE ;itraconazolepossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationofitraconazoleby6to12hours;itraconazolepossiblyincreasesplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consultaxitinibproductliterature);fluconazole,itraconazole,posaconazoleandvoriconazolepossiblyincreasetheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;itraconazolepossiblyincreasesplasmaconcentrationof CABOZANTINIB ;itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl CRIZOTINIB â€”manufacturerofcrizotinibadvisesavoidconcomitantuse;avoidanceofitraconazoleadvisedbymanufacturerof DASATINIB andl TEM SIROLIMUS  (plasmaconcentrationofdasatinibandtemsirolimuspossiblyincreased);itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl EVEROLIMUS â€”manufacturerofeverolimusadvisesavoidconcomitantuse;itraconazoleincreasesplasmaconcentrationof GEFITINIB ;fluconazole,itraconazoleandvoriconazolepossiblyincreasetheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofitraconazole,posaconazoleandvoriconazoleadvisedbymanufacturerofl LAPATINIB ;avoidanceofitraconazoleandvoriconazoleadvisedbymanufacturerofl NILOTINIB ;itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl PAZOPANIB (reducedoseofpazopanib);itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationof PONATINIB â€”considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhenfluconazole,itraconazole,posaconazoleandvoriconazolegivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature;itraconazoleandvoriconazolepossiblyincreasetheplasmaconcentrationofl CABAZITAXEL â€”manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxel;itraconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl DOCETAXEL â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose;increasedriskoftoxicitywhenitraconazolegivenwithl IRINOTECAN â€”avoidconcomitantuse;itraconazolepossiblyincreasesriskofl VINBLASTINE ,l VINDESINE ,l VINFLUNINE andl VINORELBINE toxicity;posaconazolepossiblyinhibitsmetabolismoflVINBLASTINEandl VINCRISTINE (increasedriskofneurotoxicity);itraconazoleincreasesriskoflVINCRISTINEtoxicity
Dapoxetine: manufacturerofdapoxetineadvisesdosereductionwhenfluconazolegivenwith DAPOXETINE (seeunderDapoxetine,p703);avoidanceofitraconazoleadvisedbymanufactureroflDAPOXETINE(increasedriskoftoxicity)
Diuretics: fluconazoleincreasesplasmaconcentrationof EPLERENONE (reducedoseofeplerenone);itraconazoleincreasesplasmaconcentrationoflEPLERENONEâ€”avoidconcomitantuse;plasmaconcentrationoffluconazoleincreasedby HYDROCHLOROTHIAZIDE 
Domperidone: possibleincreasedriskofventriculararrhythmiaswhenitraconazoleorvoriconazolegivenwithl DOMPERIDONE â€”avoidconcomitantuse
ErgotAlkaloids: increasedriskofergotismwhenvoriconazolegivenwithl ERGOMETRINE â€”avoidconcomitantuse;manufacturerofitraconazoleadvisesavoidconcomitantusewithlERGOMETRINE(increasedriskofergotism);increasedriskofergotismwhentriazolesgivenwithl ERGOTAMINE â€”avoidconcomitantusel5 HT 1-receptor
Ivabradine: fluconazoleincreasesplasmaconcentrationof IVABRADINE â€”reduceinitialdoseofivabradine;itraconazolepossiblyincreasesplasmaconcentrationoflIVABRADINEâ€”avoidconcomitantuse
Ivacaftor: itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl IVACAFTOR (seeunderIvacaftor,p257);fluconazoleincreasesplasmaconcentrationoflIVACAFTOR(seeunderIvacaftor,p257)
Lenalidomide: itraconazolepossiblyincreasesplasmaconcentrationofl LENALIDOMIDE (increasedriskoftoxicity)  
 TRIANGLE LeukotrieneReceptorAntagonists: fluconazoleincreasesplasmaconcentrationof ZAFIRLUKAST  
 lLipid-regulatingDrugs:  increasedriskofmyopathywhenitraconazole,posaconazoleorvoriconazolegivenwithl ATORVASTATIN ;possibleincreasedriskofmyopathywhenfluconazolegivenwithlATORVASTATINorl SIMVASTATIN ;fluconazoleincreasesplasmaconcentrationof FLUVASTATIN â€”possibleincreasedriskofmyopathy;itraconazoleincreasesplasmaconcentrationofl ROSUVASTATIN â€”adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhenitraconazoleorposaconazolegivenwithlSIMVASTATIN(avoidconcomitantuse);increasedriskofmyopathywhenvoriconazolegivenwithlSIMVASTATIN;avoidanceoftriazolesadvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased) 
 TRIANGLE Mirabegron: whengivenwithitraconazoleavoidorreducedoseof MIRABEGRON inhepaticorrenalimpairmentâ€”seeMirabegron,p671 
 TRIANGLE Oestrogens: plasmaconcentrationofvoriconazoleincreasedby OESTROGENS  
 TRIANGLE Progestogens: plasmaconcentrationofvoriconazolepossiblyincreasedby PROGESTOGENS 
Ranolazine: itraconazole,posaconazoleandvoriconazolepossiblyincreaseplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse
Retinoids: fluconazoleandvoriconazolepossiblyincreaseriskofl TRETINOIN toxicity 
 TRIANGLE Riociguat: avoidanceofitraconazoleandvoriconazoleadvisedbymanufacturerof RIOCIGUAT  
 TRIANGLE Sildenafil: itraconazoleincreasesplasmaconcentrationof SILDENAFIL â€”reduceinitialdoseofsildenafil
Sirolimus: fluconazoleandposaconazolepossiblyincreaseplasmaconcentrationofSIROLIMUS;itraconazoleandvoriconazoleincreaseplasmaconcentrationoflSIROLIMUSâ€”avoidconcomitantuse
Tacrolimus: fluconazole,itraconazole,posaconazoleandvoriconazoleincreaseplasmaconcentrationofl TACROLIMUS (considerreducingdoseoftacrolimus) 
 TRIANGLE Tadalafil: itraconazolepossiblyincreasesplasmaconcentrationof TADALAFIL 
Theophylline: fluconazolepossiblyincreasesplasmaconcentrationofl THEOPHYLLINE  
 lUlcer-healingDrugs:plasmaconcentrationofposaconazolereducedbyl CIMETIDINE andl ES OMEPRAZOLE  â€”manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;plasmaconcentrationofposaconazolepossiblyreducedbyl FAMOTIDINE ,l LANSOPRAZOLE ,l NIZATIDINE ,lOMEPRAZOLE,l PANTOPRAZOLE ,l RABEPRAZOLE andl RANITIDINE â€”manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;voriconazolepossiblyincreasesplasmaconcentrationofESOMEPRAZOLE;voriconazoleincreasesplasmaconcentrationofOMEPRAZOLE(considerreducingdoseofomeprazole);absorptionofitraconazolereducedby HISTAMINEH 2- ANTAGONISTS and PROTONPUMPINHIBITORS  
 TRIANGLE Ulipristal: avoidanceofitraconazoleadvisedbymanufacturerof ULIPRISTAL 
Vardenafil: itraconazolepossiblyincreasesplasmaconcentrationofl VARDENAFIL â€”avoidconcomitantuseAntihistamines NOTES edativeinteractionsapplytoalesserextenttothenon-sedatingantihistaminesInteractionsdonotgenerallyapplytoantihistaminesusedfortopicalaction(includinginhalation)
 TRIANGLE  Alcohol:  increasedsedativeeffectwhenantihistaminesgivenwith ALCOHOL (possiblylesseffectwithnon-sedatingantihistamines)
 Analgesics:  sedativeeffectspossiblyincreasedwhensedatingantihistaminesgivenwithl OPIOIDANALGESICS  
 TRIANGLE Antacids: absorptionoffexofenadinereducedby ANTACIDS  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenmizolastinegivenwithl AMIODARONE ,l DISOPYRAMIDE orl FLECAINIDE â€”avoidconcomitantuse;manufacturerofmizolastineadvisesavoidconcomitantusewith PROPAFENONE (possibleriskofventriculararrhythmias)
 Antibacterials:  manufacturerofloratadineadvisesplasmaconcentrationpossiblyincreasedby ERYTHROMYCIN ;metabolismofmizolastineinhibitedbylERYTHROMYCINâ€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenmizolastinegivenwithl MOXIFLOXACIN â€”avoidconcomitantuse;effectsoffexofenadinepossiblyreducedby RIFAMPICIN ;metabolismofmizolastinepossiblyinhibitedbyl MACROLIDES (avoidconcomitantuse)
 Antidepressants:  avoidanceofmizolastineadvisedbymanufacturerofl CITALOPRAM andl ESCITALOPRAM (riskofventriculararrhythmias);increasedantimuscarinicandsedativeeffectswhenantihistaminesgivenwith MAOIS or  TRICYCLIC S ;manufacturerofpromethazineadvisesavoidfor2weeksafterstoppingMAOIS;manufacturerofhydroxyzineadvisesavoidconcomitantusewithMAOIS;cyproheptadinepossiblyantagonisesantidepressanteffectof SSRIS ;possibleincreasedantimuscarinicandsedativeeffectswhenantihistaminesgivenwithTRICYCLIC- RELATEDANTIDEPRESSANTS  
 TRIANGLE Antidiabetics: thrombocytecountdepressedwhenketotifengivenwith METFORMIN (manufacturerofketotifenadvisesavoidconcomitantuse)lAntifungals:  metabolismofmizolastineinhibitedbyl ITRACONAZOLE â€”avoidconcomitantuse;metabolismofmizolastinepossiblyinhibitedbyl IMIDAZOLES (avoidconcomitantuse)
Antimalarials: avoidanceofmizolastineadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias) 
 TRIANGLE Antimuscarinics: increasedriskofantimuscarinicside-effectswhenantihistaminesgivenwith ANTIMUSCARINICS  
Antivirals:  plasmaconcentrationofchlorphenaminepossiblyincreasedby LOPINAVIR ;plasmaconcentrationofnon-sedatingantihistaminespossiblyincreasedby RITONAVIR ;increasedriskofventriculararrhythmiaswhenmizolastinegivenwithl SAQUINAVIR â€”avoidconcomitantuse 
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhenantihistaminesgivenwith ANXIOLYTICSANDHYPNOTICS  
 lBeta-blockers:increasedriskofventriculararrhythmiaswhenmizolastinegivenwithl SOTALOL â€”avoidconcomitantuse 
 TRIANGLE Betahistine: antihistaminestheoreticallyantagoniseeffectof BETAHISTINE 
Cytotoxics: possibleincreasedriskofventriculararrhythmiaswhenmizolastinegivenwithl VANDETANIB â€”avoidconcomitantuse 
 TRIANGLE GrapefruitJuice: plasmaconcentrationofbilastinereducedby GRAPEFRUITJUICE  
 TRIANGLE Histamine: antihistaminestheoreticallyantagoniseeffectsof HISTAMINE â€”manufacturerofhistamineadvisesavoidconcomitantuse 
 TRIANGLE Ulcer-healing
 Drugs: manufacturerofloratadineadvisesplasmaconcentrationpossiblyincreasedby CIMETIDINE ;plasmaconcentrationofhydroxyzineincreasedbyCIMETIDINE 
 TRIANGLE Ulipristal: manufacturerofulipristaladvisesgivefexofenadineatleast15hoursbeforeorafter ULIPRISTALA ntihistamines,Non-sedatingseeAntihistaminesAntihistamines,
 Sedating see Antihistamines 
 Antimalarials see Artemetherwith 
 Lumefantrine
,ArtenimolwithPiperaquine,Chloroquine,Hydroxychloroquine,Mefloquine,Primaquine,Proguanil,Pyrimethamine,andQuinine
 Antimetabolites see Capecitabine
 yInteractionsdonotgenerallyapplytoantimuscarinicsusedbyinhalation 
 TRIANGLE Alcohol:increasedsedativeeffectwhenhyoscinegivenwithALCOHOL 
 TRIANGLE Analgesics:possibleincreasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwith CODEINE ;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwith NEFOPAM  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhentolterodinegivenwithlAMIODARONE,lDISOPYRAMIDEorlFLECAINIDE;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithDISOPYRAMIDE 
 TRIANGLE Antibacterials:manufactureroffesoterodineadvisesdosereductionwhenfesoterodinegivenwith CLARITHROMYCIN and TELITHROMYCIN â€”consultfesoterodineproductliterature;manufactureroftolterodineadvisesavoidconcomitantusewithCLARITHROMYCINandERYTHROMYCIN;plasmaconcentrationofdarifenacinpossiblyincreasedbyERYTHROMYCIN;plasmaconcentrationofactivemetaboliteoffesoterodinereducedbyRIFAMPICIN 
 TRIANGLE Antidepressants:plasmaconcentrationofdarifenacinandprocyclidineincreasedby PAROXETINE ;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwithMAOISorTRICYCLICS;possibleincreasedantimuscarinicside-effectswhenantimuscarinicsgivenwithTRICYCLIC-RELATEDANTIDEPRESSANTS 
Antifungals:antimuscarinicsreduceabsorptionof KETOCONAZOLE ;manufactureroffesoterodineadvisesdosereductionwhenfesoterodinegivenwithITRACONAZOLEandKETOCONAZOLEâ€”consultfesoterodineproductliterature;plasmaconcentrationofdarifenacinincreasedbyKETOCONAZOLEâ€”avoidconcomitantuse;plasmaconcentrationofsolifenacinincreasedbylKETOCONAZOLEâ€”seeunderSolifenacin,p670;plasmaconcentrationofoxybutyninincreasedbyKETOCONAZOLE;manufactureroftolterodineadvisesavoidconcomitantusewithITRACONAZOLEandlKETOCONAZOLE;manufacturerofdarifenacinadvisesavoidconcomitantusewithITRACONAZOLE;plasmaconcentrationofsolifenacinpossiblyincreasedbylITRACONAZOLEâ€”seeunderSolifenacin,p670 
 TRIANGLE Antihistamines: increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwith ANTIHISTAMINES  
 TRIANGLE Antipsychotics: antimuscarinicspossiblyreduceeffectsof HALOPERIDOL ;increasedriskofantimuscarinicside-effectswhenantimuscarinicsgivenwith CLOZAPINE ;antimuscarinicsreduceplasmaconcentrationof PHENOTHIAZINES ,butriskofantimuscarinicside-effectsincreasedlAntivirals:manufactureroffesoterodineadvisesdosereductionwhenfesoterodinegivenwith ATAZANAVIR , INDINAVIR ,RITONAVIRandSAQUINAVIRâ€”consultfesoterodineproductliterature;manufacturerofdarifenacinadvisesavoidconcomitantusewithATAZANAVIR, FOSAMPRENAVIR ,INDINAVIR,LOPINAVIR,RITONAVIR,SAQUINAVIRand TIPRANAVIR ;manufactureroftolterodineadvisesavoidconcomitantusewithFOSAMPRENAVIR,INDINAVIR,LOPINAVIR,RITONAVIRandSAQUINAVIR;plasmaconcentrationofsolifenacinpossiblyincreasedbylRITONAVIRâ€”seeunderSolifenacin,p670lBeta-blockers:increasedriskofventriculararrhythmiaswhentolterodinegivenwithlSOTALOL 
 TRIANGLE Calcium-channelBlockers: plasmaconcentrationofsolifenacinincreasedby VERAPAMIL ;manufacturerofdarifenacinadvisesavoidconcomitantusewithVERAPAMIL 
 TRIANGLE CardiacGlycosides: darifenacinpossiblyincreasesplasmaconcentrationof DIGOXIN  
 TRIANGLE Ciclosporin: manufacturerofdarifenacinadvisesavoidconcomitantusewith CICLOSPORIN  
 TRIANGLE Domperidone: antimuscarinicsantagoniseeffectsof DOMPERIDONE ongastro-intestinalactivity BNF 
 TRIANGLE Dopaminergics: antimuscarinicspossiblyreduceabsorptionof CO - BENELDOPA ,CO- CARELDOPA and LEVODOPA  
 TRIANGLE Hormone
 Antagonists:  possibleincreasedriskofbradycardiawhenipratropiumoroxybutyningivenwith PASIREOTIDE  
 TRIANGLE Memantine: effectsofantimuscarinicspossiblyenhancedby MEM ANTI NE  
 TRIANGLE Metoclopramide: antimuscarinicsantagoniseeffectsof METOCLOPRAMIDE ongastro-intestinalactivity 
 TRIANGLE Nitrates: antimuscarinicspossiblyreduceeffectsofsublingualtabletsof NITRATES (failuretodissolveundertongueowingtodrymouth) 
 TRIANGLE Parasympathomimetics: antimuscarinicsantagoniseeffectsof PARASYMPATHOMIMETICSA ntipsychotics NOTEI ncreasedriskoftoxicitywithmyelosuppressivedrugs NOTEA voidconcomitantuseofclozapinewithdrugsthathaveasubstantialpotentialforcausingagranulocytosis 
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhenantipsychoticsgivenwith ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenphenothiazinesgivenwith ADRENERGICNEURONE BLOCKERS  ;higherdosesofchlorpromazineantagonisehypotensiveeffectofADRENERGICNEURONEBLOCKERS;haloperidolantagoniseshypotensiveeffectofADRENERGICNEURONEBLOCKERS 
 TRIANGLE Adsorbents: absorptionofphenothiazinespossiblyreducedby KAOLIN  
 TRIANGLE Alcohol: increasedsedativeeffectwhenantipsychoticsgivenwith ALCOHOL  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenantipsychoticsgivenwith ALPHA -BLOCKERS lAnaesthetics,General: droperidolenhanceseffectsof THIOPENTAL ;enhancedhypotensiveeffectwhenantipsychoticsgivenwithl GENERALANAESTHETICS 
Analgesics: possibleseveredrowsinesswhenhaloperidolgivenwith ACEMETACIN or INDOMETACIN ;increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongthe QT intervalgivenwithl METHADONE ;increasedriskofventriculararrhythmiaswhenamisulpridegivenwithlMETHADONEâ€”avoidconcomitantuse;increasedriskofconvulsionswhenantipsychoticsgivenwith TRAMADOL ;enhancedhypotensiveandsedativeeffectswhenantipsychoticsgivenwith OPIOIDANALGESICS  
 TRIANGLE Angiotensin- IIR eceptorAntagonists:enhancedhypotensiveeffectwhenantipsychoticsgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antacids: absorptionofphenothiazinesandsulpiridereducedby ANTACIDS  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithlANTI- ARRHYTHMICS thatprolongtheQTinterval;increasedriskofventriculararrhythmiaswhenamisulpride,droperidol,haloperidol,phenothiazines,pimozideorzuclopenthixolgivenwithl AMIODARONE â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenbenperidolgivenwithlAMIODARONEâ€”manufacturerofbenperidoladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhensulpiridegivenwithlAMIODARONEorl DISOPYRAMIDE ;increasedriskofventriculararrhythmiaswhenamisulpride,droperidol,pimozideorzuclopenthixolgivenwithlDISOPYRAMIDEâ€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlDISOPYRAMIDEâ€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenphenothiazinesgivenwithlDISOPYRAMIDE;avoidanceofphenothiazinesadvisedbymanufacturerofl DRONEDARONE (riskofventriculararrhythmias);increasedriskofarrhythmiaswhenclozapinegivenwithl FLECAINIDE 
Antidepressants: plasmaconcentrationofclozapinepossiblyincreasedby CITALOPRAM (increasedriskoftoxicity);avoidanceofhaloperidol,phenothiazinesandpimozideadvisedbymanufactureroflCITALOPRAM(riskofventriculararrhythmias);avoidanceofhaloperidol,phenothiazinesandpimozideadvisedbymanufacturerofl ESCITALOPRAM (riskofventriculararrhythmias);plasmaconcentrationofaripiprazolepossiblyincreasedbyl FLUOXETINE andl PAROXETINE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);plasmaconcentrationofclozapine,haloperidolandrisperidoneincreasedbylFLUOXETINE;manufacturerofdroperidoladvisesavoidconcomitantusewithlFLUOXETINE,l FLUVOXAMINE ,l SERTRALINE andl TRICYCLICS (riskofventriculararrhythmias);plasmaconcentrationofasenapineandhaloperidolpossiblyincreasedbyFLUVOXAMINE;plasmaconcentrationofclozapineandolanzapineincreasedbylFLUVOXAMINE;asenapinepossiblyincreasesplasmaconcentrationofPAROXETINE;plasmaconcentrationofclozapineincreasedbylPAROXETINEandlSERTRALINE;plasmaconcentrationofrisperidonepossiblyincreasedbyPAROXETINE(increasedriskoftoxicity);metabolismofperphenazineinhibitedbyPAROXETINE(reducedoseofperphenazine);plasmaconcentrationofhaloperidolincreasedby VENLAFAXINE ;clozapinepossiblyincreases CNS effectsofl MAOIS ;plasmaconcentrationofpimozidepossiblyincreasedbyl SSRIS (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);plasmaconcentrationoflurasidonepossiblyreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse;plasmaconcentrationofaripiprazolepossiblyreducedbylSTJOHNâ€™SWORT(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consult
 TRIANGLE Antidiabetics: phenothiazinespossiblyantagonisehypoglycaemiceffectof SULFONYLUREAS 
Antiepileptics: antipsychoticsantagoniseanticonvulsanteffectofl ANTIEPILEPTICS (convulsivethresholdlowered);metabolismofhaloperidol,olanzapine,quetiapineandrisperidoneacceleratedby CARBAMAZEPINE (reducedplasmaconcentration);metabolismofclozapineacceleratedbylCARBAMAZEPINE(reducedplasmaconcentration),alsoavoidconcomitantuseofdrugswithsubstantialpotentialforcausingagranulocytosis;plasmaconcentrationofaripiprazolereducedbylCARBAMAZEPINE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);plasmaconcentrationofpaliperidonereducedbyCARBAMAZEPINE;plasmaconcentrationoflurasidonepossiblyreducedbylCARBAMAZEPINE,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”avoidconcomitantuse;chlorpromazinepossiblyincreasesordecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;metabolismofclozapineandquetiapineacceleratedbyFOSPHENYTOIN(reducedplasmaconcentration);plasmaconcentrationofaripiprazolepossiblyreducedbylFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);plasmaconcentrationofhaloperidolreducedbyFOSPHENYTOINandPHENYTOIN;metabolismofhaloperidolacceleratedbyPHENOBARBITALandPRIMIDONE(reducedplasmaconcentration);plasmaconcentrationofbothdrugsreducedwhenchlorpromazinegivenwithPHENOBARBITALandPRIMIDONE;plasmaconcentrationofclozapinepossiblyreducedbyPHENOBARBITALandPRIMIDONE;metabolismofclozapineandquetiapineacceleratedbyPHENYTOIN(reducedplasmaconcentration);increasedriskofside-effectsincludingneutropeniawhenolanzapinegivenwithl SODIUMVALPROATE andl VALPROICACID ;plasmaconcentrationofclozapinepossiblyincreasedordecreasedbySODIUMVALPROATEandVALPROICACID
Antifungals: plasmaconcentrationoflurasidoneincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;metabolismofaripiprazoleinhibitedbylKETOCONAZOLE(reducedoseofaripiprazole);plasmaconcentrationoflurasidonepossiblyincreasedbyl FLUCONAZOLE (seeunderLurasidone,p315);plasmaconcentrationoflurasidonepossiblyincreasedbyl ITRACONAZOLE ,l POSACONAZOLE andl VORICONAZOLE â€”avoidconcomitantuse;plasmaconcentrationofaripiprazolepossiblyincreasedbylITRACONAZOLE(reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);side-effectsofrisperidonepossiblyincreasedbyITRACONAZOLE;plasmaconcentrationofhaloperidolpossiblyincreasedbyITRACONAZOLE;increasedriskofventriculararrhythmiaswhenpimozidegivenwithl IMIDAZOLES orl TRIAZOLES â€”avoidconcomitantuse;plasmaconcentrationofquetiapinepossiblyincreasedbylIMIDAZOLESandlTRIAZOLESâ€”manufacturerofquetiapineadvisesavoidconcomitantuse
 TRIANGLE Antimuscarinics: increasedriskofantimuscarinicside-effectswhenclozapinegivenwith ANTIMUSCARINICS ;plasmaconcentrationofphenothiazinesreducedbyANTIMUSCARINICS,butriskofantimuscarinicside-effectsincreased;effectsofhaloperidolpossiblyreducedbyANTIMUSCARINICS
Antipsychotics: increasedriskofventriculararrhythmiaswhenamisulpride,pimozideorsulpiridegivenwithl DROPERIDOL â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenphenothiazinesthatprolongthe QT intervalgivenwithlDROPERIDOLâ€”avoidconcomitantuse;avoidconcomitantuseofclozapinewithdepotformulationofl FLUPENTIXOL ,l FLUPHENAZINE ,l HALOPERIDOL ,l PIPOTIAZINE ,l RISPERIDONE orl ZUCLOPENTHIXOL ascannotbewithdrawnquicklyifneutropeniaoccurs;increasedriskofventriculararrhythmiaswhensulpiridegivenwithlHALOPERIDOL;chlorpromazinepossiblyincreasesplasmaconcentrationofHALOPERIDOL;increasedriskofventriculararrhythmiaswhendroperidolgivenwithlHALOPERIDOLâ€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenpimozidegivenwithl PHENOTHIAZINES â€”avoidconcomitantuse;lurasidonepossiblyincreasesplasmaconcentrationof PIMOZIDE (increasedriskoftoxicity);possibleincreasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithlRISPERIDONE;increasedriskofventriculararrhythmiaswhenpimozidegivenwithl SULPIRIDE 
Antivirals: plasmaconcentrationofaripiprazolepossiblyincreasedbyl ATAZANAVIR ,l DARUNAVIR ,l FOSAMPRENAVIR ,l INDINAVIR ,l LOPINAVIR ,l RITONAVIR ,l SAQUINAVIR andl TIPRANAVIR (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);plasmaconcentrationofquetiapinepossiblyincreasedbylATAZANAVIR,l BOCEPREVIR ,lDARUNAVIR,lFOSAMPRENAVIR,lINDINAVIR,lLOPINAVIR,lRITONAVIR,lSAQUINAVIR,l TELAPREVIR andlTIPRANAVIRâ€”manufacturerofquetiapineadvisesavoidconcomitantuse;plasmaconcentrationofpimozidepossiblyincreasedbylATAZANAVIRâ€”avoidconcomitantuse;avoidanceofpimozideadvisedbymanufactureroflBOCEPREVIRandlTELAPREVIR;plasmaconcentrationoflurasidonepossiblyincreasedbylBOCEPREVIR,lINDINAVIR,lRITONAVIR,lSAQUINAVIRandlTELAPREVIRâ€”avoidconcomitantuse;plasmaconcentrationofaripiprazolepossiblyreducedbyl EFAVIRENZ andl NEVIRAPINE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);plasmaconcentrationofpimozidepossiblyincreasedbylEFAVIRENZ,lINDINAVIRandlSAQUINAVIR(increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);plasmaconcentrationofpimozideincreasedbylFOSAMPRENAVIRandlRITONAVIR(increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);plasmaconcentrationofantipsychoticspossiblyincreasedbylRITONAVIR;plasmaconcentrationofolanzapinereducedbyRITONAVIRâ€”considerincreasingdoseofolanzapine;avoidanceofclozapineadvisedbymanufactureroflRITONAVIR(increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhenclozapine,haloperidolorphenothiazinesgivenwithlSAQUINAVIRâ€”avoidconcomitantuse
AnxiolyticsandHypnotics: increasedsedativeeffectwhenantipsychoticsgivenwith ANXIOLYTICSANDHYPNOTICS ;plasmaconcentrationofhaloperidolpossiblyincreasedby ALPRAZOLAM ;lurasidoneincreasesplasmaconcentrationof MIDAZOLAM ;seriousadverseeventsreportedwithconcomitantuseofclozapineand BNF 
Aprepitant: avoidanceofpimozideadvisedbymanufacturerofl APREPITANT 
Atomoxetine: increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongthe QT intervalgivenwithl ATOMOXETINE  
 lBeta-blockers:enhancedhypotensiveeffectwhenphenothiazinesgivenwith BETA - BLOCKERS ;plasmaconcentrationofbothdrugsmayincreasewhenchlorpromazinegivenwithl PROPRANOLOL ;increasedriskofventriculararrhythmiaswhendroperidolorzuclopenthixolgivenwithl SOTALOL â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenamisulpride,phenothiazines,pimozideorsulpiridegivenwithlSOTALOL;possibleincreasedriskofventriculararrhythmiaswhenrisperidonegivenwithlSOTALOL;possibleincreasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlSOTALOLâ€”avoidconcomitantuselCalcium-channelBlockers: enhancedhypotensiveeffectwhenantipsychoticsgivenwith CALCIUM - CHANNELBLOCKERS ;plasmaconcentrationoflurasidoneincreasedbyl DILTIAZEM (seeunderLurasidone,p315);plasmaconcentrationoflurasidonepossiblyincreasedbyl VERAPAMIL (seeunderLurasidone,p315)  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenphenothiazinesgivenwith CLONIDINE 
Cobicistat: plasmaconcentrationoflurasidonepossiblyincreasedbyl  CO BICISTAT â€”avoidconcomitantuse;plasmaconcentrationofpimozidepossiblyincreasedbylCOBICISTATâ€”manufacturerofcobicistatadvisesavoidconcomitantuse
Cytotoxics: avoidconcomitantuseofclozapinewithl CYTOTOXICS (increasedriskofagranulocytosis);possibleincreasedriskofventriculararrhythmiaswhenhaloperidolgivenwithl BOSUTINIB ;cautionwithpimozideadvisedbymanufacturerofl CRIZOTINIB ;avoidanceofpimozideandquetiapineadvisedbymanufacturerof IDELALISIB ;avoidanceofpimozideadvisedbymanufacturerofl LAPATINIB ;possibleincreasedriskofventriculararrhythmiaswhenamisulpride,chlorpromazine,haloperidol,pimozide,sulpirideorzuclopenthixolgivenwithl VANDETANIB â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenantipsychoticsthatprolongtheQTintervalgivenwithl ARSENICTRIOXIDE ;increasedriskofventriculararrhythmiaswhenhaloperidolgivenwithlARSENICTRIOXIDE 
 TRIANGLE Deferasirox: avoidanceofclozapineadvisedbymanufacturerof DEFERASIROX  
 TRIANGLE Desferrioxamine: manufactureroflevomepromazineadvisesavoidconcomitantusewith DESFERRIOXAMINE ;avoidanceofprochlorperazineadvisedbymanufacturerofDESFERRIOXAMINE 
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenphenothiazinesgivenwith DIAZOXIDE 
Diuretics: riskofventriculararrhythmiaswithamisulprideincreasedbyhypokalaemiacausedbyl DIURETICS ;riskofventriculararrhythmiaswithpimozideincreasedbyhypokalaemiacausedbylDIURETICS(avoidconcomitantuse);enhancedhypotensiveeffectwhenphenothiazinesgivenwithDIURETICS 
 TRIANGLE ErgotAlkaloids: lurasidonepossiblyincreasesplasmaconcentrationof ERGOTALKALOIDS (increasedriskoftoxicity)
Fosaprepitant: avoidanceofpimozideadvisedbymanufacturerofl FOSAPREPITANT 
GrapefruitJuice: manufactureroflurasidoneandpimozideadvisesavoidconcomitantusewith GRAPEFRUITJUICE ;plasmaconcentrationofquetiapinepossiblyincreasedbylGRAPEFRUITJUICEâ€”manufacturerofquetiapineadvisesavoidconcomitantuse 
 TRIANGLE Histamine: antipsychoticstheoreticallyantagoniseeffectsof HISTAMINE â€”manufacturerofhistamineadvisesavoidconcomitantuse
HormoneAntagonists: manufacturerofdroperidoladvisesavoidconcomitantusewithl TAMOXIFEN (riskofventriculararrhythmias)
Ivabradine: increasedriskofventriculararrhythmiaswhenpimozidegivenwithl IVABRADINE 
Lithium: increasedriskofextrapyramidalside-effectsandpossiblyneurotoxicitywhenclozapine,flupentixol,haloperidol,phenothiazines,risperidoneorzuclopenthixolgivenwithl LITHIUM ;possibleriskoftoxicitywhenolanzapinegivenwithLITHIUM;extrapyramidalside-effectsofquetiapinepossiblyincreasedbyLITHIUM;increasedriskofextrapyramidalside-effectswhensulpiridegivenwithLITHIUM 
 TRIANGLE Memantine: effectsofantipsychoticspossiblyreducedby MEMANTINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenantipsychoticsgivenwith METHYLDOPA (alsoincreasedriskofextrapyramidaleffects) 
 TRIANGLE Metoclopramide: increasedriskofextrapyramidalside-effectswhenantipsychoticsgivenwith METOCLOPRAMIDE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenphenothiazinesgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: promazinepossiblyenhanceseffectsof SUXAMETHONIUM  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenphenothiazinesgivenwith NITRATES 
Penicillamine: avoidconcomitantuseofclozapinewithl PENICILLAMINE (increasedriskofagranulocytosis)
PentamidineIsetionate: increasedriskofventriculararrhythmiaswhenamisulprideordroperidolgivenwithl PENTAMIDINEISETIONATE â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenphenothiazinesgivenwithlPENTAMIDINEISETIONATE 
 TRIANGLE SodiumBenzoate: haloperidolpossiblyreduceseffectsof SODIUMBENZOATE  
 TRIANGLE SodiumOxybate: antipsychoticspossiblyenhanceeffectsof SODIUMOXYBATE  
 TRIANGLE SodiumPhenylbutyrate: haloperidolpossiblyreduceseffectsof SODIUMPHENYLBUTYRATE  
 TRIANGLE Sympathomimetics: antipsychoticsantagonisehypertensiveeffectof SYMPATHOMIMETICS ;antipsychoticeffectsofchlorpromazinepossiblyantagonisedby DEXAMFETAMINE ;chlorpromazinepossiblyreduceseffectsof LISDEXAMFETAMINE ;side-effectsofrisperidonepossiblyincreasedby METHYLPHENIDATE 
Tacrolimus: manufacturerofdroperidoladvisesavoidconcomitantusewithl TACROLIMUS (riskofventriculararrhythmias) 
 TRIANGLE Tetrabenazine: increasedriskofextrapyramidalside-effectswhenantipsychoticsgivenwith TETRABENAZINE  
 TRIANGLE Ulcer-healing
 Drugs: effectsofantipsychotics,chlorpromazineandclozapinepossiblyenhancedby CIMETIDINE ;plasmaconcentrationofclozapinepossiblyreducedby OMEPRAZOLE ;absorptionofsulpiridereducedby SUCRALFATE  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenphenothiazinesgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE
 Antivirals see individualdrugs 
 Anxiolyticsand 
Hypnotics
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith AL CO HOL  
 TRIANGLE Alpha-blockers:enhancedhypotensiveandsedativeeffectswhenanxiolyticsandhypnoticsgivenwith ALPHA -BLOCKERS 
 TRIANGLE Aminophylline: effectsofbenzodiazepinespossiblyreducedby AMINOPHYLLINE  
 TRIANGLE Anaesthetics,General: increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics: metabolismofmidazolampossiblyinhibitedby FENTANYL ;increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith OPIOIDANALGESICS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS 
Antibacterials: metabolismofmidazolaminhibitedbyl CLARITHROMYCIN ,l ERYTHROMYCIN andl TELITHROMYCIN (increasedplasmaconcentrationwithincreasedsedation);plasmaconcentrationofbuspironeincreasedbyERYTHROMYCIN(reducedoseofbuspirone);metabolismofzopicloneinhibitedbyERYTHROMYCIN;manufacturerofzolpidemadvisesavoidconcomitantusewith CIPROFLOXACIN ;metabolismofbenzodiazepinespossiblyacceleratedby RIFAMPICIN (reducedplasmaconcentration);metabolismofdiazepamandzaleplonacceleratedbyRIFAMPICIN(reducedplasmaconcentration);metabolismofbuspironepossiblyacceleratedbyRIFAMPICIN;metabolismofzolpidemacceleratedbyRIFAMPICIN(reducedplasmaconcentrationandreducedeffect);plasmaconcentrationofzopiclonesignificantlyreducedbyRIFAMPICIN;metabolismofdiazepaminhibitedby ISONIAZID  
 TRIANGLE Anticoagulants: chloralmaytransientlyenhanceanticoagulanteffectof COUMARINS 
Antidepressants: plasmaconcentrationofalprazolamincreasedby FLUOXETINE ;plasmaconcentrationofmelatoninincreasedbyl FLUVOXAMINE â€”avoidconcomitantuse;plasmaconcentrationofsomebenzodiazepinesincreasedbyFLUVOXAMINE;sedativeeffectspossiblyincreasedwhenzolpidemgivenwith SERTRALINE ;manufacturerofbuspironeadvisesavoidconcomitantusewith MAOIS ;avoidanceofbuspironefor14daysafterstoppingl TRANYLCYPROMINE advisedbymanufactureroftranylcypromine;plasmaconcentrationoforalmidazolampossiblyreducedby STJOHN â€™ SWORT ;increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith MIRTAZAPINE , TRICYCLIC - RELATEDANTIDEPRESSANTS or TRICYCLICS  
 TRIANGLE Antiepileptics: plasmaconcentrationofmidazolamreducedby CARBAMAZEPINE and PERAMPANEL ;plasmaconcentrationofclonazepamoftenreducedbyCARBAMAZEPINE, FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE ;benzodiazepinespossiblyincreaseordecreaseplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;diazepamincreasesordecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwithPHENOBARBITALorPRIMIDONE;clobazampossiblyincreasesplasmaconcentrationof SODIUMVALPROATE and VALPROICACID ;plasmaconcentrationofdiazepamandlorazepampossiblyincreasedbySODIUMVALPROATE;increasedriskofside-effectswhenclonazepamgivenwithSODIUMVALPROATEorVALPROICACID;plasmaconcentrationofclobazamincreasedby STIRIPENTOL ;plasmaconcentrationofdiazepamandlorazepampossiblyincreasedbyVALPROICACID
 TRIANGLE Antihistamines: increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith ANTIHISTAMINES 
Antipsychotics: increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith ANTIPSYCHOTICS ;alprazolampossiblyincreasesplasmaconcentrationof HALOPERIDOL ;buspironeincreasesplasmaconcentrationofHALOPERIDOL;seriousadverseeventsreportedwithconcomitantuseofbenzodiazepinesandl CLOZAPINE (causalitynotestablished);plasmaconcentrationofmidazolamincreasedby LURASIDONE ;increasedriskofhypotension,bradycardiaandrespiratorydepressionwhenparenteralbenzodiazepinesgivenwithintramuscularl OLANZAPINE 
Antivirals: plasmaconcentrationofmidazolampossiblyincreasedbyl ATAZANAVIR â€”avoidconcomitantuseoforalmidazolam;plasmaconcentrationoforalmidazolamincreasedbyl BOCEPREVIR â€”manufacturerofbocepreviradvisesavoidconcomitantuse;increasedriskofprolongedsedationwhenmidazolamgivenwithl EFAVIRENZ â€”avoidconcomitantuse;plasmaconcentrationofmidazolampossiblyincreasedbyl FOSAMPRENAVIR ,l INDINAVIR ,l RITONAVIR andl TELAPREVIR (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam);increasedriskofprolongedsedationwhenalprazolamgivenwithlINDINAVIRâ€”avoidconcomitantuse;plasmaconcentrationofanxiolyticsandhypnoticspossiblyincreasedbylRITONAVIR;plasmaconcentrationofalprazolam,diazepam,flurazepamandzolpidempossiblyincreasedbylRITONAVIR(riskofextremesedationandrespiratorydepressionâ€”avoidconcomitantuse);plasmaconcentrationofbuspironeincreasedbyRITONAVIR(increasedriskoftoxicity);plasmaconcentrationofmidazolamincreasedbyl SAQUINAVIR (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam);plasmaconcentrationoforalmidazolamincreasedby SIMEPREVIR  
 TRIANGLE Aprepitant: plasmaconcentrationofmidazolamincreasedby APREPITANT (riskofprolongedsedation) 
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith CALCIUM - CHANNELBLOCKERS ;midazolamincreasesabsorptionof LERCANIDIPINE ;metabolismofmidazolaminhibitedby DILTIAZEM and VERAPAMIL (increasedplasmaconcentrationwithincreasedsedation);plasmaconcentrationofbuspironeincreasedbyDILTIAZEMandVERAPAMIL(reducedoseofbuspirone) 
 TRIANGLE CardiacGlycosides: alprazolamincreasesplasmaconcentrationof DIGOXIN (increasedriskoftoxicity) 
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith CLONIDINE 
Cobicistat: avoidanceoforalmidazolamadvisedbymanufacturerofl COBICISTAT 
Cytotoxics: plasmaconcentrationofmidazolamincreasedbyl CRIZOTINIB and NILOTINIB ;avoidanceoforalmidazolamadvisedbymanufacturerof IDELALISIB  
 TRIANGLE Deferasirox: plasmaconcentrationofmidazolampossiblyreducedby DEFERASIROX  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith DIAZOXIDE  
 TRIANGLE Disulfiram: metabolismofbenzodiazepinesinhibitedby DISULFIRAM (increasedsedativeeffects);increasedriskoftemazepamtoxicitywhengivenwithDISULFIRAM 
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith DIURETICS ;administrationofchloralwithparenteral FUROSEMIDE maydisplacethyroidhormonefrombindingsites 
 TRIANGLE Dopaminergics: benzodiazepinespossiblyantagoniseeffectsofCO- BENELDOPA ,CO- CARELDOPA and LEVODOPA  
 TRIANGLE Fosaprepitant: plasmaconcentrationofmidazolamincreasedby FOSAPREPITANT (riskofprolongedsedation) BNF 
 TRIANGLE GrapefruitJuice: plasmaconcentrationoforalmidazolampossiblyincreasedby GRAPEFRUITJUICE ;plasmaconcentrationofbuspironeincreasedbyGRAPEFRUITJUICE 
 TRIANGLE Ivacaftor: plasmaconcentrationofmidazolamincreasedby IVACAFTOR  
 TRIANGLE Lipid-regulatingDrugs:  plasmaconcentrationofmidazolampossiblyincreasedby ATORVASTATIN ;separatingadministrationfromalprazolamby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Lithium: increasedriskofneurotoxicitywhenclonazepamgivenwith LITHIUM  
 TRIANGLE Lofexidine: increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith LOFEXIDINE  
 TRIANGLE Methyldopa:  enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith METHYLDOPA 
Methylthioninium: possibleriskof CNS toxicitywhenbuspironegivenwithl METHYLTHIONINIUM â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) 
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith MOXONIDINE ;sedativeeffectspossiblyincreasedwhenbenzodiazepinesgivenwithMOXONIDINE 
 TRIANGLE MuscleRelaxants: increasedsedativeeffectwhenanxiolyticsandhypnoticsgivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith NITRATES  
 TRIANGLE Oestrogens: plasmaconcentrationofmelatoninincreasedby OESTROGENS ;plasmaconcentrationofchlordiazepoxide,diazepamandnitrazepampossiblyincreasedbyOESTROGENS;plasmaconcentrationoflorazepam,oxazepamandtemazepampossiblyreducedbyOESTROGENS 
 TRIANGLE Progestogens: plasmaconcentrationofchlordiazepoxide,diazepamandnitrazepampossiblyincreasedby PROGESTOGENS ;plasmaconcentrationoflorazepam,oxazepamandtemazepampossiblyreducedbyPROGESTOGENS
SodiumOxybate: benzodiazepinesenhanceeffectsofl SODIUMOXYBATE (avoidconcomitantuse) 
 TRIANGLE Theophylline: effectsofbenzodiazepinespossiblyreducedby THEOPHYLLINE  
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofmelatoninincreasedby CIMETIDINE ;metabolismofbenzodiazepines,clomethiazoleandzaleploninhibitedbyCIMETIDINE(increasedplasmaconcentration);metabolismofdiazepampossiblyinhibitedby ES OMEPRAZOLE  andOMEPRAZOLE(increasedplasmaconcentration) 
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenanxiolyticsandhypnoticsgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEA pixaban
Analgesics: increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins)
 Antibacterials:  manufacturerofapixabanadvisesavoidconcomitantusewith CLARITHROMYCIN and TELITHROMYCIN ;plasmaconcentrationofapixabanpossiblyreducedbyl RIFAMPICIN â€”manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism
 Anticoagulants:  increasedriskofhaemorrhagewhenapixabangivenwithotherl ANTICOAGULANTS (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency);increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)
 Antiepileptics:  plasmaconcentrationofapixabanpossiblyreducedbyl CARBAMAZEPINE â€”manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;plasmaconcentrationofapixabanpossiblyreducedbyl FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE  l
 Antifungals:  plasmaconcentrationofapixabanincreasedbyl KETOCONAZOLE â€”manufacturerofapixabanadvisesavoidconcomitantuse;manufacturerofapixabanadvisesavoidconcomitantusewith ITRACONAZOLE , POSACONAZOLE and VORICONAZOLE  
 TRIANGLE Antivirals:  manufacturerofapixabanadvisesavoidconcomitantusewith ATAZANAVIR , BOCEPREVIR , DARUNAVIR , FOSAMPRENAVIR , INDINAVIR , LOPINAVIR , RITONAVIR , SAQUINAVIR , TELAPREVIR and TIPRANAVIR  
 TRIANGLE Cobicistat: manufacturerofapixabanadvisesavoidconcomitantusewith COBICISTAT  
 TRIANGLE Sulfinpyrazone: increasedriskofbleedingwhenapixabangivenwith SULFINPYRAZONEA pomorphine 
 TRIANGLE Antipsychotics: effectsofapomorphineantagonisedby ANTIPSYCHOTICS  
 TRIANGLE Dopaminergics: effectsofapomorphinepossiblyenhancedby ENTACAPONE l5 HT 3-receptor
 Antagonists: possibleincreasedhypotensiveeffectwhenapomorphinegivenwithl ONDANSETRON â€”avoidconcomitantuse 
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPAA praclonidine 
 TRIANGLE Antidepressants:manufacturerofapraclonidineadvisesavoidconcomitantusewith MAOIS , TRICYCLIC - RELATEDANTIDEPRESSANTS and TRICYCLICS  
 TRIANGLE Sympathomimetics: manufacturerofapraclonidineadvisesavoidconcomitantusewith SYMPATHOMIMETICSA prepitant 
 TRIANGLE Antibacterials:plasmaconcentrationofaprepitantpossiblyincreasedbyCLARITHROMYCINandTELITHROMYCIN;plasmaconcentrationofaprepitantreducedbyRIFAMPICIN 
 TRIANGLE Anticoagulants:aprepitantpossiblyreducesanticoagulanteffectof WARFARIN 
Antidepressants: manufacturerofaprepitantadvisesavoidconcomitantusewithlSTJOHNâ€™SWORT 
 TRIANGLE Antidiabetics: aprepitantreducesplasmaconcentrationof TOLBUTAMIDE  
 TRIANGLE Antiepileptics:plasmaconcentrationofaprepitantpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE 
 TRIANGLE Antifungals:plasmaconcentrationofaprepitantincreasedbyKETOCONAZOLE
Antipsychotics: manufacturerofaprepitantadvisesavoidconcomitantusewithl PIMOZIDE  
 TRIANGLE Antivirals:plasmaconcentrationofaprepitantpossiblyincreasedbyRITONAVIR 
 TRIANGLE AnxiolyticsandHypnotics: aprepitantincreasesplasmaconcentrationof MIDAZOLAM (riskofprolongedsedation)
Avanafil: aprepitantpossiblyincreasesplasmaconcentrationofl AVANAFIL â€”seeunderAvanafil,p698 
 TRIANGLE Calcium-channelBlockers: plasmaconcentrationofbothdrugsmayincreasewhenaprepitantgivenwith DILTIAZEM  
 TRIANGLE Corticosteroids: aprepitantinhibitsmetabolismof DEXAMETHASONE and METHYLPREDNISOLONE (reducedoseofdexamethasoneandmethylprednisolone)
Cytotoxics: aprepitantpossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;aprepitantpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809) 
 TRIANGLE Dapoxetine: manufacturerofdapoxetineadvisesdosereductionwhenaprepitantgivenwith DAPOXETINE (seeunderDapoxetine,p703)
Oestrogens: aprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontainingl OESTROGENS (alternativecontraceptionrecommended)
Progestogens: aprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontainingl PROGESTOGENS (alternativecontraceptionrecommended)ArgatrobanlAnalgesics:  increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins)
Anticoagulants: increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN ,l DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)
 Aripiprazole see Antipsychotics 
 Arsenic 
 Trioxidel 
 Anti-arrhythmics
:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl AMIODARONE orl DISOPYRAMIDE 
Antibacterials:   increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl DELAMANID ,l ERYTHROMYCIN ,l LEVOFLOXACIN orl MOXIFLOXACIN 
 
 
Antidepressants:   increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl AMITRIPTYLINE orl CLOMIPRAMINE 
 
 
Antifungals:   increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl AMPHOTERICIN 
 
Antimalarials:   avoidanceofarsenictrioxideadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias)
 
 
Antipsychotics:   increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl ANTIPSYCHOTICS thatprolongthe QT interval;increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl HALOPERIDOL ;avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lBeta-blockers:increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl SOTALOL 
 
Cytotoxics:   possibleincreasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl VANDETANIB â€”avoidconcomitantuse
Diuretics: riskofventriculararrhythmiaswitharsenictrioxideincreasedbyhypokalaemiacausedbyl ACETAZOLAMIDE ,l LOOPDIURETICS orl THIAZIDESANDRELATEDDIURETICS 
Lithium: increasedriskofventriculararrhythmiaswhenarsenictrioxidegivenwithl LITHIUMA rtemetherwithLumefantrinelAnti-arrhythmics:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlAMIODARONE,lDISOPYRAMIDEandl FLECAINIDE (riskofventriculararrhythmias)lAntibacterials:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithl MACROLIDES andl QUINOLONES  
 lAntidepressants:possibleincreasedriskofventriculararrhythmiaswhenartemetherwithlumefantrinegivenwithl CITALOPRAM orl ESCITALOPRAM â€”avoidconcomitantuse;manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithl ANTIDEPRESSANTS  
 lAntifungals:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithl IMIDAZOLES andl TRIAZOLES  
 lAntimalarials:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithl ANTIMALARIALS ;increasedriskofventriculararrhythmiaswhenartemetherwithlumefantrinegivenwithl QUININE  
 lAntipsychotics:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithlANTIPSYCHOTICS 
 lBeta-blockers:manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithl METOPROLOL andlSOTALOL 
 lCytotoxics:possibleincreasedriskofventriculararrhythmiaswhenartemetherwithlumefantrinegivenwithlVANDETANIBâ€”avoidconcomitantuse  
 TRIANGLE  GrapefruitJuice:  plasmaconcentrationofartemetherwithlumefantrinepossiblyincreasedby GRAPEFRUITJUICE  
 TRIANGLE Histamine: avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE  
 lUlcer-healing
 Drugs: manufacturerofartemetherwithlumefantrineadvisesavoidconcomitantusewithl CIMETIDINE  
 TRIANGLE Vaccines: antimalarialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein BNFA rtenimolwithPiperaquine NOTEP iperaquinehasalonghalf-life;thereisapotentialfordruginteractionstooccurforupto3monthsaftertreatmenthasbeenstoppedlAnalgesics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithl METHADONE (possibleriskofventriculararrhythmias)lAnti-arrhythmics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlAMIODARONEandlDISOPYRAMIDE(possibleriskofventriculararrhythmias)lAntibacterials:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlMACROLIDESandlMOXIFLOXACIN(possibleriskofventriculararrhythmias);manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewith RIFAMPICIN  
 lAntidepressants:possibleincreasedriskofventriculararrhythmiaswhenartenimolwithpiperaquinegivenwithlCITALOPRAMorlESCITALOPRAMâ€”avoidconcomitantuse;manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlANTIDEPRESSANTS 
 TRIANGLE Antiepileptics: manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewith CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE  
 lAntifungals:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlIMIDAZOLESandlTRIAZOLES(possibleriskofventriculararrhythmias)
Antihistamines: manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithl MIZOLASTINE (possibleriskofventriculararrhythmias)lAntimalarials:avoidanceofantimalarialsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE  
 lAntipsychotics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithl DROPERIDOL ,lHALOPERIDOL,l PHENOTHIAZINES andl PIMOZIDE (possibleriskofventriculararrhythmias)lAntivirals:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlSAQUINAVIR(possibleriskofventriculararrhythmias)lBeta-blockers:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithlSOTALOL(possibleriskofventriculararrhythmias)lCytotoxics:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithl ARSENICTRIOXIDE (possibleriskofventriculararrhythmias);manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithl VINBLASTINE ,l VINCRISTINE ,l VINFLUNINE andl VINORELBINE 
Domperidone: manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithl DOMPERIDONE (possibleriskofventriculararrhythmias) 
 TRIANGLE GrapefruitJuice:manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewith GRAPEFRUITJUICEBNF 
 TRIANGLE Histamine: avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE 
PentamidineIsetionate: manufacturerofartenimolwithpiperaquineadvisesavoidconcomitantusewithl PENTAMIDINEISETIONATE (possibleriskofventriculararrhythmias) 
 TRIANGLE Vaccines: antimalarialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Ascorbicacid see Vitamins 
 Asenapine see Antipsychotics 
Aspirin
 TRIANGLE Anaesthetics,General: aspirinpossiblyenhanceseffectsof THIOPENTAL 
Analgesics: avoidconcomitantuseofaspirinwithl NSAIDS (increasedside-effects);antiplateleteffectofaspirinpossiblyreducedby IBUPROFEN  
 TRIANGLE Antacids:  excretionofaspirinincreasedbyalkalineurineduetosome ANTACIDS  l
 Anticoagulants:  increasedriskofbleedingwhenaspiringivenwithl COUMARINS orl PHENINDIONE (duetoantiplateleteffect);aspirinenhancesanticoagulanteffectofl HEPARINS  
 
Antidepressants:  increasedriskofbleedingwhenaspiringivenwithl SSRIS orl VENLAFAXINE  
 TRIANGLE Antiepileptics: aspirinenhanceseffectsof FOS PHENYTOIN  ,PHENYTOIN, SODIUMVALPROATE and VALPROICACID  
 TRIANGLE Clopidogrel: increasedriskofbleedingwhenaspiringivenwith CLOPIDOGREL  
 TRIANGLE Corticosteroids: increasedriskofgastro-intestinalbleedingandulcerationwhenaspiringivenwith CORTICOSTEROIDS ,alsocorticosteroidsreduceplasmaconcentrationofsalicylatelCytotoxics:  aspirinreducesexcretionofl METHOTREXATE (increasedriskoftoxicity);aspirinpossiblyreducesrenalexcretionof PEMETREXED â€”consultproductliterature
Diuretics: increasedriskoftoxicitywhenhigh-doseaspiringivenwithl ACETAZOLAMIDE ;aspirinantagonisesdiureticeffectof SPIRONOLACTONE ;possibleincreasedriskoftoxicitywhenhigh-doseaspiringivenwith LOOPDIURETICS (alsopossiblereducedeffectofloopdiuretics) 
 TRIANGLE Iloprost: increasedriskofbleedingwhenaspiringivenwith ILOPROST  
 TRIANGLE LeukotrieneReceptorAntagonists: aspirinincreasesplasmaconcentrationof ZAFIRLUKAST  
 TRIANGLE Metoclopramide: rateofabsorptionofaspirinincreasedby METOCLOPRAMIDE (enhancedeffect) 
 TRIANGLE Sulfinpyrazone: aspirinantagoniseseffectsof SULFINPYRAZONEA tazanavir 
 TRIANGLE Antacids:absorptionofatazanavirreducedbyANTACIDS(giveatleast2hoursbeforeor1hourafterantacids)lAnti-arrhythmics:atazanavirpossiblyincreasesplasmaconcentrationofl AMIODARONE andl LIDOCAINE 
Antibacterials: plasmaconcentrationofbothdrugsincreasedwhenatazanavirgivenwith CLARITHROMYCIN ;atazanavirincreasesplasmaconcentrationofl RIFABUTIN (reducedoseofrifabutin);plasmaconcentrationofatazanavirreducedbyl RIFAMPICIN â€”avoidconcomitantuse;avoidanceofconcomitantatazanavirinsevererenalandhepaticimpairmentadvisedbymanufacturerofl TELITHROMYCIN  
 TRIANGLE Anticoagulants:atazanavirmayenhanceorreduceanticoagulanteffectof WARFARIN ;avoidanceofatazanaviradvisedbymanufacturerof APIXABAN and RIVAROXABAN  
 lAntidepressants:plasmaconcentrationofatazanavirreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse
Antifungals: plasmaconcentrationofatazanavirincreasedbyl POSACONAZOLE ;atazanavirincreasesordecreasestheplasmaconcentrationofl VORICONAZOLE andplasmaconcentrationofatazanaviralsoreduced
Antimalarials: cautionwithatazanaviradvisedbymanufacturerof ARTEMETHERWITHLUMEFANTRINE ;atazanavirpossiblyincreasesplasmaconcentrationofl QUININE (increasedriskoftoxicity) 
Antipsychotics: atazanavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);atazanavirpossiblyincreasesplasmaconcentrationofl PIMOZIDE â€”avoidconcomitantuse;atazanavirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse
Antivirals: plasmaconcentrationofatazanavirreducedbyl BOCEPREVIR ;atazanavirincreasestheplasmaconcentrationofl DACLATASVIR â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);absorptionofatazanavirreducedby DIDANOSINE tablets(giveatleast2hoursbeforeor1hourafterdidanosinetablets);manufacturerofatazanaviradvisesavoidconcomitantusewithl EFAVIRENZ (plasmaconcentrationofatazanavirreduced);atazanavirboostedwithritonavirincreasesplasmaconcentrationofl ELVITEGRAVIR (reducedoseofelvitegravir);avoidconcomitantuseofatazanavirwithl INDINAVIR ;atazanavirincreasesplasmaconcentrationofl MARAVIROC (considerreducingdoseofmaraviroc);plasmaconcentrationofatazanavirpossiblyreducedbyl NEVIRAPINE â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenatazanavirgivenwithl SAQUINAVIR â€”avoidconcomitantuse;atazanavirpossiblyreducesplasmaconcentrationof TELAPREVIR ,alsoplasmaconcentrationofatazanavirpossiblyincreased;plasmaconcentrationofatazanavirreducedby TENOFOVIR ,alsoplasmaconcentrationoftenofovirpossiblyincreased;atazanavirincreasesplasmaconcentrationof TIPRANAVIR (alsoplasmaconcentrationofatazanavirreduced)
AnxiolyticsandHypnotics: atazanavirpossiblyincreasesplasmaconcentrationofl MIDAZOLAM â€”avoidconcomitantuseoforalmidazolam
Avanafil: atazanavirpossiblyincreasesplasmaconcentrationofl AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuselCalcium-channelBlockers: atazanavirincreasesplasmaconcentrationofl DILTIAZEM (reducedoseofdiltiazem);atazanavirpossiblyincreasesplasmaconcentrationof VERAPAMIL 
Ciclosporin: atazanavirpossiblyincreasesplasmaconcentrationofl CICLOSPORIN 
Colchicine: atazanavirpossiblyincreasesriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCytotoxics:atazanavirpossiblyincreasesplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consultaxitinibproductliterature);atazanavirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;atazanavirpossiblyincreasesplasmaconcentrationofl CRIZOTINIB andl EVEROLIMUS â€”manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;atazanavirpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);atazanavirpossiblyincreasesplasmaconcentrationofl PAZOPANIB (reducedoseofpazopanib);avoidanceofatazanaviradvisedbymanufacturerofl CABAZITAXEL ;atazanavirpossiblyinhibitsmetabolismofl IRINOTECAN (increasedriskoftoxicity)
Dapoxetine: avoidanceofatazanaviradvisedbymanufacturerofl DAPOXETINE (increasedriskoftoxicity)
ErgotAlkaloids: atazanavirpossiblyincreasesplasmaconcentrationofl ERGOTALKALOIDS â€”avoidconcomitantuselLipid-regulating
 Drugs: possibleincreasedriskofmyopathywhenatazanavirgivenwithl ATORVASTATIN or PRAVASTATIN ;atazanavirincreasesplasmaconcentrationofl ROSUVASTATIN â€”adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhenatazanavirgivenwithl SIMVASTATIN (avoidconcomitantuse) 
 TRIANGLE Oestrogens: atazanavirincreasesplasmaconcentrationof ETHINYLESTRADIOL 
Orlistat: absorptionofatazanavirpossiblyreducedbyl ORLISTAT  
 TRIANGLE Progestogens: atazanavirincreasesplasmaconcentrationof NORETHISTERONE 
Ranolazine: atazanavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse
Sildenafil: atazanavirpossiblyincreasesside-effectsofl SILDENAFIL 
Sirolimus: atazanavirpossiblyincreasesplasmaconcentrationofl SIROLIMUS 
Tacrolimus: atazanavirpossiblyincreasesplasmaconcentrationofl TACROLIMUS 
Ticagrelor: atazanavirpossiblyincreasesplasmaconcentrationofl TICAGRELOR â€”manufacturerofticagreloradvisesavoidconcomitantuselUlcer-healing
 Drugs: manufacturerofatazanaviradvisesadjustdosesofbothdrugswhenatazanavirgivenwith CIMETIDINE and NIZATIDINE â€”consultatazanavirproductliterature;plasmaconcentrationofatazanavirreducedbyl FAMOTIDINE andl RANITIDINE (adjustdosesofbothdrugsâ€”consultatazanavirproductliterature);plasmaconcentrationofatazanavirreducedbyl PROTONPUMPINHIBITORS â€”avoidoradjustdoseofbothdrugs(consultproductliterature)
 Atenolol see Beta-blockers 
 Atomoxetine 
 
Analgesics: increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithl METHADONE ;possibleincreasedriskofconvulsionswhenatomoxetinegivenwith TRAMADOL  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithl AMIODARONE orl DISOPYRAMIDE  l
 Antibacterials:    increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithparenterall ERYTHROMYCIN ;increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithl MOXIFLOXACIN  l
 Antidepressants:  metabolismofatomoxetinepossiblyinhibitedby FLUOXETINE and PAROXETINE ;possibleincreasedriskofconvulsionswhenatomoxetinegivenwith ANTIDEPRESSANTS ;atomoxetineshouldnotbestarteduntil2weeksafterstoppingl  MAOI S ,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingatomoxetine;increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithl TRICYCLICS 
Antimalarials: increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithl MEFLOQUINE 
Antipsychotics: increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithl ANTIPSYCHOTICS thatprolongthe QT intervallBeta-blockers:increasedriskofventriculararrhythmiaswhenatomoxetinegivenwithl SOTALOL   
 TRIANGLE Bupropion: possibleincreasedriskofconvulsionswhenatomoxetinegivenwith BUPROPION 
Diuretics: riskofventriculararrhythmiaswithatomoxetineincreasedbyhypokalaemiacausedbyl DIURETICS  
 TRIANGLE Sympathomimetics,Beta2:Increasedriskofcardiovascularside-effectswhenatomoxetinegivenwithparenteral SALBUTAMOL
 Atorvastatin see Statins 
 Atovaquonel 
 Antibacterials
:manufacturerofatovaquoneadvisesavoidconcomitantusewith RIFABUTIN (plasmaconcentrationofbothdrugsreduced);plasmaconcentrationofatovaquonereducedbyl RIFAMPICIN (andconcentrationofrifampicinincreased)â€”avoidconcomitantuse;plasmaconcentrationofatovaquonereducedby TETRACYCLINE  
Antivirals:  plasmaconcentrationofatovaquonereducedbyl EFAVIRENZ â€”avoidconcomitantuse;atovaquonepossiblyreducesplasmaconcentrationof INDINAVIR ;plasmaconcentrationofatovaquonepossiblyreducedby RITONAVIR â€”manufacturerofatovaquoneadvisesavoidconcomitantuse;atovaquoneincreasesplasmaconcentrationof ZIDOVUDINE (increasedriskoftoxicity) 
 TRIANGLE Cytotoxics: atovaquonepossiblyincreasesplasmaconcentrationof ETOPOSIDE  
 TRIANGLE Histamine: avoidanceofatovaquoneadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Metoclopramide: plasmaconcentrationofatovaquonereducedby METOCLOPRAMIDE â€”avoidconcomitantuse
 Atracurium see Muscle 
 Relaxants 
 Atropine see Antimuscarinics 
Avanafil
 TRIANGLE Alcohol: possibleenhancedhypotensiveeffectwhenavanafilgivenwith ALCOHOL  
 lAlpha-blockers:enhancedhypotensiveeffectwhenavanafilgivenwithl ALPHA - BLOCKERS â€”whenpatientisstableonthealphablockerinitiateavanafilatthelowestpossibledoselAntibacterials:plasmaconcentrationofavanafilpossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”manufacturerofavanafiladvisesavoidconcomitantuse;plasmaconcentrationofavanafilincreasedbylERYTHROMYCINâ€”seeunderAvanafil,p698;plasmaconcentrationofavanafilpossiblyreducedbyRIFAMPICINâ€”manufacturerofavanafiladvisesavoidconcomitantuse 
 TRIANGLE Antiepileptics:  plasmaconcentrationofavanafilpossiblyreducedby CARBAMAZEPINE , PHENOBARBITAL and PRIMIDONE â€”manufacturerofavanafiladvisesavoidconcomitantuse
 Antifungals:  plasmaconcentrationofavanafilincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;plasmaconcentrationofavanafilpossiblyincreasedbyl FLUCONAZOLE â€”seeunderAvanafil,p698;plasmaconcentrationofavanafilpossiblyincreasedbyl ITRACONAZOLE andl VORICONAZOLE â€”manufacturerofavanafiladvisesavoidconcomitantuselAntivirals:plasmaconcentrationofavanafilpossiblyincreasedbyl ATAZANAVIR ,lINDINAVIRandl SAQUINAVIR â€”manufacturerofavanafiladvisesavoidconcomitantuse;plasmaconcentrationofavanafilpossiblyreducedbyEFAVIRENZâ€”manufacturerofavanafiladvisesavoidconcomitantuse;plasmaconcentrationofavanafilpossiblyincreasedbyl FOSAMPRENAVIR â€”seeunderAvanafil,p698;plasmaconcentrationofavanafilsignificantlyincreasedbylRITONAVIRâ€”avoidconcomitantuse
Aprepitant: plasmaconcentrationofavanafilpossiblyincreasedbyl APREPITANT â€”seeunderAvanafil,p698 
 TRIANGLE Bosentan: plasmaconcentrationofavanafilpossiblyreducedby BOSENTAN â€”manufacturerofavanafiladvisesavoidconcomitantuselCalcium-channelBlockers: plasmaconcentrationofavanafilpossiblyincreasedbyl DILTIAZEM andl VERAPAMIL â€”seeunderAvanafil,p698 
 TRIANGLE Fosaprepitant: plasmaconcentrationofavanafilpossiblyincreasedby FOSAPREPITANT  
 TRIANGLE GrapefruitJuice: plasmaconcentrationofavanafilpossiblyincreasedby GRAPEFRUITJUICE â€”manufacturerofavanafiladvisesavoidgrapefruitjuicefor24hoursbeforeavanafil
Nicorandil: avanafilsignificantlyenhanceshypotensiveeffectofl NICORANDIL (avoidconcomitantuse)
Nitrates: avanafilsignificantlyenhanceshypotensiveeffectofl NITRATES (avoidconcomitantuse)
Riociguat: possibleenhancedhypotensiveeffectwhenavanafilgivenwithl RIOCIGUAT â€”avoidconcomitantuse
Axitinib 
 TRIANGLE Antibacterials:plasmaconcentrationofaxitinibpossiblyincreasedbyCLARITHROMYCIN,ERYTHROMYCINandTELITHROMYCIN(reducedoseofaxitinibâ€”consultaxitinibproductliterature);plasmaconcentrationofaxitinibpossiblydecreasedbyRIFABUTIN(increasedoseofaxitinibâ€”consultaxitinibproductliterature);plasmaconcentrationofaxitinibdecreasedbyRIFAMPICIN(increasedoseofaxitinibâ€”consultaxitinibproductliterature) 
 TRIANGLE Antidepressants:plasmaconcentrationofaxitinibpossiblyreducedby STJOHN â€™ SWORT â€”considerincreasingdoseofaxitinib 
 TRIANGLE Antiepileptics:plasmaconcentrationofaxitinibpossiblydecreasedbyCARBAMAZEPINE, FOS PHENYTOIN  ,PHENOBARBITAL,PHENYTOINandPRIMIDONE(increasedoseofaxitinibâ€”consultaxitinibproductliterature) 
 TRIANGLE Antifungals:plasmaconcentrationofaxitinibincreasedbyKETOCONAZOLE(reducedoseofaxitinibâ€”consultaxitinibproductliterature);plasmaconcentrationofaxitinibpossibly BNF 
 TRIANGLE  Antivirals:  plasmaconcentrationofaxitinibpossiblyincreasedby ATAZAN AV IR , INDINAVIR , RITONAVIR and SAQUINAVIR (reducedoseofaxitinibâ€”consultaxitinibproductliterature) 
 TRIANGLE Corticosteroids: plasmaconcentrationofaxitinibpossiblydecreasedby DEXAMETHASONE (increasedoseofaxitinibâ€”consultaxitinibproductliterature) 
 TRIANGLE GrapefruitJuice: plasmaconcentrationofaxitinibpossiblyincreasedby GRAPEFRUITJUICEA zathioprine 
 TRIANGLE  ACE Inhibitors:increasedriskofanaemiaorleucopeniawhenazathioprinegivenwith CAPTOPRIL especiallyinrenalimpairment;increasedriskofanaemiawhenazathioprinegivenwith ENALAPRIL especiallyinrenalimpairment
Allopurinol: enhancedeffectsandincreasedtoxicityofazathioprinewhengivenwithl ALLOPURINOL (reducedoseofazathioprinetoonequarterofusualdose)
 
Antibacterials:   increasedriskofhaematologicaltoxicitywhenazathioprinegivenwithl SULFAMETHOXAZOLE (asco-trimoxazole);increasedriskofhaematologicaltoxicitywhenazathioprinegivenwithl TRIMETHOPRIM (alsowithco-trimoxazole)lAnticoagulants:  azathioprinepossiblyreducesanticoagulanteffectofl COUMARINS 
Antivirals: myelosuppressiveeffectsofazathioprinepossiblyenhancedbyl RIBAVIRIN 
Febuxostat: avoidanceofazathioprineadvisedbymanufacturerofl FEBUXOSTAT
 Azelastine see Antihistamines 
 Azilsartan see Angiotensin-
 IIR eceptorAntagonists
 Azithromycin see Macrolides 
 Aztreonaml 
 Anticoagulants
:aztreonampossiblyenhancesanticoagulanteffectoflCOUMARINS 
 TRIANGLE Vaccines:  antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Baclofen see Muscle 
 Relaxants 
 Bambuterol see Sympathomimetics
,Beta2BasiliximablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:  riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse BCG
 Vaccine see Vaccines 
 Beclometasone see Corticosteroids 
 Bedaquilinel 
 Antibacterials
:plasmaconcentrationofbedaquilinepossiblyincreasedby CIPROFLOXACIN , CLARITHROMYCIN and ERYTHROMYCIN â€”avoidconcomitantuseifciprofloxacin,clarithromycinanderythromycingivenformorethan14days;manufacturerofbedaquilineadvisesavoidconcomitantusewith MOXIFLOXACIN ;plasmaconcentrationofbedaquilinepossiblyreducedby RIFABUTIN â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationofbedaquilinereducedbyl RIFAMPICIN â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenbedaquilinegivenwithl CLOFAZIMINE  
 TRIANGLE Antidepressants: plasmaconcentrationofbedaquilinepossiblyreducedby STJOHN â€™ SWORT â€”manufacturerofbedaquilineadvisesavoidconcomitantuse
Antiepileptics: plasmaconcentrationofbedaquilinepossiblyreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  andlPHENYTOINâ€”manufacturerofbedaquilineadvisesavoidconcomitantuse 
 TRIANGLE Antivirals:plasmaconcentrationofbedaquilinepossiblyreducedby EFAVIRENZ and ETRAVIRINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationofbedaquilinepossiblyincreasedbyRITONAVIRâ€”avoidconcomitantuseifritonavirgivenformorethan14days 
 TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNFBeeVenomExtracts
 lACE
 Inhibitors:  possiblesevereanaphylactoidreactionwhenbeevenomextractsgivenwithl  ACEINHIBITORS B elimumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINESâ€”avoidconcomitantuseBendamustinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
 Bendroflumethiazide see Diuretics 
 Benperidol see Antipsychotics 
 Benzodiazepines see Anxiolyticsand 
 Hypnotics 
 Benzthiazide see Diuretics 
 Benzylpenicillin see Penicillins 
 Beta-blockers
 NOTES incesystemicabsorptionmayfollowtopicalapplicationofbeta-blockerstotheeyethepossibilityofinteractions,inparticular,withdrugssuchasverapamilshouldbeborneinmind 
 TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenbeta-blockersgivenwithACEINHIBITORS 
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenbeta-blockersgivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenbeta-blockersgivenwith ALCOHOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenbeta-blockersgivenwith ALDESLEUKIN  
 lAlpha-blockers:enhancedhypotensiveeffectwhenbeta-blockersgivenwithl ALPHA -BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin 
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhenbeta-blockersgivenwith GENERALANAESTHETICS  lAnaesthetics,Local: propranololincreasesriskofl BUPIVACAINE toxicity 
 TRIANGLE Analgesics: hypotensiveeffectofbeta-blockersantagonisedby NSAIDS ;plasmaconcentrationofesmololpossiblyincreasedby MORPHINE  
 TRIANGLE Angiotensin-II
 ReceptorAntagonists: enhancedhypotensiveeffectwhenbeta-blockersgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 lAnti-arrhythmics:increasedmyocardialdepressionwhenbeta-blockersgivenwithl ANTI - ARRHYTHMICS ;increasedriskofventriculararrhythmiaswhensotalolgivenwithl AMIODARONE ,l DISOPYRAMIDE orl DRONEDARONE â€”avoidconcomitantuse;increasedriskofbradycardia,AVblockandmyocardialdepressionwhenbeta-blockersgivenwithlAMIODARONE;plasmaconcentrationofmetoprololandpropranololpossiblyincreasedbyDRONEDARONE;increasedriskofmyocardialdepressionandbradycardiawhenbeta-blockersgivenwithl FLECAINIDE ;propranololincreasesriskofl LIDOCAINE toxicity;nadololpossiblyincreasesriskofLIDOCAINEtoxicity;plasmaconcentrationofmetoprololandpropranololincreasedby PROPAFENONE  
 lAntibacterials:increasedriskofventriculararrhythmiaswhensotalolgivenwithlMOXIFLOXACINâ€”avoidconcomitantuse;metabolismofbisoprololandpropranololacceleratedbyRIFAMPICIN(plasmaconcentrationsignificantlyreduced);plasmaconcentrationofcarvedilol,celiprololandmetoprololreducedbyRIFAMPICIN;plasmaconcentrationoforaltimololpossiblyreducedbyRIFAMPICIN;increasedriskofventriculararrhythmiaswhensotalolgivenwithl DELAMANID 
Antidepressants: plasmaconcentrationofmetoprololincreasedby CITALOPRAM and ESCITALOPRAM ;increasedriskof
 TRIANGLE Antidiabetics: beta-blockersmaymaskwarningsignsofhypoglycaemia(suchastremor)with ANTIDIABETICS ;beta-blockersenhancehypoglycaemiceffectof INSULIN  
 TRIANGLE Antiepileptics: plasmaconcentrationofpropranololpossiblyreducedby PHENOBARBITAL and PRIMIDONE  
 TRIANGLE Antifungals: plasmaconcentrationofnadololpossiblyincreasedby KETO CO NAZOLE  l
 Antihistamines:  increasedriskofventriculararrhythmiaswhensotalolgivenwithl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: avoidanceofmetoprololandsotaloladvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;avoidanceofsotaloladvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias);increasedriskofbradycardiawhenbeta-blockersgivenwith MEFLOQUINE 
Antimuscarinics: increasedriskofventriculararrhythmiaswhensotalolgivenwithl TOLTERODINE 
Antipsychotics:   increasedriskofventriculararrhythmiaswhensotalolgivenwithl DROPERIDOL orl ZUCLOPENTHIXOL â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhensotalolgivenwithl HALOPERIDOL â€”avoidconcomitantuse;plasmaconcentrationofbothdrugsmayincreasewhenpropranololgivenwithl CHLORPROMAZINE ;increasedriskofventriculararrhythmiaswhensotalolgivenwithl AMISULPRIDE ,l PHENOTHIAZINES ,l PIMOZIDE orl SULPIRIDE ;enhancedhypotensiveeffectwhenbeta-blockersgivenwithPHENOTHIAZINES;possibleincreasedriskofventriculararrhythmiaswhensotalolgivenwithl RISPERIDONE 
Antivirals: increasedriskofventriculararrhythmiaswhensotalolgivenwithl SAQUINAVIR â€”avoidconcomitantuse;avoidanceofsotaloladvisedbymanufacturerofl TELAPREVIR (riskofventriculararrhythmias);avoidanceofmetoprololforheartfailureadvisedbymanufacturerofl TIPRANAVIR  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenbeta-blockersgivenwith ANXIOLYTICSANDHYPNOTICS 
Atomoxetine: increasedriskofventriculararrhythmiaswhensotalolgivenwithl ATOMOXETINE  
 lCalcium-channelBlockers: enhancedhypotensiveeffectwhenbeta-blockersgivenwith CALCIUM - CHANNELBLOCKERS ;possibleseverehypotensionandheartfailurewhenbeta-blockersgivenwithl NIFEDIPINE ;increasedriskofAVblockandbradycardiawhenbeta-blockersgivenwithl DILTIAZEM ;asystole,severehypotensionandheartfailurewhenbeta-blockersgivenwithl VERAPAMIL (seeunderVerapamil,p156) 
 TRIANGLE CardiacGlycosides: increasedriskofAVblockandbradycardiawhenbeta-blockersgivenwith CARDIACGLYCOSIDES 
Ciclosporin: carvedilolincreasesplasmaconcentrationofl CICLOSPORIN 
Clonidine: increasedriskofwithdrawalhypertensionwhenbeta-blockersgivenwithl CLONIDINE (withdrawbeta-blockersseveraldaysbeforeslowlywithdrawingclonidine) 
 TRIANGLE Corticosteroids: hypotensiveeffectofbeta-blockersantagonisedby CORTICOSTEROIDS 
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenbeta-blockersgivenwith DIAZOXIDE 
Diuretics: enhancedhypotensiveeffectwhenbeta-blockersgivenwith DIURETICS ;riskofventriculararrhythmiaswithsotalolincreasedbyhypokalaemiacausedbyl LOOPDIURETICS orl THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhenbeta-blockersgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE ErgotAlkaloids: increasedperipheralvasoconstrictionwhenbeta-blockersgivenwith ERGOTAMINE 
Fingolimod: possibleincreasedriskofbradycardiawhenbeta-blockersgivenwithl FINGOLIMOD  
 TRIANGLE HormoneAntagonists: possibleincreasedriskofbradycardiawhencarteolol,metoprolol,propranololorsotalolgivenwith PASIREOTIDE  
 TRIANGLE 5 HT 1-receptor
 Agonists: propranololincreasesplasmaconcentrationof RIZATRIPTAN (manufacturerofrizatriptanadviseshalvedoseandavoidwithin2hoursofpropranolol)
Ivabradine: increasedriskofventriculararrhythmiaswhensotalolgivenwithl IVABRADINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenbeta-blockersgivenwith METHYLDOPA  
 TRIANGLE Mirabegron: plasmaconcentrationofmetoprololincreasedby MIRABEGRON 
Moxisylyte: possiblesevereposturalhypotensionwhenbeta-blockersgivenwithl MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenbeta-blockersgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: propranololenhanceseffectsof MUSCLERELAXANTS ;enhancedhypotensiveeffectwhenbeta-blockersgivenwith BACLOFEN ;possibleenhancedhypotensiveeffectandbradycardiawhenbeta-blockersgivenwith TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenbeta-blockersgivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofbeta-blockersantagonisedby OESTROGENS  
 TRIANGLE Parasympathomimetics: propranololantagoniseseffectsof NEOSTIGMINE and PYRIDOSTIGMINE ;increasedriskofarrhythmiaswhenbeta-blockersgivenwith PILOCARPINE  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenbeta-blockersgivenwith ALPROSTADIL 
Ranolazine: avoidanceofsotaloladvisedbymanufacturerofl RANOLAZINE 
Sympathomimetics: increasedriskofseverehypertensionandbradycardiawhennon-cardioselectivebeta-blockersgivenwithl ADRENALINE ( EPINEPHRINE ),alsoreponsetoadrenaline(epinephrine)maybereduced;increasedriskofseverehypertensionandbradycardiawhennon-cardioselectivebeta-blockersgivenwithl DOBUTAMINE ;possibleincreasedriskofseverehypertensionandbradycardiawhennon-cardioselectivebeta-blockersgivenwithl NORADRENALINE ( NOREPINEPHRINE ) 
 TRIANGLE ThyroidHormones: metabolismofpropranololacceleratedby LEVOTHYROXINE  
 TRIANGLE Ulcer-healing
 Drugs: plasmaconcentrationoflabetalol,metoprololandpropranololincreasedby CIMETIDINE ;plasmaconcentrationoforaltimololpossiblyincreasedbyCIMETIDINE 
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenbeta-blockersgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEB etahistine 
 TRIANGLE Antihistamines:effectofbetahistinetheoreticallyantagonisedby ANTIHISTAMINES
 Betamethasone see Corticosteroids 
 Betaxolol see Beta-blockers 
 Bethanechol see Parasympathomimetics 
 Bevacizumabl 
 Antipsychotics
:avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuseBexarotenelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) BNF 
 Bezafibrate see Fibrates 
 Bicalutamide
  
 TRIANGLE Anticoagulants:   bicalutamidepossiblyenhancesanticoagulanteffectof COUMARINS  
 TRIANGLE Lipid-regulatingDrugs:separatingadministrationfrombicalutamideby12hoursadvisedbymanufacturerof LOMITAPIDE
 Biguanides see Antidiabetics 
 Bilastine see Antihistamines 
 Bile 
 Acid 
 Sequestrants see Colesevelam
,Colestipol,andColestyramineBile
Acids 
 TRIANGLE Antacids:  absorptionofbileacidspossiblyreducedby ANTACIDS  
 
Ciclosporin:  ursodeoxycholicacidincreasesabsorptionofl CICLOSPORIN  
 TRIANGLE Lipid-regulatingDrugs:absorptionofbileacidspossiblyreducedby COLESTIPOL and COLESTYRAMINE
 Bisoprolol see Beta-blockers 
Bisphosphonates
 TRIANGLE Antibacterials: increasedriskofhypocalcaemiawhenbisphosphonatesgivenwith AMINOGLYCOSIDES  
 TRIANGLE CalciumSalts: absorptionofbisphosphonatesreducedby CALCIUMSALTS 
 
Cytotoxics:   sodiumclodronateincreasesplasmaconcentrationofl ESTRAMUSTINE  
 TRIANGLE IronSalts: absorptionofbisphosphonatesreducedbyoral IRONSALTSB ivalirudin
 Analgesics:  increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins)
Anticoagulants: increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN ,l DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)Bleomycin
 
Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides:  bleomycinpossiblyreducesabsorptionof DIGOXIN tabletslCytotoxics:increasedriskofpulmonarytoxicitywhenbleomycingivenwithl BRENTUXIMABVEDOTIN â€”avoidconcomitantuse;increasedpulmonarytoxicitywhenbleomycingivenwithl CISPLATINB oceprevir 
 TRIANGLE Alpha-blockers:boceprevirpossiblyincreasesplasmaconcentrationof DOXAZOSIN and TAMSULOSIN â€”manufacturerofbocepreviradvisesavoidconcomitantuse 
 TRIANGLE Analgesics:possibleincreasedriskofprolongedsedationandrespiratorydepressionwhenboceprevirgivenwith BUPRENORPHINE ;boceprevirpossiblyaffectsplasmaconcentrationof METHADONE 
Antibacterials:   manufacturerofbocepreviradvisesavoidconcomitantusewithl RIFAMPICIN (plasmaconcentrationofboceprevirpossiblyreduced) 
 TRIANGLE Anticoagulants:avoidanceofbocepreviradvisedbymanufacturerofAPIXABAN l
 Antiepileptics:  manufacturerofbocepreviradvisesavoidconcomitantusewithl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE (plasmaconcentrationofboceprevirpossiblyreduced)
 Antifungals:  plasmaconcentrationofboceprevirincreasedbyl KETOCONAZOLE 
Antivirals: boceprevirreducesplasmaconcentrationofl ATAZANAVIR ;boceprevirpossiblyincreasestheplasmaconcentrationofl DACLATASVIR â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);avoidconcomitantuseofboceprevirwithl DARUNAVIR ;effectsofbothdrugspossiblyreducedwhenboceprevirgivenwith ETRAVIRINE ;avoidanceofbocepreviradvisedbymanufacturerofl FOSAMPRENAVIR , NEVIRAPINE and TIPRANAVIR ;manufacturersadviseavoidconcomitantuseofboceprevirwithl LOPINAVIR ;boceprevirincreasesplasmaconcentrationof MARAVIROC (considerreducingdoseofmaraviroc);plasmaconcentrationofbothdrugsreducedwhenboceprevirgivenwithl RITONAVIR 
AnxiolyticsandHypnotics: boceprevirincreasesplasmaconcentrationoforall MIDAZOLAM â€”manufacturerofbocepreviradvisesavoidconcomitantuse 
 TRIANGLE CardiacGlycosides:boceprevirpossiblyincreasesside-effectsofDIGOXIN 
 lCiclosporin:boceprevirincreasesplasmaconcentrationoflCICLOSPORIN
Cilostazol: boceprevirpossiblyincreasesplasmaconcentrationofl CILOSTAZOL (seeunderCilostazol,p206) 
 TRIANGLE Cobicistat: avoidanceofbocepreviradvisedbymanufacturerof COBICISTAT  
 lCytotoxics:boceprevirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;manufacturerofbocepreviradvisesavoidconcomitantusewithl DASATINIB ,l ERLOTINIB ,l GEFITINIB ,l IMATINIB ,l LAPATINIB ,l NILOTINIB ,l PAZOPANIB ,l SORAFENIB andl SUNITINIB ;manufacturerofruxolitinibadvisesdosereductionwhenboceprevirgivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature
Domperidone: possibleincreasedriskofventriculararrhythmiaswhenboceprevirgivenwithl DOMPERIDONE â€”avoidconcomitantuse
ErgotAlkaloids: manufacturerofbocepreviradvisesavoidconcomitantusewithl ERGOTALKALOIDS  
 lLipid-regulatingDrugs:boceprevirincreasesplasmaconcentrationof ATORVASTATIN (reducedoseofatorvastatin);boceprevirincreasesplasmaconcentrationof PRAVASTATIN ;manufacturersadviseavoidconcomitantuseofboceprevirwithl SIMVASTATIN  
 TRIANGLE Progestogens: boceprevirincreasesplasmaconcentrationof DROSPIRENONE (increasedriskoftoxicity)
Sirolimus: boceprevirincreasesplasmaconcentrationofl SIROLIMUS (increasedriskoftoxicityâ€”reducesirolimusdose)
Tacrolimus: boceprevirincreasesplasmaconcentrationofl TACROLIMUS (reducedoseoftacrolimus)BortezomiblAntibacterials:plasmaconcentrationofbortezomibreducedbylRIFAMPICINâ€”manufacturerofbortezomibadvisesavoidconcomitantuse 
 TRIANGLE Antidepressants: plasmaconcentrationofbortezomibpossiblyreducedby STJOHN â€™ SWORT â€”manufacturerofbortezomibadvisesavoidconcomitantuse 
 TRIANGLE Antiepileptics:plasmaconcentrationofbortezomibpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONEâ€”manufacturerofbortezomibadvisesavoidconcomitantuse 
 TRIANGLE Antifungals:plasmaconcentrationofbortezomibincreasedbyKETOCONAZOLE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)BosentanlAntibacterials:plasmaconcentrationofbosentanreducedbylRIFAMPICINâ€”avoidconcomitantuse 
 TRIANGLE Anticoagulants:manufacturerofbosentanrecommendsmonitoringanticoagulanteffectofCOUMARINS
Antidiabetics: increasedriskofhepatotoxicitywhenbosentangivenwithl GLIBENCLAMIDE â€”avoidconcomitantuse
 
Antifungals:   plasmaconcentrationofbosentanincreasedby KETOCONAZOLE ;plasmaconcentrationofbosentanpossiblyincreasedbyl FLUCONAZOLE â€”avoidconcomitantuse;plasmaconcentrationofbosentanpossiblyincreasedby ITRACONAZOLE  
Antivirals:  avoidanceofbosentanadvisedbymanufacturerof ELVITEGRAVIR and TIPRANAVIR ;bosentanpossiblyreducesplasmaconcentrationof INDINAVIR ;plasmaconcentrationofbosentanincreasedbyl LOPINAVIR andl RITONAVIR (considerreducingdoseofbosentan);bosentanpossiblyreducesplasmaconcentrationof TELAPREVIR ,alsoplasmaconcentrationofbosentanpossiblyincreased  
 TRIANGLE Avanafil: bosentanpossiblyreducesplasmaconcentrationof AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse
Ciclosporin: plasmaconcentrationofbosentanincreasedbyl CICLOSPORIN (alsoplasmaconcentrationofciclosporinreducedâ€”avoidconcomitantuse) 
 TRIANGLE Cobicistat: avoidanceofbosentanadvisedbymanufacturerof COBICISTAT 
Cytotoxics:   bosentanpossiblyreducesplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidconcomitantuse 
 TRIANGLE Lipid-regulatingDrugs:  bosentanreducesplasmaconcentrationof SIMVASTATIN 
Oestrogens: bosentanpossiblycausescontraceptivefailureofhormonalcontraceptivescontainingl OESTROGENS (alternativecontraceptionrecommended)
Progestogens: bosentanpossiblycausescontraceptivefailureofhormonalcontraceptivescontainingl PROGESTOGENS (alternativecontraceptionrecommended) 
 TRIANGLE Riociguat: bosentanreducesplasmaconcentrationof RIOCIGUAT  
 TRIANGLE Sildenafil: bosentanreducesplasmaconcentrationof SILDENAFIL ,alsoplasmaconcentrationofbosentanincreased 
 TRIANGLE Tadalafil: bosentanreducesplasmaconcentrationof TADALAFILB osutinib
Analgesics: possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithl METHADONE  
 TRIANGLE Antacids: manufacturerofbosutinibadvisesseparatingadministrationwith ANTACIDS byabout12hourslAnti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithl AMIODARONE andl DISOPYRAMIDE ;plasmaconcentrationofbosutinibpossiblyincreasedbyl DRONEDARONE â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib
Antibacterials:   plasmaconcentrationofbosutinibpossiblyincreasedbyl CIPROFLOXACIN ,l CLARITHROMYCIN ,l ERYTHROMYCIN andl TELITHROMYCIN â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithl MOXIFLOXACIN ;plasmaconcentrationofbosutinibpossiblyreducedbyl RIFABUTIN â€”manufacturerofbosutinibadvisesavoidconcomitantuse;plasmaconcentrationofbosutinibreducedbyl RIFAMPICIN â€”manufacturerofbosutinibadvisesavoidconcomitantuse
 Antidepressants:  plasmaconcentrationofbosutinibpossiblyreducedbyl STJOHN â€™ SWORT â€”manufacturerofbosutinibadvisesavoidconcomitantuse
Antiepileptics: plasmaconcentrationofbosutinibpossiblyreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”manufacturerofbosutinibadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofbosutinibincreasedbylKETOCONAZOLEâ€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;plasmaconcentrationofbosutinibpossiblyincreasedbylFLUCONAZOLE,lITRACONAZOLE,l POSACONAZOLE andl VORICONAZOLE â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib
 Antipsychotics:   possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithl HALOPERIDOL ;avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofbosutinibpossiblyincreasedbyl ATAZANAVIR ,l BOCEPREVIR ,l DARUNAVIR ,l FOSAMPRENAVIR ,lINDINAVIR,lRITONAVIR,l SAQUINAVIR andlTELAPREVIRâ€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;plasmaconcentrationofbosutinibpossiblyreducedbyl EFAVIRENZ andl ETRAVIRINE â€”manufacturerofbosutinibadvisesavoidconcomitantuse
Aprepitant: plasmaconcentrationofbosutinibpossiblyincreasedbyl APREPITANT â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblBeta-blockers:possibleincreasedriskofventriculararrhythmiaswhenbosutinibgivenwithl SOTALOL 
Bosentan: plasmaconcentrationofbosutinibpossiblyreducedbyl BOSENTAN â€”manufacturerofbosutinibadvisesavoidconcomitantuselCalcium-channelBlockers: plasmaconcentrationofbosutinibpossiblyincreasedbyl DILTIAZEM andl VERAPAMIL â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutiniblCytotoxics:plasmaconcentrationofbosutinibpossiblyincreasedbyl IMATINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib
 Domperidone:  manufacturerofbosutinibadvisesavoidconcomitantusewithl DOMPERIDONE (riskofventriculararrhythmias)
Fosaprepitant: plasmaconcentrationofbosutinibpossiblyincreasedbyl FOSAPREPITANT â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib
GrapefruitJuice: plasmaconcentrationofbosutinibpossiblyincreasedbyl GRAPEFRUITJUICE â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib
Modafinil: plasmaconcentrationofbosutinibpossiblyreducedbyl MODAFINIL â€”manufacturerofbosutinibadvisesavoidconcomitantuse 
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofbosutinibreducedby LANSOPRAZOLEB rentuximabvedotin 
 TRIANGLE Antibacterials:effectsofbrentuximabvedotinpossiblyreducedbyRIFAMPICIN 
 lAntifungals:possibleincreasedriskofneutropeniawhenbrentuximabvedotingivenwithlKETOCONAZOLE 
Antipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCytotoxics:increasedriskofpulmonarytoxicitywhenbrentuximabvedotingivenwithl BLEOMYCIN â€”avoidconcomitantuse
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
Brimonidine 
 TRIANGLE Antidepressants:manufacturerofbrimonidineadvisesavoidconcomitantusewith MAOIS , TRICYCLIC - RELATEDANTIDEPRESSANTS and TRICYCLICS
 Brinzolamide see Diuretics 
Bromocriptine
 TRIANGLE Antibacterials:plasmaconcentrationofbromocriptineincreasedbyERYTHROMYCIN(increasedriskoftoxicity);plasmaconcentrationofbromocriptinepossiblyincreasedby MACROLIDES (increasedriskoftoxicity) 
 TRIANGLE Antipsychotics:hypoprolactinaemicandantiparkinsonianeffectsofbromocriptineantagonisedby ANTIPSYCHOTICS  
 TRIANGLE Domperidone:hypoprolactinaemiceffectofbromocriptinepossiblyantagonisedbyDOMPERIDONE 
 TRIANGLE HormoneAntagonists: plasmaconcentrationofbromocriptineincreasedby OCTREOTIDE  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA  
 TRIANGLE Metoclopramide: hypoprolactinaemiceffectofbromocriptineantagonisedby METOCLOPRAMIDEBNF 
Sympathomimetics: riskoftoxicitywhenbromocriptinegivenwithl ISOMETHEPTENE
 Buclizine see Antihistamines 
 Budesonide see Corticosteroids 
 Bumetanide see Diuretics 
 Bupivacaine
  
 TRIANGLE  Anti-arrhythmics:increasedmyocardialdepressionwhenbupivacainegivenwith ANTI - ARRHYTHMICS  
 lBeta-blockers:increasedriskofbupivacainetoxicitywhengivenwithl PROPRANOLOL
 Buprenorphine see Opioid 
 Analgesics 
 Bupropion 
 
l
 Antidepressants:   bupropionpossiblyincreasesplasmaconcentrationof CITALOPRAM ;manufacturerofbupropionadvisesavoidfor2weeksafterstoppingl MAOIS ;manufacturerofbupropionadvisesavoidconcomitantusewithl MOCLOBEMIDE ;bupropionpossiblyincreasesplasmaconcentrationof TRICYCLICS (possibleincreasedriskofconvulsions) 
 TRIANGLE Antiepileptics:   plasmaconcentrationofbupropionreducedby CARBAMAZEPINE , FOS PHENYTOIN  andPHENYTOIN;metabolismofbupropioninhibitedby SODIUMVALPROATE and VALPROICACID  
 TRIANGLE Antivirals:   metabolismofbupropionacceleratedby EFAVIRENZ (reducedplasmaconcentration);plasmaconcentrationofbupropionreducedby RITONAVIR  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenbupropiongivenwith ATOMOXETINE  
 TRIANGLE Dopaminergics: increasedriskofside-effectswhenbupropiongivenwith AMANTADINE , CO - BENELDOPA ,CO- CARELDOPA or LEVODOPA 
HormoneAntagonists: bupropionpossiblyinhibitsmetabolismofl TAMOXIFEN toactivemetabolite(avoidconcomitantuse)
Methylthioninium: possibleriskof CNS toxicitywhenbupropiongivenwithl METHYLTHIONINIUM â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)
 Buspirone see Anxiolyticsand 
 Hypnotics 
Busulfan
 TRIANGLE Antiepileptics:plasmaconcentrationofbusulfanpossiblyreducedbyFOSPHENYTOINandPHENYTOIN 
 TRIANGLE Antifungals:  metabolismofbusulfaninhibitedby ITRACONAZOLE (increasedriskoftoxicity)l
 Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Cytotoxics: increasedriskofhepatotoxicitywhenbusulfangivenwith TIOGUANINE
 Butyrophenones see Antipsychotics 
 Cabazitaxel 
 
Antibacterials: plasmaconcentrationofcabazitaxelpossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxel;manufacturerofcabazitaxeladvisesavoidconcomitantusewithl RIFABUTIN ;plasmaconcentrationofcabazitaxelreducedbyl RIFAMPICIN â€”manufacturerofcabazitaxeladvisesavoidconcomitantuselAntidepressants:manufacturerofcabazitaxeladvisesavoidconcomitantusewithl STJOHN â€™ SWORT  
Antiepileptics:  manufacturerofcabazitaxeladvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE 
Antifungals: manufacturerofcabazitaxeladvisesavoidconcomitantusewithl KETOCONAZOLE ;plasmaconcentrationofcabazitaxelpossiblyincreasedbylITRACONAZOLEandl VORICONAZOLE â€”manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxel
 
Antivirals: manufacturerofcabazitaxeladvisesavoidconcomitantusewithl ATAZANAVIR ;plasmaconcentrationofcabazitaxelpossiblyincreasedbyl INDINAVIR ,lRITONAVIRandl SAQUINAVIR â€”manufacturerofcabazitaxeladvisesavoidorconsiderreducingdoseofcabazitaxel
 lCabergoline 
 TRIANGLE Antibacterials:plasmaconcentrationofcabergolineincreasedby ERYTHROMYCIN (increasedriskoftoxicity);plasmaconcentrationofcabergolinepossiblyincreasedby MACROLIDES (increasedriskoftoxicity) 
 TRIANGLE Antipsychotics:hypoprolactinaemicandantiparkinsonianeffectsofcabergolineantagonisedby ANTIPSYCHOTICS  
 TRIANGLE Domperidone: hypoprolactinaemiceffectofcabergolinepossiblyantagonisedby DOMPERIDONE  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA  
 TRIANGLE Metoclopramide: hypoprolactinaemiceffectofcabergolineantagonisedby METOCLOPRAMIDEC abozantiniblAntibacterials:plasmaconcentrationofcabozantinibpossiblyincreasedbyCLARITHROMYCINandERYTHROMYCIN;plasmaconcentrationofcabozantinibreducedbylRIFAMPICINâ€”avoidconcomitantuse 
 TRIANGLE Antidepressants:plasmaconcentrationofcabozantinibpossiblyreducedbySTJOHNâ€™SWORTâ€”manufacturerofcabozantinibadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofcabozantinibpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONEâ€”avoidconcomitantuse 
 TRIANGLE Antifungals:plasmaconcentrationofcabozantinibincreasedbyKETOCONAZOLE;plasmaconcentrationofcabozantinibpossiblyincreasedbyITRACONAZOLE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Antivirals:plasmaconcentrationofcabozantinibpossiblyincreasedbyRITONAVIR 
 TRIANGLE Corticosteroids:  plasmaconcentrationofcabozantinibpossiblyreducedby DEXAMETHASONE â€”manufacturerofcabozantinibadvisesavoidconcomitantuse 
 TRIANGLE GrapefruitJuice: plasmaconcentrationofcabozantinibpossiblyincreasedby GRAPEFRUITJUICEC affeinecitrate 
 TRIANGLE Aminophylline: manufacturerofcaffeinecitrateadvisesavoidconcomitantusewith AMINOPHYLLINE  
 TRIANGLE Anti-arrhythmics:caffeinecitrateantagonisesanti-arrhythmiceffectof ADENOSINE â€”manufacturerofadenosineadvisesavoidcaffeinecitrateforatleast12hoursbeforeadenosine 
 TRIANGLE Antiepileptics:plasmaconcentrationofcaffeinecitratereducedbyFOSPHENYTOINandPHENYTOIN;caffeinecitratepossiblyantagoniseseffectsofPHENOBARBITALandPRIMIDONE 
 TRIANGLE Theophylline: manufacturerofcaffeinecitrateadvisesavoidconcomitantusewith THEOPHYLLINE  
 TRIANGLE Ulcer-healing
 Drugs: plasmaconcentrationofcaffeinecitrateincreasedby CIMETIDINE
 Calcitriol see Vitamins 
 Calcium 
 Salts
 NOT
 E see also 
Antacids
 TRIANGLE Antivirals:calciumsaltsreduceabsorptionof DOLUTEGRAVIR â€”manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursaftercalciumsalts;manufacturerofrilpivirineadvisesgivecalciumsalts2hoursbeforeor4hoursafter RILPIVIRINE  
 TRIANGLE Bisphosphonates: calciumsaltsreduceabsorptionof BISPHOSPHONATES  
 TRIANGLE CardiacGlycosides: largeintravenousdosesofcalciumsaltscanprecipitatearrhythmiaswhengivenwith CARDIACGLYCOSIDES  
 TRIANGLE Corticosteroids:absorptionofcalciumsaltsreducedby CORTICOSTEROIDS 
 TRIANGLE Cytotoxics: calciumsaltsreduceabsorptionof ESTRAMUSTINE (manufacturerofestramustineadvisesavoidconcomitantadministration) 
 TRIANGLE Diuretics: increasedriskofhypercalcaemiawhencalciumsaltsgivenwith THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE Eltrombopag: calciumsaltspossiblyreduceabsorptionof ELTROMBOPAG (giveatleast4hoursapart) 
 TRIANGLE Fluorides: calciumsaltsreduceabsorptionof FLUORIDES  
 TRIANGLE IronSalts: calciumsaltsreduceabsorptionoforal IRONSALTS  
 TRIANGLE ThyroidHormones: calciumsaltsreduceabsorptionof LEVOTHYROXINE  
 TRIANGLE Zinc: calciumsaltsreduceabsorptionof ZINCC alcium-channelBlockers NOTED ihydropyridinecalcium-channelblockersincludeamlodipine,felodipine,isradipine,lacidipine,lercanidipine,nicardipine,nifedipine,andnimodipine 
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ALCOHOL ;verapamilpossiblyincreasesplasmaconcentrationofALCOHOL 
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ALDESLEUKIN  
 TRIANGLE Aliskiren: verapamilincreasesplasmaconcentrationof ALISKIREN  
 lAlpha-blockers:verapamilincreasesplasmaconcentrationof TAMSULOSIN ;enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithl ALPHA -BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin
Aminophylline: calcium-channelblockerspossiblyincreaseplasmaconcentrationofl AMINOPHYLLINE (enhancedeffect);diltiazemincreasesplasmaconcentrationofAMINOPHYLLINE;verapamilincreasesplasmaconcentrationoflAMINOPHYLLINE(enhancedeffect)
 lAnaesthetics,General: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith GENERALANAESTHETICS or ISOFLURANE ;hypotensiveeffectofverapamilenhancedbylGENERALANAESTHETICS(also AV delay) 
 TRIANGLE Analgesics: hypotensiveeffectofcalcium-channelblockersantagonisedby NSAIDS ;diltiazeminhibitsmetabolismof ALFENTANIL (riskofprolongedordelayedrespiratorydepression) 
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 lAnti-arrhythmics:increasedriskofbradycardia,AVblockandmyocardialdepressionwhendiltiazemorverapamilgivenwithl AMIODARONE ;increasedriskofmyocardialdepressionandasystolewhenverapamilgivenwithl DISOPYRAMIDE orl FLECAINIDE ;increasedriskofbradycardiaandmyocardialdepressionwhendiltiazemandverapamilgivenwithl DRONEDARONE ;nifedipineincreasesplasmaconcentrationoflDRONEDARONE
Antibacterials: metabolismofcalcium-channelblockerspossiblyinhibitedbyl CLARITHROMYCIN ,l ERYTHROMYCIN andl TELITHROMYCIN (increasedriskofside-effects);manufactureroflercanidipineadvisesavoidconcomitantusewithERYTHROMYCIN;metabolismofdiltiazem,nifedipine,nimodipineandverapamilacceleratedbyl RIFAMPICIN (plasmaconcentrationsignificantlyreduced);metabolismofisradipineandnicardipinepossiblyacceleratedbylRIFAMPICIN(possiblesignificantlyreducedplasmaconcentration);plasmaconcentrationoffelodipinepossiblyreducedbyRIFAMPICIN;avoidanceofverapamiladvisedbymanufacturerof FIDAXOMICIN 
Anticoagulants: verapamilpossiblyincreasesplasmaconcentrationofl DABIGATRAN (seeunderDabigatranEtexilate,p117)
 TRIANGLE Antidiabetics: glucosetoleranceoccasionallyimpairedwhennifedipinegivenwith INSULIN 
Antiepileptics: effectsofdihydropyridines,nicardipineandnifedipineprobablyreducedby CARBAMAZEPINE ;effectsoffelodipineandisradipinereducedbyCARBAMAZEPINE;diltiazemandverapamilenhanceeffectsoflCARBAMAZEPINE;manufacturerofnimodipineadvisesavoidconcomitantusewithCARBAMAZEPINE, FOS PHENYTOIN  andPHENYTOIN(plasmaconcentrationofnimodipinepossiblyreduced);effectsoffelodipineandverapamilreducedbyFOSPHENYTOIN;manufacturerofisradipineadvisesavoidconcomitantusewithFOSPHENYTOIN, PHENOBARBITAL ,PHENYTOINand PRIMIDONE ;diltiazemincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOINbutalsoeffectofdiltiazemreduced;effectsofcalcium-channelblockersprobablyreducedbylPHENOBARBITALandlPRIMIDONE;manufacturerofnimodipineadvisesavoidconcomitantusewithlPHENOBARBITALandlPRIMIDONE(plasmaconcentrationofnimodipinereduced);effectsoffelodipineandverapamilreducedbyPHENYTOIN
Antifungals: metabolismofdihydropyridinespossiblyinhibitedby ITRACONAZOLE and KETOCONAZOLE (increasedplasmaconcentration);metabolismoffelodipineisinhibitedbylKETOCONAZOLE(increasedplasmaconcentration)â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;manufactureroflercanidipineadvisesavoidconcomitantusewithITRACONAZOLEandKETOCONAZOLE;negativeinotropiceffectpossiblyincreasedwhencalcium-channelblockersgivenwithITRACONAZOLE;metabolismoffelodipineinhibitedbylITRACONAZOLE(increasedplasmaconcentration);plasmaconcentrationofnifedipineincreasedby MICAFUNGIN  
 TRIANGLE Antimalarials: possibleincreasedriskofbradycardiawhencalcium-channelblockersgivenwith MEFLOQUINE  
 TRIANGLE Antimuscarinics: avoidanceofverapamiladvisedbymanufacturerof DARIFENACIN ;verapamilincreasesplasmaconcentrationof SOLIFENACIN 
Antipsychotics: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ANTIPSYCHOTICS ;diltiazemincreasestheplasmaconcentrationofl LURASIDONE (seeunderLurasidone,p315);verapamilpossiblyincreasestheplasmaconcentrationoflLURASIDONE(seeunderLurasidone,p315)
Antivirals: plasmaconcentrationofverapamilpossiblyincreasedby ATAZANAVIR ;plasmaconcentrationofdiltiazemincreasedbylATAZANAVIR(reducedoseofdiltiazem);plasmaconcentrationofdiltiazemreducedby EFAVIRENZ ;manufactureroflercanidipineadvisesavoidconcomitantusewith RITONAVIR ;plasmaconcentrationofcalcium-channelblockerspossiblyincreasedbylRITONAVIR;cautionwithdiltiazem,felodipine,nicardipine,nifedipineandverapamiladvisedbymanufacturerof TELAPREVIR ;plasmaconcentrationofamlodipineincreasedbyTELAPREVIR(considerreducingdoseofamlodipine) 
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ANXIOLYTICSANDHYPNOTICS ;diltiazemandverapamilinhibitmetabolismof MIDAZOLAM (increasedplasmaconcentrationwithincreasedsedation);absorptionoflercanidipineincreasedbyMIDAZOLAM;diltiazemandverapamilincreaseplasmaconcentrationof BUSPIRONE (reducedoseofbuspirone) 
 TRIANGLE Aprepitant: plasmaconcentrationofbothdrugsmayincreasewhendiltiazemgivenwith APREPITANT 
Avanafil: diltiazemandverapamilpossiblyincreaseplasmaconcentrationofl AVANAFIL â€”seeunderAvanafil,p698lBeta-blockers:enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith BETA -BLOCKERS;increasedriskof BNF 
 TRIANGLE  Calcium-channelBlockers: plasmaconcentrationofbothdrugsmayincreasewhendiltiazemgivenwith NIFEDIPINE 
CardiacGlycosides: diltiazem,lercanidipineandnicardipineincreaseplasmaconcentrationofl DIGOXIN ;verapamilincreasesplasmaconcentrationoflDIGOXIN,alsoincreasedriskofAVblockandbradycardia;nifedipinepossiblyincreasesplasmaconcentrationoflDIGOXIN
Ciclosporin: diltiazem,nicardipineandverapamilincreaseplasmaconcentrationofl CICLOSPORIN ;combinationoflercanidipinewithlCICLOSPORINmayincreaseplasmaconcentrationofeitherdrug(orboth)â€”avoidconcomitantuse;plasmaconcentrationofnifedipinepossiblyincreasedbyCICLOSPORIN(increasedriskoftoxicityincludinggingivalhyperplasia) 
 TRIANGLE Cilostazol: diltiazemincreasesplasmaconcentrationof CILOSTAZOL (considerreducingdoseofcilostazol) 
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith CLONIDINE 
Colchicine: diltiazemandverapamilpossiblyincreaseriskofl  CO LCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) 
 TRIANGLE Corticosteroids: hypotensiveeffectofcalcium-channelblockersantagonisedby CORTICOSTEROIDS ;diltiazemincreasesplasmaconcentrationof METHYLPREDNISOLONE 
Cytotoxics: verapamilpossiblyincreasesplasmaconcentrationof DOXORUBICIN ;verapamilpossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationofverapamilby6to12hours;diltiazemandverapamilpossiblyincreasetheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;possibleincreasedriskofbradycardiawhendiltiazemorverapamilgivenwith CRIZOTINIB ;plasmaconcentrationofbothdrugsmayincreasewhenverapamilgivenwithl EVEROLIMUS (considerreducingthedoseofeverolimusâ€”consulteverolimusproductliterature);diltiazemandverapamilpossiblyincreasetheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);nifedipinepossiblyinhibitsmetabolismof VINCRISTINE  
 TRIANGLE Dapoxetine: manufacturerofdapoxetineadvisesdosereductionwhendiltiazemandverapamilgivenwith DAPOXETINE (seeunderDapoxetine,p703) 
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith DIURETICS ;diltiazemandverapamilincreaseplasmaconcentrationof EPLERE NON E (reducedoseofeplerenone) 
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA 
Fingolimod: possibleincreasedriskofbradycardiawhendiltiazemorverapamilgivenwithl FINGOLIMOD  
 TRIANGLE Fosaprepitant: plasmaconcentrationofbothdrugsmayincreasewhendiltiazemgivenwith FOSAPREPITANT  
 TRIANGLE GrapefruitJuice: plasmaconcentrationoffelodipine,isradipine,lacidipine,lercanidipine,nicardipine,nifedipine,nimodipineandverapamilincreasedby GRAPEFRUITJUICE ;plasmaconcentrationofamlodipinepossiblyincreasedbyGRAPEFRUITJUICE 
 TRIANGLE HormoneAntagonists: diltiazemandverapamilincreaseplasmaconcentrationof DUTASTERIDE ;possibleincreasedriskofbradycardiawhendiltiazemorverapamilgivenwith PASIREOTIDE 
Ivabradine: diltiazemandverapamilincreaseplasmaconcentrationofl IVABRADINE â€”avoidconcomitantuse
 TRIANGLE Lithium: neurotoxicitymayoccurwhendiltiazemorverapamilgivenwith LITHIUM withoutincreasedplasmaconcentrationoflithiumlMagnesium(parenteral):profoundhypotensionreportedwithconcomitantuseofnifedipineandl PARENTERALMAGNESIUM inpre-eclampsia 
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: verapamilenhanceseffectsofNON- DEPOLARISINGMUSCLERELAXANTS and SUXAMETHONIUM ;enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith BACLOFEN or TIZANIDINE ;manufacturerofverapamiladvisesavoidconcomitantuseofintravenous DANTROLENE ;possibleincreasedriskofventriculararrhythmiaswhendiltiazemgivenwithintravenousDANTROLENEâ€”manufacturerofdiltiazemadvisesavoidconcomitantuse;calcium-channelblockerspossiblyenhanceeffectsofNON-DEPOLARISINGMUSCLERELAXANTS 
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofcalcium-channelblockersantagonisedby OESTROGENS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith ALPROSTADIL  
 TRIANGLE Ranolazine: diltiazemandverapamilincreaseplasmaconcentrationof RANOLAZINE (considerreducingdoseofranolazine) 
 TRIANGLE Sildenafil: enhancedhypotensiveeffectwhenamlodipinegivenwith SILDENAFIL 
Sirolimus: diltiazemincreasesplasmaconcentrationofl SIROLIMUS ;plasmaconcentrationofbothdrugsincreasedwhenverapamilgivenwithlSIROLIMUS;nicardipinepossiblyincreasesplasmaconcentrationofSIROLIMUS 
 TRIANGLE Sulfinpyrazone: plasmaconcentrationofverapamilreducedby SULFINPYRAZONE 
Tacrolimus: diltiazem,nicardipineandnifedipineincreaseplasmaconcentrationofl TACROLIMUS ;felodipineandverapamilpossiblyincreaseplasmaconcentrationofTACROLIMUS
Theophylline: calcium-channelblockerspossiblyincreaseplasmaconcentrationofl THEOPHYLLINE (enhancedeffect);diltiazemincreasesplasmaconcentrationofTHEOPHYLLINE;verapamilincreasesplasmaconcentrationoflTHEOPHYLLINE(enhancedeffect) 
 TRIANGLE Ticagrelor: diltiazemincreasesplasmaconcentrationof TICAGRELOR  
 TRIANGLE Ulcer-healingDrugs:metabolismofcalcium-channelblockerspossiblyinhibitedby CIMETIDINE (increasedplasmaconcentration);plasmaconcentrationofisradipineincreasedbyCIMETIDINE(halvedoseofisradipine) 
 TRIANGLE Ulipristal: avoidanceofverapamiladvisedbymanufactureroflow-dose ULIPRISTAL  
 TRIANGLE Vardenafil: enhancedhypotensiveeffectwhennifedipinegivenwith VARDENAFIL  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhencalcium-channelblockersgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE 
Calcium-channelBlockers(dihydropyridines)seeCalcium-channe
 lBlockers
 Canagliflozin see Antidiabetics 
 Canakinumab 
 
Antipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
 Vaccines:  riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Candesartan see Angiotensin-
 IIR eceptorAntagonistsCannabisExtract
 
Antibacterials:   plasmaconcentrationofcannabisextractreducedbyl RIFAMPICIN â€”manufacturerofcannabisextractadvisesavoidconcomitantuselAntidepressants:  plasmaconcentrationofcannabisextractpossiblyreducedbyl STJOHN â€™ SWORT â€”manufacturerofcannabisextractadvisesavoidconcomitantuse;possibleincreasedriskofhypertensionandtachycardiawhencannabisextractgivenwith  TRICYCLIC S  l
 Antiepileptics:  plasmaconcentrationofcannabisextractpossiblyreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”manufacturerofcannabisextractadvisesavoidconcomitantuse  
 TRIANGLE Antifungals: plasmaconcentrationofcannabisextractincreasedby  KETOCONAZOLE C apecitabine
Allopurinol: manufacturerofcapecitabineadvisesavoidconcomitantusewithl ALLOPURINOL  
 TRIANGLE Antibacterials:metabolismofcapecitabineinhibitedby METRONIDAZOLE (increasedtoxicity)lAnticoagulants:  capecitabineenhancesanticoagulanteffectofl COUMARINS  
 TRIANGLE Antiepileptics:capecitabinepossiblyinhibitsmetabolismofFOSPHENYTOINandPHENYTOIN(increasedriskoftoxicity)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Cytotoxics:  capecitabinepossiblyincreasesplasmaconcentrationof ERLOTINIB  
 TRIANGLE Filgrastim: neutropeniapossiblyexacerbatedwhencapecitabinegivenwith FILGRASTIM 
Folates: toxicityofcapecitabineincreasedbyl FOLICACID â€”avoidconcomitantuse 
 TRIANGLE Lipegfilgrastim: neutropeniapossiblyexacerbatedwhencapecitabinegivenwith LI PEGFILGRASTIM   
 TRIANGLE Pegfilgrastim: neutropeniapossiblyexacerbatedwhencapecitabinegivenwithPEGFILGRASTIM 
 TRIANGLE Ulcer-healing
 Drugs: metabolismofcapecitabineinhibitedby CIMETIDINE (increasedplasmaconcentration)Capreomycin 
 TRIANGLE Antibacterials:increasedriskofnephrotoxicitywhencapreomycingivenwith COLISTIMETHATESODIUM or POLYMYXINS ;increasedriskofnephrotoxicityandototoxicitywhencapreomycingivenwith AMINOGLYCOSIDES or VANCOMYCIN  
 TRIANGLE Cytotoxics:increasedriskofnephrotoxicityandototoxicitywhencapreomycingivenwith PLATINUMCOMPOUNDS  
 TRIANGLE Vaccines:antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Captopril see 
 ACE Inhibitors
 sCarbamazepine 
 TRIANGLE Alcohol:  CNS side-effectsofcarbamazepinepossiblyincreasedby ALCOHOL  
 TRIANGLE Aminophylline: carbamazepineacceleratesmetabolismof AMINOPHYLLINE (reducedeffect)
Analgesics: effectsofcarbamazepineenhancedbyl DEXTROPROPOXYPHENE ;carbamazepinepossiblyacceleratesmetabolismof FENTANYL (reducedeffect);carbamazepinereducesplasmaconcentrationof METHADONE ;carbamazepinereduceseffectsof TRAMADOL ;carbamazepinepossiblyacceleratesmetabolismof PARACETAMOL (alsoisolatedreportsofhepatotoxicity)
 lAntibacterials: plasmaconcentrationofcarbamazepineincreasedbyl CLARITHROMYCIN (considerreducingdoseofcarbamazepine);plasmaconcentrationofcarbamazepineincreasedbyl ERYTHROMYCIN ;plasmaconcentrationofcarbamazepinereducedbyl RIFABUTIN ;carbamazepineacceleratesmetabolismof DOXYCYCLINE (reducedeffect);carbamazepinepossiblyreducesplasmaconcentrationofl BEDAQUILINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;avoidanceofcarbamazepineadvisedbymanufacturerof DELAMANID ;plasmaconcentrationofcarbamazepineincreasedbyl ISONIAZID (alsopossiblyincreasedisoniazidhepatotoxicity);carbamazepinereducesplasmaconcentrationofl TELITHROMYCIN (avoidduringandfor2weeksaftercarbamazepine)lAnticoagulants:carbamazepinepossiblyreducesplasmaconcentrationofl APIXABAN â€”manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;carbamazepineacceleratesmetabolismoflCOUMARINS(reducedanticoagulanteffect);carbamazepinepossiblyreducesplasmaconcentrationof DABIGATRAN â€”manufacturerofdabigatranadvisesavoidconcomitantuse;carbamazepinepossiblyreducesplasmaconcentrationofl RIVAROXABAN â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosislAntidepressants:carbamazepinepossiblyreducesplasmaconcentrationof REBOXETINE ;plasmaconcentrationofcarbamazepineincreasedbyl FLUOXETINE andl FLUVOXAMINE ;carbamazepinereducesplasmaconcentrationofl MIANSERIN , MIRTAZAPINE and TRAZODONE ;anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andlTRICYCLIC- RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);manufacturerofcarbamazepineadvisesavoidfor2weeksafterstoppinglMAOIS,alsoantagonismofanticonvulsanteffect;anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andlTRICYCLICS(convulsivethresholdlowered);plasmaconcentrationofcarbamazepinepossiblyreducedbySTJOHNâ€™SWORT;carbamazepineacceleratesmetabolismoflTRICYCLICS(reducedplasmaconcentrationandreducedeffect)
Antiepileptics: carbamazepinepossiblyreducesplasmaconcentrationof ESLICARBAZEPINE butriskofside-effectsincreased;carbamazepinepossiblyreducesplasmaconcentrationof ETHOSUXIMIDE and RETIGABINE ;plasmaconcentrationofbothdrugsoftenreducedwhencarbamazepinegivenwithFOSPHENYTOINorPHENYTOIN,alsoplasmaconcentrationoffosphenytoinorphenytoinmaybeincreased;carbamazepineoftenreducesplasmaconcentrationof LAMOTRIGINE ,alsoplasmaconcentrationofanactivemetaboliteofcarbamazepinesometimesraised(butevidenceisconflicting);possibleincreasedriskofcarbamazepinetoxicitywhengivenwith LEVETIRACETAM ;plasmaconcentrationofcarbamazepinesometimesreducedby OXCARBAZEPINE (butconcentrationofanactivemetaboliteofcarbamazepinemaybeincreased),alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepineoftenreduced;carbamazepinereducesplasmaconcentrationofl PERAMPANEL (seeunderPerampanel,p398);carbamazepinepossiblyincreasesplasmaconcentrationofPHENOBARBITALandPRIMIDONE;plasmaconcentrationofbothdrugspossiblyreducedwhencarbamazepinegivenwith RUFINAMIDE ;carbamazepinereducesplasmaconcentrationof SODIUMVALPROATE and VALPROICACID ,alsoplasmaconcentrationofactivemetaboliteofcarbamazepineincreased;plasmaconcentrationofcarbamazepineincreasedbyl STIRIPENTOL ;carbamazepinereducesplasmaconcentrationof TIAGABINE and ZONISAMIDE ;carbamazepineoftenreducesplasmaconcentrationof TOPIRAMATE 
Antifungals: plasmaconcentrationofcarbamazepinepossiblyincreasedbyKETOCONAZOLE,alsoplasmaconcentrationofketoconazolepossiblyreduced;plasmaconcentrationofcarbamazepinepossiblyincreasedby FLUCONAZOLE andBNF
Antimalarials: avoidanceofcarbamazepineadvisedbymanufacturerof ARTENIMOLWITHPIPERAQUINE ;anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE 
Antipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered);carbamazepineacceleratesmetabolismof HALOPERIDOL , OLANZAPINE , QUETIAPINE and RISPERIDONE (reducedplasmaconcentration);carbamazepinereducesplasmaconcentrationofl ARIPIPRAZOLE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);carbamazepineacceleratesmetabolismofl CLOZAPINE (reducedplasmaconcentration),alsoavoidconcomitantuseofdrugswithsubstantialpotentialforcausingagranulocytosis;carbamazepinepossiblyreducesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;carbamazepinereducesplasmaconcentrationof PALIPERIDONE 
Antivirals: avoidanceofcarbamazepineadvisedbymanufacturerofl BOCEPREVIR andl RILPIVIRINE (plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);carbamazepinepossiblyreducesplasmaconcentrationofl DACLATASVIR andl SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;carbamazepinepossiblyreducesplasmaconcentrationof DARUNAVIR , FOSAMPRENAVIR , LOPINAVIR , SAQUINAVIR and TIPRANAVIR ;avoidanceofcarbamazepineadvisedbymanufacturerof DOLUTEGRAVIR ,l ELVITEGRAVIR , ETRAVIRINE , SOFOSBUVIR andl TELAPREVIR ;plasmaconcentrationofbothdrugsreducedwhencarbamazepinegivenwith EFAVIRENZ ;carbamazepinepossiblyreducesplasmaconcentrationofl INDINAVIR ,alsoplasmaconcentrationofcarbamazepinepossiblyincreased;carbamazepinereducesplasmaconcentrationof NEVIRAPINE ;plasmaconcentrationofcarbamazepinepossiblyincreasedbyl RITONAVIR   
 TRIANGLE AnxiolyticsandHypnotics: carbamazepineoftenreducesplasmaconcentrationof CLONAZEPAM ;carbamazepinereducesplasmaconcentrationof MIDAZOLAM  
 TRIANGLE Aprepitant: carbamazepinepossiblyreducesplasmaconcentrationof APREPITANT  
 TRIANGLE Avanafil: carbamazepinepossiblyreducesplasmaconcentrationof AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse 
 TRIANGLE Bupropion: carbamazepinereducesplasmaconcentrationof BUPROPION  
 lCalcium-channelBlockers: carbamazepinereduceseffectsof FELODIPINE and ISRADIPINE ;carbamazepineprobablyreduceseffectsof DIHYDROPYRIDINES , NICARDIPINE and NIFEDIPINE ;avoidanceofcarbamazepineadvisedbymanufacturerof NIMODIPINE (plasmaconcentrationofnimodipinepossiblyreduced);effectsofcarbamazepineenhancedbyl DILTIAZEM andl VERAPAMIL 
CannabisExtract: carbamazepinepossiblyreducesplasmaconcentrationofl CANNABISEXTRACT â€”manufacturerofcannabisextractadvisesavoidconcomitantuse
Ciclosporin: carbamazepineacceleratesmetabolismofl CICLOSPORIN (reducedplasmaconcentration)
Clopidogrel: carbamazepinepossiblyreducesantiplateleteffectofl CLOPIDOGREL 
Cobicistat: carbamazepinepossiblyreducesplasmaconcentrationofl COBICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Corticosteroids: carbamazepineacceleratesmetabolismofl CORTICOSTEROIDS (reducedeffect)
Diuretics: increasedriskofhyponatraemiawhencarbamazepinegivenwith DIURETICS ;plasmaconcentrationofcarbamazepineincreasedbyl ACETAZOLAMIDE ;carbamazepinereducesplasmaconcentrationofl EPLERE NON E â€”avoidconcomitantuse 
 TRIANGLE Fingolimod: carbamazepinereducesplasmaconcentrationof FINGOLIMOD  
 TRIANGLE Fosaprepitant: carbamazepinepossiblyreducesplasmaconcentrationof FOSAPREPITANT  lHormone
 Antagonists:  carbamazepinepossiblyreducesplasmaconcentrationofl ABIRATERONE â€”manufacturerofabirateroneadvisesavoidconcomitantuse;metabolismofcarbamazepineinhibitedbyl DANAZOL (increasedriskoftoxicity);carbamazepinepossiblyacceleratesmetabolismof TOREMIFENE (reducedplasmaconcentration) 
 TRIANGLE 5 HT 3-receptorAntagonists:carbamazepineacceleratesmetabolismof ONDANSETRON (reducedeffect)
Ivacaftor: carbamazepinepossiblyreducesplasmaconcentrationofl IVACAFTOR â€”manufacturerofivacaftoradvisesavoidconcomitantuselLipid-regulating
 Drugs: carbamazepinereducesplasmaconcentrationofl SIMVASTATIN â€”considerincreasingdoseofsimvastatin 
 TRIANGLE Lithium: neurotoxicitymayoccurwhencarbamazepinegivenwith LITHIUM withoutincreasedplasmaconcentrationoflithium 
 TRIANGLE Macitentan: avoidanceofcarbamazepineadvisedbymanufacturerof MACITENTAN  
 TRIANGLE MuscleRelaxants: carbamazepineantagonisesmusclerelaxanteffectofNON- DEPOLARISINGMUSCLERELAXANTS (acceleratedrecoveryfromneuromuscularblockade)
Oestrogens: carbamazepineacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: carbamazepineacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF) 
 TRIANGLE Retinoids: plasmaconcentrationofcarbamazepinepossiblyreducedby ISOTRETINOIN  
 TRIANGLE Roflumilast: carbamazepinepossiblyinhibitseffectsof ROFLUMILAST (manufacturerofroflumilastadvisesavoidconcomitantuse) 
 TRIANGLE Theophylline: carbamazepineacceleratesmetabolismof THEOPHYLLINE (reducedeffect) 
 TRIANGLE ThyroidHormones: carbamazepineacceleratesmetabolismof THYROIDHORMONES (mayincreaserequirementsforthyroidhormonesinhypothyroidism) 
 TRIANGLE Tibolone: carbamazepineacceleratesmetabolismof TIBOLONE (reducedplasmaconcentration) 
 TRIANGLE Ticagrelor: carbamazepinepossiblyreducesplasmaconcentrationof TICAGRELOR 
 Ulipristal:  avoidanceofcarbamazepineadvisedbymanufacturerofl ULIPRISTAL (contraceptiveeffectofulipristalpossiblyreduced)  
 TRIANGLE Vitamins: carbamazepinepossiblyincreasesrequirementsfor ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL or VITAMIND
 Carbapenems see Ertapenem
,ImipenemwithCilastatin,andMeropenemCarbonicAnhydrase
 Inhibitors see Diuretics 
 Carboplatin see Platinum 
 Compounds 
 Carboprost see Prostaglandins 
 Cardiac 
Glycosides
 TRIANGLE Alpha-blockers:plasmaconcentrationofdigoxinincreasedby PRAZOSIN  
 TRIANGLE Aminosalicylates: absorptionofdigoxinpossiblyreducedby SULFASALAZINE  
 TRIANGLE Analgesics: plasmaconcentrationofcardiacglycosidespossiblyincreasedby NSAIDS ,alsopossibleexacerbationofheartfailureandreductionofrenalfunction 
 TRIANGLE Antacids: absorptionofdigoxinpossiblyreducedby ANTACIDS  
 lAnti-arrhythmics:plasmaconcentrationofdigoxinincreasedbyl AMIODARONE ,l DRONEDARONE andl PROPAFENONE (halvedoseofdigoxin) 
 TRIANGLE Antibacterials:  plasmaconcentrationofdigoxinpossiblyincreasedby GENTAMICIN , TELITHROMYCIN and TRIMETHOPRIM ;absorptionofdigoxinreducedby NEOMYCIN ;plasmaconcentrationofdigoxinpossiblyreducedby RIFAMPICIN ;plasmaconcentrationofdigoxinincreasedby MACROLIDES (increasedriskoftoxicity)
Antidepressants: plasmaconcentrationofdigoxinreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse 
 TRIANGLE Antidiabetics: plasmaconcentrationofdigoxinpossiblyreducedby ACARBOSE ;plasmaconcentrationofdigoxinincreasedby CANAGLIFLOZIN and SITAGLIPTIN  
 TRIANGLE Antiepileptics:  plasmaconcentrationofdigoxinpossiblyreducedby FOS PHENYTOIN  andPHENYTOIN
Antifungals: increasedcardiactoxicitywithcardiacglycosidesifhypokalaemiaoccurswithl AMPHOTERICIN ;plasmaconcentrationofdigoxinincreasedbyl ITRACONAZOLE 
Antimalarials: plasmaconcentrationofdigoxinpossiblyincreasedbyl CHLOROQUINE andl HYDROXYCHLOROQUINE ;possibleincreasedriskofbradycardiawhendigoxingivenwith MEFLOQUINE ;plasmaconcentrationofdigoxinincreasedbyl QUININE  
 TRIANGLE Antimuscarinics: plasmaconcentrationofdigoxinpossiblyincreasedby DARIFENACIN  l
 Antivirals:  side-effectsofdigoxinpossiblyincreasedby BOCEPREVIR ;plasmaconcentrationofdigoxinincreasedbyl DACLATASVIR , ETR AV IRINE , SIMEPREVIR and TELAPREVIR ;plasmaconcentrationofdigoxinpossiblyincreasedby RITONAVIR  
 TRIANGLE AnxiolyticsandHypnotics: plasmaconcentrationofdigoxinincreasedby ALPRAZOLAM (increasedriskoftoxicity) 
 TRIANGLE Beta-blockers:increasedriskofAVblockandbradycardiawhencardiacglycosidesgivenwith BETA - BLOCKERS  
 TRIANGLE CalciumSalts: arrhythmiascanbeprecipitatedwhencardiacglycosidesgivenwithlargeintravenousdosesof CALCIUMSALTS  
 lCalcium-channelBlockers: plasmaconcentrationofdigoxinincreasedbyl DILTIAZEM ,l LERCANIDIPINE andl NICARDIPINE ;plasmaconcentrationofdigoxinpossiblyincreasedbyl NIFEDIPINE ;plasmaconcentrationofdigoxinincreasedbyl VERAPAMIL ,alsoincreasedriskofAVblockandbradycardialCiclosporin:  plasmaconcentrationofdigoxinincreasedbyl CICLOSPORIN (increasedriskoftoxicity) 
 TRIANGLE Cobicistat: plasmaconcentrationofdigoxinpossiblyincreasedby COBICISTAT â€”reduceinitialdoseofdigoxin
 TRIANGLE Corticosteroids:  increasedriskofhypokalaemiawhencardiacglycosidesgivenwith CORTICOSTEROIDS  
 TRIANGLE Cytotoxics: absorptionofdigoxintabletspossiblyreducedby BLEOMYCIN , CARMUSTINE , CYCLOPHOSPHAMIDE , CYTARABINE , DOXORUBICIN , MELPHALAN , METHOTREXATE , PROCARBAZINE and VINCRISTINE ;possibleincreasedriskofbradycardiawhendigoxingivenwith CRIZOTINIB ;manufacturerofdigoxinadvisesgive IBRUTINIB atleast6hoursbeforeorafteribrutinib;plasmaconcentrationofdigoxinincreasedby VANDETANIB â€”possibleincreasedriskofbradycardia
Diuretics: increasedcardiactoxicitywithcardiacglycosidesifhypokalaemiaoccurswithl ACETAZOLAMIDE ,l LOOPDIURETICS orl THIAZIDESANDRELATEDDIURETICS ;plasmaconcentrationofdigoxinpossiblyincreasedby POTASSIUMCANRENOATE ;plasmaconcentrationofdigoxinincreasedbyl SPIRONOLACTONE  
 TRIANGLE Ivacaftor: plasmaconcentrationofdigoxinincreasedby IVACAFTOR  
 TRIANGLE Lenalidomide: plasmaconcentrationofdigoxinpossiblyincreasedby LENALIDOMIDE  
 TRIANGLE Lipid-regulatingDrugs:absorptionofcardiacglycosidespossiblyreducedby COLESTIPOL and COLESTYRAMINE ;plasmaconcentrationofdigoxinpossiblyincreasedby ATORVASTATIN  
 TRIANGLE Mirabegron: plasmaconcentrationofdigoxinincreasedby MIRABEGRON â€”reduceinitialdoseofdigoxin 
 TRIANGLE MuscleRelaxants: riskofventriculararrhythmiaswhencardiacglycosidesgivenwith SUXAMETHONIUM ;possibleincreasedriskofbradycardiawhencardiacglycosidesgivenwith TIZANIDINE  
 TRIANGLE Penicillamine: plasmaconcentrationofdigoxinpossiblyreducedby PENICILLAMINE  
 TRIANGLE Ranolazine: plasmaconcentrationofdigoxinincreasedby RANOLAZINE  
 TRIANGLE Sympathomimetics,Beta2:plasmaconcentrationofdigoxinpossiblyreducedby SALBUTAMOL 
Ticagrelor: plasmaconcentrationofdigoxinincreasedbyl TICAGRELOR  
 TRIANGLE Tolvaptan: plasmaconcentrationofdigoxinincreasedby TOLVAPTAN (increasedriskoftoxicity) 
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofdigoxinpossiblyslightlyincreasedby PROTONPUMPINHIBITORS ;absorptionofcardiacglycosidespossiblyreducedby SUCRALFATE  
 TRIANGLE Ulipristal:manufacturerofulipristaladvisesgivedigoxinatleast15hoursbeforeorafter ULIPRISTALC armustinelAntipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides: carmustinepossiblyreducesabsorptionof DIGOXIN tablets 
 TRIANGLE Ulcer-healingDrugs:myelosuppressiveeffectsofcarmustinepossiblyenhancedby CIMETIDINE
 Carteolol see Beta-blockers 
 Carvedilol see Beta
-blockers
 sCaspofungin 
 TRIANGLE Antibacterials:plasmaconcentrationofcaspofungininitiallyincreasedandthenreducedbyRIFAMPICIN(considerincreasingdoseofcaspofungin) 
 TRIANGLE Antiepileptics:plasmaconcentrationofcaspofunginpossiblyreducedby CARBAMAZEPINE ,FOSPHENYTOINandPHENYTOINâ€”considerincreasingdoseofcaspofungin 
 TRIANGLE Antivirals:plasmaconcentrationofcaspofunginpossiblyreducedby EFAVIRENZ and NEVIRAPINE â€”considerincreasingdoseofcaspofunginlCiclosporin:plasmaconcentrationofcaspofunginincreasedbylCICLOSPORIN(manufacturerofcaspofunginrecommendsmonitoringliverenzymes) 
 TRIANGLE Corticosteroids:plasmaconcentrationofcaspofunginpossiblyreducedby DEXAMETHASONE â€”considerincreasingdoseofcaspofungin
Tacrolimus: caspofunginreducesplasmaconcentrationofl TACROLIMUSC atumaxomablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) BNF 
 Vaccines:    riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Cefaclor see Cephalosporins 
 Cefadroxil see Cephalosporins 
 Cefalexin see Cephalosporins 
 Cefixime see Cephalosporins 
 Cefotaxime see Cephalosporins 
 Cefradine see Cephalosporins 
 Ceftaroline see Cephalosporins 
 Ceftazidime see Cephalosporins 
 Ceftriaxone see Cephalosporins 
 Cefuroxime see Cephalosporins 
 Celecoxib see 
 NSAID s
 Celiprolol see Beta-blockers 
 Cephalosporins
  
 TRIANGLE  Antacids:  absorptionofcefaclorreducedby ANTACIDS  
 TRIANGLE Antibacterials:  possibleincreasedriskofnephrotoxicitywhencephalosporinsgivenwith AMINOGLYCOSIDES  
Anticoagulants:  cephalosporinspossiblyenhanceanticoagulanteffectofl COUMARINS  
 TRIANGLE Teriflunomide: plasmaconcentrationofcefaclorincreasedby TERIFLUNOMIDE  
 TRIANGLE Vaccines:antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF C ertolizumabpegol
Abatacept: avoidconcomitantuseofcertolizumabpegolwithl ABATACEPT 
Anakinra: avoidconcomitantuseofcertolizumabpegolwithl ANAKINRA  
 
Antipsychotics:    avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lVaccines:  riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINESâ€”avoidconcomitantuse
 Cetirizine see Antihistamines 
 Cetuximabl 
 Antipsychotics
:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINESâ€”avoidconcomitantuseChenodeoxycholic
 Acid see Bile 
 Acids 
 Chloral see Anxiolyticsand 
 Hypnotics 
Chloramphenicol
Antidiabetics: chloramphenicolenhanceseffectsofl SULFONYLUREAS 
Antiepileptics: chloramphenicolincreasesplasmaconcentrationofl FOS PHENYTOIN  andlPHENYTOIN(increasedriskoftoxicity);metabolismofchloramphenicolpossiblyacceleratedbyl PHENOBARBITAL andl PRIMIDONE (reducedplasmaconcentration)lAntipsychotics:avoidconcomitantuseofchloramphenicolwithlCLOZAPINE(increasedriskofagranulocytosis)lCiclosporin:  chloramphenicolpossiblyincreasesplasmaconcentrationofl CICLOSPORIN 
Clopidogrel: chloramphenicolpossiblyreducesantiplateleteffectofl CLOPIDOGREL  
 TRIANGLE Hydroxocobalamin: chloramphenicolreducesresponseto HYDROXOCOBALAMIN 
Tacrolimus: chloramphenicolpossiblyincreasesplasmaconcentrationofl TACROLIMUS  
 TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNF
 Chlordiazepoxide see Anxiolyticsand 
 Hypnotics 
 Chloroprocaine 
 
 
Antibacterials:   chloroprocainepossiblyinhibitseffectsofl SULFONAMIDES (manufacturerofchloroprocaineadvisesavoidconcomitantuse)Chloroquine 
 TRIANGLE AgalsidaseAlfaandBeta: chloroquinepossiblyinhibitseffectsof AGALSIDASEALFAANDBETA (manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) 
 TRIANGLE Antacids:absorptionofchloroquinereducedbyANTACIDS
Anthelmintics: chloroquinereducesplasmaconcentrationofl PRAZIQUANTEL â€”considerincreasingpraziquanteldosewhengivenforsystemicinfectionslAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenchloroquinegivenwithl AMIODARONE â€”avoidconcomitantuselAntibacterials:increasedriskofventriculararrhythmiaswhenchloroquinegivenwithl MOXIFLOXACIN â€”avoidconcomitantuse
Antidepressants: possibleincreasedriskofventriculararrhythmiaswhenchloroquinegivenwithl CITALOPRAM andl ESCITALOPRAM 
Antimalarials: avoidanceofantimalarialsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;increasedriskofconvulsionswhenchloroquinegivenwithl MEFLOQUINE  
 lAntipsychotics:increasedriskofventriculararrhythmiaswhenchloroquinegivenwithl DROPERIDOL â€”avoidconcomitantuse
CardiacGlycosides: chloroquinepossiblyincreasesplasmaconcentrationofl DIGOXIN  
Ciclosporin:chloroquineincreasesplasmaconcentrationoflCICLOSPORIN(increasedriskoftoxicity)
Cytotoxics: possibleincreasedriskofventriculararrhythmiaswhenchloroquinegivenwithl BOSUTINIB  
 TRIANGLE Histamine: avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Lanthanum: absorptionofchloroquinepossiblyreducedby LANTHANUM (giveatleast2hoursapart) 
 TRIANGLE Laronidase: chloroquinepossiblyinhibitseffectsof LARONIDASE (manufactureroflaronidaseadvisesavoidconcomitantuse) 
 TRIANGLE Parasympathomimetics: chloroquinehaspotentialtoincreasesymptomsofmyastheniagravisandthusdiminisheffectof NEOSTIGMINE and PYRIDOSTIGMINE  
 TRIANGLE Ulcer-healing
 Drugs: metabolismofchloroquineinhibitedby CIMETIDINE (increasedplasmaconcentration) 
 TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNF
 Chlorothiazide see Diuretics 
 Chlorphenamine see Antihistamines 
 Chlorpromazine see Antipsychotics 
 Chlortalidone see Diuretics 
 Cholera 
 Vaccine see Vaccines 
 Ciclesonide see Corticosteroids 
 Ciclosporinl
 ACE Inhibitors:increasedriskofhyperkalaemiawhenciclosporingivenwithl ACEINHIBITORS 
Aliskiren: ciclosporinincreasesplasmaconcentrationofl ALISKIREN â€”avoidconcomitantuse 
 TRIANGLE Allopurinol: plasmaconcentrationofciclosporinpossiblyincreasedby ALLOPURINOL (riskofnephrotoxicity)
Ambrisentan: ciclosporinincreasesplasmaconcentrationofl AMBRISENTAN (seeunderAmbrisentan,p162)
Analgesics: increasedriskofnephrotoxicitywhenciclosporingivenwithl NSAIDS ;ciclosporinincreasesplasmaconcentrationofl DICLOFENAC (halvedoseofdiclofenac)lAngiotensin- IIR eceptor
 Antagonists: increasedriskofhyperkalaemiawhenciclosporingivenwithl ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Anti-arrhythmics:plasmaconcentrationofciclosporinpossiblyincreasedbyAMIODARONEand PROPAFENONE  
 lAntibacterials:metabolismofciclosporininhibitedbyl CLARITHROMYCIN andl ERYTHROMYCIN (increasedplasmaconcentration);metabolismofciclosporinacceleratedbylRIFAMPICIN(reducedplasmaconcentration);plasmaconcentrationofciclosporinpossiblyreducedbyl SULFADIAZINE ;increasedriskofnephrotoxicitywhenciclosporingivenwithlAMINOGLYCOSIDES,l POLYMYXINS ,l QUINOLONES ,lSULFONAMIDESorl VANCOMYCIN ;plasmaconcentrationofciclosporinpossiblyincreasedby
Anticoagulants: ciclosporinpossiblyincreasesplasmaconcentrationofl DABIGATRAN â€”manufacturerofdabigatranadvisesavoidconcomitantuse
Antidepressants: plasmaconcentrationofciclosporinreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse  
 TRIANGLE Antidiabetics: ciclosporinpossiblyenhanceshypoglycaemiceffectof REPAGLINIDE 
Antiepileptics: metabolismofciclosporinacceleratedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE (reducedplasmaconcentration);plasmaconcentrationofciclosporinpossiblyreducedby OXCARBAZEPINE 
Antifungals: metabolismofciclosporininhibitedbyl FLUCONAZOLE ,l ITRACONAZOLE ,l KETOCONAZOLE ,l POSACONAZOLE andl VORICONAZOLE (increasedplasmaconcentration);metabolismofciclosporinpossiblyinhibitedbyl MICONAZOLE (increasedplasmaconcentration);increasedriskofnephrotoxicitywhenciclosporingivenwithl AMPHOTERICIN ;ciclosporinincreasesplasmaconcentrationofl CASPOFUNGIN (manufacturerofcaspofunginrecommendsmonitoringliverenzymes);plasmaconcentrationofciclosporinpossiblyreducedby GRISEOFULVIN and TERBINAFINE ;plasmaconcentrationofciclosporinpossiblyincreasedby MICAFUNGIN 
Antimalarials: plasmaconcentrationofciclosporinincreasedbyl CHLOROQUINE andl HYDROXYCHLOROQUINE (increasedriskoftoxicity) 
 TRIANGLE Antimuscarinics: avoidanceofciclosporinadvisedbymanufacturerof DARIFENACIN 
Antivirals: increasedriskofnephrotoxicitywhenciclosporingivenwith ACICLOVIR or VALACICLOVIR ;plasmaconcentrationofciclosporinpossiblyincreasedbyl ATAZANAVIR andl RITONAVIR ;plasmaconcentrationofciclosporinincreasedbyl BOCEPREVIR ,l FOSAMPRENAVIR andl INDINAVIR ;plasmaconcentrationofciclosporinpossiblyreducedbyl EFAVIRENZ ;plasmaconcentrationofbothdrugsincreasedwhenciclosporingivenwithl SAQUINAVIR ;plasmaconcentrationofbothdrugsincreasedwhenciclosporingivenwithl TELAPREVIR (reducedoseofciclosporin)lBeta-blockers:plasmaconcentrationofciclosporinincreasedbyl CARVEDILOL 
BileAcids: absorptionofciclosporinincreasedbyl URSODEOXYCHOLICACID 
Bosentan: ciclosporinincreasesplasmaconcentrationofl BOSENTAN (alsoplasmaconcentrationofciclosporinreducedâ€”avoidconcomitantuse)lCalcium-channelBlockers: combinationofciclosporinwithl LERCANIDIPINE mayincreaseplasmaconcentrationofeitherdrug(orboth)â€”avoidconcomitantuse;plasmaconcentrationofciclosporinincreasedbyl DILTIAZEM ,l NICARDIPINE andl VERAPAMIL ;ciclosporinpossiblyincreasesplasmaconcentrationof NIFEDIPINE (increasedriskoftoxicityincludinggingivalhyperplasia)
CardiacGlycosides: ciclosporinincreasesplasmaconcentrationofl DIGOXIN (increasedriskoftoxicity)
Colchicine: possibleincreasedriskofnephrotoxicityandmyotoxicitywhenciclosporingivenwithl COLCHICINE â€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) 
 TRIANGLE Colestilan: manufacturerofcolestilanadvisesgiveciclosporinatleast1hourbeforeor3hoursafter COLESTILAN 
Cytotoxics: increasedriskofnephrotoxicitywhenciclosporingivenwithl MELPHALAN ;increasedriskofneurotoxicitywhenciclosporingivenwithl DOXORUBICIN ;ciclosporinincreasesplasmaconcentrationofl EPIRUBICIN andl IDARUBICIN ;ciclosporinreducesexcretionof MITOXANTRONE (increasedplasmaconcentration);riskoftoxicitywhenciclosporingivenwithl METHOTREXATE ;ciclosporinpossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationofciclosporinby6to12hours;cautionwithciclosporinadvisedbymanufacturerofl CRIZOTINIB ;ciclosporinincreasesplasmaconcentrationofl EVEROLIMUS (considerreducingthedoseofeverolimusâ€”consulteverolimusproductliterature);plasmaconcentrationofciclosporinpossiblyincreasedby IMATINIB ;invitrostudiessuggestapossibleinteractionbetweenciclosporinand DOCETAXEL (consultdocetaxelproductliterature);ciclosporinpossiblyincreasesplasmaconcentrationof ETOPOSIDE (increasedriskoftoxicity) 
 TRIANGLE Dexrazoxane: increasedriskofimmunosupressionwithciclosporinadvisedbymanufacturerof DEXRAZOXANE 
Diuretics: plasmaconcentrationofciclosporinpossiblyincreasedbyl ACETAZOLAMIDE ;increasedriskofhyperkalaemiawhenciclosporingivenwithl POTASSIUM - SPARINGDIURETICSANDALDOSTERONEANTAGONISTS ;increasedriskofnephrotoxicityandpossiblyhypermagnesaemiawhenciclosporingivenwith THIAZIDESANDRELATEDDIURETICS 
GrapefruitJuice: plasmaconcentrationofciclosporinincreasedbyl GRAPEFRUITJUICE (increasedriskoftoxicity)
HormoneAntagonists: metabolismofciclosporininhibitedbyl DANAZOL (increasedplasmaconcentration);plasmaconcentrationofciclosporinreducedby LANREOTIDE andl OCTREOTIDE ;plasmaconcentrationofciclosporinpossiblyreducedbyl PASIREOTIDE 
Lenalidomide: ciclosporinpossiblyincreasesplasmaconcentrationofl LENALIDOMIDE (increasedriskoftoxicity)lLipid-regulating
 Drugs: absorptionofciclosporinreducedbyl COLESEVELAM ;increasedriskofrenalimpairmentwhenciclosporingivenwith BEZAFIBRATE or FENOFIBRATE ;increasedriskofmyopathywhenciclosporingivenwithl ATORVASTATIN (seeunderAtorvastatin,p179);increasedriskofmyopathywhenciclosporingivenwithl FLUVASTATIN orl PRAVASTATIN ;increasedriskofmyopathywhenciclosporingivenwithl ROSUVASTATIN orl SIMVASTATIN (avoidconcomitantuse);plasmaconcentrationofbothdrugsmayincreasewhenciclosporingivenwithl EZETIMIBE ;separatingadministrationfromciclosporinby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Mannitol: possibleincreasedriskofnephrotoxicitywhenciclosporingivenwith MANNITOL 
Metoclopramide: plasmaconcentrationofciclosporinincreasedbyl METOCLOPRAMIDE  
 TRIANGLE Mifamurtide: avoidanceofciclosporinadvisedbymanufacturerof MIFAMURTIDE 
Modafinil: plasmaconcentrationofciclosporinreducedbyl MODAFINIL  
 TRIANGLE Oestrogens: plasmaconcentrationofciclosporinpossiblyincreasedby OESTROGENS 
Orlistat: absorptionofciclosporinpossiblyreducedbyl ORLISTAT 
PotassiumSalts: increasedriskofhyperkalaemiawhenciclosporingivenwithl POTASSIUMSALTS  
 TRIANGLE Progestogens: plasmaconcentrationofciclosporinpossiblyincreasedby PROGESTOGENS  
 TRIANGLE Ranolazine: plasmaconcentrationofbothdrugsmayincreasewhenciclosporingivenwith RANOLAZINE  
 TRIANGLE Sevelamer: plasmaconcentrationofciclosporinpossiblyreducedby SEVELAMER  
 TRIANGLE Sirolimus: ciclosporinincreasesplasmaconcentrationof SIROLIMUS 
Sulfinpyrazone: plasmaconcentrationofciclosporinreducedbyl SULFINPYRAZONE 
Tacrolimus: plasmaconcentrationofciclosporinincreasedbyl TACROLIMUS (increasedriskofnephrotoxicity)â€”avoidconcomitantuse BNF 
 TRIANGLE Ticagrelor: ciclosporinincreasesplasmaconcentrationof TICAGRELOR  
 lUlcer-healing
 Drugs:   plasmaconcentrationofciclosporinpossiblyincreasedbyl CIMETIDINE ;plasmaconcentrationofciclosporinpossiblyaffectedby OMEPRAZOLE  
 TRIANGLE Vitamins: plasmaconcentrationofciclosporinpossiblyaffectedby VITAMINEC ilostazol
Anagrelide: avoidanceofcilostazoladvisedbymanufacturerofl ANAGRELIDE 
 
Antibacterials:   plasmaconcentrationofcilostazolpossiblyincreasedbyl CLARITHROMYCIN (seeunderCilostazol,p206);plasmaconcentrationofcilostazolincreasedbyl ERYTHROMYCIN (seeunderCilostazol,p206)
 Antifungals:  plasmaconcentrationofcilostazolincreasedbyl KETO CO NAZOLE (seeunderCilostazol,p206);plasmaconcentrationofcilostazolpossiblyincreasedbyl ITRACONAZOLE (seeunderCilostazol,p206)lAntivirals:  plasmaconcentrationofcilostazolpossiblyincreasedbyl BOCEPREVIR ,l RITONAVIR andl TELAPREVIR (seeunderCilostazol,p206) 
 TRIANGLE Calcium-channelBlockers:  plasmaconcentrationofcilostazolincreasedby DILTIAZEM (considerreducingdoseofcilostazol) 
 TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromcilostazolby12hoursadvisedbymanufacturerof LOMITAPIDE  
 lUlcer-healingDrugs:plasmaconcentrationofcilostazolincreasedbylOMEPRAZOLE(seeunderCilostazol,p206)
 Cimetidine see Histamine 
 H
2-antagonists
 sCinacalcet 
 TRIANGLE Antifungals:metabolismofcinacalcetinhibitedbyKETOCONAZOLE(increasedplasmaconcentration)
 lHormone
 Antagonists:  cinacalcetpossiblyinhibitsmetabolismofl TAMOXIFEN toactivemetabolite(avoidconcomitantuse)
 Cinnarizine see Antihistamines 
 Ciprofibrate see Fibrates 
 Ciprofloxacin see Quinolones 
 Cisatracurium see Muscle 
 Relaxants 
 Cisplatin see Platinum 
 Compounds 
 Citalopram see Antidepressants
, SSRIC ladribine
 Antipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lAntivirals:avoidanceofcladribineadvisedbymanufacturerofl LAMIVUDINE
 Clarithromycin see Macrolides 
 Clemastine see Antihistamines 
 Clindamycin 
 
 MuscleRelaxants:  clindamycinenhanceseffectsofl NON - DEPOLARISINGMUSCLERELAXANTS andl SUXAMETHONIUM  
 TRIANGLE Parasympathomimetics: clindamycinantagoniseseffectsof NEOSTIGMINE and PYRIDOSTIGMINE  
 TRIANGLE Vaccines:  antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Clobazam see Anxiolyticsand 
 Hypnotics 
 Clofaziminel 
 Antibacterials
:possibleincreasedriskofventriculararrhythmiaswhenclofaziminegivenwithl BEDAQUILINE  
 TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNF
 Clomethiazole see Anxiolyticsand 
 Hypnotics 
 Clomipramine see Antidepressants
,Tricyclic
 Clonazepam see Anxiolyticsand 
 Hypnotics 
Clonidine
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenclonidinegivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenclonidinegivenwith ALCOHOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenclonidinegivenwith ALDESLEUKIN  
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhenclonidinegivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics:  hypotensiveeffectofclonidineantagonisedby NSAIDS  
 TRIANGLE Angiotensin- IIR eceptorAntagonists:enhancedhypotensiveeffectwhenclonidinegivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 
Antidepressants:  enhancedhypotensiveeffectwhenclonidinegivenwith MAOIS ;hypotensiveeffectofclonidinepossiblyantagonisedby MIRTAZAPINE ;hypotensiveeffectofclonidineantagonisedbyl TRICYCLICS ,alsoincreasedriskofhypertensiononclonidinewithdrawal 
 TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenclonidinegivenwith PHENOTHIAZINES  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenclonidinegivenwith ANXIOLYTICSANDHYPNOTICS  
 lBeta-blockers:increasedriskofwithdrawalhypertensionwhenclonidinegivenwithl BETA -BLOCKERS(withdrawbeta-blockersseveraldaysbeforeslowlywithdrawingclonidine) 
 TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenclonidinegivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Corticosteroids: hypotensiveeffectofclonidineantagonisedby CORTICOSTEROIDS  
 TRIANGLE Cytotoxics: possibleincreasedriskofbradycardiawhenclonidinegivenwith CRIZOTINIB  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenclonidinegivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenclonidinegivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhenclonidinegivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE Histamine: avoidanceofclonidineadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenclonidinegivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhenclonidinegivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenclonidinegivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants:enhancedhypotensiveeffectwhenclonidinegivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenclonidinegivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofclonidineantagonisedby OESTROGENS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenclonidinegivenwith ALPROSTADIL 
Sympathomimetics: possibleriskofhypertensionwhenclonidinegivenwith ADRENALINE ( EPINEPHRINE )or NORADRENALINE ( NOREPINEPHRINE );seriousadverseeventsreportedwithconcomitantuseofclonidineandl METHYLPHENIDATE (causalitynotestablished) 
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenclonidinegivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE
 Clopamide see Diuretics 
Clopidogrel
 lAntibacterials:antiplateleteffectofclopidogrelpossiblyreducedbyl CHLORAMPHENICOL ,l CIPROFLOXACIN andlERYTHROMYCIN
Anticoagulants: manufacturerofclopidogreladvisesavoidconcomitantusewithl WARFARIN ;antiplateletactionofclopidogrelenhancesanticoagulanteffectofl COUMARINS andl PHENINDIONE ;increasedriskofbleedingwhenclopidogrelgivenwith HEPARINS  
 lAntidepressants:antiplateleteffectofclopidogrelpossiblyreducedbyl FLUOXETINE ,l FLUVOXAMINE andl MOCLOBEMIDE 
Antiepileptics: antiplateleteffectofclopidogrelpossiblyreducedbyl CARBAMAZEPINE andl OXCARBAZEPINE 
Antifungals: antiplateleteffectofclopidogrelpossiblyreducedbyl FLUCONAZOLE ,lITRACONAZOLE,lKETOCONAZOLEandl VORICONAZOLE 
 TRIANGLE Dipyridamole: increasedriskofbleedingwhenclopidogrelgivenwith DIPYRIDAMOLE  
 TRIANGLE Iloprost: increasedriskofbleedingwhenclopidogrelgivenwith ILOPROST  
 lLipid-regulating
 Drugs:   clopidogrelincreasesplasmaconcentrationofl ROSUVASTATIN â€”adjustdoseofrosuvastatin(consultproductliterature) 
 TRIANGLE Prasugrel: possibleincreasedriskofbleedingwhenclopidogrelgivenwith PRASUGREL  
 lUlcer-healingDrugs:antiplateleteffectofclopidogrelpossiblyreducedbyl CIMETIDINE , LANSOPRAZOLE , PANTOPRAZOLE and RABEPRAZOLE ;antiplateleteffectofclopidogrelreducedbyl ESOMEPRAZOLE andl OMEPRAZOLE
 Clozapine see Antipsychotics 
 Co-amoxiclav see Penicillins 
 Co
-beneldopa 
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhenco-beneldopagivenwith ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenco-beneldopagivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenco-beneldopagivenwith ALPHA -BLOCKERS lAnaesthetics,General: increasedriskofarrhythmiaswhenco-beneldopagivenwithl VOLATILELIQUIDGENERALANAESTHETICS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenco-beneldopagivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antibacterials: effectsofco-beneldopapossiblyreducedby ISONIAZID  
Antidepressants:  riskofhypertensivecrisiswhenco-beneldopagivenwithl  MAOI S ,avoidco-beneldopaforatleast2weeksafterstoppingMAOIs;increasedriskofside-effectswhenco-beneldopagivenwith MOCLOBEMIDE  
 TRIANGLE Antiepileptics: effectsofco-beneldopapossiblyreducedby FOS PHENYTOIN  andPHENYTOIN 
 TRIANGLE Antimuscarinics: absorptionofco-beneldopapossiblyreducedby ANTIMUSCARINICS  
 TRIANGLE Antipsychotics: effectsofco-beneldopaantagonisedby ANTIPSYCHOTICS ;avoidanceofco-beneldopaadvisedbymanufacturerof AMISULPRIDE (antagonismofeffect) 
 TRIANGLE AnxiolyticsandHypnotics: effectsofco-beneldopapossiblyantagonisedby BENZODIAZEPINES  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenco-beneldopagivenwith BETA -BLOCKERS 
 TRIANGLE Bupropion: increasedriskofside-effectswhenco-beneldopagivenwith BUPROPION  
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenco-beneldopagivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenco-beneldopagivenwith CLONIDINE  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenco-beneldopagivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenco-beneldopagivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedeffectsandincreasedtoxicityofco-beneldopawhengivenwith SELEGILINE (reducedoseofco-beneldopa) 
 TRIANGLE IronSalts: absorptionofco-beneldopapossiblyreducedbyoral IRONSALTS  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenco-beneldopagivenwith METHYLDOPA ;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA 
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenco-beneldopagivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: possibleagitation,confusionandhallucinationswhenco-beneldopagivenwith BACLOFEN  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenco-beneldopagivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEC obicistatlAlpha-blockers:cobicistatpossiblyincreasesplasmaconcentrationofl ALFUZOSIN â€”manufacturerofcobicistatadvisesavoidconcomitantuselAnti-arrhythmics:cobicistatpossiblyincreasesplasmaconcentrationofl AMIODARONE â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Antibacterials: plasmaconcentrationofcobicistatreducedbyl RIFABUTIN (adjustdoseâ€”consultproductliterature);plasmaconcentrationofcobicistatpossiblyreducedbyl RIFAMPICIN â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Anticoagulants: avoidanceofcobicistatadvisedbymanufacturerof APIXABAN ;cobicistatpossiblyenhancesanticoagulanteffectofl RIVAROXABAN â€”avoidconcomitantuselAntidepressants:plasmaconcentrationofcobicistatpossiblyreducedbyl STJOHN â€™ SWORT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Antiepileptics: plasmaconcentrationofcobicistatpossiblyreducedbyl CARBAMAZEPINE ,lFOSPHENYTOIN,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”manufacturerofcobicistatadvisesavoidconcomitantuse 
 TRIANGLE Antifungals: cobicistatpossiblyincreasesplasmaconcentrationof ITRACONAZOLE and KETOCONAZOLE â€”manufacturerofcobicistatadvisesreducedoseofitraconazoleandketoconazole
Antipsychotics: cobicistatpossiblyincreasesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;cobicistatpossiblyincreasesplasmaconcentrationofl PIMOZIDE â€”manufacturerofcobicistatadvisesavoidconcomitantuselAntivirals:manufacturerofcobicistatadvisesavoidconcomitantusewith BOCEPREVIR ;cobicistatpossiblyincreasestheplasmaconcentrationofl DACLATASVIR â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);cobicistatpossiblyincreasesplasmaconcentrationofl MARAVIROC (reducedoseofmaraviroc);avoidanceofcobicistatadvisedbymanufacturerof NEVIRAPINE ;cobicistatpossiblyincreasesplasmaconcentrationofl SIMEPREVIR â€”manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofbothdrugsreducedwhencobicistatgivenwithl TIPRANAVIR (avoidconcomitantuse)
AnxiolyticsandHypnotics: manufacturerofcobicistatadvisesavoidconcomitantusewithorall MIDAZOLAM  
 TRIANGLE Bosentan: manufacturerofcobicistatadvisesavoidconcomitantusewith BOSENTAN  
 TRIANGLE CardiacGlycosides: cobicistatpossiblyincreasesplasmaconcentrationof DIGOXIN â€”reduceinitialdoseofdigoxin
Cytotoxics: cobicistatpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809)
Domperidone: possibleincreasedriskofventriculararrhythmiaswhencobicistatgivenwithl DOMPERIDONE â€”avoidconcomitantuse
ErgotAlkaloids: cobicistatpossiblyincreasesplasmaconcentrationofl ERGOTALKALOIDS â€”manufacturerofcobicistatadvisesavoidconcomitantuselLipid-regulatingDrugs:cobicistatpossiblyincreasesplasmaconcentrationof ATORVASTATIN â€”manufacturerofcobicistatadvisesreducedoseofatorvastatin;manufacturerofcobicistatadvisesavoidconcomitantusewithl SIMVASTATIN 
Oestrogens: cobicistatacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF ) 
 TRIANGLE Progestogens: cobicistatincreasesplasmaconcentrationof NORGESTIMATE 
Sildenafil: cobicistatpossiblyincreasesplasmaconcentrationofl SILDENAFIL â€”manufacturerofcobicistatadvisesavoidconcomitantuseofsildenafilforpulmonaryarterialBNF
 TRIANGLE  Sympathomimetics,Beta2:manufacturerofcobicistatadvisesavoidconcomitantusewith SALMETEROL 
Tadalafil: cobicistatpossiblyincreasesplasmaconcentrationofl TADALAFIL â€”manufacturerofcobicistatadvisesreducedoseoftadalafil(consultcobicistatproductliterature)
Vardenafil: cobicistatpossiblyincreasesplasmaconcentrationofl VARDENAFIL â€”manufacturerofcobicistatadvisesreducedoseofvardenafil(consultcobicistatproductliterature)Co-careldopa 
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhenco-careldopagivenwith ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenco-careldopagivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenco-careldopagivenwith ALPHA -BLOCKERS lAnaesthetics,General: increasedriskofarrhythmiaswhenco-careldopagivenwithl VOLATILELIQUIDGENERALANAESTHETICS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenco-careldopagivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antibacterials:  effectsofco-careldopapossiblyreducedby ISONIAZID 
Antidepressants: riskofhypertensivecrisiswhenco-careldopagivenwithl  MAOI S ,avoidco-careldopaforatleast2weeksafterstoppingMAOIs;increasedriskofside-effectswhenco-careldopagivenwith MOCLOBEMIDE  
 TRIANGLE Antiepileptics:  effectsofco-careldopapossiblyreducedby FOS PHENYTOIN  andPHENYTOIN 
 TRIANGLE Antimuscarinics: absorptionofco-careldopapossiblyreducedby ANTIMUSCARINICS  
 TRIANGLE Antipsychotics: effectsofco-careldopaantagonisedby ANTIPSYCHOTICS ;avoidanceofco-careldopaadvisedbymanufacturerof AMISULPRIDE (antagonismofeffect) 
 TRIANGLE AnxiolyticsandHypnotics: effectsofco-careldopapossiblyantagonisedby BENZODIAZEPINES  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenco-careldopagivenwith BETA -BLOCKERS 
 TRIANGLE Bupropion: increasedriskofside-effectswhenco-careldopagivenwith BUPROPION  
 TRIANGLE Calcium-channelBlockers:  enhancedhypotensiveeffectwhenco-careldopagivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenco-careldopagivenwith CLONIDINE  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenco-careldopagivenwith DIAZOXIDE  
 TRIANGLE Diuretics:  enhancedhypotensiveeffectwhenco-careldopagivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedeffectsandincreasedtoxicityofco-careldopawhengivenwith SELEGILINE (reducedoseofco-careldopa) 
 TRIANGLE IronSalts: absorptionofco-careldopapossiblyreducedbyoral IRONSALTS  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenco-careldopagivenwith METHYLDOPA ;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA 
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenco-careldopagivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: possibleagitation,confusionandhallucinationswhenco-careldopagivenwith BACLOFEN  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenco-careldopagivenwith NITRATES  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenco-careldopagivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE
 Codeine see Opioid 
 Analgesics 
 Co-fluampicil see Penicillins 
 Colchicinel 
 Anti
Antibacterials: possibleincreasedriskofcolchicinetoxicitywhengivenwithl AZITHROMYCIN ,l CLARITHROMYCIN ,l ERYTHROMYCIN andl TELITHROMYCIN â€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)
Antifungals: possibleincreasedriskofcolchicinetoxicitywhengivenwithl ITRACONAZOLE andl KETOCONAZOLE â€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)
Antivirals: possibleincreasedriskofcolchicinetoxicitywhengivenwithl ATAZANAVIR ,l INDINAVIR ,l RITONAVIR andl TELAPREVIR â€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCalcium-channelBlockers:possibleincreasedriskofcolchicinetoxicitywhengivenwithl DILTIAZEM andl VERAPAMIL â€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)
 CardiacGlycosides:  possibleincreasedriskofmyopathywhencolchicinegivenwithl DIGOXIN  
 Ciclosporin:   possibleincreasedriskofnephrotoxicityandmyotoxicitywhencolchicinegivenwithl CICLOSPORIN â€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)
GrapefruitJuice: possibleincreasedriskofcolchicinetoxicitywhengivenwithl GRAPEFRUITJUICE  
 lLipid-regulatingDrugs:  possibleincreasedriskofmyopathywhencolchicinegivenwithl FIBRATES orl STATINS
 Colecalciferol see Vitamins 
 Colesevelam
 NOTEO therdrugsshouldbetakenatleast4hoursbeforeoraftercolesevelamtoreducepossibleinterferencewithabsorption 
 TRIANGLE Antidiabetics:  colesevelamreducesabsorptionof GLIBENCLAMIDE and GLIPIZIDE ;colesevelamreducesabsorptionof GLIMEPIRIDE â€”manufacturerofglimepirideadvisesgiveatleast4hoursbeforecolesevelam;manufacturerofcanagliflozinadvisesgivebileacidsequestrantsatleast1hourafteror4â€“6before CANAGLIFLOZIN  
 TRIANGLE Antiepileptics:colesevelampossiblyreducesabsorptionofFOSPHENYTOINandPHENYTOIN 
Ciclosporin:colesevelamreducesabsorptionoflCICLOSPORIN 
 TRIANGLE Lipid-regulatingDrugs:bileacidsequestrantspossiblyreduceabsorptionof LOMITAPIDE (giveatleast4hoursapart) 
 TRIANGLE Oestrogens: colesevelamreducesabsorptionof ETHINYLESTRADIOL  
 TRIANGLE ThyroidHormones:  colesevelamreducesabsorptionof  LEVOTHYROXINE C olestilanNOTEOtherdrugsshouldbetakenatleast1hourbeforeor3hoursaftercolestilantoreducepossibleinterferencewithabsorption 
 TRIANGLE Ciclosporin:manufacturerofcolestilanadvisesgiveCICLOSPORINatleast1hourbeforeor3hoursaftercolestilan 
 TRIANGLE Mycophenolate: manufacturerofcolestilanadvisesgive MYCOPHENOLATE atleast1hourbeforeor3hoursaftercolestilan 
 TRIANGLE Tacrolimus: manufacturerofcolestilanadvisesgive TACROLIMUS atleast1hourbeforeor3hoursaftercolestilan 
 TRIANGLE ThyroidHormones:manufacturerofcolestilanadvisesgiveLEVOTHYROXINEatleast1hourbeforeor3hoursaftercolestilanColestipolNOTEOtherdrugsshouldbetakenatleast1hourbeforeor4â€“6hoursaftercolestipoltoreducepossibleinterferencewithabsorption 
 TRIANGLE Antibacterials:colestipolpossiblyreducesabsorptionof TETRACYCLINE  
 TRIANGLE Antidiabetics:manufacturerofcanagliflozinadvisesgivebileacidsequestrantsatleast1hourafteror4â€“6beforeCANAGLIFLOZIN 
 TRIANGLE BileAcids: colestipolpossiblyreducesabsorptionof BILEACIDS  
 TRIANGLE CardiacGlycosides:colestipolpossiblyreducesabsorptionof CARDIACGLYCOSIDES  
 TRIANGLE Diuretics:colestipolreducesabsorptionof THIAZIDESANDRELATEDDIURETICS (giveatleast2hoursapart)
 TRIANGLE  Lipid-regulatingDrugs:  bileacidsequestrantspossiblyreduceabsorptionof LOMITAPIDE (giveatleast4hoursapart) 
 TRIANGLE ThyroidHormones:  colestipolreducesabsorptionof  THYROIDHORMONES C olestyramine NOTEO therdrugsshouldbetakenatleast1hourbeforeor4â€“6hoursaftercolestyraminetoreducepossibleinterferencewithabsorption 
 TRIANGLE Analgesics:  colestyramineincreasestheexcretionof MELOXICAM ;colestyraminereducesabsorptionof PARACETAMOL  
 TRIANGLE Antibacterials: colestyraminepossiblyreducesabsorptionof TETRACYCLINE ;colestyramineantagoniseseffectsoforal VANCOMYCIN  
Anticoagulants:  colestyraminemayenhanceorreduceanticoagulanteffectofl COUMARINS andl PHENINDIONE  
 TRIANGLE Antidiabetics:  colestyraminepossiblyenhanceshypoglycaemiceffectof ACARBOSE ;manufacturerofcanagliflozinadvisesgivebileacidsequestrantsatleast1hourafteror4â€“6before CANAGLIFLOZIN  
 TRIANGLE Antiepileptics: colestyraminepossiblyreducesabsorptionof SODIUMVALPROATE and VALPROICACID  
 TRIANGLE BileAcids: colestyraminepossiblyreducesabsorptionof BILEACIDS  
 TRIANGLE CardiacGlycosides:  colestyraminepossiblyreducesabsorptionof CARDIACGLYCOSIDES  
 TRIANGLE Diuretics: colestyraminereducesabsorptionof THIAZIDESANDRELATEDDIURETICS (giveatleast2hoursapart) 
 TRIANGLE Leflunomide: colestyraminesignificantlydecreaseseffectof LEFLUNOMIDE (enhancedelimination)â€”avoidunlessdrugeliminationdesired 
 TRIANGLE Lipid-regulatingDrugs:bileacidsequestrantspossiblyreduceabsorptionofLOMITAPIDE(giveatleast4hoursapart) 
 TRIANGLE Mycophenolate: colestyraminereducesabsorptionof MYCOPHENOLATE  
 TRIANGLE Raloxifene: colestyraminereducesabsorptionof RALOXIFENE (manufacturerofraloxifeneadvisesavoidconcomitantadministration) 
 TRIANGLE Teriflunomide: colestyraminesignificantlydecreaseseffectof TERIFLUNOMIDE (enhancedelimination)â€”avoidunlessdrugeliminationdesired 
 TRIANGLE ThyroidHormones:colestyraminereducesabsorptionofTHYROIDHORMONES 
 TRIANGLE Vitamins: colestyraminepossiblyreducesabsorptionof CALCITRIOL (giveatleast1hourbeforeor4to6hoursaftercolestyramine)Colistimethate
 Sodium see Polymyxins 
 Contraceptives
,oralseeOestrogensandProgestogensCorticosteroids NOTEI nteractionsdonotgenerallyapplytocorticosteroidsusedfortopicalaction(includinginhalation)unlessspecified 
 TRIANGLE  ACE Inhibitors:corticosteroidsantagonisehypotensiveeffectof ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: corticosteroidsantagonisehypotensiveeffectof ADRENERGICNEURONE BLOCKERS  
Aldesleukin: avoidanceofcorticosteroidsadvisedbymanufacturerofl ALDESLEUKIN  
 TRIANGLE Alpha-blockers:corticosteroidsantagonisehypotensiveeffectof ALPHA -BLOCKERS 
 TRIANGLE Aminophylline: increasedriskofhypokalaemiawhencorticosteroidsgivenwith AMINOPHYLLINE  
 TRIANGLE Analgesics:increasedriskofgastro-intestinalbleedingandulcerationwhencorticosteroidsgivenwith NSAIDS ;increasedriskofgastro-intestinalbleedingandulcerationwhencorticosteroidsgivenwith ASPIRIN ,alsocorticosteroidsreduceplasmaconcentrationofsalicylate 
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: corticosteroidsantagonisehypotensiveeffectof ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antacids: absorptionofdeflazacortreducedby ANTACIDS  
 TRIANGLE Anthelmintics: dexamethasoneincreasesplasmaconcentrationofactivemetaboliteof ALBENDAZOLE ;continuoususeofdexamethasonepossiblyreducesplasmaconcentrationof PRAZIQUANTEL 
 TRIANGLE Antidiabetics:corticosteroidsantagonisehypoglycaemiceffectof ANTIDIABETICS 
Antiepileptics: metabolismofcorticosteroidsacceleratedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE (reducedeffect)
Antifungals: metabolismofcorticosteroidspossiblyinhibitedby ITRACONAZOLE and KETOCONAZOLE ;plasmaconcentrationofactivemetaboliteofciclesonideincreasedbylKETOCONAZOLE;plasmaconcentrationofinhaledmometasoneincreasedbyKETOCONAZOLE;plasmaconcentrationofinhaledandoral(andpossiblyalsointranasalandrectal)budesonideincreasedbylITRACONAZOLEandlKETOCONAZOLE;inhaledfluticasoneplasmaconcentrationispossiblyincreasedbyKETOCONAZOLE;metabolismofmethylprednisoloneinhibitedbyKETOCONAZOLE;increasedriskofhypokalaemiawhencorticosteroidsgivenwithl AMPHOTERICIN â€”avoidconcomitantuseunlesscorticosteroidsneededtocontrolreactions;plasmaconcentrationofinhaledfluticasoneincreasedbyITRACONAZOLE;metabolismofmethylprednisolonepossiblyinhibitedbyITRACONAZOLE;dexamethasonepossiblyreducesplasmaconcentrationof CASPOFUNGIN â€”considerincreasingdoseofcaspofungin
Antivirals: dexamethasonepossiblyreducesplasmaconcentrationof DACLATASVIR and SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;dexamethasonepossiblyreducesplasmaconcentrationof INDINAVIR , LOPINAVIR , SAQUINAVIR and TELAPREVIR ;avoidanceofdexamethasone(exceptwhengivenasasingledose)advisedbymanufacturerofl RILPIVIRINE ;plasmaconcentrationofinhaledandintranasalfluticasoneincreasedbyl RITONAVIR â€”increasedriskofadrenalsuppression;plasmaconcentrationofbudesonide(includinginhaled,intranasal,andrectalbudesonide)possiblyincreasedbylRITONAVIRâ€”increasedriskofadrenalsuppresion;plasmaconcentrationofcorticosteroidspossiblyincreasedbylRITONAVIRâ€”increasedriskofadrenalsuppresision;plasmaconcentrationofinhaledandintranasalbudesonideandfluticasonepossiblyincreasedbyTELAPREVIR 
 TRIANGLE Aprepitant: metabolismofdexamethasoneandmethylprednisoloneinhibitedby APREPITANT (reducedoseofdexamethasoneandmethylprednisolone) 
 TRIANGLE Beta-blockers:corticosteroidsantagonisehypotensiveeffectof BETA -BLOCKERS 
 TRIANGLE CalciumSalts: corticosteroidsreduceabsorptionof  CALCIUM SALTS  
 TRIANGLE Calcium-channelBlockers: corticosteroidsantagonisehypotensiveeffectofCALCIUM- CHANNELBLOCKERS ;plasmaconcentrationofmethylprednisoloneincreasedby DILTIAZEM  
 TRIANGLE CardiacGlycosides:increasedriskofhypokalaemiawhencorticosteroidsgivenwithCARDIACGLYCOSIDES
Ciclosporin: high-dosemethylprednisoloneincreasesplasmaconcentrationofl CICLOSPORIN (riskofconvulsions);plasmaconcentrationofprednisoloneincreasedbyCICLOSPORIN 
 TRIANGLE Clonidine: corticosteroidsantagonisehypotensiveeffectof CLONIDINE  
 TRIANGLE Cytotoxics: possibleincreasedriskofhepatoxicitywhendexamethasonegivenwithhigh-dose METHOTREXATE ;dexamethasonepossiblydecreasesplasmaconcentrationof AXITINIB (increasedoseofaxitinibâ€”consultaxitinibproductliterature);dexamethasonepossiblyreducesplasmaconcentrationof CABOZANTINIB â€”manufacturerofcabozantinibadvisesavoidconcomitantuse 
 TRIANGLE Diazoxide: corticosteroidsantagonisehypotensiveeffectof DIAZOXIDEBNF 
 TRIANGLE Diuretics: corticosteroidsantagonisediureticeffectof DIURETICS ;increasedriskofhypokalaemiawhencorticosteroidsgivenwith ACETAZOLAMIDE , LOOPDIURETICS or THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE Fosaprepitant: metabolismofdexamethasoneandmethylprednisoloneinhibitedby FOS APREPITANT  (reducedoseofdexamethasoneandmethylprednisolone)
GrapefruitJuice: plasmaconcentrationoforalbudesonideincreasedbyl GRAPEFRUITJUICE â€”avoidconcurrentuseorseparateadministrationbyasmuchaspossibleandconsiderreducingoralbudesonidedose 
 TRIANGLE Histamine: avoidanceofcorticosteroidsadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Methyldopa: corticosteroidsantagonisehypotensiveeffectof METHYLDOPA  
 TRIANGLE Mifamurtide: avoidanceofcorticosteroidsadvisedbymanufacturerof MIFAMURTIDE  
 TRIANGLE Mifepristone: effectofcorticosteroids(includinginhaledcorticosteroids)maybereducedfor3â€“4daysafter MIFEPRISTONE  
 TRIANGLE Moxonidine: corticosteroidsantagonisehypotensiveeffectof MOXONIDINE  
 TRIANGLE MuscleRelaxants: corticosteroidspossiblyantagoniseeffectsof PANCURONIUM and VECURONIUM  
 TRIANGLE Nitrates: corticosteroidsantagonisehypotensiveeffectof NITRATES  
 TRIANGLE Oestrogens: plasmaconcentrationofcorticosteroidsincreasedbyoralcontraceptivescontaining OESTROGENS  
 TRIANGLE SodiumBenzoate: corticosteroidspossiblyreduceeffectsof SODIUMBENZOATE  
 TRIANGLE SodiumPhenylbutyrate: corticosteroidspossiblyreduceeffectsof SODIUMPHENYLBUTYRATE  
 TRIANGLE Somatropin: corticosteroidsmayinhibitgrowth-promotingeffectof SOMATROPIN  
 TRIANGLE Sympathomimetics: metabolismofdexamethasoneacceleratedby EPHEDRINE  
 TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhencorticosteroidsgivenwithhighdosesof BETA 2 SYMPATHOMIMETICS  
 TRIANGLE Theophylline: increasedriskofhypokalaemiawhencorticosteroidsgivenwith THEOPHYLLINE 
Vaccines: highdosesofcorticosteroidsimpairimmuneresponsetol VACCINES â€”avoidconcomitantusewithlivevaccines 
 TRIANGLE VasodilatorAntihypertensives: corticosteroidsantagonisehypotensiveeffectof HYDRALAZINE , MINOXIDIL and SODIUMNITROPRUSSIDEC o-trimoxazoleseeTrimethoprimandSulfamethoxazoleCoumarins NOTEC hangeinpatientâ€™sclinicalcondition,particularlyassociatedwithliverdisease,intercurrentillness,ordrugadministration,necessitatesmorefrequenttestingMajorchangesindiet(especiallyinvolvingsaladsandvegetables)andinalcoholconsumptionmayalsoaffectanticoagulantcontrol
Alcohol: anticoagulantcontrolwithcoumarinsmaybeaffectedbymajorchangesinconsumptionofl ALCOHOL  
 TRIANGLE Allopurinol: anticoagulanteffectofcoumarinspossiblyenhancedby ALLOPURINOL 
AnabolicSteroids: anticoagulanteffectofcoumarinsenhancedbyl ANABOLICSTEROIDS 
Analgesics: anticoagulanteffectofcoumarinspossiblyenhancedbyl NSAIDS ;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins);anticoagulanteffectofcoumarinsenhancedbyl TRAMADOL ;increasedriskofbleedingwhencoumarinsgivenwithl ASPIRIN (duetoantiplateleteffect);anticoagulanteffectofcoumarinspossiblyenhancedbyprolongedregularuseof PARACETAMOL 
Antibacterials: experienceinanticoagulantclinicssuggeststhat INR possiblyalteredwhencoumarinsaregivenwithl NEOMYCIN (givenforlocalactionongut);anticoagulanteffectofcoumarinspossiblyenhancedbyl AZITHROMYCIN ,l AZTREONAM ,l CEPHALOSPORINS , CIPR OFLOXACIN  , LEVOFLOXACIN ,l TETRACYCLINES , TIGECYCLINE and TRIMETHOPRIM ;anticoagulanteffectofcoumarinsenhancedbyl CHLORAMPHENICOL ,l CLARITHROMYCIN ,l ERYTHROMYCIN ,l METRONIDAZOLE ,l NALIDIXICACID ,l NORFLOXACIN ,lOFLOXACINandl SULFONAMIDES ;plasmaconcentrationofwarfarinpossiblyincreasedby ORITAVANCIN ;aninteractionbetweencoumarinsandbroad-spectrum PENICILLINS hasnotbeendemonstratedinstudies,butcommonexperienceinanticoagulantclinicsisthatINRcanbealtered;metabolismofcoumarinsacceleratedbyl RIFAMYCINS (reducedanticoagulanteffect)
Anticoagulants: increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN ,l DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)
Antidepressants: anticoagulanteffectofwarfarinpossiblyenhancedbyl VENLAFAXINE ;anticoagulanteffectofwarfarinmaybeenhancedorreducedby TRAZODONE ;anticoagulanteffectofcoumarinspossiblyenhancedbyl SSRIS ;anticoagulanteffectofcoumarinsreducedbyl STJOHN â€™ SWORT (avoidconcomitantuse);anticoagulanteffectofwarfarinenhancedby MIRTAZAPINE ;anticoagulanteffectofcoumarinsmaybeenhancedorreducedbyl TRICYCLICS 
Antidiabetics: anticoagulanteffectofwarfarinpossiblyenhancedby EXENATIDE ;coumarinspossiblyenhancehypoglycaemiceffectofl SULFONYLUREAS ,alsopossiblechangestoanticoagulanteffect
Antiepileptics: metabolismofcoumarinsacceleratedbyl CARBAMAZEPINE ,l PHENOBARBITAL andl PRIMIDONE (reducedanticoagulanteffect);plasmaconcentrationofwarfarinreducedby ESLICARBAZEPINE ;metabolismofcoumarinsacceleratedbyl FOS PHENYTOIN  andlPHENYTOIN(possibilityofreducedanticoagulanteffect,butenhancementalsoreported);anticoagulanteffectofcoumarinspossiblyenhancedby SODIUMVALPROATE and VALPROICACID 
Antifungals: anticoagulanteffectofcoumarinsenhancedbyl FLUCONAZOLE ,l ITRACONAZOLE ,l KETOCONAZOLE andl VORICONAZOLE ;anticoagulanteffectofcoumarinsenhancedbyl MICONAZOLE (miconazoleoralgelandpossiblyvaginalandtopicalformulationsabsorbed);anticoagulanteffectofcoumarinsreducedbyl GRISEOFULVIN  
 TRIANGLE Antimalarials: isolatedreportsthatanticoagulanteffectofwarfarinmaybeenhancedby PROGUANIL ;plasmaconcentrationofbothdrugsincreasedwhenwarfaringivenwith QUININE 
Antivirals: anticoagulanteffectofwarfarinmaybeenhancedorreducedby ATAZANAVIR ,l NEVIRAPINE andl RITONAVIR ;plasmaconcentrationofcoumarinspossiblyaffectedbyl EFAVIRENZ ;anticoagulanteffectofcoumarinsmaybeenhancedorreducedby FOSAMPRENAVIR ;anticoagulanteffectofcoumarinspossiblyenhancedbylRITONAVIR;anticoagulanteffectofwarfarinpossiblyenhancedby SAQUINAVIR ;plasmaconcentrationofwarfarinpossiblyaffectedbyl TELAPREVIR  
 TRIANGLE AnxiolyticsandHypnotics: anticoagulanteffectofcoumarinsmaytransientlybeenhancedby CHLORAL  
 TRIANGLE Aprepitant: anticoagulanteffectofwarfarinpossiblyreducedbyAPREPITANT
Azathioprine: anticoagulanteffectofcoumarinspossiblyreducedbyl AZATHIOPRINE  
 TRIANGLE Bosentan: monitoringanticoagulanteffectofcoumarinsrecommendedbymanufacturerof BOSENTAN 
Clopidogrel: anticoagulanteffectofcoumarinsenhancedduetoantiplateletactionofl CLOPIDOGREL ;avoidanceofwarfarinadvisedbymanufactureroflCLOPIDOGREL
Corticosteroids: anticoagulanteffectofcoumarinsmaybeenhancedorreducedbyl CORTICOSTEROIDS (high-dosecorticosteroidsenhanceanticoagulanteffect)
CranberryJuice: anticoagulanteffectofcoumarinspossiblyenhancedbyl CRANBERRYJUICE â€”avoidconcomitantuselCytotoxics:  anticoagulanteffectofcoumarinspossiblyenhancedbyl ETOPOSIDE ,l IFOSFAMIDE andl SORAFENIB ;anticoagulanteffectofcoumarinsenhancedbyl CAPECITABINE ,l FLUOROURACIL andl TEGAFUR ;anticoagulanteffectofwarfarinpossiblyenhancedbyl GEFITINIB , GEMCITABINE andl VEMURAFENIB ;anticoagulanteffectofcoumarinspossiblyreducedbyl MERCAPTOPURINE andl MITOTANE ;plasmaconcentrationofwarfarinreducedby DABRAFENIB ;increasedriskofbleedingwhencoumarinsgivenwithl ERLOTINIB ;avoidanceofcoumarinsadvisedbymanufacturerof IBRUTINIB ;replacementofwarfarinwithaheparinadvisedbymanufacturerof IMATINIB (possibilityofenhancedwarfarineffect);increasedriskofbleedingwhenwarfaringivenwithl REGORAFENIB 
Dipyridamole: anticoagulanteffectofcoumarinsenhancedduetoantiplateletactionofl DIPYRIDAMOLE 
Disulfiram: anticoagulanteffectofcoumarinsenhancedbyl DISULFIRAM 
Dopaminergics: anticoagulanteffectofwarfarinenhancedbyl ENTACAPONE 
EnteralFoods: anticoagulanteffectofcoumarinsantagonisedbyvitaminK(presentinsomel ENTERALFEEDS )  
 TRIANGLE Fosaprepitant: anticoagulanteffectofwarfarinpossiblyreducedby FOSAPREPITANT 
Glucosamine: anticoagulanteffectofwarfarinenhancedbyl GLUCOSAMINE (avoidconcomitantuse)
HormoneAntagonists: anticoagulanteffectofcoumarinspossiblyenhancedby BICALUTAMIDE andl TOREMIFENE ;metabolismofcoumarinsinhibitedbyl DANAZOL (enhancedanticoagulanteffect);plasmaconcentrationofcoumarinspossiblyreducedbyl ENZALUTAMIDE ;anticoagulanteffectofcoumarinsenhancedbyl FLUTAMIDE andl TAMOXIFEN  
 TRIANGLE Iloprost: anticoagulanteffectofcoumarinspossiblyenhancedby ILOPROST  
 TRIANGLE Lactulose: anticoagulanteffectofcoumarinspossiblyenhancedby LACTULOSE  
 TRIANGLE Leflunomide: anticoagulanteffectofwarfarinpossiblyenhancedby LEFLUNOMIDE  
 TRIANGLE LeukotrieneReceptorAntagonists: anticoagulanteffectofwarfarinenhancedby ZAFIRLUKAST  
 TRIANGLE Levocarnitine: anticoagulanteffectofcoumarinspossiblyenhancedby LEVOCARNITINE  
 lLipid-regulatingDrugs:  anticoagulanteffectofcoumarinsmaybeenhancedorreducedbyl COLESTYRAMINE ;anticoagulanteffectofwarfarinmaybetransientlyreducedby ATORVASTATIN ;anticoagulanteffectofcoumarinsenhancedbyl FIBRATES andl FLUVASTATIN ;anticoagulanteffectofcoumarinspossiblyenhancedby EZETIMIBE andl ROSUVASTATIN ;anticoagulanteffectofcoumarinscanbeenhancedby SIMVASTATIN ;anticoagulanteffectofwarfarinpossiblyenhancedby LOMITAPIDE  
 TRIANGLE Memantine: anticoagulanteffectofwarfarinpossiblyenhancedby MEMANTINE  
 TRIANGLE Oestrogens: anticoagulanteffectofcoumarinsmaybeenhancedorreducedby OESTROGENS  
 TRIANGLE Orlistat: monitoringanticoagulanteffectofcoumarinsrecommendedbymanufacturerof ORLISTAT  
 TRIANGLE Prasugrel: possibleincreasedriskofbleedingwhencoumarinsgivenwith PRASUGREL  
 TRIANGLE Progestogens: anticoagulanteffectofcoumarinsmaybeenhancedorreducedby PROGESTOGENS  
 TRIANGLE Raloxifene: anticoagulanteffectofcoumarinsantagonisedby RALOXIFENE 
Retinoids: anticoagulanteffectofcoumarinspossiblyreducedbyl ACITRETIN 
Sympathomimetics: anticoagulanteffectofcoumarinspossiblyenhancedbyl METHYLPHENIDATE 
Testolactone: anticoagulanteffectofcoumarinsenhancedbyl TESTOLACTONE 
Testosterone: anticoagulanteffectofcoumarinsenhancedbyl TESTOSTERONE 
ThyroidHormones: anticoagulanteffectofcoumarinsenhancedbyl THYROIDHORMONES  
 TRIANGLE Ubidecarenone: anticoagulanteffectofwarfarinmaybeenhancedorreducedby UBIDECARENONE  
 lUlcer-healingDrugs:metabolismofcoumarinsinhibitedbyl CIMETIDINE (enhancedanticoagulanteffect);anticoagulanteffectofcoumarinspossiblyenhancedbyl ES OMEPRAZOLE  andlOMEPRAZOLE;anticoagulanteffectofcoumarinsmightbeenhancedby PANTOPRAZOLE ;absorptionofcoumarinspossiblyreducedbyl SUCRALFATE (reducedanticoagulanteffect) 
 TRIANGLE Vaccines: anticoagulanteffectofwarfarinpossiblyenhancedby INFLUENZAVACCINE 
Vitamins: anticoagulanteffectofcoumarinspossiblyenhancedbyl VITAMINE ;anticoagulanteffectofcoumarinsantagonisedbyl VITAMINKC ranberryJuice
Anticoagulants: cranberryjuicepossiblyenhancesanticoagulanteffectofl COUMARINS â€”avoidconcomitantuseCrizotinib
Analgesics: manufacturerofcrizotinibadvisescautionwithl ALFENTANIL andl FENTANYL 
Antibacterials: plasmaconcentrationofcrizotinibpossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”manufacturerofcrizotinibadvisesavoidconcomitantuse;plasmaconcentrationofcrizotinibpossiblyreducedby RIFABUTIN â€”manufacturerofcrizotinibadvisesavoidconcomitantuse;plasmaconcentrationofcrizotinibreducedbyl RIFAMPICIN â€”manufacturerofcrizotinibadvisesavoidconcomitantuse 
 TRIANGLE Antidepressants: plasmaconcentrationofcrizotinibpossiblyreducedby STJOHN â€™ SWORT â€”manufacturerofcrizotinibadvisesavoidconcomitantuse 
 TRIANGLE Antiepileptics: plasmaconcentrationofcrizotinibpossiblyreducedby CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE â€”manufacturerofcrizotinibadvisesavoidconcomitantuse
Antifungals: plasmaconcentrationofcrizotinibincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;plasmaconcentrationofcrizotinibpossiblyincreasedbyl ITRACONAZOLE andl VORICONAZOLE â€”manufacturerofcrizotinibadvisesavoidconcomitantuse 
 TRIANGLE Antimalarials: possibleincreasedriskofbradycardiawhencrizotinibgivenwith MEFLOQUINE 
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis);manufacturerofcrizotinibadvisescautionwithl PIMOZIDE 
Antivirals: plasmaconcentrationofcrizotinibpossiblyincreasedbyl ATAZANAVIR ,l INDINAVIR ,l RITONAVIR andl SAQUINAVIR â€”manufacturerofcrizotinibadvisesavoidconcomitantuse
AnxiolyticsandHypnotics: crizotinibincreasesplasmaconcentrationofl MIDAZOLAM  
 TRIANGLE Beta-blockers:possibleincreasedriskofbradycardiawhencrizotinibgivenwith BETA - BLOCKERS  
 TRIANGLE Calcium-channelBlockers: possibleincreasedriskofbradycardiawhencrizotinibgivenwith DILTIAZEM or VERAPAMIL  
 TRIANGLE CardiacGlycosides: possibleincreasedriskofbradycardiawhencrizotinibgivenwith DIGOXIN 
Ciclosporin: manufacturerofcrizotinibadvisescautionwithl CICLOSPORIN  
 TRIANGLE Clonidine: possibleincreasedriskofbradycardiawhencrizotinibgivenwith CLONIDINE  
Cytotoxics:crizotinibpossiblyincreasestheplasmaconcentrationoflIBRUTINIBâ€”reducedoseofibrutinib(seeunderIbrutinib,p809)
ErgotAlkaloids: manufacturerofcrizotinibadvisescautionwithl ERGOTALKALOIDSBNF 
GrapefruitJuice: plasmaconcentrationofcrizotinibpossiblyincreasedbyl GRAPEFRUITJUICE â€”manufacturerofcrizotinibadvisesavoidconcomitantuselOestrogens:  manufacturerofcrizotinibadvisescontraceptiveeffectofl OESTROGENS possiblyreduced  
 TRIANGLE Parasympathomimetics: possibleincreasedriskofbradycardiawhencrizotinibgivenwith PILOCARPINE  
Progestogens:  manufacturerofcrizotinibadvisescontraceptiveeffectofl PROGESTOGENS possiblyreduced
Sirolimus: manufacturerofcrizotinibadvisescautionwithl SIROLIMUS  
 
Tacrolimus:  manufacturerofcrizotinibadvisescautionwithl  TACROLIMUS 
 Cyclizine see Antihistamines 
 Cyclopenthiazide see Diuretics 
 Cyclopentolate see Antimuscarinics 
Cyclophosphamide
 
 
 
Antipsychotics:    avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides:  cyclophosphamidepossiblyreducesabsorptionof DIGOXIN tablets
 Cytotoxics:  increasedtoxicitywhenhigh-dosecyclophosphamidegivenwithl PENTOSTATIN â€”avoidconcomitantuse 
 TRIANGLE MuscleRelaxants: cyclophosphamideenhanceseffectsof SUXAMETHONIUMC ycloserine
Alcohol: increasedriskofconvulsionswhencycloserinegivenwithl ALCOHOL  
 TRIANGLE Antibacterials:  increasedriskof CNS toxicitywhencycloserinegivenwith ISONIAZID  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Cyproheptadine see Antihistamines 
Cytarabine
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides:cytarabinepossiblyreducesabsorptionofDIGOXINtablets 
 TRIANGLE Cytotoxics:intracellularconcentrationofcytarabineincreasedby FLUDARABINE
 Cytotoxics see individualdrugs 
 Dabigatran 
 
Analgesics: possibleincreasedriskofbleedingwhendabigatrangivenwithl NSAIDS ;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins)lAnti-arrhythmics:plasmaconcentrationofdabigatranincreasedbyl AMIODARONE (seeunderDabigatranEtexilate,p117);plasmaconcentrationofdabigatranincreasedbyl DRONEDARONE â€”avoidconcomitantuselAntibacterials:  possibleincreasedriskofbleedingwhendabigatrangivenwith CLARITHROMYCIN ;plasmaconcentrationofdabigatranreducedbyl RIFAMPICIN â€”manufacturerofdabigatranadvisesavoidconcomitantuse
 Anticoagulants:  increasedriskofhaemorrhagewhendabigatrangivenwithotherl ANTICOAGULANTS (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency);increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)
 TRIANGLE Antiepileptics:  plasmaconcentrationofdabigatranpossiblyreducedby CARBAMAZEPINE , FOS PHENYTOIN  andPHENYTOINâ€”manufacturerofdabigatranadvisesavoidconcomitantuse
Antifungals: plasmaconcentrationofdabigatranincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;manufacturerofdabigatranadvisesavoidconcomitantusewithITRACONAZOLE 
 TRIANGLE Antivirals: plasmaconcentrationofdabigatranpossiblyincreasedby RILPIVIRINE and TELAPREVIR  
 lCalcium-channelBlockers: plasmaconcentrationofdabigatranpossiblyincreasedbyl VERAPAMIL (seeunderDabigatranEtexilate,p117)
Ciclosporin: plasmaconcentrationofdabigatranpossiblyincreasedbyl CICLOSPORIN â€”manufacturerofdabigatranadvisesavoidconcomitantuse
Sulfinpyrazone: possibleincreasedriskofbleedingwhendabigatrangivenwithl SULFINPYRAZONE  
 lTacrolimus:plasmaconcentrationofdabigatranpossiblyincreasedbylTACROLIMUSâ€”manufacturerofdabigatranadvisesavoidconcomitantuse
Ticagrelor: plasmaconcentrationofdabigatranincreasedbyl TICAGRELOR  
 TRIANGLE Ulipristal: manufacturerofulipristaladvisesgivedabigatranatleast15hoursbeforeorafter ULIPRISTALD abrafenib 
 TRIANGLE Antibacterials:manufacturerofdabrafenibadvisesavoidconcomitantusewithRIFAMPICIN 
 TRIANGLE Anticoagulants:dabrafenibreducesplasmaconcentrationof WARFARIN  
 TRIANGLE Antidepressants:manufacturerofdabrafenibadvisesavoidconcomitantusewithSTJOHNâ€™SWORT 
 TRIANGLE Antiepileptics:manufacturerofdabrafenibadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN, PHENOBARBITAL ,PHENYTOINand PRIMIDONE  
 TRIANGLE Antifungals:plasmaconcentrationofdabrafenibincreasedbyKETOCONAZOLE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Lipid-regulatingDrugs:  plasmaconcentrationofdabrafenibincreasedby GEMFIBROZIL  
Oestrogens:manufacturerofdabrafenibadvisescontraceptiveeffectofhormonalcontraceptivescontaininglOESTROGENSpossiblyreduced(alternativecontraceptiverecommended)lProgestogens:manufacturerofdabrafenibadvisescontraceptiveeffectofhormonalcontraceptivescontaininglPROGESTOGENSpossiblyreduced(alternativecontraceptiverecommended) 
 TRIANGLE Ulcer-healingDrugs:manufacturerofdabrafenibadvisesavoidconcomitantusewith PROTONPUMPINHIBITORS (plasmaconcentrationofdabrafenibpossiblyreduced)Dacarbazine
Aldesleukin: avoidanceofdacarbazineadvisedbymanufacturerofl ALDESLEUKIN  
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)DaclatasvirlAnti-arrhythmics:possibleincreasedriskofbradycardiawhendaclatasvir(withsofosbuvir)givenwithlAMIODARONEâ€”seeunderAmiodarone,p88lAntibacterials:plasmaconcentrationofdaclatasvirpossiblyincreasedbylCLARITHROMYCINandl TELITHROMYCIN â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofdaclatasvirpossiblyreducedbyl RIFABUTIN â€”manufacturerofdaclatasviradvisesavoidconcomitantuse;plasmaconcentrationofdaclatasvirreducedbylRIFAMPICINâ€”avoidconcomitantuse 
 TRIANGLE Antidepressants:plasmaconcentrationofdaclatasvirpossiblyreducedbySTJOHNâ€™SWORTâ€”manufacturerofdaclatasviradvisesavoidconcomitantuse
Antiepileptics: plasmaconcentrationofdaclatasvirpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,l OXCARBAZEPINE ,lPHENOBARBITAL,lPHENYTOINand
 
Antivirals:   plasmaconcentrationofdaclatasvirincreasedbyl ATAZANAVIR andl TELAPREVIR â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);plasmaconcentrationofdaclatasvirpossiblyincreasedbyl BOCEPREVIR â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);manufacturerofdaclatasviradvisesavoidconcomitantusewith DARUNAVIR and LOPINAVIR (plasmaconcentrationofdaclatasvirpossiblyincreased);plasmaconcentrationofdaclatasvirreducedbyl EFAVIRENZ â€”increasedoseofdaclatasvir(seeunderDaclatasvir,p544);manufacturerofdaclatasviradvisesavoidconcomitantusewith ETRAVIRINE and NEVIRAPINE (plasmaconcentrationofdaclatasvirpossiblyreduced)
CardiacGlycosides: daclatasvirincreasesplasmaconcentrationofl DIGOXIN 
Cobicistat: plasmaconcentrationofdaclatasvirpossiblyincreasedbyl COBICISTAT â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544)  
 TRIANGLE Corticosteroids: plasmaconcentrationofdaclatasvirpossiblyreducedby DEXAMETHASONE â€”manufacturerofdaclatasviradvisesavoidconcomitantuse 
 TRIANGLE Lipid-regulating
 Drugs:   daclatasvirincreasesplasmaconcentrationof ROSUVASTATIND actinomycin
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Vitamins: dactinomycinpossiblyreduceseffectsof ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL and VITAMINDD airy
 yProducts 
 TRIANGLE Antibacterials:  dairyproductsreduceabsorptionof CIPROFLOXACIN and NORFLOXACIN ;dairyproductsreduceabsorptionof TETRACYCLINES (exceptdoxycyclineandminocycline) 
 TRIANGLE Cytotoxics: dairyproductspossiblyreduceplasmaconcentrationof MERCAPTOPURINE â€”manufacturerofmercaptopurineadvisesgiveatleast1hourbeforeor2hoursafterdairyproducts 
 TRIANGLE Eltrombopag: dairyproductspossiblyreduceabsorptionof ELTROMBOPAG (giveatleast4hoursapart)
 Dalteparin see Heparins 
 Danaparoid 
 
lAnalgesics:  increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins)lAnticoagulants:  increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN ,l DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)DanazollAnticoagulants:danazolinhibitsmetabolismofl COUMARINS (enhancedanticoagulanteffect)
Antiepileptics: danazolinhibitsmetabolismofl CARBAMAZEPINE (increasedriskoftoxicity)lCiclosporin:  danazolinhibitsmetabolismofl CICLOSPORIN (increasedplasmaconcentration)lLipid-regulatingDrugs:possibleincreasedriskofmyopathywhendanazolgivenwithl SIMVASTATIN â€”avoidconcomitantuse 
 TRIANGLE Tacrolimus: danazolpossiblyincreasesplasmaconcentrationof TACROLIMUS
 Dantrolene see Muscle 
 Relaxants 
 Dapagliflozin see Antidiabetics 
 Dapoxetine 
 
Alcohol: increasedsedativeeffectwhendapoxetinegivenwithl ALCOHOL  
Analgesics:possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithl TRAMADOL (manufacturerofdapoxetineadvisestramadolshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingtramadol)
Antibacterials: manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwith CLARITHROMYCIN and ERYTHROMYCIN (seeunderDapoxetine,p703);manufacturerofdapoxetineadvisesavoidconcomitantusewithl TELITHROMYCIN (increasedriskoftoxicity)
Antidepressants: possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithl  SSRI S ,l STJOHN â€™ SWORT ,l DULOXETINE ,l TRICYCLICS andl VENLAFAXINE (manufacturerofdapoxetineadvisesSSRIs,StJohnâ€™swort,duloxetine,tricyclicsandvenlafaxineshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingSSRIs,StJohnâ€™swort,duloxetine,tricyclicsandvenlafaxine);increasedriskofserotonergiceffectswhendapoxetinegivenwithl  MAOI S (MAOIsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingMAOIs)lAntifungals:plasmaconcentrationofdapoxetineincreasedbylKETOCONAZOLEâ€”manufacturerofdapoxetineadvisesavoidconcomitantuse;manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwith FLUCONAZOLE (seeunderDapoxetine,p703);manufacturerofdapoxetineadvisesavoidconcomitantusewithlITRACONAZOLE(increasedriskoftoxicity)lAntivirals:manufacturerofdapoxetineadvisesavoidconcomitantusewithlATAZANAVIR,l RITONAVIR andl SAQUINAVIR (increasedriskoftoxicity);manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwith FOSAMPRENAVIR (seeunderDapoxetine,p703) 
 TRIANGLE Aprepitant: manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwith APREPITANT (seeunderDapoxetine,p703) 
 TRIANGLE Calcium-channelBlockers: manufacturerofdapoxetineadvisesdosereductionwhendapoxetinegivenwith DILTIAZEM and VERAPAMIL (seeunderDapoxetine,p703)l5 HT 1-receptor
 Agonists: possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithl5HT1 AGONISTS (manufacturerofdapoxetineadvises5HT1agonistsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstopping5HT1agonists)
Lithium: possibleincreasedriskofserotonergiceffectswhendapoxetinegivenwithl LITHIUM (manufacturerofdapoxetineadviseslithiumshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppinglithium) 
 TRIANGLE Sildenafil: manufacturerofdapoxetineadvisesavoidconcomitantusewith SILDENAFIL  
 TRIANGLE Tadalafil: manufacturerofdapoxetineadvisesavoidconcomitantusewith TADALAFIL  
 TRIANGLE Vardenafil: manufacturerofdapoxetineadvisesavoidconcomitantusewith VARDENAFILD apsone 
 TRIANGLE Antibacterials:plasmaconcentrationofdapsonereducedby RIFAMYCINS ;plasmaconcentrationofbothdrugsmayincreasewhendapsonegivenwith TRIMETHOPRIM  
 lAntivirals:increasedriskofventriculararrhythmiaswhendapsonegivenwithlSAQUINAVIRâ€”avoidconcomitantuse 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF D aptomycinlCiclosporin:increasedriskofmyopathywhendaptomycingivenwithlCICLOSPORIN(preferablyavoidconcomitantuse)lLipid-regulatingDrugs:increasedriskofmyopathywhendaptomycingivenwithl FIBRATES orl STATINS (preferablyavoidconcomitantuse)BNF
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Darifenacin see Antimuscarinics 
Darunavir
 Antibacterials:   darunavirincreasesplasmaconcentrationofl RIFABUTIN (reducedoseofrifabutin);plasmaconcentrationofdarunavirsignificantlyreducedbyl RIFAMPICIN â€”avoidconcomitantuse 
 TRIANGLE Anticoagulants: avoidanceofdarunaviradvisedbymanufacturerof APIXABAN and RIVAROXABAN  
 
Antidepressants:  darunavirpossiblyreducesplasmaconcentrationof PAROXETINE and SERTRALINE ;plasmaconcentrationofdarunavirreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse 
 TRIANGLE Antiepileptics:   plasmaconcentrationofdarunavirpossiblyreducedby CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE  
 TRIANGLE Antifungals:  plasmaconcentrationofbothdrugsincreasedwhendarunavirgivenwith KETOCONAZOLE 
Antimalarials: plasmaconcentrationoflumefantrineincreasedwhendarunavirgivenwith ARTEMETHERWITHLUMEFANTRINE ;darunavirpossiblyincreasesplasmaconcentrationofl QUININE (increasedriskoftoxicity)
 Antipsychotics:    darunavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);darunavirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:  avoidconcomitantuseofdarunavirwithl BOCEPREVIR orl TELAPREVIR ;avoidanceofdarunaviradvisedbymanufacturerof DACLATASVIR (plasmaconcentrationofdaclatasvirpossiblyincreased);manufacturerofdarunaviradvisestake DIDANOSINE 1hourbeforeor2hoursafterdarunavir;plasmaconcentrationofdarunavirreducedbyl EFAVIRENZ (adjustdoseâ€”consultproductliterature);plasmaconcentrationofbothdrugsincreasedwhendarunavirgivenwith INDINAVIR ;plasmaconcentrationofdarunavirreducedbyl LOPINAVIR ,alsoplasmaconcentrationoflopinavirincreased(avoidconcomitantuse);darunavirincreasesplasmaconcentrationofl MARAVIROC (considerreducingdoseofmaraviroc);increasedriskofrashwhendarunavirgivenwith RALTEGRAVIR ;plasmaconcentrationofdarunavirreducedby SAQUINAVIR ;plasmaconcentrationofbothdrugsincreasedwhendarunavirgivenwithl SIMEPREVIR â€”manufacturerofsimepreviradvisesavoidconcomitantuse
Cytotoxics: darunavirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;darunavirpossiblyincreasesplasmaconcentrationofl EVEROLIMUS â€”manufacturerofeverolimusadvisesavoidconcomitantuse;darunavirpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809)
ErgotAlkaloids: increasedriskofergotismwhendarunavirgivenwithl ERGOTALKALOIDS â€”manufacturerofdarunaviradvisesavoidconcomitantuselLipid-regulating
 Drugs:   possibleincreasedriskofmyopathywhendarunavirgivenwith ATORVASTATIN ;darunavirpossiblyincreasesplasmaconcentrationof PRAVASTATIN ;darunavirincreasesplasmaconcentrationofl ROSUVASTATIN â€”adjustdoseofrosuvastatin(consultproductliterature);avoidanceofdarunaviradvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased)
Orlistat: absorptionofdarunavirpossiblyreducedbyl ORLISTAT 
Ranolazine: darunavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuseDasatinib
 
 TRIANGLE Antiepileptics:manufacturerofdasatinibadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE(plasmaconcentrationofdasatinibpossiblyreduced) 
 TRIANGLE Antifungals:plasmaconcentrationofdasatinibpossiblyincreasedbyKETOCONAZOLE;manufacturerofdasatinibadvisesavoidconcomitantusewith ITRACONAZOLE (plasmaconcentrationofdasatinibpossiblyincreased)
 
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lAntivirals:avoidanceofdasatinibadvisedbymanufactureroflBOCEPREVIR;manufacturerofdasatinibadvisesavoidconcomitantusewith RITONAVIR (plasmaconcentrationofdasatinibpossiblyincreased) 
 TRIANGLE GrapefruitJuice: manufacturerofdasatinibadvisesavoidconcomitantusewith GRAPEFRUITJUICE (plasmaconcentrationofdasatinibpossiblyincreased) 
 TRIANGLE Lipid-regulatingDrugs:dasatinibpossiblyincreasesplasmaconcentrationof SIMVASTATIN  
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofdasatinibpossiblyreducedby FAMOTIDINED ecitabinelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)Deferasirox
Aminophylline: deferasiroxincreasesplasmaconcentrationofl AMINOPHYLLINE (considerreducingdoseofaminophylline) 
 TRIANGLE Antacids:  absorptionofdeferasiroxpossiblyreducedby ANTACIDS containingaluminium(manufacturerofdeferasiroxadvisesavoidconcomitantuse) 
 TRIANGLE Antibacterials:plasmaconcentrationofdeferasiroxreducedbyRIFAMPICIN 
 TRIANGLE Antidiabetics: deferasiroxincreasesplasmaconcentrationof REPAGLINIDE  
 TRIANGLE Antipsychotics:manufacturerofdeferasiroxadvisesavoidconcomitantusewithCLOZAPINE 
 TRIANGLE AnxiolyticsandHypnotics: deferasiroxpossiblyreducesplasmaconcentrationof MIDAZOLAM  
 TRIANGLE MuscleRelaxants: manufacturerofdeferasiroxadvisesavoidconcomitantusewith TIZANIDINE 
Theophylline: deferasiroxincreasesplasmaconcentrationofl THEOPHYLLINE (considerreducingdoseoftheophylline)Deferiprone 
 TRIANGLE Antacids:absorptionofdeferipronepossiblyreducedbyANTACIDScontainingaluminium(manufacturerofdeferiproneadvisesavoidconcomitantuse)
 Deflazacort see Corticosteroids 
 Delamanid 
 
Analgesics: increasedriskofventriculararrhythmiaswhendelamanidgivenwithl METHADONE  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhendelamanidgivenwithl AMIODARONE orl DISOPYRAMIDE  
 lAntibacterials:possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithlCLARITHROMYCINandlERYTHROMYCIN;increasedriskofventriculararrhythmiaswhendelamanidgivenwithl MOXIFLOXACIN ;plasmaconcentrationofdelamanidreducedbylRIFAMPICIN;delamanidincreasesplasmaconcentrationof ETHAMBUTOL  
 lAntidepressants:possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithl TRICYCLICS thatprolongthe QT interval 
 TRIANGLE Antiepileptics:manufacturerofdelamanidadvisesavoidconcomitantusewithCARBAMAZEPINE 
 lAntipsychotics:increasedriskofventriculararrhythmiaswhendelamanidgivenwithl DROPERIDOL ,l HALOPERIDOL orl PIMOZIDE ;increasedriskofventriculararrhythmiaswhendelamanidgivenwithl PHENOTHIAZINES thatprolongtheQTinterval
 lBeta-blockers:increasedriskofventriculararrhythmiaswhendelamanidgivenwithl SOTALOL  
Cytotoxics:  increasedriskofventriculararrhythmiaswhendelamanidgivenwithl ARSENICTRIOXIDE orl VINFLUNINE ;possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithl VINBLASTINE ,l VINCRISTINE ,l VINDESINE andl VINORELBINE 
Domperidone: possibleincreasedriskofventriculararrhythmiaswhendelamanidgivenwithl DOMPERIDONE 
PentamidineIsetionate: increasedriskofventriculararrhythmiaswhendelamanidgivenwithl PENTAMIDINEISETIONATE   
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Demeclocycline see Tetracyclines 
Desferrioxamine
 Desflurane see Anaesthetics
,General
 Desloratadine see Antihistamines 
Desmopressin
 TRIANGLE Loperamide: plasmaconcentrationoforaldesmopressinincreasedby LOPERAMIDE
 Desogestrel see Progestogens 
 Dexamethasone see Corticosteroids 
 Dexamfetamine see Sympathomimetics 
 Dexibuprofen see 
 NSAID s
 Dexketoprofen see  NSAIDs 
 Dexrazoxane 
 
 Antiepileptics:  dexrazoxanepossiblyreducesabsorptionofl FOS PHENYTOIN  andlPHENYTOIN 
 TRIANGLE Ciclosporin: manufacturerofdexrazoxaneadvisesincreasedriskofimmunosuppressionwith CICLOSPORIN  
 TRIANGLE Tacrolimus: manufacturerofdexrazoxaneadvisesincreasedriskofimmunosuppressionwith TACROLIMUS 
Vaccines: riskofgeneralisedinfectionswhendexrazoxanegivenwithlivel VACCINES â€”avoidconcomitantuse
 Dextromethorphan see Opioid 
 Analgesics 
 Dextropropoxyphene see Opioid 
 Analgesics 
 Diamorphine see Opioid 
 Analgesics 
 Diazepam see Anxiolyticsand 
 Hypnotics 
Diazoxide
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhendiazoxidegivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhendiazoxidegivenwith AL CO HOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhendiazoxidegivenwith ALDESLEUKIN  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhendiazoxidegivenwith ALPHA -BLOCKERS 
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhendiazoxidegivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics:hypotensiveeffectofdiazoxideantagonisedby NSAIDS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhendiazoxidegivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antidepressants: enhancedhypotensiveeffectwhendiazoxidegivenwith MAOIS or TRICYCLIC - RELATEDANTIDEPRESSANTS  
 TRIANGLE Antidiabetics: diazoxideantagoniseshypoglycaemiceffectof ANTIDIABETICS  
 TRIANGLE Antiepileptics:diazoxidereducesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN,alsoeffectofdiazoxidemaybereduced 
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhendiazoxidegivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhendiazoxidegivenwith BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhendiazoxidegivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhendiazoxidegivenwith CLONIDINE  
 TRIANGLE Corticosteroids: hypotensiveeffectofdiazoxideantagonisedby CORTICOSTEROIDS  
 TRIANGLE Diuretics: enhancedhypotensiveandhyperglycaemiceffectswhendiazoxidegivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhendiazoxidegivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhendiazoxidegivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhendiazoxidegivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhendiazoxidegivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhendiazoxidegivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhendiazoxidegivenwith NITRATES  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhendiazoxidegivenwith ALPROSTADIL  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhendiazoxidegivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE
 Diclofenac see  NSAIDs 
 Dicycloverine see Antimuscarinics 
 Didanosine
 NOTEA ntacidsintabletformulationmightaffectabsorptionofotherdrugsâ€”giveatleast2hoursapart
Allopurinol: plasmaconcentrationofdidanosineincreasedbyl ALLOPURINOL (riskoftoxicity)â€”avoidconcomitantuse 
 TRIANGLE Analgesics:plasmaconcentrationofdidanosinepossiblyreducedby METHADONE  
 TRIANGLE Antibacterials: manufacturerofnorfloxacinadvisesgivedidanosineatleast2hoursbeforeorafter NORFLOXACIN  
Antivirals:didanosinetabletsreduceabsorptionof ATAZANAVIR (giveatleast2hoursbeforeor1hourafterdidanosinetablets);manufacturerofdarunaviradvisestakedidanosine1hourbeforeor2hoursafter DARUNAVIR ;plasmaconcentrationofdidanosinepossiblyincreasedby GANCICLOVIR and VALGANCICLOVIR ;didanosinetabletsreduceabsorptionof INDINAVIR (giveatleast1hourapart);increasedriskofside-effectswhendidanosinegivenwithl RIBAVIRIN â€”avoidconcomitantuse;manufacturerofrilpivirineadvisesgivedidanosine2hoursbeforeor4hoursafter RILPIVIRINE ;manufacturerofritonaviradvisesdidanosineandRITONAVIRshouldbetaken25hoursapart;increasedriskofside-effectswhendidanosinegivenwithl STAVUDINE ;plasmaconcentrationofdidanosineincreasedbyl TENOFOVIR (increasedriskoftoxicity)â€”avoidconcomitantuse;plasmaconcentrationofdidanosinereducedby TIPRANAVIR â€”manufactureroftipranaviradvisestipranaviranddidanosinecapsulesshouldbetakenatleast2hoursapartlCytotoxics:increasedriskoftoxicitywhendidanosinegivenwithl HYDROXYCARBAMIDE â€”avoidconcomitantuse
Orlistat: absorptionofdidanosinepossiblyreducedbyl ORLISTAT
 Dienogest see Progestogens 
Diethylcarbamazine
 Digoxin see Cardiac 
 Glycosides 
 Dihydrocodeine see Opioid 
 Analgesics 
 Dihydrotachysterol see Vitamins 
 Diltiazem see Calcium-channe 
 
BlockersDimethylsulfoxidelAnalgesics: avoidconcomitantuseofdimethylsulfoxidewithl SULINDAC
 Dinoprostone see Prostaglandins 
 BNF
 Diphenoxylate see Opioid 
 Analgesics 
 Diphtheria 
 Vaccines see Vaccines 
 Dipipanone see Opioid 
 Analgesics 
 Dipyridamole
  
 TRIANGLE Antacids: absorptionofdipyridamolepossiblyreducedby ANTACIDS  
 lAnti-arrhythmics:dipyridamoleenhancesandextendseffectofl ADENOSINE (importantriskoftoxicity)â€”reducedoseofadenosine,seep87
 Anticoagulants:  antiplateletactionofdipyridamoleenhancesanticoagulanteffectofl COUMARINS andl PHENINDIONE ;dipyridamoleenhancesanticoagulanteffectof HEPARINS  
 TRIANGLE Clopidogrel: increasedriskofbleedingwhendipyridamolegivenwith CLOPIDOGREL  
 TRIANGLE Cytotoxics: dipyridamolepossiblyreduceseffectsof FLUDARABINED isopyramide 
 TRIANGLE Anaesthetics,Local: increasedmyocardialdepressionwhenanti-arrhythmicsgivenwith BUPIVACAINE , LEVOBUPIVACAINE , PRILOCAINE or ROPIVACAINE  
 lAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherl ANTI - ARRHYTHMICS ;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl AMIODARONE orl DRONEDARONE â€”avoidconcomitantuse
 Antibacterials:  plasmaconcentrationofdisopyramidepossiblyincreasedbyl AZITHROMYCIN (increasedriskoftoxicity);plasmaconcentrationofdisopyramidepossiblyincreasedbyl CLARITHROMYCIN (increasedriskofventriculararrhythmias);plasmaconcentrationofdisopyramideincreasedbyl ERYTHROMYCIN (increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl MOXIFLOXACIN â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl DELAMANID ;metabolismofdisopyramideacceleratedbyl RIFAMYCINS (reducedplasmaconcentration);possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithl TELITHROMYCIN  
 TRIANGLE Anticoagulants:disopyramidemayenhanceorreduceanticoagulanteffectof WARFARIN  l
 Antidepressants:  avoidanceofdisopyramideadvisedbymanufacturerofl CITALOPRAM andl ESCITALOPRAM (riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl TRICYCLICS  
 TRIANGLE Antidiabetics: disopyramidepossiblyenhanceshypoglycaemiceffectof GLICLAZIDE , INSULIN and METFORMIN  
 TRIANGLE Antiepileptics: plasmaconcentrationofdisopyramidereducedby FOS PHENYTOIN  andPHENYTOIN;metabolismofdisopyramideacceleratedby PHENOBARBITAL and PRIMIDONE (reducedplasmaconcentration)
Antifungals: increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl KETOCONAZOLE â€”avoidconcomitantuse;avoidanceofdisopyramideadvisedbymanufacturerofl ITRACONAZOLE 
Antihistamines: increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: avoidanceofdisopyramideadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE (riskofventriculararrhythmias);avoidanceofdisopyramideadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias)
Antimuscarinics: increasedriskofantimuscarinicside-effectswhendisopyramidegivenwith ANTIMUSCARINICS ;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl TOLTERODINE 
Antivirals: plasmaconcentrationofdisopyramidepossiblyincreasedbyl RITONAVIR (increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl SAQUINAVIR â€”avoidconcomitantuse;avoidanceofdisopyramideadvisedbymanufacturerofl TELAPREVIR (riskofventriculararrhythmias)
Atomoxetine: increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl ATOMOXETINE  
 lBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithl BETA - BLOCKERS ;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl SOTALOL â€”avoidconcomitantuselCalcium-channelBlockers: increasedriskofmyocardialdepressionandasystolewhendisopyramidegivenwithl VERAPAMIL 
Cytotoxics: possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithl BOSUTINIB ;possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithl VANDETANIB â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl ARSENICTRIOXIDE 
Diuretics: increasedcardiactoxicitywithdisopyramideifhypokalaemiaoccurswithl ACETAZOLAMIDE ,l LOOPDIURETICS orl THIAZIDESANDRELATEDDIURETICS 
Fingolimod: possibleincreasedriskofbradycardiawhendisopyramidegivenwithl FINGOLIMOD 
Ivabradine: increasedriskofventriculararrhythmiaswhendisopyramidegivenwithl IVABRADINE  
 TRIANGLE Nitrates: disopyramidereduceseffectsofsublingualtabletsof NITRATES (failuretodissolveundertongueowingtodrymouth)
PentamidineIsetionate: possibleincreasedriskofventriculararrhythmiaswhendisopyramidegivenwithl PENTAMIDINEISETIONATE 
Ranolazine: avoidanceofdisopyramideadvisedbymanufacturerofl RANOLAZINE  
 TRIANGLE Sildenafil: manufacturerofdisopyramideadvisesavoidconcomitantusewith SILDENAFIL (riskofventriculararrhythmias) 
 TRIANGLE Tadalafil: manufacturerofdisopyramideadvisesavoidconcomitantusewith TADALAFIL (riskofventriculararrhythmias) 
 TRIANGLE Vardenafil: manufacturerofdisopyramideadvisesavoidconcomitantusewith VARDENAFIL (riskofventriculararrhythmias)Disulfiram 
 TRIANGLE Alcohol: disulfiramreactionwhendisulfiramgivenwith ALCOHOL  
 TRIANGLE Aminophylline: disulfiraminhibitsmetabolismof AMINOPHYLLINE (increasedriskoftoxicity) 
 TRIANGLE Antibacterials:psychoticreactionreportedwhendisulfiramgivenwith METRONIDAZOLE ; CNS effectsofdisulfirampossiblyincreasedby ISONIAZID 
Anticoagulants: disulfiramenhancesanticoagulanteffectoflCOUMARINS 
 TRIANGLE Antidepressants:increaseddisulfiramreactionwithalcoholreportedwithconcomitant AMITRIPTYLINE ;disulfiraminhibitsmetabolismofTRICYCLICS(increasedplasmaconcentration)
Antiepileptics: disulfiraminhibitsmetabolismoflFOSPHENYTOINandlPHENYTOIN(increasedriskoftoxicity) 
 TRIANGLE AnxiolyticsandHypnotics: disulfiramincreasesriskof TEMAZEPAM toxicity;disulfiraminhibitsmetabolismof BENZODIAZEPINES (increasedsedativeeffects)
Paraldehyde: riskoftoxicitywhendisulfiramgivenwithl PARALDEHYDE  
 TRIANGLE Theophylline: disulfiraminhibitsmetabolismof THEOPHYLLINE (increasedriskoftoxicity)Diuretics NOTES incesystemicabsorptionmayfollowtopicalapplicationofbrinzolamidetotheeye,thepossibilityofinteractionsshouldbeborneinmindNOTESincesystemicabsorptionmayfollowtopicalapplicationofdorzolamidetotheeye,thepossibilityofinteractionsshouldbeborneinmind
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhendiureticsgivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhendiureticsgivenwith ALCOHOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhendiureticsgivenwith ALDESLEUKIN  
 TRIANGLE Aliskiren: plasmaconcentrationoffurosemidereducedby ALISKIREN ;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithALISKIREN 
 TRIANGLE Allopurinol: increasedriskofhypersensitivitywhenthiazidesandrelateddiureticsgivenwith ALLOPURINOL especiallyinrenalimpairmentlAlpha-blockers:enhancedhypotensiveeffectwhendiureticsgivenwithl ALPHA -BLOCKERS,alsoincreasedriskoffirst-dosehypotensionwithpost-synapticalpha-blockerssuchasprazosin 
 TRIANGLE Aminophylline: increasedriskofhypokalaemiawhenacetazolamide,loopdiureticsorthiazidesandrelateddiureticsgivenwith AMINOPHYLLINE  
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhendiureticsgivenwith GENERALANAESTHETICS 
Analgesics: diureticsincreaseriskofnephrotoxicityof NSAIDS ,alsoantagonismofdiureticeffect;diureticeffectofpotassiumcanrenoatepossiblyantagonisedbyNSAIDS;possibleincreasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithNSAIDS;furosemidepossiblyincreasestheexcretionof ACEMETACIN ;effectsofdiureticsantagonisedby INDOMETACIN and KETOROLAC ;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithINDOMETACIN;occasionalreportsofreducedrenalfunctionwhentriamterenegivenwithlINDOMETACINâ€”avoidconcomitantuse;increasedriskoftoxicitywhenacetazolamidegivenwithhigh-dosel ASPIRIN ;diureticeffectofspironolactoneantagonisedbyASPIRIN;possibleincreasedriskoftoxicitywhenloopdiureticsgivenwithhigh-doseASPIRIN(alsopossiblereducedeffectofloopdiuretics)lAngiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhendiureticsgivenwithl ANGIOTENSIN - IIRECEPTORANTAGONISTS ;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithlANGIOTENSIN-IIRECEPTORANTAGONISTS 
 lAnti-arrhythmics:hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywith AMIODARONE ;plasmaconcentrationofeplerenoneincreasedbyAMIODARONE(reducedoseofeplerenone);hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywithl DISOPYRAMIDE ;hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywithl FLECAINIDE ;hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsantagonisesactionofl LIDOCAINE 
Antibacterials: plasmaconcentrationofeplerenoneincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”avoidconcomitantuse;plasmaconcentrationofeplerenoneincreasedby ERYTHROMYCIN (reducedoseofeplerenone);plasmaconcentrationofeplerenonereducedbyl RIFAMPICIN â€”avoidconcomitantuse;avoidanceofdiureticsadvisedbymanufacturerof LYMECYCLINE ;increasedriskofotoxicitywhenloopdiureticsgivenwithl AMINOGLYCOSIDES ,l POLYMYXINS orl VANCOMYCIN ;acetazolamideantagoniseseffectsofl METHENAMINE ;possibleincreasedriskofhyperkalaemiawhenspironolactonegivenwith TRIMETHOPRIM ;increasedriskofhyperkalaemiawheneplerenonegivenwithTRIMETHOPRIM
 TRIANGLE Antidiabetics: loopdiureticsandthiazidesandrelateddiureticsantagonisehypoglycaemiceffectof ANTIDIABETICS ;diureticeffectofdiureticspossiblyenhancedby CANAGLIFLOZIN ;avoidanceofloopdiureticsadvisedbymanufacturerofCANAGLIFLOZIN;diureticeffectofloopdiureticsandthiazidesandrelateddiureticspossiblyenhancedby DAPAGLIFLOZIN 
Antiepileptics: plasmaconcentrationofeplerenonereducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”avoidconcomitantuse;increasedriskofhyponatraemiawhendiureticsgivenwithCARBAMAZEPINE;acetazolamideincreasesplasmaconcentrationoflCARBAMAZEPINE;effectsoffurosemideantagonisedbyFOSPHENYTOINandPHENYTOIN;acetazolamidepossiblyincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN;increasedriskofosteomalaciawhencarbonicanhydraseinhibitorsgivenwithFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINorPRIMIDONE;hydrochlorothiazidepossiblyincreasesplasmaconcentrationof TOPIRAMATE ;avoidanceofcarbonicanhydraseinhibitorsinchildrenadvisedbymanufacturerof ZONISAMIDE 
Antifungals: plasmaconcentrationofeplerenoneincreasedbyl ITRACONAZOLE andl KETOCONAZOLE â€”avoidconcomitantuse;increasedriskofhypokalaemiawhenloopdiureticsorthiazidesandrelateddiureticsgivenwith AMPHOTERICIN ;hydrochlorothiazideincreasesplasmaconcentrationof FLUCONAZOLE ;plasmaconcentrationofeplerenoneincreasedbyFLUCONAZOLE(reducedoseofeplerenone)
Antipsychotics: hypokalaemiacausedbydiureticsincreasesriskofventriculararrhythmiaswithl AMISULPRIDE ;enhancedhypotensiveeffectwhendiureticsgivenwith PHENOTHIAZINES ;hypokalaemiacausedbydiureticsincreasesriskofventriculararrhythmiaswithl PIMOZIDE (avoidconcomitantuse)
Antivirals: plasmaconcentrationofeplerenoneincreasedbyl RITONAVIR â€”avoidconcomitantuse;plasmaconcentrationofeplerenoneincreasedby SAQUINAVIR (reducedoseofeplerenone) 
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhendiureticsgivenwith ANXIOLYTICSANDHYPNOTICS ;administrationofparenteralfurosemidewith CHLORAL maydisplacethyroidhormonefrombindingsites
Atomoxetine: hypokalaemiacausedbydiureticsincreasesriskofventriculararrhythmiaswithl ATOMOXETINE  
 lBeta-blockers:enhancedhypotensiveeffectwhendiureticsgivenwith BETA -BLOCKERS;hypokalaemiacausedbyloopdiureticsorthiazidesandrelateddiureticsincreasesriskofventriculararrhythmiaswithl SOTALOL  
 TRIANGLE CalciumSalts: increasedriskofhypercalcaemiawhenthiazidesandrelateddiureticsgivenwith  CALCIUM SALTS  
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhendiureticsgivenwithCALCIUM- CHANNELBLOCKERS ;plasmaconcentrationofeplerenoneincreasedby DILTIAZEM and VERAPAMIL (reducedoseofeplerenone)
CardiacGlycosides: hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasescardiactoxicitywithl CARDIACGLYCOSIDES ;spironolactoneincreasesplasmaconcentrationofl DIGOXIN ;potassiumcanrenoatepossiblyincreasesplasmaconcentrationofDIGOXIN
Ciclosporin: increasedriskofnephrotoxicityandpossiblyhypermagnesaemiawhenthiazidesandrelateddiureticsgivenwith CICLOSPORIN ;increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithlCICLOSPORIN;acetazolamidepossiblyincreasesplasmaconcentrationoflCICLOSPORIN 
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhendiureticsgivenwith CLONIDINE  
 TRIANGLE Corticosteroids: diureticeffectofdiureticsantagonisedby CORTICOSTEROIDS ;increasedriskofhypokalaemiawhen BNF 
 Cytotoxics:  alkalineurineduetoacetazolamideincreasesexceretionof METHOTREXATE ;hypokalaemiacausedbyacetazolamide,loopdiureticsorthiazidesandrelateddiureticsincreasesriskofventriculararrhythmiaswithl ARSENICTRIOXIDE ;avoidanceofspironolactoneadvisedbymanufacturerof MITOTANE (antagonismofeffect);increasedriskofnephrotoxicityandototoxicitywhendiureticsgivenwith PLATINUMCOMPOUNDS   
 TRIANGLE Diazoxide: enhancedhypotensiveandhyperglycaemiceffectswhendiureticsgivenwith DIAZOXIDE  
 TRIANGLE Diuretics: increasedriskofhypokalaemiawhenloopdiureticsorthiazidesandrelateddiureticsgivenwith ACETAZOLAMIDE ;profounddiuresispossiblewhenmetolazonegivenwith FUROSEMIDE ;increasedriskofhypokalaemiawhenthiazidesandrelateddiureticsgivenwith LOOPDIURETICS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhendiureticsgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE HormoneAntagonists: increasedriskofhypercalcaemiawhenthiazidesandrelateddiureticsgivenwith TOREMIFENE  
 TRIANGLE Lipid-regulating
 Drugs: absorptionofthiazidesandrelateddiureticsreducedby COLESTIPOL and COLESTYRAMINE (giveatleast2hoursapart)
Lithium: loopdiureticsandthiazidesandrelateddiureticsreduceexcretionofl LITHIUM (increasedplasmaconcentrationandriskoftoxicity)â€”loopdiureticssaferthanthiazides;potassium-sparingdiureticsandaldosteroneantagonistsreduceexcretionoflLITHIUM(increasedplasmaconcentrationandriskoftoxicity);acetazolamideincreasestheexcretionoflLITHIUM 
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhendiureticsgivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhendiureticsgivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhendiureticsgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhendiureticsgivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhendiureticsgivenwith NITRATES  
 TRIANGLE Oestrogens: diureticeffectofdiureticsantagonisedby OESTROGENS 
PotassiumSalts: increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithl POTASSIUMSALTS  
 TRIANGLE Progestogens: riskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwith DROSPIRENONE (monitorserumpotassiumduringfirstcycle) 
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhendiureticsgivenwith ALPROSTADIL  
 TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhenacetazolamide,loopdiureticsorthiazidesandrelateddiureticsgivenwithhighdosesof BETA 2 SYMPATHOMIMETICS 
Tacrolimus: increasedriskofhyperkalaemiawhenpotassium-sparingdiureticsandaldosteroneantagonistsgivenwithl TACROLIMUS  
 TRIANGLE Theophylline: increasedriskofhypokalaemiawhenacetazolamide,loopdiureticsorthiazidesandrelateddiureticsgivenwith THEOPHYLLINE  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhendiureticsgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE  
 TRIANGLE Vitamins: increasedriskofhypercalcaemiawhenthiazidesandrelateddiureticsgivenwith ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL or VITAMINDD iuretics,
 Loop see Diuretics 
 Diuretics
,Potassium-sparingandAldosterone
 Antagonists see Diuretics 
 Diuretics
,
 Thiazideandrelated see Diuretics 
 Dobutamine see Sympathomimetics 
 Docetaxel 
 
 
Antibacterials:   plasmaconcentrationofdocetaxelpossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldoselAntifungals:  invitrostudiessuggestapossibleinteractionbetweendocetaxeland KETOCONAZOLE (consultdocetaxelproductliterature);plasmaconcentrationofdocetaxelpossiblyincreasedbyl ITRACONAZOLE andl VORICONAZOLE â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
 
 
Antivirals:   plasmaconcentrationofdocetaxelpossiblyincreasedbyl INDINAVIR ,l RITONAVIR andl SAQUINAVIR â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose 
 TRIANGLE Ciclosporin: invitrostudiessuggestapossibleinteractionbetweendocetaxeland CICLOSPORIN (consultdocetaxelproductliterature) 
 TRIANGLE Cytotoxics:possibleincreasedriskofneutropeniawhendocetaxelgivenwith LAPATINIB ;plasmaconcentrationofdocetaxelincreasedby SORAFENIBD olutegravir 
 TRIANGLE Antacids: absorptionofdolutegravirreducedby ALUMINIUMHYDROXIDE and ORALMAGNESIUMSALTS â€”manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteraluminiumhydroxideandoralmagnesiumsaltslAntibacterials:plasmaconcentrationofdolutegravirreducedbyl RIFAMPICIN (seeunderDolutegravir,p557) 
 TRIANGLE Antidepressants: manufacturerofdolutegraviradvisesavoidconcomitantusewith STJOHN â€™ SWORT  
 TRIANGLE Antiepileptics: manufacturerofdolutegraviradvisesavoidconcomitantusewith CARBAMAZEPINE , FOS PHENYTOIN  , OXCARBAZEPINE , PHENOBARBITAL ,PHENYTOINand PRIMIDONE  
 lAntivirals:plasmaconcentrationofdolutegravirreducedbyl EFAVIRENZ ,l ETRAVIRINE andl TIPRANAVIR (seeunderDolutegravir,p557);plasmaconcentrationofdolutegravirreducedbyl FOSAMPRENAVIR ;plasmaconcentrationofdolutegravirpossiblyreducedbyl NEVIRAPINE (seeunderDolutegravir,p557) 
 TRIANGLE CalciumSalts: absorptionofdolutegravirreducedby CALCIUMSALTS â€”manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursaftercalciumsalts 
 TRIANGLE IronSalts: absorptionofdolutegravirreducedbyoral IRONSALTS â€”manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteroralironsalts
 sDomperidone 
 TRIANGLE Analgesics: effectsofdomperidoneongastro-intestinalactivityantagonisedby OPIOIDANALGESICS  
 lAntibacterials:possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithlCLARITHROMYCINorlTELITHROMYCINâ€”avoidconcomitantuse;plasmaconcentrationofdomperidoneincreasedbyl ERYTHROMYCIN (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithl DELAMANID  
Antifungals:avoidanceofdomperidoneadvisedbymanufactureroflKETOCONAZOLE(riskofventriculararrhythmias);possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithlITRACONAZOLEorlVORICONAZOLEâ€”avoidconcomitantuse
Antimalarials: avoidanceofdomperidoneadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias) 
 TRIANGLE Antimuscarinics: effectsofdomperidoneongastro-intestinalactivityantagonisedby ANTIMUSCARINICS  
 lAntivirals:possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithl BOCEPREVIR ,lRITONAVIR,lSAQUINAVIRorl TELAPREVIR â€”avoidconcomitantuse
Cobicistat: possibleincreasedriskofventriculararrhythmiaswhendomperidonegivenwithl COBICISTAT â€”avoidconcomitantuse
Cytotoxics: avoidanceofdomperidoneadvisedbymanufacturerofl BOSUTINIB (riskofventriculararrhythmias)
 TRIANGLE Dopaminergics: domperidonepossiblyantagoniseshypoprolactinaemiceffectsof BROMOCRIPTINE and CABERGOLINE
 Donepezil see Parasympathomimetics 
 Dopamine see Sympathomimetics 
 Dopaminergics see Amantadine
,Apomorphine,Bromocriptine,Cabergoline,Entacapone,Levodopa,Pergolide,Pramipexole,Quinagolide,Rasagiline,Ropinirole,Rotigotine,Selegiline,andTolcapone
 Dopexamine see Sympathomimetics 
 Dorzolamide see Diuretics 
 Dosulepin see Antidepressants
,Tricyclic
 cDoxapram 
 TRIANGLE Aminophylline: increased CNS stimulationwhendoxapramgivenwith AMINOPHYLLINE  lAnaesthetics,General: increasedriskofarrhythmiaswhendoxapramgivenwithl VOLATILELIQUIDGENERALANAESTHETICS (avoiddoxapramforatleast10minutesaftervolatileliquidgeneralanaesthetics) 
 TRIANGLE Antidepressants: effectsofdoxapramenhancedby  MAOI S  
 TRIANGLE Sympathomimetics: increasedriskofhypertensionwhendoxapramgivenwith SYMPATHOMIMETICS  
 TRIANGLE Theophylline: increasedCNSstimulationwhendoxapramgivenwith THEOPHYLLINE
 Doxazosin see Alpha-blockers 
 Doxepin see Antidepressants
,TricyclicDoxorubicinlAntipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Antivirals: doxorubicinpossiblyinhibitseffectsof STAVUDINE  
 TRIANGLE Calcium-channelBlockers:  plasmaconcentrationofdoxorubicinpossiblyincreasedby VERAPAMIL  
 TRIANGLE CardiacGlycosides: doxorubicinpossiblyreducesabsorptionof DIGOXIN tablets
Ciclosporin: increasedriskofneurotoxicitywhendoxorubicingivenwithl CICLOSPORIN  
 TRIANGLE Cytotoxics: plasmaconcentrationofdoxorubicinincreasedby SORAFENIB  
 TRIANGLE Ulcer-healingDrugs:  plasmaconcentrationofdoxorubicinreducedby CIMETIDINE 
Vaccines: riskofgeneralisedinfectionswhendoxorubicingivenwithlivel VACCINES â€”avoidconcomitantuse
 Doxycycline see Tetracyclines 
Dronedarone
 lAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherl ANTI - ARRHYTHMICS ;increasedriskofventriculararrhythmiaswhendronedaronegivenwithl AMIODARONE orl DISOPYRAMIDE â€”avoidconcomitantuselAntibacterials:  manufacturerofdronedaroneadvisesavoidconcomitantusewithl CLARITHROMYCIN (riskofventriculararrhythmias);plasmaconcentrationofdronedaroneincreasedbyl ERYTHROMYCIN (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);plasmaconcentrationofdronedaronereducedbyl RIFAMPICIN â€”avoidconcomitantuse;avoidanceofdronedaroneadvisedbymanufacturerof FIDAXOMICIN ;increasedriskofventriculararrhythmiaswhendronedaronegivenwithl TELITHROMYCIN â€”avoidconcomitantuselAnticoagulants:  dronedaronepossiblyenhancesanticoagulanteffectofl COUMARINS andl PHENINDIONE ;dronedaroneincreasesplasmaconcentrationofl DABIGATRAN â€”avoidconcomitantuse;avoidanceofdronedaroneadvisedbymanufacturerof RIVAROXABAN  
 
Antiepileptics: plasmaconcentrationofdronedaronepossiblyreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”avoidconcomitantuse
Antifungals: plasmaconcentrationofdronedaroneincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;manufacturerofdronedaroneadvisesavoidconcomitantusewithl ITRACONAZOLE ,l POSACONAZOLE andl VORICONAZOLE  
Antipsychotics:increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongthe QT intervalgivenwithl ANTIPSYCHOTICS thatprolongtheQTinterval;manufacturerofdronedaroneadvisesavoidconcomitantusewithl PHENOTHIAZINES (riskofventriculararrhythmias)
Antivirals: manufacturerofdronedaroneadvisesavoidconcomitantusewithl RITONAVIR ;increasedriskofventriculararrhythmiaswhendronedaronegivenwithl SAQUINAVIR â€”avoidconcomitantuselBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithl BETA - BLOCKERS ;dronedaronepossiblyincreasesplasmaconcentrationof METOPROLOL and PROPRANOLOL ;increasedriskofventriculararrhythmiaswhendronedaronegivenwithl SOTALOL â€”avoidconcomitantuselCalcium-channelBlockers:plasmaconcentrationofdronedaroneincreasedbyl NIFEDIPINE ;increasedriskofbradycardiaandmyocardialdepressionwhendronedaronegivenwithl DILTIAZEM andlVERAPAMIL
CardiacGlycosides: dronedaroneincreasesplasmaconcentrationoflDIGOXIN(halvedoseofdigoxin)
Cytotoxics: dronedaronepossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;dronedaronepossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809)
Fingolimod: possibleincreasedriskofbradycardiawhendronedaronegivenwithl FINGOLIMOD 
GrapefruitJuice: plasmaconcentrationofdronedaroneincreasedbyl GRAPEFRUITJUICE â€”avoidconcomitantuselLipid-regulatingDrugs:dronedaronepossiblyincreasesplasmaconcentrationof ATORVASTATIN ;dronedaroneincreasesplasmaconcentrationofl ROSUVASTATIN â€”adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhendronedaronegivenwithl SIMVASTATIN ;avoidanceofdronedaroneadvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased) 
 TRIANGLE Sirolimus: manufacturerofdronedaroneadvisescautionwith SIROLIMUS  
 TRIANGLE Tacrolimus: manufacturerofdronedaroneadvisescautionwith TACROLIMUS
 Droperidol see Antipsychotics 
 Drospirenone see Progestogens 
Duloxetine
Antibacterials:metabolismofduloxetineinhibitedbyl CIPROFLOXACIN â€”avoidconcomitantuselAnticoagulants:possibleincreasedriskofbleedingwhenSSRI-relatedantidepressantsgivenwithlDABIGATRAN 
 lAntidepressants:metabolismofduloxetineinhibitedbyl FLUVOXAMINE â€”avoidconcomitantuse;possibleincreasedserotonergiceffectswhenduloxetinegivenwith SSRIS ,STJOHNâ€™SWORT, AMITRIPTYLINE , CLOMIPRAMINE ,l MOCLOBEMIDE or VENLAFAXINE ;duloxetineshouldnotbestarteduntil2weeksafterstoppinglMAOIS,alsoMAOIsshouldnotbestarteduntilatleast5daysafterstoppingduloxetine;afterstoppingSSRI-relatedantidepressantsdonotstartlMOCLOBEMIDEforatleast1week
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINEBNF 
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE 
Dapoxetine: possibleincreasedriskofserotonergiceffectswhenduloxetinegivenwithl DAPOXETINE (manufacturerofdapoxetineadvisesduloxetineshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingduloxetine) 
 TRIANGLE 5 HT 1-receptor
 Agonists: possibleincreasedserotonergiceffectswhenduloxetinegivenwith5HT1 AGONISTS  
 TRIANGLE 5HT3-receptor
 Antagonists: possibleincreasedserotonergiceffectswhen SSRI -relatedantidepressantsgivenwith5HT3 ANTAGONISTS 
Methylthioninium: riskof CNS toxicitywhenSSRI-relatedantidepressantsgivenwithl METHYLTHIONINIUM â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)Dutasteride 
 TRIANGLE Calcium-channelBlockers:  plasmaconcentrationofdutasterideincreasedby DILTIAZEM and VERAPAMIL
 Dydrogesterone see Progestogens 
Efavirenz
 TRIANGLE Antibacterials: efavirenzreducesplasmaconcentrationof CLARITHROMYCIN ,alsoplasmaconcentrationofactivemetaboliteofclarithromycinincreased;efavirenzreducesplasmaconcentrationof RIFABUTIN â€”increasedoseofrifabutin;plasmaconcentrationofefavirenzreducedby RIFAMPICIN â€”increasedoseofefavirenz;efavirenzpossiblyreducesplasmaconcentrationof BEDAQUILINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse
Anticoagulants: efavirenzpossiblyaffectsplasmaconcentrationofl COUMARINS  
 
Antidepressants:  plasmaconcentrationofefavirenzreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse 
 TRIANGLE Antiepileptics: plasmaconcentrationofbothdrugsreducedwhenefavirenzgivenwith CARBAMAZEPINE 
Antifungals: efavirenzreducesplasmaconcentrationof ITRACONAZOLE ,l KETOCONAZOLE andl POSACONAZOLE ;efavirenzreducesplasmaconcentrationofl VORICONAZOLE ,alsoplasmaconcentrationofefavirenzincreased(increasevoriconazoledoseandreduceefavirenzdose);efavirenzpossiblyreducesplasmaconcentrationof CASPOFUNGIN â€”considerincreasingdoseofcaspofungin
Antimalarials: efavirenzreducesplasmaconcentrationofl ARTEMETHERWITHLUMEFANTRINE ;efavirenzpossiblyaffectsplasmaconcentrationof PROGUANIL 
Antipsychotics: efavirenzpossiblyreducesplasmaconcentrationofl ARIPIPRAZOLE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);efavirenzpossiblyincreasesplasmaconcentrationofl PIMOZIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse)
AnxiolyticsandHypnotics: increasedriskofprolongedsedationwhenefavirenzgivenwithl MIDAZOLAM â€”avoidconcomitantuse
Atovaquone: efavirenzreducesplasmaconcentrationofl ATOVAQUONE â€”avoidconcomitantuse 
 TRIANGLE Avanafil: efavirenzpossiblyreducesplasmaconcentrationof AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse 
 TRIANGLE Bupropion: efavirenzacceleratesmetabolismof BUPROPION (reducedplasmaconcentration) 
 TRIANGLE Calcium-channelBlockers:efavirenzreducesplasmaconcentrationofDILTIAZEM
Ciclosporin: efavirenzpossiblyreducesplasmaconcentrationofl CICLOSPORIN 
Cytotoxics: efavirenzpossiblyreducesplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidconcomitantuse
ErgotAlkaloids: increasedriskofergotismwhenefavirenzgivenwithl ERGOTALKALOIDS â€”avoidconcomitantuse 
 TRIANGLE GrapefruitJuice: plasmaconcentrationofefavirenzpossiblyincreasedby GRAPEFRUITJUICE  
 TRIANGLE Lipid-regulatingDrugs:  efavirenzreducesplasmaconcentrationof ATORVASTATIN , PRAVASTATIN and SIMVASTATIN  
 
Orlistat:  absorptionofefavirenzpossiblyreducedbyl ORLISTAT 
Progestogens: efavirenzpossiblyreducescontraceptiveeffectofl PROGESTOGENS 
Tacrolimus: efavirenzpossiblyaffectsplasmaconcentrationofl TACROLIMUS
 Eletriptan see 
5HT1-receptorAgonists(underHT)Eltrombopag 
 TRIANGLE Antacids:  absorptionofeltrombopagreducedby ANTACIDS (giveatleast4hoursapart) 
 TRIANGLE Antivirals:plasmaconcentrationofeltrombopagpossiblyreducedbyLOPINAVIR 
 TRIANGLE CalciumSalts: absorptionofeltrombopagpossiblyreducedby CALCIUMSALTS (giveatleast4hoursapart) 
 TRIANGLE DairyProducts: absorptionofeltrombopagpossiblyreducedby DAIRYPRODUCTS (giveatleast4hoursapart) 
 TRIANGLE IronSalts: absorptionofeltrombopagpossiblyreducedbyoral IRONSALTS (giveatleast4hoursapart)lLipid-regulatingDrugs:eltrombopagincreasesplasmaconcentrationofl ROSUVASTATIN â€”adjustdoseofrosuvastatin(consultproductliterature) 
 TRIANGLE Selenium: absorptionofeltrombopagpossiblyreducedby SELENIUM (giveatleast4hoursapart) 
 TRIANGLE Zinc: absorptionofeltrombopagpossiblyreducedby ZINC (giveatleast4hoursapart)Elvitegravir 
 TRIANGLE Antacids:absorptionofelvitegravirreducedby ALUMINIUMHYDROXIDE and ORALMAGNESIUMSALTS (giveatleast4hoursapart)
Antibacterials: plasmaconcentrationofelvitegravirreducedbylRIFABUTINalsoplasmaconcentrationofactivemetaboliteofrifabutinincreasedâ€”reducedoseofrifabutin;manufacturerofelvitegraviradvisesavoidconcomitantusewithlRIFAMPICIN 
 lAntidepressants:manufacturerofelvitegraviradvisesavoidconcomitantusewithlSTJOHNâ€™SWORT
Antiepileptics: manufacturerofelvitegraviradvisesavoidconcomitantusewithlCARBAMAZEPINE,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE 
Antivirals: plasmaconcentrationofelvitegravirincreasedbylATAZANAVIRandlLOPINAVIRboostedwithritonavir(reducedoseofelvitegravir);manufacturerofelvitegraviradvisesavoidconcomitantusewith EFAVIRENZ andNEVIRAPINE 
 TRIANGLE Bosentan: manufacturerofelvitegraviradvisesavoidconcomitantusewith BOSENTAN  
 lOrlistat:absorptionofelvitegravirpossiblyreducedbylORLISTAT
 TRIANGLE Progestogens: elvitegravirincreasesplasmaconcentrationof NORGESTIMATE
 Empagliflozin see Antidiabetics 
Emtricitabine
Orlistat:  absorptionofemtricitabinepossiblyreducedbyl ORLISTAT
 Enalapril see 
 ACE InhibitorsEnfuvirtidelOrlistat:absorptionofenfuvirtidepossiblyreducedbylORLISTAT
 Enoxaparin see Heparins 
 Enoximone see Phosphodiesterase 
 Inhibitors 
 Entacapone 
 
 
Anticoagulants:   entacaponeenhancesanticoagulanteffectofl WARFARIN 
Antidepressants:   manufacturerofentacaponeadvisescautionwith MOCLOBEMIDE , TRICYCLICS and VENLAFAXINE ;avoidconcomitantuseofentacaponewithnon-selectivel MAOIS  
 TRIANGLE Dopaminergics: entacaponepossiblyenhanceseffectsof APOMORPHINE ;entacaponepossiblyreducesplasmaconcentrationof RASAGILINE ;manufacturerofentacaponeadvisesmaxdoseof10mg SELEGILINE ifusedconcomitantly 
 TRIANGLE IronSalts: absorptionofentacaponereducedbyoral IRONSALTS  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: entacaponepossiblyenhanceseffectsof METHYLDOPA ;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA 
 TRIANGLE Sympathomimetics:  entacaponepossiblyenhanceseffectsof ADRENALINE ( EPINEPHRINE ), DOBUTAMINE , DOPAMINE and NORADRENALINE ( NOREPINEPHRINE )Entera
FoodslAnticoagulants: thepresenceofvitaminKinsomeenteralfeedscanantagonisetheanticoagulanteffectofl COUMARINS andl PHENINDIONE  
 TRIANGLE Antiepileptics:  enteralfeedspossiblyreduceabsorptionof FOS PHENYTOIN  and PHENYTOINE nzalutamide 
 TRIANGLE Antibacterials:   manufacturerofenzalutamideadvisesavoidconcomitantusewith RIFAMPICIN  
 lAnticoagulants:enzalutamidepossiblyreducesplasmaconcentrationoflCOUMARINS 
 lLipid-regulating
 Drugs:   plasmaconcentrationofenzalutamideincreasedbyl GEMFIBROZIL â€”manufacturerofenzalutamideadvisesavoidconcomitantuseorhalvedoseofenzalutamide
 Ephedrine see Sympathomimetics 
 Epinephrine
 NOTEE pinephrineinteractionsasforadrenaline,seeundersympathomimeticsEpirubicin
 Antipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Ciclosporin: plasmaconcentrationofepirubicinincreasedbyl CICLOSPORIN  
 lUlcer-healingDrugs:plasmaconcentrationofepirubicinincreasedbyl  CIMETIDINE 
 Eplerenone see Diuretics 
 Eprosartan see Angiotensin-
 IIR eceptorAntagonists
 sEptifibatide 
 TRIANGLE Iloprost: increasedriskofbleedingwheneptifibatidegivenwith ILOPROST
 Ergocalciferol see Vitamins 
 Ergometrine see Ergot 
 Alkaloids 
 Ergot 
 Alkaloids 
 
 TRIANGLE Antidepressants:possibleriskofhypertensionwhenergotaminegivenwith REBOXETINE  l
 Antifungals:  avoidanceofergotalkaloidsadvisedbymanufacturerofl KETOCONAZOLE ;avoidanceofergometrineadvisedbymanufacturerofl ITRACONAZOLE (increasedriskofergotism);increasedriskofergotismwhenergometrinegivenwithl VORICONAZOLE â€”avoidconcomitantuse;increasedriskofergotismwhenergotaminegivenwithl IMIDAZOLES orl TRIAZOLES â€”avoidconcomitantuse 
 TRIANGLE Antipsychotics:plasmaconcentrationofergotalkaloidspossiblyincreasedby LURASIDONE (increasedriskoftoxicity)lAntivirals:  plasmaconcentrationofergotalkaloidspossiblyincreasedbyl ATAZANAVIR â€”avoidconcomitantuse;avoidanceofergotalkaloidsadvisedbymanufacturerofl BOCEPREVIR andl TELAPREVIR ;increasedriskofergotismwhenergotalkaloidsgivenwithl DARUNAVIR â€”manufacturerofdarunaviradvisesavoidconcomitantuse;increasedriskofergotismwhenergotalkaloidsgivenwithl EFAVIRENZ â€”avoidconcomitantuse;increasedriskofergotismwhenergotaminegivenwithl FOSAMPRENAVIR ,l INDINAVIR ,l RITONAVIR orl SAQUINAVIR â€”avoidconcomitantuse;increasedriskofergotismwhenergometrinegivenwithlINDINAVIRorlRITONAVIRâ€”avoidconcomitantuse 
 TRIANGLE Beta-blockers:increasedperipheralvasoconstrictionwhenergotaminegivenwith BETA - BLOCKERS 
Cobicistat: plasmaconcentrationofergotalkaloidspossiblyincreasedbyl COBICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Cytotoxics: cautionwithergotalkaloidsadvisedbymanufacturerofl CRIZOTINIB ;avoidanceofergotamineadvisedbymanufacturerof IDELALISIB l5 HT 1-receptor
 Agonists: increasedriskofvasospasmwhenergotaminegivenwithl ALMOTRIPTAN ,l RIZATRIPTAN ,l SUMATRIPTAN orl ZOLMITRIPTAN (avoidergotaminefor6hoursafteralmotriptan,rizatriptan,sumatriptanorzolmitriptan,avoidalmotriptan,rizatriptan,sumatriptanorzolmitriptanfor24hoursafterergotamine);increasedriskofvasospasmwhenergotaminegivenwithl ELETRIPTAN ,l FROVATRIPTAN orl NARATRIPTAN (avoidergotaminefor24hoursaftereletriptan,frovatriptanornaratriptan,avoideletriptan,frovatriptanornaratriptanfor24hoursafterergotamine) 
 TRIANGLE Sympathomimetics:increasedriskofergotismwhenergotaminegivenwith SYMPATHOMIMETICS 
Ticagrelor: plasmaconcentrationofergotalkaloidspossiblyincreasedbyl TICAGRELOR  
 lUlcer-healingDrugs:increasedriskofergotismwhenergotaminegivenwithlCIMETIDINEâ€”avoidconcomitantuse
 Ergotamine see Ergot 
 Alkaloids 
Eribulin
 TRIANGLE Antidepressants:plasmaconcentrationoferibulinpossiblyreducedby STJOHN â€™ SWORT  
 TRIANGLE Antiepileptics:plasmaconcentrationoferibulinpossiblyreducedby CARBAMAZEPINE ,FOSPHENYTOINandPHENYTOIN 
Antipsychotics:  avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)Erlotinib
Analgesics: increasedriskofbleedingwhenerlotinibgivenwithl NSAIDS 
Antacids: plasmaconcentrationoferlotinibpossiblyreducedbyl ANTACIDS â€”giveantacidsatleast4hoursbeforeor2hoursaftererlotinib 
 TRIANGLE Antibacterials:plasmaconcentrationoferlotinibincreasedby CIPROFLOXACIN ;metabolismoferlotinibacceleratedbyRIFAMPICIN(reducedplasmaconcentration)lAnticoagulants:increasedriskofbleedingwhenerlotinibgivenwithlCOUMARINS 
 TRIANGLE Antifungals:metabolismoferlotinibinhibitedbyKETOCONAZOLE(increasedplasmaconcentration)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceoferlotinibadvisedbymanufacturerofl BOCEPREVIRBNF 
 TRIANGLE Cytotoxics: plasmaconcentrationoferlotinibpossiblyincreasedby CAPECITABINE  
 lUlcer-healingDrugs:  manufactureroferlotinibadvisesavoidconcomitantusewithl CIMETIDINE ,l ES OMEPRAZOLE  ,l FAMOTIDINE ,l LANSOPRAZOLE ,l NIZATIDINE ,l PANTOPRAZOLE andl RABEPRAZOLE ;plasmaconcentrationoferlotinibreducedbyl RANITIDINE â€”manufactureroferlotinibadvisesgiveatleast2hoursbeforeor10hoursafterranitidine;plasmaconcentrationoferlotinibreducedbylOMEPRAZOLEâ€”manufactureroferlotinibadvisesavoidconcomitantuseErtapenem
 Antiepileptics:    carbapenemsreduceplasmaconcentrationofl SODIUMVALPROATE andl VALPROICACID â€”avoidconcomitantuse 
 TRIANGLE Vaccines:  antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Erythromycin see Macrolides 
 Escitalopram see Antidepressants
, SSRIE slicarbazepine 
 TRIANGLE Anticoagulants: eslicarbazepinereducesplasmaconcentrationof WARFARIN  
 Antidepressants:   anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered) 
 TRIANGLE Antiepileptics:plasmaconcentrationofeslicarbazepinepossiblyreducedby CARBAMAZEPINE butriskofside-effectsincreased;plasmaconcentrationofeslicarbazepinereducedby FOS PHENYTOIN  andPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinincreased;manufacturerofeslicarbazepineadvisesavoidconcomitantusewith OXCARBAZEPINE  
 Antimalarials:   anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
 
 
Antipsychotics:    anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered) 
 TRIANGLE Lipid-regulatingDrugs:eslicarbazepinereducesplasmaconcentrationof ROSUVASTATIN ;eslicarbazepinereducesplasmaconcentrationof SIMVASTATIN â€”considerincreasingdoseofsimvastatin
Oestrogens: eslicarbazepineacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsinBNF)lOrlistat:  possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: eslicarbazepineacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF)
 Esmolol see Beta-blockers 
 Esomeprazole see Proton 
 Pump 
 Inhibitors 
 Estradiol see Oestrogens 
Estramustine
Bisphosphonates: plasmaconcentrationofestramustineincreasedbyl SODIUMCLODRONATE  
 TRIANGLE CalciumSalts: absorptionofestramustinereducedby CALCIUMSALTS (manufacturerofestramustineadvisesavoidconcomitantadministration)
 Estriol see Oestrogens 
 Estrone see Oestrogens 
 Etanercept 
 
Anakinra: avoidconcomitantuseofetanerceptwithl ANAKINRA 
Vaccines: riskofgeneralisedinfectionswhenetanerceptgivenwithlivel VACCINES â€”avoidconcomitantuse
Ethambutol 
 TRIANGLE Antibacterials: plasmaconcentrationofethambutolincreasedby DELAMANID  
 TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNF
 Ethinylestradiol see Oestrogens 
 Ethosuximide 
 
lAntibacterials:  metabolismofethosuximideinhibitedbyl ISONIAZID (increasedplasmaconcentrationandriskoftoxicity)lAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC-RELATEDANTIDEPRESSANTS(convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)
Antiepileptics: plasmaconcentrationofethosuximidepossiblyreducedbyCARBAMAZEPINE, PHENOBARBITAL and PRIMIDONE ;plasmaconcentrationofethosuximidepossiblyreducedbylFOSPHENYTOINandlPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofethosuximidepossiblyincreasedbySODIUMVALPROATEandVALPROICACID 
Antimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINE 
 lAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT
 Etodolac see 
 NSAID s
 Etomidate see Anaesthetics
,Genera
 Etonogestrel see Progestogens 
 Etoposidel 
 Anticoagulants
: etoposidepossiblyenhancesanticoagulanteffectofl COUMARINS  
 TRIANGLE Antiepileptics:plasmaconcentrationofetoposidepossiblyreducedbyFOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE 
 TRIANGLE Antifungals: plasmaconcentrationofetoposideincreasedby KETOCONAZOLE  
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Atovaquone: plasmaconcentrationofetoposidepossiblyincreasedby ATOVAQUONE  
 TRIANGLE Ciclosporin: plasmaconcentrationofetoposidepossiblyincreasedby CICLOSPORIN (increasedriskoftoxicity)
 Etoricoxib see  NSAIDs 
 Etravirinel 
 Antibacterials
:etravirinereducesplasmaconcentrationofl CLARITHROMYCIN (butconcentrationofanactivemetaboliteincreased),alsoplasmaconcentrationofetravirineincreased;plasmaconcentrationofbothdrugsreducedwhenetravirinegivenwithl RIFABUTIN ;manufacturerofetravirineadvisesavoidconcomitantusewith RIFAMPICIN ;etravirinepossiblyreducesplasmaconcentrationof BEDAQUILINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse 
 TRIANGLE Antidepressants:manufacturerofetravirineadvisesavoidconcomitantusewith STJOHN â€™ SWORT  
 TRIANGLE Antiepileptics:manufacturerofetravirineadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE 
 TRIANGLE Antimalarials:etravirinereducesplasmaconcentrationof ARTEMETHERWITHLUMEFANTRINE 
Antivirals: effectsofbothdrugspossiblyreducedwhenetravirinegivenwith BOCEPREVIR ;avoidanceofetravirineadvisedbymanufacturerof DACLATASVIR (plasmaconcentrationofdaclatasvirpossiblyreduced);etravirinereducestheplasmaconcentrationofl DOLUTEGRAVIR (seeunderDolutegravir,p557);plasmaconcentrationofetravirinepossiblyreducedbyl EFAVIRENZ andl NEVIRAPINE â€”
 TRIANGLE CardiacGlycosides: etravirineincreasesplasmaconcentrationof DIGOXIN 
Clopidogrel: etravirinepossiblyreducesantiplateleteffectofl CLOPIDOGREL  
 
 
Cytotoxics:    etravirinepossiblyreducesplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidconcomitantuse 
 TRIANGLE Lipid-regulatingDrugs:    etravirinepossiblyreducesplasmaconcentrationof ATORVASTATIN 
Orlistat: absorptionofetravirinepossiblyreducedbyl ORLISTAT  
 TRIANGLE Sildenafil: etravirinereducesplasmaconcentrationof SILDENAFILE verolimusl ACE Inhibitors:increasedriskofangioedemawheneverolimusgivenwithl ACEINHIBITORS 
 
Antibacterials:   plasmaconcentrationofeverolimuspossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”manufacturerofeverolimusadvisesavoidconcomitantuse;plasmaconcentrationofeverolimusincreasedbyl ERYTHROMYCIN (considerreducingthedoseofeverolimusâ€”consulteverolimusproductliterature);plasmaconcentrationofeverolimusreducedbyl RIFAMPICIN (avoidconcomitantuseorconsiderincreasingthedoseofeverolimusâ€”consulteverolimusproductliterature) 
 TRIANGLE Antidepressants: plasmaconcentrationofeverolimuspossiblyreducedby STJOHN â€™ SWORT â€”manufacturerofeverolimusadvisesavoidconcomitantuse
 Antifungals:  plasmaconcentrationofeverolimusincreasedbyl KETOCONAZOLE â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;plasmaconcentrationofeverolimuspossiblyincreasedbyl ITRACONAZOLE ,l POSACONAZOLE andl VORICONAZOLE â€”manufacturerofeverolimusadvisesavoidconcomitantuse
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Antivirals: plasmaconcentrationofeverolimuspossiblyincreasedbyl ATAZANAVIR ,l DARUNAVIR ,lINDINAVIR,l RITONAVIR andl SAQUINAVIR â€”manufacturerofeverolimusadvisesavoidconcomitantuselCalcium-channelBlockers:  plasmaconcentrationofbothdrugsmayincreasewheneverolimusgivenwithl VERAPAMIL (considerreducingthedoseofeverolimusâ€”consulteverolimusproductliterature)lCiclosporin:    plasmaconcentrationofeverolimusincreasedbyl CICLOSPORIN (considerreducingthedoseofeverolimusâ€”consulteverolimusproductliterature)lCytotoxics:plasmaconcentrationofeverolimusincreasedbyl IMATINIB (considerreducingthedoseofeverolimusâ€”consulteverolimusproductliterature) 
 TRIANGLE GrapefruitJuice: manufacturerofeverolimusadvisesavoidconcomitantusewith GRAPEFRUITJUICEE xemestane 
 TRIANGLE Antibacterials:plasmaconcentrationofexemestanepossiblyreducedby RIFAMPICIN
 Exenatide see Antidiabetics 
Ezetimibe
Ciclosporin:plasmaconcentrationofbothdrugsmayincreasewhenezetimibegivenwithlCICLOSPORIN 
 Famotidine see Histamine 
 H
2-antagonistsFampridinelUlcer-healingDrugs:manufactureroffampridineadvisesavoidconcomitantusewithl CIMETIDINEF ebuxostat
Azathioprine: manufactureroffebuxostatadvisesavoidconcomitantusewithl AZATHIOPRINE  
 lCytotoxics:manufactureroffebuxostatadvisesavoidconcomitantusewithl MERCAPTOPURINE
 Felodipine see Calcium-channel 
 Blockers 
 Fenofibrate see Fibrates 
 Fenoprofen see 
 NSAID s
 Fentanyl see Opioid 
 Analgesics 
 Ferrous 
 Fumarate see Ironsalts 
 Ferrous 
 Gluconate see Ironsalts 
 Ferrous 
 Sulfate see Ironsalts 
 Fesoterodine see Antimuscarinics 
 Fexofenadine see Antihistamines 
 Fibrates 
 
 lAntibacterials: increasedriskofmyopathywhenfibratesgivenwithl DAPTOMYCIN (preferablyavoidconcomitantuse)
Anticoagulants: fibratesenhanceanticoagulanteffectoflCOUMARINSandl PHENINDIONE 
Antidiabetics: fibratesmayimproveglucosetoleranceandhaveanadditiveeffectwith INSULIN or SULFONYLUREAS ;gemfibrozilpossiblyenhanceshypoglycaemiceffectof NATEGLINIDE ;increasedriskofseverehypoglycaemiawhengemfibrozilgivenwithl REPAGLINIDE â€”avoidconcomitantuse 
 TRIANGLE Ciclosporin:increasedriskofrenalimpairmentwhenbezafibrateorfenofibrategivenwithCICLOSPORIN
Colchicine: possibleincreasedriskofmyopathywhenfibratesgivenwithl COLCHICINE  
 lCytotoxics:gemfibrozilincreasesplasmaconcentrationof DABRAFENIB ;gemfibrozilincreasesplasmaconcentrationofl BEXAROTENE â€”avoidconcomitantuse
HormoneAntagonists: gemfibrozilincreasesplasmaconcentrationofl ENZALUTAMIDE â€”manufacturerofenzalutamideadvisesavoidconcomitantuseorhalvedoseofenzalutamide 
 TRIANGLE LeukotrieneReceptorAntagonists: gemfibrozilincreasesplasmaconcentrationof MONTELUKAST  
 lLipid-regulatingDrugs:increasedriskofmyopathywhengemfibrozilgivenwithlATORVASTATIN,l FLUVASTATIN orl PRAVASTATIN (preferablyavoidconcomitantuse);increasedriskofmyopathywhenfibratesgivenwithlROSUVASTATIN(seeunderRosuvastatin,p180);possibleincreasedriskofmyopathywhenbezafibrategivenwithl SIMVASTATIN (seeunderSimvastatin,p181);possibleincreasedriskofmyopathywhenciprofibrategivenwithlSIMVASTATIN(seeunderSimvastatin,p181);increasedriskofmyopathywhengemfibrozilgivenwithlSIMVASTATIN(avoidconcomitantuse);increasedriskofcholelithiasisandgallbladderdiseasewhenfibratesgivenwith EZETIMIBE â€”discontinueifsuspected;increasedriskofmyopathywhenfibratesgivenwithl STATINS ;reducemaximumdoseoffenofibratewhengivenwithSTATINSâ€”seeunderFenofibrate,p175Fidaxomicin 
 TRIANGLE Anti-arrhythmics:manufactureroffidaxomicinadvisesavoidconcomitantusewith AMIODARONE and DRONEDARONE  
 TRIANGLE Antibacterials:manufactureroffidaxomicinadvisesavoidconcomitantusewithCLARITHROMYCINandERYTHROMYCIN 
 TRIANGLE Antifungals:manufactureroffidaxomicinadvisesavoidconcomitantusewithKETOCONAZOLE 
 TRIANGLE Calcium-channelBlockers:manufactureroffidaxomicinadvisesavoidconcomitantusewithVERAPAMIL 
 TRIANGLE Ciclosporin:manufactureroffidaxomicinadvisesavoidconcomitantusewithCICLOSPORIN 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein BNFBNF 
Filgrastim  
 TRIANGLE  Cytotoxics:  neutropeniapossiblyexacerbatedwhenfilgrastimgivenwith CAPECITABINE , FLUOROURACIL or  TEGAFUR F ingolimodlAnti-arrhythmics:possibleincreasedriskofbradycardiawhenfingolimodgivenwithl AMIODARONE ,l DISOPYRAMIDE orl DRONEDARONE  
 TRIANGLE Antidepressants: plasmaconcentrationoffingolimodpossiblyreducedby STJOHN â€™ SWORT â€”manufactureroffingolimodadvisesavoidconcomitantuse 
 TRIANGLE Antiepileptics:   plasmaconcentrationoffingolimodreducedby CARBAMAZEPINE  l
 Antifungals:  plasmaconcentrationoffingolimodincreasedbyl KETOCONAZOLE  
 lBeta-blockers:possibleincreasedriskofbradycardiawhenfingolimodgivenwithl BETA - BLOCKERS  
 lCalcium-channelBlockers:  possibleincreasedriskofbradycardiawhenfingolimodgivenwithl DILTIAZEM orl  VERAPAMIL 
 Flavoxate see Antimuscarinics 
Flecainide
 lAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherl ANTI - ARRHYTHMICS ;plasmaconcentrationofflecainideincreasedbylAMIODARONE(halvedoseofflecainide)
Antidepressants: plasmaconcentrationofflecainideincreasedby FLUOXETINE ;increasedriskofventriculararrhythmiaswhenflecainidegivenwithl TRICYCLICS 
Antihistamines: increasedriskofventriculararrhythmiaswhenflecainidegivenwithl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: avoidanceofflecainideadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE (riskofventriculararrhythmias);plasmaconcentrationofflecainideincreasedbyl QUININE 
Antimuscarinics: increasedriskofventriculararrhythmiaswhenflecainidegivenwithl TOLTERODINE 
Antipsychotics:   increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongthe QT intervalgivenwithl ANTIPSYCHOTICS thatprolongtheQTinterval;increasedriskofarrhythmiaswhenflecainidegivenwithl CLOZAPINE 
Antivirals: plasmaconcentrationofflecainidepossiblyincreasedbyl FOSAMPRENAVIR ,l INDINAVIR ,l LOPINAVIR andl RITONAVIR (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);increasedriskofventriculararrhythmiaswhenflecainidegivenwithl SAQUINAVIR â€”avoidconcomitantuse;cautionwithflecainideadvisedbymanufacturerofl TELAPREVIR (riskofventriculararrhythmias)lBeta-blockers:increasedriskofmyocardialdepressionandbradycardiawhenflecainidegivenwithlBETA-BLOCKERS;increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERS 
 lCalcium-channelBlockers:increasedriskofmyocardialdepressionandasystolewhenflecainidegivenwithlVERAPAMIL
Diuretics: increasedcardiactoxicitywithflecainideifhypokalaemiaoccurswithl ACETAZOLAMIDE ,l LOOPDIURETICS orl THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE Ulcer-healingDrugs:  metabolismofflecainideinhibitedby CIMETIDINE (increasedplasmaconcentration)
 Flucloxacillin see Penicillins 
 Fluconazole see Antifungals
,Triazole
Flucytosine 
 TRIANGLE Antifungals:renalexcretionofflucytosinedecreasedandcellularuptakeincreasedby AMPHOTERICIN (toxicitypossiblyincreased) 
 TRIANGLE Dipyridamole: effectsoffludarabinepossiblyreducedby DIPYRIDAMOLE
 Fludrocortisone see Corticosteroids 
Fluorides
 TRIANGLE Antibacterials: metabolismoffluorouracilinhibitedby METRONIDAZOLE (increasedtoxicity)
Anticoagulants:   fluorouracilenhancesanticoagulanteffectofl COUMARINS  
 TRIANGLE Antiepileptics:fluorouracilpossiblyinhibitsmetabolismof FOS PHENYTOIN  andPHENYTOIN(increasedriskoftoxicity)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Filgrastim: neutropeniapossiblyexacerbatedwhenfluorouracilgivenwith FILGRASTIM 
Folates: toxicityoffluorouracilincreasedbyl FOLICACID â€”avoidconcomitantuse 
 TRIANGLE Lipegfilgrastim: neutropeniapossiblyexacerbatedwhenfluorouracilgivenwith LI PEGFILGRASTIM   
 TRIANGLE Pegfilgrastim: neutropeniapossiblyexacerbatedwhenfluorouracilgivenwithPEGFILGRASTIM
Temoporfin: increasedskinphotosensitivitywhentopicalfluorouracilusedwithl TEMOPORFIN  
 TRIANGLE Ulcer-healingDrugs:metabolismoffluorouracilinhibitedbyCIMETIDINE(increasedplasmaconcentration)
 Fluoxetine see Antidepressants
, SSRI
 Flupentixol see Antipsychotics 
 Fluphenazine see Antipsychotics 
 Flurazepam see Anxiolyticsand 
 Hypnotics 
 Flurbiprofen see 
 NSAID sFlutamidelAnticoagulants:flutamideenhancesanticoagulanteffectofl COUMARINS
 Fluticasone see Corticosteroids 
 Fluvastatin see Statins 
 Fluvoxamine see Antidepressants
,SSRIFolates 
 TRIANGLE Aminosalicylates: absorptionoffolicacidpossiblyreducedby SULFASALAZINE  
 TRIANGLE Antacids: absorptionoffolicacidpossiblyreducedby ANTACIDS (manufactureroffolicacidadvisesgiveatleast2hoursapart) 
 TRIANGLE Antiepileptics:folatespossiblyreduceplasmaconcentrationofFOSPHENYTOIN, PHENOBARBITAL ,PHENYTOINand PRIMIDONE  
Cytotoxics:folicacidincreasestoxicityoflCAPECITABINE,lFLUOROURACILandlTEGAFURâ€”avoidconcomitantuse;avoidanceoffolatesadvisedbymanufacturerofl RALTITREXEDF olic
 Acid see Folates 
 Folinic 
 Acid see Folates 
 Fondaparinux 
 
 Analgesics:  increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins)lAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN ,l DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)
 Formoterol see Sympathomimetics
,Beta2Fosamprenavir NOTEF osamprenavirisaprodrugofamprenavir 
 TRIANGLE Analgesics:fosamprenavirreducesplasmaconcentrationof METHADONE  
 lAnti-arrhythmics:fosamprenavirpossiblyincreasesplasmaconcentrationoflAMIODARONE,l FLECAINIDE andl PROPAFENONE (increasedriskofventriculararrhythmiasâ€”
 Antibacterials:  fosamprenavirincreasesplasmaconcentrationofl RIFABUTIN (reducedoseofrifabutin);plasmaconcentrationoffosamprenavirsignificantlyreducedbyl RIFAMPICIN â€”avoidconcomitantuse;avoidanceofconcomitantfosamprenavirinsevererenalandhepaticimpairmentadvisedbymanufacturerofl TELITHROMYCIN   
 TRIANGLE  Anticoagulants:  avoidanceoffosamprenaviradvisedbymanufacturerof APIXABAN and RIVAROXABAN ;fosamprenavirmayenhanceorreduceanticoagulanteffectof COUMARINS  
 
Antidepressants:  plasmaconcentrationoffosamprenavirreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse 
 TRIANGLE Antiepileptics:  plasmaconcentrationoffosamprenavirpossiblyreducedby CARBAMAZEPINE , PHENOBARBITAL and PRIMIDONE  
 TRIANGLE Antifungals:  fosamprenavirincreasesplasmaconcentrationof KETOCONAZOLE (alsoplasmaconcentrationoffosamprenavirpossiblyincreased);plasmaconcentrationofbothdrugsmayincreasewhenfosamprenavirgivenwith ITRACONAZOLE ;fosamprenavirpossiblyreducesplasmaconcentrationof POSACONAZOLE 
Antimalarials: cautionwithfosamprenaviradvisedbymanufacturerof ARTEMETHERWITHLUMEFANTRINE ;fosamprenavirpossiblyincreasesplasmaconcentrationofl QUININE (increasedriskoftoxicity) 
 TRIANGLE Antimuscarinics: avoidanceoffosamprenaviradvisedbymanufacturerof DARIFENACIN and TOLTERODINE  
 
Antipsychotics:  fosamprenavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);fosamprenavirincreasesplasmaconcentrationofl PIMOZIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);fosamprenavirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse
 Antivirals:  manufactureroffosamprenaviradvisesavoidconcomitantusewithl BOCEPREVIR andl RALTEGRAVIR ;fosamprenavirreducesplasmaconcentrationofl DOLUTEGRAVIR ;plasmaconcentrationoffosamprenavirincreasedbyl ETRAVIRINE (considerreducingdoseoffosamprenavir);plasmaconcentrationoffosamprenavirreducedby LOPINAVIR ,effectonlopinavirplasmaconcentrationnotpredictableâ€”avoidconcomitantuse;plasmaconcentrationoffosamprenavirreducedbyl MARAVIROC â€”avoidconcomitantuse;plasmaconcentrationoffosamprenavirpossiblyreducedby NEVIRAPINE â€”avoidunboostedfosamprenavir;manufacturersadviseavoidconcomitantuseoffosamprenavirwithl TELAPREVIR ;plasmaconcentrationoffosamprenavirreducedbyl TIPRANAVIR  l
 AnxiolyticsandHypnotics:  fosamprenavirpossiblyincreasesplasmaconcentrationofl MIDAZOLAM (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam)
 Avanafil:  fosamprenavirpossiblyincreasesplasmaconcentrationofl AVANAFIL â€”seeunderAvanafil,p698
Ciclosporin: fosamprenavirincreasesplasmaconcentrationofl CICLOSPORIN  
Cytotoxics:  fosamprenavirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;fosamprenavirpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809) 
 TRIANGLE Dapoxetine: manufacturerofdapoxetineadvisesdosereductionwhenfosamprenavirgivenwith DAPOXETINE (seeunderDapoxetine,p703)
Orlistat: absorptionoffosamprenavirpossiblyreducedbyl ORLISTAT 
Ranolazine: fosamprenavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse 
 TRIANGLE Sildenafil: fosamprenavirpossiblyincreasesplasmaconcentrationof SILDENAFIL 
Tacrolimus: fosamprenavirincreasesplasmaconcentrationofl TACROLIMUS  
 TRIANGLE Tadalafil: fosamprenavirpossiblyincreasesplasmaconcentrationof TADALAFIL  
 TRIANGLE Vardenafil: fosamprenavirpossiblyincreasesplasmaconcentrationof VARDENAFILF osaprepitant 
 TRIANGLE Antibacterials:plasmaconcentrationoffosaprepitantpossiblyincreasedby CLARITHROMYCIN andTELITHROMYCIN;plasmaconcentrationoffosaprepitantreducedbyRIFAMPICIN 
 TRIANGLE Anticoagulants:fosaprepitantpossiblyreducesanticoagulanteffectof WARFARIN  
 lAntidepressants:manufactureroffosaprepitantadvisesavoidconcomitantusewithlSTJOHNâ€™SWORT 
 TRIANGLE Antidiabetics: fosaprepitantreducesplasmaconcentrationof TOLBUTAMIDE  
 TRIANGLE Antiepileptics:plasmaconcentrationoffosaprepitantpossiblyreducedbyCARBAMAZEPINE, FOS PHENYTOIN  ,PHENOBARBITAL,PHENYTOINandPRIMIDONE 
 TRIANGLE Antifungals:plasmaconcentrationoffosaprepitantincreasedbyKETOCONAZOLE 
 lAntipsychotics:manufactureroffosaprepitantadvisesavoidconcomitantusewithlPIMOZIDE 
 TRIANGLE Antivirals:plasmaconcentrationoffosaprepitantpossiblyincreasedby RITONAVIR  
 TRIANGLE AnxiolyticsandHypnotics:fosaprepitantincreasesplasmaconcentrationofMIDAZOLAM(riskofprolongedsedation) 
 TRIANGLE Avanafil:fosaprepitantpossiblyincreasesplasmaconcentrationofAVANAFIL 
 TRIANGLE Calcium-channelBlockers: plasmaconcentrationofbothdrugsmayincreasewhenfosaprepitantgivenwith DILTIAZEM  
 TRIANGLE Corticosteroids: fosaprepitantinhibitsmetabolismof DEXAMETHASONE and METHYLPREDNISOLONE (reducedoseofdexamethasoneandmethylprednisolone)lCytotoxics:fosaprepitantpossiblyincreasestheplasmaconcentrationoflBOSUTINIBâ€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;fosaprepitantpossiblyincreasesplasmaconcentrationofIBRUTINIB 
 TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromfosaprepitantby12hoursadvisedbymanufacturerofLOMITAPIDE
Oestrogens: fosaprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontainingl OESTROGENS (alternativecontraceptionrecommended)
Progestogens: fosaprepitantpossiblycausescontraceptivefailureofhormonalcontraceptivescontainingl PROGESTOGENS (alternativecontraceptionrecommended)Foscarnet
PentamidineIsetionate: increasedriskofhypocalcaemiawhenfoscarnetgivenwithparenterall PENTAMIDINEISETIONATEF osfomycin 
 TRIANGLE Metoclopramide: plasmaconcentrationoffosfomycinreducedby METOCLOPRAMIDE  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Fosinopril see 
 ACE Inhibitors
 sFosphenytoin 
 TRIANGLE Alcohol: plasmaconcentrationoffosphenytoinpossiblyreducedbychronicheavyconsumptionof ALCOHOL 
Aminophylline: plasmaconcentrationofbothdrugsreducedwhenfosphenytoingivenwithl AMINOPHYLLINE 
Analgesics: excretionoffosphenytoinpossiblyreducedby ACEMETACIN (increasedriskoftoxicity);fosphenytoinpossiblyBNF
 TRIANGLE Antacids: absorptionoffosphenytoinreducedby ANTACIDS 
Anthelmintics: fosphenytoinreducesplasmaconcentrationofl ALBENDAZOLE andl PRAZIQUANTEL â€”considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfections;plasmaconcentrationoffosphenytoinpossiblyincreasedby LEVAMISOLE  
 lAnti-arrhythmics:metabolismoffosphenytoininhibitedbyl AMIODARONE (increasedplasmaconcentration);fosphenytoinreducesplasmaconcentrationof DISOPYRAMIDE ;fosphenytoinpossiblyreducesplasmaconcentrationofl DRONEDARONE â€”avoidconcomitantuse
Antibacterials: metabolismoffosphenytoininhibitedby CLARITHROMYCIN (increasedplasmaconcentration);metabolismoffosphenytoinpossiblyinhibitedby METRONIDAZOLE (increasedplasmaconcentration);plasmaconcentrationoffosphenytoinincreasedordecreasedby CIPROFLOXACIN ;fosphenytoinacceleratesmetabolismof DOXYCYCLINE (reducedplasmaconcentration);fosphenytoinpossiblyreducesplasmaconcentrationofl BEDAQUILINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationoffosphenytoinincreasedbyl CHLORAMPHENICOL (increasedriskoftoxicity);metabolismoffosphenytoinpossiblyinhibitedby ISONIAZID (increasedriskoftoxicity);metabolismoffosphenytoinacceleratedbyl RIFAMYCINS (reducedplasmaconcentration);plasmaconcentrationoffosphenytoinpossiblyincreasedby SULFONAMIDES ;fosphenytoinreducesplasmaconcentrationofl TELITHROMYCIN (avoidduringandfor2weeksafterfosphenytoin);plasmaconcentrationoffosphenytoinincreasedbyl TRIMETHOPRIM (alsoincreasedantifolateeffect)
Anticoagulants: fosphenytoinpossiblyreducesplasmaconcentrationofl APIXABAN ;fosphenytoinacceleratesmetabolismofl COUMARINS (possibilityofreducedanticoagulanteffect,butenhancementalsoreported);fosphenytoinpossiblyreducesplasmaconcentrationof DABIGATRAN â€”manufacturerofdabigatranadvisesavoidconcomitantuse;fosphenytoinpossiblyreducesplasmaconcentrationofl RIVAROXABAN â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Antidepressants: plasmaconcentrationoffosphenytoinincreasedbyl FLUOXETINE andl FLUVOXAMINE ;fosphenytoinreducesplasmaconcentrationofl MIANSERIN , MIRTAZAPINE and PAROXETINE ;plasmaconcentrationoffosphenytoinpossiblyincreasedby SERTRALINE ,alsoplasmaconcentrationofsertralinepossiblyreduced;anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered);plasmaconcentrationoffosphenytoinpossiblyreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse;fosphenytoinpossiblyreducesplasmaconcentrationoflTRICYCLICS 
 TRIANGLE Antidiabetics: plasmaconcentrationoffosphenytointransientlyincreasedby TOLBUTAMIDE (possibilityoftoxicity)
Antifungals: fosphenytoinreducesplasmaconcentrationofl KETOCONAZOLE andl POSACONAZOLE ;anticonvulsanteffectoffosphenytoinenhancedbyl MICONAZOLE (plasmaconcentrationoffosphenytoinincreased);plasmaconcentrationoffosphenytoinincreasedbyl FLUCONAZOLE (considerreducingdoseoffosphenytoin);fosphenytoinreducesplasmaconcentrationofl ITRACONAZOLE â€”avoidconcomitantuse;plasmaconcentrationoffosphenytoinincreasedbyl VORICONAZOLE ,alsofosphenytoinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforfosphenytointoxicity);fosphenytoinpossiblyreducesplasmaconcentrationof CASPOFUNGIN â€”considerincreasingdoseofcaspofungin
Antimalarials: avoidanceoffosphenytoinadvisedbymanufacturerof ARTENIMOLWITHPIPERAQUINE ;anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE ;anticonvulsanteffectoffosphenytoinantagonisedbyl PYRIMETHAMINE ,alsoincreasedantifolateeffect
Antipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered);fosphenytoinreducesplasmaconcentrationof HALOPERIDOL ;plasmaconcentrationoffosphenytoinpossiblyincreasedordecreasedby CHLORPROMAZINE ;fosphenytoinpossiblyreducesplasmaconcentrationofl ARIPIPRAZOLE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);fosphenytoinacceleratesmetabolismof CLOZAPINE and QUETIAPINE (reducedplasmaconcentration);fosphenytoinpossiblyreducesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse
Antivirals: fosphenytoinpossiblyreducesplasmaconcentrationof ABACAVIR , DARUNAVIR , LOPINAVIR and SAQUINAVIR ;avoidanceoffosphenytoinadvisedbymanufacturerofl BOCEPREVIR andl RILPIVIRINE (plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);fosphenytoinpossiblyreducesplasmaconcentrationofl DACLATASVIR andl SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceoffosphenytoinadvisedbymanufacturerof DOLUTEGRAVIR ,l ELVITEGRAVIR , ETRAVIRINE , SOFOSBUVIR andl TELAPREVIR ;fosphenytoinpossiblyreducesplasmaconcentrationofl INDINAVIR ,alsoplasmaconcentrationoffosphenytoinpossiblyincreased;fosphenytoinpossiblyreducesplasmaconcentrationof RITONAVIR ,alsoplasmaconcentrationoffosphenytoinpossiblyaffected;plasmaconcentrationoffosphenytoinincreasedordecreasedby ZIDOVUDINE  
 TRIANGLE AnxiolyticsandHypnotics: fosphenytoinoftenreducesplasmaconcentrationof CLONAZEPAM ;plasmaconcentrationoffosphenytoinincreasedordecreasedby DIAZEPAM ;plasmaconcentrationoffosphenytoinpossiblyincreasedordecreasedby BENZODIAZEPINES  
 TRIANGLE Aprepitant: fosphenytoinpossiblyreducesplasmaconcentrationof APREPITANT  
 TRIANGLE Bupropion: fosphenytoinreducesplasmaconcentrationof BUPROPION  
 TRIANGLE Caffeinecitrate: fosphenytoinreducesplasmaconcentrationof CAFFEINECITRATE 
CannabisExtract: fosphenytoinpossiblyreducesplasmaconcentrationofl CANNABISEXTRACT â€”manufacturerofcannabisextractadvisesavoidconcomitantuse  
 TRIANGLE CardiacGlycosides: fosphenytoinpossiblyreducesplasmaconcentrationof DIGOXIN 
Ciclosporin: fosphenytoinacceleratesmetabolismofl CICLOSPORIN (reducedplasmaconcentration)
Cobicistat: fosphenytoinpossiblyreducesplasmaconcentrationofl  CO BICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Corticosteroids: fosphenytoinacceleratesmetabolismofl CORTICOSTEROIDS (reducedeffect)
Cytotoxics: fosphenytoinpossiblyreducesplasmaconcentrationof BUSULFAN , ERIBULIN and ETOPOSIDE ;metabolismoffosphenytoinpossiblyinhibitedby CAPECITABINE , FLUOROURACIL and TEGAFUR (increasedriskoftoxicity);fosphenytoinincreasesantifolateeffectof METHOTREXATE ;plasmaconcentrationoffosphenytoinpossiblyreducedby CISPLATIN ;fosphenytoinpossiblydecreasesplasmaconcentrationof AXITINIB (increasedoseofaxitinibâ€”consultaxitinibproductliterature);fosphenytoinpossiblyreducesplasmaconcentrationof BORTEZOMIB ,l BOSUTINIB , CRIZOTINIB ,l IBRUTINIB ,l IDELALISIB and PONATINIB â€”manufacturerofbortezomib,bosutinib,crizotinib,ibrutinib,idelalisibandponatinibadvisesavoidconcomitantuse;fosphenytoinpossiblyreducesplasmaconcentrationofl CABOZANTINIB â€”avoidconcomitantuse;avoidanceoffosphenytoinadvisedbymanufacturerofl CABAZITAXEL , DABRAFENIB , GEFITINIB ,l LAPATINIB and VEMURAFENIB ;avoidanceoffosphenytoinadvisedbymanufacturerof DASATINIB andl VISMODEGIB (plasmaconcentrationofdasatinibandvismodegibpossiblyreduced);fosphenytoinreducesplasmaconcentrationofl IMATINIB â€”avoidconcomitantuse;fosphenytoinreducesplasmaconcentrationof IRINOTECAN anditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhenfosphenytoingivenwith PROCARBAZINE 
Dexrazoxane: absorptionoffosphenytoinpossiblyreducedbyl DEXRAZOXANE  
 TRIANGLE Diazoxide: plasmaconcentrationoffosphenytoinreducedby DIAZOXIDE ,alsoeffectofdiazoxidemaybereduced
Disulfiram: metabolismoffosphenytoininhibitedbyl DISULFIRAM (increasedriskoftoxicity)
Diuretics: plasmaconcentrationoffosphenytoinpossiblyincreasedbyl ACETAZOLAMIDE ;fosphenytoinantagoniseseffectsof FUROSEMIDE ;fosphenytoinreducesplasmaconcentrationofl EPLERE NON E â€”avoidconcomitantuse;increasedriskofosteomalaciawhenfosphenytoingivenwith CARBONICANHYDRASEINHIBITORS  
 TRIANGLE Dopaminergics: fosphenytoinpossiblyreduceseffectsofCO- BENELDOPA ,CO- CARELDOPA and LEVODOPA  
 TRIANGLE Entera
Foods: absorptionoffosphenytoinpossiblyreducedby ENTERALFEEDS  
 TRIANGLE Folates: plasmaconcentrationoffosphenytoinpossiblyreducedby FOLATES  
 TRIANGLE Fosaprepitant: fosphenytoinpossiblyreducesplasmaconcentrationof FOSAPREPITANT  lHormone
 Antagonists:  fosphenytoinpossiblyreducesplasmaconcentrationofl ABIRATERONE â€”manufacturerofabirateroneadvisesavoidconcomitantuse;fosphenytoinpossiblyacceleratesmetabolismof TOREMIFENE  
 TRIANGLE 5 HT 3-receptorAntagonists:fosphenytoinacceleratesmetabolismof ONDANSETRON (reducedeffect)
 TRIANGLE Leflunomide: plasmaconcentrationoffosphenytoinpossiblyincreasedby LEFLUNOMIDE  
 TRIANGLE Lipid-regulating
 Drugs:   absorptionoffosphenytoinpossiblyreducedby COLESEVELAM ;combinationoffosphenytoinwith FLUVASTATIN mayincreaseplasmaconcentrationofeitherdrug(orboth) 
 TRIANGLE Lithium: neurotoxicitymayoccurwhenfosphenytoingivenwith LITHIUM withoutincreasedplasmaconcentrationoflithium 
 TRIANGLE Macitentan: avoidanceoffosphenytoinadvisedbymanufacturerof MACITENTAN  
 TRIANGLE Modafinil: plasmaconcentrationoffosphenytoinpossiblyincreasedby MODAFINIL 
MuscleRelaxants: long-termuseoffosphenytoinreduceseffectsoflNON- DEPOLARISINGMUSCLERELAXANTS (butacuteuseoffosphenytoinmightincreaseeffectsofnon-depolarisingmusclerelaxants)
Oestrogens: fosphenytoinacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: fosphenytoinacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF) 
 TRIANGLE Roflumilast: fosphenytoinpossiblyinhibitseffectsof ROFLUMILAST (manufacturerofroflumilastadvisesavoidconcomitantuse)
Sulfinpyrazone: plasmaconcentrationoffosphenytoinincreasedbyl SULFINPYRAZONE  
 TRIANGLE Sympathomimetics: plasmaconcentrationoffosphenytoinincreasedby METHYLPHENIDATE  
 TRIANGLE Tacrolimus: fosphenytoinreducesplasmaconcentrationof TACROLIMUS ,alsoplasmaconcentrationoffosphenytoinpossiblyincreased
Theophylline: plasmaconcentrationofbothdrugsreducedwhenfosphenytoingivenwithl THEOPHYLLINE  
 TRIANGLE ThyroidHormones: fosphenytoinacceleratesmetabolismof THYROIDHORMONES (mayincreaserequirementsinhypothyroidism),alsoplasmaconcentrationoffosphenytoinpossiblyincreased 
 TRIANGLE Tibolone: fosphenytoinacceleratesmetabolismof TIBOLONE  
 TRIANGLE Ticagrelor: fosphenytoinpossiblyreducesplasmaconcentrationof TICAGRELOR  
 lUlcer-healingDrugs:metabolismoffosphenytoininhibitedbyl CIMETIDINE (increasedplasmaconcentration);effectsoffosphenytoinenhancedbyl ES OMEPRAZOLE  ;effectsoffosphenytoinpossiblyenhancedbyOMEPRAZOLE;absorptionoffosphenytoinreducedbyl SUCRALFATE 
Ulipristal: avoidanceoffosphenytoinadvisedbymanufacturerofl ULIPRISTAL (contraceptiveeffectofulipristalpossiblyreduced) 
 TRIANGLE Vaccines: effectsoffosphenytoinenhancedby INFLUENZAVACCINE  
 TRIANGLE Vitamins: fosphenytoinpossiblyincreasesrequirementsfor ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL or VITAMIND
 Frovatriptan see 
5HT1-receptorAgonists(underHT)
 Furosemide see Diuretics 
 Fusidic 
 Acid 
 
Antivirals: plasmaconcentrationofbothdrugsincreasedwhenfusidicacidgivenwithl RITONAVIR â€”avoidconcomitantuse;plasmaconcentrationofbothdrugsmayincreasewhenfusidicacidgivenwith SAQUINAVIR  
 lLipid-regulatingDrugs:riskofmyopathyandrhabdomyolysiswhenfusidicacidgivenwithl STATINS â€”avoidconcomitantuseandfor7daysafterlastfusidicaciddose 
 TRIANGLE Sugammadex: fusidicacidpossiblyreducesresponseto SUGAMMADEXBNF 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF G abapentin 
 TRIANGLE Analgesics: bioavailabilityofgabapentinincreasedby MORPHINE  
 TRIANGLE Antacids: absorptionofgabapentinreducedby ANTACIDS 
Antidepressants:   anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered)
 Antimalarials:  anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE 
 
 
 
 
Antipsychotics:     anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered)
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT
 Galantamine see Parasympathomimetics 
 Ganciclovir
 NOTEI ncreasedriskofmyelosuppressionwithothermyelosuppressivedrugsâ€”consultproductliteraturelAntibacterials:  increasedriskofconvulsionswhenganciclovirgivenwithl IMIPENEMWITHCILASTATIN  
 Antivirals:   ganciclovirpossiblyincreasesplasmaconcentrationof DIDANOSINE ;profoundmyelosuppressionwhenganciclovirgivenwithl ZIDOVUDINE (ifpossibleavoidconcomitantadministration,particularlyduringinitialganciclovirtherapy) 
 TRIANGLE Mycophenolate: plasmaconcentrationofganciclovirpossiblyincreasedby MYCOPHENOLATE ,alsoplasmaconcentrationofinactivemetaboliteofmycophenolatepossiblyincreased 
 TRIANGLE Tacrolimus: possibleincreasedriskofnephrotoxicitywhenganciclovirgivenwith TACROLIMUSG efitiniblAntibacterials:plasmaconcentrationofgefitinibreducedbyl RIFAMPICIN â€”avoidconcomitantuse
 Anticoagulants:  gefitinibpossiblyenhancesanticoagulanteffectofl WARFARIN  
 TRIANGLE Antidepressants:manufacturerofgefitinibadvisesavoidconcomitantusewith STJOHN â€™ SWORT  
 TRIANGLE Antiepileptics: manufacturerofgefitinibadvisesavoidconcomitantusewith CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE  
 TRIANGLE Antifungals: plasmaconcentrationofgefitinibincreasedby ITRACONAZOLE  
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lAntivirals:avoidanceofgefitinibadvisedbymanufacturerofl BOCEPREVIR  
 lUlcer-healingDrugs:  plasmaconcentrationofgefitinibreducedbyl RANITIDINEG emcitabine 
 TRIANGLE Anticoagulants:gemcitabinepossiblyenhancesanticoagulanteffectofWARFARIN 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
 Gemeprost see Prostaglandins 
 Gemfibrozil see Fibrates 
 Gentamicin see Aminoglycosides 
 Gestodene see Progestogens 
 Glibenclamide see Antidiabetics 
 Gliclazide see Antidiabetics 
 Glimepiride see Antidiabetics 
 Glipizide see Antidiabetics 
 Glucosamine 
 
Anticoagulants: glucosamineenhancesanticoagulanteffectoflWARFARIN(avoidconcomitantuse)Glycery
 Trinitrate see Nitrates 
 Glycopyrronium see Antimuscarinics 
 Golimumabl 
 Abatacept
Anakinra: avoidconcomitantuseofgolimumabwithl ANAKINRA  
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Granisetron see 
5 HT 3-receptorAntagonists(underHT)GrapefruitJuice
Aliskiren: grapefruitjuicereducesplasmaconcentrationofl ALISKIREN â€”avoidconcomitantuse 
 TRIANGLE Anthelmintics: grapefruitjuiceincreasesplasmaconcentrationofactivemetaboliteof ALBENDAZOLE ;grapefruitjuiceincreasesplasmaconcentrationof PRAZIQUANTEL  
 lAnti-arrhythmics:grapefruitjuiceincreasesplasmaconcentrationof AMIODARONE ;grapefruitjuiceincreasesplasmaconcentrationofl DRONEDARONE â€”avoidconcomitantuse 
 TRIANGLE Antidepressants:grapefruitjuicepossiblyincreasesplasmaconcentrationof SERTRALINE  
 TRIANGLE Antihistamines: grapefruitjuicereducesplasmaconcentrationof BILASTINE  
 TRIANGLE Antimalarials:grapefruitjuicepossiblyincreasesplasmaconcentrationof ARTEMETHERWITHLUMEFANTRINE ;avoidanceofgrapefruitjuiceadvisedbymanufacturerof ARTENIMOLWITHPIPERAQUINE  
 lAntipsychotics:avoidanceofgrapefruitjuiceadvisedbymanufacturerof LURASIDONE and PIMOZIDE ;grapefruitjuicepossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse 
 TRIANGLE Antivirals:grapefruitjuicepossiblyincreasesplasmaconcentrationof EFAVIRENZ  
 TRIANGLE AnxiolyticsandHypnotics: grapefruitjuicepossiblyincreasesplasmaconcentrationoforal MIDAZOLAM ;grapefruitjuiceincreasesplasmaconcentrationof BUSPIRONE  
 TRIANGLE Avanafil: grapefruitjuicepossiblyincreasesplasmaconcentrationof AVANAFIL â€”manufacturerofavanafiladvisesavoidgrapefruitjuicefor24hoursbeforeavanafil 
 TRIANGLE Calcium-channelBlockers: grapefruitjuicepossiblyincreasesplasmaconcentrationof AMLODIPINE ;grapefruitjuiceincreasesplasmaconcentrationof FELODIPINE , ISRADIPINE , LACIDIPINE , LERCANIDIPINE , NICARDIPINE , NIFEDIPINE , NIMODIPINE and VERAPAMIL 
Ciclosporin: grapefruitjuiceincreasesplasmaconcentrationofl CICLOSPORIN (increasedriskoftoxicity)
Colchicine: grapefruitjuicepossiblyincreasesriskofl COLCHICINE toxicity
Corticosteroids: grapefruitjuiceincreasesplasmaconcentrationoforall BUDESONIDE â€”avoidconcurrentuseorseparateadministrationbyasmuchaspossibleandconsiderreducingoralbudesonidedose
Cytotoxics: grapefruitjuicepossiblyincreasesplasmaconcentrationof AXITINIB , CABOZANTINIB and PONATINIB ;grapefruitjuicepossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;grapefruitjuicepossiblyincreasesplasmaconcentrationofl CRIZOTINIB and VINFLUNINE â€”manufacturerofcrizotinibandvinflunineadvisesavoidconcomitantuse;avoidanceofgrapefruitjuiceadvisedbymanufacturerof DASATINIB (plasmaconcentrationofdasatinibpossiblyincreased);avoidanceofgrapefruitjuiceadvisedbymanufacturerof EVEROLIMUS , IBRUTINIB ,l LAPATINIB ,l NILOTINIB andl PAZOPANIB  
 TRIANGLE Ivabradine: grapefruitjuiceincreasesplasmaconcentrationof IVABRADINE  
 TRIANGLE Ivacaftor: grapefruitjuicepossiblyincreasesplasmaconcentrationof IVACAFTOR â€”manufacturerofivacaftoradvisesavoidconcomitantuselLipid-regulatingDrugs:grapefruitjuicepossiblyincreasesplasmaconcentrationof ATORVASTATIN ;grapefruitjuiceincreasesplasmaconcentrationofl SIMVASTATIN â€”avoidconcomitantuse;avoidanceofgrapefruitjuiceadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Pirfenidone: avoidanceofgrapefruitjuiceadvisedbymanufacturerof PIRFENIDONE 
Ranolazine: grapefruitjuicepossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse  
 TRIANGLE Sildenafil: grapefruitjuicepossiblyincreasesplasmaconcentrationof SILDENAFIL 
Sirolimus: grapefruitjuiceincreasesplasmaconcentrationofl SIROLIMUS â€”avoidconcomitantuse
Tacrolimus: grapefruitjuiceincreasesplasmaconcentrationofl TACROLIMUS  
 TRIANGLE Tadalafil: grapefruitjuicepossiblyincreasesplasmaconcentrationof TADALAFIL 
Tolvaptan: grapefruitjuiceincreasesplasmaconcentrationofl TOLVAPTAN â€”avoidconcomitantuse 
 TRIANGLE Ulipristal: avoidanceofgrapefruitjuiceadvisedbymanufactureroflow-dose ULIPRISTAL 
Vardenafil: grapefruitjuicepossiblyincreasesplasmaconcentrationofl VARDENAFIL â€”avoidconcomitantuse
Griseofulvin 
 TRIANGLE Alcohol: griseofulvinpossiblyenhanceseffectsof ALCOHOL 
 
Anticoagulants:   griseofulvinreducesanticoagulanteffectofl COUMARINS  
 TRIANGLE Antiepileptics: absorptionofgriseofulvinreducedby PHENOBARBITAL and PRIMIDONE (reducedeffect) 
 TRIANGLE Ciclosporin: griseofulvinpossiblyreducesplasmaconcentrationof CICLOSPORIN  
 TRIANGLE Oestrogens: anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhengriseofulvingivenwith OESTROGENS  
 TRIANGLE Progestogens: anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhengriseofulvingivenwith PROGESTOGENS
 Guanethidine see Adrenergic 
 Neurone 
 Blockers 
 Haemophilus 
 Vaccine see Vaccines 
 Haloperidol see Antipsychotics 
 Heparin see Heparins 
Heparins
 TRIANGLE Aliskiren: increasedriskofhyperkalaemiawhenheparinsgivenwith ALISKIREN  l
 Analgesics:  possibleincreasedriskofbleedingwhenheparinsgivenwith NSAIDS ;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins);anticoagulanteffectofheparinsenhancedbyl ASPIRIN  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: increasedriskofhyperkalaemiawhenheparinsgivenwith ANGIOTENSIN - IIRECEPTOR ANTAGONISTS   
 lAnticoagulants:increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN ,l DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency) 
 TRIANGLE Clopidogrel: increasedriskofbleedingwhenheparinsgivenwith CLOPIDOGREL  
 TRIANGLE Dipyridamole: anticoagulanteffectofheparinsenhancedby DIPYRIDAMOLE  
 TRIANGLE Iloprost: anticoagulanteffectofheparinspossiblyenhancedby ILOPROST 
Nitrates: anticoagulanteffectofheparinsreducedbyinfusionofl GLYCERYLTRINITRATEH epatitis
 Vaccines see Vaccines 
Histamine
 TRIANGLE Antimalarials: manufacturerofhistamineadvisesavoidconcomitantusewith ANTIMALARIALS  
 TRIANGLE Antipsychotics:  effectsofhistaminetheoreticallyantagonisedby ANTIPSYCHOTICS â€”manufacturerofhistamineadvisesavoidconcomitantuse 
 TRIANGLE Atovaquone: manufacturerofhistamineadvisesavoidconcomitantusewith ATOVAQUONE  
 TRIANGLE Clonidine: manufacturerofhistamineadvisesavoidconcomitantusewith CLONIDINE  
 TRIANGLE Corticosteroids: manufacturerofhistamineadvisesavoidconcomitantusewith CORTICOSTEROIDS  
 TRIANGLE Ulcer-healing
 Drugs: effectsofhistaminetheoreticallyantagonisedby HISTAMINEH 2-ANTAGONISTSâ€”manufacturerofhistamineadvisesavoidconcomitantuseHistamineH2-antagonistslAlpha-blockers:cimetidineandranitidineantagoniseeffectsofl TOLAZOLINE 
Aminophylline: cimetidineinhibitsmetabolismofl AMINOPHYLLINE (increasedplasmaconcentration) 
 TRIANGLE Analgesics:cimetidineinhibitsmetabolismof OPIOIDANALGESICS (increasedplasmaconcentration) 
 TRIANGLE Anthelmintics: cimetidinepossiblyenhanceseffectsof ALBENDAZOLE ;cimetidinepossiblyinhibitsmetabolismof MEBENDAZOLE (increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationof PRAZIQUANTEL  
 lAnti-arrhythmics:cimetidineincreasesplasmaconcentrationof AMIODARONE andl PROPAFENONE ;cimetidineinhibitsmetabolismof FLECAINIDE (increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationofl LIDOCAINE (increasedriskoftoxicity) 
 TRIANGLE Antibacterials: cimetidineincreasesplasmaconcentrationof ERYTHROMYCIN (increasedriskoftoxicity,includingdeafness);cimetidineinhibitsmetabolismof METRONIDAZOLE (increasedplasmaconcentration);metabolismofcimetidineacceleratedby RIFAMPICIN (reducedplasmaconcentration)lAnticoagulants:cimetidineinhibitsmetabolismoflCOUMARINS(enhancedanticoagulanteffect) 
 TRIANGLE Antidepressants:cimetidineincreasesplasmaconcentrationof CITALOPRAM , ESCITALOPRAM , MIRTAZAPINE and SERTRALINE ;cimetidineinhibitsmetabolismof AMITRIPTYLINE , DOXEPIN , IMIPRAMINE and NORTRIPTYLINE (increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationof MOCLOBEMIDE (halvedoseofmoclobemide);cimetidinepossiblyincreasesplasmaconcentrationofTRICYCLICS 
 TRIANGLE Antidiabetics: cimetidinereducesexcretionof METFORMIN (increasedplasmaconcentration);cimetidineenhanceshypoglycaemiceffectof SULFONYLUREAS 
Antiepileptics: cimetidineinhibitsmetabolismofl CARBAMAZEPINE ,l FOS PHENYTOIN  ,lPHENYTOIN,l SODIUMVALPROATE andl VALPROICACID (increasedplasmaconcentration)
Antifungals: histamineH2-antagonistsreduceabsorptionof ITRACONAZOLE and KETOCONAZOLE ;cimetidinereducesplasmaconcentrationofl POSACONAZOLE â€”manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;famotidine,nizatidineandranitidinepossiblyreduceplasmaconcentrationoflPOSACONAZOLEâ€”manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;cimetidineincreasesplasmaconcentrationof TERBINAFINE  
 TRIANGLE Antihistamines:manufacturerofloratadineadvisescimetidinepossiblyincreasesplasmaconcentrationof LORATADINE ;cimetidineincreasesplasmaconcentrationof HYDROXYZINE 
Antimalarials: avoidanceofcimetidineadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;cimetidineinhibitsmetabolismof CHLOROQUINE , HYDROXYCHLOROQUINE and QUININE (increasedplasmaconcentration) 
 TRIANGLE Antipsychotics:cimetidinepossiblyenhanceseffectsofANTIPSYCHOTICS, CHLORPROMAZINE and CLOZAPINE 
Antivirals: manufacturerofatazanaviradvisesadjustdosesofbothdrugswhencimetidineandnizatidinegivenwith ATAZANAVIR â€”consultatazanavirproductliterature;famotidineandranitidinereducetheplasmaconcentrationoflATAZANAVIR(adjustdosesofbothdrugsâ€”consultatazanavirproductliterature);famotidineincreasesplasma BNF 
 TRIANGLE AnxiolyticsandHypnotics: cimetidineinhibitsmetabolismof BENZODIAZEPINES , CLOMETHIAZOLE and ZALEPLON (increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationof MELATONIN  
 TRIANGLE Beta-blockers:cimetidineincreasesplasmaconcentrationof LABETALOL , METOPROLOL and PROPRANOLOL ;cimetidinepossiblyincreasesplasmaconcentrationoforal TIMOLOL  
 TRIANGLE Caffeinecitrate: cimetidineincreasesplasmaconcentrationof CAFFEINECITRATE  
 TRIANGLE Calcium-channelBlockers: cimetidinepossiblyinhibitsmetabolismof CALCIUM - CHANNELBLOCKERS (increasedplasmaconcentration);cimetidineincreasesplasmaconcentrationof ISRADIPINE (halvedoseofisradipine)
Ciclosporin: cimetidinepossiblyincreasesplasmaconcentrationofl CICLOSPORIN 
Clopidogrel: cimetidinepossiblyreducesantiplateleteffectofl CLOPIDOGREL  
Cytotoxics:  cimetidinepossiblyenhancesmyelosuppressiveeffectsof CARMUSTINE and LOMUSTINE ;cimetidinereducesplasmaconcentrationof DOXORUBICIN ;cimetidineincreasesplasmaconcentrationofl EPIRUBICIN ;cimetidineinhibitsmetabolismof CAPECITABINE , FLUOROURACIL and TEGAFUR (increasedplasmaconcentration);famotidinepossiblyreducesplasmaconcentrationof DASATINIB ;avoidanceofcimetidine,famotidineandnizatidineadvisedbymanufacturerofl ERLOTINIB ;ranitidinereducesplasmaconcentrationoflERLOTINIBâ€”manufactureroferlotinibadvisesgiveatleast2hoursbeforeor10hoursafterranitidine;ranitidinereducesplasmaconcentrationofl GEFITINIB ;histamineH2-antagonistspossiblyreduceabsorptionof LAPATINIB ;histamineH2-antagonistspossiblyreduceabsorptionof PAZOPANIB â€”manufacturerofpazopanibadvisesgiveatleast2hoursbeforeor10hoursafterhistamineH2-antagonists 
 TRIANGLE Dopaminergics:  cimetidinereducesexcretionof PRAMIPEXOLE (increasedplasmaconcentration)lErgotAlkaloids:  increasedriskofergotismwhencimetidinegivenwithl ERGOTAMINE â€”avoidconcomitantuse
Fampridine: avoidanceofcimetidineadvisedbymanufacturerofl FAMPRIDINE  
 TRIANGLE Histamine: histamineH2-antagoniststheoreticallyantagoniseeffectsof HISTAMINE â€”manufacturerofhistamineadvisesavoidconcomitantuse 
 TRIANGLE HormoneAntagonists: absorptionofcimetidinepossiblydelayedby OCTREOTIDE  
 TRIANGLE 5 HT 1-receptor
 Agonists: cimetidineinhibitsmetabolismof ZOLMITRIPTAN (reducedoseofzolmitriptan) 
 TRIANGLE Lipid-regulatingDrugs:  separatingadministrationfromcimetidineandranitidineby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Roflumilast: cimetidineinhibitsthemetabolismof ROFLUMILAST  
 TRIANGLE Sildenafil: cimetidineincreasesplasmaconcentrationof SILDENAFIL â€”considerreducingdoseofsildenafilforerectiledysfunction 
 TRIANGLE Sympathomimetics: cimetidinepossiblyinhibitsmetabolismof DOBUTAMINE 
Theophylline: cimetidineinhibitsmetabolismofl THEOPHYLLINE (increasedplasmaconcentration) 
 TRIANGLE ThyroidHormones: cimetidinereducesabsorptionof LEVOTHYROXINE
 Homatropine see Antimuscarinics 
 Hormone 
 Antagonists see Abiraterone
,Bicalutamide,Danazol,Dutasteride,Enzalutamide,Exemestane,Flutamide,Lanreotide,Octreotide,Pasireotide,Tamoxifen,andToremifene5HT1-receptorAgonists
 Antidepressants:  increasedriskof CNS toxicitywhen5HT1agonistsgivenwithl CITALOPRAM (manufacturerofcitalopramadvisesavoidconcomitantuse);increasedriskofCNStoxicitywhensumatriptangivenwithlCITALOPRAM,l ESCITALOPRAM ,l FLUOXETINE ,l FLUVOXAMINE orl PAROXETINE ;metabolismoffrovatriptaninhibitedbyFLUVOXAMINE;metabolismofzolmitriptanpossiblyinhibitedbyFLUVOXAMINE(reducedoseofzolmitriptan);CNStoxicityreportedwhensumatriptangivenwith SERTRALINE ;possibleincreasedserotonergiceffectswhen5HT1agonistsgivenwith DULOXETINE or VENLAFAXINE ;riskofCNStoxicitywhenrizatriptanorsumatriptangivenwithl  MAOI S (avoidrizatriptanorsumatriptanfor2weeksafterMAOIs);riskofCNStoxicitywhenzolmitriptangivenwithlMAOISorl MOCLOBEMIDE (reducedoseofzolmitriptan);riskofCNStoxicitywhenrizatriptanorsumatriptangivenwithlMOCLOBEMIDE(avoidrizatriptanorsumatriptanfor2weeksaftermoclobemide);possibleincreasedserotonergiceffectswhennaratriptangivenwith  SSRI S ;increasedserotonergiceffectswhen5HT1agonistsgivenwithl STJOHN â€™ SWORT â€”avoidconcomitantuse
Antifungals: plasmaconcentrationofeletriptanincreasedbyl ITRACONAZOLE andl KETOCONAZOLE (riskoftoxicity)â€”avoidconcomitantuse;plasmaconcentrationofalmotriptanincreasedbyKETOCONAZOLE(increasedriskoftoxicity)
Antivirals: plasmaconcentrationofeletriptanincreasedbyl INDINAVIR andl RITONAVIR (riskoftoxicity)â€”avoidconcomitantuse 
 TRIANGLE Beta-blockers:plasmaconcentrationofrizatriptanincreasedbyPROPRANOLOL(manufacturerofrizatriptanadviseshalvedoseandavoidwithin2hoursofpropranolol)
Dapoxetine: possibleincreasedriskofserotonergiceffectswhen5HT1agonistsgivenwithl DAPOXETINE (manufacturerofdapoxetineadvises5HT1agonistsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstopping5HT1agonists) 
 TRIANGLE Dopaminergics:avoidanceof5HT1agonistsadvisedbymanufacturerof SELEGILINE  
ErgotAlkaloids:increasedriskofvasospasmwheneletriptan,frovatriptanornaratriptangivenwithlERGOTAMINE(avoidergotaminefor24hoursaftereletriptan,frovatriptanornaratriptan,avoideletriptan,frovatriptanornaratriptanfor24hoursafterergotamine);increasedriskofvasospasmwhenalmotriptan,rizatriptan,sumatriptanorzolmitriptangivenwithlERGOTAMINE(avoidergotaminefor6hoursafteralmotriptan,rizatriptan,sumatriptanorzolmitriptan,avoidalmotriptan,rizatriptan,sumatriptanorzolmitriptanfor24hoursafterergotamine) 
 TRIANGLE Lithium: possibleriskoftoxicitywhensumatriptangivenwith LITHIUM  
 TRIANGLE Ulcer-healingDrugs:metabolismofzolmitriptaninhibitedby CIMETIDINE (reducedoseofzolmitriptan)5HT3-receptor
 rAntagonists 
 TRIANGLE Analgesics: ondansetronpossiblyantagoniseseffectsof TRAMADOL  
 TRIANGLE Antibacterials:metabolismofondansetronacceleratedby RIFAMPICIN (reducedeffect) 
 TRIANGLE Antidepressants:possibleincreasedserotonergiceffectswhen5HT3antagonistsgivenwithSSRI- RELATEDANTIDEPRESSANTS orSSRIS 
 TRIANGLE Antiepileptics: metabolismofondansetronacceleratedby CARBAMAZEPINE , FOS PHENYTOIN  andPHENYTOIN(reducedeffect)lCytotoxics:increasedriskofventriculararrhythmiaswhenondansetrongivenwithl VANDETANIB â€”avoidconcomitantuse
Dopaminergics: possibleincreasedhypotensiveeffectwhenondansetrongivenwithl APOMORPHINE â€”avoidconcomitantuseHumanpapillomavirus
 Vaccine see Vaccines 
 Hydralazine see Vasodilator 
 Antihypertensives
 Hydrochlorothiazide see Diuretics 
 Hydrocortisone see Corticosteroids 
 Hydroflumethiazide see Diuretics 
 Hydromorphone see Opioid 
 Analgesics 
 Hydrotalcite see Antacids 
 Hydroxocobalamin
  
 TRIANGLE Antibacterials: responsetohydroxocobalaminreducedby CHLORAMPHENICOLH ydroxycarbamide
 
 
Antipsychotics:     avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lAntivirals:  increasedriskoftoxicitywhenhydroxycarbamidegivenwithl DIDANOSINE andl STAVUDINE â€”avoidconcomitantuse
Hydroxychloroquine 
 TRIANGLE Adsorbents: absorptionofhydroxychloroquinereducedby KAOLIN  
 TRIANGLE AgalsidaseAlfaandBeta: hydroxychloroquinepossiblyinhibitseffectsof AGALSIDASEALFAANDBETA (manufacturersofagalsidasealfaandbetaadviseavoidconcomitantuse) 
 TRIANGLE Antacids: absorptionofhydroxychloroquinereducedby ANTACIDS  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithl AMIODARONE â€”avoidconcomitantuse
 
Antibacterials:   increasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithl MOXIFLOXACIN â€”avoidconcomitantuse
Antimalarials: avoidanceofantimalarialsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;increasedriskofconvulsionswhenhydroxychloroquinegivenwithl MEFLOQUINE  
 lAntipsychotics:increasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithl DROPERIDOL â€”avoidconcomitantuse
 CardiacGlycosides:  hydroxychloroquinepossiblyincreasesplasmaconcentrationofl DIGOXIN  
Ciclosporin:  hydroxychloroquineincreasesplasmaconcentrationofl CICLOSPORIN (increasedriskoftoxicity)lCytotoxics:  possibleincreasedriskofventriculararrhythmiaswhenhydroxychloroquinegivenwithl BOSUTINIB  
 TRIANGLE Histamine: avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Lanthanum: absorptionofhydroxychloroquinepossiblyreducedby LANTHANUM (giveatleast2hoursapart) 
 TRIANGLE Laronidase: hydroxychloroquinepossiblyinhibitseffectsof LARONIDASE (manufactureroflaronidaseadvisesavoidconcomitantuse) 
 TRIANGLE Parasympathomimetics: hydroxychloroquinehaspotentialtoincreasesymptomsofmyastheniagravisandthusdiminisheffectof NEOSTIGMINE and PYRIDOSTIGMINE  
 TRIANGLE Ulcer-healingDrugs:  metabolismofhydroxychloroquineinhibitedby CIMETIDINE (increasedplasmaconcentration) 
 TRIANGLE Vaccines: antimalarialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein BNF
 Hydroxyzine see Antihistamines 
 Hyoscine see Antimuscarinics 
 Ibandronic 
 Acid see Bisphosphonates 
 Ibrutinibl 
 Anti-arrhythmics
:plasmaconcentrationofibrutinibpossiblyincreasedbylAMIODARONEandl DRONEDARONE â€”reducedoseofibrutinib(seeunderIbrutinib,p809)lAntibacterials:plasmaconcentrationofibrutinibpossiblyincreasedbyl CIPROFLOXACIN ,l CLARITHROMYCIN ,l ERYTHROMYCIN andl TELITHROMYCIN â€”reducedoseofibrutinib(seeunderIbrutinib,p809);plasmaconcentrationofibrutinibreducedbyl RIFAMPICIN â€”avoidconcomitantuse 
 TRIANGLE Anticoagulants: manufacturerofibrutinibadvisesavoidconcomitantusewith COUMARINS and PHENINDIONE  
 Antifungals:  plasmaconcentrationofibrutinibincreasedbyl KETOCONAZOLE â€”reducedoseofibrutinib(seeunderIbrutinib,p809);plasmaconcentrationofibrutinibpossiblyincreasedbyl FLUCONAZOLE ,l ITRACONAZOLE andl VORICONAZOLE â€”reducedoseofibrutinib(seeunderIbrutinib,p809)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:plasmaconcentrationofibrutinibpossiblyincreasedbyl ATAZANAVIR ,l DARUNAVIR ,l FOSAMPRENAVIR ,l INDINAVIR ,l RITONAVIR andl SAQUINAVIR â€”reducedoseofibrutinib(seeunderIbrutinib,p809)
Aprepitant: plasmaconcentrationofibrutinibpossiblyincreasedbyl APREPITANT â€”reducedoseofibrutinib(seeunderIbrutinib,p809)lCalcium-channelBlockers: plasmaconcentrationofibrutinibpossiblyincreasedbyl DILTIAZEM andl VERAPAMIL â€”reducedoseofibrutinib(seeunderIbrutinib,p809) 
 TRIANGLE CardiacGlycosides:manufacturerofibrutinibadvisesgiveDIGOXINatleast6hoursbeforeorafteribrutinib
Cobicistat: plasmaconcentrationofibrutinibpossiblyincreasedbyl COBICISTAT â€”reducedoseofibrutinib(seeunderIbrutinib,p809)lCytotoxics:plasmaconcentrationofibrutinibpossiblyincreasedbyl CRIZOTINIB andl IMATINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809) 
 TRIANGLE Fosaprepitant: plasmaconcentrationofibrutinibpossiblyincreasedby FOSAPREPITANT  
 TRIANGLE GrapefruitJuice: manufacturerofibrutinibadvisesavoidconcomitantusewith GRAPEFRUITJUICE  
 TRIANGLE Vitamins: manufacturerofibrutinibadvisesavoidconcomitantusewith VITAMINE
 Ibuprofen see 
 NSAID sIdarubicinlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCiclosporin:plasmaconcentrationofidarubicinincreasedbyl CICLOSPORINI delalisib 
 TRIANGLE Alpha-blockers:manufacturerofidelalisibadvisesavoidconcomitantusewith ALFUZOSIN  
 TRIANGLE Anti-arrhythmics:manufacturerofidelalisibadvisesavoidconcomitantusewithAMIODARONE 
 lAntibacterials:plasmaconcentrationofidelalisibreducedbylRIFAMPICINâ€”avoidconcomitantuselAntidepressants:plasmaconcentrationofidelalisibpossiblyreducedbylSTJOHNâ€™SWORTâ€”manufacturerofidelalisibadvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofidelalisibpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOINandlPHENYTOINâ€”manufacturerofidelalisibadvisesavoidconcomitantuse 
 TRIANGLE Antifungals:plasmaconcentrationofidelalisibincreasedbyKETOCONAZOLE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis);manufacturerofidelalisibadvisesavoidconcomitantusewith PIMOZIDE and QUETIAPINE  
 TRIANGLE AnxiolyticsandHypnotics: manufacturerofidelalisibadvisesavoidconcomitantuseoforal MIDAZOLAM  
 TRIANGLE ErgotAlkaloids: manufacturerofidelalisibadvisesavoidconcomitantusewith ERGOTAMINE  
 TRIANGLE Lipid-regulatingDrugs:manufacturerofidelalisibadvisesavoidconcomitantusewith SIMVASTATIN  
 TRIANGLE Sildenafil: manufacturerofidelalisibadvisesavoidconcomitantuseof SILDENAFIL forpulmonaryarterialhypertension 
 TRIANGLE Sympathomimetics,Beta2:manufacturerofidelalisibadvisesavoidconcomitantusewith SALMETEROLI fosfamide
Anticoagulants: ifosfamidepossiblyenhancesanticoagulanteffectofl COUMARINSBNF 
 TRIANGLE  Antifungals:  metabolismofifosfamideinhibitedby KETOCONAZOLE 
 
Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Cytotoxics: increasedriskofotoxicitywhenifosfamidegivenwith CISPLATINI loprost 
 TRIANGLE Analgesics:  increasedriskofbleedingwheniloprostgivenwith NSAIDS or ASPIRIN  
 TRIANGLE Anticoagulants:   iloprostpossiblyenhancesanticoagulanteffectof COUMARINS and HEPARINS ;increasedriskofbleedingwheniloprostgivenwith PHENINDIONE  
 TRIANGLE Clopidogrel: increasedriskofbleedingwheniloprostgivenwith CLOPIDOGREL  
 TRIANGLE Eptifibatide: increasedriskofbleedingwheniloprostgivenwith EPTIFIBATIDE  
 TRIANGLE Tirofiban: increasedriskofbleedingwheniloprostgivenwith TIROFIBANI matinib 
 TRIANGLE Analgesics:manufacturerofimatinibadvisescautionwith PARACETAMOL  
Antibacterials:  plasmaconcentrationofimatinibreducedbyl RIFAMPICIN â€”avoidconcomitantuse 
 TRIANGLE Anticoagulants:manufacturerofimatinibadvisesreplacementof WARFARIN withaheparin(possibilityofenhancedwarfarineffect)lAntidepressants:  plasmaconcentrationofimatinibreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse
Antiepileptics:   plasmaconcentrationofimatinibreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l OXCARBAZEPINE andlPHENYTOINâ€”avoidconcomitantuse 
 TRIANGLE Antifungals:plasmaconcentrationofimatinibincreasedbyKETOCONAZOLE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:  avoidanceofimatinibadvisedbymanufacturerofl BOCEPREVIR  
 TRIANGLE Ciclosporin: imatinibpossiblyincreasesplasmaconcentrationof CICLOSPORIN 
Cytotoxics: imatinibpossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;imatinibincreasesplasmaconcentrationofl EVEROLIMUS (considerreducingthedoseofeverolimusâ€”consulteverolimusproductliterature);imatinibpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809) 
 TRIANGLE Lipid-regulating
 Drugs: imatinibincreasesplasmaconcentrationof SIMVASTATIN  
 TRIANGLE Tacrolimus: imatinibincreasesplasmaconcentrationof TACROLIMUS  
 TRIANGLE ThyroidHormones: imatinibpossiblyreducesplasmaconcentrationof LEVOTHYROXINE
 Imidapril see 
 ACE InhibitorsImipenemwithCilastatinlAntiepileptics:carbapenemsreduceplasmaconcentrationofl SODIUMVALPROATE andl VALPROICACID â€”avoidconcomitantuselAntivirals:increasedriskofconvulsionswhenimipenemwithcilastatingivenwithl GANCICLOVIR orl VALGANCICLOVIR  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Imipramine see Antidepressants
,TricyclicImmunoglobulins
 Indacaterol see Sympathomimetics
,Beta2
 Indapamide see Diuretics 
Indinavir
 lAnti-arrhythmics:indinavirpossiblyincreasesplasmaconcentrationofl AMIODARONE â€”avoidconcomitantuse;indinavirpossiblyincreasesplasmaconcentrationofl FLECAINIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse)lAntibacterials:indinavirincreasesplasmaconcentrationofl RIFABUTIN ,alsoplasmaconcentrationofindinavirdecreased(reducedoseofrifabutinandincreasedoseofindinavir);metabolismofindinaviracceleratedbylRIFAMPICIN(reducedplasmaconcentrationâ€”avoidconcomitantuse);avoidanceofconcomitantindinavirinsevererenalandhepaticimpairmentadvisedbymanufacturerofl TELITHROMYCIN  
 TRIANGLE Anticoagulants:avoidanceofindinaviradvisedbymanufacturerof APIXABAN and RIVAROXABAN  
Antidepressants:plasmaconcentrationofindinavirreducedbylSTJOHNâ€™SWORTâ€”avoidconcomitantuselAntiepileptics:plasmaconcentrationofindinavirpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOINandlPHENYTOIN,alsoplasmaconcentrationofcarbamazepine,fosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofindinavirpossiblyreducedbyl PHENOBARBITAL andl PRIMIDONE 
Antifungals: plasmaconcentrationofindinavirincreasedbyl ITRACONAZOLE andlKETOCONAZOLE(considerreducingdoseofindinavir)
Antimalarials: cautionwithindinaviradvisedbymanufacturerof ARTEMETHERWITHLUMEFANTRINE ;indinavirpossiblyincreasesplasmaconcentrationofl QUININE (increasedriskoftoxicity) 
 TRIANGLE Antimuscarinics: avoidanceofindinaviradvisedbymanufacturerof DARIFENACIN and TOLTERODINE ;manufactureroffesoterodineadvisesdosereductionwhenindinavirgivenwith FESOTERODINE â€”consultfesoterodineproductliteraturelAntipsychotics:indinavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);indinavirpossiblyincreasesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;indinavirpossiblyincreasesplasmaconcentrationofl PIMOZIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);indinavirpossiblyincreasesplasmaconcentrationof
 Antivirals:    avoidconcomitantuseofindinavirwithl ATAZANAVIR ;plasmaconcentrationofbothdrugsincreasedwhenindinavirgivenwith DARUNAVIR ;absorptionofindinavirreducedby DIDANOSINE tablets(giveatleast1hourapart);plasmaconcentrationofindinavirreducedby EFAVIRENZ and NEVIRAPINE ;plasmaconcentrationofindinavirpossiblyreducedbyl ETRAVIRINE â€”avoidconcomitantuse;indinavirincreasesplasmaconcentrationofl MARAVIROC (considerreducingdoseofmaraviroc);plasmaconcentrationofindinavirincreasedby RITONAVIR ;indinavirincreasesplasmaconcentrationof SAQUINAVIR 
AnxiolyticsandHypnotics: increasedriskofprolongedsedationwhenindinavirgivenwithl ALPRAZOLAM â€”avoidconcomitantuse;indinavirpossiblyincreasesplasmaconcentrationofl MIDAZOLAM (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam)  
 TRIANGLE Atovaquone: plasmaconcentrationofindinavirpossiblyreducedby ATOVAQUONE 
Avanafil: indinavirpossiblyincreasesplasmaconcentrationofl AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse 
 TRIANGLE Bosentan: plasmaconcentrationofindinavirpossiblyreducedby BOSENTAN 
Ciclosporin: indinavirincreasesplasmaconcentrationofl CICLOSPORIN 
Colchicine: indinavirpossiblyincreasesriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) 
 TRIANGLE Corticosteroids: plasmaconcentrationofindinavirpossiblyreducedby DEXAMETHASONE  l
 Cytotoxics:  indinavirpossiblyincreasesplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consultaxitinibproductliterature);indinavirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB andl CABAZITAXEL â€”manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;indinavirpossiblyincreasesplasmaconcentrationofl CRIZOTINIB andl EVEROLIMUS â€”manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;indinavirpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);indinavirpossiblyincreasesplasmaconcentrationofl PAZOPANIB (reducedoseofpazopanib);indinavirpossiblyincreasesplasmaconcentrationof PONATINIB â€”considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhenindinavirgivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature;indinavirpossiblyincreasesplasmaconcentrationofl DOCETAXEL â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose
ErgotAlkaloids: increasedriskofergotismwhenindinavirgivenwithl ERGOMETRINE orl ERGOTAMINE â€”avoidconcomitantusel5 HT 1-receptor
 Agonists: indinavirincreasesplasmaconcentrationofl ELETRIPTAN (riskoftoxicity)â€”avoidconcomitantuselLipid-regulating
 Drugs: possibleincreasedriskofmyopathywhenindinavirgivenwith ATORVASTATIN ;possibleincreasedriskofmyopathywhenindinavirgivenwithl ROSUVASTATIN â€”manufacturerofrosuvastatinadvisesavoidconcomitantuse;increasedriskofmyopathywhenindinavirgivenwithl SIMVASTATIN (avoidconcomitantuse);avoidanceofindinaviradvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased)
Orlistat: absorptionofindinavirpossiblyreducedbyl ORLISTAT 
Ranolazine: indinavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse
 TRIANGLE Tadalafil: indinavirpossiblyincreasesplasmaconcentrationof TADALAFIL 
Vardenafil: indinavirincreasesplasmaconcentrationofl VARDENAFIL â€”avoidconcomitantuse
 Indometacin see 
 NSAID s
 Indoramin see Alpha-blockers 
 Infliximab 
 
Abatacept: avoidconcomitantuseofinfliximabwithl ABATACEPT 
Anakinra: avoidconcomitantuseofinfliximabwithl ANAKINRA 
Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
 Vaccines:  riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuseInfluenza
 Vaccine see Vaccines 
 Insulin see Antidiabetics 
 Interferon 
 Alfa see Interferons 
 Interferon 
 Gamma see Interferons 
 Interferons 
 
Aminophylline: interferonalfaandpeginterferonalfainhibitmetabolismofl AMINOPHYLLINE (considerreducingdoseofaminophylline)lAntivirals:cautionwithpeginterferonalfaadvisedbymanufacturerof ADEFOVIR ;increasedriskofperipheralneuropathywheninterferonalfaandpeginterferonalfagivenwithl TELBIVUDINE 
Theophylline: interferonalfaandpeginterferonalfainhibitmetabolismofl THEOPHYLLINE (considerreducingdoseoftheophylline) 
 TRIANGLE Vaccines:manufacturerofinterferongammaadvisesavoidconcomitantusewith VACCINESI pilimumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Cytotoxics:manufacturerofipilimumabadvisesavoidconcomitantusewith VEMURAFENIB 
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINESâ€”avoidconcomitantuse
 Ipratropium see Antimuscarinics 
 Irbesartan see Angiotensin-
 IIR eceptorAntagonistsIrinotecan
Antidepressants: metabolismofirinotecanacceleratedbyl STJOHN â€™ SWORT (reducedplasmaconcentrationâ€”avoidconcomitantuse) 
 TRIANGLE Antiepileptics: plasmaconcentrationofirinotecananditsactivemetabolitereducedby CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE 
Antifungals: plasmaconcentrationofirinotecanreducedbyl KETOCONAZOLE (butconcentrationofactivemetaboliteofirinotecanincreased)â€”avoidconcomitantuse;increasedriskoftoxicitywhenirinotecangivenwithl ITRACONAZOLE â€”avoidconcomitantuselAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:metabolismofirinotecanpossiblyinhibitedbylATAZANAVIR(increasedriskoftoxicity)
Cytotoxics: plasmaconcentrationofactivemetaboliteofirinotecanincreasedbyl LAPATINIB â€”considerreducingdoseofirinotecan;plasmaconcentrationofirinotecanincreasedby REGORAFENIB ;plasmaconcentrationofirinotecanpossiblyincreasedby SORAFENIBI ron
 nSalts 
 TRIANGLE Antacids: absorptionoforalironsaltsreducedby ORALMAGNESIUMSALTS (asmagnesiumtrisilicate) 
 TRIANGLE Antibacterials: oralironsaltsreduceabsorptionof CIPR OFLOXACIN  , LEVOFLOXACIN , MOXIFLOXACIN andOFLOXACIN;oralironsaltsreduceabsorptionof NORFLOXACIN (giveatleast2hoursapart);oralironsaltsreduceabsorptionof TETRACYCLINES ,alsoabsorptionoforalironsaltsreducedbytetracyclines 
 TRIANGLE Antivirals:oralironsaltsreduceabsoptionof DOLUTEGRAVIR â€”manufacturerofdolutegraviradvisesgiveatleast2hoursbeforeor6hoursafteroralironsalts BNF 
 TRIANGLE Bisphosphonates: oralironsaltsreduceabsorptionof BISPHOSPHONATES  
 TRIANGLE CalciumSalts: absorptionoforalironsaltsreducedby CALCIUMSALTS  
 TRIANGLE Dopaminergics:  oralironsaltspossiblyreduceabsorptionof CO - BENELDOPA ,CO- CARELDOPA and LEVODOPA ;oralironsaltsreduceabsorptionof ENTACAPONE  
 TRIANGLE Eltrombopag: oralironsaltspossiblyreduceabsorptionof ELTROMBOPAG (giveatleast4hoursapart) 
 TRIANGLE Methyldopa: oralironsaltsantagonisehypotensiveeffectof METHYLDOPA  
 TRIANGLE Mycophenolate: oralironsaltsreduceabsorptionof MYCOPHENOLATE  
 TRIANGLE Penicillamine: oralironsaltsreduceabsorptionof PENICILLAMINE  
 TRIANGLE ThyroidHormones: oralironsaltsreduceabsorptionof LEVOTHYROXINE (giveatleast2hoursapart) 
 TRIANGLE Trientine: absorptionoforalironsaltsreducedby TRIENTINE  
 TRIANGLE Zinc: oralironsaltsreduceabsorptionof ZINC ,alsoabsorptionoforalironsaltsreducedbyzinc
 Isocarboxazid see 
 MAOI s
 Isoflurane see Anaesthetics
,General
 Isometheptene see Sympathomimetics 
Isoniazid
 TRIANGLE Anaesthetics,General: increasedriskofhepatotoxicitywhenisoniazidgivenwith ISOFLURANE  
 TRIANGLE Analgesics:  avoidanceofisoniazidadvisedbymanufacturerof PETHIDINE  
 TRIANGLE Antacids: absorptionofisoniazidreducedby ANTACIDS  l
 Antibacterials:    increasedriskofhepatotoxicitywhenisoniazidgivenwithl RIFAMPICIN ;increasedriskof CNS toxicitywhenisoniazidgivenwith CYCLOSERINE  
Antiepileptics:  isoniazidincreasesplasmaconcentrationofl CARBAMAZEPINE (alsopossiblyincreasedisoniazidhepatotoxicity);isoniazidinhibitsmetabolismofl ETHOSUXIMIDE (increasedplasmaconcentrationandriskoftoxicity);isoniazidpossiblyinhibitsmetabolismof FOS PHENYTOIN  andPHENYTOIN(increasedriskoftoxicity) 
 TRIANGLE Antifungals: isoniazidpossiblyreducesplasmaconcentrationof KETOCONAZOLE  
 TRIANGLE AnxiolyticsandHypnotics:  isoniazidinhibitsthemetabolismof DIAZEPAM  
 TRIANGLE Corticosteroids: plasmaconcentrationofisoniazidpossiblyreducedby CORTICOSTEROIDS  
 TRIANGLE Disulfiram: isoniazidpossiblyincreasesCNSeffectsof DISULFIRAM  
 TRIANGLE Dopaminergics:isoniazidpossiblyreduceseffectsofCO-BENELDOPA,CO-CARELDOPAandLEVODOPA 
 TRIANGLE Lipid-regulatingDrugs:  separatingadministrationfromisoniazidby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Theophylline: isoniazidpossiblyincreasesplasmaconcentrationof THEOPHYLLINE  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF I sosorbide
 Dinitrate see Nitrates 
 Isosorbide 
 Mononitrate see Nitrates 
 Isotretinoin see Retinoids 
 Isradipine see Calcium-channel 
 Blockers 
 Itraconazole see Antifungals
,TriazoleIvabradinelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenivabradinegivenwithl AMIODARONE orl DISOPYRAMIDE  
Antibacterials:plasmaconcentrationofivabradinepossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenivabradinegivenwithl ERYTHROMYCIN â€”avoidconcomitantuse 
 Antimalarials:  increasedriskofventriculararrhythmiaswhenivabradinegivenwithl MEFLOQUINE  l
 Antipsychotics:  increasedriskofventriculararrhythmiaswhenivabradinegivenwithl PIMOZIDE 
Antivirals: plasmaconcentrationofivabradinepossiblyincreasedbyl RITONAVIR â€”avoidconcomitantuselBeta-blockers:increasedriskofventriculararrhythmiaswhenivabradinegivenwithl SOTALOL  
 lCalcium-channelBlockers: plasmaconcentrationofivabradineincreasedbyl DILTIAZEM andl VERAPAMIL â€”avoidconcomitantuse 
 TRIANGLE GrapefruitJuice:  plasmaconcentrationofivabradineincreasedby GRAPEFRUITJUICE 
PentamidineIsetionate: increasedriskofventriculararrhythmiaswhenivabradinegivenwithl PENTAMIDINEISETIONATEI vacaftorlAntibacterials:plasmaconcentrationofivacaftorpossiblyincreasedbylCLARITHROMYCIN,lERYTHROMYCINandlTELITHROMYCIN(seeunderIvacaftor,p257);plasmaconcentrationofivacaftorpossiblyreducedbyl RIFABUTIN â€”manufacturerofivacaftoradvisesavoidconcomitantuse;plasmaconcentrationofivacaftorreducedbylRIFAMPICINâ€”manufacturerofivacaftoradvisesavoidconcomitantuse
Antidepressants: plasmaconcentrationofivacaftorpossiblyreducedbylSTJOHNâ€™SWORTâ€”manufacturerofivacaftoradvisesavoidconcomitantuselAntiepileptics:plasmaconcentrationofivacaftorpossiblyreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”manufacturerofivacaftoradvisesavoidconcomitantuselAntifungals:plasmaconcentrationofivacaftorincreasedbylFLUCONAZOLEandlKETOCONAZOLE(seeunderIvacaftor,p257);plasmaconcentrationofivacaftorpossiblyincreasedbylITRACONAZOLE,l POSACONAZOLE andl VORICONAZOLE (seeunderIvacaftor,p257) 
 TRIANGLE AnxiolyticsandHypnotics:ivacaftorincreasesplasmaconcentrationof MIDAZOLAM  
 TRIANGLE CardiacGlycosides: ivacaftorincreasesplasmaconcentrationof DIGOXIN  
 TRIANGLE GrapefruitJuice:plasmaconcentrationofivacaftorpossiblyincreasedbyGRAPEFRUITJUICEâ€”manufacturerofivacaftoradvisesavoidconcomitantuse 
 TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromivacaftorby12hoursadvisedbymanufacturerof LOMITAPIDEI vermectin 
 TRIANGLE Anthelmintics: plasmaconcentrationofivermectinpossiblyincreasedby LEVAMISOLE  
 TRIANGLE Anticoagulants: ivermectinpossiblyenhancesanticoagulanteffectof COUMARINSJ apaneseEncephalitis
 Vaccine see Vaccines 
Kaolin
 TRIANGLE Antibacterials:kaolinpossiblyreducesabsorptionof TETRACYCLINES  
 TRIANGLE Antimalarials:kaolinreducesabsorptionof CHLOROQUINE and HYDROXYCHLOROQUINE  
 TRIANGLE Antipsychotics:kaolinpossiblyreducesabsorptionof PHENOTHIAZINES
 Ketamine see Anaesthetics
,General
 Ketoconazole see Antifungals
,Imidazole
 Ketoprofen see 
 NSAID s
 Ketorolac see  NSAIDs 
 Ketotifen see Antihistamines 
 Labetalol see Beta-blockers 
 Lacidipine see Calcium
-channelBlockersLacosamidelAntidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);
 
 
Antipsychotics:   anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered)
 
Orlistat:   possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl  ORLISTAT L actulose  
 TRIANGLE  Anticoagulants:  lactulosepossiblyenhancesanticoagulanteffectof COUMARINSL amivudine 
 TRIANGLE Antibacterials:    plasmaconcentrationoflamivudineincreasedby TRIMETHOPRIM (asco-trimoxazole)â€”avoidconcomitantuseofhigh-doseco-trimoxazole 
 TRIANGLE Antivirals:  avoidanceoflamivudineadvisedbymanufacturerof EMTRICITABINE 
 
 
Cytotoxics:   manufactureroflamivudineadvisesavoidconcomitantusewithl CLADRIBINE  
 lOrlistat:absorptionoflamivudinepossiblyreducedbylORLISTATLamotrigine
Antibacterials:   plasmaconcentrationoflamotriginereducedbyl RIFAMPICIN  
Antidepressants:  anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andlTRICYCLIC- RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered)l
 Antiepileptics:   plasmaconcentrationoflamotrigineoftenreducedby CARBAMAZEPINE ,alsoplasmaconcentrationofanactivemetaboliteofcarbamazepinesometimesraised(butevidenceisconflicting);plasmaconcentrationoflamotriginereducedby FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE ;plasmaconcentrationoflamotrigineincreasedbyl SODIUMVALPROATE andl VALPROICACID (increasedriskoftoxicityâ€”reducelamotriginedose)lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINE 
 lAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered) 
 TRIANGLE Antivirals:plasmaconcentrationoflamotriginepossiblyreducedby RITONAVIR 
Oestrogens: plasmaconcentrationoflamotriginereducedbyl OESTROGENS â€”considerincreasingdoseoflamotriginelOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT 
 TRIANGLE Progestogens: plasmaconcentrationoflamotriginepossiblyincreasedby DESOGESTRELL anreotide 
 TRIANGLE Antidiabetics:  lanreotidepossiblyreducesrequirementsfor ANTIDIABETICS  
 TRIANGLE Ciclosporin: lanreotidereducesplasmaconcentrationof  CICLOSPORIN 
 Lansoprazole see Proton 
 Pump 
 Inhibitors 
Lanthanum
 TRIANGLE Antifungals: lanthanumpossiblyreducesabsorptionof KETOCONAZOLE (giveatleast2hoursapart) 
 TRIANGLE Antimalarials:lanthanumpossiblyreducesabsorptionof CHLOROQUINE and HYDROXYCHLOROQUINE (giveatleast2hoursapart) 
Antidiabetics: manufactureroflapatinibadvisesavoidconcomitantusewithl REPAGLINIDE  
Antiepileptics:plasmaconcentrationoflapatinibreducedbylCARBAMAZEPINEâ€”avoidconcomitantuse;manufactureroflapatinibadvisesavoidconcomitantusewithlFOSPHENYTOINandlPHENYTOIN 
Antifungals:  plasmaconcentrationoflapatinibincreasedbylKETOCONAZOLEâ€”avoidconcomitantuse;manufactureroflapatinibadvisesavoidconcomitantusewithl ITRACONAZOLE ,l POSACONAZOLE andl VORICONAZOLE  
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis);manufactureroflapatinibadvisesavoidconcomitantusewithl PIMOZIDE 
Antivirals: avoidanceoflapatinibadvisedbymanufacturerofl BOCEPREVIR ;manufactureroflapatinibadvisesavoidconcomitantusewithlRITONAVIRandl SAQUINAVIR  
 lCytotoxics:lapatinibincreasesplasmaconcentrationof PAZOPANIB ;possibleincreasedriskofneutropeniawhenlapatinibgivenwith DOCETAXEL ;increasedriskofneutropeniawhenlapatinibgivenwithl PACLITAXEL ;lapatinibincreasesplasmaconcentrationofactivemetaboliteofl IRINOTECAN â€”considerreducingdoseofirinotecan
GrapefruitJuice: manufactureroflapatinibadvisesavoidconcomitantusewithl GRAPEFRUITJUICE  
 TRIANGLE Lipid-regulating
 Drugs:   separatingadministrationfromlapatinibby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Ulcer-healingDrugs:absorptionoflapatinibpossiblyreducedby HISTAMINEH 2- ANTAGONISTS and PROTONPUMPINHIBITORSL aronidase 
 TRIANGLE Antimalarials:effectsoflaronidasepossiblyinhibitedbyCHLOROQUINEandHYDROXYCHLOROQUINE(manufactureroflaronidaseadvisesavoidconcomitantuse)Leflunomide NOTEI ncreasedriskoftoxicitywithotherhaematotoxicandhepatotoxicdrugs 
 TRIANGLE Antibacterials:plasmaconcentrationofactivemetaboliteofleflunomidepossiblyincreasedbyRIFAMPICIN 
 TRIANGLE Anticoagulants:leflunomidepossiblyenhancesanticoagulanteffectof WARFARIN  
 TRIANGLE Antidiabetics:leflunomidepossiblyenhanceshypoglycaemiceffectof TOLBUTAMIDE  
 TRIANGLE Antiepileptics:leflunomidepossiblyincreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN 
 lCytotoxics:riskoftoxicitywhenleflunomidegivenwithl METHOTREXATE  
 TRIANGLE Lipid-regulatingDrugs:theeffectofleflunomideissignificantlydecreasedby COLESTYRAMINE (enhancedelimination)â€”avoidunlessdrugeliminationdesired
Vaccines: riskofgeneralisedinfectionswhenleflunomidegivenwithlivel VACCINES â€”avoidconcomitantuseLenalidomidelAntibacterials:plasmaconcentrationoflenalidomidepossiblyincreasedbyl CLARITHROMYCIN (increasedriskoftoxicity)lAntifungals:plasmaconcentrationoflenalidomidepossiblyincreasedbylITRACONAZOLEandlKETOCONAZOLE(increasedriskoftoxicity)lCalcium-channelBlockers: plasmaconcentrationoflenalidomidepossiblyincreasedbyl VERAPAMIL (increasedriskoftoxicity) 
 TRIANGLE CardiacGlycosides: lenalidomidepossiblyincreasesplasmaconcentrationof DIGOXIN 
Ciclosporin: plasmaconcentrationoflenalidomidepossiblyincreasedbylCICLOSPORIN(increasedriskoftoxicity)
 Lercanidipine see Calcium-channel 
 Blockers 
 Leukotriene 
 Receptor 
Antagonists
 TRIANGLE Analgesics: plasmaconcentrationofzafirlukastincreasedby ASPIRIN  
 TRIANGLE Antibacterials:plasmaconcentrationofzafirlukastreducedby ERYTHROMYCINBNF 
 TRIANGLE  Anticoagulants:  zafirlukastenhancesanticoagulanteffectof WARFARIN  
 TRIANGLE Antiepileptics:    plasmaconcentrationofmontelukastreducedby PHENOBARBITAL and PRIMIDONE  
 TRIANGLE Antifungals: plasmaconcentrationofzafirlukastincreasedby FLUCONAZOLE  
 TRIANGLE Lipid-regulatingDrugs:  plasmaconcentrationofmontelukastincreasedby GEMFIBROZIL  
 TRIANGLE Theophylline: zafirlukastpossiblyincreasesplasmaconcentrationof THEOPHYLLINE ,alsoplasmaconcentrationofzafirlukastreduced
 dLevamisole 
 TRIANGLE Alcohol: possibilityofdisulfiram-likereactionwhenlevamisolegivenwith ALCOHOL  
 TRIANGLE Anthelmintics: plasmaconcentrationofbothdrugspossiblyreducedwhenlevamisolegivenwith ALBENDAZOLE ;levamisolepossiblyincreasesplasmaconcentrationof IVERMECTIN 
Anticoagulants: levamisolepossiblyenhancesanticoagulanteffectoflWARFARIN 
 TRIANGLE Antiepileptics:levamisolepossiblyincreasesplasmaconcentrationof FOS PHENYTOIN  and PHENYTOINL evetiracetamlAntidepressants:  anticonvulsanteffectofantiepilepticspossiblyantagonisedby   MAO I S andl TRICYCLIC - RELATED ANTI DEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered) 
 TRIANGLE Antiepileptics:levetiracetampossiblyincreasesriskof CARBAMAZEPINE toxicity
Antimalarials: anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  l
 Antipsychotics:  anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered)
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT
 Levobunolol see Beta-blockers 
Levobupivacaine
 TRIANGLE Anticoagulants:levocarnitinepossiblyenhancesanticoagulanteffectof COUMARINS
 Levocetirizine see Antihistamines 
Levodopa
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenlevodopagivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenlevodopagivenwith ALPHA -BLOCKERS lAnaesthetics,General: increasedriskofarrhythmiaswhenlevodopagivenwithl VOLATILELIQUIDGENERALANAESTHETICS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenlevodopagivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antibacterials:  effectsoflevodopapossiblyreducedby ISONIAZID  
Antidepressants:riskofhypertensivecrisiswhenlevodopagivenwithlMAOIS,avoidlevodopaforatleast2weeksafterstoppingMAOIs;increasedriskofside-effectswhenlevodopagivenwith MOCLOBEMIDE  
 TRIANGLE Antiepileptics:effectsoflevodopapossiblyreducedbyFOSPHENYTOINandPHENYTOIN 
 TRIANGLE Antimuscarinics: absorptionoflevodopapossiblyreducedby ANTIMUSCARINICS  
 TRIANGLE Antipsychotics:effectsoflevodopaantagonisedbyANTIPSYCHOTICS;avoidanceoflevodopaadvisedbymanufacturerof AMISULPRIDE (antagonismofeffect) 
 TRIANGLE AnxiolyticsandHypnotics: effectsoflevodopapossiblyantagonisedby BENZODIAZEPINES  
 TRIANGLE Bupropion: increasedriskofside-effectswhenlevodopagivenwith BUPROPION  
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenlevodopagivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenlevodopagivenwith CLONIDINE  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenlevodopagivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenlevodopagivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedeffectsandincreasedtoxicityoflevodopawhengivenwith SELEGILINE (reducedoseoflevodopa) 
 TRIANGLE IronSalts: absorptionoflevodopapossiblyreducedbyoral IRONSALTS  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenlevodopagivenwith METHYLDOPA ;antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA 
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenlevodopagivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants:  possibleagitation,confusionandhallucinationswhenlevodopagivenwith BACLOFEN  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenlevodopagivenwith NITRATES  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenlevodopagivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE  
 TRIANGLE Vitamins: effectsoflevodopareducedby PYRIDOXINE whengivenwithoutdopa-decarboxylaseinhibitor
 Levofloxacin see Quinolones 
 Levofolinic 
 Acid see Folates 
 Levomepromazine see Antipsychotics 
 Levonorgestrel see Progestogens 
 Levothyroxine see Thyroid 
 Hormones 
 Lidocaine
 NOTEI nteractionslesslikelywhenlidocaineusedtopically 
 TRIANGLE Anaesthetics,Local: increasedmyocardialdepressionwhenanti-arrhythmicsgivenwith BUPIVACAINE , LEVOBUPIVACAINE , PRILOCAINE or ROPIVACAINE  
 lAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherlANTI-ARRHYTHMICS
Antipsychotics: increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongthe QT intervalgivenwithlANTIPSYCHOTICSthatprolongtheQTinterval
Antivirals: plasmaconcentrationoflidocainepossiblyincreasedbyl ATAZANAVIR and LOPINAVIR ;plasmaconcentrationoflidocainepossiblyincreasedby DARUNAVIR andl FOSAMPRENAVIR â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenlidocainegivenwithl SAQUINAVIR â€”avoidconcomitantuse;cautionwithintravenouslidocaineadvisedbymanufacturerof TELAPREVIR  
 lBeta-blockers:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithlBETA-BLOCKERS;possibleincreasedriskoflidocainetoxicitywhengivenwith NADOLOL ;increasedriskoflidocainetoxicitywhengivenwithl PROPRANOLOL 
Diuretics: actionoflidocaineantagonisedbyhypokalaemiacausedbyl ACETAZOLAMIDE ,l LOOPDIURETICS orl THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE MuscleRelaxants:neuromuscularblockadeenhancedandprolongedwhenlidocainegivenwith SUXAMETHONIUM  
 lUlcer-healingDrugs:plasmaconcentrationoflidocaineincreasedbyl CIMETIDINE (increasedriskoftoxicity)
 Linagliptin see Antidiabetics 
 Linezolid
 NOTEL inezolidisareversible,non-selectiveMAOinhibitorâ€”seeinteractionsofMAOIs 
 TRIANGLE Antibacterials:plasmaconcentrationoflinezolidreducedby RIFAMPICIN (possibletherapeuticfailureoflinezolid) 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Liothyronine see Thyroid 
 Hormones
Lipegfilgrastim  
 TRIANGLE  Cytotoxics:  neutropeniapossiblyexacerbatedwhenlipegfilgrastimgivenwith CAPECITABINE , FLUOROURACIL or TEGAFURL ipid-regulating
 Drugs see Colesevelam
,Colestipol,Colestyramine,Ezetimibe,Fibrates,Lomitapide,NicotinicAcid,andStatins
 Liraglutide see Antidiabetics 
 Lisdexamfetamine see Sympathomimetics 
 Lisinopril see 
 ACE InhibitorsLithium
ACEInhibitors: excretionoflithiumreducedbyl ACEINHIBITORS (increasedplasmaconcentration) 
 TRIANGLE Aminophylline: excretionoflithiumincreasedby AMINOPHYLLINE (reducedplasmaconcentration)
Analgesics: excretionoflithiumreducedbyl NSAIDS (increasedriskoftoxicity);excretionoflithiumreducedbyl KETOROLAC (increasedriskoftoxicity)â€”avoidconcomitantuselAngiotensin- IIR eceptor
 Antagonists: excretionoflithiumreducedbyl ANGIOTENSIN - IIRECEPTORANTAGONISTS (increasedplasmaconcentration) 
 TRIANGLE Antacids: excretionoflithiumincreasedby SODIUMBICARBONATE (reducedplasmaconcentration)lAnti-arrhythmics:avoidanceoflithiumadvisedbymanufacturerofl AMIODARONE (riskofventriculararrhythmias) 
 TRIANGLE Antibacterials: increasedriskoflithiumtoxicitywhengivenwith METRONIDAZOLE  l
 Antidepressants:  possibleincreasedserotonergiceffectswhenlithiumgivenwith VENLAFAXINE ;increasedriskof CNS effectswhenlithiumgivenwithl SSRIS (lithiumtoxicityreported);riskoftoxicitywhenlithiumgivenwith TRICYCLICS  
 TRIANGLE Antiepileptics: neurotoxicitymayoccurwhenlithiumgivenwith CARBAMAZEPINE , FOS PHENYTOIN  orPHENYTOINwithoutincreasedplasmaconcentrationoflithium;plasmaconcentrationoflithiumpossiblyaffectedby TOPIRAMATE 
Antipsychotics: increasedriskofextrapyramidalside-effectsandpossiblyneurotoxicitywhenlithiumgivenwith CLOZAPINE , FLUPENTIXOL , HALOPERIDOL , PHENOTHIAZINES ,l RISPERIDONE or ZUCLOPENTHIXOL ;possibleriskoftoxicitywhenlithiumgivenwith OLANZAPINE ;lithiumpossiblyincreasesextrapyramidalside-effectsof QUETIAPINE ;increasedriskofextrapyramidalside-effectswhenlithiumgivenwith SULPIRIDE  
 TRIANGLE AnxiolyticsandHypnotics:   increasedriskofneurotoxicitywhenlithiumgivenwith CLONAZEPAM  
 TRIANGLE Calcium-channelBlockers:  neurotoxicitymayoccurwhenlithiumgivenwith DILTIAZEM or VERAPAMIL withoutincreasedplasmaconcentrationoflithium
Cytotoxics: increasedriskofventriculararrhythmiaswhenlithiumgivenwithl ARSENICTRIOXIDE 
Dapoxetine: possibleincreasedriskofserotonergiceffectswhenlithiumgivenwithl DAPOXETINE (manufacturerofdapoxetineadviseslithiumshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppinglithium)
Diuretics: excretionoflithiumincreasedbyl ACETAZOLAMIDE ;excretionoflithiumreducedbyl LOOPDIURETICS andl THIAZIDESANDRELATEDDIURETICS (increasedplasmaconcentrationandriskoftoxicity)â€”loopdiureticssaferthanthiazides;excretionoflithiumreducedbyl POTASSIUM - SPARINGDIURETICSANDALDOSTERONEANTAGONISTS (increasedplasmaconcentrationandriskoftoxicity) 
 TRIANGLE 5 HT 1-receptor
 Agonists: possibleriskoftoxicitywhenlithiumgivenwith SUMATRIPTAN 
Methyldopa: neurotoxicitymayoccurwhenlithiumgivenwithl METHYLDOPA withoutincreasedplasmaconcentrationoflithium 
 TRIANGLE MuscleRelaxants: lithiumenhanceseffectsof MUSCLERELAXANTS ;hyperkinesiscausedbylithiumpossiblyaggravatedby BACLOFEN  
 TRIANGLE Theophylline: excretionoflithiumincreasedby THEOPHYLLINE (reducedplasmaconcentration)
 Lixisenatide see Antidiabetics 
 Lofepramine see Antidepressants
,Tricyclic
 cLofexidine 
 TRIANGLE Alcohol:  increasedsedativeeffectwhenlofexidinegivenwith ALCOHOL  
 TRIANGLE AnxiolyticsandHypnotics:increasedsedativeeffectwhenlofexidinegivenwith ANXIOLYTICSANDHYPNOTICSL omitapide 
 TRIANGLE Alcohol:manufactureroflomitapideadvisesavoidconcomitantusewithALCOHOL 
 lAnti-arrhythmics:manufactureroflomitapideadvisesseparatingadministrationfromAMIODARONEby12hours;manufactureroflomitapideadvisesavoidconcomitantusewithl DRONEDARONE (plasmaconcentrationoflomitapidepossiblyincreased)
Antibacterials: manufactureroflomitapideadvisesseparatingadministrationfrom AZITHROMYCIN and ISONIAZID by12hours;manufactureroflomitapideadvisesavoidconcomitantusewithl CLARITHROMYCIN ,l ERYTHROMYCIN andl TELITHROMYCIN (plasmaconcentrationoflomitapidepossiblyincreased) 
 TRIANGLE Anticoagulants: lomitapidepossiblyenhancesanticoagulanteffectof WARFARIN  
 TRIANGLE Antidepressants:manufactureroflomitapideadvisesseparatingadministrationfrom FLUOXETINE and FLUVOXAMINE by12hours 
 TRIANGLE Antidiabetics: manufactureroflomitapideadvisesseparatingadministrationfrom LINAGLIPTIN by12hours
Antifungals: plasmaconcentrationoflomitapideincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;manufactureroflomitapideadvisesavoidconcomitantusewithl TRIAZOLES (plasmaconcentrationoflomitapidepossiblyincreased)
Antivirals: manufactureroflomitapideadvisesavoidconcomitantusewithl DARUNAVIR ,l FOSAMPRENAVIR ,l INDINAVIR ,l LOPINAVIR ,l RITONAVIR ,l SAQUINAVIR ,l TELAPREVIR andl TIPRANAVIR (plasmaconcentrationoflomitapidepossiblyincreased) 
 TRIANGLE AnxiolyticsandHypnotics:manufactureroflomitapideadvisesseparatingadministrationfrom ALPRAZOLAM by12hourslCalcium-channelBlockers:manufactureroflomitapideadvisesseparatingadministrationfrom AMLODIPINE and LACIDIPINE by12hours;manufactureroflomitapideadvisesavoidconcomitantusewithlDILTIAZEMandlVERAPAMIL(plasmaconcentrationoflomitapidepossiblyincreased) 
 TRIANGLE Ciclosporin: manufactureroflomitapideadvisesseparatingadministrationfrom CICLOSPORIN by12hours 
 TRIANGLE Cilostazol: manufactureroflomitapideadvisesseparatingadministrationfrom CILOSTAZOL by12hours 
 TRIANGLE Cytotoxics:manufactureroflomitapideadvisesseparatingadministrationfrom LAPATINIB , NILOTINIB and PAZOPANIB by12hours 
 TRIANGLE Fosaprepitant: manufactureroflomitapideadvisesseparatingadministrationfrom FOSAPREPITANT by12hours 
 TRIANGLE GrapefruitJuice: manufactureroflomitapideadvisesavoidconcomitantusewith GRAPEFRUITJUICE  
 TRIANGLE HormoneAntagonists: manufactureroflomitapideadvisesseparatingadministrationfrom BICALUTAMIDE by12hours 
 TRIANGLE Ivacaftor: manufactureroflomitapideadvisesseparatingadministrationfrom IVACAFTOR by12hourslLipid-regulating
 Drugs: lomitapideincreasesplasmaconcentrationof ATORVASTATIN â€”manufactureroflomitapideadvisesreducedoseofatorvastatinbyhalforseparateadministrationby12hours;lomitapideincreasesplasmaconcentrationofl SIMVASTATIN (seeunderSimvastatin,p181);absorptionoflomitapidepossiblyreducedby BILEACIDSEQUESTRANTS (giveatleast4hoursapart) 
 TRIANGLE Oestrogens: manufactureroflomitapideadvisesseparatingadministrationfrom OESTROGENS by12hours 
 TRIANGLE Ranolazine: manufactureroflomitapideadvisesseparatingadministrationfrom RANOLAZINE by12hours 
 TRIANGLE Tacrolimus: manufactureroflomitapideadvisesseparatingadministrationfrom TACROLIMUS by12hours 
 TRIANGLE Ticagrelor: manufactureroflomitapideadvisesseparatingadministrationfrom TICAGRELOR by12hours BNF 
 TRIANGLE Tolvaptan: manufactureroflomitapideadvisesseparatingadministrationfrom TOLVAPTAN by12hours 
 TRIANGLE Ulcer-healing
 Drugs:   manufactureroflomitapideadvisesseparatingadministrationfrom CIMETIDINE and RANITIDINE by12hoursLomustinelAntipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Ulcer-healingDrugs:myelosuppressiveeffectsoflomustinepossiblyenhancedby CIMETIDINEL operamide 
 TRIANGLE Desmopressin: loperamideincreasesplasmaconcentrationoforal DESMOPRESSINL opinavir NOTEI ncombinationwithritonavirasKaletraÂ®(ritonavirispresenttoinhibitlopinavirmetabolismandincreaseplasma-lopinavirconcentration)â€”seealsoRitonavirlAnti-arrhythmics:lopinavirpossiblyincreasesplasmaconcentrationofl FLECAINIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);lopinavirpossiblyincreasesplasmaconcentrationof LIDOCAINE 
Antibacterials:   plasmaconcentrationoflopinavirreducedbyl RIFAMPICIN â€”avoidconcomitantuse;lopinavirincreasesplasmaconcentrationof DELAMANID ;avoidanceofconcomitantlopinavirinsevererenalandhepaticimpairmentadvisedbymanufacturerofl TELITHROMYCIN  
 TRIANGLE Anticoagulants: avoidanceoflopinaviradvisedbymanufacturerof APIXABAN ;manufacturersadviseavoidconcomitantuseoflopinavirwith RIVAROXABAN  l
 Antidepressants:  plasmaconcentrationoflopinavirreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse
 Antiepileptics:  plasmaconcentrationoflopinavirpossiblyreducedby CARBAMAZEPINE , FOS PHENYTOIN  ,l PHENOBARBITAL ,PHENYTOINandl PRIMIDONE  
 TRIANGLE Antihistamines: lopinavirpossiblyincreasesplasmaconcentrationof CHLORPHENAMINE  
 TRIANGLE Antimalarials: cautionwithlopinaviradvisedbymanufacturerof ARTEMETHERWITHLUMEFANTRINE  
 TRIANGLE Antimuscarinics: avoidanceoflopinaviradvisedbymanufacturerof DARIFENACIN and TOLTERODINE  
Antipsychotics:lopinavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);lopinavirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse
Antivirals: manufacturersadviseavoidconcomitantuseoflopinavirwithl BOCEPREVIR andl TELAPREVIR ;avoidanceoflopinaviradvisedbymanufacturerof DACLATASVIR (plasmaconcentrationofdaclatasvirpossiblyincreased);lopinavirreducesplasmaconcentrationofl DARUNAVIR ,alsoplasmaconcentrationoflopinavirincreased(avoidconcomitantuse);plasmaconcentrationoflopinavirreducedbyl EFAVIRENZ â€”considerincreasingdoseoflopinavir;lopinavirboostedwithritonavirincreasesplasmaconcentrationofl ELVITEGRAVIR (reducedoseofelvitegravir);lopinavirreducesplasmaconcentrationof FOSAMPRENAVIR ,effectonlopinavirplasmaconcentrationnotpredictableâ€”avoidconcomitantuse;lopinavirincreasesplasmaconcentrationofl MARAVIROC (considerreducingdoseofmaraviroc);plasmaconcentrationoflopinavirpossiblyreducedbyl NEVIRAPINE â€”considerincreasingdoseoflopinavir;increasedriskofventriculararrhythmiaswhenlopinavirgivenwithl SAQUINAVIR â€”avoidconcomitantuse;lopinavirincreasesplasmaconcentrationof TENOFOVIR ;plasmaconcentrationoflopinavirreducedbyl TIPRANAVIR 
Bosentan: lopinavirincreasesplasmaconcentrationofl BOSENTAN (considerreducingdoseofbosentan) 
 TRIANGLE Corticosteroids: plasmaconcentrationoflopinavirpossiblyreducedby DEXAMETHASONE 
Cytotoxics: manufacturerofruxolitinibadvisesdosereductionwhenlopinavirgivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature 
Orlistat: absorptionoflopinavirpossiblyreducedbyl ORLISTAT 
Ranolazine: lopinavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse 
 TRIANGLE Sirolimus: lopinavirpossiblyincreasesplasmaconcentrationof SIROLIMUS  
 TRIANGLE Sympathomimetics,Beta2:manufactureroflopinaviradvisesavoidconcomitantusewith SALMETEROL
 Loprazolam see Anxiolyticsand 
 Hypnotics 
 Loratadine see Antihistamines 
 Lorazepam see Anxiolyticsand 
 Hypnotics 
 Lormetazepam see Anxiolyticsand 
 Hypnotics 
 Losartan see Angiotensin-
 IIR eceptorAntagonists
 Lurasidone see Antipsychotics 
 Lymecycline see Tetracyclines 
 Macitentanl 
 Antibacterials
:plasmaconcentrationofmacitentanreducedbylRIFAMPICINâ€”avoidconcomitantuse 
 TRIANGLE Antidepressants:manufacturerofmacitentanadvisesavoidconcomitantusewithSTJOHNâ€™SWORT 
 TRIANGLE Antiepileptics:manufacturerofmacitentanadvisesavoidconcomitantusewithCARBAMAZEPINE,FOSPHENYTOINandPHENYTOIN 
 TRIANGLE Antifungals: plasmaconcentrationofmacitentanincreasedby KETOCONAZOLEM acrogols NOTES omemanufacturerssuggesttakingotheroralmedication1hourbeforeor1houraftermacrogolstoreducepossibleinterferencewithabsorptionMacrolidesNOTESeealsoTelithromycinNOTEInteractionsdonotapplytosmallamountsoferythromycinusedtopically
Aminophylline: clarithromycinpossiblyincreasesplasmaconcentrationof AMINOPHYLLINE ;erythromycinincreasesplasmaconcentrationoflAMINOPHYLLINE(alsoaminophyllinemayreduceabsorptionoforalerythromycin) 
 TRIANGLE Analgesics: erythromycinincreasesplasmaconcentrationof ALFENTANIL ;clarithromycinpossiblyincreasesplasmaconcentrationof FENTANYL  
 TRIANGLE Antacids: absorptionofazithromycinreducedby ANTACIDS  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithl AMIODARONE â€”avoidconcomitantuse;azithromycinpossiblyincreasesplasmaconcentrationofl DISOPYRAMIDE (increasedriskoftoxicity);erythromycinincreasesplasmaconcentrationoflDISOPYRAMIDE(increasedriskoftoxicity);clarithromycinpossiblyincreasesplasmaconcentrationoflDISOPYRAMIDE(increasedriskofventriculararrhythmias);avoidanceofclarithromycinadvisedbymanufacturerofl DRONEDARONE (riskofventriculararrhythmias);erythromycinincreasesplasmaconcentrationoflDRONEDARONE(increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse)lAntibacterials:increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithl MOXIFLOXACIN â€”avoidconcomitantuse;increasedriskofside-effectsincludingneutropeniawhenazithromycingivenwithl RIFABUTIN ;clarithromycinincreasesplasmaconcentrationoflRIFABUTIN(increasedriskoftoxicityâ€”reducerifabutindose);erythromycinpossiblyincreasesplasmaconcentrationoflRIFABUTIN(increasedriskoftoxicityâ€”reducerifabutindose);clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationof BEDAQUILINE â€”avoidconcomitantuseifclarithromycinanderythromycingivenformorethan14days;possibleincreasedriskofventriculararrhythmias
Anticoagulants: avoidanceofclarithromycinadvisedbymanufacturerof APIXABAN ;clarithromycinanderythromycinenhanceanticoagulanteffectofl COUMARINS ;azithromycinpossiblyenhancesanticoagulanteffectoflCOUMARINS;possibleincreasedriskofbleedingwhenclarithromycingivenwith DABIGATRAN 
Antidepressants: avoidanceofmacrolidesadvisedbymanufacturerofl REBOXETINE ;avoidanceofintravenouserythromycinadvisedbymanufacturerofl CITALOPRAM andl ESCITALOPRAM (riskofventriculararrhythmias);clarithromycinpossiblyincreasesplasmaconcentrationof TRAZODONE   
 TRIANGLE Antidiabetics: clarithromycinenhanceseffectsof REPAGLINIDE 
Antiepileptics: clarithromycinincreasesplasmaconcentrationofl CARBAMAZEPINE (considerreducingdoseofcarbamazepine);erythromycinincreasesplasmaconcentrationoflCARBAMAZEPINE;clarithromycininhibitsmetabolismof FOS PHENYTOIN  andPHENYTOIN(increasedplasmaconcentration);erythromycinpossiblyinhibitsmetabolismof SODIUMVALPROATE and VALPROICACID (increasedplasmaconcentration)
Antifungals: avoidanceofconcomitantclarithromycininsevererenalimapirmentadvisedbymanufacturerofl KETOCONAZOLE ;avoidanceoferythromycinadvisedbymanufacturerof FLUCONAZOLE ;clarithromycinincreasesplasmaconcentrationof ITRACONAZOLE 
Antihistamines: manufacturerofloratadineadviseserythromycinpossiblyincreasesplasmaconcentrationof LORATADINE ;macrolidespossiblyinhibitmetabolismofl MIZOLASTINE (avoidconcomitantuse);erythromycininhibitsmetabolismoflMIZOLASTINEâ€”avoidconcomitantuse
Antimalarials: avoidanceofmacrolidesadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;avoidanceofmacrolidesadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias) 
 TRIANGLE Antimuscarinics: erythromycinpossiblyincreasesplasmaconcentrationof DARIFENACIN ;manufactureroffesoterodineadvisesdosereductionwhenclarithromycingivenwith FESOTERODINE â€”consultfesoterodineproductliterature;avoidanceofclarithromycinanderythromycinadvisedbymanufacturerof TOLTERODINE 
Antipsychotics: avoidanceofmacrolidesadvisedbymanufacturerofl DROPERIDOL (riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithl ZUCLOPENTHIXOL â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenerythromycingivenwithl AMISULPRIDE â€”avoidconcomitantuse;erythromycinpossiblyincreasesplasmaconcentrationofl CLOZAPINE (possibleincreasedriskofconvulsions);clarithromycinpossiblyincreasesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;erythromycinpossiblyincreasestheplasmaconcentrationoflLURASIDONE(seeunderLurasidone,p315);increasedriskofventriculararrhythmiaswhenclarithromycingivenwithl PIMOZIDE â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenerythromycingivenwithlPIMOZIDEâ€”avoidconcomitantuse;clarithromycinpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse;erythromycinincreasesplasmaconcentrationoflQUETIAPINEâ€”manufacturerofquetiapineadvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithl SULPIRIDE 
AnxiolyticsandHypnotics: clarithromycinanderythromycininhibitmetabolismofl MIDAZOLAM (increasedplasmaconcentrationwithincreasedsedation);erythromycinincreasesplasmaconcentrationof BUSPIRONE (reducedoseofbuspirone);erythromycininhibitsthemetabolismof ZOPICLONE  
 TRIANGLE Aprepitant: clarithromycinpossiblyincreasesplasmaconcentrationof APREPITANT 
Atomoxetine: increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithl ATOMOXETINE 
Avanafil: clarithromycinpossiblyincreasesplasmaconcentrationofl AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse;erythromycinincreasesplasmaconcentrationoflAVANAFILâ€”seeunderAvanafil,p698lCalcium-channelBlockers: clarithromycinanderythromycinpossiblyinhibitmetabolismofl CALCIUM - CHANNELBLOCKERS (increasedriskofside-effects);avoidanceoferythromycinadvisedbymanufacturerof LERCANIDIPINE  
 TRIANGLE CardiacGlycosides: macrolidesincreaseplasmaconcentrationof DIGOXIN (increasedriskoftoxicity)
Ciclosporin: macrolidespossiblyinhibitmetabolismofl CICLOSPORIN (increasedplasmaconcentration);clarithromycinanderythromycininhibitmetabolismoflCICLOSPORIN(increasedplasmaconcentration)
Cilostazol: clarithromycinpossiblyincreasesplasmaconcentrationofl CILOSTAZOL (seeunderCilostazol,p206);erythromycinincreasesplasmaconcentrationoflCILOSTAZOL(seeunderCilostazol,p206)
Clopidogrel: erythromycinpossiblyreducesantiplateleteffectofl CLOPIDOGREL 
Colchicine: azithromycin,clarithromycinanderythromycinpossiblyincreaseriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) 
 TRIANGLE Corticosteroids: erythromycinpossiblyinhibitsmetabolismof CORTICOSTEROIDS ;erythromycininhibitsthemetabolismof METHYLPREDNISOLONE ;clarithromycinpossiblyincreasesplasmaconcentrationofMETHYLPREDNISOLONE
Cytotoxics: erythromycinpossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationoferythromycinby6to12hours;clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consult BNF 
 TRIANGLE Dapoxetine: manufacturerofdapoxetineadvisesdosereductionwhenclarithromycinanderythromycingivenwith DAPOXETINE (seeunderDapoxetine,p703)
Diuretics: clarithromycinincreasesplasmaconcentrationofl EPLERE NON E â€”avoidconcomitantuse;erythromycinincreasesplasmaconcentrationofEPLERENONE(reducedoseofeplerenone)
Domperidone: possibleincreasedriskofventriculararrhythmiaswhenclarithromycingivenwithl DOMPERIDONE â€”avoidconcomitantuse;erythromycinincreasesplasmaconcentrationoflDOMPERIDONE(increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse) 
 TRIANGLE Dopaminergics: erythromycinincreasesplasmaconcentrationof BROMOCRIPTINE and CABERGOLINE (increasedriskoftoxicity);macrolidespossiblyincreaseplasmaconcentrationofBROMOCRIPTINEandCABERGOLINE(increasedriskoftoxicity)
ErgotAlkaloids: increasedriskofergotismwhenclarithromycinorerythromycingivenwithl ERGOMETRINE â€”avoidconcomitantuse;increasedriskofergotismwhenmacrolidesgivenwithl ERGOTAMINE â€”avoidconcomitantuse 
 TRIANGLE Fosaprepitant: clarithromycinpossiblyincreasesplasmaconcentrationof FOSAPREPITANT l5 HT 1-receptor
 Agonists: clarithromycinanderythromycinincreaseplasmaconcentrationofl ELETRIPTAN (riskoftoxicity)â€”avoidconcomitantuse
Ivabradine: clarithromycinpossiblyincreasesplasmaconcentrationofl IVABRADINE â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenerythromycingivenwithlIVABRADINEâ€”avoidconcomitantuse
Ivacaftor: clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationofl IVACAFTOR (seeunderIvacaftor,p257)
Lenalidomide: clarithromycinpossiblyincreasesplasmaconcentrationofl LENALIDOMIDE (increasedriskoftoxicity) 
 TRIANGLE LeukotrieneReceptorAntagonists: erythromycinreducesplasmaconcentrationof ZAFIRLUKAST  
 TRIANGLE Mirabegron: whengivenwithclarithromycinavoidorreducedoseof MIRABEGRON inhepaticorrenalimpairmentâ€”seeMirabegron,p671 
 TRIANGLE Oestrogens: erythromycinincreasesplasmaconcentrationof ESTRADIOL  
 TRIANGLE Parasympathomimetics: erythromycinincreasesplasmaconcentrationof GALANTAMINE 
PentamidineIsetionate: increasedriskofventriculararrhythmiaswhenparenteralerythromycingivenwithl PENTAMIDINEISETIONATE  
 TRIANGLE Progestogens: erythromycinincreasesplasmaconcentrationof DIENOGEST 
Ranolazine: clarithromycinpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse
Sildenafil: clarithromycinincreasestheplasmaconcentrationofl SILDENAFIL â€”considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertension;erythromycinincreasesplasmaconcentrationofSILDENAFILâ€”reduceinitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytotwicedailyforpulmonaryhypertension
Sirolimus: clarithromycinincreasesplasmaconcentrationofl SIROLIMUS â€”avoidconcomitantuse;plasmaconcentrationofbothdrugsincreasedwhenerythromycingivenwithlSIROLIMUS
Tacrolimus: clarithromycinanderythromycinincreaseplasmaconcentrationofl TACROLIMUS  
 TRIANGLE Tadalafil: clarithromycinanderythromycinpossiblyincreaseplasmaconcentrationof TADALAFIL 
Theophylline: clarithromycinpossiblyincreasesplasmaconcentrationof THEOPHYLLINE ;erythromycinincreasesplasmaconcentrationoflTHEOPHYLLINE(alsotheophyllinemayreduceabsorptionoforalerythromycin)
Ticagrelor: clarithromycinpossiblyincreasesplasmaconcentrationofl TICAGRELOR â€”manufacturerofticagreloradvisesavoidconcomitantuse;erythromycinpossiblyincreasesplasmaconcentrationofTICAGRELOR 
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationoferythromycinincreasedby CIMETIDINE (increasedriskoftoxicity,includingdeafness);plasmaconcentrationofbothdrugsincreasedwhenclarithromycingivenwith OMEPRAZOLE  
 TRIANGLE Ulipristal: avoidanceofclarithromycinadvisedbymanufactureroflow-dose ULIPRISTAL ;erythromycinincreasesplasmaconcentrationoflow-doseULIPRISTALâ€”manufactureroflow-doseulipristaladvisesavoidconcomitantuse 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein BNF  
 TRIANGLE Vardenafil: clarithromycinpossiblyincreasesplasmaconcentrationof VARDENAFIL (considerreducinginitialdoseofvardenafil);erythromycinincreasesplasmaconcentrationofVARDENAFIL(reducedoseofvardenafil)Magnesium(parenteral)lCalcium-channelBlockers: profoundhypotensionreportedwithconcomitantuseofparenteralmagnesiumandl NIFEDIPINE inpre-eclampsia 
 TRIANGLE MuscleRelaxants: parenteralmagnesiumenhanceseffectsofNON- DEPOLARISINGMUSCLERELAXANTS and SUXAMETHONIUMM agnesiumSalts(oral)seeAntacids
 sMannitol 
 TRIANGLE Antibacterials: avoidanceofmannitoladvisedbymanufacturerof TOBRAMYCIN 
 TRIANGLE Ciclosporin: possibleincreasedriskofnephrotoxicitywhenmannitolgivenwith CICLOSPORIN MAO I s NOTEF orinteractionsofreversibleMAO-Ainhibitors( RIMA s)seeMoclobemide,andforinteractionsofMAO-
 Binhibitors see Rasagilineand 
 Selegiline
;theantibacterialLinezolidisareversible,non-selectiveMAOinhibitor 
 TRIANGLE  ACE Inhibitors: MAOI spossiblyenhancehypotensiveeffectof ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenMAOIsgivenwith ADRENERGICNEURONE BLOCKERS  
Alcohol: MAOIsinteractwithtyraminefoundinsomebeveragescontainingl AL CO HOL andsomedealcoholisedbeverages(hypertensivecrisis)â€”ifnotyramine,enhancedhypotensiveeffect 
 TRIANGLE Alpha2-adrenoceptor
 Stimulants: avoidanceofMAOIsadvisedbymanufacturerof APRA CLONIDINE  and BRIMONIDINE  
 lAlpha-blockers:avoidanceofMAOIsadvisedbymanufacturerofl INDORAMIN ;enhancedhypotensiveeffectwhenMAOIsgivenwith ALPHA -BLOCKERS
Analgesics: possibleincreasedserotonergiceffectswhenMAOIsgivenwith FENTANYL ; CNS excitationordepression(hypertensionorhypotension)whenMAOIsgivenwithl PETHIDINE â€”avoidconcomitantuseandfor2weeksafterstoppingMAOIs;possibleincreasedserotonergiceffectsandincreasedriskofconvulsionswhenMAOIsgivenwithl TRAMADOL â€”somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs;avoidanceofMAOIsadvisedbymanufacturerofl NEFOPAM ;possibleCNSexcitationordepression(hypertensionorhypotension)whenMAOIsgivenwithl OPIOIDANALGESICS â€”somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs 
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: MAOIspossiblyenhancehypotensiveeffectof ANGIOTENSIN - IIRECEPTORANTAGONISTS 
Antidepressants: increasedriskofhypertensionandCNSexcitationwhenMAOIsgivenwithl REBOXETINE (MAOIsshouldnotbestarteduntil1weekafterstoppingreboxetine,avoidreboxetinefor2weeksafterstoppingMAOIs);afterstoppingMAOIsdonotstartl CITALOPRAM ,l ESCITALOPRAM ,l FLUVOXAMINE ,l PAROXETINE orl SERTRALINE for2weeks,alsoMAOIsshouldnotbestarteduntilatleast1weekafterstoppingcitalopram,escitalopram,fluvoxamine,paroxetineorsertraline;afterstoppingMAOIsdonotstartl FLUOXETINE for2weeks,alsoMAOIsshouldnotbestarteduntilatleast5weeksafterstoppingfluoxetine;afterstoppingMAOIsdonotstartl DULOXETINE for2weeks,alsoMAOIsshouldnotbestarteduntilatleast5daysafterstoppingduloxetine;enhancedCNSeffectsandtoxicitywhenMAOIsgivenwithl VENLAFAXINE (venlafaxineshouldnotbestarteduntil2weeksafterstoppingMAOIs,avoidMAOIsfor1weekafterstoppingvenlafaxine);increasedriskofhypertensionandCNSexcitationwhenMAOIsgivenwithotherl MAOIS (avoidforatleast2weeksafterstoppingpreviousMAOIsandthenstartatareduceddose);afterstoppingMAOIsdonotstartl MOCLOBEMIDE foratleast1week;MAOIsincreaseCNSeffectsofl SSRIS (riskofserioustoxicity);afterstoppingMAOIsdonotstartl MIRTAZAPINE for2weeks,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingmirtazapine;afterstoppingMAOIsdonotstartl TRICYCLIC - RELATEDANTIDEPRESSANTS for2weeks,alsoMAOIsshouldnotbestarteduntilatleast1â€“2weeksafterstoppingtricyclic-relatedantidepressants;increasedriskofhypertensionandCNSexcitationwhenMAOIsgivenwithl TRICYCLICS ,tricyclicsshouldnotbestarteduntil2weeksafterstoppingMAOIs(3weeksifstartingclomipramineorimipramine),alsoMAOIsshouldnotbestartedforatleast1â€“2weeksafterstoppingtricyclics(3weeksinthecaseofclomipramineorimipramine) 
 TRIANGLE Antidiabetics: MAOIspossiblyenhancehypoglycaemiceffectof ANTIDIABETICS ;MAOIsenhancehypoglycaemiceffectof INSULIN , METFORMIN and SULFONYLUREAS 
 TRIANGLE Antihistamines: avoidanceofMAOIsadvisedbymanufacturerof HYDROXYZINE ;avoidanceofpromethazinefor2weeksafterstoppingMAOIsadvisedbymanufacturerof PROMETHAZINE ;increasedantimuscarinicandsedativeeffectswhenMAOIsgivenwith ANTI HISTAMINE S 
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE  
 TRIANGLE Antimuscarinics: increasedriskofantimuscarinicside-effectswhenMAOIsgivenwith ANTIMUSCARINICS 
Antipsychotics: CNSeffectsofMAOIspossiblyincreasedbyl CLOZAPINE 
AnxiolyticsandHypnotics: avoidanceofMAOIsadvisedbymanufacturerof BUSPIRONE ;manufactureroftranylcypromineadvisesavoidlBUSPIRONEfor14daysafterstoppingtranylcypromine
Atomoxetine: afterstoppingMAOIsdonotstartl ATOMOXETINE for2weeks,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingatomoxetine;possibleincreasedriskofconvulsionswhenantidepressantsgivenwithATOMOXETINE 
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenMAOIsgivenwith BETA -BLOCKERS
Bupropion: avoidanceofbupropionfor2weeksafterstoppingMAOIsadvisedbymanufacturerofl BUPROPION  
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenMAOIsgivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenMAOIsgivenwithCLONIDINE
Dapoxetine: increasedriskofserotonergiceffectswhenMAOIsgivenwithl DAPOXETINE (MAOIsshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingMAOIs) 
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenMAOIsgivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenMAOIsgivenwith DIURETICS 
Dopaminergics: riskofhypertensivecrisiswhenMAOIsgivenwithlCO- BENELDOPA ,lCO- CARELDOPA orl LEVODOPA ,avoidco-beneldopa,co-careldopaorlevodopaforatleast2weeksafterstoppingMAOIs;avoidconcomitantuseofnon-selectiveMAOIswithl ENTACAPONE ;riskofhypertensivecrisiswhenMAOIsgivenwithl RASAGILINE ,avoidMAOIsforatleast2weeksafterstoppingrasagiline;enhancedhypotensiveeffectwhenMAOIsgivenwithl SELEGILINE â€”manufacturerofselegilineadvisesavoidconcomitantuse;avoidconcomitantuseofMAOIswith TOLCAPONE  
 TRIANGLE Doxapram: MAOIsenhanceeffectsof DOXAPRAM  
 TRIANGLE Histamine: avoidanceofMAOIsadvisedbymanufacturerofHISTAMINEl5 HT 1-receptor
 Agonists: riskofCNStoxicitywhenMAOIsgivenwithl RIZATRIPTAN orl SUMATRIPTAN (avoidrizatriptanorsumatriptanfor2weeksafterMAOIs);riskofCNStoxicitywhenMAOIsgivenwithl ZOLMITRIPTAN (reducedoseofzolmitriptan)
Methyldopa: avoidanceofMAOIsadvisedbymanufacturerofl METHYLDOPA  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenMAOIsgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: phenelzineenhanceseffectsof SUXAMETHONIUM  
 TRIANGLE Nicorandil: enhancedhypotensiveeffectwhenMAOIsgivenwith NICORANDIL  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenMAOIsgivenwith NITRATES  
 TRIANGLE Pholcodine: avoidanceofpholcodinefor2weeksafterstoppingMAOIsadvisedbymanufacturerof PHOLCODINE 
Sympathomimetics: riskofhypertensivecrisiswhenMAOIsgivenwithl ADRENALINE ( EPINEPHRINE ),l DOBUTAMINE ,l DOPAMINE ,l NORADRENALINE ( NOREPINEPHRINE )orl XYLOMETAZOLINE ;riskofhypertensivecrisiswhenMAOIsgivenwithl DEXAMFETAMINE ,l EPHEDRINE ,l ISOMETHEPTENE , BNF 
Tetrabenazine: riskof CNS toxicitywhenMAOIsgivenwithl TETRABENAZINE (avoidtetrabenazinefor2weeksafterMAOIs)  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenMAOIsgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEMAOI s,reversibleseeMoclobemideMaravirocl
 Antibacterials:   plasmaconcentrationofmaravirocpossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN (considerreducingdoseofmaraviroc);plasmaconcentrationofmaravirocreducedbyl RIFAMPICIN â€”considerincreasingdoseofmaraviroc
Antidepressants: plasmaconcentrationofmaravirocpossiblyreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse
 Antifungals:  plasmaconcentrationofmaravirocincreasedbyl KETOCONAZOLE (considerreducingdoseofmaraviroc)
 Antivirals:  plasmaconcentrationofmaravirocincreasedbyl ATAZANAVIR , BOCEPREVIR ,l DARUNAVIR ,l INDINAVIR ,l LOPINAVIR ,l SAQUINAVIR and TELAPREVIR (considerreducingdoseofmaraviroc);plasmaconcentrationofmaravirocpossiblyreducedbyl EFAVIRENZ â€”considerincreasingdoseofmaraviroc;plasmaconcentrationofmaravirocpossiblyreducedby ETRAVIRINE ;maravirocreducesplasmaconcentrationofl FOSAMPRENAVIR â€”avoidconcomitantuse;plasmaconcentrationofmaravirocincreasedby RITONAVIR 
Cobicistat: plasmaconcentrationofmaravirocpossiblyincreasedbyl COBICISTAT (reducedoseofmaraviroc)
Orlistat: absorptionofmaravirocpossiblyreducedbyl ORLISTATM ebendazole 
 TRIANGLE Ulcer-healing
 Drugs: metabolismofmebendazolepossiblyinhibitedby CIMETIDINE (increasedplasmaconcentration)
 Medroxyprogesterone see Progestogens 
 Mefenamic 
 Acid see 
 NSAID sMefloquinelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenmefloquinegivenwithl AMIODARONE â€”avoidconcomitantuse
Antibacterials: increasedriskofventriculararrhythmiaswhenmefloquinegivenwithl MOXIFLOXACIN â€”avoidconcomitantuse;plasmaconcentrationofmefloquinereducedbylRIFAMPICINâ€”avoidconcomitantuse
Antiepileptics: mefloquineantagonisesanticonvulsanteffectofl ANTIEPILEPTICS  
 TRIANGLE Antifungals:plasmaconcentrationofmefloquineincreasedbyKETOCONAZOLE l
 Antimalarials:  avoidanceofantimalarialsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;increasedriskofconvulsionswhenmefloquinegivenwithl CHLOROQUINE orl HYDROXYCHLOROQUINE ;increasedriskofconvulsionswhenmefloquinegivenwithl QUININE (butshouldnotpreventtheuseofintravenousquinineinseverecases)l
 Antipsychotics:   possibleincreasedriskofventriculararrhythmiaswhenmefloquinegivenwithl HALOPERIDOL â€”avoidconcomitantuse;avoidanceofmefloquineadvisedbymanufacturerof AMISULPRIDE ;increasedriskofventriculararrhythmiaswhenmefloquinegivenwithl PIMOZIDE â€”avoidconcomitantuse;manufacturerofrisperidoneadvisespossibleriskofventriculararrhythmiaswhenmefloquinegivenwithl RISPERIDONE  
Atomoxetine: increasedriskofventriculararrhythmiaswhenmefloquinegivenwithl ATOMOXETINE  
 TRIANGLE Beta-blockers:increasedriskofbradycardiawhenmefloquinegivenwith BETA - BLOCKERS  
 TRIANGLE Calcium-channelBlockers: possibleincreasedriskofbradycardiawhenmefloquinegivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE CardiacGlycosides:  possibleincreasedriskofbradycardiawhenmefloquinegivenwith DIGOXIN  
 TRIANGLE Cytotoxics: possibleincreasedriskofbradycardiawhenmefloquinegivenwith CRIZOTINIB  
 TRIANGLE Histamine: avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE 
Ivabradine: increasedriskofventriculararrhythmiaswhenmefloquinegivenwithl IVABRADINE  
 TRIANGLE Vaccines: antimalarialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Megestrol see Progestogens 
 Melatonin see Anxiolyticsand 
 Hypnotics 
 Meloxicam see  NSAIDs 
Melphalan
 
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides:melphalanpossiblyreducesabsorptionofDIGOXINtablets
Ciclosporin: increasedriskofnephrotoxicitywhenmelphalangivenwithl CICLOSPORINM emantine
 lAnaesthetics,General: increasedriskofCNStoxicitywhenmemantinegivenwithl KETAMINE (manufacturerofmemantineadvisesavoidconcomitantuse)
Analgesics: increasedriskofCNStoxicitywhenmemantinegivenwithl DEXTROMETHORPHAN (manufacturerofmemantineadvisesavoidconcomitantuse) 
 TRIANGLE Anticoagulants: memantinepossiblyenhancesanticoagulanteffectof WARFARIN  
 TRIANGLE Antimuscarinics: memantinepossiblyenhanceseffectsof ANTIMUSCARINICS  
 TRIANGLE Antipsychotics:memantinepossiblyreduceseffectsof ANTIPSYCHOTICS 
Dopaminergics: memantinepossiblyenhanceseffectsof DOPAMINERGICS and SELEGILINE ;increasedriskofCNStoxicitywhenmemantinegivenwithl AMANTADINE (manufacturerofmemantineadvisesavoidconcomitantuse) 
 TRIANGLE MuscleRelaxants: memantinepossiblymodifieseffectsof BACLOFEN and DANTROLENEM eningococcal
 Vaccines see Vaccines 
Mepacrine
 Meprobamate see Anxiolyticsand 
 Hypnotics 
 Meptazinol see Opioid 
 Analgesics 
 Mercaptopurine 
 
Allopurinol: enhancedeffectsandincreasedtoxicityofmercaptopurinewhengivenwithl ALLOPURINOL (reducedoseofmercaptopurinetoonequarterofusualdose)lAntibacterials:increasedriskofhaematologicaltoxicitywhenmercaptopurinegivenwithl SULFAMETHOXAZOLE (asco-trimoxazole);increasedriskofhaematologicaltoxicitywhenmercaptopurinegivenwithl TRIMETHOPRIM (alsowithco-trimoxazole)
Anticoagulants: mercaptopurinepossiblyreducesanticoagulanteffectofl COUMARINS  
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE DairyProducts: plasmaconcentrationofmercaptopurinepossiblyreducedby DAIRYPRODUCTS â€”manufacturerofmercaptopurineadvisesgiveatleast1hourbeforeor2hoursafterdairyproducts
Febuxostat: avoidanceofmercaptopurineadvisedbymanufacturerofl FEBUXOSTAT 
Meropenem
 Antiepileptics:  carbapenemsreduceplasmaconcentrationofl SODIUMVALPROATE andl VALPROICACID â€”avoidconcomitantuse  
 TRIANGLE  Vaccines:  antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Mestranol see Oestrogens 
 Metaraminol see Sympathomimetics 
 Metformin see Antidiabetics 
 Methadone see Opioid 
 Analgesics 
Methenamine
Antibacterials:  increasedriskofcrystalluriawhenmethenaminegivenwithl SULFONAMIDES 
Diuretics:   effectsofmethenamineantagonisedbyl ACETAZOLAMIDE  
 TRIANGLE PotassiumSalts: avoidconcomitantuseofmethenaminewith POTASSIUMCITRATE  
 TRIANGLE SodiumCitrate: avoidconcomitantuseofmethenaminewith SODIUMCITRATE  
 TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNF
 Methocarbamol see Muscle 
 Relaxants 
Methotrexate
 Anaesthetics,General:  antifolateeffectofmethotrexateincreasedbyl NITROUSOXIDE â€”avoidconcomitantuse
 Analgesics:  excretionofmethotrexateprobablyreducedbyl NSAIDS (increasedriskoftoxicity);excretionofmethotrexatereducedbyl ASPIRIN ,l DICLOFENAC ,l IBUPROFEN ,l INDOMETACIN ,l KETOPROFEN ,l MELOXICAM andl NAPROXEN (increasedriskoftoxicity)lAntibacterials:absorptionofmethotrexatepossiblyreducedby NEOMYCIN ;excretionofmethotrexatepossiblyreducedby CIPROFLOXACIN (increasedriskoftoxicity);increasedriskofhaematologicaltoxicitywhenmethotrexategivenwithl SULFAMETHOXAZOLE (asco-trimoxazole);increasedriskofmethotrexatetoxicitywhengivenwith DOXYCYCLINE ,SULFONAMIDESor TETRACYCLINE ;excretionofmethotrexatereducedby PENICILLINS (increasedriskoftoxicity);increasedriskofhaematologicaltoxicitywhenmethotrexategivenwithl TRIMETHOPRIM (alsowithco-trimoxazole) 
 TRIANGLE Antiepileptics:antifolateeffectofmethotrexateincreasedby FOS PHENYTOIN  andPHENYTOIN
Antimalarials: antifolateeffectofmethotrexateincreasedbyl PYRIMETHAMINE  l
 Antipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides: methotrexatepossiblyreducesabsorptionof DIGOXIN tablets
Ciclosporin: riskoftoxicitywhenmethotrexategivenwithl CICLOSPORIN  
 TRIANGLE Corticosteroids:  possibleincreasedriskofhepatoxicitywhenhigh-dosemethotrexategivenwith DEXAMETHASONE 
Cytotoxics: increasedpulmonarytoxicitywhenmethotrexategivenwithl CISPLATIN  
 TRIANGLE Diuretics:excretionofmethotrexateincreasedbyalkalineurineduetoACETAZOLAMIDE
Leflunomide: riskoftoxicitywhenmethotrexategivenwithl LEFLUNOMIDE 
Retinoids: plasmaconcentrationofmethotrexateincreasedbyl ACITRETIN (alsoincreasedriskofhepatotoxicity)â€”avoidconcomitantuse 
 TRIANGLE Theophylline: methotrexatepossiblyincreasesplasmaconcentrationof THEOPHYLLINE  
 TRIANGLE Ulcer-healing
 Drugs: excretionofmethotrexatepossiblyreducedby PROTONPUMPINHIBITORS (increasedriskoftoxicity)Methyldopa 
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhenmethyldopagivenwith ACEINHIBITORS  
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenmethyldopagivenwith AL CO HOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenmethyldopagivenwith ALDESLEUKIN  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenmethyldopagivenwith ALPHA -BLOCKERS 
 TRIANGLE Anaesthetics,General:enhancedhypotensiveeffectwhenmethyldopagivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics:hypotensiveeffectofmethyldopaantagonisedbyNSAIDS 
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenmethyldopagivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
Antidepressants:  manufacturerofmethyldopaadvisesavoidconcomitantusewithl MAOIS  
 TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenmethyldopagivenwith ANTIPSYCHOTICS (alsoincreasedriskofextrapyramidaleffects) 
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenmethyldopagivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenmethyldopagivenwith BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenmethyldopagivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenmethyldopagivenwith CLONIDINE  
 TRIANGLE Corticosteroids:hypotensiveeffectofmethyldopaantagonisedby CORTICOSTEROIDS  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenmethyldopagivenwith DIAZOXIDE  
 TRIANGLE Diuretics:enhancedhypotensiveeffectwhenmethyldopagivenwith DIURETICS  
 TRIANGLE Dopaminergics: methyldopaantagonisesantiparkinsonianeffectof DOPAMINERGICS ;increasedriskofextrapyramidalside-effectswhenmethyldopagivenwith AMANTADINE ;enhancedhypotensiveeffectwhenmethyldopagivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA ;effectsofmethyldopapossiblyenhancedby ENTACAPONE  
 TRIANGLE IronSalts: hypotensiveeffectofmethyldopaantagonisedbyoral IRONSALTS 
Lithium: neurotoxicitymayoccurwhenmethyldopagivenwithl LITHIUM withoutincreasedplasmaconcentrationoflithium 
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhenmethyldopagivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenmethyldopagivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhenmethyldopagivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenmethyldopagivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofmethyldopaantagonisedby OESTROGENS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenmethyldopagivenwith ALPROSTADIL  
 lSympathomimetics,Beta2:acutehypotensionreportedwhenmethyldopagivenwithinfusionofl SALBUTAMOL  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenmethyldopagivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE
 Methylphenidate see Sympathomimetics 
 Methylprednisolone see Corticosteroids 
 Methylthioniniuml 
 Antidepressants
:riskof CNS toxicitywhenmethylthioniniumgivenwithl SSRI - RELATEDANTIDEPRESSANTS ,l SSRIS andl CLOMIPRAMINE â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration);possibleriskofCNStoxicitywhenmethylthioniniumgivenwithl MIRTAZAPINE â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)
AnxiolyticsandHypnotics: possibleriskofCNStoxicitywhenmethylthioniniumgivenwithl BUSPIRONE â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestBNF
Bupropion: possibleriskof CNS toxicitywhenmethylthioniniumgivenwithl BUPROPION â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)Metoclopramide  
 TRIANGLE  Alcohol:  metoclopramidepossiblyincreasesabsorptionof ALCOHOL  
 TRIANGLE Anaesthetics,General: metoclopramideenhanceseffectsof THIOPENTAL  
 TRIANGLE Analgesics:   metoclopramideincreasesrateofabsorptionof ASPIRIN (enhancedeffect);effectsofmetoclopramideongastro-intestinalactivityantagonisedby OPIOIDANALGESICS ;metoclopramideincreasesrateofabsorptionof PARACETAMOL  
 TRIANGLE Antibacterials:  metoclopramidereducesplasmaconcentrationof FOSFOMYCIN  
 TRIANGLE Antidepressants: CNStoxicityreportedwhenmetoclopramidegivenwith SSRIS  
 TRIANGLE Antimuscarinics: effectsofmetoclopramideongastro-intestinalactivityantagonisedby ANTIMUSCARINICS  
 TRIANGLE Antipsychotics: increasedriskofextrapyramidalside-effectswhenmetoclopramidegivenwith ANTIPSYCHOTICS  
 TRIANGLE Atovaquone: metoclopramidereducesplasmaconcentrationof ATOVAQUONE â€”avoidconcomitantuse
Ciclosporin:   metoclopramideincreasesplasmaconcentrationofl CICLOSPORIN  
 TRIANGLE Dopaminergics: metoclopramideantagoniseshypoprolactinaemiceffectsof BROMOCRIPTINE and CABERGOLINE ;metoclopramideantagonisesantiparkinsonianeffectof PERGOLIDE ;avoidanceofmetoclopramideadvisedbymanufacturerof ROPINIROLE and ROTIGOTINE (antagonismofeffect) 
 TRIANGLE MuscleRelaxants: metoclopramideenhanceseffectsof SUXAMETHONIUM  
 TRIANGLE Tetrabenazine: increasedriskofextrapyramidalside-effectswhenmetoclopramidegivenwith TETRABENAZINE
 Metolazone see Diuretics 
 Metoprolol see Beta-blockers 
 Metronidazole
 NOTEI nteractionsdonotapplytotopicalmetronidazolepreparations 
 TRIANGLE Alcohol:disulfiram-likereactionwhenmetronidazolegivenwithALCOHOL l
 Anticoagulants:  metronidazoleenhancesanticoagulanteffectofl COUMARINS  
 TRIANGLE Antiepileptics:  metronidazolepossiblyinhibitsmetabolismof FOS PHENYTOIN  andPHENYTOIN(increasedplasmaconcentration);metabolismofmetronidazoleacceleratedby PHENOBARBITAL and PRIMIDONE (reducedeffect)
Cytotoxics: metronidazoleincreasesplasmaconcentrationofl BUSULFAN (increasedriskoftoxicity);metronidazoleinhibitsmetabolismof CAPECITABINE , FLUOROURACIL and TEGAFUR (increasedtoxicity) 
 TRIANGLE Disulfiram: psychoticreactionreportedwhenmetronidazolegivenwith DISULFIRAM  
 TRIANGLE Lithium: metronidazoleincreasesriskof LITHIUM toxicity 
 TRIANGLE Mycophenolate: metronidazolepossiblyreducesbioavailabilityof MYCOPHENOLATE  
 TRIANGLE Ulcer-healingDrugs:  metabolismofmetronidazoleinhibitedby CIMETIDINE (increasedplasmaconcentration) 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Mianserin see Antidepressants
,Tricyclic(related)Micafungin 
 TRIANGLE Antifungals:   micafunginpossiblyincreasesplasmaconcentrationof AMPHOTERICIN ;micafunginincreasesplasmaconcentrationof ITRACONAZOLE (considerreducingdoseofitraconazole) 
 TRIANGLE Ciclosporin:micafunginpossiblyincreasesplasmaconcentrationofCICLOSPORIN 
 TRIANGLE Sirolimus: micafunginincreasesplasmaconcentrationof SIROLIMUS
 Miconazole see Antifungals
,Imidazole
 Midazolam see Anxiolyticsand 
 Hypnotics 
Mifamurtide
 TRIANGLE Ciclosporin:manufacturerofmifamurtideadvisesavoidconcomitantusewithCICLOSPORIN 
 TRIANGLE Corticosteroids:  manufacturerofmifamurtideadvisesavoidconcomitantusewith CORTICOSTEROIDS  
 TRIANGLE Tacrolimus: manufacturerofmifamurtideadvisesavoidconcomitantusewith TACROLIMUSM ifepristone 
 TRIANGLE Corticosteroids:mifepristonemayreduceeffectofCORTICOSTEROIDS(includinginhaledcorticosteroids)for3â€“4days
 Milrinone see Phosphodiesterase 
 Inhibitors 
 Minocycline see Tetracyclines 
 Minoxidil see Vasodilator 
 Antihypertensives 
Mirabegron
 TRIANGLE Antifungals:avoidorreducedoseofmirabegroninhepaticorrenalimpairmentwhengivenwithITRACONAZOLEand KETOCONAZOLE â€”seeMirabegron,p671 
 TRIANGLE Antivirals: avoidorreducedoseofmirabegroninhepaticorrenalimpairmentwhengivenwith RITONAVIR â€”seeMirabegron,p671 
 TRIANGLE Beta-blockers:mirabegronincreasesplasmaconcentrationof METOPROLOL  
 TRIANGLE CardiacGlycosides: mirabegronincreasesplasmaconcentrationof DIGOXIN â€”reduceinitialdoseofdigoxinMirtazapine
Alcohol: increasedsedativeeffectwhenmirtazapinegivenwithlALCOHOL 
 TRIANGLE Analgesics:possibleincreasedserotonergiceffectswhenmirtazapinegivenwith TRAMADOL  
 TRIANGLE Anticoagulants:mirtazapineenhancesanticoagulanteffectof WARFARIN 
Antidepressants: possibleincreasedserotonergiceffectswhenmirtazapinegivenwith FLUOXETINE , FLUVOXAMINE or VENLAFAXINE ;mirtazapineshouldnotbestarteduntil2weeksafterstoppingl  MAOI S ,alsoMAOIsshouldnotbestarteduntilatleast2weeksafterstoppingmirtazapine;afterstoppingmirtazapinedonotstartl MOCLOBEMIDE foratleast1week 
 TRIANGLE Antiepileptics:plasmaconcentrationofmirtazapinereducedby CARBAMAZEPINE ,FOSPHENYTOINandPHENYTOIN 
 TRIANGLE Antifungals:plasmaconcentrationofmirtazapineincreasedbyKETOCONAZOLE
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE  
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhenmirtazapinegivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE  
 TRIANGLE Clonidine: mirtazapinepossiblyantagoniseshypotensiveeffectof CLONIDINE 
Methylthioninium: possibleriskofCNStoxicitywhenmirtazapinegivenwithl METHYLTHIONINIUM â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration) 
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofmirtazapineincreasedby CIMETIDINEM itomycin
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Mitotane
Anticoagulants: mitotanepossiblyreducesanticoagulanteffectofl  CO UMARINS  
 Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)  
 TRIANGLE Diuretics:   manufacturerofmitotaneadvisesavoidconcomitantuseof SPIRONOLACTONE (antagonismofeffect)MitoxantronelAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Ciclosporin: excretionofmitoxantronereducedby CICLOSPORIN (increasedplasmaconcentration)
 Mivacurium see Muscle 
 Relaxants 
 Mizolastine see Antihistamines
 MMR
 Vaccine see Vaccines 
 Moclobemide 
 
 Analgesics:  possible CNS excitationordepression(hypertensionorhypotension)whenmoclobemidegivenwithl DEXTROMETHORPHAN orl PETHIDINE â€”avoidconcomitantuse;possibleCNSexcitationordepression(hypertensionorhypotension)whenmoclobemidegivenwithl OPIOIDANALGESICS â€”manufacturerofmoclobemideadvisesconsiderreducingdoseofopioidanalgesics
 Antidepressants:  moclobemideshouldnotbestartedforatleast1weekafterstoppingl MAOIS ,l SSRI - RELATEDANTIDEPRESSANTS ,l CITALOPRAM ,l FLUVOXAMINE ,l MIRTAZAPINE ,l PAROXETINE ,l SERTRALINE ,l TRICYCLIC -RELATEDANTIDEPRESSANTSorl TRICYCLICS ;increasedriskofCNStoxicitywhenmoclobemidegivenwithl ESCITALOPRAM ,preferablyavoidconcomitantuse;moclobemideshouldnotbestarteduntil5weeksafterstoppingl FLUOXETINE ;possibleincreasedserotonergiceffectswhenmoclobemidegivenwithl DULOXETINE 
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE 
Bupropion: avoidanceofmoclobemideadvisedbymanufacturerofl BUPROPION 
Clopidogrel: moclobemidepossiblyreducesantiplateleteffectofl CLOPIDOGREL  l
 Dopaminergics:  increasedriskofside-effectswhenmoclobemidegivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA ;cautionwithmoclobemideadvisedbymanufacturerof ENTACAPONE ;avoidconcomitantuseofmoclobemidewithl SELEGILINE l5 HT 1-receptor
 Agonists: riskofCNStoxicitywhenmoclobemidegivenwithl RIZATRIPTAN orl SUMATRIPTAN (avoidrizatriptanorsumatriptanfor2weeksaftermoclobemide);riskofCNStoxicitywhenmoclobemidegivenwithl ZOLMITRIPTAN (reducedoseofzolmitriptan)
Sympathomimetics: riskofhypertensivecrisiswhenmoclobemidegivenwithl SYMPATHOMIMETICS  
 TRIANGLE Ulcer-healing
 Drugs: plasmaconcentrationofmoclobemideincreasedby CIMETIDINE (halvedoseofmoclobemide)Modafinil 
 TRIANGLE Antiepileptics: modafinilpossiblyincreasesplasmaconcentrationof FOS PHENYTOIN  andPHENYTOIN
Ciclosporin: modafinilreducesplasmaconcentrationoflCICLOSPORIN
Cytotoxics: modafinilpossiblyreducesplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidconcomitantuse
Oestrogens: modafinilacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
 Moexipril see 
 ACE Inhibitors
 Mometasone see Corticosteroids 
 Monobactams see Aztreonam 
 Monoclonalantibodies see individualdrugs 
 Montelukast see Leukotriene 
 Receptor 
 Antagonists 
 Morphine see Opioid 
 Analgesics 
 Moxifloxacin see Quinolones 
Moxisylyte
 TRIANGLE AdrenergicNeuroneBlockers:  enhancedhypotensiveeffectwhenmoxisylytegivenwith ADRENERGICNEURONE BLOCKERS   
 lAlpha-blockers:possiblesevereposturalhypotensionwhenmoxisylytegivenwithl ALPHA -BLOCKERS 
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenmoxisylytegivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 lBeta-blockers:possiblesevereposturalhypotensionwhenmoxisylytegivenwithl BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers:  enhancedhypotensiveeffectwhenmoxisylytegivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine:  enhancedhypotensiveeffectwhenmoxisylytegivenwith CLONIDINE  
 TRIANGLE Diazoxide:  enhancedhypotensiveeffectwhenmoxisylytegivenwith DIAZOXIDE  
 TRIANGLE Diuretics:enhancedhypotensiveeffectwhenmoxisylytegivenwith DIURETICS  
 TRIANGLE Methyldopa:  enhancedhypotensiveeffectwhenmoxisylytegivenwith METHYLDOPA  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenmoxisylytegivenwith MOXONIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenmoxisylytegivenwith NITRATES  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenmoxisylytegivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEM oxonidine 
 TRIANGLE ACEInhibitors:enhancedhypotensiveeffectwhenmoxonidinegivenwithACEINHIBITORS 
 TRIANGLE AdrenergicNeuroneBlockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithADRENERGICNEURONEBLOCKERS 
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenmoxonidinegivenwith ALCOHOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenmoxonidinegivenwith ALDESLEUKIN  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithALPHA-BLOCKERS 
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhenmoxonidinegivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics:hypotensiveeffectofmoxonidineantagonisedby NSAIDS  
 TRIANGLE Angiotensin-II
 ReceptorAntagonists: enhancedhypotensiveeffectwhenmoxonidinegivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS 
 TRIANGLE Antidepressants:enhancedhypotensiveeffectwhenmoxonidinegivenwithMAOIS;hypotensiveeffectofmoxonidinepossiblyantagonisedbyTRICYCLICS(manufacturerofmoxonidineadvisesavoidconcomitantuse) 
 TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenmoxonidinegivenwith PHENOTHIAZINES  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenmoxonidinegivenwith ANXIOLYTICSANDHYPNOTICS ;sedativeeffectspossiblyincreasedwhenmoxonidinegivenwith BENZODIAZEPINES  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithBETA-BLOCKERS 
 TRIANGLE Calcium-channelBlockers:enhancedhypotensiveeffectwhenmoxonidinegivenwithCALCIUM-CHANNELBLOCKERS 
 TRIANGLE Clonidine:enhancedhypotensiveeffectwhenmoxonidinegivenwithCLONIDINE 
 TRIANGLE Corticosteroids: hypotensiveeffectofmoxonidineantagonisedby CORTICOSTEROIDS  
 TRIANGLE Diazoxide:enhancedhypotensiveeffectwhenmoxonidinegivenwithDIAZOXIDE 
 TRIANGLE Diuretics:enhancedhypotensiveeffectwhenmoxonidinegivenwithDIURETICS 
 TRIANGLE Dopaminergics:enhancedhypotensiveeffectwhenmoxonidinegivenwithCO-BENELDOPA,CO-CARELDOPAorLEVODOPA 
 TRIANGLE Methyldopa:enhancedhypotensiveeffectwhenmoxonidinegivenwithMETHYLDOPA 
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhenmoxonidinegivenwith MOXISYLYTEBNF 
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhenmoxonidinegivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Nitrates:  enhancedhypotensiveeffectwhenmoxonidinegivenwith NITRATES  
 TRIANGLE Oestrogens:  hypotensiveeffectofmoxonidineantagonisedby OESTROGENS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenmoxonidinegivenwith ALPROSTADIL  
 TRIANGLE VasodilatorAntihypertensives:  enhancedhypotensiveeffectwhenmoxonidinegivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEM uscle
Relaxants 
 TRIANGLE  ACE Inhibitors:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: increasedsedativeeffectwhenbaclofen,methocarbamolortizanidinegivenwith AL CO HOL  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith ALPHA -BLOCKERS lAnaesthetics,General: effectsofatracuriumenhancedby KETAMINE ;increasedriskofmyocardialdepressionandbradycardiawhensuxamethoniumgivenwithl PROPOFOL ;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedby VOLATILELIQUIDGENERALANAESTHETICS  
 TRIANGLE Analgesics: excretionofbaclofenpossiblyreducedby NSAIDS (increasedriskoftoxicity);excretionofbaclofenreducedby IBUPROFEN (increasedriskoftoxicity);increasedsedativeeffectwhenbaclofengivenwith FENTANYL or MORPHINE  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Anti-arrhythmics:neuromuscularblockadeenhancedandprolongedwhensuxamethoniumgivenwith LIDOCAINE  
 
Antibacterials:  effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedby PIPERACILLIN ;plasmaconcentrationoftizanidineincreasedbyl CIPROFLOXACIN (increasedriskoftoxicity)â€”avoidconcomitantuse;plasmaconcentrationoftizanidinepossiblyincreasedby NORFLOXACIN (increasedriskoftoxicity);plasmaconcentrationoftizanidinepossiblyreducedby RIFAMPICIN ;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbyl AMINOGLYCOSIDES ;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbyl CLINDAMYCIN ;effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedbyl POLYMYXINS ;effectsofsuxamethoniumenhancedbyl VANCOMYCIN 
Antidepressants: plasmaconcentrationoftizanidineincreasedbyl FLUVOXAMINE (increasedriskoftoxicity)â€”avoidconcomitantuse;effectsofsuxamethoniumenhancedby PHENELZINE ;musclerelaxanteffectofbaclofenenhancedby TRICYCLICS 
Antiepileptics: musclerelaxanteffectofnon-depolarisingmusclerelaxantsantagonisedby CARBAMAZEPINE (acceleratedrecoveryfromneuromuscularblockade);effectsofnon-depolarisingmusclerelaxantsreducedbylong-termuseofl FOS PHENYTOIN  andlPHENYTOIN(buteffectsofnon-depolarisingmusclerelaxantsmightbeincreasedbyacuteuseoffosphenytoinandphenytoin) 
 TRIANGLE Antimalarials: effectsofsuxamethoniumpossiblyenhancedby QUININE  
 TRIANGLE Antipsychotics: effectsofsuxamethoniumpossiblyenhancedby PROMAZINE  
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhenbaclofenortizanidinegivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenbaclofengivenwith BETA -BLOCKERS;possibleenhancedhypotensiveeffectandbradycardiawhentizanidinegivenwithBETA-BLOCKERS;effectsofmusclerelaxantsenhancedby PROPRANOLOL  
 TRIANGLE CardiacGlycosides: possibleincreasedriskofbradycardiawhentizanidinegivenwith CARDIACGLYCOSIDES ;riskofventriculararrhythmiaswhensuxamethoniumgivenwithCARDIACGLYCOSIDES 
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith CLONIDINE  
 TRIANGLE Corticosteroids: effectsofpancuroniumandvecuroniumpossiblyantagonisedby CORTICOSTEROIDS  
 TRIANGLE Cytotoxics: effectsofsuxamethoniumenhancedby CYCLOPHOSPHAMIDE and THIOTEPA  
 TRIANGLE Deferasirox: avoidanceoftizanidineadvisedbymanufacturerof DEFERASIROX  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith DIURETICS  
 TRIANGLE Dopaminergics: possibleagitation,confusionandhallucinationswhenbaclofengivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE Lithium: effectsofmusclerelaxantsenhancedby LITHIUM ;baclofenpossiblyaggravateshyperkinesiscausedbyLITHIUM 
 TRIANGLE Magnesium(parenteral):effectsofnon-depolarisingmusclerelaxantsandsuxamethoniumenhancedby PARENTERALMAGNESIUM  
 TRIANGLE Memantine: effectsofbaclofenanddantrolenepossiblymodifiedby MEMANTINE  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith METHYLDOPA  
 TRIANGLE Metoclopramide: effectsofsuxamethoniumenhancedby METOCLOPRAMIDE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwith MOXONIDINE  
 TRIANGLE Nitrates:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithNITRATES 
 TRIANGLE Oestrogens:plasmaconcentrationoftizanidinepossiblyincreasedbyOESTROGENS(increasedriskoftoxicity) 
 TRIANGLE Parasympathomimetics: effectsofnon-depolarisingmusclerelaxantspossiblyantagonisedby DONEPEZIL ;effectsofsuxamethoniumpossiblyenhancedbyDONEPEZIL;effectsofsuxamethoniumenhancedby GALANTAMINE , NEOSTIGMINE , PYRIDOSTIGMINE and RIVASTIGMINE ;effectsofnon-depolarisingmusclerelaxantsantagonisedbyNEOSTIGMINE,PYRIDOSTIGMINEandRIVASTIGMINE 
 TRIANGLE Progestogens: plasmaconcentrationoftizanidinepossiblyincreasedby PROGESTOGENS (increasedriskoftoxicity) 
 TRIANGLE Sympathomimetics,Beta2:effectsofsuxamethoniumenhancedby BAMBUTEROL  
 TRIANGLE VasodilatorAntihypertensives:enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithHYDRALAZINE;enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithMINOXIDIL;enhancedhypotensiveeffectwhenbaclofenortizanidinegivenwithSODIUMNITROPRUSSIDEMuscleRelaxants,depolarisingseeMuscleRelaxantsMuscleRelaxants,non-depolarisingseeMuscleRelaxants
 sMycophenolate 
 TRIANGLE Antacids: absorptionofmycophenolatereducedby ANTACIDS  
 lAntibacterials:bioavailabilityofmycophenolatepossiblyreducedby METRONIDAZOLE andNORFLOXACIN;plasmaconcentrationofmycophenolatepossiblyreducedbyCO- AMOXICLAV ;plasmaconcentrationofactivemetaboliteofmycophenolatereducedbylRIFAMPICIN 
 TRIANGLE Antivirals: mycophenolateincreasesplasmaconcentrationof ACICLOVIR and VALACICLOVIR ,alsoplasmaconcentrationofinactivemetaboliteofmycophenolateincreased;mycophenolatepossiblyincreasesplasmaconcentrationof
 TRIANGLE Colestilan: manufacturerofcolestilanadvisesgivemycophenolateatleast1hourbeforeor3hoursafter COLESTILAN  
 TRIANGLE IronSalts: absorptionofmycophenolatereducedbyoral IRONSALTS  
 TRIANGLE Lipid-regulating
 Drugs:   absorptionofmycophenolatereducedby COLESTYRAMINE  
 TRIANGLE Sevelamer: plasmaconcentrationofmycophenolatepossiblyreducedby SEVELAMER
 Nabumetone see 
 NSAID s
 Nadolol see Beta-blockers 
 Nalidixic 
 Acid see Quinolones 
 Nalmefene 
 
 Analgesics:  manufacturerofnalmefeneadvisesavoidconcomitantusewithl OPIOIDANALGESICS
 Nandrolone see Anabolic 
 Steroids 
 Naproxen see  NSAIDs 
 Naratriptan see 
5 HT 1-receptorAgonists(underHT)Natalizumub
 
Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Nateglinide see Antidiabetics 
 Nebivolol see Beta-blockers 
 Nefopam 
 
l
 Antidepressants:   manufacturerofnefopamadvisesavoidconcomitantusewithl MAOIS ;side-effectspossiblyincreasedwhennefopamgivenwith TRICYCLICS  
 TRIANGLE Antimuscarinics: increasedriskofantimuscarinicside-effectswhennefopamgivenwith ANTIMUSCARINICS
 Neomycin see Aminoglycosides 
 Neostigmine see Parasympathomimetics 
Nevirapine
Antibacterials: nevirapinereducesplasmaconcentrationof CLARITHROMYCIN (butconcentrationofanactivemetaboliteincreased),alsoplasmaconcentrationofnevirapineincreased;nevirapinepossiblyincreasesplasmaconcentrationof RIFABUTIN ;plasmaconcentrationofnevirapinereducedbyl RIFAMPICIN â€”avoidconcomitantuse
Anticoagulants: nevirapinemayenhanceorreduceanticoagulanteffectofl WARFARIN  
Antidepressants:plasmaconcentrationofnevirapinereducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse 
 TRIANGLE Antiepileptics: plasmaconcentrationofnevirapinereducedby CARBAMAZEPINE 
 TRIANGLE Cobicistat: manufacturerofnevirapineadvisesavoidconcomitantusewith COBICISTAT 
Oestrogens: nevirapineacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Orlistat: absorptionofnevirapinepossiblyreducedbyl ORLISTAT 
Progestogens: nevirapineacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF)
 Nicardipine see Calcium-channel 
 Blockers 
Nicorandil
 TRIANGLE Antidepressants:enhancedhypotensiveeffectwhennicorandilgivenwithMAOIS;hypotensiveeffectofnicorandilpossiblyenhancedbyTRICYCLICS
Avanafil: hypotensiveeffectofnicorandilsignificantlyenhancedbyl AVANAFIL (avoidconcomitantuse)
Sildenafil: hypotensiveeffectofnicorandilsignificantlyenhancedbyl SILDENAFIL (avoidconcomitantuse)
Tadalafil: hypotensiveeffectofnicorandilsignificantlyenhancedbyl TADALAFIL (avoidconcomitantuse)
Vardenafil: possibleincreasedhypotensiveeffectwhennicorandilgivenwithl VARDENAFIL â€”avoidconcomitantuse 
 TRIANGLE VasodilatorAntihypertensives: possibleenhancedhypotensiveeffectwhennicorandilgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEN icotine 
 TRIANGLE Anti-arrhythmics:nicotinepossiblyenhanceseffectsof ADENOSINEN icotinicAcidlLipid-regulatingDrugs:increasedriskofmyopathywhennicotinicacidgivenwithl STATINS (appliestolipidregulatingdosesofnicotinicacid)
 Nifedipine see Calcium-channe 
 
BlockersNilotiniblAntibacterials: manufacturerofnilotinibadvisesavoidconcomitantusewithlCLARITHROMYCINandl TELITHROMYCIN ;plasmaconcentrationofnilotinibreducedbylRIFAMPICINâ€”avoidconcomitantuselAntifungals:plasmaconcentrationofnilotinibincreasedbylKETOCONAZOLEâ€”avoidconcomitantuse;manufacturerofnilotinibadvisesavoidconcomitantusewithlITRACONAZOLEandl VORICONAZOLE  
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lAntivirals:avoidanceofnilotinibadvisedbymanufactureroflBOCEPREVIR;plasmaconcentrationofnilotinibpossiblyincreasedby RITONAVIR â€”manufacturerofnilotinibadvisesavoidconcomitantuse 
 TRIANGLE AnxiolyticsandHypnotics: nilotinibincreasesplasmaconcentrationof MIDAZOLAM 
GrapefruitJuice: manufacturerofnilotinibadvisesavoidconcomitantusewithl GRAPEFRUITJUICE  
 TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromnilotinibby12hoursadvisedbymanufacturerof LOMITAPIDE
 Nimodipine see Calcium-channe 
 
BlockersNintedaniblAntibacterials: plasmaconcentrationofnintedanibreducedbylRIFAMPICINâ€”avoidconcomitantuselAntifungals:plasmaconcentrationofnintedanibincreasedbyl KETOCONAZOLEBNF 
Nitrates  
 TRIANGLE   ACE Inhibitors:enhancedhypotensiveeffectwhennitratesgivenwith ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers:  enhancedhypotensiveeffectwhennitratesgivenwith ADRENERGICNEURONE BLOCKERS   
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhennitratesgivenwith AL CO HOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhennitratesgivenwith ALDESLEUKIN  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhennitratesgivenwith ALPHA -BLOCKERS 
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhennitratesgivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics: hypotensiveeffectofnitratesantagonisedby  NSAID S  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhennitratesgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Anti-arrhythmics:effectsofsublingualtabletsofnitratesreducedby DISOPYRAMIDE (failuretodissolveundertongueowingtodrymouth)lAnticoagulants:  infusionofglyceryltrinitratereducesanticoagulanteffectofl HEPARINS  
 TRIANGLE Antidepressants: enhancedhypotensiveeffectwhennitratesgivenwith MAOIS ;effectsofsublingualtabletsofnitratespossiblyreducedby TRICYCLIC - RELATEDANTIDEPRESSANTS (failuretodissolveundertongueowingtodrymouth);effectsofsublingualtabletsofnitratesreducedby TRICYCLICS (failuretodissolveundertongueowingtodrymouth) 
 TRIANGLE Antimuscarinics: effectsofsublingualtabletsofnitratespossiblyreducedby ANTIMUSCARINICS (failuretodissolveundertongueowingtodrymouth) 
 TRIANGLE Antipsychotics:  enhancedhypotensiveeffectwhennitratesgivenwith PHENOTHIAZINES  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhennitratesgivenwith ANXIOLYTICSANDHYPNOTICS 
Avanafil: hypotensiveeffectofnitratessignificantlyenhancedbyl AVANAFIL (avoidconcomitantuse) 
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhennitratesgivenwith BETA -BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhennitratesgivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhennitratesgivenwith CLONIDINE  
 TRIANGLE Corticosteroids: hypotensiveeffectofnitratesantagonisedby CORTICOSTEROIDS  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhennitratesgivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhennitratesgivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhennitratesgivenwithCO- BENELDOPA ,CO- CARELDOPA or LEVODOPA  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhennitratesgivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhennitratesgivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhennitratesgivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhennitratesgivenwith BACLOFEN or TIZANIDINE  
 TRIANGLE Oestrogens: hypotensiveeffectofnitratesantagonisedby OESTROGENS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhennitratesgivenwith ALPROSTADIL 
Riociguat: possibleenhancedhypotensiveeffectwhennitratesgivenwithl RIOCIGUAT â€”avoidconcomitantuse
Sildenafil: hypotensiveeffectofnitratessignificantlyenhancedbyl SILDENAFIL (avoidconcomitantuse)
Tadalafil: hypotensiveeffectofnitratessignificantlyenhancedbyl TADALAFIL (avoidconcomitantuse)
Vardenafil: possibleincreasedhypotensiveeffectwhennitratesgivenwithl VARDENAFIL â€”avoidconcomitantuse 
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhennitratesgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDE
 Nitrazepam see Anxiolyticsand 
 Hypnotics 
Nitrofurantoin
 TRIANGLE Antibacterials: nitrofurantoinpossiblyantagoniseseffectsof NALIDIXICACID  
 TRIANGLE Sulfinpyrazone: excretionofnitrofurantoinreducedby SULFINPYRAZONE (increasedriskoftoxicity) 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Nitroimidazoles see Metronidazoleand 
 Tinidazole 
 Nitrous 
 Oxide see Anaesthetics
,General
 Nizatidine see Histamine 
 H
2-antagonists
 Nomegestrol see Progestogens 
 Noradrenaline
(norepinephrine)seeSympathomimetics
 Norelgestromin see Progestogens 
 Norepinephrine
 NOTEN orepinephrineinteractionsasfornoradrenaline,seeundersympathomimetics
 Norethisterone see Progestogens 
 Norfloxacin see Quinolones 
 Norgestimate see Progestogens 
 Norgestrel see Progestogens 
 Normal 
 Immunoglobulin see Immunoglobulins 
 Nortriptyline see Antidepressants
,TricyclicNSAIDs NOTES eealsoAspirinInteractionsdonotgenerallyapplytotopicalNSAIDs 
 TRIANGLE ACE
 Inhibitors: increasedriskofrenalimpairmentwhenNSAIDsgivenwithACEINHIBITORS,alsohypotensiveeffectantagonised 
 TRIANGLE AdrenergicNeuroneBlockers:NSAIDsantagonisehypotensiveeffectofADRENERGICNEURONEBLOCKERS 
 TRIANGLE Aliskiren: NSAIDspossiblyantagonisehypotensiveeffectof ALISKIREN  
 TRIANGLE Alpha-blockers:NSAIDsantagonisehypotensiveeffectofALPHA-BLOCKERS
Analgesics: avoidconcomitantuseofNSAIDswithlNSAIDSorl ASPIRIN (increasedside-effects);avoidconcomitantuseofNSAIDswithl KETOROLAC (increasedside-effectsandhaemorrhage);ibuprofenpossiblyreducesantiplateleteffectofASPIRIN 
 TRIANGLE Angiotensin-II
 ReceptorAntagonists: increasedriskofrenalimpairmentwhenNSAIDsgivenwithANGIOTENSIN-IIRECEPTORANTAGONISTS,alsohypotensiveeffectantagonised 
 TRIANGLE Antacids:absorptionofacemetacinpossiblyreducedby ANTACIDS 
Antibacterials: indometacinpossiblyincreasesplasmaconcentrationof AMIKACIN and GENTAMICIN inneonates;plasmaconcentrationofcelecoxib,diclofenacandetoricoxibreducedby RIFAMPICIN ;possibleincreasedriskofconvulsionswhenNSAIDsgivenwithl QUINOLONES  
Anticoagulants:increasedriskofhaemorrhagewhenintravenousdiclofenacgivenwithl ANTICOAGULANTS (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenketorolacgivenwithlANTICOAGULANTS(avoidconcomitantuse,includinglow-doseheparins);NSAIDspossiblyenhanceanticoagulanteffectofl COUMARINS andl PHENINDIONE ;possibleincreasedriskofbleedingwhenNSAIDsgivenwithl DABIGATRAN orHEPARINS
Antidepressants: increasedriskofbleedingwhenNSAIDsgivenwithl SSRIS orl VENLAFAXINE 
Antidiabetics: NSAIDspossiblyenhanceeffectsofl SULFONYLUREAS  
 TRIANGLE Antiepileptics: acemetacinpossiblyreducesexcretionof FOS PHENYTOIN  andPHENYTOIN(increasedriskoftoxicity) 
 TRIANGLE Antifungals: plasmaconcentrationofparecoxibincreasedby FLUCONAZOLE (reducedoseofparecoxib);plasmaconcentrationofcelecoxibincreasedbyFLUCONAZOLE(halvedoseofcelecoxib);plasmaconcentrationofflurbiprofenandibuprofenincreasedbyFLUCONAZOLE;plasmaconcentrationofdiclofenacandibuprofenincreasedby VORICONAZOLE  
 TRIANGLE Antipsychotics:possibleseveredrowsinesswhenacemetacinorindometacingivenwith HALOPERIDOL 
 TRIANGLE  Beta-blockers:NSAIDsantagonisehypotensiveeffectof BETA - BLOCKERS  
 TRIANGLE Calcium-channelBlockers: NSAIDsantagonisehypotensiveeffectof CALCIUM - CHANNELBLOCKERS  
 TRIANGLE CardiacGlycosides: NSAIDspossiblyincreaseplasmaconcentrationof CARDIACGLYCOSIDES ,alsopossibleexacerbationofheartfailureandreductionofrenalfunctionlCiclosporin:  increasedriskofnephrotoxicitywhenNSAIDsgivenwithl CICLOSPORIN ;plasmaconcentrationofdiclofenacincreasedbylCICLOSPORIN(halvedoseofdiclofenac) 
 TRIANGLE Clonidine: NSAIDsantagonisehypotensiveeffectof CLONIDINE  
 TRIANGLE Clopidogrel: increasedriskofbleedingwhenNSAIDsgivenwith CLOPIDOGREL  
 TRIANGLE Corticosteroids: increasedriskofgastro-intestinalbleedingandulcerationwhenNSAIDsgivenwith CORTICOSTEROIDS 
Cytotoxics: NSAIDsprobablyreduceexcretionofl METHOTREXATE (increasedriskoftoxicity);diclofenac,ibuprofen,indometacin,ketoprofen,meloxicamandnaproxenreduceexcretionoflMETHOTREXATE(increasedriskoftoxicity);NSAIDspossiblyreducerenalexcretionof PEMETREXED â€”consultproductliterature;increasedriskofbleedingwhenNSAIDsgivenwithl ERLOTINIB ;avoidanceofmefenamicacidadvisedbymanufacturerof REGORAFENIB  
 TRIANGLE Desmopressin: indometacinenhanceseffectsof DESMOPRESSIN  
 TRIANGLE Diazoxide: NSAIDsantagonisehypotensiveeffectof DIAZOXIDE 
Dimethylsulfoxide: avoidconcomitantuseofsulindacwithl DIMETHYLSULFOXIDE 
Diuretics: riskofnephrotoxicityofNSAIDsincreasedby DIURETICS ,alsoantagonismofdiureticeffect;indometacinandketorolacantagoniseeffectsofDIURETICS;excretionofacemetacinpossiblyincreasedby FUROSEMIDE ;NSAIDspossiblyantagonisediureticeffectof  POTASSIUM CANRENOATE ;occasionalreportsofreducedrenalfunctionwhenindometacingivenwithl TRIAMTERENE â€”avoidconcomitantuse;possibleincreasedriskofhyperkalaemiawhenNSAIDsgivenwithPOTASSIUM- SPARINGDIURETICSANDALDOSTERONEANTAGONISTS ;increasedriskofhyperkalaemiawhenindometacingivenwithPOTASSIUM-SPARINGDIURETICSANDALDOSTERONEANTAGONISTS 
 TRIANGLE Iloprost: increasedriskofbleedingwhenNSAIDsgivenwith ILOPROST  
 TRIANGLE Lipid-regulatingDrugs:  excretionofmeloxicamincreasedby COLESTYRAMINE 
Lithium: NSAIDsreduceexcretionofl LITHIUM (increasedriskoftoxicity);ketorolacreducesexcretionoflLITHIUM(increasedriskoftoxicity)â€”avoidconcomitantuse 
 TRIANGLE Methyldopa: NSAIDsantagonisehypotensiveeffectof METHYLDOPA  
 TRIANGLE Mifamurtide: avoidanceofhighdosesofNSAIDsadvisedbymanufacturerof MIFAMURTIDE  
 TRIANGLE Moxonidine: NSAIDsantagonisehypotensiveeffectof MOXONIDINE  
 TRIANGLE MuscleRelaxants: ibuprofenreducesexcretionof BACLOFEN (increasedriskoftoxicity);NSAIDspossiblyreduceexcretionofBACLOFEN(increasedriskoftoxicity) 
 TRIANGLE Nitrates: NSAIDsantagonisehypotensiveeffectof NITRATES  
 TRIANGLE Oestrogens: etoricoxibincreasesplasmaconcentrationof ETHINYLESTRADIOL  
 TRIANGLE Penicillamine: possibleincreasedriskofnephrotoxicitywhenNSAIDsgivenwith PENICILLAMINE 
Pentoxifylline: possibleincreasedriskofbleedingwhenNSAIDsgivenwith PENTOXIFYLLINE ;increasedriskofbleedingwhenketorolacgivenwithlPENTOXIFYLLINE(avoidconcomitantuse) 
 TRIANGLE Prasugrel: possibleincreasedriskofbleedingwhenNSAIDsgivenwith PRASUGREL 
 TRIANGLE VasodilatorAntihypertensives: NSAIDsantagonisehypotensiveeffectof HYDRALAZINE , MINOXIDIL and SODIUMNITROPRUSSIDEO binutuzumab
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
Octreotide 
 TRIANGLE Antidiabetics:  octreotidepossiblyreducesrequirementsfor ANTIDIABETICS  
Ciclosporin:octreotidereducesplasmaconcentrationoflCICLOSPORIN 
 TRIANGLE Dopaminergics: octreotideincreasesplasmaconcentrationof BROMOCRIPTINE  
 TRIANGLE Ulcer-healingDrugs:octreotidepossiblydelaysabsorptionof CIMETIDINEO estrogens 
 TRIANGLE  ACE Inhibitors:oestrogensantagonisehypotensiveeffectof ACEINHIBITORS  
 TRIANGLE AdrenergicNeuroneBlockers: oestrogensantagonisehypotensiveeffectof ADRENERGICNEURONEBLOCKERS  
 TRIANGLE Alpha-blockers:oestrogensantagonisehypotensiveeffectof ALPHA -BLOCKERS 
 TRIANGLE Aminophylline: oestrogensincreaseplasmaconcentrationof AMINOPHYLLINE (considerreducingdoseofaminophylline) 
 TRIANGLE Analgesics: plasmaconcentrationofethinylestradiolincreasedby ETORICOXIB  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: oestrogensantagonisehypotensiveeffectof ANGIOTENSIN - IIRECEPTORANTAGONISTS 
Antibacterials: plasmaconcentrationofestradiolincreasedby ERYTHROMYCIN ;metabolismofoestrogensacceleratedbyl RIFAMYCINS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Anticoagulants: oestrogensmayenhanceorreduceanticoagulanteffectof COUMARINS ;oestrogensantagoniseanticoagulanteffectofl PHENINDIONE 
Antidepressants: contraceptiveeffectofoestrogensreducedbyl STJOHN â€™ SWORT (avoidconcomitantuse);oestrogensantagoniseantidepressanteffectof TRICYCLICS (butside-effectsoftricyclicspossiblyincreasedduetoincreasedplasmaconcentration) 
 TRIANGLE Antidiabetics:oestrogensantagonisehypoglycaemiceffectofANTIDIABETICS
Antiepileptics: metabolismofoestrogensacceleratedbyl CARBAMAZEPINE ,l ESLICARBAZEPINE ,l FOS PHENYTOIN  ,l OXCARBAZEPINE ,l PHENOBARBITAL ,lPHENYTOIN,l PRIMIDONE ,l RUFINAMIDE andl TOPIRAMATE (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsinBNF);oestrogensreduceplasmaconcentrationofl LAMOTRIGINE â€”considerincreasingdoseoflamotrigine;ethinylestradiolpossiblyreducesplasmaconcentrationof SODIUMVALPROATE and VALPROICACID  
 TRIANGLE Antifungals: oestrogensincreaseplasmaconcentrationof VORICONAZOLE ;anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhenoestrogensgivenwith GRISEOFULVIN ;anecdotalreportsofcontraceptivefailurewhenoestrogensgivenwith IMIDAZOLES ;occasionalreportsofbreakthroughbleedingwhenoestrogens(usedforcontraception)givenwith TERBINAFINE  
Antivirals:plasmaconcentrationofethinylestradiolincreasedby ATAZANAVIR ;metabolismofoestrogensacceleratedbyl NEVIRAPINE andlRITONAVIR(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsinBNF);plasmaconcentrationofethinylestradiolpossiblyreducedbyl TELAPREVIR â€”manufactureroftelapreviradvisesadditionalcontraceptiveprecautions 
 TRIANGLE AnxiolyticsandHypnotics: oestrogenspossiblyincreaseplasmaconcentrationof CHLORDIAZEPOXIDE , DIAZEPAM and NITRAZEPAM ;oestrogenspossiblyreduceplasmaconcentrationof LORAZEPAM , OXAZEPAM and TEMAZEPAM ;oestrogensincreaseplasmaconcentrationof MELATONINBNF 
Aprepitant: possiblecontraceptivefailureofhormonalcontraceptivescontainingoestrogenswhengivenwithl APREPITANT (alternativecontraceptionrecommended)  
 TRIANGLE  Beta-blockers:oestrogensantagonisehypotensiveeffectof BETA - BLOCKERS 
Bosentan: possiblecontraceptivefailureofhormonalcontraceptivescontainingoestrogenswhengivenwithl BOSENTAN (alternativecontraceptionrecommended) 
 TRIANGLE Calcium-channelBlockers: oestrogensantagonisehypotensiveeffectof CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Ciclosporin: oestrogenspossiblyincreaseplasmaconcentrationof CICLOSPORIN  
 TRIANGLE Clonidine: oestrogensantagonisehypotensiveeffectof CLONIDINE 
Cobicistat: metabolismofoestrogensacceleratedbyl COBICISTAT (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF ) 
 TRIANGLE Corticosteroids: oralcontraceptivescontainingoestrogensincreaseplasmaconcentrationof CORTICOSTEROIDS 
Cytotoxics: possiblereductionincontraceptiveeffectofoestrogensadvisedbymanufacturerofl CRIZOTINIB andl VEMURAFENIB ;possiblereducedcontraceptiveeffectofhormonalcontraceptivescontainingoestrogensadvisedbymanufacturerofl DABRAFENIB (alternativecontraceptionrecommended) 
 TRIANGLE Diuretics: oestrogensantagonisediureticeffectof DIURETICS 
Dopaminergics: oestrogensincreaseplasmaconcentrationof ROPINIROLE ;oestrogensincreaseplasmaconcentrationofl SELEGILINE â€”manufacturerofselegilineadvisesavoidconcomitantuse
Fosaprepitant: possiblecontraceptivefailureofhormonalcontraceptivescontainingoestrogenswhengivenwithl FOSAPREPITANT (alternativecontraceptionrecommended) 
 TRIANGLE Lipid-regulating
 Drugs: absorptionofethinylestradiolreducedby COLESEVELAM ;plasmaconcentrationofethinylestradiolincreasedby ATORVASTATIN and ROSUVASTATIN ;separatingadministrationfromoestrogensby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Methyldopa: oestrogensantagonisehypotensiveeffectof METHYLDOPA 
Modafinil: metabolismofoestrogensacceleratedbyl MODAFINIL (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsinBNF) 
 TRIANGLE Moxonidine: oestrogensantagonisehypotensiveeffectof MOXONIDINE  
 TRIANGLE MuscleRelaxants: oestrogenspossiblyincreaseplasmaconcentrationof TIZANIDINE (increasedriskoftoxicity) 
 TRIANGLE Nitrates: oestrogensantagonisehypotensiveeffectof NITRATES  
 TRIANGLE Somatropin: oestrogens(whenusedasoralreplacementtherapy)mayincreasedoserequirementsof SOMATROPIN  
 TRIANGLE Tacrolimus: ethinylestradiolpossiblyincreasesplasmaconcentrationof TACROLIMUS  
 TRIANGLE Teriflunomide: plasmaconcentrationofethinylestradiolincreasedby TERIFLUNOMIDE  
 TRIANGLE Theophylline: oestrogensincreaseplasmaconcentrationof THEOPHYLLINE (considerreducingdoseoftheophylline) 
 TRIANGLE ThyroidHormones: oestrogensmayincreaserequirementsfor THYROIDHORMONES inhypothyroidism 
 TRIANGLE VasodilatorAntihypertensives: oestrogensantagonisehypotensiveeffectof HYDRALAZINE , MINOXIDIL and SODIUMNITROPRUSSIDEO estrogens,conjugatedseeOestrogensOfatumumab
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Ofloxacin see Quinolones 
 Olanzapine see Antipsychotics 
 Olmesartan see Angiotensin-
 IIR eceptorAntagonists
 Olodaterol see Sympathomimetics
,Beta2
 Omeprazole see Proton 
 Pump 
 Inhibitors 
 Ondansetron see 
5 HT 3-receptorAntagonists(underHT)Opioid
 dAnalgesics 
 TRIANGLE Alcohol: enhancedhypotensiveandsedativeeffectswhenopioidanalgesicsgivenwith ALCOHOL  
 TRIANGLE Anaesthetics,General: fentanylinhibitsmetabolismof ETOMIDATE (considerreducingdoseofetomidate);opioidanalgesicspossiblyenhanceeffectsof INTRAVENOUSGENERALANAESTHETICS and VOLATILELIQUIDGENERALANAESTHETICS  
 TRIANGLE Analgesics: avoidanceofbuprenorphineadvisedbymanufacturerof FENTANYL ;manufactureroffentanyladvisesavoidconcomitantusewith PENTAZOCINE 
Antibacterials: plasmaconcentrationoffentanylpossiblyincreasedby CLARITHROMYCIN ;plasmaconcentrationofalfentanilincreasedby ERYTHROMYCIN ;metabolismofalfentanil,codeine,fentanyl,methadoneandmorphineacceleratedby RIFAMPICIN (reducedeffect);metabolismofoxycodonepossiblyacceleratedbyRIFAMPICIN;increasedriskofventriculararrhythmiaswhenmethadonegivenwithl DELAMANID ;manufacturerofpethidineadvisesavoidconcomitantusewith ISONIAZID ;metabolismofoxycodoneinhibitedby TELITHROMYCIN ;possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithlTELITHROMYCIN
Anticoagulants: tramadolenhancesanticoagulanteffectofl COUMARINS 
Antidepressants: plasmaconcentrationofmethadonepossiblyincreasedby FLUOXETINE , FLUVOXAMINE , PAROXETINE and SERTRALINE ;possibleincreasedserotonergiceffectswhenpethidineortramadolgivenwith DULOXETINE ;possibleincreasedserotonergiceffectswhentramadolgivenwith MIRTAZAPINE or VENLAFAXINE ;possible CNS excitationordepression(hypertensionorhypotension)whenopioidanalgesicsgivenwithl  MAOI S â€”somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs;possibleincreasedserotonergiceffectsandincreasedriskofconvulsionswhentramadolgivenwithlMAOISâ€”somemanufacturersadviseavoidconcomitantuseandfor2weeksafterstoppingMAOIs;CNSexcitationordepression(hypertensionorhypotension)whenpethidinegivenwithlMAOISâ€”avoidconcomitantuseandfor2weeksafterstoppingMAOIs;possibleincreasedserotonergiceffectswhenfentanylgivenwithMAOIS, SSRI - RELATEDANTIDEPRESSANTS or SSRIS ;possibleCNSexcitationordepression(hypertensionorhypotension)whenopioidanalgesicsgivenwithl MOCLOBEMIDE â€”manufacturerofmoclobemideadvisesconsiderreducingdoseofopioidanalgesics;possibleCNSexcitationordepression(hypertensionorhypotension)whendextromethorphanorpethidinegivenwithlMOCLOBEMIDEâ€”avoidconcomitantuse;increasedriskofCNStoxicitywhentramadolgivenwithlSSRISorl TRICYCLICS ;plasmaconcentrationofmethadonepossiblyreducedby STJOHN â€™ SWORT ;sedativeeffectspossiblyincreasedwhenopioidanalgesicsgivenwithTRICYCLICS
Antiepileptics: effectsoftramadolreducedby CARBAMAZEPINE ;plasmaconcentrationofmethadonereducedbyCARBAMAZEPINE, PHENOBARBITAL and PRIMIDONE ;metabolismoffentanylpossiblyacceleratedbyCARBAMAZEPINE, FOS PHENYTOIN  andPHENYTOIN(reducedeffect);dextropropoxypheneenhanceseffectsoflCARBAMAZEPINE;metabolismofmethadoneacceleratedbyFOSPHENYTOINandPHENYTOIN(reducedeffectandriskofwithdrawaleffects);possibleincreasedriskofpethidinetoxicitywhengivenwithlFOSPHENYTOINandlPHENYTOIN;morphineincreasesbioavailabilityof GABAPENTIN 
Antifungals: metabolismofbuprenorphineinhibitedbyl KETOCONAZOLE (reducedoseofbuprenorphine);possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithlKETOCONAZOLEâ€”manufacturerofketoconazoleadvisesavoidconcomitantuse;plasmaconcentrationofoxycodoneincreasedby ITRACONAZOLE ,KETOCONAZOLEandl VORICONAZOLE ;metabolismofalfentanilinhibitedby FLUCONAZOLE (riskofprolongedordelayedrespiratorydepression);plasmaconcentrationofmethadoneincreasedbyFLUCONAZOLE;metabolismofalfentanilpossiblyinhibitedbyITRACONAZOLE;plasmaconcentrationofmethadone
Antihistamines: sedativeeffectspossiblyincreasedwhenopioidanalgesicsgivenwithl SEDATINGANTIHISTAMINES  
 
Antimalarials:  avoidanceofmethadoneadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias)  
 TRIANGLE Antimuscarinics: possibleincreasedriskofantimuscarinicside-effectswhencodeinegivenwith ANTIMUSCARINICS  
 
Antipsychotics:  enhancedhypotensiveandsedativeeffectswhenopioidanalgesicsgivenwith ANTIPSYCHOTICS ;increasedriskofventriculararrhythmiaswhenmethadonegivenwithlANTIPSYCHOTICSthatprolongthe QT interval;increasedriskofconvulsionswhentramadolgivenwithANTIPSYCHOTICS;increasedriskofventriculararrhythmiaswhenmethadonegivenwithl AMISULPRIDE â€”avoidconcomitantuse
 
Antivirals:   plasmaconcentrationofmethadonepossiblyreducedby ABACAVIR , NEVIRAPINE and RILPIVIRINE ;plasmaconcentrationofmethadonepossiblyaffectedby BOCEPREVIR ;possibleincreasedriskofprolongedsedationandrespiratorydepressionwhenbuprenorphinegivenwithBOCEPREVIR;methadonepossiblyreducesplasmaconcentrationof DIDANOSINE ;plasmaconcentrationofmethadonereducedby EFAVIRENZ , FOSAMPRENAVIR and RITONAVIR ;plasmaconcentrationofbuprenorphinepossiblyincreasedbyRITONAVIR;plasmaconcentrationofalfentanilandfentanylincreasedbylRITONAVIR;plasmaconcentrationofpethidinereducedbylRITONAVIR,butplasmaconcentrationoftoxicpethidinemetaboliteincreased(avoidconcomitantuse);plasmaconcentrationofmorphinepossiblyreducedbyRITONAVIR;plasmaconcentrationofdextropropoxypheneincreasedbylRITONAVIR(riskoftoxicity)â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenalfentanil,fentanylormethadonegivenwithl SAQUINAVIR â€”avoidconcomitantuse;cautionwithmethadoneadvisedbymanufacturerofl TELAPREVIR (riskofventriculararrhythmias);buprenorphinepossiblyreducesplasmaconcentrationof TIPRANAVIR ;methadonepossiblyincreasesplasmaconcentrationof ZIDOVUDINE  
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhenopioidanalgesicsgivenwith ANXIOLYTICSANDHYPNOTICS ;fentanylpossiblyinhibitsmetabolismof MIDAZOLAM 
Atomoxetine: increasedriskofventriculararrhythmiaswhenmethadonegivenwithl ATOMOXETINE ;possibleincreasedriskofconvulsionswhentramadolgivenwithATOMOXETINE 
 TRIANGLE Beta-blockers:morphinepossiblyincreasesplasmaconcentrationof ESMOLOL  
 TRIANGLE Calcium-channelBlockers: metabolismofalfentanilinhibitedby DILTIAZEM (riskofprolongedordelayedrespiratorydepression)
Cytotoxics: possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithl BOSUTINIB ;cautionwithalfentanilandfentanyladvisedbymanufacturerofl CRIZOTINIB ;possibleincreasedriskofventriculararrhythmiaswhenmethadonegivenwithl VANDETANIB â€”avoidconcomitantuse
Dapoxetine: possibleincreasedriskofserotonergiceffectswhentramadolgivenwithl DAPOXETINE (manufacturerofdapoxetineadvisestramadolshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingtramadol) 
 TRIANGLE Domperidone: opioidanalgesicsantagoniseeffectsof DOMPERIDONE ongastro-intestinalactivity
 TRIANGLE Hormone
 Antagonists:  plasmaconcentrationofdextromethorphanincreasedby ABIRATERONE  
 TRIANGLE 5 HT 3-receptorAntagonists:effectsoftramadolpossiblyantagonisedby ONDANSETRON 
Memantine: increasedriskofCNStoxicitywhendextromethorphangivenwithl MEMANTINE (manufacturerofmemantineadvisesavoidconcomitantuse) 
 TRIANGLE Metoclopramide: opioidanalgesicsantagoniseeffectsof METOCLOPRAMIDE ongastro-intestinalactivity 
 TRIANGLE MuscleRelaxants: increasedsedativeeffectwhenfentanylormorphinegivenwith BACLOFEN 
Nalmefene: avoidanceofopioidanalgesicsadvisedbymanufacturerofl NALMEFENE 
SodiumOxybate: opioidanalgesicsenhanceeffectsofl SODIUMOXYBATE (avoidconcomitantuse) 
 TRIANGLE Ulcer-healing
 Drugs: metabolismofopioidanalgesicsinhibitedby CIMETIDINE (increasedplasmaconcentration)Oritavancin 
 TRIANGLE Anticoagulants:  oritavancinpossiblyincreasesplasmaconcentrationof WARFARIN  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF O rlistat 
 TRIANGLE Anti-arrhythmics:orlistatpossiblyreducesplasmaconcentrationof AMIODARONE  
 TRIANGLE Anticoagulants:manufactureroforlistatrecommendsmonitoringanticoagulanteffectof COUMARINS  
 TRIANGLE Antidiabetics: manufactureroforlistatadvisesavoidconcomitantusewith ACARBOSE  
Antiepileptics:  possibleincreasedriskofconvulsionswhenorlistatgivenwithl ANTIEPILEPTICS  
 lAntivirals:orlistatpossiblyreducesabsorptionoflABACAVIR,l ATAZANAVIR ,l DARUNAVIR ,lDIDANOSINE,lEFAVIRENZ,l ELVITEGRAVIR ,l EMTRICITABINE ,l ENFUVIRTIDE ,l ETRAVIRINE ,lFOSAMPRENAVIR,l INDINAVIR ,l LAMIVUDINE ,l LOPINAVIR ,l MARAVIROC ,lNEVIRAPINE,l RALTEGRAVIR ,lRILPIVIRINE,lRITONAVIR,lSAQUINAVIR,l STAVUDINE ,l TENOFOVIR ,lTIPRANAVIRandlZIDOVUDINE
Ciclosporin: orlistatpossiblyreducesabsorptionofl CICLOSPORIN  
 TRIANGLE ThyroidHormones: possibleincreasedriskofhypothyroidismwhenorlistatgivenwith LEVOTHYROXINE
 Orphenadrine see Antimuscarinics 
 Oxaliplatin see Platinum 
 Compounds 
 Oxandrolone see Anabolic 
 Steroids 
 Oxazepam see Anxiolyticsand 
 Hypnotics 
 Oxcarbazepine 
 
Antidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered)lAntiepileptics:oxcarbazepinesometimesreducesplasmaconcentrationof CARBAMAZEPINE (butconcentrationofanactivemetaboliteofcarbamazepinemaybeincreased),alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepineoftenreduced;avoidanceofoxcarbazepineadvisedbymanufacturerof ESLICARBAZEPINE ;oxcarbazepineincreasesplasmaconcentrationof FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE ,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;oxcarbazepinereducesplasmaconcentrationofl PERAMPANEL (seeunderPerampanel,p398);plasmaconcentrationofanactivemetaboliteofoxcarbazepinesometimesreducedby SODIUMVALPROATE and VALPROICACID  
 lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
 lAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)lAntivirals:oxcarbazepinepossiblyreducesplasmaconcentrationofl DACLATASVIR andl SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofoxcarbazepineadvisedbyBNF
 TRIANGLE Ciclosporin: oxcarbazepinepossiblyreducesplasmaconcentrationof CICLOSPORIN 
Clopidogrel: oxcarbazepinepossiblyreducesantiplateleteffectofl CLOPIDOGREL  
 
Cytotoxics:    oxcarbazepinereducesplasmaconcentrationofl IMATINIB â€”avoidconcomitantuse
Oestrogens: oxcarbazepineacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: oxcarbazepineacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF)
 Oxprenolol see Beta-blockers 
 Oxybutynin see Antimuscarinics 
 Oxycodone see Opioid 
 Analgesics 
 Oxymetazoline see Sympathomimetics 
 Oxytetracycline see Tetracyclines 
Oxytocin
 TRIANGLE Prostaglandins: uterotoniceffectofoxytocinpotentiatedby PROSTAGLANDINS  
 TRIANGLE Sympathomimetics: riskofhypertensionwhenoxytocingivenwithvasoconstrictor SYMPATHOMIMETICS (duetoenhancedvasopressoreffect)Paclitaxel
Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Antivirals: plasmaconcentrationofpaclitaxelincreasedby RITONAVIR  
 lCytotoxics:increasedriskofneutropeniawhenpaclitaxelgivenwithl LAPATINIB
 Paliperidone see Antipsychotics 
 Pamidronate 
 Disodium see Bisphosphonates 
Pancreatin
 Pancuronium see Muscle 
 Relaxants 
 Panitumumabl 
 Antipsychotics
:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Pantoprazole see Proton 
 Pump 
 Inhibitors 
 Papaveretum see Opioid 
 Analgesics 
Paracetamol
 TRIANGLE Antidiabetics:absorptionofparacetamolpossiblyreducedwhengiven1to4hoursafter LIXISENATIDE  
 TRIANGLE Antiepileptics: metabolismofparacetamolpossiblyacceleratedby CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE (alsoisolatedreportsofhepatotoxicity) 
 TRIANGLE Antifungals:   avoidanceofparacetamoladvisedbymanufacturerof KETOCONAZOLE  
 TRIANGLE Cytotoxics:paracetamolpossiblyinhibitsmetabolismofintravenous BUSULFAN (manufacturerofintravenousbusulfanadvisescautionwithin72hoursofparacetamol);cautionwithparacetamoladvisedbymanufacturerofIMATINIB 
 TRIANGLE Lipid-regulating
 Drugs: absorptionofparacetamolreducedby COLESTYRAMINE  
 TRIANGLE Metoclopramide: rateofabsorptionofparacetamolincreasedby METOCLOPRAMIDEP araldehyde
Alcohol: increasedsedativeeffectwhenparaldehydegivenwithl ALCOHOL 
Disulfiram: riskoftoxicitywhenparaldehydegivenwithl DISULFIRAMP arasympathomimetics 
 TRIANGLE Anti-arrhythmics:effectsofneostigmineandpyridostigminepossiblyantagonisedby PROPAFE NON E  
Antibacterials:  plasmaconcentrationofgalantamineincreasedby ERYTHROMYCIN ;effectsofneostigmineandpyridostigmineantagonisedbyl AMINOGLYCOSIDES ;effectsofneostigmineandpyridostigmineantagonisedby CLINDAMYCIN ;effectsofneostigmineandpyridostigmineantagonisedbyl POLYMYXINS  
 TRIANGLE Antidepressants: plasmaconcentrationofgalantamineincreasedby PAROXETINE  
 TRIANGLE Antifungals:plasmaconcentrationofgalantamineincreasedbyKETOCONAZOLE 
 TRIANGLE Antimalarials: effectsofneostigmineandpyridostigminemaybediminishedbecauseofpotentialfor CHLOROQUINE toincreasesymptomsofmyastheniagravis;effectsofneostigmineandpyridostigminemaybediminishedbecauseofpotentialfor HYDROXYCHLOROQUINE toincreasesymptomsofmyastheniagravis 
 TRIANGLE Antimuscarinics:  effectsofparasympathomimeticsantagonisedby ANTIMUSCARINICS  
 TRIANGLE Beta-blockers:increasedriskofarrhythmiaswhenpilocarpinegivenwith BETA - BLOCKERS ;effectsofneostigmineandpyridostigmineantagonisedby PROPRANOLOL  
 TRIANGLE Cytotoxics:possibleincreasedriskofbradycardiawhenpilocarpinegivenwith CRIZOTINIB  
 TRIANGLE Lithium: effectsofneostigmineantagonisedby LITHIUM  
 TRIANGLE MuscleRelaxants: donepezilpossiblyenhanceseffectsof SUXAMETHONIUM ;galantamine,neostigmine,pyridostigmineandrivastigmineenhanceeffectsofSUXAMETHONIUM;neostigmine,pyridostigmineandrivastigmineantagoniseeffectsofNON- DEPOLARISINGMUSCLERELAXANTS ;donepezilpossiblyantagoniseseffectsofNON- DEPOLARISINGMUSCLERELAXANTS
 Parecoxib see 
 NSAID s
 Paricalcitol see Vitamins 
 Paroxetine see Antidepressants
, SSRIP asireotide 
 TRIANGLE Antidiabetics:pasireotidepossiblyreducesrequirementsfor ANTIDIABETICS  
 TRIANGLE Antifungals:avoidanceofpasireotideadvisedbymanufacturerofKETOCONAZOLE 
 TRIANGLE Antimuscarinics:possibleincreasedriskofbradycardiawhenpasireotidegivenwith IPRATROPIUM or OXYBUTYNIN  
 TRIANGLE Beta-blockers:possibleincreasedriskofbradycardiawhenpasireotidegivenwith CARTEOLOL , METOPROLOL ,PROPRANOLOLor SOTALOL  
 TRIANGLE Calcium-channelBlockers: possibleincreasedriskofbradycardiawhenpasireotidegivenwith DILTIAZEM or VERAPAMIL 
Ciclosporin: pasireotidepossiblyreducesplasmaconcentrationofl CICLOSPORINP azopaniblAntibacterials:plasmaconcentrationofpazopanibpossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN (reducedoseofpazopanib);plasmaconcentrationofpazopanibpossiblyreducedbyl RIFAMPICIN 
Antifungals: plasmaconcentrationofpazopanibincreasedbylKETOCONAZOLE(reducedoseofpazopanib);plasmaconcentrationofpazopanibpossiblyincreasedbyl ITRACONAZOLE andl VORICONAZOLE (reducedoseofpazopanib)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
Antivirals: plasmaconcentrationofpazopanibpossiblyincreasedbyl ATAZANAVIR ,l INDINAVIR andlRITONAVIR(reducedoseofpazopanib);avoidanceofpazopanibadvisedbymanufacturerofl BOCEPREVIR ;increasedriskofventriculararrhythmiaswhenpazopanibgivenwithl SAQUINAVIR â€”avoidconcomitantuse
 TRIANGLE Cytotoxics:   plasmaconcentrationofpazopanibincreasedby LAPATINIB 
GrapefruitJuice: manufacturerofpazopanibadvisesavoidconcomitantusewithl GRAPEFRUITJUICE  
 TRIANGLE Lipid-regulatingDrugs:  separatingadministrationfrompazopanibby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Ulcer-healingDrugs:absorptionofpazopanibpossiblyreducedby HISTAMINEH 2- ANTAGONISTS â€”manufacturerofpazopanibadvisesgiveatleast2hoursbeforeor10hoursafterhistamineH2-antagonists;absorptionofpazopanibpossiblyreducedby PROTONPUMPINHIBITORS â€”manufacturerofpazopanibadvisesgiveatthesametimeasprotonpumpinhibitors
 sPegfilgrastim 
 TRIANGLE Cytotoxics:neutropeniapossiblyexacerbatedwhenpegfilgrastimgivenwith CAPECITABINE , FLUOROURACIL or TEGAFURP eginterferon
 Alfa see Interferons 
Pemetrexed
 
 
Antimalarials:   antifolateeffectofpemetrexedincreasedbyl PYRIMETHAMINE 
 
 
Antipsychotics:     avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)Penicillamine 
 TRIANGLE Analgesics:possibleincreasedriskofnephrotoxicitywhenpenicillaminegivenwithNSAIDS 
 TRIANGLE Antacids: absorptionofpenicillaminereducedby ANTACIDS  
 lAntipsychotics:avoidconcomitantuseofpenicillaminewithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides: penicillaminepossiblyreducesplasmaconcentrationof DIGOXIN  
 TRIANGLE IronSalts: absorptionofpenicillaminereducedbyoral IRONSALTS  
 TRIANGLE SodiumAurothiomalate: manufacturerofpenicillamineadvisesavoidconcomitantusewith SODIUMAUROTHIOMALATE (increasedriskoftoxicity) 
 TRIANGLE Zinc: penicillaminereducesabsorptionof ZINC ,alsoabsorptionofpenicillaminereducedbyzinc
 cPenicillins 
 TRIANGLE Allopurinol: increasedriskofrashwhenamoxicillin,ampicillinorco-amoxiclavgivenwith ALLOPURINOL  
 TRIANGLE Antibacterials: absorptionofphenoxymethylpenicillinreducedby NEOMYCIN ;effectsofpenicillinspossiblyantagonisedby TETRACYCLINES  
 TRIANGLE Anticoagulants: aninteractionbetweenbroad-spectrumpenicillinsand COUMARINS and PHENINDIONE hasnotbeendemonstratedinstudies,butcommonexperienceinanticoagulantclinicsisthat INR canbealteredlAntiepileptics:  manufacturerofpivmecillinamadvisesavoidconcomitantusewithl SODIUMVALPROATE andl VALPROICACID  
 TRIANGLE Cytotoxics:penicillinsreduceexcretionof METHOTREXATE (increasedriskoftoxicity) 
 TRIANGLE MuscleRelaxants: piperacillinenhanceseffectsof NON - DEPOLARISINGMUSCLERELAXANTS and SUXAMETHONIUM  
 TRIANGLE Mycophenolate: co-amoxiclavpossiblyreducesplasmaconcentrationof MYCOPHENOLATE  
 TRIANGLE Sulfinpyrazone: excretionofpenicillinsreducedby SULFINPYRAZONE  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF P entamidineIsetionatelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl AMIODARONE â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl DISOPYRAMIDE 
Antidepressants:  avoidanceofpentamidineisetionateadvisedbymanufacturerofl CITALOPRAM andl ESCITALOPRAM (riskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl  TRICYCLIC S  
 TRIANGLE Antifungals:  possibleincreasedriskofnephrotoxicitywhenpentamidineisetionategivenwith AMPHOTERICIN  
 lAntimalarials:avoidanceofpentamidineisetionateadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias)lAntipsychotics:increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl AMISULPRIDE orl DROPERIDOL â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl PHENOTHIAZINES 
Antivirals: increasedriskofhypocalcaemiawhenparenteralpentamidineisetionategivenwithl FOSCARNET ;increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl SAQUINAVIR â€”avoidconcomitantuselCytotoxics:  possibleincreasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl VANDETANIB â€”avoidconcomitantuse
Ivabradine: increasedriskofventriculararrhythmiaswhenpentamidineisetionategivenwithl IVABRADINE
 Pentazocine see Opioid 
 Analgesics 
 Pentostatinl 
 Antipsychotics
:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCytotoxics:increasedtoxicitywhenpentostatingivenwithhigh-dosel CYCLOPHOSPHAMIDE â€”avoidconcomitantuse;increasedpulmonarytoxicitywhenpentostatingivenwithl FLUDARABINE (unacceptablyhighincidenceoffatalities)Pentoxifylline 
 TRIANGLE Aminophylline: pentoxifyllineincreasesplasmaconcentrationof AMINOPHYLLINE 
Analgesics: possibleincreasedriskofbleedingwhenpentoxifyllinegivenwithNSAIDS;increasedriskofbleedingwhenpentoxifyllinegivenwithl KETOROLAC (avoidconcomitantuse) 
 TRIANGLE Theophylline: pentoxifyllineincreasesplasmaconcentrationof THEOPHYLLINEP erampanellAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andlTRICYCLIC- RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:plasmaconcentrationofperampanelreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l OXCARBAZEPINE andlPHENYTOIN(seeunderPerampanel,p398);plasmaconcentrationofperampanelreducedby TOPIRAMATE  
 TRIANGLE Antifungals:plasmaconcentrationofperampanelincreasedby KETOCONAZOLE  
 lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
 lAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered) 
 TRIANGLE AnxiolyticsandHypnotics: perampanelreducesplasmaconcentrationof MIDAZOLAM 
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: perampanelacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF)BNF
Pergolide  
 TRIANGLE Antipsychotics: effectsofpergolideantagonisedby ANTIPSYCHOTICS  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA  
 TRIANGLE Metoclopramide: antiparkinsonianeffectofpergolideantagonisedby METOCLOPRAMIDE
 Pericyazine see Antipsychotics 
 Perindopril see 
 ACE Inhibitors
 Perphenazine see Antipsychotics 
 Pertuzumab 
 
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Pethidine see Opioid 
 Analgesics 
 Phenelzine see 
 MAOI sPhenindione NOTEC hangeinpatientâ€™sclinicalconditionparticularlyassociatedwithliverdisease,intercurrentillness,ordrugadministration,necessitatesmorefrequenttestingMajorchangesindiet(especiallyinvolvingsaladsandvegetables)andinalcoholconsumptionmayalsoaffectanticoagulantcontrol
 Alcohol:  anticoagulantcontrolwithphenindionemaybeaffectedbymajorchangesinconsumptionofl ALCOHOL 
AnabolicSteroids: anticoagulanteffectofphenindioneenhancedbyl ANABOLICSTEROIDS  l
 Analgesics:  anticoagulanteffectofphenindionepossiblyenhancedbyl NSAIDS ;increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofbleedingwhenphenindionegivenwithl ASPIRIN (duetoantiplateleteffect)lAnti-arrhythmics:metabolismofphenindioneinhibitedbyl AMIODARONE (enhancedanticoagulanteffect);anticoagulanteffectofphenindionepossiblyenhancedbyl DRONEDARONE  
 
Antibacterials:  experienceinanticoagulantclinicssuggeststhat INR possiblyalteredwhenphenindioneisgivenwithl NEOMYCIN (givenforlocalactionongut);anticoagulanteffectofphenindionepossiblyenhancedby LEVOFLOXACIN andl TETRACYCLINES ;aninteractionbetweenphenindioneandbroad-spectrum PENICILLINS hasnotbeendemonstratedinstudies,butcommonexperienceinanticoagulantclinicsisthatINRcanbealtered;metabolismofphenindionepossiblyinhibitedby SULFONAMIDES  
Anticoagulants:  increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN ,l DABIGATRAN andl RIVAROXABAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)
Antivirals: anticoagulanteffectofphenindionepossiblyenhancedbyl RITONAVIR 
Clopidogrel: anticoagulanteffectofphenindioneenhancedduetoantiplateletactionofl CLOPIDOGREL  
 TRIANGLE Corticosteroids: anticoagulanteffectofphenindionemaybeenhancedorreducedby CORTICOSTEROIDS  
 TRIANGLE Cytotoxics: avoidanceofphenindioneadvisedbymanufacturerof IBRUTINIB 
Dipyridamole: anticoagulanteffectofphenindioneenhancedduetoantiplateletactionofl DIPYRIDAMOLE 
EnteralFoods: anticoagulanteffectofphenindioneantagonisedbyvitaminK(presentinsomel ENTERALFEEDS ) 
 TRIANGLE Iloprost: increasedriskofbleedingwhenphenindionegivenwith ILOPROST  
 lLipid-regulating
Oestrogens: anticoagulanteffectofphenindioneantagonisedbyl OESTROGENS  
 TRIANGLE Prasugrel: possibleincreasedriskofbleedingwhenphenindionegivenwith PRASUGREL 
Progestogens: anticoagulanteffectofphenindioneantagonisedbyl PROGESTOGENS 
Testolactone: anticoagulanteffectofphenindioneenhancedbyl TESTOLACTONE 
Testosterone: anticoagulanteffectofphenindioneenhancedbyl TESTOSTERONE 
ThyroidHormones: anticoagulanteffectofphenindioneenhancedbyl THYROIDHORMONES 
Vitamins: anticoagulanteffectofphenindioneantagonisedbyl VITAMINKP henobarbital 
 TRIANGLE Alcohol:increasedsedativeeffectwhenphenobarbitalgivenwithALCOHOL
Aminophylline: phenobarbitalacceleratesmetabolismofl AMINOPHYLLINE (reducedeffect) 
 TRIANGLE Analgesics:phenobarbitalreducesplasmaconcentrationof METHADONE ;phenobarbitalpossiblyacceleratesmetabolismof PARACETAMOL (alsoisolatedreportsofhepatotoxicity)
Anthelmintics: phenobarbitalreducesplasmaconcentrationofl ALBENDAZOLE andl PRAZIQUANTEL â€”considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfectionslAnti-arrhythmics:phenobarbitalacceleratesmetabolismof DISOPYRAMIDE (reducedplasmaconcentration);phenobarbitalpossiblyreducesplasmaconcentrationoflDRONEDARONEâ€”avoidconcomitantuse;phenobarbitalpossiblyacceleratesmetabolismof PROPAFENONE  
 lAntibacterials:phenobarbitalacceleratesmetabolismof METRONIDAZOLE (reducedeffect);phenobarbitalpossiblyreducesplasmaconcentrationof RIFAMPICIN ;phenobarbitalacceleratesmetabolismof DOXYCYCLINE (reducedplasmaconcentration);phenobarbitalpossiblyacceleratesmetabolismofl CHLORAMPHENICOL (reducedplasmaconcentration);phenobarbitalreducesplasmaconcentrationofl TELITHROMYCIN (avoidduringandfor2weeksafterphenobarbital)lAnticoagulants:phenobarbitalpossiblyreducesplasmaconcentrationoflAPIXABAN;phenobarbitalacceleratesmetabolismofl COUMARINS (reducedanticoagulanteffect);phenobarbitalpossiblyreducesplasmaconcentrationoflRIVAROXABANâ€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Antidepressants: phenobarbitalpossiblyreducesplasmaconcentrationof REBOXETINE ;phenobarbitalreducesplasmaconcentrationof PAROXETINE ;phenobarbitalacceleratesmetabolismofl MIANSERIN (reducedplasmaconcentration);anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered);plasmaconcentrationofphenobarbitalpossiblyreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse;phenobarbitalpossiblyacceleratesmetabolismoflTRICYCLICS(reducedplasmaconcentration)
Antiepileptics: plasmaconcentrationofphenobarbitalpossiblyincreasedby CARBAMAZEPINE ;phenobarbitalpossiblyreducesplasmaconcentrationof ETHOSUXIMIDE , RUFINAMIDE and TOPIRAMATE ;plasmaconcentrationofphenobarbitaloftenincreasedby FOS PHENYTOIN  andPHENYTOIN,plasmaconcentrationoffosphenytoinandphenytoinoftenreducedbutmaybeincreased;phenobarbitalreducesplasmaconcentrationof LAMOTRIGINE , TIAGABINE and ZONISAMIDE ;plasmaconcentrationofphenobarbitalincreasedby OXCARBAZEPINE ,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;plasmaconcentrationofphenobarbitalincreasedby SODIUMVALPROATE and VALPROICACID (alsoplasmaconcentrationofsodiumvalproateandvalproicacidreduced);plasmaconcentrationofphenobarbitalincreasedbyl STIRIPENTOL 
Antifungals: phenobarbitalpossiblyreducesplasmaconcentrationof ITRACONAZOLE andl POSACONAZOLE ;
Antimalarials: avoidanceofphenobarbitaladvisedbymanufacturerof ARTENIMOLWITHPIPERAQUINE ;anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE 
Antipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered);phenobarbitalacceleratesmetabolismof HALOPERIDOL (reducedplasmaconcentration);plasmaconcentrationofbothdrugsreducedwhenphenobarbitalgivenwith CHLORPROMAZINE ;phenobarbitalpossiblyreducesplasmaconcentrationofl ARIPIPRAZOLE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);phenobarbitalpossiblyreducesplasmaconcentrationof CLOZAPINE ;phenobarbitalpossiblyreducesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse
Antivirals: phenobarbitalpossiblyreducesplasmaconcentrationof ABACAVIR , DARUNAVIR , FOSAMPRENAVIR ,l INDINAVIR ,l LOPINAVIR andl SAQUINAVIR ;avoidanceofphenobarbitaladvisedbymanufacturerofl BOCEPREVIR andl RILPIVIRINE (plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);phenobarbitalpossiblyreducesplasmaconcentrationofl DACLATASVIR andl SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofphenobarbitaladvisedbymanufacturerof DOLUTEGRAVIR ,l ELVITEGRAVIR , ETRAVIRINE , SOFOSBUVIR andl TELAPREVIR   
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhenphenobarbitalgivenwith ANXIOLYTICSANDHYPNOTICS ;phenobarbitaloftenreducesplasmaconcentrationof CLONAZEPAM  
 TRIANGLE Aprepitant: phenobarbitalpossiblyreducesplasmaconcentrationof APREPITANT  
 TRIANGLE Avanafil: phenobarbitalpossiblyreducesplasmaconcentrationof AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse 
 TRIANGLE Beta-blockers:phenobarbitalpossiblyreducesplasmaconcentrationof PROPRANOLOL  
 TRIANGLE Caffeinecitrate: effectsofphenobarbitalpossiblyantagonisedby CAFFEINECITRATE  
 lCalcium-channelBlockers: phenobarbitalprobablyreduceseffectsofl CALCIUM - CHANNELBLOCKERS ;avoidanceofphenobarbitaladvisedbymanufacturerof ISRADIPINE ;avoidanceofphenobarbitaladvisedbymanufacturerofl NIMODIPINE (plasmaconcentrationofnimodipinereduced)
CannabisExtract: phenobarbitalpossiblyreducesplasmaconcentrationofl CANNABISEXTRACT â€”manufacturerofcannabisextractadvisesavoidconcomitantuse
Ciclosporin: phenobarbitalacceleratesmetabolismofl CICLOSPORIN (reducedplasmaconcentration)
Cobicistat: phenobarbitalpossiblyreducesplasmaconcentrationofl COBICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Corticosteroids: phenobarbitalacceleratesmetabolismofl CORTICOSTEROIDS (reducedeffect)
Diuretics: phenobarbitalreducesplasmaconcentrationofl EPLERENONE â€”avoidconcomitantuse;increasedriskofosteomalaciawhenphenobarbitalgivenwith CARBONICANHYDRASEINHIBITORS  
 TRIANGLE Folates: plasmaconcentrationofphenobarbitalpossiblyreducedby FOLATES  
 TRIANGLE Fosaprepitant: phenobarbitalpossiblyreducesplasmaconcentrationof FOSAPREPITANT 
HormoneAntagonists: phenobarbitalpossiblyreducesplasmaconcentrationofl ABIRATERONE â€”manufacturerofabirateroneadvisesavoidconcomitantuse;phenobarbitalacceleratesmetabolismof TOREMIFENE (reducedplasmaconcentration)
Ivacaftor: phenobarbitalpossiblyreducesplasmaconcentrationofl IVACAFTOR â€”manufacturerofivacaftoradvisesavoidconcomitantuse 
 TRIANGLE LeukotrieneReceptorAntagonists: phenobarbitalreducesplasmaconcentrationof MONTELUKAST 
Oestrogens: phenobarbitalacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: phenobarbitalacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF) 
 TRIANGLE Roflumilast: phenobarbitalpossiblyinhibitseffectsof ROFLUMILAST (manufacturerofroflumilastadvisesavoidconcomitantuse) 
 TRIANGLE SodiumOxybate: avoidanceofphenobarbitaladvisedbymanufacturerof SODIUMOXYBATE  
 TRIANGLE Sympathomimetics: plasmaconcentrationofphenobarbitalpossiblyincreasedby METHYLPHENIDATE 
Tacrolimus: phenobarbitalreducesplasmaconcentrationofl TACROLIMUS 
Theophylline: phenobarbitalacceleratesmetabolismofl THEOPHYLLINE (reducedeffect) 
 TRIANGLE ThyroidHormones: phenobarbitalacceleratesmetabolismof THYROIDHORMONES (mayincreaserequirementsforthyroidhormonesinhypothyroidism) 
 TRIANGLE Ticagrelor: phenobarbitalpossiblyreducesplasmaconcentrationof TICAGRELOR 
Ulipristal: avoidanceofphenobarbitaladvisedbymanufacturerofl ULIPRISTAL (contraceptiveeffectofulipristalpossiblyreduced) 
 TRIANGLE Vitamins: phenobarbitalpossiblyincreasesrequirementsfor ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL or VITAMIND
 Phenothiazines see Antipsychotics 
 Phenoxybenzamine see Alpha-blockers 
 Phenoxymethylpenicillin see Penicillins 
 Phentolamine see Alpha
-blockers
 Phenylephrine see Sympathomimetics 
Phenytoin
Aminophylline: plasmaconcentrationofbothdrugsreducedwhenphenytoingivenwithl AMINOPHYLLINE 
Analgesics: excretionofphenytoinpossiblyreducedby ACEMETACIN (increasedriskoftoxicity);phenytoinpossiblyacceleratesmetabolismof FENTANYL (reducedeffect);phenytoinacceleratesmetabolismof METHADONE (reducedeffectandriskofwithdrawaleffects);phenytoinpossiblyincreasesriskofl PETHIDINE toxicity;effectsofphenytoinenhancedby ASPIRIN ;phenytoinpossiblyacceleratesBNF
 TRIANGLE Antacids: absorptionofphenytoinreducedby ANTACIDS 
Anthelmintics: phenytoinreducesplasmaconcentrationofl ALBENDAZOLE andl PRAZIQUANTEL â€”considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfections;plasmaconcentrationofphenytoinpossiblyincreasedby LEVAMISOLE  
 lAnti-arrhythmics:metabolismofphenytoininhibitedbyl AMIODARONE (increasedplasmaconcentration);phenytoinreducesplasmaconcentrationof DISOPYRAMIDE ;phenytoinpossiblyreducesplasmaconcentrationofl DRONEDARONE â€”avoidconcomitantuse
Antibacterials: metabolismofphenytoininhibitedby CLARITHROMYCIN (increasedplasmaconcentration);metabolismofphenytoinpossiblyinhibitedby METRONIDAZOLE (increasedplasmaconcentration);plasmaconcentrationofphenytoinincreasedordecreasedby CIPROFLOXACIN ;phenytoinacceleratesmetabolismof DOXYCYCLINE (reducedplasmaconcentration);phenytoinpossiblyreducesplasmaconcentrationofl BEDAQUILINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;plasmaconcentrationofphenytoinincreasedbyl CHLORAMPHENICOL (increasedriskoftoxicity);metabolismofphenytoinpossiblyinhibitedby ISONIAZID (increasedriskoftoxicity);metabolismofphenytoinacceleratedbyl RIFAMYCINS (reducedplasmaconcentration);plasmaconcentrationofphenytoinpossiblyincreasedby SULFONAMIDES ;phenytoinreducesplasmaconcentrationofl TELITHROMYCIN (avoidduringandfor2weeksafterphenytoin);plasmaconcentrationofphenytoinincreasedbyl TRIMETHOPRIM (alsoincreasedantifolateeffect)
Anticoagulants: phenytoinpossiblyreducesplasmaconcentrationofl APIXABAN ;phenytoinacceleratesmetabolismofl COUMARINS (possibilityofreducedanticoagulanteffect,butenhancementalsoreported);phenytoinpossiblyreducesplasmaconcentrationof DABIGATRAN â€”manufacturerofdabigatranadvisesavoidconcomitantuse;phenytoinpossiblyreducesplasmaconcentrationofl RIVAROXABAN â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Antidepressants: plasmaconcentrationofphenytoinincreasedbyl FLUOXETINE andl FLUVOXAMINE ;phenytoinreducesplasmaconcentrationofl MIANSERIN , MIRTAZAPINE and PAROXETINE ;plasmaconcentrationofphenytoinpossiblyincreasedby SERTRALINE ,alsoplasmaconcentrationofsertralinepossiblyreduced;anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered);plasmaconcentrationofphenytoinpossiblyreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse;phenytoinpossiblyreducesplasmaconcentrationoflTRICYCLICS 
 TRIANGLE Antidiabetics: plasmaconcentrationofphenytointransientlyincreasedby TOLBUTAMIDE (possibilityoftoxicity)
Antifungals: phenytoinreducesplasmaconcentrationofl KETOCONAZOLE andl POSACONAZOLE ;anticonvulsanteffectofphenytoinenhancedbyl MICONAZOLE (plasmaconcentrationofphenytoinincreased);plasmaconcentrationofphenytoinincreasedbyl FLUCONAZOLE (considerreducingdoseofphenytoin);phenytoinreducesplasmaconcentrationofl ITRACONAZOLE â€”avoidconcomitantuse;plasmaconcentrationofphenytoinincreasedbyl VORICONAZOLE ,alsophenytoinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforphenytointoxicity);phenytoinpossiblyreducesplasmaconcentrationof CASPOFUNGIN â€”considerincreasingdoseofcaspofungin
Antimalarials: avoidanceofphenytoinadvisedbymanufacturerof ARTENIMOLWITHPIPERAQUINE ;anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE ;anticonvulsanteffectofphenytoinantagonisedbyl PYRIMETHAMINE ,alsoincreasedantifolateeffect
Antipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered);phenytoinreducesplasmaconcentrationof HALOPERIDOL ;plasmaconcentrationofphenytoinpossiblyincreasedordecreasedby CHLORPROMAZINE ;phenytoinpossiblyreducesplasmaconcentrationofl ARIPIPRAZOLE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);phenytoinacceleratesmetabolismof CLOZAPINE and QUETIAPINE (reducedplasmaconcentration);phenytoinpossiblyreducesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse
Antivirals: phenytoinpossiblyreducesplasmaconcentrationof ABACAVIR , DARUNAVIR , LOPINAVIR and SAQUINAVIR ;avoidanceofphenytoinadvisedbymanufacturerofl BOCEPREVIR andl RILPIVIRINE (plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);phenytoinpossiblyreducesplasmaconcentrationofl DACLATASVIR andl SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofphenytoinadvisedbymanufacturerof DOLUTEGRAVIR ,l ELVITEGRAVIR , ETRAVIRINE , SOFOSBUVIR andl TELAPREVIR ;phenytoinpossiblyreducesplasmaconcentrationofl INDINAVIR ,alsoplasmaconcentrationofphenytoinpossiblyincreased;phenytoinpossiblyreducesplasmaconcentrationof RITONAVIR ,alsoplasmaconcentrationofphenytoinpossiblyaffected;plasmaconcentrationofphenytoinincreasedordecreasedby ZIDOVUDINE  
 TRIANGLE AnxiolyticsandHypnotics: phenytoinoftenreducesplasmaconcentrationof CLONAZEPAM ;plasmaconcentrationofphenytoinincreasedordecreasedby DIAZEPAM ;plasmaconcentrationofphenytoinpossiblyincreasedordecreasedby BENZODIAZEPINES  
 TRIANGLE Aprepitant: phenytoinpossiblyreducesplasmaconcentrationof APREPITANT  
 TRIANGLE Bupropion: phenytoinreducesplasmaconcentrationof BUPROPION  
 TRIANGLE Caffeinecitrate: phenytoinreducesplasmaconcentrationof CAFFEINECITRATE  
 lCalcium-channelBlockers: phenytoinreduceseffectsof FELODIPINE and VERAPAMIL ;avoidanceofphenytoinadvisedbymanufacturerof ISRADIPINE ;avoidanceofphenytoinadvisedbymanufacturerof NIMODIPINE (plasmaconcentrationofnimodipinepossiblyreduced);plasma
CannabisExtract: phenytoinpossiblyreducesplasmaconcentrationofl CANNABISEXTRACT â€”manufacturerofcannabisextractadvisesavoidconcomitantuse  
 TRIANGLE CardiacGlycosides: phenytoinpossiblyreducesplasmaconcentrationof DIGOXIN 
Ciclosporin: phenytoinacceleratesmetabolismofl CICLOSPORIN (reducedplasmaconcentration)
Cobicistat: phenytoinpossiblyreducesplasmaconcentrationofl  CO BICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Corticosteroids: phenytoinacceleratesmetabolismofl CORTICOSTEROIDS (reducedeffect)
Cytotoxics: phenytoinpossiblyreducesplasmaconcentrationof BUSULFAN , ERIBULIN and ETOPOSIDE ;metabolismofphenytoinpossiblyinhibitedby CAPECITABINE , FLUOROURACIL and TEGAFUR (increasedriskoftoxicity);phenytoinincreasesantifolateeffectof METHOTREXATE ;plasmaconcentrationofphenytoinpossiblyreducedby CISPLATIN ;phenytoinpossiblydecreasesplasmaconcentrationof AXITINIB (increasedoseofaxitinibâ€”consultaxitinibproductliterature);phenytoinpossiblyreducesplasmaconcentrationof BORTEZOMIB ,l BOSUTINIB , CRIZOTINIB ,l IBRUTINIB ,l IDELALISIB and PONATINIB â€”manufacturerofbortezomib,bosutinib,crizotinib,ibrutinib,idelalisibandponatinibadvisesavoidconcomitantuse;phenytoinpossiblyreducesplasmaconcentrationofl CABOZANTINIB â€”avoidconcomitantuse;avoidanceofphenytoinadvisedbymanufacturerofl CABAZITAXEL , DABRAFENIB , GEFITINIB ,l LAPATINIB and VEMURAFENIB ;avoidanceofphenytoinadvisedbymanufacturerof DASATINIB andl VISMODEGIB (plasmaconcentrationofdasatinibandvismodegibpossiblyreduced);phenytoinreducesplasmaconcentrationofl IMATINIB â€”avoidconcomitantuse;phenytoinreducesplasmaconcentrationof IRINOTECAN anditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhenphenytoingivenwith PROCARBAZINE 
Dexrazoxane: absorptionofphenytoinpossiblyreducedbyl DEXRAZOXANE  
 TRIANGLE Diazoxide: plasmaconcentrationofphenytoinreducedby DIAZOXIDE ,alsoeffectofdiazoxidemaybereduced
Disulfiram: metabolismofphenytoininhibitedbyl DISULFIRAM (increasedriskoftoxicity)
Diuretics: plasmaconcentrationofphenytoinpossiblyincreasedbyl ACETAZOLAMIDE ;phenytoinantagoniseseffectsof FUROSEMIDE ;phenytoinreducesplasmaconcentrationofl EPLERE NON E â€”avoidconcomitantuse;increasedriskofosteomalaciawhenphenytoingivenwith CARBONICANHYDRASEINHIBITORS  
 TRIANGLE Dopaminergics: phenytoinpossiblyreduceseffectsofCO- BENELDOPA ,CO- CARELDOPA and LEVODOPA  
 TRIANGLE Entera
Foods: absorptionofphenytoinpossiblyreducedby ENTERALFEEDS  
 TRIANGLE Folates: plasmaconcentrationofphenytoinpossiblyreducedby FOLATES  
 TRIANGLE Fosaprepitant: phenytoinpossiblyreducesplasmaconcentrationof FOSAPREPITANT  lHormone
 Antagonists:  phenytoinpossiblyreducesplasmaconcentrationofl ABIRATERONE â€”manufacturerofabirateroneadvisesavoidconcomitantuse;phenytoinpossiblyacceleratesmetabolismof TOREMIFENE  
 TRIANGLE 5 HT 3-receptorAntagonists:phenytoinacceleratesmetabolismof ONDANSETRON (reducedeffect)
Ivacaftor: phenytoinpossiblyreducesplasmaconcentrationofl IVACAFTOR â€”manufacturerofivacaftoradvisesavoidconcomitantuse 
 TRIANGLE Leflunomide: plasmaconcentrationofphenytoinpossiblyincreasedby LEFLUNOMIDE  
 TRIANGLE Lithium: neurotoxicitymayoccurwhenphenytoingivenwith LITHIUM withoutincreasedplasmaconcentrationoflithium 
 TRIANGLE Macitentan: avoidanceofphenytoinadvisedbymanufacturerof MACITENTAN  
 TRIANGLE Modafinil: plasmaconcentrationofphenytoinpossiblyincreasedby MODAFINIL 
MuscleRelaxants: long-termuseofphenytoinreduceseffectsoflNON- DEPOLARISINGMUSCLERELAXANTS (butacuteuseofphenytoinmightincreaseeffectsofnon-depolarisingmusclerelaxants)
Oestrogens: phenytoinacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: phenytoinacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF) 
 TRIANGLE Roflumilast: phenytoinpossiblyinhibitseffectsof ROFLUMILAST (manufacturerofroflumilastadvisesavoidconcomitantuse)
Sulfinpyrazone: plasmaconcentrationofphenytoinincreasedbyl SULFINPYRAZONE  
 TRIANGLE Sympathomimetics: plasmaconcentrationofphenytoinincreasedby METHYLPHENIDATE  
 TRIANGLE Tacrolimus: phenytoinreducesplasmaconcentrationof TACROLIMUS ,alsoplasmaconcentrationofphenytoinpossiblyincreased
Theophylline: plasmaconcentrationofbothdrugsreducedwhenphenytoingivenwithl THEOPHYLLINE  
 TRIANGLE ThyroidHormones: phenytoinacceleratesmetabolismof THYROIDHORMONES (mayincreaserequirementsinhypothyroidism),alsoplasmaconcentrationofphenytoinpossiblyincreased 
 TRIANGLE Tibolone: phenytoinacceleratesmetabolismof TIBOLONE  
 TRIANGLE Ticagrelor: phenytoinpossiblyreducesplasmaconcentrationof TICAGRELOR  
 lUlcer-healingDrugs:metabolismofphenytoininhibitedbyl CIMETIDINE (increasedplasmaconcentration);effectsofphenytoinenhancedbyl ES OMEPRAZOLE  ;effectsofphenytoinpossiblyenhancedbyOMEPRAZOLE;absorptionofphenytoinreducedbyl SUCRALFATE 
Ulipristal: avoidanceofphenytoinadvisedbymanufacturerofl ULIPRISTAL (contraceptiveeffectofulipristalpossiblyreduced) 
 TRIANGLE Vaccines: effectsofphenytoinenhancedby INFLUENZAVACCINE  
 TRIANGLE Vitamins: phenytoinpossiblyincreasesrequirementsfor ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL or VITAMINDP holcodine 
 TRIANGLE Antidepressants: manufacturerofpholcodineadvisesavoidfor2weeksafterstopping MAOISP hosphodiesteraseType-3Inhibitors
Anagrelide: avoidanceofenoximoneandmilrinoneadvisedbymanufacturerofl ANAGRELIDE
 Pilocarpine see Parasympathomimetics 
 Pimozide see Antipsychotics 
 Pindolol see Beta-blockers 
 Pioglitazone see Antidiabetics 
 Piperacillin see Penicillins 
 Piperaquine see Artenimolwith 
 Piperaquine 
 Pipotiazine see Antipsychotics 
 Pirfenidone 
 
Antibacterials: plasmaconcentrationofpirfenidoneincreasedbyl CIPROFLOXACIN â€”seeunderPirfenidone,p260
Antidepressants: plasmaconcentrationofpirfenidoneincreasedbyl FLUVOXAMINE â€”manufacturerofpirfenidoneadvisesavoidconcomitantuse 
 TRIANGLE GrapefruitJuice: manufacturerofpirfenidoneadvisesavoidconcomitantusewith GRAPEFRUITJUICEBNF 
 Piroxicam see 
 NSAID s
 Pivmecillinam see Penicillins 
 Pixantrone 
 
 Antipsychotics:    avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
 Vaccines:  riskofgeneralisedinfectionswhenpixantronegivenwithlivel VACCINES â€”avoidconcomitantusePizotifen  
 TRIANGLE AdrenergicNeuroneBlockers: pizotifenantagoniseshypotensiveeffectof ADRENERGICNEURONEBLOCKERSP latinumCompounds
Aldesleukin: avoidanceofcisplatinadvisedbymanufacturerofl ALDESLEUKIN  l
 Antibacterials:    increasedriskofnephrotoxicityandpossiblyofototoxicitywhenplatinumcompoundsgivenwithl AMINOGLYCOSIDES orl POLYMYXINS ;increasedriskofnephrotoxicityandototoxicitywhenplatinumcompoundsgivenwith CAPREOMYCIN ;increasedriskofnephrotoxicityandpossiblyofototoxicitywhencisplatingivenwith VANCOMYCIN  
 TRIANGLE Antiepileptics:  cisplatinpossiblyreducesplasmaconcentrationof FOS PHENYTOIN  andPHENYTOIN 
Antipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lCytotoxics:  increasedriskofotoxicitywhencisplatingivenwith IFOSFAMIDE ;increasedpulmonarytoxicitywhencisplatingivenwithl BLEOMYCIN andl METHOTREXATE  
 TRIANGLE Diuretics: increasedriskofnephrotoxicityandototoxicitywhenplatinumcompoundsgivenwith DIURETICSP neumococcal
 Vaccine see Vaccines 
 Poliomyelitis 
 Vaccine see Vaccines 
Polymyxins
 TRIANGLE Antifungals:   increasedriskofnephrotoxicitywhenpolymyxinsgivenwith AMPHOTERICIN  
 
Ciclosporin:  increasedriskofnephrotoxicitywhenpolymyxinsgivenwithl CICLOSPORIN  
Cytotoxics:increasedriskofnephrotoxicityandpossiblyofototoxicitywhenpolymyxinsgivenwithl PLATINUMCOMPOUNDS  
 
Diuretics:  increasedriskofotoxicitywhenpolymyxinsgivenwithl LOOPDIURETICS 
MuscleRelaxants: polymyxinsenhanceeffectsofl NON - DEPOLARISINGMUSCLERELAXANTS andl SUXAMETHONIUM 
Parasympathomimetics: polymyxinsantagoniseeffectsofl NEOSTIGMINE andl PYRIDOSTIGMINE  
 TRIANGLE Vaccines:antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF P olysaccharide-iron
 Complex see Ironsalts 
 Polystyrene 
 Sulfonate 
Resins
 TRIANGLE ThyroidHormones: polystyrenesulfonateresinsreduceabsorptionof LEVOTHYROXINEP omalidomide
 TRIANGLE Antidepressants:plasmaconcentrationofponatinibpossiblyreducedby STJOHN â€™ SWORT â€”manufacturerofponatinibadvisesavoidconcomitantuse 
 TRIANGLE Antiepileptics:plasmaconcentrationofponatinibpossiblyreducedby CARBAMAZEPINE ,FOSPHENYTOIN, PHENOBARBITAL ,PHENYTOINand PRIMIDONE â€”manufacturerofponatinibadvisesavoidconcomitantuse 
 TRIANGLE Antifungals:plasmaconcentrationofponatinibincreasedby KETOCONAZOLE ;plasmaconcentrationofponatinibpossiblyincreasedby ITRACONAZOLE and VORICONAZOLE â€”considerreducinginitialdoseofponatinib(seeunderPonatinib,p814)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Antivirals: plasmaconcentrationofponatinibpossiblyincreasedby INDINAVIR , RITONAVIR and SAQUINAVIR â€”considerreducinginitialdoseofponatinib(seeunderPonatinib,p814) 
 TRIANGLE GrapefruitJuice: plasmaconcentrationofponatinibpossiblyincreasedby GRAPEFRUITJUICE
 Posaconazole see Antifungals
,TriazolePotassium
 Canrenoate see Diuretics 
 Potassium 
Aminobenzoate
 Bicarbonate see Potassium 
 Salts 
 Potassium 
 Chloride see Potassium 
 Salts 
 Potassium 
 Citrate see Potassium 
 Salts 
 Potassium 
 Salts
 NOTEI ncludessaltsubstitutesl ACE Inhibitors:increasedriskofseverehyperkalaemiawhenpotassiumsaltsgivenwithl ACEINHIBITORS  
 TRIANGLE Aliskiren: increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwith ALISKIREN  
 lAngiotensin- IIR eceptor
 Antagonists: increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithl ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antibacterials:avoidconcomitantuseofpotassiumcitratewith METHENAMINE  
 lCiclosporin:increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithlCICLOSPORIN 
 lDiuretics:increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithl POTASSIUM - SPARINGDIURETICSANDALDOSTERONEANTAGONISTS 
Tacrolimus: increasedriskofhyperkalaemiawhenpotassiumsaltsgivenwithl TACROLIMUS  
 TRIANGLE Ulcer-healingDrugs:  avoidanceofpotassiumcitrateadvisedbymanufacturerof SUCRALFATEP ramipexole 
 TRIANGLE Antipsychotics:manufacturerofpramipexoleadvisesavoidconcomitantuseof ANTIPSYCHOTICS (antagonismofeffect) 
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA  
 TRIANGLE Ulcer-healingDrugs:excretionofpramipexolereducedby CIMETIDINE (increasedplasmaconcentration)Prasugrel 
 TRIANGLE Analgesics: possibleincreasedriskofbleedingwhenprasugrelgivenwith NSAIDS  
 TRIANGLE Anticoagulants: possibleincreasedriskofbleedingwhenprasugrelgivenwith COUMARINS or PHENINDIONE  
 TRIANGLE Clopidogrel: possibleincreasedriskofbleedingwhenprasugrelgivenwith CLOPIDOGREL
 Pravastatin see Statins 
 Praziquantell 
 Antibacterials
:plasmaconcentrationofpraziquantelreducedbylRIFAMPICINâ€”avoidconcomitantuse
Antiepileptics: plasmaconcentrationofpraziquantelreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONEâ€”considerincreasingpraziquanteldosewhengivenforsystemicinfections 
 TRIANGLE Antifungals:plasmaconcentrationofpraziquantelincreasedbyKETOCONAZOLE
 TRIANGLE Corticosteroids: plasmaconcentrationofpraziquantelpossiblyreducedbycontinuoususeof DEXAMETHASONE  
 TRIANGLE GrapefruitJuice: plasmaconcentrationofpraziquantelincreasedby GRAPEFRUITJUICE  
 TRIANGLE Ulcer-healing
 Drugs: plasmaconcentrationofpraziquantelincreasedby CIMETIDINE
 Prazosin see Alpha-blockers 
 Prednisolone see Corticosteroids 
 Prednisone see Corticosteroids 
 Pregabalin 
 
lAntidepressants:  anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATED ANTI DEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered)lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
 
Antipsychotics:  anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered)
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTATP rilocaine 
 TRIANGLE Anti-arrhythmics:increasedmyocardialdepressionwhenprilocainegivenwithANTI- ARRHYTHMICS  
 TRIANGLE Antibacterials: increasedriskofmethaemoglobinaemiawhenprilocainegivenwith SULFONAMIDESP rimaquinelAntimalarials:avoidanceofantimalarialsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE  
 TRIANGLE Histamine: avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Mepacrine: plasmaconcentrationofprimaquineincreasedby MEPACRINE (increasedriskoftoxicity) 
 TRIANGLE Vaccines: antimalarialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF P rimidone 
 TRIANGLE Alcohol: increasedsedativeeffectwhenprimidonegivenwith ALCOHOL 
Aminophylline: primidoneacceleratesmetabolismofl AMINOPHYLLINE (reducedeffect) 
 TRIANGLE Analgesics: primidonereducesplasmaconcentrationof METHADONE ;primidonepossiblyacceleratesmetabolismof PARACETAMOL (alsoisolatedreportsofhepatotoxicity)
Anthelmintics: primidonereducesplasmaconcentrationofl ALBENDAZOLE andl PRAZIQUANTEL â€”considerincreasingalbendazoleandpraziquanteldosewhengivenforsystemicinfectionslAnti-arrhythmics:primidoneacceleratesmetabolismof DISOPYRAMIDE (reducedplasmaconcentration);primidonepossiblyreducesplasmaconcentrationofl DRONEDARONE â€”avoidconcomitantuse;primidonepossiblyacceleratesmetabolismof PROPAFENONE 
Antibacterials: primidoneacceleratesmetabolismof METRONIDAZOLE (reducedeffect);primidonepossiblyreducesplasmaconcentrationof RIFAMPICIN ;primidoneacceleratesmetabolismof DOXYCYCLINE (reducedplasmaconcentration);primidonepossiblyacceleratesmetabolismofl CHLORAMPHENICOL (reducedplasmaconcentration);primidonereducesplasmaconcentrationofl TELITHROMYCIN (avoidduringandfor2weeksafterprimidone)
Antiepileptics: plasmaconcentrationofprimidonepossiblyincreasedby CARBAMAZEPINE ;primidonepossiblyreducesplasmaconcentrationof ETHOSUXIMIDE , RUFINAMIDE and TOPIRAMATE ;plasmaconcentrationofprimidoneoftenincreasedby FOS PHENYTOIN  andPHENYTOIN,plasmaconcentrationoffosphenytoinandphenytoinoftenreducedbutmaybeincreased;primidonereducesplasmaconcentrationof LAMOTRIGINE , TIAGABINE and ZONISAMIDE ;plasmaconcentrationofprimidoneincreasedby OXCARBAZEPINE ,alsoplasmaconcentrationofanactivemetaboliteofoxcarbazepinereduced;plasmaconcentrationofprimidoneincreasedby SODIUMVALPROATE and VALPROICACID (alsoplasmaconcentrationofsodiumvalproateandvalproicacidreduced);plasmaconcentrationofprimidoneincreasedbyl STIRIPENTOL 
Antifungals: primidonepossiblyreducesplasmaconcentrationof ITRACONAZOLE andl POSACONAZOLE ;primidonepossiblyreducesplasmaconcentrationofl VORICONAZOLE â€”avoidconcomitantuse;primidonereducesabsorptionof GRISEOFULVIN (reducedeffect)lAntimalarials:avoidanceofprimidoneadvisedbymanufacturerof ARTENIMOLWITHPIPERAQUINE ;anticonvulsanteffectofantiepilepticsantagonisedbylMEFLOQUINE 
 lAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered);primidoneacceleratesmetabolismof HALOPERIDOL (reducedplasmaconcentration);plasmaconcentrationofbothdrugsreducedwhenprimidonegivenwith CHLORPROMAZINE ;primidonepossiblyreducesplasmaconcentrationofl ARIPIPRAZOLE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);primidonepossiblyreducesplasmaconcentrationof CLOZAPINE ;primidonepossiblyreducesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse
Antivirals: primidonepossiblyreducesplasmaconcentrationof ABACAVIR , DARUNAVIR , FOSAMPRENAVIR ,l INDINAVIR ,l LOPINAVIR andl SAQUINAVIR ;avoidanceofprimidoneadvisedbymanufacturerofl BOCEPREVIR andl RILPIVIRINE (plasmaconcentrationofboceprevirandrilpivirinepossiblyreduced);primidonepossiblyreducesplasmaconcentrationofl DACLATASVIR andl SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;avoidanceofprimidoneadvisedbymanufacturerof DOLUTEGRAVIR ,l ELVITEGRAVIR , ETRAVIRINE , SOFOSBUVIR andl TELAPREVIR  
 TRIANGLE AnxiolyticsandHypnotics: increasedsedativeeffectwhenprimidonegivenwith ANXIOLYTICSANDHYPNOTICS ;primidoneoftenreducesplasmaconcentrationof CLONAZEPAM  
 TRIANGLE Aprepitant: primidonepossiblyreducesplasmaconcentrationof APREPITANT  
 TRIANGLE Avanafil: primidonepossiblyreducesplasmaconcentrationof AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse 
 TRIANGLE Beta-blockers:primidonepossiblyreducesplasmaconcentrationof PROPRANOLOL  
 TRIANGLE Caffeinecitrate: effectsofprimidonepossiblyantagonisedby CAFFEINECITRATE  
 lCalcium-channelBlockers: primidoneprobablyreduceseffectsofl CALCIUM - CHANNELBLOCKERS ;avoidanceofprimidoneadvisedbymanufacturerof ISRADIPINE ;avoidanceofprimidoneadvisedbymanufacturerofl NIMODIPINE (plasmaconcentrationofnimodipinereduced)
CannabisExtract: primidonepossiblyreducesplasmaconcentrationofl CANNABISEXTRACT â€”manufacturerofcannabisextractadvisesavoidconcomitantuseBNF
 Ciclosporin:  primidoneacceleratesmetabolismofl CICLOSPORIN (reducedplasmaconcentration)
 Cobicistat:  primidonepossiblyreducesplasmaconcentrationofl COBICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Corticosteroids: primidoneacceleratesmetabolismofl CORTICOSTEROIDS (reducedeffect)
Cytotoxics: primidonepossiblydecreasesplasmaconcentrationof AXITINIB (increasedoseofaxitinibâ€”consultaxitinibproductliterature);primidonepossiblyreducesplasmaconcentrationof BORTEZOMIB ,l BOSUTINIB , CRIZOTINIB and PONATINIB â€”manufacturerofbortezomib,bosutinib,crizotinibandponatinibadvisesavoidconcomitantuse;primidonepossiblyreducesplasmaconcentrationofl CABOZANTINIB â€”avoidconcomitantuse;avoidanceofprimidoneadvisedbymanufacturerofl CABAZITAXEL , DABRAFENIB and GEFITINIB ;avoidanceofprimidoneadvisedbymanufacturerof DASATINIB and VANDETANIB (plasmaconcentrationofdasatinibandvandetanibpossiblyreduced);primidonepossiblyreducesplasmaconcentrationof ETOPOSIDE ;primidonereducesplasmaconcentrationof IRINOTECAN anditsactivemetabolite;manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhenprimidonegivenwith PROCARBAZINE 
Diuretics: primidonereducesplasmaconcentrationofl EPLERENONE â€”avoidconcomitantuse;increasedriskofosteomalaciawhenprimidonegivenwith CARBONICANHYDRASEINHIBITORS   
 TRIANGLE Folates: plasmaconcentrationofprimidonepossiblyreducedby FOLATES  
 TRIANGLE Fosaprepitant: primidonepossiblyreducesplasmaconcentrationof FOS APREPITANT  
HormoneAntagonists: primidonepossiblyreducesplasmaconcentrationofl ABIRATERONE â€”manufacturerofabirateroneadvisesavoidconcomitantuse;primidoneacceleratesmetabolismof TOREMIFENE (reducedplasmaconcentration)
Ivacaftor: primidonepossiblyreducesplasmaconcentrationofl IVACAFTOR â€”manufacturerofivacaftoradvisesavoidconcomitantuse 
 TRIANGLE LeukotrieneReceptorAntagonists: primidonereducesplasmaconcentrationof MONTELUKAST 
Oestrogens: primidoneacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT 
Progestogens: primidoneacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF) 
 TRIANGLE Roflumilast: primidonepossiblyinhibitseffectsof ROFLUMILAST (manufacturerofroflumilastadvisesavoidconcomitantuse) 
 TRIANGLE SodiumOxybate: avoidanceofprimidoneadvisedbymanufacturerof SODIUMOXYBATE  
 TRIANGLE Sympathomimetics: plasmaconcentrationofprimidonepossiblyincreasedby METHYLPHENIDATE 
Tacrolimus: primidonereducesplasmaconcentrationofl TACROLIMUS 
Theophylline: primidoneacceleratesmetabolismofl THEOPHYLLINE (reducedeffect) 
 TRIANGLE ThyroidHormones: primidoneacceleratesmetabolismof THYROIDHORMONES (mayincreaserequirementsforthyroidhormonesinhypothyroidism) 
 TRIANGLE Ticagrelor: primidonepossiblyreducesplasmaconcentrationof TICAGRELOR 
 TRIANGLE Vitamins: primidonepossiblyincreasesrequirementsfor ALFACALCIDOL , CALCITRIOL , COLECALCIFEROL , DIHYDROTACHYSTEROL , ERGOCALCIFEROL , PARICALCITOL or VITAMINDP rocarbazine 
 TRIANGLE Alcohol: disulfiram-likereactionwhenprocarbazinegivenwith ALCOHOL  
 TRIANGLE Antiepileptics: manufacturerofprocarbazineadvisespossibleincreasedriskofhypersensitivityreactionswhengivenwith CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE 
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE CardiacGlycosides: procarbazinepossiblyreducesabsorptionof DIGOXIN tablets
 Prochlorperazine see Antipsychotics 
 Procyclidine see Antimuscarinics 
 Progesterone see Progestogens 
 Progestogens 
 
Antibacterials: plasmaconcentrationofdienogestincreasedby ERYTHROMYCIN ;metabolismofprogestogensacceleratedbyl RIFAMYCINS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF)
Anticoagulants: progestogensmayenhanceorreduceanticoagulanteffectof COUMARINS ;progestogensantagoniseanticoagulanteffectofl PHENINDIONE 
Antidepressants: contraceptiveeffectofprogestogensreducedbyl STJOHN â€™ SWORT (avoidconcomitantuse) 
 TRIANGLE Antidiabetics: progestogensantagonisehypoglycaemiceffectof ANTIDIABETICS 
Antiepileptics: metabolismofprogestogensacceleratedbylCARBAMAZEPINE,l ESLICARBAZEPINE ,lFOSPHENYTOIN,l OXCARBAZEPINE ,l PERAMPANEL ,lPHENOBARBITAL,lPHENYTOIN,lPRIMIDONE,l RUFINAMIDE andl TOPIRAMATE (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF);desogestrelpossiblyincreasesplasmaconcentrationof LAMOTRIGINE  
 TRIANGLE Antifungals: progestogenspossiblyincreaseplasmaconcentrationof VORICONAZOLE ;anecdotalreportsofcontraceptivefailureandmenstrualirregularitieswhenprogestogensgivenwith GRISEOFULVIN ;occasionalreportsofbreakthroughbleedingwhenprogestogens(usedforcontraception)givenwith TERBINAFINE 
Antivirals: plasmaconcentrationofnorethisteroneincreasedby ATAZANAVIR ;plasmaconcentrationofdrospirenoneincreasedby BOCEPREVIR (increasedriskoftoxicity);contraceptiveeffectofprogestogenspossiblyreducedbyl EFAVIRENZ ;plasmaconcentrationofnorgestimateincreasedby ELVITEGRAVIR ;metabolismofprogestogensacceleratedbyl NEVIRAPINE (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF) 
 TRIANGLE AnxiolyticsandHypnotics: progestogenspossiblyincreaseplasmaconcentrationof CHLORDIAZEPOXIDE , DIAZEPAM and NITRAZEPAM ;progestogenspossiblyreduceplasmaconcentrationof LORAZEPAM , OXAZEPAM and TEMAZEPAM 
Aprepitant: possiblecontraceptivefailureofhormonalcontraceptivescontainingprogestogenswhengivenwithlAPREPITANT(alternativecontraceptionrecommended)
Bosentan: possiblecontraceptivefailureofhormonalcontraceptivescontainingprogestogenswhengivenwithl BOSENTAN (alternativecontraceptionrecommended) 
 TRIANGLE Ciclosporin:progestogenspossiblyincreaseplasmaconcentrationofCICLOSPORIN 
 TRIANGLE Cobicistat:plasmaconcentrationofnorgestimateincreasedbyCOBICISTAT
Cytotoxics: possiblereductionincontraceptiveeffectofprogestogensadvisedbymanufacturerofl CRIZOTINIB andl VEMURAFENIB ;possiblereducedcontraceptiveeffectofhormonalcontraceptivescontainingprogestogensadvisedbymanufacturerofl DABRAFENIB (alternativecontraceptionrecommended)  
 TRIANGLE  Diuretics:  riskofhyperkalaemiawhendrospirenonegivenwith POTASSIUM - SPARING DIURETICS ANDALDOSTERONEANTAGONISTS (monitorserumpotassiumduringfirstcycle)
Dopaminergics: progestogensincreaseplasmaconcentrationofl SELEGILINE â€”manufacturerofselegilineadvisesavoidconcomitantuse
Fosaprepitant: possiblecontraceptivefailureofhormonalcontraceptivescontainingprogestogenswhengivenwithl FOSAPREPITANT (alternativecontraceptionrecommended) 
 TRIANGLE Lipid-regulatingDrugs:  plasmaconcentrationofnorethisteroneincreasedby ATORVASTATIN ;plasmaconcentrationofactivemetaboliteofnorgestimateincreasedby ROSUVASTATIN ;plasmaconcentrationofnorgestrelincreasedbyROSUVASTATIN 
 TRIANGLE MuscleRelaxants: progestogenspossiblyincreaseplasmaconcentrationof TIZANIDINE (increasedriskoftoxicity) 
 TRIANGLE Sugammadex: plasmaconcentrationofprogestogenspossiblyreducedby SUGAMMADEX â€”manufacturerofsugammadexadvisesadditionalcontraceptiveprecautions 
 TRIANGLE Teriflunomide: plasmaconcentrationoflevonorgestrelincreasedby TERIFLUNOMIDE 
Ulipristal: contraceptiveeffectofprogestogenspossiblyreducedbyl ULIPRISTALP roguanil 
 TRIANGLE Antacids:  absorptionofproguanilreducedby ORALMAGNESIUMSALTS (asmagnesiumtrisilicate) 
 TRIANGLE Anticoagulants: isolatedreportsthatproguanilmayenhanceanticoagulanteffectof WARFARIN 
Antimalarials: avoidanceofantimalarialsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;increasedantifolateeffectwhenproguanilgivenwith PYRIMETHAMINE  
 TRIANGLE Antivirals: plasmaconcentrationofproguanilpossiblyaffectedby EFAVIRENZ  
 TRIANGLE Histamine: avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Vaccines: antimalarialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Promazine see Antipsychotics 
 Promethazine see Antihistamines 
Propafenone
 TRIANGLE Anaesthetics,Local: increasedmyocardialdepressionwhenanti-arrhythmicsgivenwith BUPIVACAINE , LEVOBUPIVACAINE , PRILOCAINE or ROPIVACAINE  
 lAnti-arrhythmics:increasedmyocardialdepressionwhenanti-arrhythmicsgivenwithotherl ANTI - ARRHYTHMICS  l
 Antibacterials:  metabolismofpropafenoneacceleratedbyl RIFAMPICIN (reducedeffect)lAnticoagulants:  propafenoneenhancesanticoagulanteffectofl COUMARINS  l
 Antidepressants:  metabolismofpropafenonepossiblyinhibitedby FLUOXETINE and PAROXETINE ;increasedriskofarrhythmiaswhenpropafenonegivenwithl TRICYCLICS  
 TRIANGLE Antiepileptics: metabolismofpropafenonepossiblyacceleratedby PHENOBARBITAL and PRIMIDONE  
 TRIANGLE Antihistamines: avoidanceofpropafenoneadvisedbymanufacturerof MIZOLASTINE (possibleriskofventriculararrhythmias)
Antipsychotics: increasedriskofventriculararrhythmiaswhenanti-arrhythmicsthatprolongthe QT intervalgivenwithl ANTIPSYCHOTICS thatprolongtheQTinterval
CardiacGlycosides: propafenoneincreasesplasmaconcentrationofl DIGOXIN (halvedoseofdigoxin) 
 TRIANGLE Ciclosporin: propafenonepossiblyincreasesplasmaconcentrationof CICLOSPORIN  
 TRIANGLE Parasympathomimetics: propafenonepossiblyantagoniseseffectsof NEOSTIGMINE and PYRIDOSTIGMINE  
 TRIANGLE Theophylline: propafenoneincreasesplasmaconcentrationof THEOPHYLLINE  
 lUlcer-healingDrugs:plasmaconcentrationofpropafenoneincreasedbyl CIMETIDINE
 Propantheline see Antimuscarinics 
 Propiverine see Antimuscarinics 
 Propofol see Anaesthetics
,General
 Propranolol see Beta-blockers 
Prostaglandins
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenalprostadilgivenwith ADRENERGICNEURONEBLOCKERS  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenalprostadilgivenwith ALPHA -BLOCKERS 
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: enhancedhypotensiveeffectwhenalprostadilgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenalprostadilgivenwithBETA-BLOCKERS 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenalprostadilgivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenalprostadilgivenwith CLONIDINE  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenalprostadilgivenwith DIAZOXIDE  
 TRIANGLE Diuretics:enhancedhypotensiveeffectwhenalprostadilgivenwithDIURETICS 
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenalprostadilgivenwith METHYLDOPA  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenalprostadilgivenwith MOXONIDINE  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenalprostadilgivenwith NITRATES  
 TRIANGLE Oxytocin: prostaglandinspotentiateuterotoniceffectof OXYTOCIN  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenalprostadilgivenwith HYDRALAZINE , MINOXIDIL or SODIUMNITROPRUSSIDEP roteinKinase
 Inhibitors see individualdrugs 
 Proton 
 Pump 
Inhibitors
 TRIANGLE Antibacterials:plasmaconcentrationofbothdrugsincreasedwhenomeprazolegivenwith CLARITHROMYCIN  
Anticoagulants:pantoprazolemightenhancetheanticoagulanteffectofCOUMARINS;esomeprazoleandomeprazolepossiblyenhanceanticoagulanteffectoflCOUMARINS 
 TRIANGLE Antidepressants:omeprazoleincreasesplasmaconcentrationof ESCITALOPRAM ;plasmaconcentrationoflansoprazolepossiblyincreasedby FLUVOXAMINE ;plasmaconcentrationofomeprazolepossiblyreducedby STJOHN â€™ SWORT 
Antiepileptics: omeprazolepossiblyenhanceseffectsof FOS PHENYTOIN  andPHENYTOIN;esomeprazoleenhanceseffectsoflFOSPHENYTOINandlPHENYTOIN
Antifungals: protonpumpinhibitorsreduceabsorptionof ITRACONAZOLE and KETOCONAZOLE ;esomeprazolereducesplasmaconcentrationofl POSACONAZOLE â€”manufacturerofposaconazolesuspensionadvisesavoidconcomitantuse;lansoprazole,omeprazole,pantoprazoleandrabeprazoleBNF
 TRIANGLE Antipsychotics: omeprazolepossiblyreducesplasmaconcentrationof CLOZAPINE  l
 Antivirals:  protonpumpinhibitorsreduceplasmaconcentrationofl ATAZANAVIR â€”avoidoradjustdoseofbothdrugs(consultproductliterature);omeprazoleincreasesplasmaconcentrationof RALTEGRAVIR ;avoidanceofesomeprazole,lansoprazole,pantoprazoleandrabeprazoleadvisedbymanufacturerof RILPIVIRINE (plasmaconcentrationofrilpivirinepossiblyreduced);omeprazolereducesplasmaconcentrationoflRILPIVIRINEâ€”avoidconcomitantuse;esomeprazole,lansoprazole,pantoprazoleandrabeprazolepossiblyincreaseplasmaconcentrationofl SAQUINAVIR â€”manufacturerofsaquinaviradvisesavoidconcomitantuse;omeprazoleincreasesplasmaconcentrationoflSAQUINAVIRâ€”manufacturerofsaquinaviradvisesavoidconcomitantuse;plasmaconcentrationofesomeprazoleandomeprazolereducedbyl TIPRANAVIR  
 TRIANGLE AnxiolyticsandHypnotics: esomeprazoleandomeprazolepossiblyinhibitmetabolismof DIAZEPAM (increasedplasmaconcentration) 
 TRIANGLE CardiacGlycosides: protonpumpinhibitorspossiblyslightlyincreaseplasmaconcentrationof DIGOXIN  
 TRIANGLE Ciclosporin: omeprazolepossiblyaffectsplasmaconcentrationof CICLOSPORIN 
Cilostazol: omeprazoleincreasesplasmaconcentrationofl CILOSTAZOL (seeunderCilostazol,p206)
Clopidogrel: esomeprazoleandomeprazolereduceantiplateleteffectofl CLOPIDOGREL ;lansoprazole,pantoprazoleandrabeprazolepossiblyreduceantiplateleteffectofCLOPIDOGREL 
Cytotoxics:  protonpumpinhibitorspossiblyreduceexcretionof METHOTREXATE (increasedriskoftoxicity);lansoprazolereducesplasmaconcentrationof BOSUTINIB ;avoidanceofprotonpumpinhibitorsadvisedbymanufacturerof DABRAFENIB (plasmaconcentrationofdabrafenibpossiblyreduced);avoidanceofesomeprazole,lansoprazole,pantoprazoleandrabeprazoleadvisedbymanufacturerofl ERLOTINIB ;omeprazolereducesplasmaconcentrationoflERLOTINIBâ€”manufactureroferlotinibadvisesavoidconcomitantuse;protonpumpinhibitorspossiblyreduceabsorptionof LAPATINIB ;protonpumpinhibitorspossiblyreduceabsorptionof PAZOPANIB â€”manufacturerofpazopanibadvisesgiveatthesametimeasprotonpumpinhibitors 
 TRIANGLE Tacrolimus: omeprazolepossiblyincreasesplasmaconcentrationof TACROLIMUS  
 TRIANGLE Ulcer-healingDrugs:  absorptionoflansoprazolepossiblyreducedby SUCRALFATE
 Pseudoephedrine see Sympathomimetics 
Pyrazinamide
 TRIANGLE Vaccines:   antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Pyridostigmine see Parasympathomimetics 
 Pyridoxine see Vitamins 
 Pyrimethamine 
 
 
Antibacterials:   increasedantifolateeffectwhenpyrimethaminegivenwithl SULFONAMIDES orl TRIMETHOPRIM 
Antiepileptics: pyrimethamineantagonisesanticonvulsanteffectofl FOS PHENYTOIN  andlPHENYTOIN,alsoincreasedantifolateeffectlAntimalarials:  avoidanceofantimalarialsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;increasedantifolateeffectwhenpyrimethaminegivenwith PROGUANIL  
 TRIANGLE Histamine:  avoidanceofantimalarialsadvisedbymanufacturerof HISTAMINE  
 TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccinein BNF
 Quetiapine see Antipsychotics 
Quinagolide
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA
 Quinapril see 
 ACE InhibitorsQuininelAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenquininegivenwithl AMIODARONE â€”avoidconcomitantuse;quinineincreasesplasmaconcentrationofl FLECAINIDE  
 lAntibacterials:increasedriskofventriculararrhythmiaswhenquininegivenwithl MOXIFLOXACIN â€”avoidconcomitantuse;plasmaconcentrationofquininereducedbyl RIFAMPICIN  
 TRIANGLE Anticoagulants: plasmaconcentrationofbothdrugsincreasedwhenquininegivenwith WARFARIN 
Antidepressants: possibleincreasedriskofventriculararrhythmiaswhenquininegivenwithl CITALOPRAM orl ESCITALOPRAM â€”avoidconcomitantuselAntimalarials:avoidanceofantimalarialsadvisedbymanufactureroflARTEMETHERWITHLUMEFANTRINE;increasedriskofventriculararrhythmiaswhenquininegivenwithlARTEMETHERWITHLUMEFANTRINE;increasedriskofconvulsionswhenquininegivenwithl MEFLOQUINE (butshouldnotpreventtheuseofintravenousquinineinseverecases)
Antipsychotics: increasedriskofventriculararrhythmiaswhenquininegivenwithl DROPERIDOL orl PIMOZIDE â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenquininegivenwithl HALOPERIDOL â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenquininegivenwithl RISPERIDONE 
Antivirals: plasmaconcentrationofquininepossiblyincreasedbylATAZANAVIR,l DARUNAVIR ,l FOSAMPRENAVIR ,l INDINAVIR andlTIPRANAVIR(increasedriskoftoxicity);plasmaconcentrationofquinineincreasedbyl RITONAVIR (increasedriskoftoxicity);increasedriskofventriculararrhythmiaswhenquininegivenwithlSAQUINAVIRâ€”avoidconcomitantuse
CardiacGlycosides: quinineincreasesplasmaconcentrationoflDIGOXIN 
 TRIANGLE Dopaminergics: quininepossiblyincreasesplasmaconcentrationof AMANTADINE  
 TRIANGLE Histamine:avoidanceofantimalarialsadvisedbymanufacturerofHISTAMINE 
 TRIANGLE MuscleRelaxants: quininepossiblyenhanceseffectsof SUXAMETHONIUM  
 TRIANGLE Ulcer-healingDrugs:metabolismofquinineinhibitedby CIMETIDINE (increasedplasmaconcentration) 
 TRIANGLE Vaccines:antimalarialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNFQuinolones
Aminophylline: possibleincreasedriskofconvulsionswhenquinolonesgivenwithl AMINOPHYLLINE ;ciprofloxacinandnorfloxacinincreaseplasmaconcentrationoflAMINOPHYLLINE
Analgesics: possibleincreasedriskofconvulsionswhenquinolonesgivenwithl NSAIDS  
 TRIANGLE Antacids: absorptionofciprofloxacin,levofloxacin,moxifloxacin,norfloxacinandofloxacinreducedby ANTACIDS  
 lAnti-arrhythmics:increasedriskofventriculararrhythmiaswhenlevofloxacinormoxifloxacingivenwithlAMIODARONEâ€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl DISOPYRAMIDE â€”avoidconcomitantuselAntibacterials:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithparenterall ERYTHROMYCIN â€”avoidconcomitantuse;ciprofloxacinpossiblyincreasesplasma
 Anticoagulants:  nalidixicacid,norfloxacinandofloxacinenhanceanticoagulanteffectofl COUMARINS ;ciprofloxacinandlevofloxacinpossiblyenhanceanticoagulanteffectofCOUMARINS;levofloxacinpossiblyenhancesanticoagulanteffectof PHENINDIONE 
Antidepressants: avoidanceofmoxifloxacinadvisedbymanufacturerofl CITALOPRAM andl ESCITALOPRAM (riskofventriculararrhythmias);ciprofloxacininhibitsmetabolismofl DULOXETINE â€”avoidconcomitantuse;avoidanceofciprofloxacinadvisedbymanufacturerofl AGOMELATINE ;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl TRICYCLICS â€”avoidconcomitantuse  
 TRIANGLE Antidiabetics: norfloxacinpossiblyenhanceseffectsof GLIBENCLAMIDE  
 TRIANGLE Antiepileptics: ciprofloxacinincreasesordecreasesplasmaconcentrationof FOS PHENYTOIN  andPHENYTOIN
Antihistamines: increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: avoidanceofquinolonesadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE ;avoidanceofmoxifloxacinadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl CHLOROQUINE ,l HYDROXYCHLOROQUINE ,l MEFLOQUINE orl QUININE â€”avoidconcomitantuselAntipsychotics:  increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl BENPERIDOL â€”manufacturerofbenperidoladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl DROPERIDOL ,l HALOPERIDOL ,l PHENOTHIAZINES ,l PIMOZIDE orl ZUCLOPENTHIXOL â€”avoidconcomitantuse;ciprofloxacinincreasesplasmaconcentrationof CLOZAPINE ;ciprofloxacinpossiblyincreasesplasmaconcentrationof OLANZAPINE  
Antivirals:  manufacturerofnorfloxacinadvisesgive DIDANOSINE atleast2hoursbeforeorafternorfloxacin;increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl SAQUINAVIR â€”avoidconcomitantuse 
 TRIANGLE AnxiolyticsandHypnotics: avoidanceofciprofloxacinadvisedbymanufacturerof ZOLPIDEM 
Atomoxetine: increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl ATOMOXETINE  
 lBeta-blockers:increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl SOTALOL â€”avoidconcomitantuse 
 TRIANGLE CalciumSalts: absorptionofciprofloxacinreducedby CALCIUMSALTS 
Ciclosporin: increasedriskofnephrotoxicitywhenquinolonesgivenwithl CICLOSPORIN 
Clopidogrel: ciprofloxacinpossiblyreducesantiplateleteffectofl CLOPIDOGREL 
 TRIANGLE DairyProducts: absorptionofciprofloxacinandnorfloxacinreducedby DAIRYPRODUCTS  
 TRIANGLE Dopaminergics: ciprofloxacinincreasesplasmaconcentrationof RASAGILINE ;ciprofloxacininhibitsmetabolismof ROPINIROLE (increasedplasmaconcentration) 
 TRIANGLE 5 HT 1-receptor
 Agonists: quinolonespossiblyinhibitmetabolismof ZOLMITRIPTAN (reducedoseofzolmitriptan) 
 TRIANGLE IronSalts: absorptionofciprofloxacin,levofloxacin,moxifloxacinandofloxacinreducedbyoral IRONSALTS ;absorptionofnorfloxacinreducedbyoralIRONSALTS(giveatleast2hoursapart) 
 TRIANGLE Lanthanum: absorptionofquinolonespossiblyreducedby LANTHANUM (giveatleast2hoursbeforeor4hoursafterlanthanum)
MuscleRelaxants: ciprofloxacinincreasesplasmaconcentrationofl TIZANIDINE (increasedriskoftoxicity)â€”avoidconcomitantuse;norfloxacinpossiblyincreasesplasmaconcentrationofTIZANIDINE(increasedriskoftoxicity) 
 TRIANGLE Mycophenolate: norfloxacinpossiblyreducesbioavailabilityof MYCOPHENOLATE 
PentamidineIsetionate: increasedriskofventriculararrhythmiaswhenmoxifloxacingivenwithl PENTAMIDINEISETIONATE â€”avoidconcomitantuse
Pirfenidone: ciprofloxacinincreasesplasmaconcentrationofl PIRFENIDONE â€”seeunderPirfenidone,p260 
 TRIANGLE Sevelamer: bioavailabilityofciprofloxacinreducedby SEVELAMER  
 TRIANGLE StrontiumRanelate: absorptionofquinolonesreducedby STRONTIUMRANELATE (manufacturerofstrontiumranelateadvisesavoidconcomitantuse)
Theophylline: possibleincreasedriskofconvulsionswhenquinolonesgivenwithl THEOPHYLLINE ;ciprofloxacinandnorfloxacinincreaseplasmaconcentrationoflTHEOPHYLLINE 
 TRIANGLE Ulcer-healing
 Drugs:   absorptionofciprofloxacin,levofloxacin,moxifloxacinandofloxacinreducedby SUCRALFATE ;absorptionofnorfloxacinreducedbySUCRALFATE(giveatleast2hoursapart) 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein BNF  
 TRIANGLE Zinc: absorptionofciprofloxacin,levofloxacin,moxifloxacinandofloxacinreducedby ZINC ;absorptionofnorfloxacinreducedbyZINC(giveatleast2hoursapart)
 Rabeprazole see Proton 
 Pump 
 Inhibitors 
 Rabies 
 Vaccine see Vaccines 
Raloxifene
 TRIANGLE Lipid-regulatingDrugs:absorptionofraloxifenereducedby COLESTYRAMINE (manufacturerofraloxifeneadvisesavoidconcomitantadministration)Raltegravir 
 TRIANGLE Antacids: plasmaconcentrationofraltegravirreducedby ALUMINIUMHYDROXIDE and ORALMAGNESIUMSALTS â€”manufacturerofraltegraviradvisesavoidconcomitantuse
Antibacterials: plasmaconcentrationofraltegravirreducedbyl RIFAMPICIN â€”considerincreasingdoseofraltegravirlAntivirals:increasedriskofrashwhenraltegravirgivenwith DARUNAVIR ;avoidanceofraltegraviradvisedbymanufacturerofl FOSAMPRENAVIR 
Orlistat: absorptionofraltegravirpossiblyreducedbyl ORLISTAT  
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofraltegravirincreasedby FAMOTIDINE and OMEPRAZOLER altitrexedlAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
Folates: manufacturerofraltitrexedadvisesavoidconcomitantusewithl FOLATES
 Ramipril see 
 ACE Inhibitors
 Ranitidine see Histamine 
 H
2-antagonistsRanolazinelAnti-arrhythmics:manufacturerofranolazineadvisesavoidconcomitantusewithl DISOPYRAMIDEBNF 
 Antibacterials:  plasmaconcentrationofranolazinepossiblyincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”manufacturerofranolazineadvisesavoidconcomitantuse;plasmaconcentrationofranolazinereducedbyl RIFAMPICIN â€”manufacturerofranolazineadvisesavoidconcomitantuse  
 TRIANGLE Antidepressants: plasmaconcentrationofranolazineincreasedby PAROXETINE  
 
 
 
Antifungals:    plasmaconcentrationofranolazineincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;plasmaconcentrationofranolazinepossiblyincreasedbyl ITRACONAZOLE ,l POSACONAZOLE andl VORICONAZOLE â€”manufacturerofranolazineadvisesavoidconcomitantuselAntivirals:  plasmaconcentrationofranolazinepossiblyincreasedbyl ATAZANAVIR ,l DARUNAVIR ,l FOSAMPRENAVIR ,l INDINAVIR ,l LOPINAVIR ,l RITONAVIR ,l SAQUINAVIR andl TIPRANAVIR â€”manufacturerofranolazineadvisesavoidconcomitantuselBeta-blockers:manufacturerofranolazineadvisesavoidconcomitantusewithl SOTALOL  
 TRIANGLE Calcium-channelBlockers: plasmaconcentrationofranolazineincreasedby DILTIAZEM and VERAPAMIL (considerreducingdoseofranolazine) 
 TRIANGLE CardiacGlycosides: ranolazineincreasesplasmaconcentrationof DIGOXIN  
 TRIANGLE Ciclosporin: plasmaconcentrationofbothdrugsmayincreasewhenranolazinegivenwith CICLOSPORIN 
GrapefruitJuice: plasmaconcentrationofranolazinepossiblyincreasedbyl GRAPEFRUITJUICE â€”manufacturerofranolazineadvisesavoidconcomitantuselLipid-regulatingDrugs:  ranolazineincreasesplasmaconcentrationofl SIMVASTATIN (seeunderSimvastatin,p181);separatingadministrationfromranolazineby12hoursadvisedbymanufacturerof LOMITAPIDE 
Tacrolimus: ranolazineincreasesplasmaconcentrationofl TACROLIMUSR asagiline NOTER asagilineisa MAO -Binhibitor
 Analgesics:  avoidconcomitantuseofrasagilinewithl DEXTROMETHORPHAN ;riskof CNS toxicitywhenrasagilinegivenwithl PETHIDINE (avoidpethidinefor2weeksafterrasagiline) 
 TRIANGLE Antibacterials:plasmaconcentrationofrasagilineincreasedby CIPROFLOXACIN 
 
 
Antidepressants:   afterstoppingrasagilinedonotstartl FLUOXETINE for2weeks,alsorasagilineshouldnotbestarteduntilatleast5weeksafterstoppingfluoxetine;afterstoppingrasagilinedonotstartl FLUVOXAMINE for2weeks;riskofhypertensivecrisiswhenrasagilinegivenwithl  MAOI S ,avoidMAOIsforatleast2weeksafterstoppingrasagiline;increasedriskofCNStoxicitywhenrasagilinegivenwithl SSRIS orl  TRICYCLIC S  
 TRIANGLE Dopaminergics: plasmaconcentrationofrasagilinepossiblyreducedby ENTACAPONE  
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA 
Sympathomimetics: avoidconcomitantuseofrasagilinewithl SYMPATHOMIMETICSR eboxetine
 
Antibacterials:   manufacturerofreboxetineadvisesavoidconcomitantusewithl MACROLIDES  
 lAntidepressants:manufacturerofreboxetineadvisesavoidconcomitantusewithlFLUVOXAMINE;increasedriskofhypertensionandCNSexcitationwhenreboxetinegivenwithlMAOIS(MAOIsshouldnotbestarteduntil1weekafterstoppingreboxetine,avoidreboxetinefor2weeksafterstoppingMAOIs) 
 TRIANGLE Antiepileptics:   plasmaconcentrationofreboxetinepossiblyreducedby CARBAMAZEPINE , PHENOBARBITAL and PRIMIDONE  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE  
 TRIANGLE Diuretics: possibleincreasedriskofhypokalaemiawhenreboxetinegivenwith LOOPDIURETICS or THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE ErgotAlkaloids: possibleriskofhypertensionwhenreboxetinegivenwith ERGOTAMINER egorafenib 
 TRIANGLE Analgesics:manufacturerofregorafenibadvisesavoidconcomitantusewith MEFENAMICACID  
 lAntibacterials:plasmaconcentrationofregorafenibreducedbylRIFAMPICINâ€”manufacturerofregorafenibadvisesavoidconcomitantuselAnticoagulants:  increasedriskofbleedingwhenregorafenibgivenwithl WARFARIN  
 lAntifungals:plasmaconcentrationofregorafenibincreasedbylKETOCONAZOLEâ€”avoidconcomitantuselAntipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Cytotoxics: regorafenibincreasesplasmaconcentrationof IRINOTECAN
 Remifentanil see Opioid 
 Analgesics 
 Repaglinide see Antidiabetics 
Retigabine
 lAntidepressants:anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandlTRICYCLIC- RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbylSSRISandlTRICYCLICS(convulsivethresholdlowered) 
 TRIANGLE Antiepileptics:plasmaconcentrationofretigabinepossiblyreducedbyCARBAMAZEPINE, FOS PHENYTOIN  andPHENYTOIN 
Antimalarials:anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
Antipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered)
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTATR etinoids
Alcohol: etretinateformedfromacitretininpresenceoflALCOHOL(increasedriskofteratogenicityinwomenofchild-bearingpotential)lAntibacterials:possibleincreasedriskofbenignintracranialhypertensionwhenretinoidsgivenwithl TETRACYCLINES (avoidconcomitantuse)lAnticoagulants:acitretinpossiblyreducesanticoagulanteffectofl COUMARINS  
 TRIANGLE Antiepileptics:isotretinoinpossiblyreducesplasmaconcentrationofCARBAMAZEPINE 
 lAntifungals:plasmaconcentrationofalitretinoinincreasedbyKETOCONAZOLE;possibleincreasedriskoftretinointoxicitywhengivenwithl FLUCONAZOLE ,lKETOCONAZOLEandlVORICONAZOLE
Cytotoxics: acitretinincreasesplasmaconcentrationofl METHOTREXATE (alsoincreasedriskofhepatotoxicity)â€”avoidconcomitantuse 
 TRIANGLE Lipid-regulatingDrugs:alitretinoinreducesplasmaconcentrationofSIMVASTATIN
Vitamins: riskofhypervitaminosisAwhenretinoidsgivenwithl VITAMINA â€”avoidconcomitantuseRibavirinlAntivirals:effectsofribavirinpossiblyreducedbyl ABACAVIR ;increasedriskofside-effectswhenribaviringivenwithl DIDANOSINE â€”avoidconcomitantuse;increasedriskoftoxicitywhenribaviringivenwithl STAVUDINE ;increasedriskofanaemiawhenribaviringivenwithl ZIDOVUDINE â€”avoidconcomitantuse
Azathioprine: ribavirinpossiblyenhancesmyelosuppressiveeffectsofl AZATHIOPRINE 
 Rifabutin see Rifamycins 
 Rifampicin see Rifamycins 
 Rifamycins
 NOTEI nteractionsdonotapplytorifaximin  
 TRIANGLE   ACE Inhibitors:rifampicinreducesplasmaconcentrationofactivemetaboliteof IMIDAPRIL (reducedantihypertensiveeffect) 
 TRIANGLE Aliskiren: rifampicinreducesplasmaconcentrationof ALISKIREN  
 TRIANGLE Ambrisentan: rifampicinpossiblyincreasesplasmaconcentrationof AMBRISENTAN  
 TRIANGLE Aminophylline: rifampicinacceleratesmetabolismof AMINOPHYLLINE (reducedplasmaconcentration) 
 TRIANGLE Analgesics: rifampicinreducesplasmaconcentrationof CELECOXIB , DICLOFENAC and ETORICOXIB ;rifampicinacceleratesmetabolismof ALFENTANIL , CODEINE , FENTANYL , METHADONE and MORPHINE (reducedeffect);rifampicinpossiblyacceleratesmetabolismof OXYCODONE  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: rifampicinreducesplasmaconcentrationof LOSARTAN anditsactivemetabolite 
 TRIANGLE Antacids: absorptionofrifampicinreducedby ANTACIDS 
Anthelmintics: rifampicinreducesplasmaconcentrationofl PRAZIQUANTEL â€”avoidconcomitantuselAnti-arrhythmics:rifamycinsacceleratemetabolismofl DISOPYRAMIDE (reducedplasmaconcentration);rifampicinreducesplasmaconcentrationofl DRONEDARONE â€”avoidconcomitantuse;rifampicinacceleratesmetabolismofl PROPAFENONE (reducedeffect)
Antibacterials: increasedriskofside-effectsincludingneutropeniawhenrifabutingivenwithl AZITHROMYCIN ;rifamycinsreduceplasmaconcentrationof CLARITHROMYCIN and DAPSONE ;plasmaconcentrationofrifabutinincreasedbylCLARITHROMYCIN(increasedriskoftoxicityâ€”reducerifabutindose);plasmaconcentrationofrifabutinpossiblyincreasedbyl ERYTHROMYCIN (increasedriskoftoxicityâ€”reducerifabutindose);rifampicinpossiblyreducesplasmaconcentrationof TINIDAZOLE and TRIMETHOPRIM ;rifampicinreducesplasmaconcentrationof DOXYCYCLINE â€”considerincreasingdoseofdoxycycline;rifabutinpossiblyreducesplasmaconcentrationof BEDAQUILINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflBEDAQUILINEâ€”manufacturerofbedaquilineadvisesavoidconcomitantuse;rifampicinacceleratesmetabolismof CHLORAMPHENICOL (reducedplasmaconcentration);rifampicinreducesplasmaconcentrationofl DELAMANID ;increasedriskofhepatotoxicitywhenrifampicingivenwithl ISONIAZID ;rifampicinreducesplasmaconcentrationof LINEZOLID (possibletherapeuticfailureoflinezolid);rifampicinreducesplasmaconcentrationofl TELITHROMYCIN (avoidduringandfor2weeksafterrifampicin)
Anticoagulants: rifampicinpossiblyreducesplasmaconcentrationofl APIXABAN â€”manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;rifamycinsacceleratemetabolismofl COUMARINS (reducedanticoagulanteffect);rifampicinreducesplasmaconcentrationofl DABIGATRAN â€”manufacturerofdabigatranadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationofl RIVAROXABAN â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Antidiabetics: rifamycinsacceleratemetabolismofl TOLBUTAMIDE (reducedeffect);rifampicinreducesplasmaconcentrationofl CANAGLIFLOZIN and NATEGLINIDE ;rifampicinpossiblyreduceseffectsof LINAGLIPTIN ;rifampicinpossiblyantagoniseshypoglycaemiceffectof REPAGLINIDE ;rifamycinspossiblyacceleratemetabolismofl SULFONYLUREAS (reducedeffect)
Antifungals: rifampicinacceleratesmetabolismofl KETOCONAZOLE (reducedplasmaconcentration),alsoplasmaconcentrationofrifampicinmaybereducedbyketoconazole;plasmaconcentrationofrifabutinincreasedbyl FLUCONAZOLE (increasedriskofuveitisâ€”reducerifabutindose);rifampicinacceleratesmetabolismoflFLUCONAZOLE(reducedplasmaconcentration);rifabutinandrifampicinreduceplasmaconcentrationofl ITRACONAZOLE â€”manufacturerofitraconazoleadvisesavoidconcomitantuse;plasmaconcentrationofrifabutinincreasedbyl POSACONAZOLE (alsoplasmaconcentrationofposaconazolereduced);rifampicinreducesplasmaconcentrationoflPOSACONAZOLEandl TERBINAFINE ;plasmaconcentrationofrifabutinincreasedbyl VORICONAZOLE ,alsorifabutinreducesplasmaconcentrationofvoriconazole(increasedoseofvoriconazoleandalsomonitorforrifabutintoxicity);rifampicinreducesplasmaconcentrationoflVORICONAZOLEâ€”avoidconcomitantuse;rifampicininitiallyincreasesandthenreducesplasmaconcentrationof CASPOFUNGIN (considerincreasingdoseofcaspofungin);plasmaconcentrationofrifabutinpossiblyincreasedbyl TRIAZOLES (increasedriskofuveitisâ€”reducerifabutindose) 
 TRIANGLE Antihistamines: rifampicinpossiblyreduceseffectsof FEXOFENADINE 
Antimalarials: avoidanceofrifampicinadvisedbymanufacturerof ARTENIMOLWITHPIPERAQUINE ;rifampicinreducesplasmaconcentrationofl MEFLOQUINE â€”avoidconcomitantuse;rifampicinreducesplasmaconcentrationofl QUININE  
 TRIANGLE Antimuscarinics: rifampicinreducesplasmaconcentrationofactivemetaboliteof FESOTERODINE 
Antipsychotics: rifampicinacceleratesmetabolismofl HALOPERIDOL (reducedplasmaconcentration);rifabutinandrifampicinpossiblyreduceplasmaconcentrationofl ARIPIPRAZOLE (avoidconcomitantuseorconsiderincreasingthedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);rifampicinpossiblyreducesplasmaconcentrationof CLOZAPINE ;rifampicinreducesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse
Antivirals: rifampicinpossiblyreducesplasmaconcentrationof ABACAVIR ;plasmaconcentrationofrifabutinincreasedbyl ATAZANAVIR ,l DARUNAVIR ,l FOSAMPRENAVIR andl TIPRANAVIR (reducedoseofrifabutin);rifampicinreducesplasmaconcentrationoflATAZANAVIR,l DACLATASVIR ,l LOPINAVIR ,l NEVIRAPINE andl RILPIVIRINE â€”avoidconcomitantuse;avoidanceofrifampicinadvisedbymanufacturerofl BOCEPREVIR (plasmaconcentrationofboceprevirpossiblyreduced);rifabutinpossiblyreducesplasmaconcentrationoflDACLATASVIRand SIMEPREVIR â€”manufacturerofdaclatasvirandsimepreviradvisesavoidconcomitantuse;rifampicinsignificantlyreducesplasmaconcentrationoflDARUNAVIR,lFOSAMPRENAVIRandl TELAPREVIR â€”avoidconcomitantuse;rifampicinreducestheplasmaconcentrationofl DOLUTEGRAVIR (seeunderDolutegravir,p557);rifampicinreducesplasmaconcentrationof EFAVIRENZ â€”increasedoseofefavirenz;plasmaconcentrationofrifabutinreducedbyEFAVIRENZâ€”increasedoseofrifabutin;avoidanceofrifampicinadvisedbymanufacturerofl ELVITEGRAVIR , ETRAVIRINE , SOFOSBUVIR and ZIDOVUDINE ;rifabutinreducesplasmaconcentrationoflELVITEGRAVIRalsoplasmaconcentrationofactivemetaboliteofrifabutinincreasedâ€”reducedoseofrifabutin;plasmaconcentrationofbothdrugsreducedwhenrifabutingivenwithlETRAVIRINE;rifampicinacceleratesmetabolismofl INDINAVIR (reducedplasmaconcentrationâ€”avoidconcomitantuse);plasmaconcentrationofrifabutinincreasedbylINDINAVIR,alsoplasmaconcentrationofindinavirdecreased(reducedoseofrifabutinandincreasedoseofindinavir);rifampicinreducesplasmaconcentrationofl MARAVIROC andl RALTEGRAVIR â€”considerincreasingdoseofmaravirocandraltegravir;plasmaconcentrationofrifabutinpossiblyincreasedbyNEVIRAPINE;rifabutindecreasesplasmaconcentrationoflRILPIVIRINE(increasedoseofrilpivirineâ€”consultrilpivirineproductliterature); BNF 
 TRIANGLE AnxiolyticsandHypnotics: rifampicinacceleratesmetabolismof DIAZEPAM and ZALEPLON (reducedplasmaconcentration);rifampicinpossiblyacceleratesmetabolismof BENZODIAZEPINES (reducedplasmaconcentration);rifampicinpossiblyacceleratesmetabolismof BUSPIRONE ;rifampicinacceleratesmetabolismof ZOLPIDEM (reducedplasmaconcentrationandreducedeffect);rifampicinsignificantlyreducesplasmaconcentrationof ZOPICLONE  
 TRIANGLE Aprepitant: rifampicinreducesplasmaconcentrationof APREPITANT 
Atovaquone: avoidanceofconcomitantrifabutinadvisedbymanufacturerof ATOVAQUONE (plasmaconcentrationofbothdrugsreduced);rifampicinreducesplasmaconcentrationoflATOVAQUONE(andconcentrationofrifampicinincreased)â€”avoidconcomitantuse 
 TRIANGLE Avanafil: rifampicinpossiblyreducesplasmaconcentrationof AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuse 
 TRIANGLE Beta-blockers:rifampicinacceleratesmetabolismof BISOPROLOL and PROPRANOLOL (plasmaconcentrationsignificantlyreduced);rifampicinreducesplasmaconcentrationof CARVEDILOL , CELIPROLOL and METOPROLOL ;rifampicinpossiblyreducesplasmaconcentrationoforal TIMOLOL 
Bosentan: rifampicinreducesplasmaconcentrationofl BOSENTAN â€”avoidconcomitantuselCalcium-channelBlockers: rifampicinpossiblyreducesplasmaconcentrationof FELODIPINE ;rifampicinpossiblyacceleratesmetabolismofl ISRADIPINE andl NICARDIPINE (possiblesignificantlyreducedplasmaconcentration);rifampicinacceleratesmetabolismofl DILTIAZEM ,l NIFEDIPINE ,l NIMODIPINE andl VERAPAMIL (plasmaconcentrationsignificantlyreduced)
CannabisExtract: rifampicinreducesplasmaconcentrationofl CANNABISEXTRACT â€”manufacturerofcannabisextractadvisesavoidconcomitantuse 
 TRIANGLE CardiacGlycosides: rifampicinpossiblyreducesplasmaconcentrationof DIGOXIN 
Ciclosporin: rifampicinacceleratesmetabolismofl CICLOSPORIN (reducedplasmaconcentration)
Cobicistat: rifabutinreducesplasmaconcentrationofl COBICISTAT (adjustdoseâ€”consultproductliterature);rifampicinpossiblyreducesplasmaconcentrationoflCOBICISTATâ€”manufacturerofcobicistatadvisesavoidconcomitantuse
Corticosteroids: rifamycinsacceleratemetabolismofl CORTICOSTEROIDS (reducedeffect)
 TRIANGLE Deferasirox: rifampicinreducesplasmaconcentrationof DEFERASIROX 
Diuretics: rifampicinreducesplasmaconcentrationofl EPLERENONE â€”avoidconcomitantuse 
 TRIANGLE Fosaprepitant: rifampicinreducesplasmaconcentrationof FOSAPREPITANT  lHormone
 Antagonists:  rifabutinpossiblyreducesplasmaconcentrationofl ABIRATERONE â€”manufacturerofabirateroneadvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflABIRATERONEâ€”manufacturerofabirateroneadvisesavoidconcomitantuse;avoidanceofrifampicinadvisedbymanufacturerof ENZALUTAMIDE ;rifampicinpossiblyreducesplasmaconcentrationof EXEMESTANE ;rifampicinacceleratesmetabolismof TAMOXIFEN (reducedplasmaconcentration) 
 TRIANGLE 5 HT 3-receptorAntagonists:rifampicinacceleratesmetabolismof ONDANSETRON (reducedeffect)
Ivacaftor: rifabutinpossiblyreducesplasmaconcentrationofl IVACAFTOR â€”manufacturerofivacaftoradvisesavoidconcomitantuse;rifampicinreducesplasmaconcentrationoflIVACAFTORâ€”manufacturerofivacaftoradvisesavoidconcomitantuse 
 TRIANGLE Leflunomide: rifampicinpossiblyincreasesplasmaconcentrationofactivemetaboliteof LEFLUNOMIDE  
 TRIANGLE Lipid-regulating
 Drugs: rifampicinpossiblyreducesplasmaconcentrationof ATORVASTATIN and SIMVASTATIN ;rifampicinacceleratesmetabolismof FLUVASTATIN (reducedeffect)
Macitentan: rifampicinreducesplasmaconcentrationofl MACITENTAN â€”avoidconcomitantuse 
 TRIANGLE MuscleRelaxants: rifampicinpossiblyreducesplasmaconcentrationof TIZANIDINE 
Mycophenolate: rifampicinreducesplasmaconcentrationofactivemetaboliteofl MYCOPHENOLATE 
Nintedanib: rifampicinreducesplasmaconcentrationofl NINTEDANIB â€”avoidconcomitantuse
Oestrogens: rifamycinsacceleratemetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Progestogens: rifamycinsacceleratemetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF)
Ranolazine: rifampicinreducesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse
Roflumilast: rifampicininhibitseffectsofl ROFLUMILAST (manufacturerofroflumilastadvisesavoidconcomitantuse)
Sirolimus: rifabutinandrifampicinreduceplasmaconcentrationoflSIROLIMUSâ€”avoidconcomitantuse
Tacrolimus: rifabutinpossiblyreducesplasmaconcentrationof TACROLIMUS ;rifampicinreducesplasmaconcentrationoflTACROLIMUS 
Tadalafil:  rifampicinreducesplasmaconcentrationofl TADALAFIL â€”manufactureroftadalafiladvisesavoidconcomitantuse  
 TRIANGLE Teriflunomide: rifampicinreducesplasmaconcentrationof TERIFLUNOMIDE  
 TRIANGLE Theophylline: rifampicinacceleratesmetabolismof THEOPHYLLINE (reducedplasmaconcentration) 
 TRIANGLE ThyroidHormones: rifampicinacceleratesmetabolismof LEVOTHYROXINE (mayincreaserequirementsforlevothyroxineinhypothyroidism) 
 TRIANGLE Tibolone: rifampicinacceleratesmetabolismof TIBOLONE (reducedplasmaconcentration)
Ticagrelor: rifampicinreducesplasmaconcentrationofl TICAGRELOR  
 TRIANGLE Tolvaptan: rifampicinreducesplasmaconcentrationof TOLVAPTAN  
 TRIANGLE Ulcer-healingDrugs:  rifampicinacceleratesmetabolismof CIMETIDINE (reducedplasmaconcentration)
Ulipristal: avoidanceofrifampicinadvisedbymanufacturerofl ULIPRISTAL (contraceptiveeffectofulipristalpossiblyreduced) 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF R ilpivirine 
 TRIANGLE Analgesics: rilpivirinepossiblyreducesplasmaconcentrationof METHADONE  
 TRIANGLE Antacids:  manufacturerofrilpivirineadvisesgive ANTACIDS 2hoursbeforeor4hoursafterrilpivirinelAntibacterials:  manufacturerofrilpivirineadvisesavoidconcomitantusewithl CLARITHROMYCIN andl ERYTHROMYCIN (plasmaconcentrationofrilpivirinepossiblyincreased);plasmaconcentrationofrilpivirinedecreasedbyl RIFABUTIN (increasedoseofrilpivirineâ€”consultrilpivirineproductliterature);plasmaconcentrationofrilpivirinereducedbyl RIFAMPICIN â€”avoidconcomitantuse 
 TRIANGLE Anticoagulants: rilpivirinepossiblyincreasesplasmaconcentrationof DABIGATRAN  
Antidepressants:  manufacturerofrilpivirineadvisesavoidconcomitantusewithl STJOHN â€™ SWORT (plasmaconcentrationofrilpivirinepossiblyreduced)lAntiepileptics:  manufacturerofrilpivirineadvisesavoidconcomitantusewithl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l OXCARBAZEPINE ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE (plasmaconcentrationofrilpivirinepossiblyreduced) 
 TRIANGLE Antivirals:  manufacturerofrilpivirineadvisesgive DIDANOSINE 2hoursbeforeor4hoursafterrilpivirine;avoidanceofrilpivirineadvisedbymanufacturerof NEVIRAPINE  
 TRIANGLE CalciumSalts: manufacturerofrilpivirineadvisesgive CALCIUMSALTS 2hoursbeforeor4hoursafterrilpivirine
Corticosteroids: manufacturerofrilpivirineadvisesavoidconcomitantusewithl DEXAMETHASONE (exceptwhengivenasasingledose)
Orlistat: absorptionofrilpivirinepossiblyreducedbyl ORLISTAT  
 lUlcer-healingDrugs:manufacturerofrilpivirineadvisesavoidconcomitantusewith ES OMEPRAZOLE  , LANSOPRAZOLE , PANTOPRAZOLE and RABEPRAZOLE (plasmaconcentrationofrilpivirinepossiblyreduced);plasmaconcentrationofrilpivirinereducedbylOMEPRAZOLEâ€”avoidconcomitantuse;manufacturerofrilpivirineadvisesavoid HISTAMINEH 2- ANTAGONISTS for12hoursbeforeor4hoursafterrilpivirineâ€”consultproductliterature
Riociguat 
 TRIANGLE Antacids:absorptionofriociguatreducedbyANTACIDS(giveatleast2hoursbeforeor1hourafterriociguat) 
 TRIANGLE Antifungals: manufacturerofriociguatadvisesavoidconcomitantusewith ITRACONAZOLE , KETOCONAZOLE and VORICONAZOLE  
Avanafil: possibleenhancedhypotensiveeffectwhenriociguatgivenwithl AVANAFIL â€”avoidconcomitantuse 
 TRIANGLE Bosentan: plasmaconcentrationofriociguatreducedby BOSENTAN 
Nitrates: possibleenhancedhypotensiveeffectwhenriociguatgivenwithl NITRATES â€”avoidconcomitantuse
Sildenafil: enhancedhypotensiveeffectwhenriociguatgivenwithl SILDENAFIL â€”avoidconcomitantuselTadalafil:possibleenhancedhypotensiveeffectwhenriociguatgivenwithlTADALAFILâ€”avoidconcomitantuse
Vardenafil: possibleenhancedhypotensiveeffectwhenriociguatgivenwithl VARDENAFIL â€”avoidconcomitantuseRisedronate
 Sodium see Bisphosphonates 
 Risperidone see Antipsychotics 
 Ritonavirl 
 Alpha-blockers
:ritonavirpossiblyincreasesplasmaconcentrationofl ALFUZOSIN â€”avoidconcomitantuse
Aminophylline: ritonaviracceleratesmetabolismofl AMINOPHYLLINE (reducedplasmaconcentration)
Analgesics: ritonavirpossiblyincreasesplasmaconcentrationof NSAIDS and BUPRENORPHINE ;ritonavirincreasesplasmaconcentrationofl DEXTROPROPOXYPHENE andl PIROXICAM (riskoftoxicity)â€”avoidconcomitantuse;ritonavirincreasesplasmaconcentrationofl ALFENTANIL andl FENTANYL ;ritonavirreducesplasmaconcentrationofMETHADONE;ritonavirpossiblyreducesplasmaconcentrationof MORPHINE ;ritonavirreducesplasmaconcentrationofl PETHIDINE ,butincreasesplasmaconcentrationoftoxicmetaboliteofpethidine(avoidconcomitantuse)
Anthelmintics: ritonavirpossiblyreducesplasmaconcentrationofactivemetaboliteofl ALBENDAZOLE â€”considerincreasingalbendazoledosewhengivenforsystemicinfectionslAnti-arrhythmics:ritonavirincreasesplasmaconcentrationofl AMIODARONE andl PROPAFENONE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);ritonavirpossiblyincreasesplasmaconcentrationofl DISOPYRAMIDE (increasedriskoftoxicity);avoidanceofritonaviradvisedbymanufacturerofl DRONEDARONE ;ritonavirpossiblyincreasesplasmaconcentrationofl FLECAINIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse)lAntibacterials:ritonavirpossiblyincreasesplasmaconcentrationof AZITHROMYCIN andERYTHROMYCIN;ritonavirincreasesplasmaconcentrationoflCLARITHROMYCIN(reducedoseofclarithromycininrenalimpairment);ritonavirincreasesplasmaconcentrationoflRIFABUTIN(increasedriskoftoxicityâ€”reducerifabutindose);plasmaconcentrationofritonavirreducedbyRIFAMPICIN;ritonavirpossiblyincreasesplasmaconcentrationof BEDAQUILINE â€”avoidconcomitantuseifritonavirgivenformorethan14days;ritonavirincreasesplasmaconcentrationof DELAMANID ;plasmaconcentrationofbothdrugsincreasedwhenritonavirgivenwithl FUSIDICACID â€”avoidconcomitantuse;avoidanceofconcomitantritonavirinsevererenalandhepaticimpairmentadvisedbymanufacturerofl TELITHROMYCIN 
Anticoagulants: ritonavirmayenhanceorreduceanticoagulanteffectofl WARFARIN ;avoidanceofritonaviradvisedbymanufacturerof APIXABAN ;ritonavirpossiblyenhancesanticoagulanteffectofl COUMARINS andl PHENINDIONE ;ritonavirincreasesplasmaconcentrationofl RIVAROXABAN â€”avoidconcomitantuselAntidepressants:ritonavirpossiblyreducesplasmaconcentrationof PAROXETINE ;ritonavirincreasesplasmaconcentrationofl TRAZODONE (increasedriskoftoxicity);ritonavirpossiblyincreasesplasmaconcentrationofl SSRIS andl TRICYCLICS ;plasmaconcentrationofritonavirreducedbylSTJOHNâ€™SWORTâ€”avoidconcomitantuse 
 TRIANGLE Antidiabetics: ritonavirpossiblyincreasesplasmaconcentrationof TOLBUTAMIDE  
Antiepileptics:ritonavirpossiblyincreasesplasmaconcentrationoflCARBAMAZEPINE;plasmaconcentrationofritonavirpossiblyreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyaffected;ritonavirpossiblyreducesplasmaBNF
Antifungals: ritonavirincreasesplasmaconcentrationofl KETOCONAZOLE (reducedoseofketoconazole);plasmaconcentrationofritonavirincreasedby FLUCONAZOLE ;combinationofritonavirwithl ITRACONAZOLE mayincreaseplasmaconcentrationofeitherdrug(orboth);ritonavirreducesplasmaconcentrationofl VORICONAZOLE â€”avoidconcomitantuse  
 TRIANGLE Antihistamines: ritonavirpossiblyincreasesplasmaconcentrationof NON - SEDATINGANTIHISTAMINES 
Antimalarials: cautionwithritonaviradvisedbymanufacturerof ARTEMETHERWITHLUMEFANTRINE ;plasmaconcentrationofritonavirpossiblyreducedby MEFLOQUINE ;ritonavirincreasesplasmaconcentrationofl QUININE (increasedriskoftoxicity)
Antimuscarinics: avoidanceofritonaviradvisedbymanufacturerof DARIFENACIN and TOLTERODINE ;manufactureroffesoterodineadvisesdosereductionwhenritonavirgivenwith FESOTERODINE â€”consultfesoterodineproductliterature;ritonavirpossiblyincreasesplasmaconcentrationofl SOLIFENACIN â€”seeunderSolifenacin,p670
Antipsychotics: ritonavirpossiblyincreasesplasmaconcentrationofl ANTIPSYCHOTICS ;ritonavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);manufacturerofritonaviradvisesavoidconcomitantusewithl CLOZAPINE (increasedriskoftoxicity);ritonavirpossiblyincreasesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;ritonavirreducesplasmaconcentrationof OLANZAPINE â€”considerincreasingdoseofolanzapine;ritonavirincreasesplasmaconcentrationofl PIMOZIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);ritonavirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse
Antivirals: plasmaconcentrationofbothdrugsreducedwhenritonavirgivenwithl BOCEPREVIR ;manufacturerofritonaviradvisesritonavirand DIDANOSINE shouldbetaken25hoursapart;ritonavirincreasesthetoxicityofl EFAVIRENZ ,monitorliverfunctiontestsâ€”manufacturerofAtriplaÂ®advisesavoidconcomitantusewithhigh-doseritonavir;ritonavirincreasesplasmaconcentrationof INDINAVIR , MARAVIROC andl SAQUINAVIR ;ritonavirincreasesplasmaconcentrationofl SIMEPREVIR â€”manufacturerofsimepreviradvisesavoidconcomitantuse;ritonavirpossiblyreducesplasmaconcentrationof TELAPREVIR 
AnxiolyticsandHypnotics: ritonavirpossiblyincreasesplasmaconcentrationofl ANXIOLYTICSANDHYPNOTICS ;ritonavirpossiblyincreasesplasmaconcentrationofl ALPRAZOLAM ,l DIAZEPAM ,l FLURAZEPAM andl ZOLPIDEM (riskofextremesedationandrespiratorydepressionâ€”avoidconcomitantuse);ritonavirpossiblyincreasesplasmaconcentrationofl MIDAZOLAM (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam);ritonavirincreasesplasmaconcentrationof BUSPIRONE (increasedriskoftoxicity) 
 TRIANGLE Aprepitant: ritonavirpossiblyincreasesplasmaconcentrationof APREPITANT  
 TRIANGLE Atovaquone: ritonavirpossiblyreducesplasmaconcentrationof ATOVAQUONE â€”manufacturerofatovaquoneadvisesavoidconcomitantuse
Avanafil: ritonavirsignificantlyincreasesplasmaconcentrationofl AVANAFIL â€”avoidconcomitantuse
Bosentan: ritonavirincreasesplasmaconcentrationofl BOSENTAN (considerreducingdoseofbosentan) 
 TRIANGLE Bupropion: ritonavirreducesplasmaconcentrationof BUPROPION  
 lCalcium-channelBlockers: ritonavirpossiblyincreasesplasmaconcentrationofl CALCIUM - CHANNELBLOCKERS ;avoidanceofritonaviradvisedbymanufacturerof LERCANIDIPINE  
 TRIANGLE CardiacGlycosides: ritonavirpossiblyincreasesplasmaconcentrationof DIGOXIN 
Cilostazol: ritonavirpossiblyincreasesplasmaconcentrationofl CILOSTAZOL (seeunderCilostazol,p206)
Colchicine: ritonavirpossiblyincreasesriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)
Corticosteroids: ritonavirpossiblyincreasesplasmaconcentrationofl CORTICOSTEROIDS â€”increasedriskofadrenalsupression;ritonavirpossiblyincreasesplasmaconcentrationofl BUDESONIDE (includinginhaled,intranasal,andrectalbudesonide)â€”increasedriskofadrenalsuppresion;ritonavirincreasesplasmaconcentrationofinhaledandintranasall FLUTICASONE â€”increasedriskofadrenalsuppression
Cytotoxics: ritonavirincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationofritonavirby6to12hours;ritonavirpossiblyincreasesplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consultaxitinibproductliterature);ritonavirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB andl CABAZITAXEL â€”manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;ritonavirpossiblyincreasesplasmaconcentrationof CABOZANTINIB and VINBLASTINE ;ritonavirpossiblyincreasesplasmaconcentrationofl CRIZOTINIB ,l EVEROLIMUS , NILOTINIB andl VINFLUNINE â€”manufacturerofcrizotinib,everolimus,nilotinibandvinflunineadvisesavoidconcomitantuse;avoidanceofritonaviradvisedbymanufacturerof DASATINIB (plasmaconcentrationofdasatinibpossiblyincreased);ritonavirpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofritonaviradvisedbymanufacturerofl LAPATINIB ;ritonavirpossiblyincreasesplasmaconcentrationofl PAZOPANIB (reducedoseofpazopanib);ritonavirpossiblyincreasesplasmaconcentrationof PONATINIB â€”considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhenritonavirgivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature;ritonavirpossiblyincreasesplasmaconcentrationofl DOCETAXEL â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose;ritonavirincreasesplasmaconcentrationof PACLITAXEL 
Dapoxetine: avoidanceofritonaviradvisedbymanufacturerofl DAPOXETINE (increasedriskoftoxicity)
Diuretics: ritonavirincreasesplasmaconcentrationofl EPLERENONE â€”avoidconcomitantuse
Domperidone: possibleincreasedriskofventriculararrhythmiaswhenritonavirgivenwithl DOMPERIDONE â€”avoidconcomitantuse
ErgotAlkaloids: increasedriskofergotismwhenritonavirgivenwithl ERGOMETRINE orl ERGOTAMINE â€”avoidconcomitantuse 
 TRIANGLE Fosaprepitant: ritonavirpossiblyincreasesplasmaconcentrationof FOSAPREPITANT l5 HT 1-receptor
 Agonists: ritonavirincreasesplasmaconcentrationofl ELETRIPTAN (riskoftoxicity)â€”avoidconcomitantuse
Ivabradine: ritonavirpossiblyincreasesplasmaconcentrationofl IVABRADINE â€”avoidconcomitantuselLipid-regulating
 Drugs: possibleincreasedriskofmyopathywhenritonavirgivenwith ATORVASTATIN ;possibleincreasedriskofmyopathywhenritonavirgivenwithl ROSUVASTATIN â€”manufacturerofrosuvastatinadvisesavoidconcomitantuse;increasedriskofmyopathywhenritonavirgivenwithl SIMVASTATIN (avoidconcomitantuse);avoidanceofritonaviradvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased) 
 TRIANGLE Mirabegron: whengivenwithritonaviravoidorreducedoseof MIRABEGRON inhepaticorrenalimpairmentâ€”seeMirabegron,p671
Oestrogens: ritonaviracceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )
Ranolazine: ritonavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse  
 TRIANGLE Riociguat: avoidanceofritonaviradvisedbymanufacturerof RIOCIGUAT 
Sildenafil: ritonavirsignificantlyincreasesplasmaconcentrationofl SILDENAFIL â€”avoidconcomitantuse 
 TRIANGLE Sympathomimetics: ritonavirpossiblyincreasesplasmaconcentrationof DEXAMFETAMINE  
 TRIANGLE Sympathomimetics,Beta2:manufacturerofritonaviradvisesavoidconcomitantusewith SALMETEROL 
Tacrolimus: ritonavirpossiblyincreasesplasmaconcentrationofl TACROLIMUS 
Tadalafil: ritonavirincreasesplasmaconcentrationofl TADALAFIL â€”manufactureroftadalafiladvisesavoidconcomitantuse
 Theophylline:  ritonaviracceleratesmetabolismofl THEOPHYLLINE (reducedplasmaconcentration)
Ticagrelor: ritonavirpossiblyincreasesplasmaconcentrationofl TICAGRELOR â€”manufacturerofticagreloradvisesavoidconcomitantuse
Ulipristal: avoidanceofritonaviradvisedbymanufacturerofl ULIPRISTAL (contraceptiveeffectofulipristalpossiblyreduced)
Vardenafil: ritonavirincreasesplasmaconcentrationofl VARDENAFIL â€”avoidconcomitantuseRituximab
 
Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuseRivaroxaban
Analgesics: increasedriskofhaemorrhagewhenanticoagulantsgivenwithintravenousl DICLOFENAC (avoidconcomitantuse,includinglow-doseheparins);increasedriskofhaemorrhagewhenanticoagulantsgivenwithl KETOROLAC (avoidconcomitantuse,includinglow-doseheparins) 
 TRIANGLE Anti-arrhythmics:manufacturerofrivaroxabanadvisesavoidconcomitantusewith DRONEDARONE  
 Antibacterials:   plasmaconcentrationofrivaroxabanreducedbyl RIFAMPICIN â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Anticoagulants: increasedriskofhaemorrhagewhenrivaroxabangivenwithotherl  ANTI COAGULANTS (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency);increasedriskofhaemorrhagewhenotheranticoagulantsgivenwithl APIXABAN andl DABIGATRAN (avoidconcomitantuseexceptwhenswitchingwithotheranticoagulantsorusingheparintomaintaincatheterpatency)
 
Antidepressants:   plasmaconcentrationofrivaroxabanpossiblyreducedbyl STJOHN â€™ SWORT â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Antiepileptics:   plasmaconcentrationofrivaroxabanpossiblyreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Antifungals: plasmaconcentrationofrivaroxabanincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;manufacturerofrivaroxabanadvisesavoidconcomitantusewith ITRACONAZOLE , POSACONAZOLE and VORICONAZOLE 
Antivirals: manufacturerofrivaroxabanadvisesavoidconcomitantusewith ATAZANAVIR , DARUNAVIR , FOSAMPRENAVIR , INDINAVIR , SAQUINAVIR and TIPRANAVIR ;manufacturersadviseavoidconcomitantuseofrivaroxabanwith LOPINAVIR ;plasmaconcentrationofrivaroxabanincreasedbyl RITONAVIR â€”avoidconcomitantuse
Cobicistat: anticoagulanteffectofrivaroxabanpossiblyenhancedbyl COBICISTAT â€”avoidconcomitantuse
 Rivastigmine see Parasympathomimetics 
 Rizatriptan see 
5 HT 1-receptorAgonists(underHT)
 Rocuronium see Muscle 
 Relaxants 
Roflumilast
Antibacterials:effectsofroflumilastinhibitedbylRIFAMPICIN(manufacturerofroflumilastadvisesavoidconcomitantuse) 
 TRIANGLE Antidepressants:metabolismofroflumilastinhibitedby FLUVOXAMINE  
 TRIANGLE Antiepileptics:effectsofroflumilastpossiblyinhibitedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE(manufacturerofroflumilastadvisesavoidconcomitantuse) 
 TRIANGLE Theophylline:manufacturerofroflumilastadvisesavoidconcomitantusewithTHEOPHYLLINE 
 TRIANGLE Ulcer-healing
 Drugs: metabolismofroflumilastinhibitedby CIMETIDINER opinirole 
 TRIANGLE Antibacterials:metabolismofropiniroleinhibitedby CIPROFLOXACIN (increasedplasmaconcentration) 
 TRIANGLE Antipsychotics:manufacturerofropiniroleadvisesavoidconcomitantuseof ANTIPSYCHOTICS (antagonismofeffect) 
 TRIANGLE Memantine:  effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa:  antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA  
 TRIANGLE Metoclopramide:  manufacturerofropiniroleadvisesavoidconcomitantuseof METOCLOPRAMIDE (antagonismofeffect) 
 TRIANGLE Oestrogens: plasmaconcentrationofropiniroleincreasedby  OESTROGENS R opivacaine 
 TRIANGLE Anti-arrhythmics:increasedmyocardialdepressionwhenropivacainegivenwithANTI- ARRHYTHMICS  
 TRIANGLE Antidepressants:metabolismofropivacaineinhibitedbyFLUVOXAMINEâ€”avoidprolongedadministrationofropivacaine
 Rosuvastatin see Statins 
 Rotavirus 
 Vaccine see Vaccines 
Rotigotine
 TRIANGLE Memantine:effectsofdopaminergicspossiblyenhancedbyMEMANTINE 
 TRIANGLE Methyldopa:antiparkinsonianeffectofdopaminergicsantagonisedbyMETHYLDOPA 
 TRIANGLE Metoclopramide:manufacturerofrotigotineadvisesavoidconcomitantuseofMETOCLOPRAMIDE(antagonismofeffect)Rufinamide
 lAntidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered) 
 TRIANGLE Antiepileptics:plasmaconcentrationofbothdrugspossiblyreducedwhenrufinamidegivenwithCARBAMAZEPINE;plasmaconcentrationofrufinamidepossiblyreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationofrufinamidepossiblyreducedbyPHENOBARBITALandPRIMIDONE;plasmaconcentrationofrufinamidepossiblyincreasedby SODIUMVALPROATE and VALPROICACID (reducedoseofrufinamide)
Antimalarials: anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  lAntipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbylANTIPSYCHOTICS(convulsivethresholdlowered)
Oestrogens: rufinamideacceleratesmetabolismoflOESTROGENS(reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT
Progestogens: rufinamideacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,BNF
Antifungals:  manufacturerofruxolitinibadvisesdosereductionwhenruxolitinibgivenwithl FLUCONAZOLE ,l ITRACONAZOLE ,l KETOCONAZOLE ,l POSACONAZOLE andl VORICONAZOLE â€”consultruxolitinibproductliteraturelAntipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lAntivirals:  manufacturerofruxolitinibadvisesdosereductionwhenruxolitinibgivenwithl BOCEPREVIR ,l INDINAVIR ,l LOPINAVIR ,l RITONAVIR ,l SAQUINAVIR andl TELAPREVIR â€”consultruxolitinibproductliteratureStJohnâ€™sWort  
 TRIANGLE Aminophylline: StJohnâ€™swortpossiblyreducesplasmaconcentrationof AMINOPHYLLINE  
 TRIANGLE Analgesics: StJohnâ€™swortpossiblyreducesplasmaconcentrationof METHADONE  
 lAnti-arrhythmics:StJohnâ€™swortpossiblyreducesplasmaconcentrationofl DRONEDARONE â€”avoidconcomitantuselAntibacterials:StJohnâ€™swortpossiblyreducesplasmaconcentrationof BEDAQUILINE â€”manufacturerofbedaquilineadvisesavoidconcomitantuse;StJohnâ€™swortreducesplasmaconcentrationoflTELITHROMYCIN(avoidduringandfor2weeksafterStJohnâ€™swort)
Anticoagulants: StJohnâ€™swortpossiblyreducesplasmaconcentrationofl APIXABAN â€”manufacturerofapixabanadvisesavoidconcomitantusewhengivenfortreatmentofdeep-veinthrombosisorpulmonaryembolism;StJohnâ€™swortreducesanticoagulanteffectofl COUMARINS (avoidconcomitantuse);StJohnâ€™swortpossiblyreducesplasmaconcentrationof DABIGATRAN â€”manufacturerofdabigatranadvisesavoidconcomitantuse;StJohnâ€™swortpossiblyreducesplasmaconcentrationofl RIVAROXABAN â€”manufacturerofrivaroxabanadvisesmonitorforsignsofthrombosis
Antidepressants: possibleincreasedserotonergiceffectswhenStJohnâ€™swortgivenwith DULOXETINE or VENLAFAXINE ;StJohnâ€™swortreducesplasmaconcentrationof AMITRIPTYLINE ;increasedserotonergiceffectswhenStJohnâ€™swortgivenwithl SSRIS â€”avoidconcomitantuse
Antiepileptics: StJohnâ€™swortpossiblyreducesplasmaconcentrationof CARBAMAZEPINE ;StJohnâ€™swortpossiblyreducesplasmaconcentrationofl FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”avoidconcomitantuselAntifungals:StJohnâ€™swortreducesplasmaconcentrationoflVORICONAZOLEâ€”avoidconcomitantuse
Antimalarials: avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE  
 TRIANGLE AnxiolyticsandHypnotics: StJohnâ€™swortpossiblyreducesplasmaconcentrationoforal MIDAZOLAM 
Aprepitant: avoidanceofStJohnâ€™swortadvisedbymanufacturerofl APREPITANT  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE  
 lCalcium-channelBlockers: StJohnâ€™swortpossiblyreducesplasmaconcentrationof AMLODIPINE and FELODIPINE ;StJohnâ€™swortreducesplasmaconcentrationof NIFEDIPINE ;StJohnâ€™swortsignificantlyreducesplasmaconcentrationofl VERAPAMIL 
CannabisExtract: StJohnâ€™swortpossiblyreducesplasmaconcentrationofl CANNABISEXTRACT â€”manufacturerofcannabisextractadvisesavoidconcomitantuse
CardiacGlycosides: StJohnâ€™swortreducesplasmaconcentrationofl DIGOXIN â€”avoidconcomitantuse
Ciclosporin: StJohnâ€™swortreducesplasmaconcentrationofl CICLOSPORIN â€”avoidconcomitantuse
Cobicistat: StJohnâ€™swortpossiblyreducesplasmaconcentrationofl COBICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuse
Cytotoxics: StJohnâ€™swortpossiblyreducesplasmaconcentrationof AXITINIB â€”considerincreasingdoseofaxitinib;StJohnâ€™swortpossiblyreducesplasmaconcentrationof BORTEZOMIB ,l BOSUTINIB , CABOZANTINIB , CRIZOTINIB , EVEROLIMUS ,l IBRUTINIB ,l IDELALISIB , PONATINIB andl VINFLUNINE â€”manufacturerofbortezomib,bosutinib,cabozantinib,crizotinib,everolimus,ibrutinib,idelalisib,ponatinibandvinflunineadvisesavoidconcomitantuse;avoidanceofStJohnâ€™swortadvisedbymanufacturerofl CABAZITAXEL , DABRAFENIB , GEFITINIB ,l LAPATINIB and VEMURAFENIB ;StJohnâ€™swortreducesplasmaconcentrationofl IMATINIB â€”avoidconcomitantuse;avoidanceofStJohnâ€™swortadvisedbymanufacturerof VANDETANIB andl VISMODEGIB (plasmaconcentrationofvandetanibandvismodegibpossiblyreduced);StJohnâ€™swortpossiblyreducesplasmaconcentrationof ERIBULIN ;StJohnâ€™swortacceleratesmetabolismofl IRINOTECAN (reducedplasmaconcentrationâ€”avoidconcomitantuse)
Dapoxetine: possibleincreasedriskofserotonergiceffectswhenStJohnâ€™swortgivenwithl DAPOXETINE (manufacturerofdapoxetineadvisesStJohnâ€™swortshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingStJohnâ€™swort)
Diuretics: StJohnâ€™swortreducesplasmaconcentrationofl EPLERENONE â€”avoidconcomitantuse 
 TRIANGLE Fingolimod: StJohnâ€™swortpossiblyreducesplasmaconcentrationof FINGOLIMOD â€”manufactureroffingolimodadvisesavoidconcomitantuse
Fosaprepitant: avoidanceofStJohnâ€™swortadvisedbymanufacturerofl FOSAPREPITANT 
HormoneAntagonists: StJohnâ€™swortpossiblyreducesplasmaconcentrationofl ABIRATERONE â€”manufacturerofabirateroneadvisesavoidconcomitantusel5 HT 1-receptor
 Agonists: increasedserotonergiceffectswhenStJohnâ€™swortgivenwithl5HT1 AGONISTS â€”avoidconcomitantuse 
 TRIANGLE Ivabradine: StJohnâ€™swortreducesplasmaconcentrationof IVABRADINE â€”avoidconcomitantuse
Ivacaftor: StJohnâ€™swortpossiblyreducesplasmaconcentrationofl IVACAFTOR â€”manufacturerofivacaftoradvisesavoidconcomitantuse 
 TRIANGLE Lipid-regulating
 Drugs: StJohnâ€™swortreducesplasmaconcentrationof SIMVASTATIN  
 TRIANGLE Macitentan: avoidanceofStJohnâ€™swortadvisedbymanufacturerof MACITENTAN 
Oestrogens: StJohnâ€™swortreducescontraceptiveeffectofl OESTROGENS (avoidconcomitantuse)
Progestogens: StJohnâ€™swortreducescontraceptiveeffectofl PROGESTOGENS (avoidconcomitantuse)
Tacrolimus: StJohnâ€™swortreducesplasmaconcentrationofl TACROLIMUS â€”avoidconcomitantuse
 TRIANGLE Theophylline: StJohnâ€™swortpossiblyreducesplasmaconcentrationof THEOPHYLLINE  
 TRIANGLE Ulcer-healingDrugs:  StJohnâ€™swortpossiblyreducesplasmaconcentrationof OMEPRAZOLE 
Ulipristal: avoidanceofStJohnâ€™swortadvisedbymanufacturerofl ULIPRISTAL (contraceptiveeffectofulipristalpossiblyreduced)
 Salbutamol see Sympathomimetics
,Beta2
 Salmeterol see Sympathomimetics
,Beta2Saquinavir
Analgesics: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl ALFENTANIL ,l FENTANYL orl METHADONE â€”avoidconcomitantuselAnti-arrhythmics:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl AMIODARONE ,l DISOPYRAMIDE ,l DRONEDARONE ,l FLECAINIDE ,l LIDOCAINE orl PROPAFENONE â€”avoidconcomitantuse
Antibacterials: plasmaconcentrationofbothdrugspossiblyincreasedwhensaquinavirgivenwithl CLARITHROMYCIN (increasedriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl DAPSONE ,l ERYTHROMYCIN orl MOXIFLOXACIN â€”avoidconcomitantuse;saquinavirincreasesplasmaconcentrationofl RIFABUTIN (alsoplasmaconcentrationofsaquinavirreduced)â€”reducerifabutindose;plasmaconcentrationofsaquinavirsignificantlyreducedbyl RIFAMPICIN ,alsoriskofhepatotoxicityâ€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl DELAMANID ;plasmaconcentrationofbothdrugsmayincreasewhensaquinavirgivenwith FUSIDICACID ;avoidanceofsaquinaviradvisedbymanufacturerofl TELITHROMYCIN (riskofventriculararrhythmias) 
 TRIANGLE Anticoagulants: saquinavirpossiblyenhancesanticoagulanteffectof WARFARIN ;avoidanceofsaquinaviradvisedbymanufacturerof APIXABAN and RIVAROXABAN 
Antidepressants: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl TRAZODONE orl TRICYCLICS â€”avoidconcomitantuse;plasmaconcentrationofsaquinavirreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse
Antiepileptics: plasmaconcentrationofsaquinavirpossiblyreducedby CARBAMAZEPINE , FOS PHENYTOIN  ,l PHENOBARBITAL ,PHENYTOINandl PRIMIDONE 
Antifungals: plasmaconcentrationofsaquinavirincreasedbyl KETOCONAZOLE â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;plasmaconcentrationofsaquinavirpossiblyincreasedby IMIDAZOLES and TRIAZOLES 
Antihistamines: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: cautionwithsaquinaviradvisedbymanufacturerof ARTEMETHERWITHLUMEFANTRINE ;avoidanceofsaquinaviradvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE (possibleriskofventriculararrhythmias);increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl QUININE â€”avoidconcomitantuse 
 TRIANGLE Antimuscarinics: avoidanceofsaquinaviradvisedbymanufacturerof DARIFENACIN and TOLTERODINE ;manufactureroffesoterodineadvisesdosereductionwhensaquinavirgivenwith FESOTERODINE â€”consultfesoterodineproductliterature
Antipsychotics: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl CLOZAPINE ,l HALOPERIDOL orl PHENOTHIAZINES â€”avoidconcomitantuse;saquinavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);saquinavirpossiblyincreasesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;saquinavirpossiblyincreasesplasmaconcentrationofl PIMOZIDE (increasedriskofventriculararrhythmiasâ€”avoidconcomitantuse);saquinavirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse
AnxiolyticsandHypnotics: saquinavirincreasesplasmaconcentrationofl MIDAZOLAM (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam)
Avanafil: saquinavirpossiblyincreasesplasmaconcentrationofl AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuselBeta-blockers:increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl SOTALOL â€”avoidconcomitantuse
Ciclosporin: plasmaconcentrationofbothdrugsincreasedwhensaquinavirgivenwithl CICLOSPORIN  
 TRIANGLE Corticosteroids: plasmaconcentrationofsaquinavirpossiblyreducedby DEXAMETHASONE 
Cytotoxics: saquinavirpossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationofsaquinavirby6to12hours;saquinavirpossiblyincreasesplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consultaxitinibproductliterature);saquinavirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB andl CABAZITAXEL â€”manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;saquinavirpossiblyincreasesplasmaconcentrationofl CRIZOTINIB andl EVEROLIMUS â€”manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;saquinavirpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceofsaquinaviradvisedbymanufacturerofl LAPATINIB ;increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl PAZOPANIB â€”avoidconcomitantuse;saquinavirpossiblyincreasesplasmaconcentrationof PONATINIB â€”considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhensaquinavirgivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature;saquinavirpossiblyincreasesplasmaconcentrationofl DOCETAXEL â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose
Dapoxetine: avoidanceofsaquinaviradvisedbymanufacturerofl DAPOXETINE (increasedriskoftoxicity) 
 TRIANGLE Diuretics: saquinavirincreasesplasmaconcentrationof EPLERENONE (reducedoseofeplerenone)
Domperidone: possibleincreasedriskofventriculararrhythmiaswhensaquinavirgivenwithl DOMPERIDONE â€”avoidconcomitantuse
ErgotAlkaloids: increasedriskofergotismwhensaquinavirgivenwithl ERGOTAMINE â€”avoidconcomitantuselLipid-regulatingDrugs:possibleincreasedriskofmyopathywhensaquinavirgivenwith ATORVASTATIN ;possibleincreasedriskofmyopathywhensaquinavirgivenwithl ROSUVASTATIN â€”manufacturerofrosuvastatinadvisesavoidconcomitantuse;increasedriskofmyopathywhensaquinavirgivenwithl SIMVASTATIN (avoidconcomitantuse);avoidanceofsaquinaviradvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased)
Orlistat: absorptionofsaquinavirpossiblyreducedbyl ORLISTAT 
PentamidineIsetionate: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl PENTAMIDINEISETIONATE â€”avoidconcomitantuse
Ranolazine: saquinavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse
Sildenafil: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl SILDENAFIL â€”avoidconcomitantuse
Tacrolimus: saquinavirincreasesplasmaconcentrationofl TACROLIMUS (considerreducingdoseoftacrolimus)
Tadalafil: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl TADALAFIL â€”avoidconcomitantuse BNF 
Vardenafil: increasedriskofventriculararrhythmiaswhensaquinavirgivenwithl VARDENAFIL â€”avoidconcomitantuse
 Saxagliptin see Antidiabetics 
 Selegiline
 NOTES elegilineisa MAO -Binhibitor
Analgesics: hyperpyrexiaand CNS toxicityreportedwhenselegilinegivenwithl PETHIDINE (avoidconcomitantuse);manufacturerofselegilineadvisesavoidconcomitantusewith OPIOIDANALGESICS 
Antidepressants: manufacturerofselegilineadvisesavoidconcomitantusewith CITALOPRAM and ESCITALOPRAM ;increasedriskofhypertensionandCNSexcitationwhenselegilinegivenwithl FLUOXETINE (selegilineshouldnotbestarteduntil5weeksafterstoppingfluoxetine,avoidfluoxetinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenselegilinegivenwithl FLUVOXAMINE ,l SERTRALINE orl VENLAFAXINE (selegilineshouldnotbestarteduntil1weekafterstoppingfluvoxamine,sertralineorvenlafaxine,avoidfluvoxamine,sertralineorvenlafaxinefor2weeksafterstoppingselegiline);increasedriskofhypertensionandCNSexcitationwhenselegilinegivenwithl PAROXETINE (selegilineshouldnotbestarteduntil2weeksafterstoppingparoxetine,avoidparoxetinefor2weeksafterstoppingselegiline);enhancedhypotensiveeffectwhenselegilinegivenwithl MAOIS â€”manufacturerofselegilineadvisesavoidconcomitantuse;avoidconcomitantuseofselegilinewithl MOCLOBEMIDE ;CNStoxicityreportedwhenselegilinegivenwithl TRICYCLICS   
 TRIANGLE Dopaminergics: selegilineenhanceseffectsandincreasestoxicityof CO - BENELDOPA ,CO- CARELDOPA or LEVODOPA (reducedoseofco-beneldopa,co-careldopaorlevodopa);maxdoseof10mgselegilineadvisedbymanufacturerof ENTACAPONE ifusedconcomitantly 
 TRIANGLE 5 HT 1-receptor
 Agonists: manufacturerofselegilineadvisesavoidconcomitantusewith5HT1 AGONISTS  
 TRIANGLE Memantine: effectsofdopaminergicsandselegilinepossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPA 
Oestrogens: plasmaconcentrationofselegilineincreasedbyl OESTROGENS â€”manufacturerofselegilineadvisesavoidconcomitantuse
Progestogens: plasmaconcentrationofselegilineincreasedbyl PROGESTOGENS â€”manufacturerofselegilineadvisesavoidconcomitantuse
Sympathomimetics: manufacturerofselegilineadvisesavoidconcomitantusewith SYMPATHOMIMETICS ;riskofhypertensivecrisiswhenselegilinegivenwithl DOPAMINES elenium 
 TRIANGLE Eltrombopag: seleniumpossiblyreducesabsorptionof ELTROMBOPAG (giveatleast4hoursapart) 
 TRIANGLE Vitamins:  absorptionofseleniumpossiblyreducedby ASCORBICACID (giveatleast4hoursapart)
 Sertraline see Antidepressants
, SSRIS evelamer 
 TRIANGLE Antibacterials: sevelamerreducesbioavailabilityof CIPROFLOXACIN  
 TRIANGLE Ciclosporin: sevelamerpossiblyreducesplasmaconcentrationof CICLOSPORIN  
 TRIANGLE Mycophenolate: sevelamerpossiblyreducesplasmaconcentrationof MYCOPHENOLATE  
 TRIANGLE Tacrolimus: sevelamerpossiblyreducesplasmaconcentrationof TACROLIMUS  
 TRIANGLE Vitamins:sevelamerreducesabsorptionof CALCITRIOL (giveatleast1hourbeforeor3hoursaftersevelamer)
 Sevoflurane see Anaesthetics
,GeneralSildenafillAlpha-blockers:enhancedhypotensiveeffectwhensildenafilgivenwithl ALPHA - BLOCKERS (avoidalpha-blockersfor4hoursaftersildenafil)â€”whenpatientisstableonthealphablockerinitiatesildenafilatthelowestpossibledose 
 TRIANGLE Anti-arrhythmics:avoidanceofsildenafiladvisedbymanufacturerof DISOPYRAMIDE (riskofventriculararrhythmias)lAntibacterials:  plasmaconcentrationofsildenafilincreasedbyl CLARITHROMYCIN â€”considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertension;plasmaconcentrationofsildenafilincreasedby ERYTHROMYCIN â€”reduceinitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytotwicedailyforpulmonaryhypertension;plasmaconcentrationofsildenafilpossiblyincreasedbyl TELITHROMYCIN â€”considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertension
Antifungals: plasmaconcentrationofsildenafilincreasedbyl KETOCONAZOLE â€”reduceinitialdoseofsildenafilforerectiledysfunctionandavoidconcomitantuseofsildenafilforpulmonaryhypertension;plasmaconcentrationofsildenafilincreasedby ITRACONAZOLE â€”reduceinitialdoseofsildenafil
Antivirals: side-effectsofsildenafilpossiblyincreasedbyl ATAZANAVIR ;plasmaconcentrationofsildenafilreducedby ETRAVIRINE ;plasmaconcentrationofsildenafilpossiblyincreasedby FOSAMPRENAVIR ;plasmaconcentrationofsildenafilincreasedbyl INDINAVIR â€”reduceinitialdoseofsildenafil;plasmaconcentrationofsildenafilsignificantlyincreasedbyl RITONAVIR â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhensildenafilgivenwithl SAQUINAVIR â€”avoidconcomitantuse;avoidanceofsildenafiladvisedbymanufacturerofl TELAPREVIR ;avoidanceofsildenafilforpulmonaryarterialhypertensionadvisedbymanufacturerof TIPRANAVIR  
 TRIANGLE Bosentan: plasmaconcentrationofsildenafilreducedby BOSENTAN ,alsoplasmaconcentrationofbosentanincreased 
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhensildenafilgivenwith AMLODIPINE 
Cobicistat: plasmaconcentrationofsildenafilpossiblyincreasedbyl COBICISTAT â€”manufacturerofcobicistatadvisesavoidconcomitantuseofsildenafilforpulmonaryarterialhypertensionorreducedoseofsildenafilforerectiledysfunctionâ€”consultcobicistatproductliterature 
 TRIANGLE Cytotoxics: avoidanceofsildenafilforpulmonaryarterialhypertensionadvisedbymanufacturerof IDELALISIB  
 TRIANGLE Dapoxetine: avoidanceofsildenafiladvisedbymanufacturerof DAPOXETINE  
 TRIANGLE GrapefruitJuice: plasmaconcentrationofsildenafilpossiblyincreasedby GRAPEFRUITJUICE 
Nicorandil: sildenafilsignificantlyenhanceshypotensiveeffectofl NICORANDIL (avoidconcomitantuse)
Nitrates: sildenafilsignificantlyenhanceshypotensiveeffectofl NITRATES (avoidconcomitantuse)
Riociguat: enhancedhypotensiveeffectwhensildenafilgivenwithl RIOCIGUAT â€”avoidconcomitantuse 
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofsildenafilincreasedbyCIMETIDINEâ€”considerreducingdoseofsildenafilforerectiledysfunctionSiltuximab
Antipsychotics: avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuseSimeprevirlAnti-arrhythmics:possibleincreasedriskofbradycardiawhensimeprevir(withsofosbuvir)givenwithl AMIODARONE â€”seeunderAmiodarone,p88lAntibacterials:plasmaconcentrationofsimeprevirpossiblyincreasedbylCLARITHROMYCINandlTELITHROMYCINâ€”
 Antidepressants:  plasmaconcentrationofsimeprevirpossiblyreducedbyl STJOHN â€™ SWORT â€”manufacturerofsimepreviradvisesavoidconcomitantuse
 
Antiepileptics:   plasmaconcentrationofsimeprevirpossiblyreducedbyl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l OXCARBAZEPINE ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE â€”manufacturerofsimepreviradvisesavoidconcomitantuse
Antifungals:   manufacturerofsimepreviradvisesavoidconcomitantusewithl KETOCONAZOLE ;plasmaconcentrationofsimeprevirpossiblyincreasedbyl FLUCONAZOLE ,l ITRACONAZOLE ,l POSACONAZOLE andl VORICONAZOLE â€”manufacturerofsimepreviradvisesavoidconcomitantuselAntivirals:  plasmaconcentrationofbothdrugsincreasedwhensimeprevirgivenwithl DARUNAVIR â€”manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofsimeprevirreducedby EFAVIRENZ ;manufacturerofsimepreviradvisesavoidconcomitantusewith ETRAVIRINE ;plasmaconcentrationofsimeprevirpossiblyreducedbyl NEVIRAPINE â€”manufacturerofsimepreviradvisesavoidconcomitantuse;plasmaconcentrationofsimeprevirincreasedbyl RITONAVIR â€”manufacturerofsimepreviradvisesavoidconcomitantuse  
 TRIANGLE AnxiolyticsandHypnotics: simeprevirincreasesplasmaconcentrationoforal MIDAZOLAM  
 TRIANGLE CardiacGlycosides: simeprevirincreasesplasmaconcentrationof DIGOXIN 
Cobicistat: plasmaconcentrationofsimeprevirpossiblyincreasedbyl COBICISTAT â€”manufacturerofsimepreviradvisesavoidconcomitantuse 
 TRIANGLE Corticosteroids:   plasmaconcentrationofsimeprevirpossiblyreducedby DEXAMETHASONE â€”manufacturerofsimepreviradvisesavoidconcomitantuse 
 TRIANGLE Lipid-regulatingDrugs:  simeprevirincreasesplasmaconcentrationof ATORVASTATIN , ROSUVASTATIN and SIMVASTATIN (considerreducingdoseofatorvastatin,rosuvastatinandsimvastatin)
 Simvastatin see Statins 
Sirolimus
 Antibacterials:  plasmaconcentrationofsirolimusincreasedbyl CLARITHROMYCIN andl TELITHROMYCIN â€”avoidconcomitantuse;plasmaconcentrationofbothdrugsincreasedwhensirolimusgivenwithlERYTHROMYCIN;plasmaconcentrationofsirolimusreducedbylRIFABUTINandlRIFAMPICINâ€”avoidconcomitantuselAntifungals:plasmaconcentrationofsirolimusincreasedbylITRACONAZOLE,lKETOCONAZOLEandlVORICONAZOLEâ€”avoidconcomitantuse;plasmaconcentrationofsirolimusincreasedby MICAFUNGIN andl MICONAZOLE ;plasmaconcentrationofsirolimuspossiblyincreasedbyFLUCONAZOLEandPOSACONAZOLE 
 TRIANGLE Ciclosporin: plasmaconcentrationofsirolimusincreasedby CICLOSPORIN 
Cytotoxics: cautionwithsirolimusadvisedbymanufacturerofl CRIZOTINIB 
GrapefruitJuice: plasmaconcentrationofsirolimusincreasedbyl GRAPEFRUITJUICE â€”avoidconcomitantuse
 Sitagliptin see Antidiabetics 
 Smallpox 
 Vaccine see Vaccines 
 Sodium 
 Aurothiomalatel
 ACE Inhibitors:flushingandhypotensionreportedwhensodiumaurothiomalategivenwithl ACEINHIBITORS  
 TRIANGLE Penicillamine: avoidanceofsodiumaurothiomalateadvisedbymanufacturerof PENICILLAMINE (increasedriskoftoxicity)Sodium
 mBenzoate 
 TRIANGLE Antiepileptics:effectsofsodiumbenzoatepossiblyreducedby SODIUMVALPROATE and VALPROICACID  
 TRIANGLE Antipsychotics:   effectsofsodiumbenzoatepossiblyreducedby HALOPERIDOL  
 TRIANGLE Corticosteroids:effectsofsodiumbenzoatepossiblyreducedby CORTICOSTEROIDSS odium
 Bicarbonate see Antacids 
 Sodium 
Citrate
 TRIANGLE Ulcer-healingDrugs:avoidanceofsodiumcitrateadvisedbymanufacturerof SUCRALFATES odium
 Clodronate see Bisphosphonates 
 Sodium 
 Ferredate see Ironsalts 
 Sodium 
 Nitroprusside see Vasodilator 
 Antihypertensives 
 Sodium 
 Oxybate 
 
 Analgesics:  effectsofsodiumoxybateenhancedbyl OPIOIDANALGESICS (avoidconcomitantuse) 
 TRIANGLE Antidepressants:increasedriskofside-effectswhensodiumoxybategivenwith  TRICYCLIC S  
 lAntiepileptics:  manufacturerofsodiumoxybateadvisesavoidconcomitantusewithPHENOBARBITALandPRIMIDONE;plasmaconcentrationofsodiumoxybateincreasedbylSODIUMVALPROATEandlVALPROICACID(seeunderSodiumOxybate,p425) 
 TRIANGLE Antipsychotics:effectsofsodiumoxybatepossiblyenhancedby ANTIPSYCHOTICS 
AnxiolyticsandHypnotics: effectsofsodiumoxybateenhancedbyl BENZODIAZEPINES (avoidconcomitantuse)Sodium
 mPhenylbutyrate 
 TRIANGLE Antiepileptics:effectsofsodiumphenylbutyratepossiblyreducedbySODIUMVALPROATEandVALPROICACID 
 TRIANGLE Antipsychotics:effectsofsodiumphenylbutyratepossiblyreducedbyHALOPERIDOL 
 TRIANGLE Corticosteroids:effectsofsodiumphenylbutyratepossiblyreducedbyCORTICOSTEROIDSSodiumStibogluconatelAntifungals:possibleincreasedriskofarrhythmiaswhensodiumstibogluconategivenbeforel AMPHOTERICIN â€”manufacturerofsodiumstibogluconateadvisesgiving14daysapartSodium
 mValproate 
 TRIANGLE Analgesics:effectsofsodiumvalproateenhancedby ASPIRIN 
Antibacterials: metabolismofsodiumvalproatepossiblyinhibitedbyERYTHROMYCIN(increasedplasmaconcentration);avoidanceofsodiumvalproateadvisedbymanufacturerofl PIVMECILLINAM ;plasmaconcentrationofsodiumvalproatereducedbyl CARBAPENEMS â€”avoidconcomitantuse 
 TRIANGLE Anticoagulants: sodiumvalproatepossiblyenhancesanticoagulanteffectof COUMARINS 
Antidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andlTRICYCLIC- RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andlTRICYCLICS(convulsivethresholdlowered)lAntiepileptics:plasmaconcentrationofsodiumvalproatereducedbyCARBAMAZEPINE,alsoplasmaconcentrationofactivemetaboliteofcarbamazepineincreased;sodiumvalproatepossiblyincreasesplasmaconcentrationof ETHOSUXIMIDE ;sodiumvalproateincreasesorpossibly BNF 
Antimalarials: anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
Antipsychotics:  anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered);sodiumvalproatepossiblyincreasesordecreasesplasmaconcentrationof CLOZAPINE ;increasedriskofside-effectsincludingneutropeniawhensodiumvalproategivenwithl OLANZAPINE   
 TRIANGLE Antivirals: plasmaconcentrationofsodiumvalproatepossiblyreducedby RITONAVIR ;sodiumvalproatepossiblyincreasesplasmaconcentrationof ZIDOVUDINE (increasedriskoftoxicity) 
 TRIANGLE AnxiolyticsandHypnotics: plasmaconcentrationofsodiumvalproatepossiblyincreasedby CLOBAZAM ;increasedriskofside-effectswhensodiumvalproategivenwith CLONAZEPAM ;sodiumvalproatepossiblyincreasesplasmaconcentrationof DIAZEPAM and LORAZEPAM  
 TRIANGLE Bupropion: sodiumvalproateinhibitsthemetabolismof BUPROPION  
 TRIANGLE Cytotoxics:  sodiumvalproateincreasesplasmaconcentrationof TEMOZOLOMIDE  
 TRIANGLE Lipid-regulatingDrugs:  absorptionofsodiumvalproatepossiblyreducedby COLESTYRAMINE  
 TRIANGLE Oestrogens:  plasmaconcentrationofsodiumvalproatepossiblyreducedby ETHINYLESTRADIOL 
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT  
 TRIANGLE SodiumBenzoate: sodiumvalproatepossiblyreduceseffectsof SODIUMBENZOATE 
SodiumOxybate: sodiumvalproateincreasestheplasmaconcentrationofl SODIUMOXYBATE (seeunderSodiumOxybate,p425) 
 TRIANGLE SodiumPhenylbutyrate: sodiumvalproatepossiblyreduceseffectsof SODIUMPHENYLBUTYRATE  
 lUlcer-healingDrugs:metabolismofsodiumvalproateinhibitedbyl CIMETIDINE (increasedplasmaconcentration)SofosbuvirlAnti-arrhythmics:possibleincreasedriskofbradycardiawhensofosbuvirgivenwithl AMIODARONE â€”seeunderAmiodarone,p88 
 TRIANGLE Antibacterials:  manufacturerofsofosbuviradvisesavoidconcomitantusewith RIFABUTIN and RIFAMPICIN  
 TRIANGLE Antidepressants:  manufacturerofsofosbuviradvisesavoidconcomitantusewith STJOHN â€™ SWORT  
 TRIANGLE Antiepileptics: manufacturerofsofosbuviradvisesavoidconcomitantusewith CARBAMAZEPINE ,FOSPHENYTOIN,OXCARBAZEPINE,PHENOBARBITAL,PHENYTOINand PRIMIDONE
 Solifenacin see Antimuscarinics 
Somatropin
 TRIANGLE Oestrogens:increaseddosesofsomatropinmaybeneededwhengivenwith OESTROGENS (whenusedasoralreplacementtherapy)Sorafenib 
 TRIANGLE Antibacterials:bioavailabilityofsorafenibreducedby NEOMYCIN ;plasmaconcentrationofsorafenibreducedbyRIFAMPICIN 
 
 TRIANGLE Cytotoxics:sorafenibincreasesplasmaconcentrationof DOCETAXEL and DOXORUBICIN ;sorafenibpossiblyincreasesplasmaconcentrationof IRINOTECAN
 Sotalol see Beta-blockers 
 Spironolactone see Diuretics 
Statins
 lAnti-arrhythmics:increasedriskofmyopathywhensimvastatingivenwithlAMIODARONE(seeunderSimvastatin,p181);plasmaconcentrationofrosuvastatinincreasedbyl DRONEDARONE â€”adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhensimvastatingivenwithlDRONEDARONE;plasmaconcentrationofatorvastatinpossiblyincreasedbyDRONEDARONE
Antibacterials: plasmaconcentrationofatorvastatinandpravastatinincreasedbyl CLARITHROMYCIN ;increasedriskofmyopathywhensimvastatingivenwithlCLARITHROMYCIN,l ERYTHROMYCIN orl TELITHROMYCIN (avoidconcomitantuse);plasmaconcentrationofrosuvastatinreducedbyERYTHROMYCIN;possibleincreasedriskofmyopathywhenatorvastatingivenwithERYTHROMYCIN;plasmaconcentrationofpravastatinincreasedbyERYTHROMYCIN;plasmaconcentrationofatorvastatinandsimvastatinpossiblyreducedbyRIFAMPICIN;metabolismoffluvastatinacceleratedbyRIFAMPICIN(reducedeffect);increasedriskofmyopathywhenstatinsgivenwithl DAPTOMYCIN (preferablyavoidconcomitantuse);riskofmyopathyandrhabdomyolysiswhenstatinsgivenwithl FUSIDICACID â€”avoidconcomitantuseandfor7daysafterlastfusidicaciddose;increasedriskofmyopathywhenatorvastatingivenwithlTELITHROMYCIN(avoidconcomitantuse);possibleincreasedriskofmyopathywhenpravastatingivenwithTELITHROMYCIN 
 lAnticoagulants:atorvastatinmaytransientlyreduceanticoagulanteffectof WARFARIN ;rosuvastatinpossiblyenhancesanticoagulanteffectoflCOUMARINSandl PHENINDIONE ;simvastatincanenhancetheanticoagulanteffectofCOUMARINS;fluvastatinenhancesanticoagulanteffectoflCOUMARINS 
 TRIANGLE Antidepressants:plasmaconcentrationofsimvastatinreducedbySTJOHNâ€™SWORT 
 TRIANGLE Antidiabetics: fluvastatinpossiblyincreasesplasmaconcentrationof GLIBENCLAMIDE 
Antiepileptics: plasmaconcentrationofsimvastatinreducedbylCARBAMAZEPINEand ESLICARBAZEPINE â€”considerincreasingdoseofsimvastatin;plasmaconcentrationofrosuvastatinreducedbyESLICARBAZEPINE;combinationoffluvastatinwithFOSPHENYTOINorPHENYTOINmayincreaseplasmaconcentrationofeitherdrug(orboth)
Antifungals: possibleincreasedriskofmyopathywhenatorvastatingivenwithl KETOCONAZOLE â€”manufacturerofketoconazoleadvisesavoidconcomitantuse;increasedriskofmyopathywhensimvastatingivenwithl ITRACONAZOLE ,lKETOCONAZOLEorl POSACONAZOLE (avoidconcomitantuse);possibleincreasedriskofmyopathywhensimvastatingivenwithl FLUCONAZOLE orl MICONAZOLE ;possibleincreasedriskofmyopathywhenatorvastatingivenwithlFLUCONAZOLEor IMIDAZOLES ;plasmaconcentrationoffluvastatinincreasedbyFLUCONAZOLEâ€”possibleincreasedriskofmyopathy;plasmaconcentrationofrosuvastatinincreasedbylITRACONAZOLEâ€”adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhenatorvastatingivenwithlITRACONAZOLE,lPOSACONAZOLEorl VORICONAZOLE ;increasedriskofmyopathywhensimvastatingivenwithlVORICONAZOLE 
Antivirals:possibleincreasedriskofmyopathywhenatorvastatinorpravastatingivenwithl ATAZANAVIR ;plasmaconcentrationofrosuvastatinincreasedbylATAZANAVIR,l DARUNAVIR ,l LOPINAVIR andl TIPRANAVIR â€”adjustdoseofrosuvastatin(consultproductliterature);increasedriskofmyopathywhensimvastatingivenwithlATAZANAVIR,
 TRIANGLE  AnxiolyticsandHypnotics:  atorvastatinpossiblyincreasesplasmaconcentrationof MIDAZOLAM  
 TRIANGLE Bosentan: plasmaconcentrationofsimvastatinreducedby BOSENTAN  
 lCalcium-channelBlockers: possibleincreasedriskofmyopathywhensimvastatingivenwithl AMLODIPINE andl DILTIAZEM (seeunderSimvastatin,p181);plasmaconcentrationofatorvastatinincreasedbyDILTIAZEMâ€”possibleincreasedriskofmyopathy;increasedriskofmyopathywhensimvastatingivenwithl VERAPAMIL (seeunderSimvastatin,p181);atorvastatinincreasesplasmaconcentrationoflVERAPAMIL,alsopossibleincreasedriskofmyopathy(considerreducingdoseofatorvastatin) 
 TRIANGLE CardiacGlycosides: atorvastatinpossiblyincreasesplasmaconcentrationof DIGOXIN 
Ciclosporin: increasedriskofmyopathywhenrosuvastatinorsimvastatingivenwithl CICLOSPORIN (avoidconcomitantuse);increasedriskofmyopathywhenatorvastatingivenwithlCICLOSPORIN(seeunderAtorvastatin,p179);increasedriskofmyopathywhenfluvastatinorpravastatingivenwithlCICLOSPORIN
Clopidogrel: plasmaconcentrationofrosuvastatinincreasedbyl CLOPIDOGREL â€”adjustdoseofrosuvastatin(consultproductliterature)
Cobicistat: plasmaconcentrationofatorvastatinpossiblyincreasedby COBICISTAT â€”manufacturerofcobicistatadvisesreducedoseofatorvastatin;avoidanceofsimvastatinadvisedbymanufactureroflCOBICISTAT
Colchicine: possibleincreasedriskofmyopathywhenstatinsgivenwithl COLCHICINE  
 TRIANGLE Cytotoxics: plasmaconcentrationofsimvastatinpossiblyincreasedby DASATINIB ;avoidanceofsimvastatinadvisedbymanufacturerof IDELALISIB ;plasmaconcentrationofsimvastatinincreasedby IMATINIB 
Eltrombopag: plasmaconcentrationofrosuvastatinincreasedbyl ELTROMBOPAG â€”adjustdoseofrosuvastatin(consultproductliterature)
GrapefruitJuice: plasmaconcentrationofatorvastatinpossiblyincreasedby GRAPEFRUITJUICE ;plasmaconcentrationofsimvastatinincreasedbylGRAPEFRUITJUICEâ€”avoidconcomitantuse
HormoneAntagonists: possibleincreasedriskofmyopathywhensimvastatingivenwithl DANAZOL â€”avoidconcomitantuselLipid-regulating
 TRIANGLE Oestrogens: atorvastatinandrosuvastatinincreaseplasmaconcentrationof ETHINYLESTRADIOL  
 TRIANGLE Progestogens: atorvastatinincreasesplasmaconcentrationof NORETHISTERONE ;rosuvastatinincreasesplasmaconcentrationofactivemetaboliteof NORGESTIMATE ;rosuvastatinincreasesplasmaconcentrationof NORGESTREL 
Ranolazine: plasmaconcentrationofsimvastatinincreasedbyl RANOLAZINE (seeunderSimvastatin,p181) 
 TRIANGLE Retinoids: plasmaconcentrationofsimvastatinreducedby ALITRETINOIN 
Teriflunomide: plasmaconcentrationofrosuvastatinincreasedbyl TERIFLUNOMIDE (considerreducingdoseofrosuvastatin)
Ticagrelor: plasmaconcentrationofsimvastatinincreasedbyl TICAGRELOR (increasedriskoftoxicity)Stavudine
Antivirals: increasedriskofside-effectswhenstavudinegivenwithl DIDANOSINE ;increasedriskoftoxicitywhenstavudinegivenwithl RIBAVIRIN ;effectsofstavudinepossiblyinhibitedbyl ZIDOVUDINE (manufacturersadviseavoidconcomitantuse)
Cytotoxics: effectsofstavudinepossiblyinhibitedby DOXORUBICIN ;increasedriskoftoxicitywhenstavudinegivenwithl HYDROXYCARBAMIDE â€”avoidconcomitantuselOrlistat:  absorptionofstavudinepossiblyreducedbyl ORLISTATS tiripentol
Antidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered)
Antiepileptics: stiripentolincreasesplasmaconcentrationofl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE 
Antimalarials: anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE 
Antipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered) 
 TRIANGLE AnxiolyticsandHypnotics:stiripentolincreasesplasmaconcentrationof CLOBAZAM  
Orlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT
 Streptomycin see Aminoglycosides 
 Strontium 
Ranelate
 TRIANGLE Aminophylline: sucralfatepossiblyreducesabsorptionof AMINOPHYLLINE (giveatleast2hoursapart) 
 TRIANGLE Antibacterials:sucralfatereducesabsorptionof CIPR OFLOXACIN  , LEVOFLOXACIN , MOXIFLOXACIN ,OFLOXACINandTETRACYCLINES; BNF 
 Antiepileptics:   sucralfatereducesabsorptionofl FOS PHENYTOIN  andlPHENYTOIN  
 TRIANGLE  Antifungals:  sucralfatereducesabsorptionof KETOCONAZOLE  
 TRIANGLE Antipsychotics: sucralfatereducesabsorptionof SULPIRIDE  
 TRIANGLE CardiacGlycosides:  sucralfatepossiblyreducesabsorptionof CARDIACGLYCOSIDES  
 TRIANGLE PotassiumSalts: manufacturerofsucralfateadvisesavoidconcomitantusewith POTASSIUMCITRATE  
 TRIANGLE SodiumCitrate: manufacturerofsucralfateadvisesavoidconcomitantusewith SODIUMCITRATE  
 TRIANGLE Theophylline:  sucralfatepossiblyreducesabsorptionof THEOPHYLLINE (giveatleast2hoursapart) 
 TRIANGLE ThyroidHormones: sucralfatereducesabsorptionof LEVOTHYROXINE  
 TRIANGLE Ulcer-healing
 Drugs: sucralfatepossiblyreducesabsorptionof LANSOPRAZOLES ugammadex 
 TRIANGLE Antibacterials:   responsetosugammadexpossiblyreducedby FUSIDICACID  
 TRIANGLE Progestogens: sugammadexpossiblyreducesplasmaconcentrationof PROGESTOGENS â€”manufacturerofsugammadexadvisesadditionalcontraceptiveprecautions
 Sulfadiazine see Sulfonamides 
 Sulfadoxine see Sulfonamides 
 Sulfamethoxazole see Sulfonamides 
Sulfasalazine
 TRIANGLE Folates: sulfasalazinepossiblyreducesabsorptionof FOLICACIDS ulfinpyrazone 
 TRIANGLE Aminophylline:  sulfinpyrazonereducesplasmaconcentrationof AMINOPHYLLINE  
 TRIANGLE Analgesics: effectsofsulfinpyrazoneantagonisedby ASPIRIN  
 TRIANGLE Antibacterials:sulfinpyrazonereducesexcretionof NITROFURANTOIN (increasedriskoftoxicity);sulfinpyrazonereducesexcretionof PENICILLINS ;effectsofsulfinpyrazoneantagonisedby PYRAZINAMIDE  
 
Anticoagulants:increasedriskofbleedingwhensulfinpyrazonegivenwith APIXABAN ;sulfinpyrazoneenhancesanticoagulanteffectoflCOUMARINS;possibleincreasedriskofbleedingwhensulfinpyrazonegivenwithl DABIGATRAN  l
 Antidiabetics:  sulfinpyrazoneenhanceseffectsofl SULFONYLUREAS  
Antiepileptics:sulfinpyrazoneincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN 
 TRIANGLE Calcium-channelBlockers: sulfinpyrazonereducesplasmaconcentrationof VERAPAMIL  
 
Ciclosporin:  sulfinpyrazonereducesplasmaconcentrationofl CICLOSPORIN  
 TRIANGLE Theophylline:sulfinpyrazonereducesplasmaconcentrationof THEOPHYLLINES ulfonamides 
 TRIANGLE Anaesthetics,General: sulfonamidesenhanceeffectsof THIOPENTAL  lAnaesthetics,Local: effectsofsulfonamidespossiblyinhibitedbyl CHLOROPROCAINE (manufacturerofchloroprocaineadvisesavoidconcomitantuse);increasedriskofmethaemoglobinaemiawhensulfonamidesgivenwith PRILOCAINE  
 TRIANGLE Anti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhensulfamethoxazole(asco-trimoxazole)givenwith AMIODARONE â€”manufacturerofamiodaroneadvisesavoidconcomitantuseofco-trimoxazole
 TRIANGLE Antidiabetics:sulfonamidesrarelyenhancetheeffectsofSULFONYLUREAS 
 TRIANGLE Antiepileptics:sulfonamidespossiblyincreaseplasmaconcentrationofFOSPHENYTOINandPHENYTOIN
Antimalarials: increasedantifolateeffectwhensulfonamidesgivenwithl PYRIMETHAMINE  
Antipsychotics:  avoidconcomitantuseofsulfonamideswithl CLOZAPINE (increasedriskofagranulocytosis)
Azathioprine: increasedriskofhaematologicaltoxicitywhensulfamethoxazole(asco-trimoxazole)givenwithl AZATHIOPRINE  
 lCiclosporin:increasedriskofnephrotoxicitywhensulfonamidesgivenwithlCICLOSPORIN;sulfadiazinepossiblyreducesplasmaconcentrationoflCICLOSPORIN
Cytotoxics: increasedriskofhaematologicaltoxicitywhensulfamethoxazole(asco-trimoxazole)givenwithl MERCAPTOPURINE orl METHOTREXATE ;sulfonamidesincreaseriskofMETHOTREXATEtoxicity 
 TRIANGLE PotassiumAminobenzoate: effectsofsulfonamidesinhibitedby POTASSIUMAMINOBENZOATE  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Sulfonylureas see Antidiabetics 
 Sulindac see 
 NSAID s
 Sulpiride see Antipsychotics 
 Sumatriptan see 
5 HT 1-receptorAgonists(underHT)Sunitinib 
 TRIANGLE Antibacterials:metabolismofsunitinibacceleratedby RIFAMPICIN (reducedplasmaconcentration) 
 TRIANGLE Antifungals:metabolismofsunitinibinhibitedbyKETOCONAZOLE(increasedplasmaconcentration)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
Antivirals: avoidanceofsunitinibadvisedbymanufacturerofl BOCEPREVIR
 Suxamethonium see Muscle 
 Relaxants 
 Sympathomimetics 
 
AdrenergicNeuroneBlockers: ephedrine,isometheptene,metaraminol,methylphenidate,noradrenaline(norepinephrine),oxymetazoline,phenylephrine,pseudoephedrineandxylometazolineantagonisehypotensiveeffectofl ADRENERGICNEURONEBLOCKERS ;dexamfetamineandlisdexamfetamineantagonisehypotensiveeffectofl GUANETHIDINE ;increasedriskofhypertensionwhenadrenaline(epinephrine)givenwithlGUANETHIDINE 
 TRIANGLE Alcohol: effectsofmethylphenidatepossiblyenhancedby ALCOHOL  
 TRIANGLE Alpha2-adrenoceptor
 Stimulants: avoidanceofsympathomimeticsadvisedbymanufacturerof APRACLONIDINE  
 lAlpha-blockers:avoidconcomitantuseofadrenaline(epinephrine)ordopaminewithl TOLAZOLINE  
 TRIANGLE Aminophylline:avoidanceofephedrineinchildrenadvisedbymanufacturerofAMINOPHYLLINE lAnaesthetics,General: avoidanceofsympathomimeticsadvisedbymanufacturerofl ISOFLURANE (riskofventriculararrhythmias);increasedriskofarrhythmiaswhenadrenaline(epinephrine)ornoradrenaline(norepinephrine)givenwithl VOLATILELIQUIDGENERALANAESTHETICS ;increasedriskofhypertensionwhenmethylphenidategivenwithlVOLATILELIQUIDGENERALANAESTHETICS 
 TRIANGLE Antacids: absorptionofpseudoephedrinepossiblyincreasedby ALUMINIUMHYDROXIDE  
 lAnticoagulants:methylphenidatepossiblyenhancesanticoagulanteffectoflCOUMARINS
Antidepressants: riskofhypertensivecrisiswhenadrenaline(epinephrine),dobutamine,dopamine,noradrenaline(norepinephrine)orxylometazolinegivenwithl MAOIS ;riskofhypertensivecrisiswhendexamfetamine,ephedrine,isometheptene,lisdexamfetamine,metaraminol,
 TRIANGLE Antiepileptics: methylphenidateincreasesplasmaconcentrationof FOS PHENYTOIN  andPHENYTOIN;methylphenidatepossiblyincreasesplasmaconcentrationof PHENOBARBITAL and PRIMIDONE  
 TRIANGLE Antipsychotics: hypertensiveeffectofsympathomimeticsantagonisedby ANTIPSYCHOTICS ;effectsoflisdexamfetaminepossiblyreducedby CHLORPROMAZINE ;dexamfetaminepossiblyantagonisesantipsychoticeffectsofCHLORPROMAZINE;methylphenidatepossiblyincreasesside-effectsof RISPERIDONE  
 TRIANGLE Antivirals: plasmaconcentrationofdexamfetaminepossiblyincreasedby RITONAVIR  
 lBeta-blockers:increasedriskofseverehypertensionandbradycardiawhenadrenaline(epinephrine)givenwithnon-cardioselectivel BETA - BLOCKERS ,alsoresponsetoadrenaline(epinephrine)maybereduced;increasedriskofseverehypertensionandbradycardiawhendobutaminegivenwithnon-cardioselectivelBETA-BLOCKERS;possibleincreasedriskofseverehypertensionandbradycardiawhennoradrenaline(norepinephrine)givenwithnon-cardioselectivelBETA-BLOCKERS
Clonidine: possibleriskofhypertensionwhenadrenaline(epinephrine)ornoradrenaline(norepinephrine)givenwith CLONIDINE ;seriousadverseeventsreportedwithconcomitantuseofmethylphenidateandlCLONIDINE(causalitynotestablished) 
 TRIANGLE Corticosteroids:  ephedrineacceleratesmetabolismof DEXAMETHASONE 
Dopaminergics: riskoftoxicitywhenisometheptenegivenwithl BROMOCRIPTINE ;effectsofadrenaline(epinephrine),dobutamine,dopamineandnoradrenaline(norepinephrine)possiblyenhancedby ENTACAPONE ;avoidconcomitantuseofsympathomimeticswithl RASAGILINE ;avoidanceofsympathomimeticsadvisedbymanufacturerof SELEGILINE ;riskofhypertensivecrisiswhendopaminegivenwithlSELEGILINE 
 TRIANGLE Doxapram: increasedriskofhypertensionwhensympathomimeticsgivenwith DOXAPRAM  
 TRIANGLE ErgotAlkaloids: increasedriskofergotismwhensympathomimeticsgivenwith ERGOTAMINE  
 TRIANGLE Oxytocin: riskofhypertensionwhenvasoconstrictorsympathomimeticsgivenwith OXYTOCIN (duetoenhancedvasopressoreffect)
Sympathomimetics: effectsofadrenaline(epinephrine)possiblyenhancedbyl DOPEXAMINE ;dopexaminepossiblyenhanceseffectsofl NORADRENALINE ( NOREPINEPHRINE ) 
 TRIANGLE Theophylline:  avoidanceofephedrineinchildrenadvisedbymanufacturerof THEOPHYLLINE  
 TRIANGLE Ulcer-healing
 Drugs: metabolismofdobutaminepossiblyinhibitedby CIMETIDINES ympathomimetics,Beta2 
 TRIANGLE Aminophylline: increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwith AMINOPHYLLINE  
 
 TRIANGLE Atomoxetine: Increasedriskofcardiovascularside-effectswhenparenteralsalbutamolgivenwith ATOMOXETINE  
 TRIANGLE CardiacGlycosides: salbutamolpossiblyreducesplasmaconcentrationof DIGOXIN  
 TRIANGLE Cobicistat: avoidanceofsalmeteroladvisedbymanufacturerof COBICISTAT  
 TRIANGLE Corticosteroids:increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwith CORTICOSTEROIDS  
 TRIANGLE Cytotoxics: avoidanceofsalmeteroladvisedbymanufacturerof IDELALISIB  
 TRIANGLE Diuretics: increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwith ACETAZOLAMIDE , LOOPDIURETICS or THIAZIDESANDRELATEDDIURETICS 
Methyldopa: acutehypotensionreportedwheninfusionofsalbutamolgivenwithl METHYLDOPA  
 TRIANGLE MuscleRelaxants: bambuterolenhanceseffectsof SUXAMETHONIUM  
 TRIANGLE Theophylline:increasedriskofhypokalaemiawhenhighdosesofbeta2sympathomimeticsgivenwith THEOPHYLLINET acrolimus NOTEI nteractionsdonotgenerallyapplytotacrolimususedtopically;riskoffacialflushingandskinirritationwithtopicaltacrolimusonconsumptionofalcohol
Analgesics: possibleincreasedriskofnephrotoxicitywhentacrolimusgivenwith NSAIDS ;increasedriskofnephrotoxicitywhentacrolimusgivenwithl IBUPROFEN  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: increasedriskofhyperkalaemiawhentacrolimusgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Anti-arrhythmics:cautionwithtacrolimusadvisedbymanufacturerof DRONEDARONE 
Antibacterials: plasmaconcentrationoftacrolimusincreasedbyl CLARITHROMYCIN andl ERYTHROMYCIN ;plasmaconcentrationoftacrolimuspossiblyreducedby RIFABUTIN ;plasmaconcentrationoftacrolimusreducedbyl RIFAMPICIN ;increasedriskofnephrotoxicitywhentacrolimusgivenwithl AMINOGLYCOSIDES ;plasmaconcentrationoftacrolimuspossiblyincreasedbyl CHLORAMPHENICOL andl TELITHROMYCIN ;possibleincreasedriskofnephrotoxicitywhentacrolimusgivenwith VANCOMYCIN 
Anticoagulants: tacrolimuspossiblyincreasesplasmaconcentrationofl DABIGATRAN â€”manufacturerofdabigatranadvisesavoidconcomitantuse
Antidepressants: plasmaconcentrationoftacrolimusreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse
Antiepileptics: plasmaconcentrationoftacrolimusreducedbyFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased;plasmaconcentrationoftacrolimusreducedbylPHENOBARBITALandlPRIMIDONE 
 lAntifungals:plasmaconcentrationoftacrolimusincreasedbyl FLUCONAZOLE ,l ITRACONAZOLE ,lKETOCONAZOLE,l POSACONAZOLE andl VORICONAZOLE (considerreducingdoseoftacrolimus);plasmaconcentrationoftacrolimuspossiblyincreasedbyl MICONAZOLE oralgel;increasedriskofnephrotoxicitywhentacrolimusgivenwithl AMPHOTERICIN ;plasmaconcentrationoftacrolimusreducedbyl CASPOFUNGIN 
Antipsychotics: avoidanceoftacrolimusadvisedbymanufacturerofl DROPERIDOL (riskofventriculararrhythmias)lAntivirals:possibleincreasedriskofnephrotoxicitywhentacrolimusgivenwith ACICLOVIR , GANCICLOVIR , VALACICLOVIR or VALGANCICLOVIR ;plasmaconcentrationoftacrolimuspossiblyincreasedbyl ATAZANAVIR andlRITONAVIR;plasmaconcentrationoftacrolimusincreasedbyl BOCEPREVIR (reducedoseoftacrolimus);plasmaconcentrationoftacrolimuspossiblyaffectedbyl EFAVIRENZ ;plasmaconcentrationoftacrolimusincreasedbyl FOSAMPRENAVIR ;plasmaconcentrationoftacrolimusincreasedbyl SAQUINAVIR (considerreducingdoseoftacrolimus);plasma BNF 
Ciclosporin: tacrolimusincreasesplasmaconcentrationofl CICLOSPORIN (increasedriskofnephrotoxicity)â€”avoidconcomitantuse  
 TRIANGLE Colestilan: manufacturerofcolestilanadvisesgivetacrolimusatleast1hourbeforeor3hoursafter COLESTILAN 
Cytotoxics: tacrolimuspossiblyincreasestheplasmaconcentrationof AFATINIB â€”manufacturerofafatinibadvisesseparatingadministrationoftacrolimusby6to12hours;cautionwithtacrolimusadvisedbymanufacturerofl CRIZOTINIB ;plasmaconcentrationoftacrolimusincreasedby IMATINIB  
 TRIANGLE Dexrazoxane: increasedriskofimmunosupressionwithtacrolimusadvisedbymanufacturerof DEXRAZOXANE 
Diuretics: increasedriskofhyperkalaemiawhentacrolimusgivenwithl POTASSIUM - SPARINGDIURETICSANDALDOSTERONEANTAGONISTS  l
 GrapefruitJuice:  plasmaconcentrationoftacrolimusincreasedbyl GRAPEFRUITJUICE  
 TRIANGLE HormoneAntagonists: plasmaconcentrationoftacrolimuspossiblyincreasedby DANAZOL  
 TRIANGLE Lipid-regulating
 Drugs:   separatingadministrationfromtacrolimusby12hoursadvisedbymanufacturerof LOMITAPIDE  
 TRIANGLE Mifamurtide: avoidanceoftacrolimusadvisedbymanufacturerof MIFAMURTIDE  
 TRIANGLE Oestrogens: plasmaconcentrationoftacrolimuspossiblyincreasedby ETHINYLESTRADIOL 
PotassiumSalts: increasedriskofhyperkalaemiawhentacrolimusgivenwithl POTASSIUMSALTS 
Ranolazine: plasmaconcentrationoftacrolimusincreasedbyl RANOLAZINE  
 TRIANGLE Sevelamer: plasmaconcentrationoftacrolimuspossiblyreducedby SEVELAMER  
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationoftacrolimuspossiblyincreasedby OMEPRAZOLET adalafillAlpha-blockers:enhancedhypotensiveeffectwhentadalafilgivenwithl DOXAZOSIN â€”manufactureroftadalafiladvisesavoidconcomitantuse;enhancedhypotensiveeffectwhentadalafilgivenwithl ALPHA - BLOCKERS â€”whenpatientisstableonthealphablockerinitiatetadalafilatthelowestpossibledose 
 TRIANGLE Anti-arrhythmics:avoidanceoftadalafiladvisedbymanufacturerof DISOPYRAMIDE (riskofventriculararrhythmias)
 
Antibacterials:   plasmaconcentrationoftadalafilpossiblyincreasedby CLARITHROMYCIN and ERYTHROMYCIN ;plasmaconcentrationoftadalafilreducedbyl RIFAMPICIN â€”manufactureroftadalafiladvisesavoidconcomitantuse
Antifungals: tadalafilconcentrationisincreasedbyl KETOCONAZOLE â€”avoidconcomitantuseoftadalafilforpulmonaryhypertension;plasmaconcentrationoftadalafilpossiblyincreasedby ITRACONAZOLE 
Antivirals: plasmaconcentrationoftadalafilpossiblyincreasedby FOSAMPRENAVIR and INDINAVIR ;plasmaconcentrationoftadalafilincreasedbyl RITONAVIR â€”manufactureroftadalafiladvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhentadalafilgivenwithl SAQUINAVIR â€”avoidconcomitantuse;avoidanceofhighdosesoftadalafiladvisedbymanufactureroflTELAPREVIRâ€”consultproductliterature 
 TRIANGLE Bosentan: plasmaconcentrationoftadalafilreducedby BOSENTAN 
Cobicistat: plasmaconcentrationoftadalafilpossiblyincreasedbyl COBICISTAT â€”manufacturerofcobicistatadvisesreducedoseoftadalafil(consultcobicistatproductliterature) 
 TRIANGLE GrapefruitJuice:plasmaconcentrationoftadalafilpossiblyincreasedbyGRAPEFRUITJUICE
Nicorandil: tadalafilsignificantlyenhanceshypotensiveeffectofl NICORANDIL (avoidconcomitantuse)
Nitrates: tadalafilsignificantlyenhanceshypotensiveeffectofl NITRATES (avoidconcomitantuse)
Riociguat: possibleenhancedhypotensiveeffectwhentadalafilgivenwithl RIOCIGUAT â€”avoidconcomitantuse
Tamoxifen 
 TRIANGLE Antibacterials:metabolismoftamoxifenacceleratedbyRIFAMPICIN(reducedplasmaconcentration)
Anticoagulants:   tamoxifenenhancesanticoagulanteffectofl COUMARINS  
 
Antidepressants:  metabolismoftamoxifentoactivemetabolitepossiblyinhibitedbyl FLUOXETINE andl PAROXETINE (avoidconcomitantuse)lAntipsychotics:  avoidanceoftamoxifenadvisedbymanufacturerofl DROPERIDOL (riskofventriculararrhythmias)
Bupropion: metabolismoftamoxifentoactivemetabolitepossiblyinhibitedbyl BUPROPION (avoidconcomitantuse)
Cinacalcet: metabolismoftamoxifentoactivemetabolitepossiblyinhibitedbyl CINACALCET (avoidconcomitantuse)
 Tamsulosin see Alpha-blockers 
 Tapentadol see Opioid 
 Analgesics 
 Taxanes see Cabazitaxel
,Docetaxel,andPaclitaxel
 lTegafur 
 TRIANGLE Antibacterials:metabolismoftegafurinhibitedby METRONIDAZOLE (increasedtoxicity)lAnticoagulants:tegafurenhancesanticoagulanteffectoflCOUMARINS 
 TRIANGLE Antiepileptics: tegafurpossiblyinhibitsmetabolismof FOS PHENYTOIN  andPHENYTOIN(increasedriskoftoxicity)lAntipsychotics:avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE Filgrastim: neutropeniapossiblyexacerbatedwhentegafurgivenwith FILGRASTIM 
Folates: toxicityoftegafurincreasedbyl FOLICACID â€”avoidconcomitantuse 
 TRIANGLE Lipegfilgrastim: neutropeniapossiblyexacerbatedwhentegafurgivenwith LI PEGFILGRASTIM   
 TRIANGLE Pegfilgrastim: neutropeniapossiblyexacerbatedwhentegafurgivenwithPEGFILGRASTIM 
 TRIANGLE Ulcer-healingDrugs:metabolismoftegafurinhibitedby CIMETIDINE (increasedplasmaconcentration)Teicoplanin 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF T elaprevirlAlpha-blockers:manufactureroftelapreviradvisesavoidconcomitantusewithl ALFUZOSIN 
Analgesics: manufactureroftelapreviradvisescautionwithl METHADONE (riskofventriculararrhythmias)lAnti-arrhythmics:manufactureroftelapreviradvisesavoidconcomitantusewithl AMIODARONE andlDISOPYRAMIDE(riskofventriculararrhythmias);manufactureroftelapreviradvisescautionwithl FLECAINIDE andl PROPAFENONE (riskofventriculararrhythmias);manufactureroftelapreviradvisescautionwithintravenous LIDOCAINE  lAntibacterials: plasmaconcentrationofbothdrugspossiblyincreasedwhentelaprevirgivenwithlCLARITHROMYCIN,lERYTHROMYCINandl TELITHROMYCIN (increasedriskofventriculararrhythmias);manufactureroftelapreviradvisesavoidconcomitantusewithl RIFABUTIN ;plasmaconcentrationoftelaprevirsignificantlyreducedbylRIFAMPICINâ€”avoidconcomitantuselAnticoagulants:telaprevirpossiblyaffectsplasmaconcentrationofl WARFARIN ;avoidanceoftelapreviradvisedbymanufacturerof APIXABAN ;telaprevirpossiblyincreasesplasmaconcentrationof DABIGATRAN  
 lAntidepressants:telaprevirpossiblyincreasesplasmaconcentrationof TRAZODONE ;manufactureroftelapreviradvisesavoidconcomitantusewithl STJOHN â€™ SWORT 
 TRIANGLE Antidiabetics: telaprevirincreasesplasmaconcentrationof METFORMIN (considerreducingdoseofmetformin)lAntiepileptics:  manufactureroftelapreviradvisesavoidconcomitantusewithl CARBAMAZEPINE ,l FOS PHENYTOIN  ,l PHENOBARBITAL ,lPHENYTOINandl PRIMIDONE  
Antifungals:  plasmaconcentrationofbothdrugspossiblyincreasedwhentelaprevirgivenwith KETOCONAZOLE (increasedriskofventriculararrhythmias)â€”reducedoseofketoconazole;telaprevirpossiblyincreasesplasmaconcentrationof ITRACONAZOLE ;telaprevirpossiblyincreasesplasmaconcentrationofl POSACONAZOLE (increasedriskofventriculararrhythmias);telaprevirpossiblyaffectsplasmaconcentrationofl VORICONAZOLE (possibleincreasedriskofventriculararrhythmias)lAntipsychotics:  telaprevirpossiblyincreasesplasmaconcentrationofl LURASIDONE â€”avoidconcomitantuse;manufactureroftelapreviradvisesavoidconcomitantusewithl PIMOZIDE ;telaprevirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuselAntivirals:  plasmaconcentrationoftelaprevirpossiblyreducedby ATAZANAVIR ,alsoplasmaconcentrationofatazanavirpossiblyincreased;telaprevirincreasestheplasmaconcentrationofl DACLATASVIR â€”reducedoseofdaclatasvir(seeunderDaclatasvir,p544);avoidconcomitantuseoftelaprevirwithl DARUNAVIR ;plasmaconcentrationoftelaprevirreducedbyl EFAVIRENZ â€”increasedoseoftelaprevir;manufacturersadviseavoidconcomitantuseoftelaprevirwithl FOSAMPRENAVIR andl LOPINAVIR ;telaprevirincreasesplasmaconcentrationof MARAVIROC (considerreducingdoseofmaraviroc);plasmaconcentrationoftelaprevirpossiblyreducedby NEVIRAPINE â€”considerincreasingdoseoftelaprevir;plasmaconcentrationoftelaprevirpossiblyreducedby RITONAVIR ;telaprevirincreasesplasmaconcentrationof TENOFOVIR ;avoidanceoftelapreviradvisedbymanufacturerof TIPRANAVIR 
AnxiolyticsandHypnotics: telaprevirpossiblyincreasesplasmaconcentrationofl MIDAZOLAM (riskofprolongedsedationâ€”avoidconcomitantuseoforalmidazolam)lBeta-blockers:manufactureroftelapreviradvisesavoidconcomitantusewithl SOTALOL (riskofventriculararrhythmias) 
 TRIANGLE Bosentan: plasmaconcentrationoftelaprevirpossiblyreducedby BOSENTAN ,alsoplasmaconcentrationofbosentanpossiblyincreased 
 TRIANGLE Calcium-channelBlockers: telaprevirincreasesplasmaconcentrationof AMLODIPINE (considerreducingdoseofamlodipine);manufactureroftelapreviradvisescautionwith DILTIAZEM , FELODIPINE , NICARDIPINE , NIFEDIPINE and VERAPAMIL  
 TRIANGLE CardiacGlycosides: telaprevirincreasesplasmaconcentrationof DIGOXIN 
Ciclosporin: plasmaconcentrationofbothdrugsincreasedwhentelaprevirgivenwithl CICLOSPORIN (reducedoseofciclosporin)
Cilostazol: telaprevirpossiblyincreasesplasmaconcentrationofl CILOSTAZOL (seeunderCilostazol,p206)
Colchicine: telaprevirpossiblyincreasesriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment) 
 TRIANGLE Corticosteroids: telaprevirpossiblyincreasesplasmaconcentrationofinhaledandintranasal BUDESONIDE and FLUTICASONE ;plasmaconcentrationoftelaprevirpossiblyreducedby DEXAMETHASONE 
Cytotoxics: telaprevirpossiblyincreasestheplasmaconcentrationofl BOSUTINIB â€”manufacturerofbosutinibadvisesavoidorconsiderreducingdoseofbosutinib;manufacturerofruxolitinibadvisesdosereductionwhentelaprevirgivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature
Domperidone: possibleincreasedriskofventriculararrhythmiaswhentelaprevirgivenwithl DOMPERIDONE â€”avoidconcomitantuse
 Drugs: manufactureroftelapreviradvisesavoidconcomitantusewithl ATORVASTATIN ;manufacturersadviseavoidconcomitantuseoftelaprevirwithl SIMVASTATIN ;avoidanceoftelapreviradvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased)
Oestrogens: telaprevirpossiblyreducesplasmaconcentrationofl ETHINYLESTRADIOL â€”manufactureroftelapreviradvisesadditionalcontraceptiveprecautions
Sildenafil: manufactureroftelapreviradvisesavoidconcomitantusewithl SILDENAFIL 
Sirolimus: plasmaconcentrationofbothdrugsincreasedwhentelaprevirgivenwithl SIROLIMUS (reducedoseofsirolimus)lSympathomimetics,Beta2:manufactureroftelapreviradvisesavoidconcomitantusewithl SALMETEROL (riskofventriculararrhythmias)
Tacrolimus: plasmaconcentrationofbothdrugsincreasedwhentelaprevirgivenwithl TACROLIMUS (reducedoseoftacrolimus)
Tadalafil: manufactureroftelapreviradvisesavoidconcomitantusewithhighdosesofl TADALAFIL â€”consultproductliterature
Vardenafil: manufactureroftelapreviradvisesavoidconcomitantusewithl VARDENAFILT elavancin 
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF T elbivudine
Interferons: increasedriskofperipheralneuropathywhentelbivudinegivenwithl INTERFERONALFA andl PEGINTERFERONALFAT elithromycin
Analgesics: possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithl METHADONE ;telithromycininhibitsthemetabolismof OXYCODONE  
 lAnti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithl AMIODARONE andl DISOPYRAMIDE ;increasedriskofventriculararrhythmiaswhentelithromycingivenwithl DRONEDARONE â€”avoidconcomitantuse
Antibacterials: possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithl MOXIFLOXACIN ;plasmaconcentrationoftelithromycinreducedbyl RIFAMPICIN (avoidduringandfor2weeksafterrifampicin) 
 TRIANGLE Anticoagulants: avoidanceoftelithromycinadvisedbymanufacturerof APIXABAN 
Antidepressants: possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithl CITALOPRAM andl TRICYCLICS ;plasmaconcentrationoftelithromycinreducedbyl STJOHN â€™ SWORT (avoidduringandfor2weeksafterStJohnâ€™swort)lAntiepileptics:plasmaconcentrationoftelithromycinreducedbylCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(avoidduringandfor2weeksaftercarbamazepine,fosphenytoin,phenobarbital,phenytoinandprimidone)lAntifungals:plasmaconcentrationoftelithromycinincreasedbylKETOCONAZOLEâ€”avoidinsevererenalandhepaticimpairment 
 TRIANGLE Antimuscarinics: manufactureroffesoterodineadvisesdosereductionwhentelithromycingivenwith FESOTERODINE â€”consultfesoterodineproductliteraturelAntipsychotics:possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithl CHLORPROMAZINE ;telithromycinpossiblyincreasesplasmaconcentrationoflLURASIDONEâ€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhentelithromycingivenwithlPIMOZIDEâ€”avoidconcomitantuse;telithromycinpossiblyincreasesplasmaconcentrationofQUETIAPINE 
Antivirals:manufactureroftelithromycinadvisesavoidconcomitantusewithlATAZANAVIR,lFOSAMPRENAVIR,l INDINAVIR ,lLOPINAVIR,lRITONAVIRandlTIPRANAVIRinsevererenalandhepaticimpairment;telithromycinpossiblyincreasestheplasmaconcentrationoflDACLATASVIRâ€”reduceBNF
AnxiolyticsandHypnotics: telithromycininhibitsmetabolismofl MIDAZOLAM (increasedplasmaconcentrationwithincreasedsedation)  
 TRIANGLE Aprepitant: telithromycinpossiblyincreasesplasmaconcentrationof APREPITANT 
Avanafil: telithromycinpossiblyincreasesplasmaconcentrationofl AVANAFIL â€”manufacturerofavanafiladvisesavoidconcomitantuselCalcium-channelBlockers: telithromycinpossiblyinhibitsmetabolismofl CALCIUM - CHANNELBLOCKERS (increasedriskofside-effects) 
 TRIANGLE CardiacGlycosides: telithromycinpossiblyincreasesplasmaconcentrationof DIGOXIN  l
 Ciclosporin:  telithromycinpossiblyincreasesplasmaconcentrationofl CICLOSPORIN 
Colchicine: telithromycinpossiblyincreasesriskofl COLCHICINE toxicityâ€”suspendorreducedoseofcolchicine(avoidconcomitantuseinhepaticorrenalimpairment)lCytotoxics:  telithromycinpossiblyincreasesplasmaconcentrationof AXITINIB (reducedoseofaxitinibâ€”consultaxitinibproductliterature);telithromycinpossiblyincreasestheplasmaconcentrationofl BOSUTINIB andl CABAZITAXEL â€”manufacturerofbosutinibandcabazitaxeladvisesavoidorconsiderreducingdoseofbosutinibandcabazitaxel;telithromycinpossiblyincreasesplasmaconcentrationofl CRIZOTINIB andl EVEROLIMUS â€”manufacturerofcrizotinibandeverolimusadvisesavoidconcomitantuse;avoidanceoftelithromycinadvisedbymanufacturerof DASATINIB (plasmaconcentrationofdasatinibpossiblyincreased);telithromycinpossiblyincreasestheplasmaconcentrationofl IBRUTINIB â€”reducedoseofibrutinib(seeunderIbrutinib,p809);avoidanceoftelithromycinadvisedbymanufacturerofl LAPATINIB andl NILOTINIB ;telithromycinpossiblyincreasesplasmaconcentrationofl PAZOPANIB (reducedoseofpazopanib);telithromycinpossiblyincreasesplasmaconcentrationof PONATINIB â€”considerreducinginitialdoseofponatinib(seeunderPonatinib,p814);manufacturerofruxolitinibadvisesdosereductionwhentelithromycingivenwithl RUXOLITINIB â€”consultruxolitinibproductliterature;telithromycinpossiblyincreasesplasmaconcentrationofl DOCETAXEL â€”manufacturerofdocetaxeladvisesavoidconcomitantuseorconsiderreducingdocetaxeldose
Dapoxetine: avoidanceoftelithromycinadvisedbymanufacturerofl DAPOXETINE (increasedriskoftoxicity)
Diuretics: telithromycinincreasesplasmaconcentrationofl EPLERENONE â€”avoidconcomitantuse
Domperidone: possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithl DOMPERIDONE â€”avoidconcomitantuse
ErgotAlkaloids: increasedriskofergotismwhentelithromycingivenwithl ERGOTAMINE â€”avoidconcomitantuse 
 TRIANGLE Fosaprepitant: telithromycinpossiblyincreasesplasmaconcentrationof FOSAPREPITANT 
Ivabradine: telithromycinpossiblyincreasesplasmaconcentrationofl IVABRADINE â€”avoidconcomitantuse
PentamidineIsetionate: possibleincreasedriskofventriculararrhythmiaswhentelithromycingivenwithparenterall PENTAMIDINEISETIONATE 
Ranolazine: telithromycinpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse
Sildenafil: telithromycinpossiblyincreasesplasmaconcentrationofl SILDENAFIL â€”considerreducinginitialdoseofsildenafilforerectiledysfunctionorreducesildenafildosefrequencytooncedailyforpulmonaryhypertension
Sirolimus: telithromycinincreasesplasmaconcentrationofl SIROLIMUS â€”avoidconcomitantuse
Tacrolimus: telithromycinpossiblyincreasesplasmaconcentrationofl TACROLIMUS  
 TRIANGLE Ulipristal: avoidanceoftelithromycinadvisedbymanufactureroflow-dose ULIPRISTAL  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Telmisartan see Angiotensin-
 IIR eceptorAntagonists
 Temazepam see Anxiolyticsand 
 Hypnotics 
 Temocillin see Penicillins 
 Temoporfinl 
 Cytotoxics
:increasedskinphotosensitivitywhentemoporfingivenwithtopicall FLUOROURACILT emozolomide 
 TRIANGLE Antiepileptics: plasmaconcentrationoftemozolomideincreasedby SODIUMVALPROATE and VALPROICACID  
Antipsychotics:  avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)Temsirolimus NOTET hemainactivemetaboliteoftemsirolimusissirolimusâ€”seealsointeractionsofsirolimusandconsultproductliteraturelAntibacterials:  plasmaconcentrationofactivemetaboliteoftemsirolimusreducedbyl RIFAMPICIN â€”avoidconcomitantuse
 Antifungals:  plasmaconcentrationofactivemetaboliteoftemsirolimusincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;manufactureroftemsirolimusadvisesavoidconcomitantusewithl ITRACONAZOLE (plasmaconcentrationoftemsirolimuspossiblyincreased)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)Tenofovir
Antivirals: manufactureroftenofoviradvisesavoidconcomitantusewith ADEFOVIR ;tenofovirreducesplasmaconcentrationof ATAZANAVIR ,alsoplasmaconcentrationoftenofovirpossiblyincreased;tenofovirincreasesplasmaconcentrationofl DIDANOSINE (increasedriskoftoxicity)â€”avoidconcomitantuse;plasmaconcentrationoftenofovirincreasedby LOPINAVIR andTELAPREVIR
Orlistat: absorptionoftenofovirpossiblyreducedbyl ORLISTAT
 Tenoxicam see 
 NSAID s
 Terazosin see Alpha-blockers 
 Terbinafinel 
 Antibacterials
:plasmaconcentrationofterbinafinereducedbylRIFAMPICIN 
 TRIANGLE Antidepressants: terbinafinepossiblyincreasesplasmaconcentrationof PAROXETINE and TRICYCLICS  
 TRIANGLE Antifungals:terbinafineincreasesplasmaconcentrationof FLUCONAZOLE  
 TRIANGLE Ciclosporin:terbinafinepossiblyreducesplasmaconcentrationofCICLOSPORIN 
 TRIANGLE Oestrogens: occasionalreportsofbreakthroughbleedingwhenterbinafinegivenwith OESTROGENS (whenusedforcontraception) 
 TRIANGLE Progestogens: occasionalreportsofbreakthroughbleedingwhenterbinafinegivenwith PROGESTOGENS (whenusedforcontraception) 
 TRIANGLE Ulcer-healingDrugs:plasmaconcentrationofterbinafineincreasedby CIMETIDINE
 Terbutaline see Sympathomimetics
,Beta
Teriflunomide  
 TRIANGLE  Antibacterials:  teriflunomideincreasesplasmaconcentrationof CEFACLOR ;plasmaconcentrationofteriflunomidereducedby RIFAMPICIN  
 TRIANGLE Antidiabetics:   teriflunomideincreasesplasmaconcentrationof REPAGLINIDE  
 lLipid-regulating
 Drugs:   theeffectofteriflunomideissignificantlydecreasedby COLESTYRAMINE (enhancedelimination)â€”avoidunlessdrugeliminationdesired;teriflunomideincreasesplasmaconcentrationofl ROSUVASTATIN (considerreducingdoseofrosuvastatin) 
 TRIANGLE Oestrogens:  teriflunomideincreasesplasmaconcentrationof ETHINYLESTRADIOL  
 TRIANGLE Progestogens: teriflunomideincreasesplasmaconcentrationof LEVONORGESTREL  l
 Vaccines:  riskofgeneralisedinfectionswhenteriflunomidegivenwithlivel VACCINES â€”avoidconcomitantuseTestolactone
 
Anticoagulants:   testolactoneenhancesanticoagulanteffectofl COUMARINS andl  PHENINDIONE T estosteronelAnticoagulants:testosteroneenhancesanticoagulanteffectoflCOUMARINSandlPHENINDIONE 
 TRIANGLE Antidiabetics:testosteronepossiblyenhanceshypoglycaemiceffectof ANTIDIABETICST etrabenazinelAntidepressants:  riskof CNS toxicitywhentetrabenazinegivenwithl  MAOI S (avoidtetrabenazinefor2weeksafterMAOIs) 
 TRIANGLE Antipsychotics: increasedriskofextrapyramidalside-effectswhentetrabenazinegivenwith ANTIPSYCHOTICS  
 TRIANGLE Dopaminergics: increasedriskofextrapyramidalside-effectswhentetrabenazinegivenwith AMANTADINE  
 TRIANGLE Metoclopramide: increasedriskofextrapyramidalside-effectswhentetrabenazinegivenwith METOCLOPRAMIDE
 Tetracosactide see Corticosteroids 
 Tetracycline see Tetracyclines 
Tetracyclines
 TRIANGLE Adsorbents: absorptionoftetracyclinespossiblyreducedby KAOLIN  
 TRIANGLE Antacids: absorptionoftetracyclinesreducedby ANTACIDS  
 TRIANGLE Antibacterials:plasmaconcentrationofdoxycyclinereducedbyRIFAMPICINâ€”considerincreasingdoseofdoxycycline;tetracyclinespossiblyantagoniseeffectsof PENICILLINS  
 lAnticoagulants:tetracyclinespossiblyenhanceanticoagulanteffectoflCOUMARINSandlPHENINDIONE 
 TRIANGLE Antidiabetics:tetracyclinespossiblyenhancehypoglycaemiceffectof SULFONYLUREAS  
 TRIANGLE Antiepileptics: metabolismofdoxycyclineacceleratedby CARBAMAZEPINE (reducedeffect);metabolismofdoxycyclineacceleratedby FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE (reducedplasmaconcentration) 
 TRIANGLE Atovaquone: tetracyclinereducesplasmaconcentrationof ATOVAQUONE  
 TRIANGLE CalciumSalts: absorptionoftetracyclinereducedby  CALCIUM SALTS  
 TRIANGLE Cytotoxics:  doxycyclineortetracyclineincreaseriskof METHOTREXATE toxicity 
 TRIANGLE DairyProducts: absorptionoftetracyclines(exceptdoxycyclineandminocycline)reducedby DAIRYPRODUCTS  
 TRIANGLE Diuretics:  manufactureroflymecyclineadvisesavoidconcomitantusewith DIURETICS  
 TRIANGLE ErgotAlkaloids: increasedriskofergotismwhentetracyclinesgivenwith ERGOTAMINE  
 TRIANGLE IronSalts: absorptionoftetracyclinesreducedbyoral IRONSALTS ,alsoabsorptionoforalironsaltsreducedbytetracyclines 
 TRIANGLE Lipid-regulatingDrugs:absorptionoftetracyclinepossiblyreducedby COLESTIPOL andCOLESTYRAMINE
 TRIANGLE StrontiumRanelate: absorptionoftetracyclinesreducedby STRONTIUMRANELATE (manufacturerofstrontiumranelateadvisesavoidconcomitantuse) 
 TRIANGLE Ulcer-healingDrugs:absorptionoftetracyclinesreducedby SUCRALFATE and TRIPOTASSIUMDICITRATOBISMUTHATE  
 TRIANGLE Vaccines:antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein BNF  
 TRIANGLE Zinc: absorptionoftetracyclinesreducedby ZINC ,alsoabsorptionofzincreducedbytetracyclines
 sTheophylline 
 TRIANGLE Allopurinol: plasmaconcentrationoftheophyllinepossiblyincreasedby ALLOPURINOL  
 TRIANGLE Anaesthetics,General: increasedriskofconvulsionswhentheophyllinegivenwith KETAMINE  
 TRIANGLE Anti-arrhythmics:theophyllineantagonisesanti-arrhythmiceffectof ADENOSINE â€”manufacturerofadenosineadvisesavoidtheophyllinefor24hoursbeforeadenosine;plasmaconcentrationoftheophyllineincreasedby PROPAFENONE 
Antibacterials: plasmaconcentrationoftheophyllinepossiblyincreasedby CLARITHROMYCIN and ISONIAZID ;plasmaconcentrationoftheophyllineincreasedbyl ERYTHROMYCIN (alsotheophyllinemayreduceabsorptionoforalerythromycin);plasmaconcentrationoftheophyllineincreasedbyl CIPROFLOXACIN andl NORFLOXACIN ;metabolismoftheophyllineacceleratedbyRIFAMPICIN(reducedplasmaconcentration);possibleincreasedriskofconvulsionswhentheophyllinegivenwithl QUINOLONES  
Antidepressants:plasmaconcentrationoftheophyllineincreasedbyl FLUVOXAMINE (concomitantuseshouldusuallybeavoided,butwherenotpossiblehalvetheophyllinedoseandmonitorplasma-theophyllineconcentration);plasmaconcentrationoftheophyllinepossiblyreducedby STJOHN â€™ SWORT 
Antiepileptics: metabolismoftheophyllineacceleratedbyCARBAMAZEPINE,lPHENOBARBITALandlPRIMIDONE(reducedeffect);plasmaconcentrationofbothdrugsreducedwhentheophyllinegivenwithlFOSPHENYTOINandlPHENYTOIN
Antifungals: plasmaconcentrationoftheophyllinepossiblyincreasedbyl FLUCONAZOLE andl KETOCONAZOLE 
Antivirals: plasmaconcentrationoftheophyllinepossiblyincreasedby ACICLOVIR and VALACICLOVIR ;metabolismoftheophyllineacceleratedbyl RITONAVIR (reducedplasmaconcentration) 
 TRIANGLE AnxiolyticsandHypnotics: theophyllinepossiblyreduceseffectsof BENZODIAZEPINES  
 TRIANGLE Caffeinecitrate: avoidanceoftheophyllineadvisedbymanufacturerof CAFFEINECITRATE  
 lCalcium-channelBlockers: plasmaconcentrationoftheophyllinepossiblyincreasedbylCALCIUM- CHANNELBLOCKERS (enhancedeffect);plasmaconcentrationoftheophyllineincreasedby DILTIAZEM ;plasmaconcentrationoftheophyllineincreasedbyl VERAPAMIL (enhancedeffect) 
 TRIANGLE Corticosteroids: increasedriskofhypokalaemiawhentheophyllinegivenwith CORTICOSTEROIDS  
 TRIANGLE Cytotoxics:plasmaconcentrationoftheophyllinepossiblyincreasedbyMETHOTREXATE
Deferasirox: plasmaconcentrationoftheophyllineincreasedbyl DEFERASIROX (considerreducingdoseoftheophylline) 
 TRIANGLE Disulfiram: metabolismoftheophyllineinhibitedby DISULFIRAM (increasedriskoftoxicity) 
 TRIANGLE Diuretics:increasedriskofhypokalaemiawhentheophyllinegivenwith ACETAZOLAMIDE , LOOPDIURETICS or THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE Doxapram: increasedCNSstimulationwhentheophyllinegivenwith DOXAPRAM 
Interferons: metabolismoftheophyllineinhibitedbyl INTERFERONALFA andl PEGINTERFERONALFA (considerreducingdoseoftheophylline) 
 TRIANGLE LeukotrieneReceptorAntagonists: plasmaconcentrationoftheophyllinepossiblyincreasedby ZAFIRLUKAST ,alsoplasmaconcentrationofzafirlukastreduced 
 TRIANGLE Lithium: theophyllineincreasesexcretionof LITHIUM (reducedplasmaconcentration) 
 TRIANGLE Oestrogens:plasmaconcentrationoftheophyllineincreasedby OESTROGENS (considerreducingdoseoftheophylline)BNF
 TRIANGLE Pentoxifylline: plasmaconcentrationoftheophyllineincreasedby PENTOXIFYLLINE  
 TRIANGLE Roflumilast: avoidanceoftheophyllineadvisedbymanufacturerof ROFLUMILAST  
 TRIANGLE Sulfinpyrazone: plasmaconcentrationoftheophyllinereducedby SULFINPYRAZONE  
 TRIANGLE Sympathomimetics: manufactureroftheophyllineadvisesavoidconcomitantusewith EPHEDRINE inchildren 
 TRIANGLE Sympathomimetics,Beta2:increasedriskofhypokalaemiawhentheophyllinegivenwithhighdosesof BETA 2 SYMPATHOMIMETICS  
 lUlcer-healingDrugs:    metabolismoftheophyllineinhibitedbyl CIMETIDINE (increasedplasmaconcentration);absorptionoftheophyllinepossiblyreducedby SUCRALFATE (giveatleast2hoursapart) 
 TRIANGLE Vaccines:   plasmaconcentrationoftheophyllinepossiblyincreasedby INFLUENZAVACCINE
 Thiazolidinediones see Antidiabetics 
 Thiopental see Anaesthetics
,Genera
ThiotepalAntipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis) 
 TRIANGLE MuscleRelaxants: thiotepaenhanceseffectsof SUXAMETHONIUM
 Thioxanthenes see Antipsychotics 
 Thyroid 
Hormones
 TRIANGLE Anti-arrhythmics:serumconcentrationsofthyroidhormonescanbeaffectedby AMIODARONE â€”monitorthyroidfunctionclosely 
 TRIANGLE Antibacterials:   metabolismoflevothyroxineacceleratedby RIFAMPICIN (mayincreaserequirementsforlevothyroxineinhypothyroidism)l
 Anticoagulants:   thyroidhormonesenhanceanticoagulanteffectofl COUMARINS andl PHENINDIONE  
 TRIANGLE Antidepressants:  thyroidhormonesenhanceeffectsof AMITRIPTYLINE and IMIPRAMINE ;thyroidhormonespossiblyenhanceeffectsof  TRICYCLIC S  
 TRIANGLE Antiepileptics:    metabolismofthyroidhormonesacceleratedby CARBAMAZEPINE , PHENOBARBITAL and PRIMIDONE (mayincreaserequirementsforthyroidhormonesinhypothyroidism);metabolismofthyroidhormonesacceleratedby FOS PHENYTOIN  andPHENYTOIN(mayincreaserequirementsinhypothyroidism),alsoplasmaconcentrationoffosphenytoinandphenytoinpossiblyincreased 
 TRIANGLE Beta-blockers:levothyroxineacceleratesmetabolismof PROPRANOLOL  
 TRIANGLE CalciumSalts: absorptionoflevothyroxinereducedby CALCIUMSALTS  
 TRIANGLE Colestilan: manufacturerofcolestilanadvisesgivelevothyroxineatleast1hourbeforeor3hoursafter COLESTILAN  
 TRIANGLE Cytotoxics:  plasmaconcentrationoflevothyroxinepossiblyreducedby IMATINIB  
 TRIANGLE IronSalts: absorptionoflevothyroxinereducedbyoral IRONSALTS (giveatleast2hoursapart) 
 TRIANGLE Lanthanum: absorptionoflevothyroxinereducedby LANTHANUM (giveatleast2hoursapart) 
 TRIANGLE Lipid-regulatingDrugs:absorptionoflevothyroxinereducedby COLESEVELAM ;absorptionofthyroidhormonesreducedby COLESTIPOL and COLESTYRAMINE  
 TRIANGLE Oestrogens: requirementsforthyroidhormonesinhypothyroidismmaybeincreasedby OESTROGENS  
 TRIANGLE Orlistat: possibleincreasedriskofhypothyroidismwhenlevothyroxinegivenwith ORLISTAT  
 TRIANGLE PolystyreneSulfonateResins: absorptionoflevothyroxinereducedby POLYSTYRENESULFONATERESINS  
 TRIANGLE Sevelamer: absorptionoflevothyroxinepossiblyreducedby SEVELAMER  
 TRIANGLE Ulcer-healingDrugs:absorptionoflevothyroxinereducedbyCIMETIDINEand SUCRALFATET iagabine
 TRIANGLE Antiepileptics:plasmaconcentrationoftiagabinereducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE
Antimalarials: anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
Antipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered)
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTATT iaprofenic
 Acid see 
 NSAID s
 sTibolone 
 TRIANGLE Antibacterials:metabolismoftiboloneacceleratedbyRIFAMPICIN(reducedplasmaconcentration) 
 TRIANGLE Antiepileptics:metabolismoftiboloneacceleratedbyCARBAMAZEPINE(reducedplasmaconcentration);metabolismoftiboloneacceleratedbyFOSPHENYTOINand PHENYTOINT icagrelor
Antibacterials: plasmaconcentrationofticagrelorpossiblyincreasedbyl CLARITHROMYCIN â€”manufacturerofticagreloradvisesavoidconcomitantuse;plasmaconcentrationofticagrelorpossiblyincreasedby ERYTHROMYCIN ;plasmaconcentrationofticagrelorreducedbylRIFAMPICIN 
Anticoagulants:ticagrelorincreasesplasmaconcentrationofl DABIGATRAN  
 TRIANGLE Antidepressants:possibleincreasedriskofbleedingwhenticagrelorgivenwith CITALOPRAM , PAROXETINE or SERTRALINE  
 TRIANGLE Antiepileptics:plasmaconcentrationofticagrelorpossiblyreducedbyCARBAMAZEPINE,FOSPHENYTOIN,PHENOBARBITAL,PHENYTOINandPRIMIDONE
Antifungals: plasmaconcentrationofticagrelorincreasedbyl KETOCONAZOLE â€”manufacturerofticagreloradvisesavoidconcomitantuse
Antivirals: plasmaconcentrationofticagrelorpossiblyincreasedbyl ATAZANAVIR andl RITONAVIR â€”manufacturerofticagreloradvisesavoidconcomitantuse 
 TRIANGLE Calcium-channelBlockers: plasmaconcentrationofticagrelorincreasedby DILTIAZEM 
CardiacGlycosides: ticagrelorincreasesplasmaconcentrationofl DIGOXIN  
 TRIANGLE Ciclosporin: plasmaconcentrationofticagrelorincreasedby CICLOSPORIN 
ErgotAlkaloids: ticagrelorpossiblyincreasesplasmaconcentrationofl ERGOTALKALOIDS  
 lLipid-regulatingDrugs:ticagrelorincreasesplasmaconcentrationofl SIMVASTATIN (increasedriskoftoxicity);separatingadministrationfromticagrelorby12hoursadvisedbymanufacturerof LOMITAPIDE
 Ticarcillin see Penicillins 
 Tick-borne 
 Encephalitis 
 Vaccine see Vaccines 
Tigecycline
 TRIANGLE Vaccines:antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Timolol see Beta-blockers 
Tinidazole
 TRIANGLE Antibacterials:plasmaconcentrationoftinidazolepossiblyreducedbyRIFAMPICIN 
 TRIANGLE Vaccines:antibacterialsinactivateORALTYPHOIDVACCINEâ€”seeunderTyphoidVaccineinBNF
 Tinzaparin see Heparins 
 Tioguaninel 
 Antipsychotics
:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Cytotoxics:increasedriskofhepatotoxicitywhentioguaninegivenwith BUSULFAN
 Tiotropium see Antimuscarinics
Tipranavir  
 TRIANGLE Analgesics: plasmaconcentrationoftipranavirpossiblyreducedby BUPRENORPHINE  
 TRIANGLE Antacids: absorptionoftipranavirreducedby ANTACIDS (giveatleast2hoursapart)
 Antibacterials:  tipranavirincreasesplasmaconcentrationofl CLARITHROMYCIN (reducedoseofclarithromycininrenalimpairment),alsoplasmaconcentrationoftipranavirincreasedbyclarithromycin;tipranavirincreasesplasmaconcentrationofl RIFABUTIN (reducedoseofrifabutin);plasmaconcentrationoftipranavirpossiblyreducedbyl RIFAMPICIN â€”avoidconcomitantuse;avoidanceofconcomitanttipranavirinsevererenalandhepaticimpairmentadvisedbymanufacturerofl TELITHROMYCIN  
 TRIANGLE Anticoagulants: avoidanceoftipranaviradvisedbymanufacturerof APIXABAN and RIVAROXABAN  l
 Antidepressants:  plasmaconcentrationoftipranavirpossiblyreducedbyl STJOHN â€™ SWORT â€”avoidconcomitantuse 
 TRIANGLE Antiepileptics: plasmaconcentrationoftipranavirpossiblyreducedby CARBAMAZEPINE  
 TRIANGLE Antifungals:  plasmaconcentrationoftipranavirincreasedby FLUCONAZOLE  
 
Antimalarials:  cautionwithtipranaviradvisedbymanufacturerof ARTEMETHERWITHLUMEFANTRINE ;tipranavirpossiblyincreasesplasmaconcentrationofl QUININE (increasedriskoftoxicity) 
 TRIANGLE Antimuscarinics: avoidanceoftipranaviradvisedbymanufacturerof DARIFENACIN 
 
Antipsychotics:   tipranavirpossiblyincreasesplasmaconcentrationofl ARIPIPRAZOLE (reducedoseofaripiprazoleâ€”consultaripiprazoleproductliterature);tipranavirpossiblyincreasesplasmaconcentrationofl QUETIAPINE â€”manufacturerofquetiapineadvisesavoidconcomitantuse
Antivirals: tipranavirreducesplasmaconcentrationofl ABACAVIR ,l FOSAMPRENAVIR ,l LOPINAVIR ,l SAQUINAVIR andl ZIDOVUDINE ;plasmaconcentrationoftipranavirincreasedby ATAZANAVIR (alsoplasmaconcentrationofatazanavirreduced);manufactureroftipranaviradvisesavoidconcomitantusewith BOCEPREVIR and TELAPREVIR ;tipranavirreducesplasmaconcentrationof DIDANOSINE â€”manufactureroftipranaviradvisestipranaviranddidanosinecapsulesshouldbetakenatleast2hoursapart;tipranavirreducestheplasmaconcentrationofl DOLUTEGRAVIR (seeunderDolutegravir,p557);tipranavirreducesplasmaconcentrationofl ETRAVIRINE ,alsoplasmaconcentrationoftipranavirincreased(avoidconcomitantuse)lBeta-blockers:manufactureroftipranaviradvisesavoidconcomitantusewithl METOPROLOL forheartfailure 
 TRIANGLE Bosentan: manufactureroftipranaviradvisesavoidconcomitantusewith BOSENTAN 
Cobicistat: plasmaconcentrationofbothdrugsreducedwhentipranavirgivenwithl COBICISTAT (avoidconcomitantuse)lLipid-regulating
 Drugs:   increasedriskofmyopathywhentipranavirgivenwithl ATORVASTATIN (seeunderAtorvastatin,p179);tipranavirincreasesplasmaconcentrationofl ROSUVASTATIN â€”adjustdoseofrosuvastatin(consultproductliterature);tipranavirpossiblyincreasesplasmaconcentrationofl SIMVASTATIN â€”avoidconcomitantuse;avoidanceoftipranaviradvisedbymanufacturerofl LOMITAPIDE (plasmaconcentrationoflomitapidepossiblyincreased)lOrlistat:  absorptionoftipranavirpossiblyreducedbyl ORLISTAT 
Ranolazine: tipranavirpossiblyincreasesplasmaconcentrationofl RANOLAZINE â€”manufacturerofranolazineadvisesavoidconcomitantuse 
 TRIANGLE Sildenafil: manufactureroftipranaviradvisesavoidconcomitantuseof SILDENAFIL forpulmonaryarterialhypertension 
 TRIANGLE Sympathomimetics,Beta2:manufactureroftipranaviradvisesavoidconcomitantusewith SALMETEROL  
 lUlcer-healingDrugs:tipranavirreducesplasmaconcentrationofl ES OMEPRAZOLE  andlOMEPRAZOLE 
 TRIANGLE Vitamins: increasedriskofbleedingwhentipranavirgivenwithhighdosesof VITAMINET irofiban 
 TRIANGLE Iloprost: increasedriskofbleedingwhentirofibangivenwith ILOPROST
 Tizanidine see Muscle 
 Relaxants 
 Tobramycin see Aminoglycosides 
 Tocilizumabl 
 Antipsychotics
:avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
 Tolazoline see Alpha-blockers 
 Tolbutamide see Antidiabetics 
Tolcapone
 TRIANGLE Memantine: effectsofdopaminergicspossiblyenhancedby MEMANTINE  
 TRIANGLE Methyldopa: antiparkinsonianeffectofdopaminergicsantagonisedby METHYLDOPAT olfenamic
 Acid see 
 NSAID s
 Tolterodine see Antimuscarinics 
Tolvaptan
 TRIANGLE Antifungals:plasmaconcentrationoftolvaptanincreasedby KETOCONAZOLE â€”manufacturerofketoconazoleadvisesavoidconcomitantuse 
 TRIANGLE CardiacGlycosides: tolvaptanincreasesplasmaconcentrationof DIGOXIN (increasedriskoftoxicity)
GrapefruitJuice: plasmaconcentrationoftolvaptanincreasedbyl GRAPEFRUITJUICE â€”avoidconcomitantuse 
 TRIANGLE Lipid-regulatingDrugs:separatingadministrationfromtolvaptanby12hoursadvisedbymanufacturerof LOMITAPIDET opiramate
Antidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered) 
 TRIANGLE Antidiabetics: topiramatepossiblyincreasesplasmaconcentrationof METFORMIN ;topiramatepossiblyreducesplasmaconcentrationof GLIBENCLAMIDE 
Antiepileptics: plasmaconcentrationoftopiramateoftenreducedbyCARBAMAZEPINE;topiramateincreasesplasmaconcentrationofl FOS PHENYTOIN  andlPHENYTOIN(alsoplasmaconcentrationoftopiramatereduced);topiramatereducesplasmaconcentrationof PERAMPANEL ;plasmaconcentrationoftopiramatepossiblyreducedby PHENOBARBITAL and PRIMIDONE ;hyperammonaemiaand CNS toxicityreportedwhentopiramategivenwith SODIUMVALPROATE and VALPROICACID  
 lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
 lAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered) 
 TRIANGLE Diuretics: plasmaconcentrationoftopiramatepossiblyincreasedby HYDROCHLOROTHIAZIDE  
 TRIANGLE Lithium: topiramatepossiblyaffectsplasmaconcentrationof LITHIUM 
Oestrogens: topiramateacceleratesmetabolismofl OESTROGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,contraceptivepatches,andvaginalringsâ€”seeContraceptiveInteractionsin BNF )lOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT
Progestogens: topiramateacceleratesmetabolismofl PROGESTOGENS (reducedcontraceptiveeffectwithcombinedoralcontraceptives,progestogen-onlyoralcontraceptives,contraceptivepatches,vaginalrings,etonogestrel-releasingimplant,andemergencyhormonalcontraceptionâ€”seeContraceptiveInteractionsinBNF)BNF
 Torasemide see Diuretics 
 Toremifene 
 
 Anticoagulants:    toremifenepossiblyenhancesanticoagulanteffectofl COUMARINS   
 TRIANGLE Antiepileptics: metabolismoftoremifenepossiblyacceleratedby CARBAMAZEPINE (reducedplasmaconcentration);metabolismoftoremifenepossiblyacceleratedby FOS PHENYTOIN  andPHENYTOIN;metabolismoftoremifeneacceleratedby PHENOBARBITAL and PRIMIDONE (reducedplasmaconcentration)lCytotoxics:  possibleincreasedriskofventriculararrhythmiaswhentoremifenegivenwithl VANDETANIB â€”avoidconcomitantuse 
 TRIANGLE Diuretics:  increasedriskofhypercalcaemiawhentoremifenegivenwith THIAZIDESANDRELATEDDIURETICST rabectedin
Alcohol: manufactureroftrabectedinadvisesavoidconcomitantusewithl ALCOHOL 
 
Antibacterials:   plasmaconcentrationoftrabectedinreducedbyl RIFAMPICIN 
Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)l
 Vaccines:   riskofgeneralisedinfectionswhentrabectedingivenwithlivel VACCINES â€”avoidconcomitantuse
 Tramadol see Opioid 
 Analgesics 
 Trandolapril see 
 ACE Inhibitors
 Tranylcypromine see 
 MAOI sTrastuzumablAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINESâ€”avoidconcomitantuse
 Trazodone see Antidepressants
,Tricyclic(related)
 Tretinoin see Retinoids 
 Triamcinolone see Corticosteroids 
 Triamterene see Diuretics 
Trientine
 TRIANGLE Zinc: trientinereducesabsorptionof ZINC ,alsoabsorptionoftrientinereducedbyzinc
 Trifluoperazine see Antipsychotics 
 Trihexyphenidyl see Antimuscarinics 
Trimethoprim
 Inhibitors: possibleincreasedriskofhyperkalaemiawhentrimethoprimgivenwith ACEINHIBITORS  
 TRIANGLE Angiotensin- IIR eceptor
 Antagonists: possibleincreasedriskofhyperkalaemiawhentrimethoprimgivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Anti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhentrimethoprim(asco-trimoxazole)givenwith AMIODARONE â€”manufacturerofamiodaroneadvisesavoidconcomitantuseofco-trimoxazole 
 TRIANGLE Antibacterials:plasmaconcentrationoftrimethoprimpossiblyreducedbyRIFAMPICIN;plasmaconcentrationofbothdrugsmayincreasewhentrimethoprimgivenwith DAPSONE  
 TRIANGLE Anticoagulants:trimethoprimpossiblyenhancesanticoagulanteffectofCOUMARINS 
 TRIANGLE Antidiabetics: trimethoprimpossiblyenhanceshypoglycaemiceffectof REPAGLINIDE â€”manufactureradvisesavoidconcomitantuse;trimethoprimrarelyenhancestheeffectsof SULFONYLUREAS  
Antiepileptics:  trimethoprimincreasesplasmaconcentrationoflFOSPHENYTOINandlPHENYTOIN(alsoincreasedantifolateeffect)
Antimalarials: increasedantifolateeffectwhentrimethoprimgivenwithl PYRIMETHAMINE  
 TRIANGLE Antivirals: trimethoprim(asco-trimoxazole)increasesplasmaconcentrationof LAMIVUDINE â€”avoidconcomitantuseofhigh-doseco-trimoxazole
Azathioprine: increasedriskofhaematologicaltoxicitywhentrimethoprim(alsowithco-trimoxazole)givenwithl AZATHIOPRINE  
Ciclosporin: increasedriskofnephrotoxicitywhentrimethoprimgivenwithl CICLOSPORIN ,alsoplasmaconcentrationofciclosporinreducedbyintravenoustrimethoprimlCytotoxics:increasedriskofhaematologicaltoxicitywhentrimethoprim(alsowithco-trimoxazole)givenwithl MERCAPTOPURINE orl METHOTREXATE  
 TRIANGLE Diuretics:increasedriskofhyperkalaemiawhentrimethoprimgivenwith EPLERENONE ;possibleincreasedriskofhyperkalaemiawhentrimethoprimgivenwith SPIRONOLACTONE  
 TRIANGLE Vaccines:antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF 
 Trimipramine see Antidepressants
,TricyclicTripotassium
 mDicitratobismuthate 
 TRIANGLE Antibacterials:tripotassiumdicitratobismuthatereducesabsorptionof TETRACYCLINES
 Tropicamide see Antimuscarinics 
 Trospium see Antimuscarinics 
 Typhoid 
 Vaccine
(oral)seeVaccinesTyphoidVaccine(parenteral)seeVaccines
 sUbidecarenone 
 TRIANGLE Anticoagulants:ubidecarenonemayenhanceorreduceanticoagulanteffectof WARFARINU lcer-healing
 Drugs see Histamine 
 H
2-antagonists,ProtonPumpInhibitors,Sucralfate,andTripotassiumDicitratobismuthateUlipristal
 lAntibacterials: manufactureroflow-doseulipristaladvisesavoidconcomitantusewith CLARITHROMYCIN and TELITHROMYCIN ;plasmaconcentrationoflow-doseulipristalincreasedby ERYTHROMYCIN â€”manufactureroflow-doseulipristaladvisesavoidconcomitantuse;manufacturerofulipristaladvisesavoidconcomitantusewithlRIFAMPICIN(contraceptiveeffectofulipristalpossiblyreduced) 
 TRIANGLE Anticoagulants:manufacturerofulipristaladvisesgive DABIGATRAN atleast15hoursbeforeorafterulipristal
Antidepressants: manufacturerofulipristaladvisesavoidconcomitantusewithl STJOHN â€™ SWORT (contraceptiveeffectofulipristalpossiblyreduced)lAntiepileptics:manufacturerofulipristaladvisesavoidconcomitantusewithlCARBAMAZEPINE,lFOSPHENYTOIN,lPHENOBARBITAL,lPHENYTOINandlPRIMIDONE(contraceptiveeffectofulipristalpossiblyreduced) 
 TRIANGLE Antifungals: plasmaconcentrationoflow-doseulipristalincreasedby KETOCONAZOLE â€”manufactureroflow-doseulipristaladvisesavoidconcomitantuse;manufacturerofulipristaladvisesavoidconcomitantusewith ITRACONAZOLE  
 TRIANGLE Antihistamines: manufacturerofulipristaladvisesgive FEXOFENADINE atleast15hoursbeforeorafterulipristal
Antivirals: manufacturerofulipristaladvisesavoidconcomitantusewithl RITONAVIR (contraceptiveeffectofulipristalpossiblyreduced) 
 TRIANGLE Calcium-channelBlockers: manufactureroflow-doseulipristaladvisesavoidconcomitantusewith VERAPAMIL  
 TRIANGLE CardiacGlycosides:manufacturerofulipristaladvisesgiveDIGOXINatleast15hoursbeforeorafterulipristal 
 TRIANGLE GrapefruitJuice: manufactureroflow-doseulipristaladvisesavoidconcomitantusewith GRAPEFRUITJUICE 
Progestogens: ulipristalpossiblyreducescontraceptiveeffectofl PROGESTOGENS
 Umeclidinium see Antimuscarinics 
 Ursodeoxycholic 
 Acid see Bile 
 Acids 
 Ustekinumabl 
 Antipsychotics
:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)lVaccines:riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivelVACCINESâ€”avoidconcomitantuseVaccines
Abatacept: riskofgeneralisedinfectionswhenlivevaccinesgivenwithl ABATACEPT â€”avoidconcomitantuse 
 TRIANGLE Aminophylline: influenzavaccinepossiblyincreasesplasmaconcentrationof AMINOPHYLLINE 
Anakinra: riskofgeneralisedinfectionswhenlivevaccinesgivenwithl ANAKINRA â€”avoidconcomitantuse  
 TRIANGLE Antibacterials: oraltyphoidvaccineinactivatedby  ANTI BACTERIALS â€”seeunderTyphoidVaccinein BNF  
 TRIANGLE Anticoagulants:  influenzavaccinepossiblyenhancesanticoagulanteffectof WARFARIN  
 TRIANGLE Antiepileptics: influenzavaccineenhanceseffectsof FOS PHENYTOIN  andPHENYTOIN 
 TRIANGLE Antimalarials: oraltyphoidvaccineinactivatedby ANTIMALARIALS â€”seeunderTyphoidVaccineinBNF
Corticosteroids: immuneresponsetovaccinesimpairedbyhighdosesofl CORTICOSTEROIDS â€”avoidconcomitantusewithlivevaccines
 Cytotoxics:  riskofgeneralisedinfectionswhenlivevaccinesgivenwithl DOXORUBICIN ,l MONOCLONALANTIBODIES ,l PIXANTRONE orl TRABECTEDIN â€”avoidconcomitantuse
Dexrazoxane: riskofgeneralisedinfectionswhenlivevaccinesgivenwithl DEXRAZOXANE â€”avoidconcomitantuse
Etanercept: riskofgeneralisedinfectionswhenlivevaccinesgivenwithl ETANERCEPT â€”avoidconcomitantuse
Immunoglobulins: impairedimmuneresponsetooralpoliomyelitisvaccinemightoccurwithlANTI- DIMMUNOGLOBULINS andl NORMALIMMUNOGLOBULIN â€”giveoralpoliomyelitisvaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;impairedimmuneresponseto BCG vaccine, MMR vaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccinemightoccurwithlANTI-DIMMUNOGLOBULINSâ€”giveBCGvaccine,MMRvaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulins;impairedimmuneresponsetoliveinfluenzavaccinemightoccurwithlANTI-DIMMUNOGLOBULINSandlNORMALIMMUNOGLOBULINâ€”giveliveinfluenzavaccineatleast3weeksbeforeor3monthsafteranti-dimmunoglobulinsandnormalimmunoglobulin;impairedimmuneresponsetoBCGvaccine,MMRvaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccinemightoccurwithlNORMALIMMUNOGLOBULINâ€”giveBCGvaccine,MMRvaccine,oraltyphoidvaccine,rotavirusvaccine,smallpoxvaccine,varicella-zostervaccineandyellowfevervaccineatleast3weeksbeforeor3monthsafternormalimmunoglobulin 
 TRIANGLE Interferons: avoidanceofvaccinesadvisedbymanufacturerof INTERFERONGAMMA 
Leflunomide: riskofgeneralisedinfectionswhenlivevaccinesgivenwithl LEFLUNOMIDE â€”avoidconcomitantuse
Teriflunomide: riskofgeneralisedinfectionswhenlivevaccinesgivenwithl TERIFLUNOMIDE â€”avoidconcomitantuse 
 TRIANGLE Theophylline:  influenzavaccinepossiblyincreasesplasmaconcentrationof THEOPHYLLINEV alaciclovir 
 TRIANGLE Aminophylline: valaciclovirpossiblyincreasesplasmaconcentrationof AMINOPHYLLINE  
 TRIANGLE Ciclosporin: increasedriskofnephrotoxicitywhenvalaciclovirgivenwith CICLOSPORIN  
 TRIANGLE Mycophenolate:  plasmaconcentrationofvalaciclovirincreasedby MYCOPHENOLATE ,alsoplasmaconcentrationofinactivemetaboliteofmycophenolateincreased 
 TRIANGLE Tacrolimus:  possibleincreasedriskofnephrotoxicitywhenvalaciclovirgivenwith TACROLIMUS  
 TRIANGLE Theophylline:valaciclovirpossiblyincreasesplasmaconcentrationofTHEOPHYLLINEValganciclovirlAntibacterials:  increasedriskofconvulsionswhenvalganciclovirgivenwithl IMIPENEMWITHCILASTATIN  l
 Antivirals:  valganciclovirpossiblyincreasesplasmaconcentrationof DIDANOSINE ;profoundmyelosuppressionwhenvalganciclovirgivenwithl ZIDOVUDINE (ifpossibleavoidconcomitantadministration,particularlyduringinitialvalganciclovirtherapy) 
 TRIANGLE Tacrolimus:possibleincreasedriskofnephrotoxicitywhenvalganciclovirgivenwith TACROLIMUSV alproic
 cAcid 
 TRIANGLE Analgesics: effectsofvalproicacidenhancedby ASPIRIN  
Antibacterials:metabolismofvalproicacidpossiblyinhibitedby ERYTHROMYCIN (increasedplasmaconcentration);avoidanceofvalproicacidadvisedbymanufacturerofl PIVMECILLINAM ;plasmaconcentrationofvalproicacidreducedbyl CARBAPENEMS â€”avoidconcomitantuse 
 TRIANGLE Anticoagulants:valproicacidpossiblyenhancesanticoagulanteffectof COUMARINS 
Antidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered)
Antiepileptics: plasmaconcentrationofvalproicacidreducedby CARBAMAZEPINE ,alsoplasmaconcentrationofactivemetaboliteofcarbamazepineincreased;valproicacidpossiblyincreasesplasmaconcentrationof ETHOSUXIMIDE ;valproicacidincreasesorpossiblydecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN,alsoplasmaconcentrationofvalproicacidreduced;valproicacidincreasesplasmaconcentrationofl LAMOTRIGINE (increasedriskoftoxicityâ€”reducelamotriginedose);valproicacidsometimesreducesplasmaconcentrationofanactivemetaboliteof OXCARBAZEPINE ;valproicacidincreasesplasmaconcentrationof PHENOBARBITAL and PRIMIDONE (alsoplasmaconcentrationofvalproicacidreduced);valproicacidpossiblyincreasesplasmaconcentrationof RUFINAMIDE (reducedoseofrufinamide);hyperammonaemiaand CNS toxicityreportedwhenvalproicacidgivenwith TOPIRAMATE 
Antimalarials: anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE 
Antipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered);valproicacidpossiblyincreasesordecreasesplasmaconcentrationof CLOZAPINE ;increasedriskofside-effectsincludingneutropeniawhenvalproicacidgivenwithl OLANZAPINE  
 TRIANGLE Antivirals:plasmaconcentrationofvalproicacidpossiblyreducedby RITONAVIR ;valproicacidpossiblyincreasesplasmaconcentrationofZIDOVUDINE(increasedriskoftoxicity) 
 TRIANGLE AnxiolyticsandHypnotics: plasmaconcentrationofvalproicacidpossiblyincreasedby CLOBAZAM ;increasedriskofside-effectswhenvalproicacidgivenwith CLONAZEPAM ;valproicacidpossiblyincreasesplasmaconcentrationof DIAZEPAM and LORAZEPAM  
 TRIANGLE Bupropion: valproicacidinhibitsthemetabolismof BUPROPION  
 TRIANGLE Cytotoxics:valproicacidincreasesplasmaconcentrationof TEMOZOLOMIDE  
 TRIANGLE Lipid-regulatingDrugs:  absorptionofvalproicacidpossiblyreducedby COLESTYRAMINE  
 TRIANGLE Oestrogens: plasmaconcentrationofvalproicacidpossiblyreducedby ETHINYLESTRADIOL 
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT  
 TRIANGLE SodiumBenzoate: valproicacidpossiblyreduceseffectsof SODIUMBENZOATE 
SodiumOxybate: valproicacidincreasestheplasmaconcentrationofl SODIUMOXYBATE (seeunderSodiumOxybate,p425) 
 TRIANGLE SodiumPhenylbutyrate: valproicacidpossiblyreduceseffectsof SODIUMPHENYLBUTYRATE  
 lUlcer-healingDrugs:metabolismofvalproicacidinhibitedbyl CIMETIDINE (increasedplasmaconcentration)
 Valsartan see Angiotensin-
 IIR eceptorAntagonists
 sVancomycin 
 TRIANGLE Anaesthetics,General: hypersensitivity-likereactionscanoccurwhenintravenousvancomycingivenwith GENERALANAESTHETICSBNF 
 Antibacterials:   increasedriskofnephrotoxicityandototoxicitywhenvancomycingivenwithl AMINOGLYCOSIDES , CAPREOMYCIN or COLISTIMETHATESODIUM ;increasedriskofnephrotoxicitywhenvancomycingivenwith POLYMYXINS   
 TRIANGLE Antifungals: possibleincreasedriskofnephrotoxicitywhenvancomycingivenwith AMPHOTERICIN 
Ciclosporin: increasedriskofnephrotoxicitywhenvancomycingivenwithl CICLOSPORIN  
 TRIANGLE Cytotoxics: increasedriskofnephrotoxicityandpossiblyofototoxicitywhenvancomycingivenwith CISPLATIN 
Diuretics: increasedriskofotoxicitywhenvancomycingivenwithl LOOPDIURETICS  
 TRIANGLE Lipid-regulating
 Drugs: effectsoforalvancomycinantagonisedby COLESTYRAMINE 
MuscleRelaxants: vancomycinenhanceseffectsofl SUXAMETHONIUM  
 TRIANGLE Tacrolimus: possibleincreasedriskofnephrotoxicitywhenvancomycingivenwith TACROLIMUS  
 TRIANGLE Vaccines: antibacterialsinactivate ORALTYPHOIDVACCINE â€”seeunderTyphoidVaccinein  BNF V andetanib
 Analgesics:  possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl METHADONE â€”avoidconcomitantuselAnti-arrhythmics:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl AMIODARONE orl DISOPYRAMIDE â€”avoidconcomitantuselAntibacterials:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithparenterall ERYTHROMYCIN â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl MOXIFLOXACIN â€”avoidconcomitantuse;plasmaconcentrationofvandetanibreducedbyl RIFAMPICIN â€”manufacturerofvandetanibadvisesavoidconcomitantuse 
 TRIANGLE Antidepressants:  manufacturerofvandetanibadvisesavoidconcomitantusewith STJOHN â€™ SWORT (plasmaconcentrationofvandetanibpossiblyreduced) 
 TRIANGLE Antidiabetics: vandetanibpossiblyincreasesplasmaconcentrationof METFORMIN (considerreducingdoseofmetformin) 
 TRIANGLE Antiepileptics: manufacturerofvandetanibadvisesavoidconcomitantusewith CARBAMAZEPINE , PHENOBARBITAL and PRIMIDONE (plasmaconcentrationofvandetanibpossiblyreduced)
Antihistamines: possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl MIZOLASTINE â€”avoidconcomitantuse
Antimalarials: possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl ARTEMETHERWITHLUMEFANTRINE â€”avoidconcomitantuse
 Antipsychotics:  possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl AMISULPRIDE ,l CHLORPROMAZINE ,l HALOPERIDOL ,l PIMOZIDE ,l SULPIRIDE orl ZUCLOPENTHIXOL â€”avoidconcomitantuse;avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)lBeta-blockers:possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl SOTALOL â€”avoidconcomitantuse 
 TRIANGLE CardiacGlycosides: vandetanibincreasesplasmaconcentrationof DIGOXIN â€”possibleincreasedriskofbradycardia
Cytotoxics: possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl ARSENICTRIOXIDE â€”avoidconcomitantuse
HormoneAntagonists:   possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl TOREMIFENE â€”avoidconcomitantusel5 HT 3-receptorAntagonists:increasedriskofventriculararrhythmiaswhenvandetanibgivenwithl ONDANSETRON â€”avoidconcomitantuse
PentamidineIsetionate: possibleincreasedriskofventriculararrhythmiaswhenvandetanibgivenwithl PENTAMIDINEISETIONATE â€”avoidconcomitantuseVardenafillAlpha-blockers:enhancedhypotensiveeffectwhenvardenafilgivenwithl ALPHA - BLOCKERS â€”whenpatientisstableonthealphablockerinitiatevardenafilatthelowestpossibledoseâ€”separatedosesby6hours(exceptwithtamsulosin) 
 TRIANGLE Anti-arrhythmics:avoidanceofvardenafiladvisedbymanufacturerofDISOPYRAMIDE(riskofventriculararrhythmias) 
 TRIANGLE Antibacterials:plasmaconcentrationofvardenafilpossiblyincreasedby CLARITHROMYCIN (considerreducinginitialdoseofvardenafil);plasmaconcentrationofvardenafilincreasedbyERYTHROMYCIN(reducedoseofvardenafil)
Antifungals: plasmaconcentrationofvardenafilincreasedbyl KETOCONAZOLE â€”avoidconcomitantuse;plasmaconcentrationofvardenafilpossiblyincreasedbyl ITRACONAZOLE â€”avoidconcomitantuse
Antivirals: plasmaconcentrationofvardenafilpossiblyincreasedby FOSAMPRENAVIR ;plasmaconcentrationofvardenafilincreasedbyl INDINAVIR andl RITONAVIR â€”avoidconcomitantuse;increasedriskofventriculararrhythmiaswhenvardenafilgivenwithl SAQUINAVIR â€”avoidconcomitantuse;avoidanceofvardenafiladvisedbymanufacturerofl TELAPREVIR ;cautionwithvardenafiladvisedbymanufacturerof TIPRANAVIR  
 TRIANGLE Calcium-channelBlockers: enhancedhypotensiveeffectwhenvardenafilgivenwith NIFEDIPINE 
Cobicistat: plasmaconcentrationofvardenafilpossiblyincreasedbyl COBICISTAT â€”manufacturerofcobicistatadvisesreducedoseofvardenafil(consultcobicistatproductliterature) 
 TRIANGLE Dapoxetine: avoidanceofvardenafiladvisedbymanufacturerof DAPOXETINE 
GrapefruitJuice: plasmaconcentrationofvardenafilpossiblyincreasedbyl GRAPEFRUITJUICE â€”avoidconcomitantuse
Nicorandil: possibleincreasedhypotensiveeffectwhenvardenafilgivenwithl NICORANDIL â€”avoidconcomitantuse
Nitrates: possibleincreasedhypotensiveeffectwhenvardenafilgivenwithl NITRATES â€”avoidconcomitantuse
Riociguat: possibleenhancedhypotensiveeffectwhenvardenafilgivenwithl RIOCIGUAT â€”avoidconcomitantuseVaricella-zoster
 Vaccine see Vaccines 
 Vasodilator 
Antihypertensives
 TRIANGLE AdrenergicNeuroneBlockers: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith ADRENERGICNEURONEBLOCKERS  
 TRIANGLE Alcohol: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith ALCOHOL  
 TRIANGLE Aldesleukin: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith ALDESLEUKIN  
 TRIANGLE Alpha-blockers:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithALPHA-BLOCKERS 
 TRIANGLE Anaesthetics,General: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith GENERALANAESTHETICS  
 TRIANGLE Analgesics:hypotensiveeffectofhydralazine,minoxidilandsodiumnitroprussideantagonisedby NSAIDS  
 TRIANGLE Angiotensin- IIR eceptorAntagonists:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith ANGIOTENSIN - IIRECEPTORANTAGONISTS  
 TRIANGLE Antidepressants:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith MAOIS ;enhancedhypotensiveeffectwhenhydralazineorsodiumnitroprussidegivenwith TRICYCLIC - RELATEDANTIDEPRESSANTS  
 TRIANGLE Antipsychotics:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith PHENOTHIAZINES  
 TRIANGLE AnxiolyticsandHypnotics: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith ANXIOLYTICSANDHYPNOTICS  
 TRIANGLE Beta-blockers:enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith BETA -BLOCKERS
 TRIANGLE  Calcium-channelBlockers: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith CALCIUM - CHANNELBLOCKERS  
 TRIANGLE Clonidine: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith CLONIDINE  
 TRIANGLE Corticosteroids: hypotensiveeffectofhydralazine,minoxidilandsodiumnitroprussideantagonisedby  CO RTICOSTEROIDS  
 TRIANGLE Diazoxide: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith DIAZOXIDE  
 TRIANGLE Diuretics: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith DIURETICS  
 TRIANGLE Dopaminergics: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithCO- BENELDOPA ;enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwithCO- CARELDOPA ;enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith LEVODOPA  
 TRIANGLE Methyldopa: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith METHYLDOPA  
 TRIANGLE Moxisylyte: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith MOXISYLYTE  
 TRIANGLE Moxonidine: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith MOXONIDINE  
 TRIANGLE MuscleRelaxants: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith BACLOFEN ;enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith TIZANIDINE  
 TRIANGLE Nicorandil: possibleenhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith NICORANDIL  
 TRIANGLE Nitrates: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith NITRATES  
 TRIANGLE Oestrogens: hypotensiveeffectofhydralazine,minoxidilandsodiumnitroprussideantagonisedby OESTROGENS  
 TRIANGLE Prostaglandins: enhancedhypotensiveeffectwhenhydralazine,minoxidilorsodiumnitroprussidegivenwith ALPROSTADIL  
 TRIANGLE VasodilatorAntihypertensives: enhancedhypotensiveeffectwhenhydralazinegivenwith MINOXIDIL or SODIUMNITROPRUSSIDE ;enhancedhypotensiveeffectwhenminoxidilgivenwith SODIUMNITROPRUSSIDE
 Vecuronium see Muscle 
 Relaxants 
 Vedolizumab 
 
l
 Antipsychotics:   avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)
Vaccines: riskofgeneralisedinfectionswhenmonoclonalantibodiesgivenwithlivel VACCINES â€”avoidconcomitantuse
Vemurafenib 
 TRIANGLE Antibacterials: manufacturerofvemurafenibadvisesavoidconcomitantusewith RIFABUTIN and RIFAMPICIN  
 
Anticoagulants:  vemurafenibpossiblyenhancesanticoagulanteffectofl WARFARIN  
 TRIANGLE Antidepressants: manufacturerofvemurafenibadvisesavoidconcomitantusewith STJOHN â€™ SWORT  
 TRIANGLE Antiepileptics:  manufacturerofvemurafenibadvisesavoidconcomitantusewith CARBAMAZEPINE , FOS PHENYTOIN  andPHENYTOIN 
 
 
Antipsychotics:  avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Cytotoxics: avoidanceofvemurafenibadvisedbymanufacturerof IPILIMUMAB 
Oestrogens: manufacturerofvemurafenibadvisescontraceptiveeffectoflOESTROGENSpossiblyreduced
Progestogens: manufacturerofvemurafenibadvisescontraceptiveeffectofl PROGESTOGENS possiblyreducedVenlafaxine
Analgesics: increasedriskofbleedingwhenvenlafaxinegivenwithl NSAIDS orl ASPIRIN ;possibleincreasedserotonergiceffectswhen SSRI -relatedantidepressantsgivenwith FENTANYL ;possibleincreasedserotonergiceffectswhenvenlafaxinegivenwith TRAMADOL  
Antidepressants: possibleincreasedserotonergiceffectswhenvenlafaxinegivenwithSTJOHNâ€™SWORT, DULOXETINE or MIRTAZAPINE ;enhanced CNS effectsandtoxicitywhenvenlafaxinegivenwithl  MAOI S (venlafaxineshouldnotbestarteduntil2weeksafterstoppingMAOIs,avoidMAOIsfor1weekafterstoppingvenlafaxine);afterstoppingSSRI-relatedantidepressantsdonotstartl MOCLOBEMIDE foratleast1week
 
Antimalarials:   avoidanceofantidepressantsadvisedbymanufacturerofl ARTEMETHERWITHLUMEFANTRINE andl ARTENIMOLWITHPIPERAQUINE  
 TRIANGLE Antipsychotics:venlafaxineincreasesplasmaconcentrationof HALOPERIDOL  
 TRIANGLE Atomoxetine: possibleincreasedriskofconvulsionswhenantidepressantsgivenwith ATOMOXETINE 
Dapoxetine: possibleincreasedriskofserotonergiceffectswhenvenlafaxinegivenwithl DAPOXETINE (manufacturerofdapoxetineadvisesvenlafaxineshouldnotbestarteduntil1weekafterstoppingdapoxetine,avoiddapoxetinefor2weeksafterstoppingvenlafaxine)
Dopaminergics: cautionwithvenlafaxineadvisedbymanufacturerof ENTACAPONE ;increasedriskofhypertensionandCNSexcitationwhenvenlafaxinegivenwithl SELEGILINE (selegilineshouldnotbestarteduntil1weekafterstoppingvenlafaxine,avoidvenlafaxinefor2weeksafterstoppingselegiline) 
 TRIANGLE 5 HT 1-receptor
 Agonists: possibleincreasedserotonergiceffectswhenvenlafaxinegivenwith5HT1 AGONISTS  
 TRIANGLE 5HT3-receptor
 Antagonists: possibleincreasedserotonergiceffectswhenSSRI-relatedantidepressantsgivenwith5HT3 ANTAGONISTS  
 TRIANGLE Lithium: possibleincreasedserotonergiceffectswhenvenlafaxinegivenwith LITHIUM 
Methylthioninium: riskofCNStoxicitywhenSSRI-relatedantidepressantsgivenwithl METHYLTHIONINIUM â€”avoidconcomitantuse(ifavoidancenotpossible,uselowestpossibledoseofmethylthioniniumandobservepatientforupto4hoursafteradministration)
 Verapamil see Calcium-channe 
 
BlockersVigabatrinlAntidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedbyMAOISandl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered) 
 TRIANGLE Antiepileptics:vigabatrinreducesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN 
 lAntimalarials:anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE  
 lAntipsychotics:anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered)
Orlistat: possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithl ORLISTAT
 Vilanterol see Sympathomimetics
,Beta2
 Vildagliptin see Antidiabetics 
 Vinblastine 
 
Aldesleukin: avoidanceofvinblastineadvisedbymanufacturerofl ALDESLEUKIN 
Antibacterials: toxicityofvinblastineincreasedbyl ERYTHROMYCIN â€”avoidconcomitantuse;possibleincreasedriskofventriculararrhythmiaswhenvinblastinegivenwithl DELAMANID 
Antifungals: possibleincreasedriskofvinblastinetoxicitywhengivenwithl ITRACONAZOLE ;metabolismofvinblastinepossiblyinhibitedbyl POSACONAZOLE (increasedriskofneurotoxicity)lAntimalarials:avoidanceofvinblastineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis) 
 TRIANGLE Antivirals: plasmaconcentrationofvinblastinepossiblyincreasedby RITONAVIRBNF 
Vincristine
Antibacterials:       possibleincreasedriskofventriculararrhythmiaswhenvincristinegivenwithl DELAMANID  
 Antifungals:     increasedriskofvincristinetoxicitywhengivenwithl ITRACONAZOLE ;metabolismofvincristinepossiblyinhibitedbyl POSACONAZOLE (increasedriskofneurotoxicity)
 Antimalarials:    avoidanceofvincristineadvisedbymanufacturerofl ARTENIMOLWITHPIPERAQUINE 
 
 
 
Antipsychotics:     avoidconcomitantuseofcytotoxicswithl CLOZAPINE (increasedriskofagranulocytosis)  
 TRIANGLE  Calcium-channelBlockers: metabolismofvincristinepossiblyinhibitedby NIFEDIPINE  
 TRIANGLE CardiacGlycosides: vincristinepossiblyreducesabsorptionof DIGOXIN tabletsVindesinelAntibacterials:possibleincreasedriskofventriculararrhythmiaswhenvindesinegivenwithlDELAMANID
 
Antifungals: possibleincreasedriskofvindesinetoxicitywhengivenwithlITRACONAZOLE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)VinfluninelAntibacterials:plasmaconcentrationofvinfluninepossiblyreducedbyl RIFAMPICIN â€”manufacturerofvinflunineadvisesavoidconcomitantuse;increasedriskofventriculararrhythmiaswhenvinfluninegivenwithlDELAMANID 
Antidepressants:  plasmaconcentrationofvinfluninepossiblyreducedbyl STJOHN â€™ SWORT â€”manufacturerofvinflunineadvisesavoidconcomitantuselAntifungals:plasmaconcentrationofvinflunineincreasedbyl KETOCONAZOLE â€”manufacturerofvinflunineadvisesavoidconcomitantuse;possibleincreasedriskofvinfluninetoxicitywhengivenwithlITRACONAZOLE 
 
Antimalarials:avoidanceofvinflunineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)
 Antivirals:  plasmaconcentrationofvinfluninepossiblyincreasedbyl RITONAVIR â€”manufacturerofvinflunineadvisesavoidconcomitantuse 
 TRIANGLE GrapefruitJuice: plasmaconcentrationofvinfluninepossiblyincreasedby GRAPEFRUITJUICE â€”manufacturerofvinflunineadvisesavoidconcomitantuseVinorelbinelAntibacterials:possibleincreasedriskofneutropeniawhenvinorelbinegivenwithl CLARITHROMYCIN ;possibleincreasedriskofventriculararrhythmiaswhenvinorelbinegivenwithlDELAMANID 
 lAntifungals:possibleincreasedriskofvinorelbinetoxicitywhengivenwithlITRACONAZOLE 
 lAntimalarials:avoidanceofvinorelbineadvisedbymanufactureroflARTENIMOLWITHPIPERAQUINE 
 lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)VismodegiblAntibacterials:manufacturerofvismodegibadvisesavoidconcomitantusewithlRIFAMPICIN(plasmaconcentrationofvismodegibpossiblyreduced)lAntidepressants:manufacturerofvismodegibadvisesavoidconcomitantusewithlSTJOHNâ€™SWORT(plasmaconcentrationofvismodegibpossiblyreduced)
Antiepileptics:   manufacturerofvismodegibadvisesavoidconcomitantusewithl CARBAMAZEPINE ,l FOS PHENYTOIN  andlPHENYTOIN(plasmaconcentrationofvismodegibpossiblyreduced)lAntipsychotics:avoidconcomitantuseofcytotoxicswithlCLOZAPINE(increasedriskofagranulocytosis)Vitamin
 A see Vitamins 
 Vitamin 
 D see Vitamins 
 Vitamin 
 E see Vitamins 
 Vitamin 
 K
(Phytomenadione)seeVitamins
 sVitamins 
Anticoagulants: vitaminEpossiblyenhancesanticoagulanteffectofl COUMARINS ;vitaminKantagonisesanticoagulanteffectoflCOUMARINSandl PHENINDIONE  
 TRIANGLE Antiepileptics:alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithCARBAMAZEPINE;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithFOSPHENYTOIN;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwith PHENOBARBITAL ;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwithPHENYTOIN;alfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDrequirementspossiblyincreasedwhengivenwith PRIMIDONE  
 TRIANGLE Antifungals:plasmaconcentrationofparicalcitolpossiblyincreasedbyKETOCONAZOLE;effectsofalfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolandvitaminDpossiblyreducedby MICONAZOLE  
 TRIANGLE Antivirals:increasedriskofbleedingwhenhighdosesofvitaminEgivenwith TIPRANAVIR  
 TRIANGLE Ciclosporin: vitaminEpossiblyaffectsplasmaconcentrationof CICLOSPORIN  
 TRIANGLE Cytotoxics: effectsofalfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolandvitaminDpossiblyreducedby DACTINOMYCIN ;avoidanceofvitaminEadvisedbymanufacturerof IBRUTINIB  
 TRIANGLE Diuretics: increasedriskofhypercalcaemiawhenalfacalcidol,calcitriol,colecalciferol,dihydrotachysterol,ergocalciferol,paricalcitolorvitaminDgivenwith THIAZIDESANDRELATEDDIURETICS  
 TRIANGLE Dopaminergics: pyridoxinereduceseffectsof LEVODOPA whengivenwithoutdopa-decarboxylaseinhibitor 
 TRIANGLE Lipid-regulating
 Drugs: absorptionofcalcitriolpossiblyreducedby COLESTYRAMINE (giveatleast1hourbeforeor4to6hoursaftercolestyramine)
Retinoids: riskofhypervitaminosisAwhenvitaminAgivenwithl RETINOIDS â€”avoidconcomitantuse 
 TRIANGLE Selenium: ascorbicacidpossiblyreducesabsorptionof SELENIUM (giveatleast4hoursapart) 
 TRIANGLE Sevelamer: absorptionofcalcitriolreducedby SEVELAMER (giveatleast1hourbeforeor3hoursaftersevelamer)
 Voriconazole see Antifungals
,Triazole
 Warfarin see Coumarins 
 Wasp 
 Venom 
 Extractsl
 ACE Inhibitors:possiblesevereanaphylactoidreactionwhenwaspvenomextractsgivenwithl ACEINHIBITORS
 Xipamide see Diuretics 
 Xylometazoline see Sympathomimetics 
 Yellow 
 Fever 
 Vaccine see Vaccines 
 Zafirlukast see Leukotriene 
 Receptor 
 Antagonists 
 Zaleplon see Anxiolyticsand 
 Hypnotics 
 Zidovudine
 NOTEI ncreasedriskoftoxicitywithnephrotoxicandmyelosuppressivedrugsâ€”forfurtherdetailsconsultproductliterature 
 TRIANGLE Analgesics: increasedriskofhaematologicaltoxicitywhenzidovudinegivenwith NSAIDS ;plasmaconcentrationofzidovudinepossiblyincreasedby METHADONE  
 TRIANGLE Antibacterials:absorptionofzidovudinereducedbyCLARITHROMYCINtablets(giveatleast2hoursapart);manufacturerofzidovudineadvisesavoidconcomitantusewithRIFAMPICIN 
 TRIANGLE Antiepileptics:zidovudineincreasesordecreasesplasmaconcentrationofFOSPHENYTOINandPHENYTOIN;plasmaconcentrationofzidovudinepossiblyincreasedby SODIUMVALPROATE and VALPROICACID (increasedriskoftoxicity)lAntifungals:plasmaconcentrationofzidovudineincreasedbyl FLUCONAZOLE (increasedriskoftoxicity) 
 TRIANGLE Antimalarials:increasedantifolateeffectwhenzidovudinegivenwith PYRIMETHAMINE 
Antivirals: profoundmyelosuppressionwhenzidovudinegivenwithl GANCICLOVIR orl VALGANCICLOVIR (ifpossibleavoidconcomitantadministration,particularlyduringinitialganciclovirorvalganciclovirtherapy);increasedriskofgranulocytopeniawhenzidovudinegivenwithl NEVIRAPINE ;increasedriskofanaemiawhenzidovudinegivenwithl RIBAVIRIN â€”avoidconcomitantuse;zidovudinepossiblyinhibitseffectsofl STAVUDINE (manufacturersadviseavoidconcomitantuse);plasmaconcentrationofzidovudinereducedbyl TIPRANAVIR   
 TRIANGLE Atovaquone: plasmaconcentrationofzidovudineincreasedby ATOVAQUONE (increasedriskoftoxicity)lOrlistat:  absorptionofzidovudinepossiblyreducedbyl ORLISTATZ inc 
 TRIANGLE Antibacterials: zincreducesabsorptionof CIPR OFLOXACIN  , LEVOFLOXACIN , MOXIFLOXACIN andOFLOXACIN;zincreducesabsorptionof NORFLOXACIN (giveatleast2hoursapart);zincreducesabsorptionof TETRACYCLINES ,alsoabsorptionofzincreducedbytetracyclines 
 TRIANGLE CalciumSalts: absorptionofzincreducedby CALCIUMSALTS  
 TRIANGLE Eltrombopag: zincpossiblyreducesabsorptionof ELTROMBOPAG (giveatleast4hoursapart) 
 TRIANGLE IronSalts: absorptionofzincreducedbyoral IRONSALTS ,alsoabsorptionoforalironsaltsreducedbyzinc 
 TRIANGLE Penicillamine: absorptionofzincreducedby PENICILLAMINE ,alsoabsorptionofpenicillaminereducedbyzinc 
 TRIANGLE Trientine: absorptionofzincreducedby TRIENTINE ,alsoabsorptionoftrientinereducedbyzincZoledronic
 Acid see Bisphosphonates 
 Zolmitriptan see 
5 HT 1-receptorAgonists(underHT)
 Zolpidem see Anxiolyticsand 
 Hypnotics 
 Zonisamide 
 
Antidepressants: anticonvulsanteffectofantiepilepticspossiblyantagonisedby MAOIS andl TRICYCLIC - RELATEDANTIDEPRESSANTS (convulsivethresholdlowered);anticonvulsanteffectofantiepilepticsantagonisedbyl SSRIS andl TRICYCLICS (convulsivethresholdlowered) 
 TRIANGLE Antiepileptics: plasmaconcentrationofzonisamidereducedby CARBAMAZEPINE , FOS PHENYTOIN  , PHENOBARBITAL ,PHENYTOINand PRIMIDONE 
Antimalarials: anticonvulsanteffectofantiepilepticsantagonisedbyl MEFLOQUINE 
Antipsychotics: anticonvulsanteffectofantiepilepticsantagonisedbyl ANTIPSYCHOTICS (convulsivethresholdlowered) 
 TRIANGLE Diuretics: manufacturerofzonisamideadvisesavoidconcomitantusewith CARBONICANHYDRASEINHIBITORS inchildrenlOrlistat:possibleincreasedriskofconvulsionswhenantiepilepticsgivenwithlORLISTAT
 Zopiclone see Anxiolyticsand 
 Hypnotics 
 Zuclopenthixol see Antipsychotics
 BNF 
[]
